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Addiction, increasingly perceived as a heterogeneous brain disorder, is one of the 
most peculiar psychiatric pathologies in that its management involves various, often 
non-overlapping, resources from the biological, psychological, medical, economical, 
social, and legal realms. Despite extensive efforts from the players of these various 
fields, to date there are no reliably effective treatments of addiction. This may stem 
from a lack of understanding of the etiology and pathophysiology of this disorder 
as well as from the lack of interest into the potential differences among patients in 
the way they interact compulsively with their drug. This book offers an overview 
of the psychobiology of addiction and its current management strategies from 
pharmacological, social, behavioural, and psychiatric points of view.
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Addiction is the psychiatric disorder for which the definition has evolved the most in 
the last thirty years. From the DSM-III in which addiction was defined as tolerance 
and withdrawal to the current clinical definition in the DSM-IV and upcoming DSM-
V, with five out of seven criteria referring to loss of control over, and compulsive use 
of, drugs, the social and medical views of addictions have dramatically changed.  
Drug addiction is no longer a question of altered “psychophysical need” of the drug. It 
is beyond this, an alteration of both the basic, i.e., reward, and sophisticated systems of 
the brain, including attention, behavioural control, decision making, memory, and 
even insight.  
Despite this updated neurological understanding, drug addicts remain considered by 
the general public as mere criminals with very weak willpower. This general wisdom 
must change especially in the face of the current trends towards increasing 
recreational use of drugs worldwide, and the emergence of the easy access to online 
casinos and gaming Indeed, most of us, if not all, have already been exposed to a 
stimulus with addictive properties, thereby having gambled with a potential fall into 
the vicious cycle that is addiction. As such, it is important to keep in mind that tobacco 
and alcohol, including wine, are among the most dangerous addictive drugs, causing 
the majority of drug-related deaths.  
Behind the legal status of drugs and the relative failure in law enforcement 
management, remains our lack of understanding of the psychological, neurobiological, 
and environmental factors that contribute to the transition from controlled recreational 
drug use to compulsive drug use. In other words, to date, we still do not know why 
some people exposed to addictive stimuli will develop an addiction while others will 
be able to use these drugs recreationally throughout their life without succumbing to 
the negative personal, societal, and legal side effects of drug consumption. Hence, we 
have no effective prevention strategies nor do we have effective individual-based 
therapeutic treatments to offer. 
In the search for an effective treatment, as a psychobiologist, I suggest that addiction is 
a loss of prefrontal executive control over a maladaptive incentive habit process that 
bridges limbic pavlovian impulses originating from the amygdala and the insula to a 
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rigid habit system dependent upon the dorsolateral striatum. We therefore must find a 
way to counteract this between-systems adaptation, with the most promising 
approach being pharmacological tools. However, this psychobiolgical model does not 
capture key aspects of the pathology, such as the economic status of the addict, his 
current social and personal environment, the unique history that drove him to the use 
of a particular drug, whether his addiction involves the use of several different drug 
classes and so on. 
Since the now well-accepted claim that addiction is a brain disease has opened the 
potential development of pharmacological treatment based on a better understanding 
of addiction pathophysiology, many researchers have focused on the understanding of 
the neurobiological adaptations to drug exposure. They have forgotten that the 
neurobiological adaptations to exposure to addictive drugs are common to all that are 
exposed to drugs, whether they be addicted or not. It is only recently that the interest 
in inter-individual vulnerability to compulsive drug use has emerged in the field of 
neuroscience, and the additional potential role of environmental conditions is only 
emerging.  
Several outstanding books have now been published covering the neurobiology of 
drug addiction and aiming to provide a rather exhaustive overview of the current state 
of addiction research integrating these issues.  
Here, we offer an alternative point of view focusing on the complexity and 
heterogeneity of treatment management of addictions involving players from the 
legal, medical, social, psychological, neurobiological, psychiatric, and psychoanalytical 
fields.  
None of these fields and associated management strategies has so far proven to have 
developed effective treatment to prevent relapse of compulsive drug use in drug 
addicts. This lack of success may stem from the fact that there are several forms of 
addiction with specific etiologies and pathophysiologies that we have no insights into, 
but it may also be explained by a lack of interaction and understanding among the 
different approaches involved in the management of addiction. Indeed, not only a 
brain disease, addiction should be additionally considered in terms of comorbidity, 
both at the psychiatric and somatic levels. By emphasizing how much the definition of 
addiction and the foreseen potential treatments differ among biologists, psychologists, 
psychoanalysts, or GPs, this book provides an original framework whereby one can 
reach beyond an initial area of interest regarding addictions.  
This book also provides insights into the experimental approaches of drug addiction, 
both in preclinical models and in humans, as well as the neurobiological mechanisms 
that may be associated with addictions. It provides a synthesis of the current and 
emerging pharmacological tools for the management of addiction to different drugs 
and opens new perspectives on various management strategies of drug addicts. 
Gathering experts in different fields, from basic research to the clinic, involved in the 
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care of drug addicts, the present book aims at providing the reader with an original 
overview of the strategies implemented to treat drug addiction. This may be of interest 
for those who share the wisdom that refined and more effective treatments lie in the 
adequate combination of pharmacological and psychological/psychosocial strategies.  
I am extremely grateful to the authors of the various chapters for the quality of their 
contribution to this book. I would like to acknowledge Ms Masa Vidovic, the patient 
project manager at InTech, for her support and Ms Gorana Scerbe for initiating this 
book project. I would like to thank the members of my research team for their support. 
Finally, I would like to dedicate this book to the two pillars of my research and 
personal life: my mentor, Barry Everitt, and the one to whom I am addicted, my wife, 
Aude Belin-Rauscent.  
 
David Belin, PhD 
INSERM European Associated Laboratory  
Psychobiology of Compulsive Habits,  
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Drug Addictions:  
An Historical and Ethological Overview 
Aude Belin-Rauscent and David Belin  
INSERM U 1084, LNEC, Université de Poitiers,  
INSERM AVENIR Team “Psychology of Compulsive Disorders”, Poitiers,  
France 
1. Introduction 
1.1 Preliminary considerations: Focus on cocaine and heroin 
It is well established that several psychoactive substances can lead to addiction. These 
include legal drugs such as alcohol and nicotine which generate the major part of the 
addiction-related social and economical costs to modern societies (1), and a pleiad of illegal 
drugs amongst which cannabis, cocaine and heroin are the most commonly used. 
When one wants to consider the harmful consequences of an addictive drug, both the 
dependence and physical harm potencies of the drug should be considered for these two 
aspects contribute to the deterioration of the user’s life. A recent classification of the major 
classes of addictive drugs reveals that heroin and cocaine are clearly the most dangerous 
ones since both their addictive properties and physical harm potency are high (2). Cocaine 
and heroin are followed by barbiturates and street methadone, but tobacco is shown to have 
addictive property of the same magnitude as cocaine, thereby demonstrating that the legal 
status of a substance is not a predictive factor of least addictive properties. 
In the present chapter, we will consider exclusively cocaine and heroin addictions, not only 
because these two drugs are clearly the most dangerous ones, but mainly because cocaine 
and heroin use have been increasing among western countries populations in the last ten 
years. This focus is one limitation of the general conclusions that will be provided in the 
following chapters that will also address alcoholism and food addiction that will be joined 
by another addiction, namely pathological gambling, in the clinical definition of addictions 
in the upcoming DSM-V. Thus, addictions are increasingly recognised as abnormal 
persistent maladaptive behaviours driven by specific, initially reinforcing, stimuli in the 
environment that are not anymore restricted to psychoactive substances. 
1.2 Drug use: A behaviour as old as humankind? 
Drug use seems to have entered human customs as early as the emergence of human 
societies. Evidences that recreational drug use has emerged early on after human 
sedentarisation, perhaps with the development of religious rites, can be found for several 
drugs and routes of administration. 
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Fig. 1. Rational scale to assess the harm of drugs of potential misuse, after (2).  
The addictive potential of a drug varies from substance to substance, and from individual to 
individual. Dose, frequency, pharmacokinetics of a particular substance, route of 
administration, and time are critical factors for physical harm and addictive potency. Heroin 
and cocaine are clearly the most dangerous ones since both their addictive properties and 
physical harm potency are high. 
Thus, 5000 B.C. the sumerians used opium, as suggested by the fact that they had an 
ideogram for it which has been translated as HUL, meaning « joy » or « rejoicing » (3). A 
3500 B.C. egyptian papyrus provides the earliest historical record of the production of 
alcohol in the description of a brewery (4). 
Interestingly, 3000 B.C. is also the approximate date of the supposed origin of the use of tea 
in China. It is likely that coca leaf chewing began in the Andes at the same time since traces 
of coca have been found in mummies dating 3000 years back (5). The cocaine content of coca 
leaf is under 1% but after 1859, when cocaine was first isolated from coca leaf by Albert 
Niemann, cocaine was available legally in concentrations that were nearly 100% pure. 
Cocaine was first used recreationally in the 1860s, almost as soon as it was synthesised. A 
few years after its synthesis by Richard Willstätter in 1898 (6), cocaine appeared in 
cigarettes, ointments, nasal sprays, and tonics. The most popular cocaine-based product was 
Mariani Wine (Vin Mariani). It was a wine and cocaine mixture that was launched in 1863. 
Nearly all popular personalities of the day, including Queen Victoria, Thomas Edison and 
Pope Leon XIII endorsed it. Cocaine has also been popularised by Sigmund Freud who 
prescribed it for the treatment of digestive disorders, asthma, depression or opiate and 
alcohol dependence (7). 
At the same time, more precisely in 1898, heroin (diacetylmorphine) was synthesized by 
Felix Hoffmann, 23 years after a first academic synthesis by Alder Wright. Akin to the 
launch of cocaine as a medicine, heroin was then introduced by Bayer as “safe preparation 
free from addiction-forming properties“. 
 
Drug Addictions: An Historical and Ethological Overview 5 
The broad availability of the pure form of cocaine and heroin has contributed to the marked 
development of addiction to these substances which, in their primary forms and routes of 
administration, were far less addictive. This phenomenon has been suggested to stem from a 
discrepancy between our brain and our modern environment, i.e, Nesse and Berridge wrote 
in 1997: «We are vulnerable to such fitness-decreasing incentives because our brains are not 
designed to cope with ready access to pure drugs, video games, and snack foods. Hundreds 
of generations of exposure would likely shape resistance to their allure and their deleterious 
effects» (8). This interesting consideration suggests that drug addiction may be a matter of 
mismatch between Human evolution and the recent revolution of human environment, a 
problem to which Evolution may be the best solution. 
 
Fig. 2. Illicit drug use state at the beginning of the 21st century  
Top panel: Annual prevalence of global, worldwide, illicit drug use over the period 1998-
2001 (11). Bottom. A trend to increased cocaine use in European countries (10). 
However, before these evolutionary, and rather fatalistic considerations, human societies 
have developed social and legal strategies to cope with addiction, as early as 10 years 
following the synthesis of heroin and cocaine. Indeed, the United States prohibited the 
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following the synthesis of heroin and cocaine. Indeed, the United States prohibited the 
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importation of smoking opium (9) and the manufacture of heroin in 1909 and 1924, 
respectively, while the Harrison Narcotics Act of 1914 prohibited the use of cocaine. Since 
then law enforcement has limited, but not eradicated, heroin and cocaine use, as illustrated 
by figure 2 (EMCDDA) (10), the bottom panel of which shows a general increase in cocaine 
use within European countries over the past 20 years. Such a trend may induce an increase 
in the prevalence of drug-related health problems, and most importantly, of drug addiction. 
1.3 Drug use: An evolutionary feature of animal kingdom 
Drug use seems inherent to animal behaviour, perhaps because of the evolutionary selection of 
a reward system developed to maintain species survival, bringing animals towards sources of 
reinforcement. Thus spontaneous drug use has been observed in several species in the wild. 
Elephants would intoxicate with alcohol contained in ripe fruits and baboons would readily 
eat over-ripe fruits from the marula tree until they cannot walk anymore. Birds also use 
alcohol in that song thrush, for instance, struggle to fly after eating ripe grapes. 
An exhaustive list of examples of spontaneous drug use in animal kingdom is beyond the 
scope of this chapter, but a last example should be enough to emphasise how broad are 
sources of intoxication in mammals: in the south of the United States, sheep and horses eat 
astragalus and then show hyperactive behaviour akin to human beings. 
In experimental settings, it has been demonstrated that all drugs abused by humans are 
reinforcing in many species including planarians (12) and flies (13, 14), and they are readily 
self-administered by vertebrates such as mice (15-21) or rats (22-26), dogs (27, 28) and non 
human primates (29, 30). 
Thus not only is drug used common to several species of the animal kingdom but the 
demonstration that pure forms of psychoactive drugs have reinforcing properties in animals 
under experimental conditions suggests that drug taking is not a specific behavioural 
feature of human beings. Drug use in animals seems rather to be the evidence that the 
neurobiological substrates of primary motivational and reinforcement processes selected by 
evolution have been shaped early on and maintained from planarians to human beings, and 
that drugs highjack these systems. 
However, it remains unclear the extent to which these findings help inform our 
understanding of drug addiction in humans since it is a brain disorder that is clearly far 
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(figure 3). The diagnostic of drug addiction is currently based on a categorial dichotomous 
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Fig. 3. Clinical features of drug addiction according to the DSM-IV-R (44). 
The subject is diagnosed addicted to the substance if they show at least three out of the 7 
clinical criteria over the last 12 months. 
However, all addicted patients are not equally severely affected and a dimensional 
addiction severity scale has been developed to assess general behavioural, health and social 
drug-induced impairments (45-49). 
Indeed, drug addicts do not only take drugs, they spend great amounts of time foraging 
for their drugs, compulsively take drugs, lose control over drug intake, and persist in 
taking drugs despite the many adverse consequences of doing so, including 
compromising their health, family relationships, friendships and work. Many drug 
addicts resort to criminal behaviour to obtain the funds necessary to sustain their 
compulsive drug use and the great majority eventually relapse to drug use even after 
prolonged periods of abstinence. 
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This negative behavioural picture illustrates how drug addiction is not merely a drug taking 
disorder. Indeed, among the individuals exposed to drugs, and there are many who 
occasionally drink only a glass or two of an alcoholic beverage, or smoke a cigarette or two, 
only 15 to 30% overall will switch from casual, ‘recreational’ drug use to drug abuse and 
drug addiction (1, 50) (figure 4). 
 
Fig. 4. We are not equally vulnerable to drug addiction 
A substantial proportion of the general population experiences drugs at least once in a 
lifetime. Of the recreational users who control their drug intake, some will shift to more 
chronic drug use. Only a subgroup of these individuals will develop drug abuse and 
eventually drug addiction. Epidemiological studies reveal that of the individuals who have 
been exposed to addictive drugs, 15 to 20 % eventually develop addiction. 
Despite considerable research we still do not understand why some individuals develop a 
compulsive use of drugs nor do we have effective treatments (51) to reduce the substantial 
social and economic burden (52); for review, see (1) of drug addiction (figure 5). 
Nevertheless, there is increasing evidence suggesting that drug addiction results from 
gradual adaptation processes in the brain of vulnerable subjects in response to chronic drug 
exposure. Not only do these between-systems adaptations trigger an emotional allostatic 
state (hedonic allostasis) (1, 53-55) characterised for instance by increased anxiety, irritability 
and depression but they may ultimately lead to a shift in the psychological mechanisms that 
govern drug seeking and drug taking behaviours, including habits (36, 37, 41, 42, 56, 57) as 
aberrant instrumental learning mechanisms controlled by Pavlovian cues, altered 
behavioural control (39, 58-60), decision-making and self-monitoring processes (61, 61). 
Similarly, Everitt and colleagues have argued that, during the development of drug 
addiction, drug seeking is initially goal-directed but becomes habitual, and ultimately 
compulsive, thereby emphasizing the potential importance of maladaptive automatic 
instrumental learning mechanisms and their control by Pavlovian incentive processes, so 
called incentive habits (37, 42), in the emergence of compulsive drug use (35, 37, 42, 59). 
Additionally, drug-induced adaptations may also facilitate the shift from impulsivity to 
compulsivity that has been suggested to occur in the development of drug addiction (figure 
6) whereby only vulnerable subjects would show a transition from impulse-related 
recreational drug use to compulsive drug intake (1). 
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Fig. 5. Strategic targets of therapeutic treatment in the course of drug addiction (reproduced 
from (51)) 
 
Fig. 6. A progressive shift from impulsivity to compulsivity in the development of drug 
addiction (42) 
2.2 Behavioural and psychological profile of drug addicts 
Besides their disinterest for alternative sources of reinforcement and their focus on the drug, 
drug addicts are characterised by several behavioural and cognitive deficits including 
impaired inhibitory control (62-67), decision making (68-75) and insight (76-78). 
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However, major differences can be observed between addicts depending on their preferred 
drug of abuse. For instance, although opiate and stimulant addicts both display increased 
sensation seeking (79-81) and impulsivity (82-87), they nevertheless differ in other respects, 
with heroin addicts showing greater anxiety than cocaine addicts (88), while the latter 
display higher impulsivity (62, 89, 90). 
Thus not only are several personality traits, including sensation seeking, anxiety and 
impulsivity, associated with increased vulnerability to use drugs (91-94), but different 
personality traits are preferentially associated with use (95) and addiction to specific 
drugs (91, 92, 94, 96-103). It is therefore possible that heroin and cocaine addicts may self-
medicate different personality characteristics or affective states (104-107), with 
impulsivity being preferentially self-medicated by cocaine use. However, as discussed in 
chapter 2 of this book, the relative contribution of a behavioural trait to the choice of a 
drug does not necessarily predict its implication in the transition to compulsive drug use. 
Drug addicts also show several comorbid psychiatric disorders (108-111), as stated by 
O’Brien (112): «Psychiatric disorders commonly coexist with addictive disorders. These 
include anxiety disorders, psychotic disorders, and affective disorders such as depression. 
Although some of these so-called “dual diagnosis” cases are simply a coincidental 
occurrence of common disorders, the overlap is greater than would be expected by chance 
on the basis of population prevalences (109)». However, it remains unknown whether 
comorbid elements contribute to increased vulnerability to drug addiction (113) or 
whether chronic drug exposure facilitates the emergence of psychiatric comorbidity (for 
discussion see (112)). Similarly, while some personality, or behavioural, traits are 
triggered by chronic drug use, there is evidence that personality variables are associated 
with increased vulnerability to develop drug addiction (92, 114). This rather blur picture 
not only suggests that several sub-populations exist within drug addicts (115), but it 
clearly illustrates how little is known about the factors involved in the vulnerability to 
develop drug addiction. 
To date a triadic model of contributing factors has been established that accounts well for 
both clinical and preclinical literature. Thus, vulnerability to drug addiction is suggested to 
result from the interaction between a vulnerable phenotype, or personality (being the 
interaction between genes and history), the drug and the environment (figure 7). 
There is clearly a genetic vulnerability to addiction. Genetic factors may contribute up to 40% 
to the development of drug addiction (51). This estimation gives genetic factors a limited 
contribution to the vulnerability to drug addiction and highlights the importance of both the 
drug and the environment in the development of the pathology. There is indeed compelling 
evidence that life experiences and environments highly influence the effects of drugs of abuse 
and play a critical role in the transition from controlled to compulsive drug use (116, 117). For 
instance, drug addiction seems to be more frequent in people living in degraded areas or in 
people that undergo difficult experiences during their childhood. Such specific environmental 
conditions at either perinatal, developmental or adulthood stages may alter one’s personality 
construction so that they become more vulnerable to use or abuse drugs (118). On the other 
hand, positive family relationships, friendships, involvement and attachment appear to 
somehow protect against the development of drug addiction (119, 120). 
 




Fig. 7. Triad of influences underlying vulnerability to drug addiction 
A number of interacting factors are hypothesised to influence the pathway to addiction, 
including biological determinants (genes), drug exposure and the environment. Genetic 
influences may account for up to 40% of the vulnerability for drug addiction  
Thus, the present general strategies developed to treat addictions should perhaps be re-
oriented towards a more patient-based medication strategy once better insights are gained 
in the understanding of the etiological and neurobiological substrates of individual 
vulnerabilities to addictions. 
2.3 Biological correlates of drug addiction in humans: Insights from imaging studies 
An exhaustive synthesis of the neurobiological correlates of drug addiction is beyond the 
scope of this chapter. Overall, drug exposure impacts both brain structure and function. 
Thus at the morphological level, drug addicts have decreased grey matter volumes in 
prefrontal (121-125) and cerebellar regions of the brain (126). Functionally, when presented 
with drug-related cues that induce craving, drug addicts show abnormal activation of limbic 
structures including the amygdala (127, 128), the insular (40, 129) and orbitofrontal cortices 
(39, 130) as well as cognitive prefrontal areas such as the cingulate (127, 128, 131) and 
dorsolateral prefrontal cortices (74). 
Moreover, drug addicts are characterised by decreased levels of striatal D2/3 dopamine 
receptors (132-134) and reduced metabolism in the orbitofrontal cortex (132). These two 
alterations are highly correlated (132), thereby providing the orbitofrontal-limbic striatum 
circuit a prominent implication in addiction (134, 135), even though other networks, including 
the thalamo-cortical systems, have been identified to be impaired in drug addicts (136). 
Interestingly, a growing body of evidence points towards an implication of non limbic 
striatal areas in the pathophysiology of drug addiction since dopamine transmission is 
specifically increased in the dorsal striatum of cocaine addicts experiencing craving in 
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response to presentation of drug-associated cues (137, 138), providing a neurobiological 
evidence for a progressive involvement of dorsal striatum-dependent habits (139-141) in 
drug addiction (35-37, 41, 42). 
A major limitation of human studies is that the data obtained, though clearly informative, 
are based on the comparison of current or former drug addicts and drug naive control 
subjects. Thereby, human studies cannot control for the effects of protracted drug exposure 
on the brain nor can they define whether the abnormalities observed in drug addicts are a 
pathological biological adaptation to drug exposure or predated drug use and hence are 
instead endophenotypes of vulnerability to drug addiction. 
This is where the case for animal experimentation in addiction research is revealed 
compelling. Besides the aforementioned limitations, studies in human addicts are often 
prone to interpretative issues not least due to inter-subject variability in drug exposure, the 
frequent co-abuse of several drugs often in combination with alcohol, cannabis and nicotine, 
the regular occurrence of co-morbid brain disorders such as depression, conduct disorder 
and attention-deficit/hyperactivity disorder (ADHD) and the difficulty in controlling pre-
morbid cognitive and intellectual abilities. 
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1. Introduction 
The study of drug addiction integrates a broad range of research fields including social 
sciences, psychology, psychiatry, behavioural neurosciences, pharmacology or genetics, 
each of which being represented in the different chapters of this book. Preclinical studies 
involving behaving animals have been pivotal for our increasing insights into the 
psychobiological substrates of addiction and so for about 100 years. Even today, our 
understanding and knowledge of addiction increase in parallel with the refinement of 
animal models of this pathology. 
1.1 Necessity for animal models in drug addiction research 
Whilst animal models can never reproduce the complex social and often personal reasons 
why people abuse drugs they nevertheless provide a rigorous means to precisely control 
environmental context, drug exposure as well as assessing behavioural and cognitive 
performance prior to drug administration. They also allow neural manipulations (e.g., using 
selective ligands) and so establish the causal influences of putative neural loci and, in turn, 
the cellular and molecular substrates, of drug addiction. Thus, to date, animal models 
provide a valuable means to investigate the different stages of the drug addiction cycle 
including especially the initiation of drug taking, the maintenance phase, which is often 
accompanied by binges and escalation of drug intake, and finally the switch to compulsive 
drug intake defined operationally by an increased motivation to take the drug, an inability 
to inhibit drug seeking and continued dug use despite negative or adverse consequences. 
1.2 Definition and validity criteria of animal models 
1.2.1 Definition of an animal model 
An animal model is a preparation in one organism that allows for the study of one or several 
aspects of a human condition. Thus a model of drug addiction must provide insights into 
the neurobiological, psychological or etiological mechanisms of the pathology in humans, at 
least mimicking some aspects of the pathology. 
Two strategies are generally used when designing animal models of drug addiction. Firstly, 
the model can address a specific symptom, a neurobiological or psychological feature or  
a behavioural / neurobiological construct associated with the pathology (figure 1).  
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Fig. 1. Animal models of drug addiction in reference to the DSM IV diagnostic criteria for 
drug addiction (adapted from the DSM-IV [97])) 
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These models have been widely developed the last 40 years and have provided substantial 
informations about the molecular targets of addictive drugs as well as the neurobiological 
and psychological adaptations resulting from either acute or chronic drug exposure. Indeed, 
models that focus on defined features of drug addiction provide a powerful heuristic 
framework for determining the brain mechanisms underlying the pathology. However, they 
rarely address other clinical dimensions of the disorder such as behavioural predictive 
factors or interactions between different symptoms of the pathology. Thus, the second type 
of models are those that try to incorporate several symptoms of the pathology in humans, 
thereby providing powerful tools for longitudinal studies or even testing pharmacological 
treatments, but are somewhat limited in the identification of underlying mechanisms. 
Indeed, the behavioural complexity of these models makes it difficult to implement causal 
investigative studies where the end-point is well defined. We discuss the general utility and 
application of both modelling approaches as complementary tools to investigate the 
neurobiological and psychological mechanisms of drug addiction and its vulnerability. 
1.2.2 Validity criteria of animal models 
The validation of animal models of addiction is based upon the same principles that have 
been established for models in general, namely fulfilling standard criteria amongst which 
reliability and predictive validity are the most important [1]. However, there are other 
criteria that have been used widely in validating animal models of drug addiction, including 
face validity and construct validity [1]. Briefly, reliability refers to the consistency and 
stability with which the independent and the dependent variables are measured. Thus a 
reliable model of drug addiction must allow for a precise and reproducible manipulation of 
the independent variable and an objective and reproducible measure of the dependent 
variable in standard conditions. A further key criterion for the validation of an animal 
model is its predictive validity. A valid animal model should predict either the therapeutical 
potential of a compound in humans (pharmacological isomorphism) or a variable that may 
influence both the dependent variable of the model and the process under investigation in 
humans. 
Face validity refers to the similarities between the dependent variable of the model, i.e., 
behaviour in the case of drug addiction, and the human condition, i.e. the symptoms of the 
pathology. Thus face validity may be important in designing the model but is unlikely an 
objective criterion to actually assess its validity. Indeed, it is very difficult, if not impossible, 
to provide an objective criterion to evaluate the similarities between the behavioural output 
of a rat preparation and drug addiction in humans when the behavioural repertoire of the 
two species is so different. 
Construct validity has been increasingly considered in animal models of drug addiction. It 
refers to the ability of a model to take into account psychological or neurobiological 
constructs that characterise the specific pathological processes in humans. Thus, incentive 
sensitisation, habit formation or top-down prefrontal executive control failure are examples 
of constructs which have been investigated in animal models. 
2. Reinforcing effects of drugs of abuse, abuse liability  
As previously mentioned all addictive substances show reinforcing properties in animals. 
Indeed, the abuse liability of a substance is often measured by its ability to support self-
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These models have been widely developed the last 40 years and have provided substantial 
informations about the molecular targets of addictive drugs as well as the neurobiological 
and psychological adaptations resulting from either acute or chronic drug exposure. Indeed, 
models that focus on defined features of drug addiction provide a powerful heuristic 
framework for determining the brain mechanisms underlying the pathology. However, they 
rarely address other clinical dimensions of the disorder such as behavioural predictive 
factors or interactions between different symptoms of the pathology. Thus, the second type 
of models are those that try to incorporate several symptoms of the pathology in humans, 
thereby providing powerful tools for longitudinal studies or even testing pharmacological 
treatments, but are somewhat limited in the identification of underlying mechanisms. 
Indeed, the behavioural complexity of these models makes it difficult to implement causal 
investigative studies where the end-point is well defined. We discuss the general utility and 
application of both modelling approaches as complementary tools to investigate the 
neurobiological and psychological mechanisms of drug addiction and its vulnerability. 
1.2.2 Validity criteria of animal models 
The validation of animal models of addiction is based upon the same principles that have 
been established for models in general, namely fulfilling standard criteria amongst which 
reliability and predictive validity are the most important [1]. However, there are other 
criteria that have been used widely in validating animal models of drug addiction, including 
face validity and construct validity [1]. Briefly, reliability refers to the consistency and 
stability with which the independent and the dependent variables are measured. Thus a 
reliable model of drug addiction must allow for a precise and reproducible manipulation of 
the independent variable and an objective and reproducible measure of the dependent 
variable in standard conditions. A further key criterion for the validation of an animal 
model is its predictive validity. A valid animal model should predict either the therapeutical 
potential of a compound in humans (pharmacological isomorphism) or a variable that may 
influence both the dependent variable of the model and the process under investigation in 
humans. 
Face validity refers to the similarities between the dependent variable of the model, i.e., 
behaviour in the case of drug addiction, and the human condition, i.e. the symptoms of the 
pathology. Thus face validity may be important in designing the model but is unlikely an 
objective criterion to actually assess its validity. Indeed, it is very difficult, if not impossible, 
to provide an objective criterion to evaluate the similarities between the behavioural output 
of a rat preparation and drug addiction in humans when the behavioural repertoire of the 
two species is so different. 
Construct validity has been increasingly considered in animal models of drug addiction. It 
refers to the ability of a model to take into account psychological or neurobiological 
constructs that characterise the specific pathological processes in humans. Thus, incentive 
sensitisation, habit formation or top-down prefrontal executive control failure are examples 
of constructs which have been investigated in animal models. 
2. Reinforcing effects of drugs of abuse, abuse liability  
As previously mentioned all addictive substances show reinforcing properties in animals. 
Indeed, the abuse liability of a substance is often measured by its ability to support self-
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administration and a conditioned place preference [2]. In this section are reviewed the 
experimental designs that have been developed to investigate the reinforcing properties of 
addictive drugs. These procedures, combined with molecular biology and pharmacology, 
have been crucial in the identification and functional characterisation of the molecular 
targets of addictive drugs. 
The seminal discovery by Olds and Milner of intra-cranial self-stimulation (ICSS) in 1954 
marked a major turning point for research on the neural mechanisms of addiction [3]. The 
discovery that dopaminergic projections from the ventral tegmental area (VTA) to limbic 
cortico-striatal structures (nucleus accumbens, Acb), olfactory tubercle, amygdala, 
orbitofrontal cortex (OFC), medial prefrontal cortex (mPFC) were effective substrates for 
ICSS sparked considerable interest in the brain dopamine systems as neural substrates for 
the rewarding properties of both natural [food] and drug reinforcers. A few years later 
Weeks developed an operant procedure to deliver intravenous morphine infusions to 
relatively unrestrained rats [4], a method still widely used in many pre-clinical research 
laboratories today. That research continued on the opioid drugs morphine and heroin for 
some considerable time thereafter was no surprise given the strong emphasis at that time in 
the DSM-III on the symptomatology of opioid dependence and withdrawal [5]. 
Since then it has been established that addictive substances exert powerful effects on 
primary and secondary (i.e. conditioned) reinforcement mechanisms. As instrumental 
reinforcers they strongly encourage behaviours that lead to the availability of a drug, a 
process subserved by stimulus-response associative mechanisms (instrumental 
conditioning). Abused drugs also facilitate Pavlovian conditioning whereby previously 
neutral stimuli in the environment become conditioned to the drug, and can predict it, or 
even act as conditioned reinforcers. 
In operational terms, a reinforcer is a stimulus that increases the probability of a response 
consequent upon its presentation. Thus, all addictive drugs are reinforcers since they are 
self-administered by animals and humans and support conditioned place preference (a form 
of contextual Pavlovian conditioning). Pavlovian conditioned stimuli can act as conditioned 
reinforcers when presented contingently. Then they can have powerful motivational effects 
and support long sequences of instrumental drug-seeking behaviour by bridging delays to 
future drug reinforcement [6-8]. 
2.1 Conditioned place preference 
Conditioned place preference (CPP), has been used extensively to probe the psychological 
[9] and neurobiological [10-11] mechanisms underlying the rewarding properties of 
addictive drugs [10;12], as well as negative emotional states associated with drug 
withdrawal [13-15]. Indeed, through Pavlovian conditioning, the negative affective state 
caused by drug withdrawal can induce a reliable conditioned place aversion [13-15]. 
The first study based on the modern paradigm of CPP was reported by Rossi and Reid in 
1976 [16] although earlier demonstration of preference for a drug paired environment was 
published as early as the 1940’s [10]. In this procedure two different unconditioned stimuli 
(US) are paired with two distinct environments. These contextual cues differ in their spatial 
configuration, colour, flooring, and sometimes even olfactory cues. Briefly, the CPP 
procedure involves injecting animals with either the drug in question or a control solution, 
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each being administered in a different environment often over successive days. The 
conditioning phase may combine several pairings, ideally according to a Latin square and 
unbiased design such that every pairing does not predict subsequent pairings, and that any 
spontaneous bias or preference for a compartment is initially controlled for. CPP is then 
tested during a drug-free choice phase where subjects are given access to both 
compartments. Preference for the drug-paired environment is indicative of the rewarding 
properties of the drug. CPP can be established not only for addictive drugs but also for 
natural rewards such as food, water, sexual partner and novelty [10]. Based on a plethora of 
studies, it is widely accepted that increased dopamine transmission is necessary for the 
establishment of CPP [17]. Although some authors suggest that CPP is a model of drug 
seeking behaviour [or drug craving], being essentially dependent upon Pavlovian 
associations, CPP alone cannot account for the instrumental nature of drug seeking and 
drug taking behaviour, which is perhaps better modelled by drug self-administration 
procedures. 
2.2 Drug self-administration models 
Drug self-administration procedures lie at the core of the most sophisticated preclinical 
models of drug addiction that have been developed over the last twenty years, ranging from 
relapse to drug taking [18-20], to loss of control over intake [21-22], compulsive drug taking 
[23-25] and addiction-like behaviour [8;26-28]. 
Addictive drugs act as reinforcers, in that they increase the probability of a behavioural 
response that leads to their presentation, through instrumental conditioning. Thus, animals 
can readily detect the contingency between an instrumental response and the delivery of a 
particular drug (e.g., an intravenous infusion of heroin, cocaine, nicotine or THC, or a small 
volume of alcohol in a magazine) and respond in an instrumental manner to obtain such 
drugs. The acquisition of drug self-administration is a behavioural marker of its reinforcing 
properties and abuse liability [2]. Indeed, apart from LSD, all drugs abused by human are 
self-administered by animals. 
Drugs of abuse can be self-administered by a variety of routes across preclinical models, 
including intramuscular, intranasal, oral, and intravenous [29]. 
Drug self-administration was initially developed in non human primates, however since the 
pioneering work of Weeks (1962), rats have extensively been used to investigate the 
psychological, neural and cellular mechanisms underlying drug self-administration. 
Self-administration procedures can be arranged according to different schedules of 
reinforcement [29]. In fixed ratio schedules, the drug is delivered after the completion of a 
fixed number of responses by the animal, thereby providing a direct relationship between 
the actual response and drug delivery. By contrast, in fixed interval schedules, the animal is 
trained to seek the drug for prolonged periods of time. 
Different schedules allow for the investigation of different processes of drug taking or drug 
seeking behaviour which are beyond the scope of this chapter. However, insightful 
descriptions of, and discussions about, these schedules can be found in [6;29-32]. 
The acquisition of drug self-administration is widely considered to depend on the functional 
integrity of the olfactory tubercle and the shell of the nucleus accumbens (AcbS) [7]. An 
 
Addictions – From Pathophysiology to Treatment 24
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studies, it is widely accepted that increased dopamine transmission is necessary for the 
establishment of CPP [17]. Although some authors suggest that CPP is a model of drug 
seeking behaviour [or drug craving], being essentially dependent upon Pavlovian 
associations, CPP alone cannot account for the instrumental nature of drug seeking and 
drug taking behaviour, which is perhaps better modelled by drug self-administration 
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models of drug addiction that have been developed over the last twenty years, ranging from 
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response that leads to their presentation, through instrumental conditioning. Thus, animals 
can readily detect the contingency between an instrumental response and the delivery of a 
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volume of alcohol in a magazine) and respond in an instrumental manner to obtain such 
drugs. The acquisition of drug self-administration is a behavioural marker of its reinforcing 
properties and abuse liability [2]. Indeed, apart from LSD, all drugs abused by human are 
self-administered by animals. 
Drugs of abuse can be self-administered by a variety of routes across preclinical models, 
including intramuscular, intranasal, oral, and intravenous [29]. 
Drug self-administration was initially developed in non human primates, however since the 
pioneering work of Weeks (1962), rats have extensively been used to investigate the 
psychological, neural and cellular mechanisms underlying drug self-administration. 
Self-administration procedures can be arranged according to different schedules of 
reinforcement [29]. In fixed ratio schedules, the drug is delivered after the completion of a 
fixed number of responses by the animal, thereby providing a direct relationship between 
the actual response and drug delivery. By contrast, in fixed interval schedules, the animal is 
trained to seek the drug for prolonged periods of time. 
Different schedules allow for the investigation of different processes of drug taking or drug 
seeking behaviour which are beyond the scope of this chapter. However, insightful 
descriptions of, and discussions about, these schedules can be found in [6;29-32]. 
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important role for mesolimbic dopamine in this process was inferred by findings in freely 
moving rats that dopamine concentration is greatly increased in the striatum, and especially 
the Acb, following the self-administration of drugs commonly abused by humans [33]. This 
important study supported the influential hypothesis at that time that addictive drugs exert 
their primary reinforcing effects and addictive properties through activation of the 
mesolimbic dopamine system [34-37]. Although it is now clear that increased dopamine 
release in the Acb does not provide a sufficient account for the addictive properties of drugs 
such as cocaine, alcohol and heroin, dopamine still remains one of the most important 
neurotransmitters in the aetiology and pathophysiology of drug addiction, a role 
underscored by its proposed involvement in salience detection and learning [7;38-52]. 
In its classic form, the drug self-administration paradigm has provided valuable insights 
into the brain substrates mediating drug taking behaviour, which differ somewhat 
according to the particular drug under investigation [53-56]. Addictive drugs not only 
influence the function of the mesolimbic dopamine system [33] they also trigger a variety of 
between-systems anatomical [57-62] and functional neuroadaptations [63-66] as well as 
changes in gene transcription and function in a number of brain systems including the 
hypothalamus [67], the VTA [68], the amygdala [69-74], Acb [75-79], dorsal striatum [80], 
orbital [81-82] and prefrontal cortices [83-85], with important effects on stress responsivity 
[86-88] and epigenetic processes in the limbic system [77;89-92]. 
However, even though these data have increased our knowledge about the neurobiological 
substrates of the reinforcing effects of addictive drugs and the neurobiological adaptations 
to drug self-administration, they provide only limited insights into the neurobiology of drug 
addiction. As very well brought to remembrance by Serge Ahmed [93], intravenous 
(intrajugular) self-administration of saline had been demonstrated in water-deprived 
monkeys [94] a year before the pioneer morphine self-administration work in rats of Weeks 
(1962), thereby demonstrating that drug self-administration is a measure of instrumental 
conditioning, but not really a model of drug addiction. 
Thus, when one considers working on drug addiction one has to keep in mind that studying 
drug taking behaviour is not a way of studying drug addiction. This was already stated long 
ago by Wise and Bozart [95] and quoted by Robinson & Berridge [96]: “To assert that all 
addictive drugs are reinforcers is to do little more than redefine the phenomenon of 
addiction.”…”To identify a drug as reinforcing goes no further than to identify the drug as 
addicting“; indeed, there is an obvious gulf between taking a drug on a social basis, as most 
of us often do, at least when one considers a glass of wine, and compulsively taking drugs. 
Nevertheless, even after the publication of the DSM-IV in 1994 [97] and the new diagnostic 
criteria for compulsive drug use that now form the hallmark of the clinical features of drug 
addiction many, if not all, of the early animal models focused on the “rewarding“ properties 
of addictive drugs and their acute and chronic neurobiological effects. 
Thus, during the last ten years pre-clinical research in drug addiction has attempted to 
better integrate one or more clinical features of the pathology according to the DSM-IV 
diagnostic criteria. New phenotypes have been identified based on craving or either 
reinstatement [20;98-99] or relapse to drug seeking [100], a loss of control over drug taking 
[21-22], habitual / compulsive cocaine seeking and taking [6;23-25;101] and inter-individual 
vulnerability to addiction-like behaviour [8;26-28]. 
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3. Monodimensional animal models of addiction 
3.1 Craving and relapse 
Drug addicts show a high propensity to relapse, even after protracted abstinence [102]. This 
hallmark feature of addiction can be modelled in animals using two main procedures: 
extinction-reinstatement, initially developed by Stewart and colleagues [18-19] and 
abstinence-relapse [103]. Reinstatement of responding for drug can be induced by stress, 
low doses of the drug itself and by the presentation of drug-associated cues [20;104-112]. In 
the extinction-reinstatement procedure [18-19], animals experience a series of extinction 
sessions following a short period of drug self-administration, leading to a progressive 
decline in responding. Following extinction, responding for drug is reinstated by a stressful 
stimulus, a priming injection of drug, a presentation of a conditioned stimulus (CS) or by 
placing the animal in a drug-associated environment. 
Reinstatement of drug seeking depends upon a broad neurobiological network which 
subsets are recruited based on the nature of the trigger of reinstatement, be it stress, the 
drug or drug associated cues and context [105]. Overall, reinstatement to drug seeking 
depends upon the extended amygdala, prefrontal cortex and dopaminergic neurons 
[105;113-114]. A large impetus has recently been put on the prominent role of glutamate 
homeostasis in reinstatement to drug seeking, especially focusing on prefrontal – accumbens 
pathways [111;115-116]. 
Interestingly, it has been shown that levels of reinstatement induced by contingent 
presentations of drug-associated cues increase with prolonged time of withdrawal. This 
observation suggests that drug craving increases with withdrawal duration [117-118], an 
adaptation that was specifically related to increase dopamine transporter (DAT) and N-
Methyl-D-Aspartate receptor 1 (NMDA R1) protein levels in respectively the prefrontal 
cortex and the mesolimbic system [118]. However, incubation process has also been 
reported for food and fear, thereby suggesting that it is a common neurobehavioural 
adaptation to cessation of stimulation, whatever the nature of the unconditioned stimulus, 
rather than a specific neurobiological substrate of drug addiction. 
In the abstinence-relapse procedure [103], animals are given a forced abstinence period after 
a brief period of drug self-administration. They are then maintained in their home cage until 
they are exposed again to the self-administration chamber where they are tested under 
extinction. 
Whereas the reinstatement procedure clearly involves the Acb and both its dopaminergic 
and glutamatergic inputs, relapse to drug seeking depends upon the dorsolateral striatum 
[100;103]. Thereby, this neurobiological dissociation suggests that parallel, not necessarily 
mutually exclusive, neurobiological systems are involved in relapse to drug seeking. 
However, their respective contribution to the human craving and relapse situation remains 
unclear, especially the one of reinstatement since the situation in which human addicts go 
through extinction before responding to drug-associated stimuli or stress is very unfrequent. 
3.2 Escalation of drug taking 
The first well-established animal model of loss of control over drug intake, namely 
escalation of drug self-administration, is based on the fourth diagnostic criterion of drug 
addiction and was developed by Serge Ahmed and George Koob in 1998 for cocaine [21] 
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and 2000 for heroin [22]. Short access (“ShA“) to addictive drugs generally results in stable 
levels of self-administration such that plasma drug levels are controlled within an optimal 
level of reinforcement [119]. As mentioned previously, this pattern of self-administration 
does not account for the clinical features of drug addiction in humans. Ahmed and Koob 
thus gave extended access to cocaine to a group of animals (“LgA“, or long access) following 
a period of moderate exposure (ShA, fixed ratio 1, one hour a day). A second group of rats 
received short access to cocaine throughout the experiment. 
Introduction of the long access was immediately associated with higher drug intake, as 
compared to ShA rats. In other words, the LgA rats escalated their rate of cocaine self-
administration compared with ShA rats, which maintained a constant level of cocaine intake. 
LgA rats also exhibited higher rates of cocaine self-administration during the first hour of each 
session. Escalation of cocaine intake has been associated with an upward shift in the 
intracranial self-administration threshold (ICSS), indicative of reward dysfunction [21] that has 
been postulated by the hedonic allostasis theory [2;86-88]. However, escalation of cocaine self-
administration is not associated with psychomotor sensitisation but, instead, with a 
sensitization of the incentive motivational properties of cocaine [120], thereby suggesting a 
dissociation between loss of control over drug intake and behavioural sensitisation. 
Escalation of drug intake has also been associated with higher resistance to shock-induced 
suppression of drug self-administration and conditioned suppression [24;121], and therefore 
might contribute to the instantiation of addiction. 
However, all rats subjected to extended access to heroin do not necessarily escalate their 
intake [122]. Thus, when the upper and lower quartile of a population of Lister-Hooded rats 
are selected on the basis of the escalation slope (a direct measure of the magnitude of 
escalation of drug intake over time), marked differences can be observed [122]. Whereas low 
escalation (LE) rats show a marked increase in their intake when extended access is 
introduced and then reach a plateau in their daily drug intake, high escalation (HE) rats 
tend to show a slower adaptation to extended access, in that they do not increase their 
intake as quickly as LE rats, but progressively lose control over heroin self-administration 
(figure 2). This first formal description of inter-individual differences in the propensity to 
escalate heroin intake lead to the investigation of the behavioural markers of loss of control 
over heroin and cocaine intake (see “Vulnerabilities to drug addiction” section). This 
observation may resonate well with the demonstration that escalation of drug intake does 
not necessarily render rats insensitive to alternative reinforcers, i.e., despite escalation of 
cocaine self-administration rats have been reported to prefer a saccharine solution when 
given the choice between this reinforcer and the drug [123]. This suggests that schedule-
induced escalation of drug intake, when considered without the individual dimension, does 
capture one criterion of drug addiction, namely, drug is used in larger amounts, but not 
necessarily extends to other criteria. However, inter-individual differences can also be 
observed in the resistance to alternative reinforcers after extended access to cocaine [93]. 
3.3 Animal models of drug seeking: The distinction between drug seeking and drug 
taking behaviour: Second-order and two-link heterogeneous chained schedules of 
reinforcement 
Drug addiction does not involve only taking drugs, drug addicts spend most of their time 
foraging for the drug. It is therefore vital to dissociate drug taking from drug seeking. In 
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trying to separate drug seeking from drug taking, schedules of reinforcement must be 
implemented in which operant responding for the drug during the drug seeking phase is 
not affected by the drug itself, i.e., so that drug seeking behaviour can be measured without 
interference by stimulant or sedative actions of the self-administered drug. 
 
Fig. 2. Inter-individual propensity to lose control over heroin intake, after (122) 
Marked inter-individual differences were revealed when the upper (high-escalation rats, HE, n=5) and 
lower quartile (low-escalation rats, LE, n=5) of a population of lister hooded rats were selected based on 
the slope of drug intake over all 18 days of the LgA phase [group: F1,8 = 59.44, P < 0.001]. Thus, HE and 
LE rats displayed a different profile both in terms of heroin intake (A) and escalation ratio (B) [group x 
session interaction: F22,176 = 8.26, P < 0.001 and F16,128 = 10.20, P < 0.001, respectively]. Post-hoc analysis 
confirmed that HE rats displayed a daily increase in both intake and escalation ratio from the 4th and 
6th day of extended access, respectively (vs. LgA d1, all Ps < 0.05), whereas LE rats showed no 
escalation at all.  
Two-link heterogeneous chained schedules of reinforcement aim to dissociate spatially, 
temporally, and instrumentally drug seeking from drug taking behaviour. Second-order 
schedules of reinforcement allow the investigation of cue-controlled drug seeking over 
prolonged periods of time. 
3.3.1 Two-link heterogeneous chain schedules of reinforcement 
In this procedure completion of the first link of the chain, designated as the seeking link, 
results in access to the second link, or taking link, which permits, once performed, the delivery 
of the reinforcer. Acquisition of the chain schedule is achieved through successive steps of 
increasing complexity which start with introduction of the taking lever. A lever press is then 
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and 2000 for heroin [22]. Short access (“ShA“) to addictive drugs generally results in stable 
levels of self-administration such that plasma drug levels are controlled within an optimal 
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Introduction of the long access was immediately associated with higher drug intake, as 
compared to ShA rats. In other words, the LgA rats escalated their rate of cocaine self-
administration compared with ShA rats, which maintained a constant level of cocaine intake. 
LgA rats also exhibited higher rates of cocaine self-administration during the first hour of each 
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suppression of drug self-administration and conditioned suppression [24;121], and therefore 
might contribute to the instantiation of addiction. 
However, all rats subjected to extended access to heroin do not necessarily escalate their 
intake [122]. Thus, when the upper and lower quartile of a population of Lister-Hooded rats 
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escalate heroin intake lead to the investigation of the behavioural markers of loss of control 
over heroin and cocaine intake (see “Vulnerabilities to drug addiction” section). This 
observation may resonate well with the demonstration that escalation of drug intake does 
not necessarily render rats insensitive to alternative reinforcers, i.e., despite escalation of 
cocaine self-administration rats have been reported to prefer a saccharine solution when 
given the choice between this reinforcer and the drug [123]. This suggests that schedule-
induced escalation of drug intake, when considered without the individual dimension, does 
capture one criterion of drug addiction, namely, drug is used in larger amounts, but not 
necessarily extends to other criteria. However, inter-individual differences can also be 
observed in the resistance to alternative reinforcers after extended access to cocaine [93]. 
3.3 Animal models of drug seeking: The distinction between drug seeking and drug 
taking behaviour: Second-order and two-link heterogeneous chained schedules of 
reinforcement 
Drug addiction does not involve only taking drugs, drug addicts spend most of their time 
foraging for the drug. It is therefore vital to dissociate drug taking from drug seeking. In 
 
Animal Models of Drug Addiction 29 
trying to separate drug seeking from drug taking, schedules of reinforcement must be 
implemented in which operant responding for the drug during the drug seeking phase is 
not affected by the drug itself, i.e., so that drug seeking behaviour can be measured without 
interference by stimulant or sedative actions of the self-administered drug. 
 
Fig. 2. Inter-individual propensity to lose control over heroin intake, after (122) 
Marked inter-individual differences were revealed when the upper (high-escalation rats, HE, n=5) and 
lower quartile (low-escalation rats, LE, n=5) of a population of lister hooded rats were selected based on 
the slope of drug intake over all 18 days of the LgA phase [group: F1,8 = 59.44, P < 0.001]. Thus, HE and 
LE rats displayed a different profile both in terms of heroin intake (A) and escalation ratio (B) [group x 
session interaction: F22,176 = 8.26, P < 0.001 and F16,128 = 10.20, P < 0.001, respectively]. Post-hoc analysis 
confirmed that HE rats displayed a daily increase in both intake and escalation ratio from the 4th and 
6th day of extended access, respectively (vs. LgA d1, all Ps < 0.05), whereas LE rats showed no 
escalation at all.  
Two-link heterogeneous chained schedules of reinforcement aim to dissociate spatially, 
temporally, and instrumentally drug seeking from drug taking behaviour. Second-order 
schedules of reinforcement allow the investigation of cue-controlled drug seeking over 
prolonged periods of time. 
3.3.1 Two-link heterogeneous chain schedules of reinforcement 
In this procedure completion of the first link of the chain, designated as the seeking link, 
results in access to the second link, or taking link, which permits, once performed, the delivery 
of the reinforcer. Acquisition of the chain schedule is achieved through successive steps of 
increasing complexity which start with introduction of the taking lever. A lever press is then 
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reinforced under a fixed ratio (FR) 1 schedule so that each lever press produces drug 
reinforcement accompanied by the withdrawal of the taking lever. After several sessions of 
stable responding, the seeking lever is introduced while the taking lever is retracted. The first 
press on the seeking lever initiates a random interval (RI) schedule with the first seeking lever 
press occurring after the RI has elapsed terminating the first link of the chain; this results in 
retraction of the seeking lever and insertion of the taking lever to initiate the second link. One 
press on the taking lever results in the presentation of the reinforcer followed by a time-out 
period. Thereafter, the seeking lever is reinserted to start the next cycle of the schedule. The 
effects of experimental manipulation can thus be assessed through measures of seeking 
responding (latency, number or response rate) as well as taking responding (latency). The 
interest in dissociating seeking and taking behaviour is obvious when considering that the two 
instrumental components are influenced by dissociable processes since they are differentially 
sensitive to devaluation, incentive learning or Pavlovian manipulations [124]. In addition, 
cocaine seeking performance is monotonically related to the dose of drug with a relatively 
long time out [125]. Whereas early cocaine seeking performance is profoundly affected by 
extinction of the taking link [126-127] but not by inactivation of the dorsolateral striatum [127], 
after extended training it becomes automatic, i.e., insensitive to extinction of the taking lever 
and sensitive to inactivation of the dorsolateral striatum [127], thereby suggesting a shift in 
both the psychological and neurobiological mechanisms governing drug seeking when it 
becomes well established [128]. 
3.3.2 Second-order schedule of cocaine reinforcement 
In the street, drug seeking behaviour is stimulus-bond in that drug addicts forage for their 
drug under the control of stimuli in the environment, acting as conditioned reinforcers, that 
support long sequences of behaviour in the absence of the outcome. More formally, 
conditioned reinforcers are stimuli that have themselves acquired rewarding properties after 
repeated associations with unconditioned rewards. Conditioned reinforcers bridge delays 
between seeking and obtaining the drug. Psychostimulants, opiates, speedball, cannabis, or 
nicotine-associated CSs act as powerful conditioned reinforcers since they greatly enhance 
drug seeking behaviour when presented contingently, but not non-contingently, upon 
instrumental responding during, usually, interval schedules of reinforcement [6;30;32;129-
130]. Conditioned reinforcers can also support the acquisition of a new instrumental 
response [131-132]. Such properties are clearly demonstrated in procedures where animals 
work to obtain presentation of a conditioned stimulus, often in the absence of the 
unconditioned reward. 
In second-order schedules of reinforcement, the CS is presented response-contingently 
usually under a fixed ratio schedule, during an overall fixed interval or fixed ratio schedule 
for the primary reinforcer, and markedly enhances and maintains responding for long 
periods of time (figure 3). Thus, under a second-order schedule of reinforcement, a strong 
contingency exists between the instrumental response and the presentation of the CS (under 
a fixed ratio) as well as the relatively weaker contingency that is arranged between 
instrumental performance and the outcome (the drug) that is reinforced only after 
completion of the first ratio after each interval has elapsed. Such schedules therefore 
facilitate the development of stimulus-response (S-R) control over instrumental responding. 
In addition, it has been shown that omission of CS presentation in second-order schedules of 
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reinforcement disrupts cocaine seeking more than food seeking behaviour [130], suggesting 
that prolonged psychostimulant seeking is particularly dependent upon conditioned 
reinforcement. 
Thus, instrumental responding during the first interval of a second-order schedule of 
reinforcement shows face and construct validity with regards to the behavioural features of 
drug seeking in humans: stimulus-bound, somewhat dissociated from the unconditioned 
effects of the drug and long lasting. 
 
Fig. 3. Acquisition of cocaine seeking under a second-order schedule of reinforcement. 
Instrumental performance of a population of 24 Lister Hooded rats during the first interval of a FI15 
and FI15(FR10:S) schedule of reinforcement (see text for explanation). Once animals have acquired self-
administration under continuous reinforcement, the reinforcement schedule is switched to fixed 
intervals, with daily increments: FI1 min, FI2 min, FI4 min, FI8 min, FI10 min, and FI15 min. After 3 
days of training under the FI15 schedule (left part of the figure), contingent presentations of the CS are 
introduced under a FR10 schedule such that rats are now trained under a FI15(FR10:S) second-order 
schedule of reinforcement. This acquisition procedure provides a direct measure of the potentiation of 
responding during interval schedules by the contingent presentation of the CS since they are introduced 
only once responding under fixed interval has stabilized. Thus, although the average response rate is 50 
during the first interval of a FI15 schedule, it reaches 90-100 when the CS is contingently presented 
(Belin-Rauscent & Belin, unpublished). 
Second-order schedules of cocaine and heroin self-administration were initially developed 
by Goldberg and colleagues in non human primates to assess the influence of environmental 
stimuli upon drug self-administration [30;129-130]. Everitt and colleagues have also 
established second-order schedules of drug reinforcement in rats [133]. In the study by 
Arroyo and colleagues (1998), rats were initially required to learn cocaine to self-administer 
under continuous reinforcement, i.e., FR1. After stabilisation of responding, (5 to 7 daily 2 
hours sessions), a second-order schedule with fixed ratio components of the type FRx(Fry:S) 
was introduced, with initial values of x and y set to 1, so that each active lever press resulted 
in the presentation of the CS and and the delivery of 0.25 mg of cocaine. Then x and y values 
were progressively increased with increments in response requirements starting with x i.e., 
FR5(FR1:S) and FR10(FR1:S), then y, i.e., FR10(FR2:S), FR10(FR4:S), FR10(FR7:S) and 
FR10(FR10:S). After stabilisation of responding under this FR10(FR10:S) schedule of 
 
Addictions – From Pathophysiology to Treatment 30
reinforced under a fixed ratio (FR) 1 schedule so that each lever press produces drug 
reinforcement accompanied by the withdrawal of the taking lever. After several sessions of 
stable responding, the seeking lever is introduced while the taking lever is retracted. The first 
press on the seeking lever initiates a random interval (RI) schedule with the first seeking lever 
press occurring after the RI has elapsed terminating the first link of the chain; this results in 
retraction of the seeking lever and insertion of the taking lever to initiate the second link. One 
press on the taking lever results in the presentation of the reinforcer followed by a time-out 
period. Thereafter, the seeking lever is reinserted to start the next cycle of the schedule. The 
effects of experimental manipulation can thus be assessed through measures of seeking 
responding (latency, number or response rate) as well as taking responding (latency). The 
interest in dissociating seeking and taking behaviour is obvious when considering that the two 
instrumental components are influenced by dissociable processes since they are differentially 
sensitive to devaluation, incentive learning or Pavlovian manipulations [124]. In addition, 
cocaine seeking performance is monotonically related to the dose of drug with a relatively 
long time out [125]. Whereas early cocaine seeking performance is profoundly affected by 
extinction of the taking link [126-127] but not by inactivation of the dorsolateral striatum [127], 
after extended training it becomes automatic, i.e., insensitive to extinction of the taking lever 
and sensitive to inactivation of the dorsolateral striatum [127], thereby suggesting a shift in 
both the psychological and neurobiological mechanisms governing drug seeking when it 
becomes well established [128]. 
3.3.2 Second-order schedule of cocaine reinforcement 
In the street, drug seeking behaviour is stimulus-bond in that drug addicts forage for their 
drug under the control of stimuli in the environment, acting as conditioned reinforcers, that 
support long sequences of behaviour in the absence of the outcome. More formally, 
conditioned reinforcers are stimuli that have themselves acquired rewarding properties after 
repeated associations with unconditioned rewards. Conditioned reinforcers bridge delays 
between seeking and obtaining the drug. Psychostimulants, opiates, speedball, cannabis, or 
nicotine-associated CSs act as powerful conditioned reinforcers since they greatly enhance 
drug seeking behaviour when presented contingently, but not non-contingently, upon 
instrumental responding during, usually, interval schedules of reinforcement [6;30;32;129-
130]. Conditioned reinforcers can also support the acquisition of a new instrumental 
response [131-132]. Such properties are clearly demonstrated in procedures where animals 
work to obtain presentation of a conditioned stimulus, often in the absence of the 
unconditioned reward. 
In second-order schedules of reinforcement, the CS is presented response-contingently 
usually under a fixed ratio schedule, during an overall fixed interval or fixed ratio schedule 
for the primary reinforcer, and markedly enhances and maintains responding for long 
periods of time (figure 3). Thus, under a second-order schedule of reinforcement, a strong 
contingency exists between the instrumental response and the presentation of the CS (under 
a fixed ratio) as well as the relatively weaker contingency that is arranged between 
instrumental performance and the outcome (the drug) that is reinforced only after 
completion of the first ratio after each interval has elapsed. Such schedules therefore 
facilitate the development of stimulus-response (S-R) control over instrumental responding. 
In addition, it has been shown that omission of CS presentation in second-order schedules of 
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reinforcement disrupts cocaine seeking more than food seeking behaviour [130], suggesting 
that prolonged psychostimulant seeking is particularly dependent upon conditioned 
reinforcement. 
Thus, instrumental responding during the first interval of a second-order schedule of 
reinforcement shows face and construct validity with regards to the behavioural features of 
drug seeking in humans: stimulus-bound, somewhat dissociated from the unconditioned 
effects of the drug and long lasting. 
 
Fig. 3. Acquisition of cocaine seeking under a second-order schedule of reinforcement. 
Instrumental performance of a population of 24 Lister Hooded rats during the first interval of a FI15 
and FI15(FR10:S) schedule of reinforcement (see text for explanation). Once animals have acquired self-
administration under continuous reinforcement, the reinforcement schedule is switched to fixed 
intervals, with daily increments: FI1 min, FI2 min, FI4 min, FI8 min, FI10 min, and FI15 min. After 3 
days of training under the FI15 schedule (left part of the figure), contingent presentations of the CS are 
introduced under a FR10 schedule such that rats are now trained under a FI15(FR10:S) second-order 
schedule of reinforcement. This acquisition procedure provides a direct measure of the potentiation of 
responding during interval schedules by the contingent presentation of the CS since they are introduced 
only once responding under fixed interval has stabilized. Thus, although the average response rate is 50 
during the first interval of a FI15 schedule, it reaches 90-100 when the CS is contingently presented 
(Belin-Rauscent & Belin, unpublished). 
Second-order schedules of cocaine and heroin self-administration were initially developed 
by Goldberg and colleagues in non human primates to assess the influence of environmental 
stimuli upon drug self-administration [30;129-130]. Everitt and colleagues have also 
established second-order schedules of drug reinforcement in rats [133]. In the study by 
Arroyo and colleagues (1998), rats were initially required to learn cocaine to self-administer 
under continuous reinforcement, i.e., FR1. After stabilisation of responding, (5 to 7 daily 2 
hours sessions), a second-order schedule with fixed ratio components of the type FRx(Fry:S) 
was introduced, with initial values of x and y set to 1, so that each active lever press resulted 
in the presentation of the CS and and the delivery of 0.25 mg of cocaine. Then x and y values 
were progressively increased with increments in response requirements starting with x i.e., 
FR5(FR1:S) and FR10(FR1:S), then y, i.e., FR10(FR2:S), FR10(FR4:S), FR10(FR7:S) and 
FR10(FR10:S). After stabilisation of responding under this FR10(FR10:S) schedule of 
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reinforcement which therefore requires 100 active lever presses and 10 one second 
presentations of the CS to obtain a cocaine infusion, a final fixed interval schedule 
FI15(FR10:S) was introduced such that a cocaine infusion was delivered only following the 
tenth active lever press that occurred when the 15 min interval had elapsed. Finally rats 
were allowed to perform cocaine seeking behaviour under this schedule for ten days. This 
acquisition procedure produces robust and stable CS-dependent rates of responding [133] 
and has been used extensively to probe the neural mechanisms involved in the acquisition, 
and the performance of, cue-controlled cocaine-seeking [101;134-135]. 
It is also possible to decrease the acquisition period to 11 days [101;136] (figure 3). In this 
case the training phase consists of three days of FR1 training, 2 hour daily sessions, 30 
infusions (0.25 mg cocaine / infusion) followed by the introduction of interval schedules, 
with daily increments: FI1 min, FI2 min, FI4 min, FI 8 min, FI10 min, FI15 min. After three 
days of training under the FI15 schedule, contingent presentations of the CS are introduced 
under a FR10 schedule such that rats are now trained under a FI15(FR10:S) second-order 
schedule of reinforcement. This acquisition procedure provides a direct measure of the 
potentiation of responding during interval schedules by the contingent presentation of the 
CS since they are introduced only once responding under fixed interval has stabilised. 
Thus, although the average response rate is 50-70 during the first interval of a FI15 schedule, 
it reaches 100-150 when the CS is contingently presented (figure 3), as described in several 
studies from Everitt’s laboratory [101;137-138]. Indeed, short and long-term training under 
second-order schedules of reinforcement for cocaine have been very useful for investigating 
the neural mechanisms involved in the transition from newly acquired to well established or 
habitual cue-controlled cocaine seeking. Thus, acquisition of cue-controlled cocaine seeking 
depends upon the core of the Acb (AcbC) and its functional relationships with the 
basolateral amygdala [139] as well as dopamine transmission into the posterior dorsolateral 
striatum [137]. However, when it is well established, or habitual, cue-controlled cocaine 
seeking rather depends upon dopamine transmission into the dorsolateral striatum and its 
functional relationship with the AcbC, as demonstrated by functional disconnections 
between these two structures [101]. 
A dorsomedial to dorsolateral striatal shift in the control over drug seeking has recently 
been demonstrated to occur in alcohol self-administration after eight weeks of training 
[140a] and cocaine seeking after two weeks of training under an FI15(FR10:S) schedule of 
reinfocement [140b], a stage at which alcohol seeking was shown to be impervious to 
devaluation, i.e., was habitual. Thus addiction to both stimulants and alcohol may be 
dependent upon a shift from goal-directedness to habits that parallels, at the neural systems 
level, a progressive recruitment of the dorsolateral striatum. These data obtained in 
preclinical models resonate well with the recent demonstration of dorsal striatum 
implication cue-induced in alcohol [141] or cocaine [142] craving in humans. 
3.4 Animal models of compulsive drug seeking and drug taking 
As emphasised previously, addicted individuals not only consume large amounts of drugs 
but are also unable to repress their drug use regardless its consequences. Thus addiction 
shares common features with other compulsive disorders which are characterised as the 
uncontrollable and irresistible urge to performance an act, often to relieve anxiety or stress, 
but regardless of the rationality of the motivation. 
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The compulsive aspect of drug use in addicted subjects is even more obvious when 
similarities between addiction and obsessive compulsive disorder (OCD) are considered. 
Indeed, compulsive behaviour in the 4th version of the DSM [97] as a criterion for OCD is 
defined by the repetitive behaviours or mental acts that the person feels driven to perform 
in response to an obsession, or according to rules that must be applied rigidly aiming at 
preventing or reducing distress or some dreaded event or situation; but are either not 
connected to the issue or are excessive. Similarities between addiction and OCD have led, 
based on a modified version of the Yale–Brown Obsessive Compulsive Scale (Y-BOCS-hd) 
[143-144], to the development of the Obsessive Compulsive Drinking Scale (OCDS), a self-
rated questionnaire which is able accurately to discriminate between alcoholic out-patients 
and social drinkers with high sensitivity and specificity [145], suggesting that obsessionality 
and compulsivity are key features of the heavily addicted individual [145]. 
Clinical data on abstinence from cocaine use suggest that the negative consequences directly 
related to use are a major reason for cessation [146]. Indeed, drug use is a high risk 
behaviour as it often compromised health, work and social relationships [147-148]. 
Preclinical models of drug addiction might therefore attempt to resemble in several respects 
the human conditions of compulsivity and fulfil some important features of the pathology in 
order to meet the necessary requirements of construct, face and predictive validity essential 
for the clinical application of data obtained from animal studies [1]. Of course, in animals it 
is extremely difficult to exactly reproduce compulsive drug seeking and taking as seen in 
human drug addicts because of obvious limitations including the absence of direct personal 
costs such as family or society problems associated with drug abuse, or limited alternative 
reinforcement choices. 
However, despite such limitations, compulsivity in preclinical models of drug addiction 
should and must be defined as an inability to cease drug seeking and taking under 
conditions in which the drug is constantly available but its obtainment is associated with 
adverse consequences. 
In recent years, progress has been made in an attempt to mimic human conditions of 
compulsive drug use. 
3.4.1 Maintained drug use despite adverse consequences 
1. Resistance to devaluation / adulteration 
In addition to their reinforcing properties, most addictive drugs have toxic effects, which 
after repeated use can lead to severe health complications. Such aversive properties would 
normally progressively devalue any reinforcer, and facilitate the engagement of the subject 
in alternative responses, incompatible with the pursuit of the initial reinforcer. However, 
despite often acknowledging the deleterious outcome of drug use, addicts rarely achieve 
spontaneous voluntary abstinence, and when they manage to do so, often relapse to 
compulsive drug use. 
Similarly, rats differentially respond to devaluation of drugs of abuse and natural 
reinforcers. Performance for food is markedly affected by pairing its ingestion with illness 
produced by injection of lithium chloride. In contrast, devaluation of orally administered 
alcohol and cocaine does not greatly decrease drug seeking performance [140;149-150]. 
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reinforcement which therefore requires 100 active lever presses and 10 one second 
presentations of the CS to obtain a cocaine infusion, a final fixed interval schedule 
FI15(FR10:S) was introduced such that a cocaine infusion was delivered only following the 
tenth active lever press that occurred when the 15 min interval had elapsed. Finally rats 
were allowed to perform cocaine seeking behaviour under this schedule for ten days. This 
acquisition procedure produces robust and stable CS-dependent rates of responding [133] 
and has been used extensively to probe the neural mechanisms involved in the acquisition, 
and the performance of, cue-controlled cocaine-seeking [101;134-135]. 
It is also possible to decrease the acquisition period to 11 days [101;136] (figure 3). In this 
case the training phase consists of three days of FR1 training, 2 hour daily sessions, 30 
infusions (0.25 mg cocaine / infusion) followed by the introduction of interval schedules, 
with daily increments: FI1 min, FI2 min, FI4 min, FI 8 min, FI10 min, FI15 min. After three 
days of training under the FI15 schedule, contingent presentations of the CS are introduced 
under a FR10 schedule such that rats are now trained under a FI15(FR10:S) second-order 
schedule of reinforcement. This acquisition procedure provides a direct measure of the 
potentiation of responding during interval schedules by the contingent presentation of the 
CS since they are introduced only once responding under fixed interval has stabilised. 
Thus, although the average response rate is 50-70 during the first interval of a FI15 schedule, 
it reaches 100-150 when the CS is contingently presented (figure 3), as described in several 
studies from Everitt’s laboratory [101;137-138]. Indeed, short and long-term training under 
second-order schedules of reinforcement for cocaine have been very useful for investigating 
the neural mechanisms involved in the transition from newly acquired to well established or 
habitual cue-controlled cocaine seeking. Thus, acquisition of cue-controlled cocaine seeking 
depends upon the core of the Acb (AcbC) and its functional relationships with the 
basolateral amygdala [139] as well as dopamine transmission into the posterior dorsolateral 
striatum [137]. However, when it is well established, or habitual, cue-controlled cocaine 
seeking rather depends upon dopamine transmission into the dorsolateral striatum and its 
functional relationship with the AcbC, as demonstrated by functional disconnections 
between these two structures [101]. 
A dorsomedial to dorsolateral striatal shift in the control over drug seeking has recently 
been demonstrated to occur in alcohol self-administration after eight weeks of training 
[140a] and cocaine seeking after two weeks of training under an FI15(FR10:S) schedule of 
reinfocement [140b], a stage at which alcohol seeking was shown to be impervious to 
devaluation, i.e., was habitual. Thus addiction to both stimulants and alcohol may be 
dependent upon a shift from goal-directedness to habits that parallels, at the neural systems 
level, a progressive recruitment of the dorsolateral striatum. These data obtained in 
preclinical models resonate well with the recent demonstration of dorsal striatum 
implication cue-induced in alcohol [141] or cocaine [142] craving in humans. 
3.4 Animal models of compulsive drug seeking and drug taking 
As emphasised previously, addicted individuals not only consume large amounts of drugs 
but are also unable to repress their drug use regardless its consequences. Thus addiction 
shares common features with other compulsive disorders which are characterised as the 
uncontrollable and irresistible urge to performance an act, often to relieve anxiety or stress, 
but regardless of the rationality of the motivation. 
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The compulsive aspect of drug use in addicted subjects is even more obvious when 
similarities between addiction and obsessive compulsive disorder (OCD) are considered. 
Indeed, compulsive behaviour in the 4th version of the DSM [97] as a criterion for OCD is 
defined by the repetitive behaviours or mental acts that the person feels driven to perform 
in response to an obsession, or according to rules that must be applied rigidly aiming at 
preventing or reducing distress or some dreaded event or situation; but are either not 
connected to the issue or are excessive. Similarities between addiction and OCD have led, 
based on a modified version of the Yale–Brown Obsessive Compulsive Scale (Y-BOCS-hd) 
[143-144], to the development of the Obsessive Compulsive Drinking Scale (OCDS), a self-
rated questionnaire which is able accurately to discriminate between alcoholic out-patients 
and social drinkers with high sensitivity and specificity [145], suggesting that obsessionality 
and compulsivity are key features of the heavily addicted individual [145]. 
Clinical data on abstinence from cocaine use suggest that the negative consequences directly 
related to use are a major reason for cessation [146]. Indeed, drug use is a high risk 
behaviour as it often compromised health, work and social relationships [147-148]. 
Preclinical models of drug addiction might therefore attempt to resemble in several respects 
the human conditions of compulsivity and fulfil some important features of the pathology in 
order to meet the necessary requirements of construct, face and predictive validity essential 
for the clinical application of data obtained from animal studies [1]. Of course, in animals it 
is extremely difficult to exactly reproduce compulsive drug seeking and taking as seen in 
human drug addicts because of obvious limitations including the absence of direct personal 
costs such as family or society problems associated with drug abuse, or limited alternative 
reinforcement choices. 
However, despite such limitations, compulsivity in preclinical models of drug addiction 
should and must be defined as an inability to cease drug seeking and taking under 
conditions in which the drug is constantly available but its obtainment is associated with 
adverse consequences. 
In recent years, progress has been made in an attempt to mimic human conditions of 
compulsive drug use. 
3.4.1 Maintained drug use despite adverse consequences 
1. Resistance to devaluation / adulteration 
In addition to their reinforcing properties, most addictive drugs have toxic effects, which 
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in alternative responses, incompatible with the pursuit of the initial reinforcer. However, 
despite often acknowledging the deleterious outcome of drug use, addicts rarely achieve 
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compulsive drug use. 
Similarly, rats differentially respond to devaluation of drugs of abuse and natural 
reinforcers. Performance for food is markedly affected by pairing its ingestion with illness 
produced by injection of lithium chloride. In contrast, devaluation of orally administered 
alcohol and cocaine does not greatly decrease drug seeking performance [140;149-150]. 
 
Addictions – From Pathophysiology to Treatment 34
Similarly, extended access to free choice between drug solutions and water interrupted by 
periods of withdrawal in rats results in high levels of drug intake even when solutions are 
adulterated with bitter tasting quinine, evidencing the compulsive pattern of alcohol 
drinking after protracted exposure to the drug [151-153]. 
2. Conditioned suppression 
Until drug users explicitly experience the aversive consequences of drug use, drug taking is 
mainly moderated through warnings rather than actual punishment. Once experienced, 
aversive stimuli temporally distant from drug intake can appear, thereby rendering aversive 
contingencies less distinguishable. Moreover, the aversive consequences of drug use are 
counter-conditioned by previously extended drug presentation, which has been described as 
retarding the development of the conditioned emotional response [154]. All these processes 
may facilitate the attribution of aversive consequences to irrelevant stimuli. Adding a 
stimulus previously associated with an aversive outcome to the training context should 
normally reduce the frequency of a conditioned response. Indeed, although the aversive 
stimuli are not directly associated with drug use itself, a conditioned suppressor may be 
viewed as ‘devaluing’ the drug reinforcer since subjects would be required to respond for 
the drug in a state of conditioned fear [121]. 
However, Vanderschuren and Everitt (2004) found that the presentation of a Pavlovian 
conditioned fear stimulus after an extended self-administration training history failed to 
suppress cocaine self–administration, whereas after a brief cocaine taking history it did. 
These data support the view that while instrumental behaviour directed at obtaining drugs 
is initially a flexible, goal-directed form of behaviour, following prolonged drug exposure, 
drug seeking becomes insensitive to signals of punishment, thereby indicating its 
compulsive nature. However, it remains unclear whether in the multi-operant environment 
that drug addicts are normally exposed to, presentation of aversive conditioned stimuli may 
favour avoidance rather than abstinence. 
4. Punishment 
Aversive stimuli might eventually be perceived as directly associated with drug use. 
Punishment has often been debated as a treatment procedure, both in terms of its ethical 
acceptability and its efficacy. Nevertheless, it remains an undoubtedly important component 
of the every day life of drug addicts. 
In animals, even though differing in many procedural parameters such as the locus or 
intensity of punishment, foot shock-induced punishment has been used in several recent 
models of compulsive drug seeking and drug taking behaviour. Thus we will focus here on 
this punisher, although foot shock-induced suppression may not easily be generalised to the 
human condition. 
In most of the studies on drug taking despite adverse consequences, mild foot shocks, set at 
a constant intensity, are applied contingently upon a response reinforced by a constant dose 
of drug. In this case resistance to punishment is assessed through the persistence of the 
instrumental response despite contingent delivery of the punisher. Alternatively, the degree 
of response suppression is both dependent upon the magnitude of the reinforcer, the 
intensity of the punishment event, the schedule of their respective presentation and the 
delay between the instrumental responses and their consequences [155]. 
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Consequently, Cooper et al. [156] increased daily by 0.04 mA the intensity of a shock that 
was initially set to 0.25 mA until rats stopped responding (lever pressing) during the 30 min 
daily sessions for three consecutive days. Whereas such a procedure has the advantage of 
assigning for each rat the final shock intensity that led to self-imposed abstinence, it 
constrains the opportunity for repeated testing when required. 
The punishment contingency has been used at different loci of the instrumental drug taking 
action. Thus taking [157] or seeking behaviour [24] have been specifically punished. Since 
preparatory and consummatory responses have been shown to be under the influence of 
dissociable processes [158], it is conceivable they are differentially sensitive to punishment. 
In order to assess the sensitivity of seeking and taking responses to punishment Pelloux et 
al. used punishment in the seeking taking task that spatially and temporally dissociates the 
“preparatory” and “consummatory” behaviours [125]. Pelloux et al. conducted a study 
where either 50% of the seeking sequences where associated with the delivery of a shock 
instead of the activation of the taking lever or 50% of the instrumental responses on the 
taking lever were punished. With this probabilistic schedule of punishment both types of 
punishment induced a progressive suppression in performance but punishment of the 
taking response resulted in less suppression than punishment of the seeking response. 
Finally, the efficacy of the punishment of drug seeking or taking seems to greatly depend on 
drug history. After short exposure to amphetamine or an opiate (remifentanil) punishment 
produces robust suppression of self-administration that resumed for the opiate in all 
subjects approximately 5 days after punishment was discontinued [159]. However, the 
punishment effect obtained for amphetamine lasted much longer [157]. After extended 
access to cocaine, punishment produced suppression of a seeking response except in a 
subgroup of animals (about 25%). Thus, compulsive drug seeking appears, as in humans, 
only after extended exposure to the drug in a small proportion of subjects conferring on 
these models good predictive validity. 
5. Multidimensional animal model of drug addiction: addiction-like behaviour 
As previously presented, there are two main strategies when developing preclinical models 
of drug addiction. The first category refers to models developed to understand the 
psychobiological, neurological, cellular and molecular processes involved in a particular 
aspect of the pathology. Therefore, these models specifically address one aspect of the 
pathology, whether a diagnostic criterion, such as escalation of intake, resistance to 
punishment, high motivation for the drug, habitual instrumental performance, vulnerability 
to relapse, or impaired cognitive flexibility. They may also be relevant to influential theories 
such as behavioural sensitisation [44;96;160-161] and hedonic allostasis [2;86-88]. Such 
models generally assume that drug exposure triggers rather similar behavioural, neural or 
molecular effects in all the subjects tested. 
However, these models cannot address other crucial aspects of drug addiction, such as inter-
individual differences in the vulnerability to develop the pathology and their behavioural 
and biological correlates. They also fail to capture the multi-symptomatic nature of drug 
addiction. Thus, the second category of animal models of drug addiction takes into accounts 
both inter-individual differences and the complementary strategy of meeting diagnostic 
criteria of the pathology in humans according to the DSM-IV. Thus, to be diagnosed as 
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‘addicted’ an individual must fulfil three out of seven diagnostic criteria of drug addiction 
over the last 12 months. This approach forms the basis of a new pre-clinical animal model 
based on vulnerability to addiction-like behaviour in the rat [26]. 
In this model, three diagnostic criteria, namely [i] an inability to refrain from drug seeking, 
[ii] high motivation for the drug, and [iii] maintained drug use despite negative 
consequences, have been operationalised by, respectively, [i] drug seeking during periods 
when the drug is not available and signalled as so, [ii] break points during progressive ratio 
schedules of reinforcement, and [iii] persistence of self-administration despite punishment 
by contingent electric foot-shocks. 
When the population is large enough, as it has been the case in several of our studies [26;28], 
a systematic analysis of the distributions of each of the three addiction-like behaviours 
revealed that the distribution of the motivation for the drug and the persistence of drug 
seeking (n=40) were best fitted by a log-normal regression (Khi² and K-S: p>0.05, R2 = 0.96 
and 0.99, respectively) (figure 4, left and middle panel). In contrast the distribution of 
resistance to punishment was bimodal, composed of a first log-normal distribution (n=27 or 
67.5% of the total population, K-S: d = 0.22451, p>0.1), and a second normal sub-distribution 
(n=13 or 32.5% of the total population, K-S: d = 0.15604 p>0.1) (figure 4, right panel) which 
general regression fit can be described as a 3 order polynomial equation y=3.24x3 + 37.33x2 
+130.86x +146.67 [28]. 
 
Fig. 4. Distribution of each of the addiction-like criteria, after (28) 
The distribution of motivation for the drug and persistence of drug seeking (left and middle panel, 
respectively) (n=40) were best fitted by a log-normal regression (Khi2 and K-S: P>0.05). In contrast the 
distribution of resistance to punishment was bimodal, composed of a first log-normal distribution (n=27 
or 67.5% of the total population, K-S: d=0.22451, p> 0.1) , and a second normal sub-distribution (n=13 or 
32.5% of the total population, K-S: d=0.15604, p>0.1) (right panel) which general regression fit can be 
described as a 3 order polynomial equation: y=3.24x3+37.33x2+130.86x+146.67 
The bimodal nature of the distribution of resistance to punishment we demonstrated in this 
study is in agreement with the observation of Pelloux et al. [24]. Bimodal distributions are 
very common in life science literature, especially during speciation process [162] whereby 
one whole population is somehow giving birth to two independent populations [163]. Rare 
in behavioural neuroscience, bimodal distributions have however been observed for drug-
induced behaviours [164], suggesting that the neurobiological substrates of behavioural 
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inter-individual differences need in some cases to be challenged in order to reveal bimodal 
distribution. Our results suggest that a specific subpopulation in the rat has diverged so that 
it has become specifically more vulnerable to maintain drug use despite averse 
consequences, as measured as resistance to punishment, when chronically exposed to the 
drug. This hypothesis, although speculative, when transferred to the human situation may 
actually resonate well with the Nesse and Berridge’s suggestion that the vulnerability to 
drug addiction is a matter of evolution [165]. 
In practical terms, this bimodal distribution is particularly handy because it provides us 
with an objective criterion to determine a threshold in the population in order to carry out a 
dichotomous, categorial, strategy to identify animals that show addiction-like behaviour, 
i.e., 30-40% highest part of the population, depending on the study. Thus, for each of these 
three addiction-like criteria animals are ranked according to their score. If a rat’s score is 
included in the 30-40% highest percentile of the distribution, this rat is considered positive 
for that addiction-like criterion and is given an arbitrary criterion score of 1. Then the 
arbitrary criteria scores for each of the three addiction-like criteria are added, and 
consequently four distinct groups are identified according to the number of positive scores: 
0 criteria, 1 criterion, 2 criteria and 3 criteria rats (figure 5). 
 
Fig. 5. Selection strategy of rats addicted (3crit rats) and rats resistant (0crit rats) to cocaine 
Data analysed from (11). For each of these three addiction-like criteria animals are ranked according to 
their score. If a rat’s score is included in the 30-40% highest percentile of the distribution, this rat is 
considered positive for that addiction-like criterion and is given an arbitrary criterion score of 1. Then 
the arbitrary criteria scores for each of the three addiction-like criteria are added, and consequently four 
distinct groups are identified according to the number of positive scores: 0 criteria, 1 criterion, 2 criteria 
and 3 criteria rats 
Behaviourally, the categorial selection is associated with a criteria-dependent magnitude in 
each of the addiction-like criteria (figure 6). Our model is based on the comparison of three 
criteria (3crit) and 0 criteria (0crit) rats. 3crit rats show high scores for each of the three 
addiction-like criteria and are therefore considered “addicted“, whereas 0crit rats are 
considered resistant to addiction. 3crit rats represent approximately 20% of the population 
exposed to cocaine, an incidence observed in several independent studies with Lister-
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Hooded or Sprague-Dawley rats as well as either nose-poke or lever press as instrumental 
response [26;28;101;166], that is remarkably similar to that reported in humans [167]. 
 
Fig. 6. Behavioural characterisation of addiction-like behaviour in the rat 
A dichotomous approach to the diagnosis of addiction-like behaviour can be implemented in preclinical 
models of addiction on the understanding that some, but not all, animals chronically exposed to drug 
self-administration eventually develop one or more behavioural features resembling a clinical criterion 
for drug addiction as defined in the DSM-IV (see table 13.1). Thus we have operationally defined three 
addiction-like criteria, namely, (i) an inability to refrain from drug seeking (A), (ii) maintained drug use 
despite aversive consequences (B) and (iii) increased motivation to take the drug (C). Rats positive for 
none of the three criteria (0 criteria rats) are resistant to addiction, whereas rats that have three 
addiction-like criteria (3 criteria rats) are considered “addicted,” and represent 15 to 20% of the 
population initially exposed to cocaine (D). Importantly these behavioural differences are not 
attributable to differential levels of cocaine intake, since throughout protracted exposure 3 criteria and 0 
criteria rats do not differ in this measure (E). Although selected on three addiction-like criteria, 3criteria 
rats display complementary features of drug addiction, such as inability to limit drug intake when 
offered extended access to cocaine (F) and high vulnerability to relapse, as measured by reinstatement 
of cocaine seeking behaviour by increasing doses of non contingent cocaine infusions (G). A-E: after 
(11), F: after (8) 
Although 3crit rats do not differ significantly from 0crit rats in terms of cocaine self-
administration [26;28;166], 3crit rats eventually develop higher motivation for the drug, an 
inability to refrain from drug-seeking, and resistance to punishment [8;26;28;101;166]. 
More importantly, although selected on three addiction-like behaviours, 3crit rats also 
display enhanced escalation of cocaine self-administration as compared to 0crit rats (figure 
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6F). 3crit rats therefore fulfil a fourth criterion of addiction, namely an inability to control 
drug intake [26] classically established after extended access to the drug [21]. This results 
demonstrate that loss of control over drug intake does not necessarily follow extended 
access to the drug, but instead develops in some vulnerable subjects exposed to cocaine self-
administration for prolonged periods of time. 
The predictive validity of the model is further supported by de demonstration that 3crit rats 
also show a high vulnerability to relapse in response to non-contingent infusions of cocaine 
(figure 6G) [8] or contingent presentations of a drug-associated stimulus [26]. Thus, even 
though selected on three addiction-like criteria, after chronic exposure to cocaine, 3crit rats 
display important features of clinical addiction as defined in the DSM-IV. These 
observations provide the model with both construct and predictive validities. 
Moreover, since addiction-like behaviour emerges in three criteria rats only after extended 
exposure to the drug, i.e., after at least 50 daily self-administration sessions, these results 
highlight the importance of the interaction between a vulnerable phenotype and chronic 
drug exposure in the development of compulsive drug self-administration. 
6. Vulnerabilities to drug addictions  
Like many other psychiatric disorders, we are not all equally vulnerable to develop drug 
addiction. Epidemiological studies have revealed that between 15 to 35% of the population 
exposed to addictive drugs will develop compulsive drug use [167]. The results described in 
the previous section illustrate very well that inter-individual differences in vulnerability to 
develop compulsive cocaine self-administration can also be observed in rats. Thus, in any 
given population of rats exposed to cocaine only some develop addiction-like behaviour, 
thereby demonstrating that animal models provide a realistic estimate of risk for addiction 
in humans [41;166;169]. 
As already discussed, the underlying aetiology of the different pathways to addiction are 
likely to involve interactions between a vulnerable phenotype, environmental influences 
and drug exposure itself [170-171]. It is therefore important to identify the psychobiological 
substrates of vulnerability to develop compulsive drug use both in drug naive subjects and 
drug experienced individuals, thereby being able to develop preventive and therapeutic 
strategies at different stages of drug use history. 
6.1 Psychobiological factors of vulnerability to drug addiction: contribution of 
behavioural traits 
Epidemiological studies in human populations have revealed striking associations between 
drug use [172-173b], and certain behavioural traits [174-189] such as anxiety [190-193], 
impulsivity [187;194-195] and sensation-seeking [176;183;196-199]. The relevance of these 
traits for animal models of addiction is discussed below. 
6.1.1 Anxiety 
Anxiety can be assessed in preclinical models using various procedures which include the 
elevated plus maze (EPM) [200-201]. During the classic 5-min test session on the EPM a 
variety of behaviours are measured including the ratio of open and closed arms entries, time 
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variety of behaviours are measured including the ratio of open and closed arms entries, time 
 
Addictions – From Pathophysiology to Treatment 40
spent in the open and closed arms, as well as self-grooming which are all indices of anxiety. 
High levels of anxiety including high grooming behaviour and a low percentage of time 
spent in the open arms of the EPM have been associated with an enhanced propensity to 
acquire cocaine CPP [202] as well as an increased motivation to self-administer cocaine 
[203], but see [204]. Trait anxiety has also been associated with an enhanced preference for 
alcohol [205-206], consistent with the notion that alcohol use may self-medicate underlying 
mood disorders related to anxiety and stress [207-208]. 
We have recently established that high anxiety in the EPM predicts escalation of cocaine, but 
not heroin self-administration in the rat (figure 7) [209]. 
 
Fig. 7. High anxiety trait predicts loss of control over cocaine, but not heroin, self- 
administration in the rat, after (122) 
High anxious (HA) and low anxious (LA) rats were selected in the upper and lower 33% of a Lister 
Hooded population (A & D). Whereas HA did not differ from either LA and the overall population in 
their escalation of heroin intake throughout 12 sessions of 6 h extended access to the drug (B) HA rats 
showed a marked increase in their cocaine intake as compared to LA or the overall population (E). 
Thus, high anxiety is related to the magnitude of cocaine escalation (F) whereas it is not related to the 
slope of escalation of heroin intake (C). 
These data suggest that if high anxiety trait may contribute to the choice of the drug used, 
i.e., preference for alcohol or opiates [210], it does not necessarily contribute to the 
development of compulsive use when the drug is initially used as a self-medication [211]. 
However, the striking relationship between high anxiety levels in the EPM and subsequent 
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vulnerability to escalate cocaine intake suggest that high anxiety may facilitate a tolerance to 
anxiogenic properties of cocaine [212] perhaps because of a ceiling effect, or, instead 
enhance the potential anxiolytic properties of cocaine that have been suggested for low 
doses of the drug [213]. 
6.1.2 Sensation seeking / Novelty-seeking 
Sensation- and novelty-seeking traits have been the focus of a large number of pre-clinical 
studies on addiction vulnerability (for review, see [12]). 
In preclinical studies, sensation/novelty seeking trait has been suggested to be modelled 
both by high locomotor reactivity to a new inescapable environment (high responder 
phenotype, HR) [214-215], and high propensity to visit a new environment in a free-choice, 
novelty-induced CPP, paradigm (high novelty preferring phenotype, HNP) [12;216]. 
Piazza and colleagues were the first to investigate the role of sensation-seeking in this 
context by measuring the locomotor response of rats to an inescapable novel environment 
[217]. In this model, rats are placed for two hours in a new environment and their horizontal 
activity is monitored. Based on inter-individual differences in locomotor response animals 
are either selected as high (HR) or low responders (LR) according to a median division [217]. 
HR rats show a greater propensity to acquire psychostimulant self-administration [217] 
since they more readily self-administer low doses of amphetamine than LR rats [2;217]. 
Moreover, HR rats show a greater propensity for drug-induced neural plasticity [218-219] 
and increased stress-evoked dopamine release in the Acb than LR rats [220]. 
However, sensation seeking does not predict the acquisition of CPP for addictive drugs, 
which instead is predicted by novelty-seeking [12;216;221-223], the latter being a 
behavioural trait dissociable from the former [9;28;224]. 
Novelty-seeking is normally assessed by measuring the preference of rats for a novel versus 
familiar compartment using a procedure quite similar to CPP [225], although broad 
methodological differences are observed in the literature that can impact onto the nature of 
the behavioural construct one is investigating. Indeed, depending on the study, novelty 
preference has been measured as (1) the number and time duration of visits of a new arm in 
a Y-maze during the first 2 or 5 min, respectively, of a test session taking place 30 min after 
the habituation to the other two arms of the set-up [226], (2), novelty-induced place 
preference tested for 15 min on the third day of a protocol during which animal were 
exposed 30 min daily to one compartment of a CPP box [223-224] whereas locomotor 
reactivity to novelty has been measured in (1) circular corridors [226-227], playground maze 
[228] or (2) activity chambers [216;229], each environment differing from one other in terms 
of light intensity, openness and area. 
Overall, animals selected as novelty-seekers, or novelty-preferring (HNP), are those that fall in 
the upper quartile range. Unlike animals selected from the lower quartile of the population, 
high novelty seekers readily develop a conditioned place preference to amphetamine [224;228] 
and self-administration of cocaine under an autoshaping procedure [230]. 
Thus, although both traits are dependent upon the dopaminergic system [12], they are 
mutually exclusive [12;216], but see [231] and therefore may predict different dimensions of 
vulnerability to drug addiction [12]. 
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We have investigated the respective role of HR and HNP phenotypes in inter-individual 
vulnerability to switch from controlled to compulsive cocaine SA. A cohort of rats were 
tested for their locomotor response to inescapable novelty and, subsequently for their 
preference propensity to express novelty-induced CPP. 
After extended cocaine self-administration these rats were tested for each of the three 
addiction-like criteria. Whereas LR and HR rats were highly represented in the 0 and 1crit 
populations, 60% of the LNP rats were included in the 0crit population as opposed to 70% of 
the HNP rats that showed 2 or 3 addiction-like criteria, none belonging to the 0crit 
population (figure 8A). This asymmetric distribution specific to LNP and HNP rats was 
further investigated, as illustrated in figure 8B-D which depict the representativity of LR, 
HR, LNP and HNP rats within the distributions for each of the addiction-like criteria. 
Importantly, HNP rats, as opposed to LNP rats, represented the great majority of the 




Fig. 8. High novelty preference (HNP) and sensation seekers (HR) rats are not equally 
distributed within the different addiction-like criteria. 
A. Addiction score.The great majority of HNP rats are represented in the 2 and 3crit subgroups of the 
population whereas HR rats are equally distributed throughout the different groups. B-C. HNP and 
LNP rats are distributed asymmetrically within the population relative to persistence of drug seeking 
(B) and motivation for the drug (C). LNP rats are clustered on the right side of the distribution whereas 
HNP rats are also represented in the right part of the distribution. Such asymmetry is not observed for 
LR and HR rats which are equally distributed throughout the overall population for these two criteria. 
D. Distribution of LNP, HNP, LR and HR rats for compulsive cocaine self-administration. Whereas LR 
and HR rats did not show any difference in their distribution throughout the population, HNP rats 
were highly clustered in the compulsive subpopulation as emphasised by the encircling square. Thus 
HNP rats may be highly vulnerable to compulsive cocaine self-administration. Analysis of data from 
(28) 
Thus although no differences were observed between HR and LR rats for their scores in 
each of their addiction-like criteria, HNP rats displayed higher scores than LNP rats in each 
of the addiciton-like criteria, namely resistance to punishment, inability to refrain from 
cocaine-seeking even if the drug is not available since they persisted, responded, more on 
the active nose-poke than LNP rats during “no-drug“ periods and motivation for cocaine 
(figure 9D). 
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Fig. 9. Novelty Preference, but not locomotor reactivity to novelty predicts the switch to 
compulsive cocaine self-administration. 
ANOVAs with HNP/LNP groups as between-subject factors revealed that HNP rats showed higher 
addiction score than LNP rats [F1,18=10.59, p<0.01] (A). Compared to LNP rats, HNP rats developed 
compulsive cocaine SA as measured by high level of resistance to punishment [F1,18=11.16, p<0.01] (B) 
and were unable to stop seeking cocaine when it was not available and signaled as so [F1,18=9.03, p<0.01] 
(C). HNP rats tend to show higher motivation for cocaine than LNP though this difference did not reach 
statistical significance (D). These behavioral differences between HNP and LNP rats could not be 
attributable to differential cocaine intake since the two groups have been exposed to the same amount 
of cocaine throughout the experiment [F1,18<1] (E). When compared to LR rats, HR rats showed no 
difference in the addiction-like behavioral measures. These two groups had behavioral scores similar to 
those of LNP rats, thereby illustrating that locomotor reactivity to novelty, as opposed to novelty 
preference, doesn’t predict addiction-like behavior for cocaine. 
The relationship between high novelty preference trait and vulnerability to switch to 
compulsive cocaine SA was further supported by a clear relationship assessed with a non 
parametric Spearman correlation analysis R=0.32, p<0.05, with the percentage of time spent 
in the new environment of the novelty-induced place preference procedure and the 
percentage of infusions compared to baseline when punished contingently by electric foot 
shocks as variables. However, no relationship was observed between locomotor reactivity to 
novelty and resistance to punishment (Spearman R=-0.15, p=0.36). Importantly, the 
behavioural differences observed between HNP and LNP rats cannot be attributed to a 
difference in the total amount of cocaine intake since the two groups did not differ for their 
total cocaine intake during the 60 days preceding the assessment of the addiction-like 
criteria [F1,18<1] (figure 9E). 
Since a great majority of the HNP, and none of the LNP, rats was clustered in the 
compulsive subpopulation, HNP rats, even though identified from a normally distributed 
population, may represent a specific sub-population vulnerable to compulsive cocaine 
intake after protracted exposure to the drug. Thereby the high novelty preference trait in the 
rat, as identified as the upper quartile of the population tested with the present paradigm is 
a promising behavioural tool for the study of the neurobiological substrates of vulnerability 
to compulsive cocaine intake. 
While providing the first evidence for a causal relationship between novelty preference and 
compulsive cocaine use, this study confirms that locomotor reactivity to novelty does not 
predict the vulnerability to develop cocaine addiction, but does rather predict the 
propensity to self-administer drugs [27;217]. Altogether, these data suggest that the HR 
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phenotype and its underlying neurobiological mechanisms may be involved in facilitating 
cocaine use, but not in the transition to switch from controlled to compulsive cocaine use, 
the hallmark of cocaine addiction [97]. 
Thus two different behavioural measures suggested to reveal a putative sensation/novelty 
seeking trait in rats [12], namely novelty-induced locomotor activity and novelty preference, 
are differentially predictive of inter individual propensity to self-administer cocaine and to 
switch from controlled to compulsive cocaine use, respectively. 
These preclinical data suggest that the correlates of the increased propensity shown by 
human sensation seekers to use addictive drugs [175] should be dissociated from those 
associated with the transition from controlled to compulsive drug use. Indeed, not only is 
sensation seeking a heterogeneous, multifaceted, construct [232] but it is quantified 
according to different, not necessarily overlapping [233], personality scales including the 
Zuckerman, Eysenck, Arnett and Cloninger’s scales. A factorial analysis of the different 
items of the sensation seeking scale developed by Zuckerman [197] revealed four 
dimensions [234] namely Thrill and Adventure Seeking [TAS], Experience Seeking [ES], 
Disinhibition [Dis], and Boredom Susceptibility [BS], of which the TAS and DIS sub-scales 
have been suggested to refer to sensation seeking whereas the ES and BS sub-scales would 
refer to novelty seeking [234-235]. Further research is needed to investigate which of these 
sub-scales is the most predictive of the vulnerability to switch to compulsive cocaine use, 
thereby clearly refining the relationships between sensation seeking trait and vulnerability 
to cocaine addiction. 
6.1.3 Impulsivity 
A popular paradigm used to assess impulsivity in rodents is the 5-choice serial reaction time 
task (5-CSRTT), which was developed originally as an analogue of the human continuous 
performance task of sustained attention [236]. The 5-CSRTT requires animals to detect brief 
flashes of light presented pseudo-randomly in one of five holes and to make a nose-poke 
response in the correct spatial location in order to receive a food reward. The rat is thus 
required to monitor a horizontal array of apertures and to withhold from responding until 
the onset of the stimulus. Generally, the accuracy of stimulus discrimination provides an 
index of attentional capacity, while premature responses – made before the presentation of 
the stimulus – are regarded as a form of impulsive behaviour and hence a failure in impulse 
control [237-238]. The neural and neurochemical basis of impulsivity on the 5-CSRTT has 
been extensively investigated, involving important contributions from the anterior cingulate 
cortex (ACC), infralimbic cortex, Acb, medial striatum and by the ascending monoaminergic 
systems [239-240]. 
More recently, the 5-CSRTT has been used to screen for spontaneously high levels of 
impulsivity in rats, a phenotype associated with increased cocaine, sucrose and nicotine self-
administration [241-243]. Interestingly, Dalley and colleagues have recently shown using 
microPET brain imaging that high impulsive rats have lower dopamine D2/3-binding levels 
in the ventral striatum as compared to low impulsive littermates [241], thereby suggesting 
that alteration of dopamine D2/3-receptors in the Acb may contribute to high impulsivity 
and vulnerability to drug addiction. 
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We have used the animal model of addiction-like behaviour for cocaine described in 
previous sections to investigate whether high impulsivity trait predicts the switch to 
compulsive cocaine SA. 
A cohort of 40 Lister Hooded rats was screened in the 5-CSRTT for their impulse control. 
These rats were then tested for their locomotor response to a new, inescapable environment. 
Thus, prior to cocaine exposure, rats were identified as high (HI) and low (LI) impulsive or 
HR and LR (figure 10). 
 
Fig. 10. Impulsivity and novelty-induced locomotor activity: two distinct phenotypes. After 
(27) 
On two baseline days (B), premature responses in the 5_CSRTT were measured. (A and B) During long 
intertrail intervals (LITIS), HI rats showed more premature responses than LI rats (Group: F3,36 = 14.4, 
p<0.01; scedule: F8,288 = 130.22, p<0.01; Schedule x Group: F24,288 = 7.01, p<0.01) (***p<0,001) (A) and HR 
(p<0.01) or LR rats (p<0.05) (B). HR rats did not differ from LR rats or from LI subjects (B). (C and D) 
HR rats were more reactive to novelty tha LR rats (F3,35 = 17.63, p<0.01). HI and LI subjects never 
differed from each other. *Comparison with HR: *p<0.05, **p<0.01, ***p<0.001. (D) Pink and blue dotted 
lines represent the average premature responses during the last two intertrial intervals for HI and LI 
rats, respectively. 
High impulsivity trait and locomotor response to novelty were demonstrated to be 
independent behavioural traits. We then tested whether high locomotor response to novelty 
and high impulsivity traits predicted higher propensity to acquire cocaine self-
administration. We allowed animals to acquire cocaine SA with daily increasing doses of the 
drug. We demonstrated that HR rats acquire cocaine self-administration at doses at which 
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intertrail intervals (LITIS), HI rats showed more premature responses than LI rats (Group: F3,36 = 14.4, 
p<0.01; scedule: F8,288 = 130.22, p<0.01; Schedule x Group: F24,288 = 7.01, p<0.01) (***p<0,001) (A) and HR 
(p<0.01) or LR rats (p<0.05) (B). HR rats did not differ from LR rats or from LI subjects (B). (C and D) 
HR rats were more reactive to novelty tha LR rats (F3,35 = 17.63, p<0.01). HI and LI subjects never 
differed from each other. *Comparison with HR: *p<0.05, **p<0.01, ***p<0.001. (D) Pink and blue dotted 
lines represent the average premature responses during the last two intertrial intervals for HI and LI 
rats, respectively. 
High impulsivity trait and locomotor response to novelty were demonstrated to be 
independent behavioural traits. We then tested whether high locomotor response to novelty 
and high impulsivity traits predicted higher propensity to acquire cocaine self-
administration. We allowed animals to acquire cocaine SA with daily increasing doses of the 
drug. We demonstrated that HR rats acquire cocaine self-administration at doses at which 
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LR rats do not, thereby confirming that HR rats are more prone to acquire stimulants self-
administration than LR animals [217]. However, HI rats did not differ from LI in their 
propensity to acquire cocaine SA (figure 11). 
 
 
Fig. 11. Novelty-induced locomotor activity predicts the propensity to acquire cocaine self- 
administration, after (27) 
(A) HR rats showed an upward shift of the cocaine dose-response curve compared with LR littermates 
(Group: F1,16 = 4.9, p<0.05; Dose: F6,96 = 11.73, p<0.01; Group x Dose: F6,96 = 4.39, p<0.01). HR rats infused 
more cocaine at the lowest three doses than vehicle (p<0.01). (B) HI and LI subjects did not differ in the 
number of self-administered cocaine infusions (Group: F1,16<1; Dose: F6,96 =10.79, p<0.01; Group x Dose: 
F6,96<1) 
When subsequently exposed to protracted cocaine self-administration and tested for their 
addiction-like behaviour, rats were identified as 0, 1, 2 and 3crit rats and each animal was 
given an addiction score (figure 12). We then retrospectively compared HI vs LI and HR vs 
LR rats for their addiction score and revealed that HI rats had higher addiction score than LI 
whereas HR did not differ from LR rats. 
This increased addiction score observed in HI rats was specifically attributed to the 
development of compulsive cocaine SA in these rats since they maintained cocaine SA 
despite punishment to the same extent as 3crit rats did. However, HR and LR rats did not 
differ in this behavioural criterion. The specific relationship between high impulsivity and 
compulsivity was further demonstrated by a correlational analysis between the percentage 
of premature responses in the 5-CSRTT and resistance to punishment, as assessed by a non 
parametric correlation analysis (figure 12). 
This evidence suggests that the predisposition to initiate drug use is independent of the 
vulnerability to shift from controlled to compulsive drug taking, and therefore provides 
new insights into the various behavioural and psychological factors that influence the 
pathways to addiction. In particular, the demonstration that the high impulsive trait 
predicts the shift to compulsive drug taking behaviour is of major interest since a shift from 
impulse control failure to compulsivity has been suggested to play a major role in the 
development of drug addiction in humans [87;244] (figure 13). 
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Together with the demonstration that novelty preference predicts addiction-like behaviour 
for cocaine [28] the present data suggest that further investigations should focus on the 
additive or interactive contribution of high impulsivity and novelty seeking traits to the 
vulnerability to switch to compulsive cocaine SA. 
This suggestion is timely since we [245] have recently demonstrated that high impulsive 
rats, as identified in the 5-CSRTT, prefer a novel compartment in a novelty-induced CPP 
procedure [245] (figure 14). 
Thus both novelty preference and impulsivity, but not locomotor response to novelty, 
contribute to inter-individual propensity to switch from controlled to compulsive cocaine SA. 
However, this conclusion may be taken with caution since it might be true only for stimulants. 
Indeed, we [122] have recently demonstrated that high impulsivity trait does not predict inter-
individual differences in escalation of heroin self-administration (figure 15). This propensity 
was instead predicted by pharmacological flexibility in response to extended access to heroin, 
i.e., increased titration in response to increased availability of the drug. 
 
Fig. 12. Impulsivity predicts the transition to compulsivity 
After extended exposure to cocaine SA 0, 1, 2 and 3crit rats were identified and were distributed 
similarly to previously described (A) in that 3 crit rats represented 20% of the overall population. When 
ranked on a linear addiction scale (R2 = 0.99, Group: F3,19=34.43, p<0.01), three-criteria rats had addiction 
scores (2.8 ± 0.6) above the standard deviation (2.1), and higher than all the other groups (B). (C) HI rats 
displayed higher addiction score than LI rats (F1,9 = 7.55, *p<0.05), whereas HR rats did not differ from 
LR rats. (D) HI rats (n=5) displayed higher resistance to punishment than LI rats (n=6) (F1,9 = 12.79, 
p<0.01), whereas HR (n=5) rats did not differ from LR rats (n=5). (E) Impulsivity predicts compulsive 
cocaine self-administration (R= 0.42, p<0.05). Gray and black shadings represent LI and HI rats, 
respectively. 
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Fig. 13. Impulsivity and compulsivity in drug addiction. 
It has been suggested that a shift occurs from impulsivity to compulsivity in the control over drug seeking 
during the development of drug addiction (left). According to this theoretical framework, drug use is 
initially controlled by the positive reinforcing properties of drugs. However, when addiction develops 
drug taking is no longer controlled by positive reinforcement but, instead, is controlled by negative 
reinforcement and the need to avoid the negative consequences of withdrawal. Other theoretical 
frameworks suggest a contribution of both impulsivity and compulsivity to different stages of the 
addiction cycle (right). Impulsivity might then be associated with drug taking and relapse, whereas 
compulsivity might be associated with craving, bingeing and insensitivity to negative feedback.  
 
 
Fig. 14. High impulsive rats seek novelty 
HI rats explored the novel compartment of the CPP apparatus for significantly longer period of time 
compared with the familiar compartment, a preference that was not observed in LI rats (group x 
compartment interraction: F1,24 = 6.53, p=0,017; post hoc t-test p=0.031). Howerver, there was no 
significant difference between HI and LI rat in the total time spent in the novel compartment. LI rats 
showed a trend increase in time spent in the familiar compartment compared with HI rats (p=0.059).  
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Fig. 15. High impulsivity trait does not predict a greater propensity to escalate heroin SA. 
After (122) 
Extended access to heroin resulted in escalation of heroin SA over time in both HI and LI rats (a-d). 
After 5 days of 1-hour access to heroin, an 18-day 6-hour daily self-administration period was 
introduced. Following initiation of the LgA sessions, HI rats (n=5) and LI rats (n=5) did not differ in 
their time-dependent increase in active lever presses (a), heroin infusion (b), and intake (calculated as 
the amount of heroin self-administered by each rat in milligrammes per kilogramme bidy weight) (c). A 
dimentional analysis based on the overall population tested (n=19) did not reveal any correlation 
between the individual level of impulsivity (percentage of premature responses during the last two 7 s-
LITI sessions) and the propensity to escalated heroin SA (escalation score; calculated as the slope of 
intake over 18 days od LgA for each subject) (d). Consequently, HI and LI rats differed neither in their 
escalation slope (e) not in the increase of their ER (intake for each LgA day divided by intake for day 1) 
over the 18 LgA sessions (f). 
This observation is of interest since it suggests that pharmacological flexibility in response to 
changes in drug availability and individual propensity to titrate drug intake according to 
drug availability may protect against loss of control over heroin SA. Nevertheless, the 
marked dissociation between high impulsivity trait and individual propensity to lose 
control over heroin intake is in marked contrast with the demonstration that high 
impulsivity predicts increased vulnerability to lose control over cocaine SA [241]. Such 
dissociation suggests that heroin and cocaine addiction may not necessarily share common 
etiological factors, or, since impulsivity is a multifaceted construct [246], that other forms of 
impulsivity predict vulnerability to opiates addiction. 
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7. Conclusions 
Major advances in the understanding of the neurobiological substrates of addictive drugs 
and their short and long-term consequences on the brain have been provided by CPP or self-
administration models. Refined preclinical models, that go beyond drug reinforcement or 
neurobiological adaptations to repeated exposure to addictive drugs, hence with heuristic 
value with regards to the compulsive nature of drug seeking in drug addicts, have provided 
new insights into the aetiology and pathophysiology of drug addiction. Nevertheless, to 
date several critical behavioural aspects of drug addiction remain under-investigated, 
including the influence of alternative reinforcers during self-administration sessions and the 
role of environmental conditions, and especially environmental enrichment in inter-
individual vulnerability to switch to compulsive drug use. Additionally, the recent data we 
have acquired on inter-individual differences in loss of control over heroin intake and the 
marked dissociation between high impulsivity trait and escalation of heroin SA reveal the 
necessity to develop preclinical models of addiction-like behaviour for other classes of drugs 
than stimulants. Only then will we be able to determine whether drug addiction is one 
pathology characterised by common etiological and pathophysiological factors or whether it 
should instead be considered as multifaceted, with different etiological and 
pathophysiological pathways, depending, at least, on the drug [56]. 
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The term addiction, derived from a Latin word meaning ‘‘bound to’’ or ‘‘enslaved by,’’ was 
initially not linked to substance use. However, over the past several hundred years, 
addiction became associated with excessive alcohol and then drug use, such that by the late 
1980s it was largely synonymous with compulsive drug use (O’Brien et al., 2006). The core 
features of addiction are manifest in the continued performance of the behavior despite 
adverse consequences, compulsive engagement or diminished control over the behavior, 
and an appetitive urge or craving state prior to the behavioral engagement representing core 
elements (Holden, 2010). 
Addiction is a state of compulsive drug use; despite treatment and other attempts to control 
drug taking, addiction tends to persist. Hyman (2005) has summarized several studies 
where the authors have suggested that if the neurobiology is ultimately to contribute to the 
development of successful treatments for drug addiction, researchers must elucidate the 
molecular mechanisms by which drug-seeking behaviors are consolidated into compulsive 
use. Evidence at different levels of analysis suggest that addiction represents a pathological 
state of the neural mechanisms of learning and memory that, under normal circumstances, 
serve to shape survival behaviors related to the pursuit of rewards and the cues that predict 
them (Shultz et el., 1997; Montague et al., 2004; see Badiani et al., 2011 for review). The major 
substrates of persistent compulsive drug use are hypothesized to be molecular and cellular 
mechanisms that underlie long-term associative memories in several forebrain circuits 
(involving the ventral and dorsal striatum and prefrontal cortex) which receive inputs from 
midbrain dopamine neurons (see Hyman et al., 2006, for review). Also, the basolateral 
amygdala and nucleus accumbens core are key structures within limbic cortical-striatal 
circuitry where reconsolidation of a cue-drug memory occurs (Théberge et al., 2010). 
Vulnerability to stimulant addiction may depend on an impulsivity endophenotype. 
Impulsivity is the tendency to act prematurely without foresight, and is commonly 
associated with addiction to drugs, though its causal role in human addiction is unclear. 
Different groups (Dalley et al., 2007; Bezze et al., 2007 and Dalley et al., 2011) have 
characterized, in neurobehavioral and neurochemical terms, a rodent model of impulsivity 
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based on premature responses in an attentional task. Evidence suggests that high 
impulsivity on this task precedes the subsequent escalation of cocaine self-administration 
behavior (Dalley et al., 2007, and also a tendency towards compulsive cocaine-seeking (Belin 
et al., 2008) and to relapse (Economidou et al., 2009). On the other hand, excessive 
consumption of palatable food can trigger neuroadaptive responses in brain reward 
circuitries similar to those produced by drugs of abuse. Thus, congruent genetic 
vulnerabilities in brain reward systems can increase predisposition to drug addiction and 
obesity. Kenny (2011) has recently advanced our understanding of the brain circuitries that 
regulate hedonic aspects of feeding behavior, with evidence suggesting that obesity and 
drug addiction may share common mechanisms.  
Individuals take addictive drugs to elevate mood, but after repeated use these drugs 
produce serious unwanted effects, which include: tolerance to some drug effects, 
sensitization to others, and an adapted state–dependence, these setting the stage for 
withdrawal symptoms when drug use stops. The most serious consequence of repetitive 
drug taking is however addiction: a persistent state in which compulsive drug use escapes 
control, even when serious negative consequences ensue. Addiction is characterized by a 
long-lasting risk of relapse, which is often initiated by exposure to drug-related cues. 
Substantial progress has been made in understanding the molecular and cellular 
mechanisms of tolerance, dependence and withdrawal but, as yet, we understand little of 
the neural substrates of compulsive drug use and its remarkable persistence. Evidence exists 
for the possibility that compulsion and its persistence are based on a pathological 
usurpation of molecular mechanisms that are normally involved in memory (see Hyman 
and Malenka 2001 for review). 
Genetic studies to date have been most successful at identifying factors that influence the 
transition from regular use to dependence. Numerous and large twin studies have indicated 
a significant genetic contribution to the process of conversion from eventual use to 
established use before development of dependence. The availability of large cohort samples 
for nicotine and alcohol dependence has resulted in significant progress being made in 
understanding at least some of the genetic contributions to these addictions (Tsuang et al., 
1998, Kendler et al., 2003). Fewer studies have replicated specific genetic contributions to 
illicit drug use. Substance dependence can be thought of as a pharmacogenetic illness and, 
most likely, hundreds and more probably thousands of genetic variants will be required to 
fully explain the genetic input to this disease (see Bierut, 211 for review). 
1.1 Neurobiology of addiction 
Addictive drugs have in common the property that they are voluntarily self-administered 
by laboratory animals (usually avidly) (Di Chiara et al., 2004), and that they enhance the 
functioning of the reward circuitry of the brain (producing the 'high' that the drug user 
seeks). The core reward circuitry consists of an 'in-series' circuit linking the ventral 
tegmental area (VTA), nucleus accumbens (NAc) and ventral pallidum via the medial 
forebrain bundle. All addictive drugs have in common that they enhance (directly or 
indirectly or even transsynaptically) dopaminergic synaptic function in the NAc (Di Chiara 
et al., 2004), which is implicated in the reward process. Drug self-administration is regulated 
by NAc dopamine (DA) levels, which are retained within a specific elevated range (to 
maintain a desired hedonic level). The three classical sets of craving and relapse triggers are 
(a) reexposure to addictive drugs, (b) stress, and (c) reexposure to environmental cues 
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(people, places, things) previously associated with drug-taking behavior. Knowledge of the 
neuroanatomy, neurophysiology, neurochemistry and neuropharmacology of addictive 
drug action in the brain is currently producing a variety of strategies for 
pharmacotherapeutic treatment of drug addiction, some of which appear promising 
(Gardner, 2011). Addictive drugs target the mesocorticolimbic dopamine (DA) system. This 
system originates in the VTA and projects mainly to the NAc and prefrontal cortex (PFC), 
affecting glutamatergic and GABAergic synaptic transmission in all three brain areas. These 
changes are refered to as drug-evoked synaptic plasticity, which outlasts the presence of the 
drug in the brain and contributes to the reorganization of neural circuits. While in most 
cases these early changes are not sufficient to induce the disease, with repetitive drug 
exposure, they may add up and contribute to addictive behavior (see Lüscher and Malenka, 
2011 for review). 
1.2 Learning and memory in addictive behavior 
Two forms of cellular and synaptic plasticity, long-term potentiation (LTP) and long-term 
depression (LTD) remain the most extensively studied. They are considered the cellular and 
molecular basis of learning and memory (Kandel, 2004; Negrete-Díaz et al., 2007; Adermark 
et al., 2009; Abusch and Akirav, 2010; Collingridge et al., 2010; Huang et al., 2011, Figure 1).  
 
Fig. 1. LTP and LTD. Induction protocols and cellular mechanisms. Ai transverse hippocampal 
slice and estándar positioning of stimulating and recording electrodes. Hippocampus is the 
structure in which plasticity mechanisms have been more extensively estudied. Aii, 
representation of presynaptic and postsynaptic neurons at synapse between CA3 and CA1 
pyramidal cells. Bi, LTP protocol,  tetanic (100 Hz, 1s) stimulation of presynaptic neurons 
induce and increase of the amplitude of excitatory postsynaptic potencial EPSP (Bii) recorded 
from postsynaptic neurons. Ci, LTD protocol, stimulation at 1 Hz during 15 minutes induce a 
decrease of the amplitude of the EPSP (Cii) recorded from postsynaptic neurons. D, schematic 
description of intracellular mechanisms involved in LTP and LTD 
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In addition, they can be used to demonstrate the repertoire of enduring modifications of 
individual synapses, circuits or neural networks. A classic triad arrangement of DA terminal 
varicosities, dendritic spines, and cortical inputs allows dopamine to enhance spike-time-
dependent plasticity (STDP) at active cortico-striatal and cortico-cortical synapses. The 
induced LTP and LTD are candidate mechanisms for phasic DA signal to mediate 
behavioral learning. Thus, by affecting striatal and cortical plasticity, addictive drugs could 
lead to long-lasting changes of the motor, reward, and cognitive functions of these 
structures, striatum and PFC (Schultz, 2011). Conditioned stimuli (CSs) by Pavlovian 
association with reinforcing drugs (unconditioned stimuli; US) are thought to play an 
important role in the acquisition, maintenance and relapse of drug dependence. Bassareo et 
al. (2007) using microdialysis investigated the impact of pavlovian drug CSs on behaviour 
and on basal and drug-stimulated transmitter levels in three terminal DA areas: NAc shell 
and core, and the PFC. Drug CSs elicited incentive reactions and released DA; pre-exposure 
to CSs potentiated DA release to drug (Schultz, 2011). Théberge et al. (2010) demonstrated 
that the basolateral amygdala (BLA) and the NAc core are two structures importantly 
involved in the reconsolidation of a cocaine–CS memory. They show that, depending on the 
psychological processes involved, different neural substrates within limbic cortical-ventral 
striatal circuitry are required for the reconsolidation of a Pavlovian memory. Milton and 
Everitt, 2010, have shown with more detail the memory reconsolidation mechanisms 
underlying conditioned reinforcement and its relationship to drug addiction and the 
subsequent translation to the clinic of preclinical works.  
1.3 Dopamine in addiction  
DA's contribution appears to chiefly cause 'wanting' for hedonic rewards, more than 'liking' 
of or learning of those rewards (Schultz, 2011). However, the debate continues over the 
precise causal contribution made by mesolimbic DA systems to reward. Recent evidence 
indicates that DA is neither necessary nor sufficient to mediate changes in hedonic 'liking' 
for sensory pleasures. Other recent evidence indicates that DA is not needed for new 
learning, and not sufficient to directly mediate learning by causing teaching or prediction 
signals. Drugs of abuse promote DA signals, short circuit and sensitize dynamic mesolimbic 
mechanisms that evolved to attribute incentive salience to rewards (Berridge, 2007). The 
potential use of drugs to enhance cognition, emotion, and executive function has 
engendered controversy despite the fact that few such agents exist today. Hyman (2011) 
provided a context for discussions based on medical, regulatory, and ethical concerns that 
have been raised by the possibility that enhancers will emerge from current efforts to 
discover drugs for neuropsychiatric disorders. Addiction coopts the brain's neuronal circuits 
necessary for insight, reward, motivation, and social behaviors. This functional overlap 
results in addicted individuals making poor choices despite awareness of the negative 
consequences (Volkow et al., 2011). This explains why previously rewarding life situations 
and the threat of judicial punishment cannot stop drug taking and why a medical rather 
than a retributional approach is more effective in curtailing addiction.  
We describe in this chapter the effects of cannabinoids, cocaine and amphetamines on the 
nervous system with particular emphasis on the effects of these compounds in plasticity 
processes. As the DA transporter is central to the effects of these drugs, we dedicate some 
special attention to the physiology of this type of transporter.  
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2. Cannabinoids (Table 1) 
The use of marijuana for recreational and medicinal purposes has resulted in a large 
prevalence of chronic marijuana users (WHO, 2012). In the present decade, cannabis abuse 
has grown more rapidly than cocaine and opiate abuse. About 147 million people, 2.5% of 
the world population, consume cannabis (annual prevalence) compared with 0.2% 
consuming cocaine and 0.6% consuming amphetamine (WHO, 2012). The most rapid 
growth in cannabis abuse since the 1960s has been in developed countries in North America, 
Western Europe and Australia (WHO, 2012). Consequences of chronic cannabinoid 
administration include profound behavioral tolerance and withdrawal symptoms upon 
drug cessation. A marijuana withdrawal syndrome is only recently gaining acceptance as 
being clinically significant. Similarly, laboratory animals exhibit both tolerance and 
dependence following chronic administration of cannabinoids. These animal models are 
being used to evaluate the high degree of plasticity that occurs at the molecular level in 
various brain regions following chronic cannabinoid exposure (Lichtman and Martin, 2005).  
2.1 The endocannabinoid (eCB) signaling system 
The isolation and identification, in 1964 (Gaoni and Mechoulam, 1964), of delta-9-
tetrahydrocannabinol (Δ9-THC), the primary psychoactive compound in cannabis, opened 
the door to a whole new field of medical research. The exploration of the therapeutic 
potential of THC and other natural and synthetic cannabinoid compounds was paralleled by 
the discovery of the endocannabinoid system, comprising cannabinoid receptors and their 
endogenous ligands, which offered exciting new insights into brain function (see Isbell et al., 
1967 for review). Besides its well-known involvement in specific brain functions, such as 
control of movement (Di Marzo et al., 2000; Keeney et al., 2008; Fuss and Gass, 2010), 
memory (Deadwyler et al., 2007; Deadwyler and Hampson, 2008) and emotions (Paule et al., 
2005; Tan et al., 2010), the endocannabinoid system plays an important role in fundamental 
developmental processes such as cell proliferation, migration and differentiation (Trezza et 
al., 2008, 2012). For this reason, changes in its activity during stages of high neuronal 
plasticity, such as the perinatal and the adolescent period, can have long-lasting 
neurobehavioral consequences (see Trezza et al., 2008 for review). Two subtypes of 
cannabinoid receptors (CBRs) have been identified to date, the CB1 receptor, essentially 
located in the CNS, but also in peripheral tissues, and the CB2 receptor, found only at the 
periphery. Many of the effects of cannabinoids, such as delta (9)-THC (Δ9-THC), the 
psychoactive principle of cannabis sativa, and endocannabinoids (eCBs) are mediated by 
these two metabotropic receptors, although additional receptors may be implicated. Both 
CB1 and CB2 are G-protein-coupled receptors (GPCRs), primarily operating through 
inhibitory G proteins, and are subject to the same pharmacological influences of other 
GPCRs (Chaperon and Thiébot, 1999; Basavarajappa et al., 2009). Freund et al. (2003) 
described a fine-grain anatomical distribution of the neuronal cannabinoid receptor CB1 in 
brain areas, emphasizing its general presynaptic localization and role in controlling 
neurotransmitter release, synaptic plasticity and network activity patterns. The eCBs as 
ligands for these CB1 and CB2 receptors are a family of lipidic mediators that signal through 
the same cell surface receptors that are targeted by Δ9-THC. Unlike neurotransmitter 
molecules that are typically held in vesicles before synaptic release, eCBs are liberated 
directly after synthesis and, once released, travel in a retrograde direction to suppress 
presynaptic neurotransmitter release through activation of CBRs (Basavarajappa, 2007). 
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Table 1. Plastic changes on brain regions by chronic use of marijuana, Δ9-THC 
administration or CB1R pharmacological manipulation. 
(Abbreviations: BLA: basolateral amygdale; CB1R: type 1 cannabinoid receptor; eCB: endocannabinoid; 
GABA: gamma aminobutyric acid; LTP: long-term potentiation; LTD: long-term depression; mPFC: 
medial prefrontal cortex; PLC: prelimbic cortex; PFC: prefrontal cortex). 
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Recent results have suggested that the eCB system may play an important role in early 
neuronal development having been detected from the earliest stages of embryogenesis and 
throughout pre- and postnatal development. Additionally, the eCB signaling system is 
being found to be involved in an increasing number of neuropathological conditions, with 
widespread roles being invoked in neurodegenerative disorders. The fact that eCB signaling 
is mostly inhibitory, imparts eCBs with the ability to modulate synaptic efficacy with a wide 
range of functional consequences and provides unique therapeutic possibilities in central 
nervous system (CNS) diseases, including alcoholism, Alzheimer's disease, Parkinson's 
disease, Huntington's disease, and multiple sclerosis (see Basavarajappa, 2007; 
Basavarajappa et al., 2009 for reviews).  
Although CB1 receptors are distributed throughout the brain, they are found at very high 
levels in the cerebellum. Edwards and Skosnik (2007) have integrated two separate literatures. 
The first literature demonstrates that the eCB system mediates synaptic plasticity, specifically 
LTD of parallel fibers at the parallel fiber-Purkinje junction in the cerebellar cortex. The second 
literature suggests that LTD at this junction is necessary for the acquisition of the primary 
dependent variable in delay eyeblink conditioning. Also, they discuss recent evidence from 
CB1 knockout mice, human cannabis users, and schizophrenia patients, with the expectation 
that translational research on the cannabinoid system will be advanced. Wiskerke et al. (2008) 
summarize studies in which have been used CB1R knockout mice as well as CB1 antagonists 
to elucidate the role of this neurotransmitter system in psychostimulant addiction. CB1 
receptors appear not to be involved in psychostimulant reward, nor in the development of 
dependence to such substances. In contrast, the eCB system appears to play a role in the 
persistence of psychostimulant addiction (see Wiskerke et al., 2008 for review). Interactions of 
the eCB system with afferent glutamatergic and possibly dopaminergic projections to the 
nucleus accumbens are most likely involved and CB1 receptors seem to modulate drug-related 
memories, in line with the hypothesized role of the eCB system in memory-related plasticity. 
Together, these findings suggest that modulators of the eCB system represent a promising 
novel type of therapy to treat drug addiction.  
2.2 The reward system 
The reward circuitry of the brain consists of neurons that synaptically connect a wide 
variety of nuclei. Of these brain regions, the VTA and the NAc play key roles in the 
processing of rewarding environmental stimuli and in drug addiction. The psychoactive 
properties of marijuana are produced by Δ9-THC, interacting primarily with CB1 receptors 
in a large number of brain areas. However, it is the activation of CB1 receptors located in 
reward circuits that is thought to be instrumental in sustaining the self-administration of 
marijuana in humans, and in mediating the anxiolytic and pleasurable effects of the drug. It 
has been suggested that, whereas Δ9-THC alters the activity of central reward pathways in a 
manner that is consistent with other abused drugs, the cellular mechanism through which 
this occurs is likely different, relying upon the combined regulation of several afferent 
pathways to the VTA (see Lupica et al., 2004 for review). 
2.3 Cannabis, cannabinoids and neuronal plasticity 
Changes in synaptic efficacy are thought to be crucial to experience-dependent 
modifications of neural function. eCB-mediated plasticity encompasses many forms of 
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Recent results have suggested that the eCB system may play an important role in early 
neuronal development having been detected from the earliest stages of embryogenesis and 
throughout pre- and postnatal development. Additionally, the eCB signaling system is 
being found to be involved in an increasing number of neuropathological conditions, with 
widespread roles being invoked in neurodegenerative disorders. The fact that eCB signaling 
is mostly inhibitory, imparts eCBs with the ability to modulate synaptic efficacy with a wide 
range of functional consequences and provides unique therapeutic possibilities in central 
nervous system (CNS) diseases, including alcoholism, Alzheimer's disease, Parkinson's 
disease, Huntington's disease, and multiple sclerosis (see Basavarajappa, 2007; 
Basavarajappa et al., 2009 for reviews).  
Although CB1 receptors are distributed throughout the brain, they are found at very high 
levels in the cerebellum. Edwards and Skosnik (2007) have integrated two separate literatures. 
The first literature demonstrates that the eCB system mediates synaptic plasticity, specifically 
LTD of parallel fibers at the parallel fiber-Purkinje junction in the cerebellar cortex. The second 
literature suggests that LTD at this junction is necessary for the acquisition of the primary 
dependent variable in delay eyeblink conditioning. Also, they discuss recent evidence from 
CB1 knockout mice, human cannabis users, and schizophrenia patients, with the expectation 
that translational research on the cannabinoid system will be advanced. Wiskerke et al. (2008) 
summarize studies in which have been used CB1R knockout mice as well as CB1 antagonists 
to elucidate the role of this neurotransmitter system in psychostimulant addiction. CB1 
receptors appear not to be involved in psychostimulant reward, nor in the development of 
dependence to such substances. In contrast, the eCB system appears to play a role in the 
persistence of psychostimulant addiction (see Wiskerke et al., 2008 for review). Interactions of 
the eCB system with afferent glutamatergic and possibly dopaminergic projections to the 
nucleus accumbens are most likely involved and CB1 receptors seem to modulate drug-related 
memories, in line with the hypothesized role of the eCB system in memory-related plasticity. 
Together, these findings suggest that modulators of the eCB system represent a promising 
novel type of therapy to treat drug addiction.  
2.2 The reward system 
The reward circuitry of the brain consists of neurons that synaptically connect a wide 
variety of nuclei. Of these brain regions, the VTA and the NAc play key roles in the 
processing of rewarding environmental stimuli and in drug addiction. The psychoactive 
properties of marijuana are produced by Δ9-THC, interacting primarily with CB1 receptors 
in a large number of brain areas. However, it is the activation of CB1 receptors located in 
reward circuits that is thought to be instrumental in sustaining the self-administration of 
marijuana in humans, and in mediating the anxiolytic and pleasurable effects of the drug. It 
has been suggested that, whereas Δ9-THC alters the activity of central reward pathways in a 
manner that is consistent with other abused drugs, the cellular mechanism through which 
this occurs is likely different, relying upon the combined regulation of several afferent 
pathways to the VTA (see Lupica et al., 2004 for review). 
2.3 Cannabis, cannabinoids and neuronal plasticity 
Changes in synaptic efficacy are thought to be crucial to experience-dependent 
modifications of neural function. eCB-mediated plasticity encompasses many forms of 
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transient and long-lasting synaptic depression and is found at both excitatory and inhibitory 
synapses. Thus, the eCB system is emerging as a major player in synaptic plasticity and, 
given the wide distribution of CB1 receptors in the CNS, the list of brain structures and 
synapses expressing eCB-mediated plasticity is likely to expand (see Chevaleyre et al., 2006 
for review). Glutamate is the principal excitatory neurotransmitter in CNS and altered 
glutamatergic transmission during critical periods (such as first postnatal weeks) may 
disturb circuitry in specific brain areas (including cortex and hippocampus), particularly in 
experience-dependent maturation. Recent hypotheses regarding disturbances in 
strengthening and pruning of synaptic connections in the PFC, and the link with latent 
psychotic disorders suggest that cannabis-induced schizophrenia is due to a distortion of 
normal late postnatal brain maturation (see Bossong and Niesink, 2010 for review). In this 
respect, cannabis use during adolescence increases the risk of developing psychotic 
disorders later in life. In animals, Bossong and Niesink (2010) postulated that adolescent 
exposure to Δ9-THC transiently disturbs physiological control of the eCB system over 
glutamate and GABA release. As a result, Δ9-THC may adversely affect adolescent 
experience-dependent maturation of neural circuitries within prefrontal cortical areas. 
Depending on dose, exact time window and duration of exposure, this may ultimately lead 
to the development of psychoses like schizophrenia. 
There is substantial evidence that cannabis abuse is a risk factor for psychosis in genetically 
predisposed people, may lead to a worse outcome of the disease, or it can affect normal 
brain development during adolescence, increasing the risk for schizophrenia in adulthood. 
On the other hand, the eCB system is altered in schizophrenia (increased density of CB1 
receptors binding in corticolimbic regions). Dysregulation of this system can interact with 
neurotransmitter systems in such a way that a "cannabinoid hypothesis" can be integrated in 
the neurobiological hypotheses of schizophrenia. Also, there is evidence that some genetic 
alterations of the CNR1 gene can act as a protectant factor against schizophrenia or can 
induce a better pharmacological response to atypical antipsychotics (see Fernandez-Espejo 
et al., 2009 for review). Awareness of cannabis dependence as a clinically relevant issue has 
grown in recent years. Clinical and laboratory studies demonstrate that chronic marijuana 
smokers can experience withdrawal symptoms upon cessation of marijuana smoking and 
have difficulty abstaining from marijuana use. The behavioral effects that directly contribute 
to the maintenance of chronic marijuana smoking are reward, subjective effects, and the 
positive and negative reinforcing effects of marijuana, Δ9-THC or synthetic cannabinoids 
(Cooper and Haney, 2008). 
Studies using population codes derived from ensembles of hippocampal neurons have been 
assessed to determine whether eCBs were active when rats performed a short-term memory 
task in presence or absence of CB1 receptor antagonists or agonists. Results show that eCBs, 
like marijuana, reduced hippocampal encoding necessary to perform long-delay trials 
(Deadwyler et al., 2007). Also, CB1 receptor antagonism blocked an inherent hippocampal 
memory encoding bias used by all animals. These findings suggest a direct relationship 
between the actions of cannabinoids on hippocampal processes and the ability to encode 
information into short-term memory Deadwyler and Hampson, 2008. Considerable 
evidence demonstrates that cannabinoid receptor agonists impair, whereas cannabinoid 
receptor antagonists improve, memory and plasticity (Ademark et al., 2009; Fan et al., 2010). 
However, recent studies suggest that the effects of cannabinoids on learning do not 
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necessarily follow these simple patterns, particularly when emotional memory processes are 
involved. Abush and Akirav (2010) have investigated the involvement of the CB system in 
hippocampal learning and plasticity using behavioral task and cellular models of learning 
and memory (LTP and LTD). They found that i.p. agonist administration impaired LTP in 
the Schaffer collateral-CA1 projection, whereas an inhibitor of eCB reuptake facilitated LTD. 
These findings suggest that the diverse effects of the cannabinoid system on CA1 memory 
and plasticity cannot be categorized simply into an impairing or an enhancing effect of 
cannabinoid activation and deactivation, respectively. Previous studies have indicated that 
eCB mobilization at excitatory synapses might be regulated by afferent activation. LTD at 
striatal synapses is mediated by postsynaptic eCB release and presynaptic CB1 receptor 
activation. Adermark et al. (2009) have examined changes in synaptic strength induced by 
activation of L-type calcium channels at glutamatergic and gamma-aminobutyric acid 
(GABA)ergic synapses in the striatum. They found that the basic mechanisms for eCB 
signaling are the same at glutamatergic and GABAergic synapses. LTD was blocked in slices 
treated with AM251, a CB1 receptor antagonist, but established depression was not reversed 
at either glutamatergic and GABAergic synapses. It is suggested that the level of neuronal 
firing regulates eCB signaling by modulating release from the postsynaptic cell, as well as 
interacting with presynaptic mechanisms to induce LTD at both glutamatergic and 
GABAergic synapses in the striatum. 
Chronic use of marijuana impairs synaptic plasticity and cognitive function. Fan et al. (2010) 
found that repeated in vivo exposures to Δ9-THC for 7 consecutive days significantly 
impaired hippocampal LTP of excitatory glutamatergic synaptic transmission, and this 
decrease in LTP was prevented by pharmacological inhibition or deletion of the CB1 
receptor. They showed that reduced expression and function of the GluR subunits and 
phosphorylation of cAMP response element-binding (CREB) may underlie the impaired 
long-term synaptic plasticity induced by repeated in vivo exposure to Δ9-THC. In animal 
models, the CB system has been convincingly implicated in the regulation of long-lasting 
synaptic plasticity. Both LTP and LTD can be induced in the human motor cortex by 
transcranial magnetic theta burst stimulation (TBS). Koch et al. (2009) explored the potential 
involvement of the CB system in TBS-induced synaptic plasticity in humans with multiple 
sclerosis. Continuous TBS induced the expected inhibition of motor-evoked potentials 
(MEPs) before cannabis-based preparation exposure (Sativex), whereas it caused a persisting 
enhancement of MEP amplitude 4 weeks after. The LTP-like phenomenon induced by 
intermittent TBS was conversely unaffected by preparation exposure. These results indicate 
that cannabis ingredients have metaplastic effects on the motor cortex. Laviolette and Grace 
(2006), using in vivo single-unit recordings in rats, found that a CB1 receptor agonist 
potentiated the response of medial prefrontal cortical (mPFC) neurons to olfactory cues 
paired previously with a footshock, whereas this associative responding was prevented by a 
CB1 receptor antagonist, providing the first demonstration that CB signaling in the mPFC 
can modulate the magnitude of neuronal emotional learning plasticity and memory 
formation through functional inputs from the basolateral amygdala (BLA, Laviolette and 
Grace, 2006). 
Individuals with an “at risk mental state” (ARMS) are greatly more susceptible to 
developing a psychotic illness. There has been considerable interest in the interaction 
between psychosis risk and substance use. Cannabis at low to moderate intake may be 
associated with lower gray matter in both ARMS subjects and healthy volunteers, possibly 
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There is substantial evidence that cannabis abuse is a risk factor for psychosis in genetically 
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grown in recent years. Clinical and laboratory studies demonstrate that chronic marijuana 
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evidence demonstrates that cannabinoid receptor agonists impair, whereas cannabinoid 
receptor antagonists improve, memory and plasticity (Ademark et al., 2009; Fan et al., 2010). 
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necessarily follow these simple patterns, particularly when emotional memory processes are 
involved. Abush and Akirav (2010) have investigated the involvement of the CB system in 
hippocampal learning and plasticity using behavioral task and cellular models of learning 
and memory (LTP and LTD). They found that i.p. agonist administration impaired LTP in 
the Schaffer collateral-CA1 projection, whereas an inhibitor of eCB reuptake facilitated LTD. 
These findings suggest that the diverse effects of the cannabinoid system on CA1 memory 
and plasticity cannot be categorized simply into an impairing or an enhancing effect of 
cannabinoid activation and deactivation, respectively. Previous studies have indicated that 
eCB mobilization at excitatory synapses might be regulated by afferent activation. LTD at 
striatal synapses is mediated by postsynaptic eCB release and presynaptic CB1 receptor 
activation. Adermark et al. (2009) have examined changes in synaptic strength induced by 
activation of L-type calcium channels at glutamatergic and gamma-aminobutyric acid 
(GABA)ergic synapses in the striatum. They found that the basic mechanisms for eCB 
signaling are the same at glutamatergic and GABAergic synapses. LTD was blocked in slices 
treated with AM251, a CB1 receptor antagonist, but established depression was not reversed 
at either glutamatergic and GABAergic synapses. It is suggested that the level of neuronal 
firing regulates eCB signaling by modulating release from the postsynaptic cell, as well as 
interacting with presynaptic mechanisms to induce LTD at both glutamatergic and 
GABAergic synapses in the striatum. 
Chronic use of marijuana impairs synaptic plasticity and cognitive function. Fan et al. (2010) 
found that repeated in vivo exposures to Δ9-THC for 7 consecutive days significantly 
impaired hippocampal LTP of excitatory glutamatergic synaptic transmission, and this 
decrease in LTP was prevented by pharmacological inhibition or deletion of the CB1 
receptor. They showed that reduced expression and function of the GluR subunits and 
phosphorylation of cAMP response element-binding (CREB) may underlie the impaired 
long-term synaptic plasticity induced by repeated in vivo exposure to Δ9-THC. In animal 
models, the CB system has been convincingly implicated in the regulation of long-lasting 
synaptic plasticity. Both LTP and LTD can be induced in the human motor cortex by 
transcranial magnetic theta burst stimulation (TBS). Koch et al. (2009) explored the potential 
involvement of the CB system in TBS-induced synaptic plasticity in humans with multiple 
sclerosis. Continuous TBS induced the expected inhibition of motor-evoked potentials 
(MEPs) before cannabis-based preparation exposure (Sativex), whereas it caused a persisting 
enhancement of MEP amplitude 4 weeks after. The LTP-like phenomenon induced by 
intermittent TBS was conversely unaffected by preparation exposure. These results indicate 
that cannabis ingredients have metaplastic effects on the motor cortex. Laviolette and Grace 
(2006), using in vivo single-unit recordings in rats, found that a CB1 receptor agonist 
potentiated the response of medial prefrontal cortical (mPFC) neurons to olfactory cues 
paired previously with a footshock, whereas this associative responding was prevented by a 
CB1 receptor antagonist, providing the first demonstration that CB signaling in the mPFC 
can modulate the magnitude of neuronal emotional learning plasticity and memory 
formation through functional inputs from the basolateral amygdala (BLA, Laviolette and 
Grace, 2006). 
Individuals with an “at risk mental state” (ARMS) are greatly more susceptible to 
developing a psychotic illness. There has been considerable interest in the interaction 
between psychosis risk and substance use. Cannabis at low to moderate intake may be 
associated with lower gray matter in both ARMS subjects and healthy volunteers, possibly 
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representing low-level cortical damage or change in neural plasticity (Stone et al., 2011). The 
CB1 receptor system is functionally involved in the processing and encoding of emotionally 
salient sensory information, learning and memory. The CB1 receptor is found in high 
concentrations in brain structures that are critical for emotional processing, including the 
BLA and the mPFC. Synaptic plasticity in the form of LTP within the BLA-mPFC pathway is 
an established correlate of exposure to emotionally salient events (Laviolette and Grace, 
2006). In vivo LTP studies showed that systemic pretreatment with AM-251, dose-
dependently block LTP along the BLA-PLC pathway, and also the behavioral acquisition of 
conditioned fear memories (Tan et al., 2010). Experiments show that when CB1 receptor 
transmission within the BLA-PFC circuit was pharmacologically blocked, this prevented the 
acquisition of emotionally salient associative memory. These results indicate that 
coordinated CB1 receptor transmission within the BLA-PFC pathway is critically involved 
in the encoding of emotional fear memories and modulates neural plasticity related to the 
encoding of emotionally salient associative learning (Tan et al., 2010). 
3. Cocaine (Table 2) 
Behavioral sensitization is the augmented motor-stimulant response that occurs with 
repeated, intermittent exposure to most drugs of abuse, including cocaine. Sensitization, 
which is a long-lasting phenomenon, is thought to underlie drug craving and relapse to 
drug use (Steketee et al., 2003). The neural mechanisms of sensitization have focused on the 
NAc and VTA that comprise a part of the mesolimbic DA system. Cocaine sensitization 




Effect on brain plasticity and 
behaviour 
Structures Autor 
Cocaine Induced behavioural sensitization mPFC, NAc, VTA Steketee, 2003; 2005 
Induced conditioned place 
preference  
mPFC, NAc shell, 
VTA 
McBride et al., 1999 
↑ BDNF, ↓ mGluR5, LTD impared NAc shell Huang et al., 2011 
↑ DA transmission and induce CTA NAc shell Di Chiara et al., 2004 
Behavioral deficits at birth and/or 
during adulthood  
Limbic system Lidow, 2003 
 









Aston-Jones et al., 
2009 
Shift from impulsivity to 
compulsivity during the 
development of addictive behavior 
PFC,  ventral and 
dorsal striatum 
Belin et al., 2008 
Increased MeCP2 expression and 
microRNA  
Dorsal striatum Welberg, 2010 
Table 2. Plastic changes on brain regions by chronic use of cocaine.  
(Abbreviations: BDNF: brain-derived neurotrophic factor; CTA: conditioned taste avoidance; DA: 
dopamine; LTD: long-term depression; MeCP2: methyl CpG binding protein 2; mGluR5: type 5 
metabotropic glutamate receptor; mPFC: medial prefrontal cortex; NAc: nucleus accumbens; VTA: 
ventral tegmental area). 
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to the VTA and NAc. Repeated cocaine exposure alters DA, gamma-aminobutyric acid 
(GABA), and glutamate regulation of pyramidal cell activity (Di Chiara et al., 2004; Huang 
et al., 2011), with cocaine-induced alterations in cortical transmission occuring in two 
phases. During early withdrawal from repeated cocaine exposure, changes in 
neurotransmitter release are thought to underlie the decreased inhibitory modulation of 
pyramidal projection neurons. Following more prolonged withdrawal, the attenuation in 
inhibitory transmission appears to occur at the receptor level (Steketee, 2005). 
3.1 Cocaine and dopaminergic system 
Neuroadaptation in the NAc, a central component of the mesolimbic DA system, has been 
implicated in the development of cocaine-induced psychomotor sensitization and relapse to 
cocaine seeking (Zhang et al., 2001; Anderson et al., 2003; see Steketee, 2005 for review). 
Recent results suggest that withdrawal from repeated cocaine exposure may result in 
increased brain-derived neurotrophic factor (BDNF) levels in the NAc shell, which leads to a 
selective downregulation of mGluR5 and thereby impairs the induction of mGluR-
dependent LTD (Huang et al., 2011). The effects of BDNF on cocaine-seeking are brain 
region-specific. Infusion of BDNF into subcortical structures, like the NAc and VTA, 
enhances cocaine-induced behavioral sensitization and cocaine-seeking. Conversely, 
repeated administration of BDNF antiserum into the NAc during chronic cocaine self-
administration attenuates cocaine-induced reinstatement. Three weeks after BDNF 
antiserum infusion in animals with a cocaine self-administration history, suppressed basal 
levels of glutamate are normalized, and a cocaine prime-induced increase in extracellular 
glutamate levels in the NAc is prevented (McGinty et al., 2010). Although the development 
of behavioral sensitization to psychostimulants such as cocaine and amphetamine is 
confined mainly to one nucleus in the brain, the VTA, this process is nonetheless complex, 
involving an interplay between neurotransmitters, neuropeptides and trophic factors. 
Calcium-stimulated signalling molecules, including the calcium/calmodulin-dependent 
protein kinases, and the Ras/mitogen-activated protein kinases, represent the major 
biochemical pathways whereby converging extracellular signals are integrated and 
amplified, resulting in the biochemical and molecular changes in DA neurons in the VTA 
that represent the critical neuronal correlates of the development of behavioral sensitization 
to psychostimulants (see Licata and Pierce, 2003 for review).  
Using a mouse model of behavioral sensitization, Huang et al. (2011) showed that animals 
withdrawn from repeated cocaine exposure have a selective deficit in the ability to elicit 
metabotropic glutamate receptor (mGluR)-dependent LTD in the shell of the NAc in 
response to bath application of the group I mGluR agonist DHPG. Experiments 
demonstrated that the impaired DHPG-LTD is likely attributable to a loss of mGluR5 
function. Quantitative real-time reverse transcriptase-PCR and Western blot analysis 
revealed significant downregulation of mGluR5, but not mGluR1, mRNA or protein levels 
in the NAc shell. The inhibitory effect of repeated cocaine exposure on DHPG-LTD was 
selectively prevented when cocaine was coadministered with a selective D1 receptor 
antagonist. Furthermore, the levels of BDNF protein in the NAc shell increased 
progressively after cocaine withdrawal, and crucially, the impairment of DHPG-LTD in the 
NAc shell was not found in slices from BDNF-knock-out mice after cocaine withdrawal. 
Recent evidence suggests that CB1Rs may represent effective targets for therapeutic agents 
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representing low-level cortical damage or change in neural plasticity (Stone et al., 2011). The 
CB1 receptor system is functionally involved in the processing and encoding of emotionally 
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an established correlate of exposure to emotionally salient events (Laviolette and Grace, 
2006). In vivo LTP studies showed that systemic pretreatment with AM-251, dose-
dependently block LTP along the BLA-PLC pathway, and also the behavioral acquisition of 
conditioned fear memories (Tan et al., 2010). Experiments show that when CB1 receptor 
transmission within the BLA-PFC circuit was pharmacologically blocked, this prevented the 
acquisition of emotionally salient associative memory. These results indicate that 
coordinated CB1 receptor transmission within the BLA-PFC pathway is critically involved 
in the encoding of emotional fear memories and modulates neural plasticity related to the 
encoding of emotionally salient associative learning (Tan et al., 2010). 
3. Cocaine (Table 2) 
Behavioral sensitization is the augmented motor-stimulant response that occurs with 
repeated, intermittent exposure to most drugs of abuse, including cocaine. Sensitization, 
which is a long-lasting phenomenon, is thought to underlie drug craving and relapse to 
drug use (Steketee et al., 2003). The neural mechanisms of sensitization have focused on the 
NAc and VTA that comprise a part of the mesolimbic DA system. Cocaine sensitization 
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behaviour 
Structures Autor 
Cocaine Induced behavioural sensitization mPFC, NAc, VTA Steketee, 2003; 2005 
Induced conditioned place 
preference  
mPFC, NAc shell, 
VTA 
McBride et al., 1999 
↑ BDNF, ↓ mGluR5, LTD impared NAc shell Huang et al., 2011 
↑ DA transmission and induce CTA NAc shell Di Chiara et al., 2004 
Behavioral deficits at birth and/or 
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Limbic system Lidow, 2003 
 









Aston-Jones et al., 
2009 
Shift from impulsivity to 
compulsivity during the 
development of addictive behavior 
PFC,  ventral and 
dorsal striatum 
Belin et al., 2008 
Increased MeCP2 expression and 
microRNA  
Dorsal striatum Welberg, 2010 
Table 2. Plastic changes on brain regions by chronic use of cocaine.  
(Abbreviations: BDNF: brain-derived neurotrophic factor; CTA: conditioned taste avoidance; DA: 
dopamine; LTD: long-term depression; MeCP2: methyl CpG binding protein 2; mGluR5: type 5 
metabotropic glutamate receptor; mPFC: medial prefrontal cortex; NAc: nucleus accumbens; VTA: 
ventral tegmental area). 
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to the VTA and NAc. Repeated cocaine exposure alters DA, gamma-aminobutyric acid 
(GABA), and glutamate regulation of pyramidal cell activity (Di Chiara et al., 2004; Huang 
et al., 2011), with cocaine-induced alterations in cortical transmission occuring in two 
phases. During early withdrawal from repeated cocaine exposure, changes in 
neurotransmitter release are thought to underlie the decreased inhibitory modulation of 
pyramidal projection neurons. Following more prolonged withdrawal, the attenuation in 
inhibitory transmission appears to occur at the receptor level (Steketee, 2005). 
3.1 Cocaine and dopaminergic system 
Neuroadaptation in the NAc, a central component of the mesolimbic DA system, has been 
implicated in the development of cocaine-induced psychomotor sensitization and relapse to 
cocaine seeking (Zhang et al., 2001; Anderson et al., 2003; see Steketee, 2005 for review). 
Recent results suggest that withdrawal from repeated cocaine exposure may result in 
increased brain-derived neurotrophic factor (BDNF) levels in the NAc shell, which leads to a 
selective downregulation of mGluR5 and thereby impairs the induction of mGluR-
dependent LTD (Huang et al., 2011). The effects of BDNF on cocaine-seeking are brain 
region-specific. Infusion of BDNF into subcortical structures, like the NAc and VTA, 
enhances cocaine-induced behavioral sensitization and cocaine-seeking. Conversely, 
repeated administration of BDNF antiserum into the NAc during chronic cocaine self-
administration attenuates cocaine-induced reinstatement. Three weeks after BDNF 
antiserum infusion in animals with a cocaine self-administration history, suppressed basal 
levels of glutamate are normalized, and a cocaine prime-induced increase in extracellular 
glutamate levels in the NAc is prevented (McGinty et al., 2010). Although the development 
of behavioral sensitization to psychostimulants such as cocaine and amphetamine is 
confined mainly to one nucleus in the brain, the VTA, this process is nonetheless complex, 
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biochemical pathways whereby converging extracellular signals are integrated and 
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to psychostimulants (see Licata and Pierce, 2003 for review).  
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metabotropic glutamate receptor (mGluR)-dependent LTD in the shell of the NAc in 
response to bath application of the group I mGluR agonist DHPG. Experiments 
demonstrated that the impaired DHPG-LTD is likely attributable to a loss of mGluR5 
function. Quantitative real-time reverse transcriptase-PCR and Western blot analysis 
revealed significant downregulation of mGluR5, but not mGluR1, mRNA or protein levels 
in the NAc shell. The inhibitory effect of repeated cocaine exposure on DHPG-LTD was 
selectively prevented when cocaine was coadministered with a selective D1 receptor 
antagonist. Furthermore, the levels of BDNF protein in the NAc shell increased 
progressively after cocaine withdrawal, and crucially, the impairment of DHPG-LTD in the 
NAc shell was not found in slices from BDNF-knock-out mice after cocaine withdrawal. 
Recent evidence suggests that CB1Rs may represent effective targets for therapeutic agents 
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used to treat cocaine relapse. Li et al. (2008) determinated whether CBRs play a similar role 
in relapse to ketamine abuse. To establish a ketamine reinstatement model in the 
conditioned place preference paradigm, rats were trained to develop place preference 
conditioned by ketamine, which was subsequently extinguished through daily exposure to 
the test chambers in the absence of ketamine. The effects of rimonabant, a CB1Rs antagonist, 
were investigated on reinstatement of ketamine-induced place preference. While ketamine 
priming injections reinstated extinguished place preference, rimonabant administration 
significantly attenuated the reinstatement of ketamine-induced place preference in a dose-
dependent manner. Importantly, rimonabant itself did not produce conditioned place 
preference or place aversion. Since the reinstatement effects of ketamine administration 
were inhibited by rimonabant, these findings suggest that a CB1 receptor antagonist may be 
useful in preventing relapse to ketamine abuse. VTA DA neurons play a pivotal role in 
processing reward-related information and are involved in drug addiction and mental 
illness in humans (Wise, 2004). Information is conveyed to the VTA in the large part by 
glutamatergic afferents that arise in various brain nuclei, including the pedunculopontine 
nucleus (PPN).  
In rat brain slice preparations, Good and Lupica (2010) found that PPN stimulation activates 
afferents targeting GluR2-containing AMPA receptors (AMPAR) on VTA DA neurons, and 
these afferents did not exhibit long-term depression (LTD). In contrast, activation of 
glutamate afferents onto the same DA neurons via stimulation within the VTA evoked both, 
excitatory postsynaptic currents EPSCs mediated by GluR2-lacking AMPARs which showed 
LTD, and EPSCs mediated by GluR2-containing AMPA receptors that did not express LTD. 
Single cocaine injections increase GluR2-lacking AMPA receptors at all glutamate synapses 
on VTA dopamine neurons (and this permitted LTD expression in both pathways), whereas 
Δ9-THC selectively increased GluR2-lacking AMPA receptors at subcortical PPN synapses 
(and permitted LTD in the PPN pathway only), suggesting that different drugs of abuse 
may exert influence over distinct sets of glutamatergic afferents to VTA DA neurons, which 
may thereby be associated with different reinforcing or addictive properties of these drugs. 
Microdialysis studies in animals have shown that addictive drugs preferentially increase 
extracellular DA levels in the NAc rather than in the core. However, by acting directly on 
the brain, drugs bypass the adaptive mechanisms (habituation) that constrain the 
responsiveness of accumbens shell DA to food reward, abnormally facilitating Pavlovian 
incentive learning and promoting the acquisition of abnormal DA-releasing properties by 
drug conditioned stimuli (See Di Chiara & Bassareo, 2007 for review). Thus, whereas 
Pavlovian food conditioned stimuli release core but not shell DA, drug conditioned stimuli 
do the opposite, releasing shell but not core DA. This process, which results in the 
acquisition of excessive incentive-motivational properties by drug conditioned stimuli has 
been suggested to contribute to the initiation of the drug addiction process (Imperato and Di 
Chiara, 1986; Di Chiara and Bassareo, 2007).  
Brain imaging studies, while extending these finding to humans, have shown a correlation 
between psychostimulant-induced increase of extracellular DA in the striatum and self-
reported measures of liking and euphoria (Volkow et al., 2002a; 2002b). Although a correlate of 
drug reward, independent from associative learning and performance is difficult to obtain in 
animals, conditioned taste avoidance (CTA) might meet these requirements. Addictive drugs 
induce CTA to saccharin most likely as a result of anticipatory contrast of saccharin over drug 
reward. Consistently with a role of DA in drug reward, D2 or combined D1/D2 receptor 
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blockade abolishes cocaine, amphetamine and nicotine CTA. Intracranial self-administration 
studies with mixtures of D1 and D2 receptor agonists point to the NAc shell as the critical site 
of DA reward (Di Chiara et al., 2004; Bassareo et al., 2007). NAc shell DA acting on D1 
receptors is also involved in Pavlovian learning through pre-trial and post-trial consolidation 
mechanisms and in the utilization of spatial short-term memory for goal-directed behaviour 
(Volkow et al., 2011). Stimulation of NAc shell DA transmission by addictive drugs is shared 
by a natural reward like food, but lacks its adaptive properties (habituation and inhibition by 
predictive stimuli). These peculiarities of drug-induced stimulation of DA transmission in the 
NAc shell result in striking differences in the impact of drug-conditioned stimuli on DA 
transmission. It is speculated that drug addiction results from the impact exerted on behavior 
by the abnormal DA stimulant properties acquired by drug-conditioned stimuli as a result of 
their association with addictive drugs (Di Chiara et al., 2004; Everitt & Robbins, 2005). Di 
Chiara and Bassareo (2007) have summarized that addictive drugs share with palatable food, 
the property of increasing extracellular DA, preferentially in the NAc shell rather than in the 
core. However, by acting directly on the brain, drugs bypass the adaptive mechanisms 
(habituation) that constrain the responsiveness of NAc shell DA to food reward, abnormally 
facilitating Pavlovian incentive learning and promoting the acquisition of abnormal DA-
releasing properties by drug conditioned stimuli. Thus, whereas Pavlovian foods conditioned 
stimuli release core but not NAc shell DA, drug conditioned stimuli do the opposite, releasing 
shell but not NAc core DA. Neuroadaptive processes related to the chronic influence of drugs 
on subcortical DA might secondarily impair the function of prefronto-striatal loops, resulting 
in impairments in impulse control and decision making that form the basis for the compulsive 
feature of drug seeking and its relapsing character (Belin and Everitt, 2010). 
3.2 Prenatal cocaine exposure 
The extent to which cocaine abuse by pregnant women can affect development of  
their offspring remains a matter of significant debate. In large part, this is due to difficulties 
in accurate determination of the type, dose, and pattern of cocaine administration by drug 
abusing women as well as to difficulties in controlling for a wide range of potentially 
confounding variables, such as other drugs used, race, socioeconomic status, and level of 
prenatal care. Examination of the effects of prenatal cocaine exposure in highly controlled 
nonhuman primate models represents an important complement to the human research. 
Data obtained in several different rhesus monkey models of cocaine exposure in utero, has 
demonstrated the potential of prenatal cocaine exposure to interfere with structural and 
biochemical development of the brain leading to behavioral deficits at birth and/or during 
adulthood. The differences in the outcomes between individual models also suggest that the 
specific types and severity of cocaine effects are likely dependent on the route, dose, 
gestational period, and daily pattern of administration (see Lidow, 2003 for review). 
Nonhuman primates (rhesus monkeys, Macaca mulatta) have been used to study the effects 
of chronic drug exposures on brain function during different stages of development. In the 
case of the marijuana studies, exposures occurred during the adolescent period; for the 
cocaine studies, exposures occurred in utero. A battery of behavioral tasks, designed to 
assess aspects of motivation, visual discrimination, time perception, short-term memory, 
and learning, was used to monitor treatment effects. Chronic marijuana smoke exposure 
resulted in an 'amotivational' syndrome. In utero cocaine exposure was shown to cause 
behavioral rigidity or lack of plasticity as evidenced by the difficulty of subjects to adjust to 
rules changes for some tasks. These effects were seen in adult subjects suggesting that the 
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used to treat cocaine relapse. Li et al. (2008) determinated whether CBRs play a similar role 
in relapse to ketamine abuse. To establish a ketamine reinstatement model in the 
conditioned place preference paradigm, rats were trained to develop place preference 
conditioned by ketamine, which was subsequently extinguished through daily exposure to 
the test chambers in the absence of ketamine. The effects of rimonabant, a CB1Rs antagonist, 
were investigated on reinstatement of ketamine-induced place preference. While ketamine 
priming injections reinstated extinguished place preference, rimonabant administration 
significantly attenuated the reinstatement of ketamine-induced place preference in a dose-
dependent manner. Importantly, rimonabant itself did not produce conditioned place 
preference or place aversion. Since the reinstatement effects of ketamine administration 
were inhibited by rimonabant, these findings suggest that a CB1 receptor antagonist may be 
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illness in humans (Wise, 2004). Information is conveyed to the VTA in the large part by 
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these afferents did not exhibit long-term depression (LTD). In contrast, activation of 
glutamate afferents onto the same DA neurons via stimulation within the VTA evoked both, 
excitatory postsynaptic currents EPSCs mediated by GluR2-lacking AMPARs which showed 
LTD, and EPSCs mediated by GluR2-containing AMPA receptors that did not express LTD. 
Single cocaine injections increase GluR2-lacking AMPA receptors at all glutamate synapses 
on VTA dopamine neurons (and this permitted LTD expression in both pathways), whereas 
Δ9-THC selectively increased GluR2-lacking AMPA receptors at subcortical PPN synapses 
(and permitted LTD in the PPN pathway only), suggesting that different drugs of abuse 
may exert influence over distinct sets of glutamatergic afferents to VTA DA neurons, which 
may thereby be associated with different reinforcing or addictive properties of these drugs. 
Microdialysis studies in animals have shown that addictive drugs preferentially increase 
extracellular DA levels in the NAc rather than in the core. However, by acting directly on 
the brain, drugs bypass the adaptive mechanisms (habituation) that constrain the 
responsiveness of accumbens shell DA to food reward, abnormally facilitating Pavlovian 
incentive learning and promoting the acquisition of abnormal DA-releasing properties by 
drug conditioned stimuli (See Di Chiara & Bassareo, 2007 for review). Thus, whereas 
Pavlovian food conditioned stimuli release core but not shell DA, drug conditioned stimuli 
do the opposite, releasing shell but not core DA. This process, which results in the 
acquisition of excessive incentive-motivational properties by drug conditioned stimuli has 
been suggested to contribute to the initiation of the drug addiction process (Imperato and Di 
Chiara, 1986; Di Chiara and Bassareo, 2007).  
Brain imaging studies, while extending these finding to humans, have shown a correlation 
between psychostimulant-induced increase of extracellular DA in the striatum and self-
reported measures of liking and euphoria (Volkow et al., 2002a; 2002b). Although a correlate of 
drug reward, independent from associative learning and performance is difficult to obtain in 
animals, conditioned taste avoidance (CTA) might meet these requirements. Addictive drugs 
induce CTA to saccharin most likely as a result of anticipatory contrast of saccharin over drug 
reward. Consistently with a role of DA in drug reward, D2 or combined D1/D2 receptor 
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blockade abolishes cocaine, amphetamine and nicotine CTA. Intracranial self-administration 
studies with mixtures of D1 and D2 receptor agonists point to the NAc shell as the critical site 
of DA reward (Di Chiara et al., 2004; Bassareo et al., 2007). NAc shell DA acting on D1 
receptors is also involved in Pavlovian learning through pre-trial and post-trial consolidation 
mechanisms and in the utilization of spatial short-term memory for goal-directed behaviour 
(Volkow et al., 2011). Stimulation of NAc shell DA transmission by addictive drugs is shared 
by a natural reward like food, but lacks its adaptive properties (habituation and inhibition by 
predictive stimuli). These peculiarities of drug-induced stimulation of DA transmission in the 
NAc shell result in striking differences in the impact of drug-conditioned stimuli on DA 
transmission. It is speculated that drug addiction results from the impact exerted on behavior 
by the abnormal DA stimulant properties acquired by drug-conditioned stimuli as a result of 
their association with addictive drugs (Di Chiara et al., 2004; Everitt & Robbins, 2005). Di 
Chiara and Bassareo (2007) have summarized that addictive drugs share with palatable food, 
the property of increasing extracellular DA, preferentially in the NAc shell rather than in the 
core. However, by acting directly on the brain, drugs bypass the adaptive mechanisms 
(habituation) that constrain the responsiveness of NAc shell DA to food reward, abnormally 
facilitating Pavlovian incentive learning and promoting the acquisition of abnormal DA-
releasing properties by drug conditioned stimuli. Thus, whereas Pavlovian foods conditioned 
stimuli release core but not NAc shell DA, drug conditioned stimuli do the opposite, releasing 
shell but not NAc core DA. Neuroadaptive processes related to the chronic influence of drugs 
on subcortical DA might secondarily impair the function of prefronto-striatal loops, resulting 
in impairments in impulse control and decision making that form the basis for the compulsive 
feature of drug seeking and its relapsing character (Belin and Everitt, 2010). 
3.2 Prenatal cocaine exposure 
The extent to which cocaine abuse by pregnant women can affect development of  
their offspring remains a matter of significant debate. In large part, this is due to difficulties 
in accurate determination of the type, dose, and pattern of cocaine administration by drug 
abusing women as well as to difficulties in controlling for a wide range of potentially 
confounding variables, such as other drugs used, race, socioeconomic status, and level of 
prenatal care. Examination of the effects of prenatal cocaine exposure in highly controlled 
nonhuman primate models represents an important complement to the human research. 
Data obtained in several different rhesus monkey models of cocaine exposure in utero, has 
demonstrated the potential of prenatal cocaine exposure to interfere with structural and 
biochemical development of the brain leading to behavioral deficits at birth and/or during 
adulthood. The differences in the outcomes between individual models also suggest that the 
specific types and severity of cocaine effects are likely dependent on the route, dose, 
gestational period, and daily pattern of administration (see Lidow, 2003 for review). 
Nonhuman primates (rhesus monkeys, Macaca mulatta) have been used to study the effects 
of chronic drug exposures on brain function during different stages of development. In the 
case of the marijuana studies, exposures occurred during the adolescent period; for the 
cocaine studies, exposures occurred in utero. A battery of behavioral tasks, designed to 
assess aspects of motivation, visual discrimination, time perception, short-term memory, 
and learning, was used to monitor treatment effects. Chronic marijuana smoke exposure 
resulted in an 'amotivational' syndrome. In utero cocaine exposure was shown to cause 
behavioral rigidity or lack of plasticity as evidenced by the difficulty of subjects to adjust to 
rules changes for some tasks. These effects were seen in adult subjects suggesting that the 
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effects of gestational cocaine exposure are long-term or permanent (see Paul, 2005 for 
review). 
3.3 Orexins in drug-seeking 
Orexins (also known as hypocretins) are recently discovered neuropeptides, synthetised 
exclusively in hypothalamic neurons, which have been shown to be important in 
narcolepsy/cataplexy and arousal (Zhou et al., 2008). Aston-Jones et al. (2009) conducted 
behavioral, anatomical and neurophysiological studies that show that a subset of these cells, 
located specifically in lateral hypothalamus (LH), are involved in reward processing and 
addictive behaviors. They found that Fos expression in LH orexin neurons varied in 
proportion to preference for cocaine or food. Recently, using a self-administration paradigm, 
it was discovered that the Ox1 orexin receptor antagonist, SB-334867 (SB), blocks cocaine-
seeking induced by discrete or contextual cues, but not by a priming injection of cocaine. 
Neurophysiological studies revealed that locally applied orexin often augmented responses 
of VTA DA neurons to activation of the mPFC, consistent with the view that orexin 
facilitates activation of VTA DA neurons by stimulus-reward associations. These findings 
are consistent with results from others showing that orexins facilitate glutamate-mediated 
responses, and are necessary for glutamate-dependent long-term potentiation, in VTA DA 
neurons (Anston-Jones et al., 2010). Boutrel et al., (2005) show that intracerebroventricular 
infusions of hypocretin-1 lead to a dose-related reinstatement of cocaine seeking without 
altering cocaine intake in rats and elevates intracranial self-stimulation threshold. The effect 
was prevented by blockade of noradrenergic and corticotrophin releasing factor systems, 
suggesting that hypocretin-1 reinstated drug seeking through induction of a stress-like state. 
3.4 Regulation of cocaine intake 
Recent studies have started to reveal the contribution of epigenetic regulation to addiction-
related behaviours and neuroadaptation. Two studies focused on the role of the X-linked 
transcriptional repressor methyl CpG-binding protein 2 (MeCP2), wich contributes to the 
development and function of CNS synapses. They showed that drugs of abuse regulate the 
expression and/or activity of MeCP2 and that this contributes to behavioural and neural 
responses to the drug. MeCP2, known for its role in the neurodevelopmental disorder Rett 
syndrome, is emerging as an important regulator of neuroplasticity in postmitotic neurons. 
Cocaine addiction is commonly viewed as a disorder of neuroplasticity (White, 1996; Everitt 
et al., 1999; Di Chiara, 1999). Heh-In et al. (2010) identified a key role for MeCP2 in the 
dorsal striatum in the escalating cocaine intake seen in rats with extended access to the drug, 
a process that resembles in some rats subjected to extended daily access to the drug, the 
increasingly uncontrolled cocaine use seen in addicted humans (See Badiani et al., 2011 for 
review). MeCP2 regulates cocaine intake through homeostatic interactions with microRNA-
212 (miR-212) to control the effects of cocaine on striatal BDNF levels. They suggest that 
homeostatic interactions between MeCP2 and miR-212 in dorsal striatum may be important 
in regulating vulnerability to cocaine addiction. Deng et al. (2010) have shown that acute 
viral manipulation of MeCP2 expression in the NAc bidirectionally modulates amphetamine 
(AMPH)-induced conditioned place preference. Mecp2 hypomorphic mutant mice have 
more NAc GABAergic synapses and show deficient AMPH-induced structural plasticity of 
NAc dendritic spines. Furthermore, these mice show deficient plasticity of striatal 
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immediate early gene inducibility after repeated AMPH administration. Notably, 
psychostimulants induce phosphorylation of MeCP2 at Ser421, a site that regulates MeCP2’s 
function as a repressor. Phosphorylation is selectively induced in GABAergic interneurons 
of the NAc, and its extent strongly predicts the degree of behavioral sensitization. These 
data reveal new roles for MeCP2, both, in mesolimbocortical circuit development, and in the 
regulation of psychostimulant-induced behaviors. Also, Im et al (2010) reported increased 
MeCP2 expression and miR-212 (as well as miR-132) levels in the dorsal striatum in rats that 
had extended access to cocaine. Knocking down striatal MeCP2 expression using small 
hairpin RNA (shRNA) promoted the cocaine-induced increase in miR-212 expression. It also 
prevented the escalation of cocaine intake that normally occurs with prolonged cocaine 
access, an effect that could be blocked by disruption of miR-212 signalling using an 
antisense oligonucleotide. Furthermore, overexpressing miR-212 in the dorsal striatum, a 
neurobiological locus of control of habitual (Belin and Everitt 2008; Belin et al., 2009, 2010, 
Zapata et al., 2010, Murray et al., 2012) and compulsive (Jonkman et al., 2012) cocaine 
seeking, using a lentiviral vector reduced MeCP2 levels and decreased cocaine intake in rats 
with extended access to the drug (Im et al., 2010). These findings indicate that miR-212 and 
MeCP2 homeostatically regulate one another in the dorsal striatum and suggest that this 
interaction has a role in controlling compulsive cocaine intake. Taken together, these results 
suggest a role for MeCP2 in the behavioural response to psychostimulant drugs, although 
many questions remain regarding the undoubtedly complex mechanisms involved in its 
interactions with microRNAs and its modulation of synaptic plasticity (Welberg, 2010).  
4. Amphetamine (Table 3) 
4.1 Dopaminergic system 
The fundamental principle that unites addictive drugs appears to be that each enhances 
synaptic DA by means that dissociate it from normal behavioral control, so that they act to 
reinforce their own acquisition. This occurs via the modulation of synaptic mechanisms that 
can be involved in learning, including enhanced excitation or disinhibition of DA neuron 
activity, blockade of DA reuptake, and altering the state of the presynaptic terminal to 
enhance evoked over basal transmission. Amphetamines offer an exception to such 
modulation in that they combine multiple effects to produce nonexocytotic, stimulation-
independent release of neurotransmitter, via reverse-transport, independent from normal 
presynaptic function (Sulzer, 2011). In addition, behavioral sensitization is accompanied by 
an increase in postsynaptic DA receptors; an increase in DA synthesis; an increase in DA 
utilization and/or release (Kalivas and Stewart, 1991; Flores et al., 2011). There is strong 
evidence to support the notion that behavioral sensitization is due to enhanced 
mesotelencephalic DA release, especially upon re-exposure to the drug (Robinson and 
Becker, 1986). The mesocorticolimbic dopamine system, which arises in the VTA and 
innervates the NAc, among numerous other regions, has been implicated in processes 
associated with drug addiction, including behavioral sensitization. The mPFC, defined as 
the cortical region that has a reciprocal innervation with the mediodorsal nucleus of the 
thalamus, is also a terminal region of the mesocorticolimbic DA system. The mPFC contains 
pyramidal glutamatergic neurons that serve as the primary output of this region and mPFC 
transmitter systems are involved in the development of behavioral sensitization to cocaine 
and amphetamine (Steketee, 2003). 
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a process that resembles in some rats subjected to extended daily access to the drug, the 
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immediate early gene inducibility after repeated AMPH administration. Notably, 
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Table 3. Plastic changes on brain regions by chronic use of amphetamine. 
(Abbreviations: AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CaMKII: 
Ca2+/calmodulin-dependent protein kinase II CTA: conditioned taste avoidance; DA: dopamine; DAR: 
dopamine receptor eCB: endocannabinoid; LTP: long-term potentiation; LTD: long-term depression; 
mGluR: metabotropic glutamate receptor; mPFC: medial prefrontal cortex; NAc: nucleus accumbens; 
NMDA: N-Methyl-D-aspartic acid; OFC: orbital frontal cortex; PFC: prefrontal cortex; VTA: ventral 
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Intracranial self-administration (ICSA) and intracranial place conditioning (ICPC) 
methodologies have been mainly used to study drug reward mechanisms, but they have 
also been applied toward examining brain reward mechanisms (McBride et al., 1999; Di 
Chiara et al., 2004). ICSA studies in rodents have established that the VTA is a site 
supporting reinforcement. The NAc also appears to have a major role in brain reward 
mechanisms. Rodents will self-infuse a variety of drugs of abuse (amphetamine and cocaine) 
into the NAc, and this occurs primarily in the shell region. ICPC studies also indicate that 
injection of amphetamine into the shell portion of the NAc produces conditioned place 
preference (CPP). Activation of the DA system within the shell subregion of the NAc 
appears to play a key role in brain reward mechanisms. The PFC supports the ICSA of 
cocaine and phencyclidine. The DA system also seems to play a role in this behavior since 
cocaine self-infusion into the PFC can be blocked by co-infusing a D2 antagonist. Among 
other regions, ICPC findings suggest that cocaine and amphetamine are rewarding in the 
rostral ventral pallidum (VP). Finally, substance P-mediated systems within the caudal VP 
(nucleus basalis magnocellularis) and serotonin systems of the dorsal and median raphe 
nuclei may also be important anatomical components involved in brain reward 
mechanisms. Overall, the ICSA and ICPC studies indicate that there are a number discrete 
CNS sites involved in brain reward mechanisms (McBride et al., 1999). 
4.2 Amphetamine alters learning, LTP and LTD 
Recent studies suggest LTP expression in locally activated glutamate synapses onto DA 
neurons (local Glu-DA synapses) of the midbrain VTA following a single or chronic 
exposure to many drugs of abuse, whereas a single exposure to cannabinoid did not 
significantly affect synaptic plasticity at these synapses. It is unknown whether chronic 
exposure of cannabis (marijuana or cannabinoids), the most commonly used illicit drug 
worldwide, induce LTP or LTD at these synapses. Pleiotrophin (PTN) is a cytokine with 
important roles in the modulation of synaptic plasticity, which levels of expression are 
significantly regulated by amphetamine administration. Gramage et al. (2011), have 
reported that amphetamine during adolescence causes long-term cognitive deficits in rats. 
Periadolescent amphetamine treatment daily during 10 days in normal and in PTN 
genetically deficient mice result in significant deficits in the passive avoidance and Y-maze 
tests (two tasks related to learning and memory abilities), only observed in amphetamine-
pretreated PTN mutant mice. However, 13 and 26 days after the last administration, they 
did not find significant differences in Y-maze between amphetamine- and saline-pretreated 
PTN-/- mice. A significantly enhanced LTP in CA1 hippocampal slices from saline-
pretreated PTN-/- mice compared with saline-pretreated PTN+/+ mice was observed. 
Interestingly, amphetamine pre-treatment during adolescence significantly enhanced LTP in 
adult PTN+/+ mice but did not cause any effect in PTN-/- mice, suggesting LTP 
mechanisms saturation in naïve PTN-/- mice. The data demonstrate that periadolescent 
amphetamine treatment causes transient cognitive deficits and long-term alterations of 
hippocampal LTP depending on the endogenous expression of PTN. Pleiotrophin (PTN) is a 
growth factor that has been shown to be involved in hippocampal synaptic plasticity and 
learning. Del Olmo et al. (2009), using in vitro electrophysiological recordings in PTN-
stimulated CA1 from rat hippocampal slices, found that PTN inhibited hippocampal LTP 
induced by high-frequency stimulation (HFS). Also, they observed significant differences in 
recognition memory between PTN genetically deficient (PTN-/-) mice and wild type (WT) 
mice using the Y-maze test, whereas WT mice showed disruption of recognition memory, 
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worldwide, induce LTP or LTD at these synapses. Pleiotrophin (PTN) is a cytokine with 
important roles in the modulation of synaptic plasticity, which levels of expression are 
significantly regulated by amphetamine administration. Gramage et al. (2011), have 
reported that amphetamine during adolescence causes long-term cognitive deficits in rats. 
Periadolescent amphetamine treatment daily during 10 days in normal and in PTN 
genetically deficient mice result in significant deficits in the passive avoidance and Y-maze 
tests (two tasks related to learning and memory abilities), only observed in amphetamine-
pretreated PTN mutant mice. However, 13 and 26 days after the last administration, they 
did not find significant differences in Y-maze between amphetamine- and saline-pretreated 
PTN-/- mice. A significantly enhanced LTP in CA1 hippocampal slices from saline-
pretreated PTN-/- mice compared with saline-pretreated PTN+/+ mice was observed. 
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adult PTN+/+ mice but did not cause any effect in PTN-/- mice, suggesting LTP 
mechanisms saturation in naïve PTN-/- mice. The data demonstrate that periadolescent 
amphetamine treatment causes transient cognitive deficits and long-term alterations of 
hippocampal LTP depending on the endogenous expression of PTN. Pleiotrophin (PTN) is a 
growth factor that has been shown to be involved in hippocampal synaptic plasticity and 
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PTN -/- mice maintained the recognition memory. The data demonstrate that PTN inhibits 
hippocampal LTP in vitro and might play a role in memory processes in vivo. 
Synaptic plasticity in the mesolimbic DA system is critically involved in reward-based 
conditioning and the development of drug addiction (Schultz et al., 1998; Wise, 2004). Ca2+ 
signals triggered by postsynaptic action potentials (APs) drive the induction of synaptic 
plasticity in the CNS. Ahn et al. (2010) have recently proposed that enhancement of mGluR-
dependent n-methyl-d-aspartate receptor (NMDAR) plasticity in the VTA may promote the 
learning of environmental stimuli repeatedly associated with amphetamine experience. In 
this study, using brain slices prepared from male rats, it was shown that repeated in vivo 
exposure to the psychostimulant amphetamine upregulates mGluR-dependent facilitation of 
burst-evoked Ca2+ signals in DA neurons of the VTA. Protein kinase A (PKA)-induced 
sensitization of IP3 receptors mediates this upregulation of mGluR action. As a consequence, 
NMDAR-mediated transmission becomes more susceptible to LTP induction after repeated 
amphetamine exposure. It was also found that the magnitude of amphetamine-conditioned 
place preference (CPP) in behaving rats correlates with the magnitude of mGluR-dependent 
Ca2+ signal facilitation measured in VTA slices prepared from these rats.  
Major drugs of abuse such as cocaine, amphetamine, morphine, heroine, nicotine, and ethanol 
act on glutamatergic synapses on midbrain DA neurons and lead to NMDA-dependent, 
AMPA-mediated long-term potentiation in DA neurons. Thus, excitatory influences on these 
neurons become enhanced; in particular NMDA-dependent burst firing. Amphetamine also 
leads to reduction of LTD in DA neurons (Swope et al., 1999; Ahn et al., 2010; Liu et al., 2010, 
Good and Lupica, 2010). Thus, subthreshold fluctuations of excitatory inputs to DA neurons 
would increase or even generate action potentials in the absence of reward, generating a false 
reward signal (Schultz, 2011). There are glutamatergic projections from the hippocampus to 
the NAc, which regulate DA transmission in this structure. Ventral hippocampal (VH) 
glutamatergic neurons project to the NAc shell region, whereas the dorsal hippocampus (DH) 
sends glutamatergic projections to the NAc core region. Tan (2008) investigated the roles of 
hippocampal NMDA receptors and NAc D1 receptor in AMPH-produced conditioned place 
preference (AMPH-CPP) in rats. It was shown that AMPH-CPP results in the enhancement of 
hippocampal CaMKII activity which can be impaired by NMDA antagonist (AP5). 
Inactivation of hippocampal area (dorsal hippocampus or ventral hippocampus) impaired 
AMPH-CPP, but its effect was diminished by the activation of D1 receptors in NAc core or 
NAc shell. It was concluded that if the deterioration of AMPH-CPP expression resembles the 
formation of new learning, then this active process might have been facilitated by the 
hippocampal NMDA receptor activations during testing. 
4.3 Amphetamine sensitization 
Muhammad et al. (2011a) studied the effect of postnatal tactile stimulation (TS) on juvenile 
behavior, adult amphetamine (AMPH) sensitization, and the interaction of TS and AMPH on 
prefrontal cortical (PFC) thickness and striatum size. AMPH administration resulted in 
gradual increase in behavioral sensitization that persisted at least for 2 weeks. However, TS 
rats exhibited attenuated AMPH sensitization compared to sex-matched controls. 
Neuroanatomically, AMPH reduced the PFC thickness in control females but enlarged the 
posterior striatum in control males. It was suggested that TS during development modulated 
the response to novel objects and altered social behaviors and attenuated AMPH-induced 
behavioral sensitization by preventing drug-induced structural alteration in the PFC and the 
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striatum, brain regions implicated in drug abuse. Subsequently, these same investigators 
studied the effect of prenatal stress (PS) on juvenile behavior and adult AMPH sensitization, as 
well as the effect of the interaction between experience and drug on cortical thickness and 
neuronal morphology in corticolimbic regions in rats. PS did not influence AMPH-induced 
behavioral sensitization in either male or female rats. Moreover, PS increased the spine density 
in the NAc and decreased it in the mPFC without any alteration in the orbital frontal cortex 
(OFC). Similarly, AMPH administration increased spine density in the NAc and mPFC, 
whereas a decrease was observed in the OFC. However, PS prevented the drug-induced 
alterations in the spine density observed in controls. In sum, PS modulated juvenile behavior 
and altered brain morphology without influencing AMPH-induced behavioral sensitization 
substantially (Muhammad and Kolb, 2011b). Also, more recently Muhammad and Kolb 
(2011c) studied the long-term influence of maternal separation (MS) on periadolescent 
behavior, adult amphetamine (AMPH) sensitization, and structural plasticity in the 
corticolimbic regions in rats. Male and female pups, separated daily for 3h from the dam 
during postnatal day 3-21, were tested for periadolescent exploratory, emotional, cognitive, 
and social behaviors. The results showed that MS enhanced anxiety-like behavior in males. 
Repeated AMPH administration increased the spine density in the NAc and the mPFC, and 
decreased it in the OFC. MS blocked the drug-induced alteration in these regions. MS during 
development influenced periadolescent behavior in males, and structurally reorganized 
cortical and subcortical brain regions without affecting AMPH-induced behavioral 
sensitization. 
4.4 Amphetamine and mental disorders 
Individuals who repeatedly use stimulant drugs, such as AMPH, develop an AMPH-
induced psychosis that is similar to paranoid schizophrenia. There has been, therefore, 
considerable interest in characterizing the effects of chronic stimulant drug treatment on 
brain and behavior in non-human animals (Robinson and Becker, 1986). 
5. Dopamine transporter and neural plasticity 
Dopamine (DA) is one of the most important neurotransmitters affecting fine brain processes. 
Dysfunction of dopaminergic neurotransmission precipitates diseases such as Parkinson’s 
disease (PD), schizophrenia, attention-deficit hyperactivity disorder (ADHD), and drug 
addiction (see Zhang et al., 2010 for review). DA synthesis occurs within the DA neurons. 
Tyrosine is transported into the cell via amino acid carriers in the blood–brain barrier and cell 
membranes. Once in the intracellular space, tyrosine is hydroxylated to L-3,4-
dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH). L-DOPA is then 
decarboxylated by aromatic acid decarboxylase (AADC) to DA (for review see Miyake et al., 
2011). Extracellular DA concentration and lifetime after release is regulated by diffusion, 
dilution as well as reuptake (for review see Rice and Cragge, 2008). Reuptake of synaptic DA 
by the dopamine transporter (DAT) is the principal mechanism regulating dopamine 
neurotransmission, and is often used as a marker for presynaptic DA function (for review see 
Zhang et al., 2010). In addition DA itself can regulate DAT via its interaction with the 
transporter or presynaptic autoreceptors (Williams and Galli, 2006). Interestingly, a recent 
report has found that unmedicated bipolar disorder (BPD) subjects had significantly lower 
DAT availability relative to healthy controls in bilateral dorsal caudate (Anand et al., 2011), 
thus the authors suggest that DAT availability may be related to the neuropathology of BPD. 
 
Addictions – From Pathophysiology to Treatment 
 
84
PTN -/- mice maintained the recognition memory. The data demonstrate that PTN inhibits 
hippocampal LTP in vitro and might play a role in memory processes in vivo. 
Synaptic plasticity in the mesolimbic DA system is critically involved in reward-based 
conditioning and the development of drug addiction (Schultz et al., 1998; Wise, 2004). Ca2+ 
signals triggered by postsynaptic action potentials (APs) drive the induction of synaptic 
plasticity in the CNS. Ahn et al. (2010) have recently proposed that enhancement of mGluR-
dependent n-methyl-d-aspartate receptor (NMDAR) plasticity in the VTA may promote the 
learning of environmental stimuli repeatedly associated with amphetamine experience. In 
this study, using brain slices prepared from male rats, it was shown that repeated in vivo 
exposure to the psychostimulant amphetamine upregulates mGluR-dependent facilitation of 
burst-evoked Ca2+ signals in DA neurons of the VTA. Protein kinase A (PKA)-induced 
sensitization of IP3 receptors mediates this upregulation of mGluR action. As a consequence, 
NMDAR-mediated transmission becomes more susceptible to LTP induction after repeated 
amphetamine exposure. It was also found that the magnitude of amphetamine-conditioned 
place preference (CPP) in behaving rats correlates with the magnitude of mGluR-dependent 
Ca2+ signal facilitation measured in VTA slices prepared from these rats.  
Major drugs of abuse such as cocaine, amphetamine, morphine, heroine, nicotine, and ethanol 
act on glutamatergic synapses on midbrain DA neurons and lead to NMDA-dependent, 
AMPA-mediated long-term potentiation in DA neurons. Thus, excitatory influences on these 
neurons become enhanced; in particular NMDA-dependent burst firing. Amphetamine also 
leads to reduction of LTD in DA neurons (Swope et al., 1999; Ahn et al., 2010; Liu et al., 2010, 
Good and Lupica, 2010). Thus, subthreshold fluctuations of excitatory inputs to DA neurons 
would increase or even generate action potentials in the absence of reward, generating a false 
reward signal (Schultz, 2011). There are glutamatergic projections from the hippocampus to 
the NAc, which regulate DA transmission in this structure. Ventral hippocampal (VH) 
glutamatergic neurons project to the NAc shell region, whereas the dorsal hippocampus (DH) 
sends glutamatergic projections to the NAc core region. Tan (2008) investigated the roles of 
hippocampal NMDA receptors and NAc D1 receptor in AMPH-produced conditioned place 
preference (AMPH-CPP) in rats. It was shown that AMPH-CPP results in the enhancement of 
hippocampal CaMKII activity which can be impaired by NMDA antagonist (AP5). 
Inactivation of hippocampal area (dorsal hippocampus or ventral hippocampus) impaired 
AMPH-CPP, but its effect was diminished by the activation of D1 receptors in NAc core or 
NAc shell. It was concluded that if the deterioration of AMPH-CPP expression resembles the 
formation of new learning, then this active process might have been facilitated by the 
hippocampal NMDA receptor activations during testing. 
4.3 Amphetamine sensitization 
Muhammad et al. (2011a) studied the effect of postnatal tactile stimulation (TS) on juvenile 
behavior, adult amphetamine (AMPH) sensitization, and the interaction of TS and AMPH on 
prefrontal cortical (PFC) thickness and striatum size. AMPH administration resulted in 
gradual increase in behavioral sensitization that persisted at least for 2 weeks. However, TS 
rats exhibited attenuated AMPH sensitization compared to sex-matched controls. 
Neuroanatomically, AMPH reduced the PFC thickness in control females but enlarged the 
posterior striatum in control males. It was suggested that TS during development modulated 
the response to novel objects and altered social behaviors and attenuated AMPH-induced 
behavioral sensitization by preventing drug-induced structural alteration in the PFC and the 
 
Addictive Drugs and Synaptic Plasticity 
 
85 
striatum, brain regions implicated in drug abuse. Subsequently, these same investigators 
studied the effect of prenatal stress (PS) on juvenile behavior and adult AMPH sensitization, as 
well as the effect of the interaction between experience and drug on cortical thickness and 
neuronal morphology in corticolimbic regions in rats. PS did not influence AMPH-induced 
behavioral sensitization in either male or female rats. Moreover, PS increased the spine density 
in the NAc and decreased it in the mPFC without any alteration in the orbital frontal cortex 
(OFC). Similarly, AMPH administration increased spine density in the NAc and mPFC, 
whereas a decrease was observed in the OFC. However, PS prevented the drug-induced 
alterations in the spine density observed in controls. In sum, PS modulated juvenile behavior 
and altered brain morphology without influencing AMPH-induced behavioral sensitization 
substantially (Muhammad and Kolb, 2011b). Also, more recently Muhammad and Kolb 
(2011c) studied the long-term influence of maternal separation (MS) on periadolescent 
behavior, adult amphetamine (AMPH) sensitization, and structural plasticity in the 
corticolimbic regions in rats. Male and female pups, separated daily for 3h from the dam 
during postnatal day 3-21, were tested for periadolescent exploratory, emotional, cognitive, 
and social behaviors. The results showed that MS enhanced anxiety-like behavior in males. 
Repeated AMPH administration increased the spine density in the NAc and the mPFC, and 
decreased it in the OFC. MS blocked the drug-induced alteration in these regions. MS during 
development influenced periadolescent behavior in males, and structurally reorganized 
cortical and subcortical brain regions without affecting AMPH-induced behavioral 
sensitization. 
4.4 Amphetamine and mental disorders 
Individuals who repeatedly use stimulant drugs, such as AMPH, develop an AMPH-
induced psychosis that is similar to paranoid schizophrenia. There has been, therefore, 
considerable interest in characterizing the effects of chronic stimulant drug treatment on 
brain and behavior in non-human animals (Robinson and Becker, 1986). 
5. Dopamine transporter and neural plasticity 
Dopamine (DA) is one of the most important neurotransmitters affecting fine brain processes. 
Dysfunction of dopaminergic neurotransmission precipitates diseases such as Parkinson’s 
disease (PD), schizophrenia, attention-deficit hyperactivity disorder (ADHD), and drug 
addiction (see Zhang et al., 2010 for review). DA synthesis occurs within the DA neurons. 
Tyrosine is transported into the cell via amino acid carriers in the blood–brain barrier and cell 
membranes. Once in the intracellular space, tyrosine is hydroxylated to L-3,4-
dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH). L-DOPA is then 
decarboxylated by aromatic acid decarboxylase (AADC) to DA (for review see Miyake et al., 
2011). Extracellular DA concentration and lifetime after release is regulated by diffusion, 
dilution as well as reuptake (for review see Rice and Cragge, 2008). Reuptake of synaptic DA 
by the dopamine transporter (DAT) is the principal mechanism regulating dopamine 
neurotransmission, and is often used as a marker for presynaptic DA function (for review see 
Zhang et al., 2010). In addition DA itself can regulate DAT via its interaction with the 
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The DAT is a target for the development of pharmacotherapies for a number of central 
disorders including PD, Alzheimer's disease, schizophrenia, Tourette's syndrome, Lesch-
Nyhan disease, ADHD, obesity, depression, and stimulant abuse, as well as normal aging 
(for review see Runyon and Carroll, 2006). DAT is located on the presynaptic membrane of 
DA terminals and regulates phasic DA transmission at the synapse by rapidly removing DA 
from the synaptic cleft through reuptake (for review see Rice and Cragge, 2008). 
Interestingly, this protein is expressed exclusively by DA neurons and is found 
extrasynaptically on DA axons in CPu and NAc (for review see Rice and Cragge, 2008). In 
addition, DA receptors are also predominantly extrasynaptic (Sesack et al., 1994; Yung et al., 
1995; Hersch et al., 1995; Khan et al., 1998). Interestingly, several recent reports suggest that 
synuclein proteins have a critical role in monoamine neurotransmitter homeostasis. In 
addition, the physical interactions between synuclein proteins and monoamine transporters 
(DA, serotonin (5HT) and norepinephrine (NE) transporters) indicate an important role for 
the synucleins in regulating transporter function, trafficking and distribution at the DA, 5HT 
and NE synapses (for review see Oaks and Sidhu, 2011).  
The synuclein family of proteins includes α-synuclein (α-Syn), β-synuclein (β-Syn), and γ-
synuclein (γ-Syn). The genes cloned from multiple species demonstrate that synucleins, a 
group of prevalent pre-synaptic proteins, are highly conserved, but unique to vertebrate 
organisms (Surguchov, 2008). In addition, these proteins participate in numerous 
interactions with other proteins, lipid membranes, and nucleic acids, suggesting a possible 
role in the chaperoning or trafficking of biomolecules (Surguchov, 2008). Two-hybrid and 
immunoprecipitation experiments have identified a physical interaction between α-Syn and 
the carboxy terminal of DAT (Lee et al., 2001). In addition, release of DA synthesized by DA 
neurons in the brain requires packaging of the neurotransmitter into vesicles by the 
vesicular monoamine transporter 2 (VMAT2). VMAT2 co-localizes with α-Syn in the Lewy 
bodies of PD (Yamamoto, 2006), and overexpression of α-Syn can disrupt VMAT2 function 
(Surguchov, 2008). However, the influence of β-Syn and γ-Syn upon VMAT2 expression and 
activity are not known. Recent reports suggest that psychostimulants such as amphetamines 
and cocaine induced overexpression of α-synuclein (Fornai et al., 2005; Mauceli et al., 2006; 
Ajjimaporn et al., 2007; Klongpanichapak et al., 2008; Mukda et al., 2011, Sae-Ung et al., 
2011). Interestingly, recent reports suggest that low levels of the γ-synuclein in the NAc 
results to an increased self-administration of cocaine in the rat (Boyer et al., 2011). In 
addition, cocaine induced a 1.9-fold increase in locomotor activity after overexpression of α-
synuclein in the NAc (Boyer and Dreyer, 2007). It is noteworthy that the neurotoxicity 
induced by the psychostimulants such as amphetamine are mediated by enhanced oxidative 
stress and these effects are abolished by melatonin (Govitrapong et al., 2010), a main 
secretory product of pineal gland. Interestingly, a recent report suggested that this 
melatonin effect is mediated by the reduction of the overexpression of α-synuclein induced 
by amphetamine (Sae-Ung et al., 2011). 
Amphetamines and cocaine are psychostimulants with a target in the monoaminergic 
system. These drugs reverse the action of monoamine transporters and enhance the release 
of DA as well as norepinephrine and 5-hydroxytriptamine (5-HT, serotonin) into the 
synaptic cleft, increasing their availability to act upon post-synaptic receptors. Reuptake 
blocking and decreased degradation of these neurotransmitters increases their 
concentrations in the synaptic cleft.  
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Locomotor activity induced by psychostimulants such as amphetamine is the result  
of increases in synaptic DA, by blocking or reversing the direction of DAT (Sulzer et al., 
1995; Sulzer et al., 2005), which in turn acts on postsynaptic receptors. Interestingly, mice 
lacking DAT exhibit spontaneous hyperlocomotion and are unresponsive to amphetamine 
(Giros et al., 1996). Recent reports suggest that DAT, but not the serotonin transport (SERT), 
is critical in mediating the reinforcing effects of cocaine. In addition, mice lacking DAT 
generally failed to acquire and maintain cocaine self-administration (Thompson et al., 2009) 
compared to wild-type or SERT-/- mice. Therefore, DAT may play a role in mediating the 
long-lasting neural changes associated with drug addiction (Martin et al., 2011; Schmitt and 
Reith 2010). 
Drug addiction involves several molecules such as CART (Cocaine-and amphetamine-
regulated transcript) peptide. This peptide is a neurotransmitter believed to play a 
homeostatic role in psychostimulant reward and reinforcement, as well as in other processes 
(Jaworski and Jones, 2006; Rogge et al., 2008). CART has also been proved to attenuate 
locomotion induced by direct intraaccumbal injections of DA (Jaworski et al., 2003). 
Recently, it has been documented that the role of CART peptide in the NAc is to 
homeostatically regulate the activity of the DA system (Rogge et al., 2008). Moreover CART 
mRNA and CART peptide are found abundantly in the NAc (Douglass et al., 1995; Koylu et 
al., 1998). CART peptide (CART55-1029) has been shown to have minor psychostimulant-
like properties when injected into the VTA, inducing locomotor activity and producing a 
slightly conditioned place preference (Kimmel et al., 2000, 2002). In this sense, a new study 
supports the idea that CART peptide reduces the effects of psychostimulants by modulating 
the simultaneous activation of both D1 and D2 receptors, rather than by affecting the action 
of any individual DA receptor (Moffett et al., 2011). In addition, our recent report suggests 
that prenatal amphetamine exposure produced, at postpubertal age, an enhanced DAT in 
the NAc (Flores et al., 2011, Figures 2, 3, 4) and children with prenatal psychostimulant 





































































































Fig. 2. Effect of amphetamine on locomotor behavior in a novel environment. A) Analysis of 
total activity scores revealed that the rats at PD60 were more active after amphetamine 
injection than their corresponding control group. B) Temporal profile of locomotor activity 
at PD60. C) Rats with prenatal amphetamine exposure were less active than control animals. 
Modified from Flores et al., 2011. 
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Fig. 2. Effect of amphetamine on locomotor behavior in a novel environment. A) Analysis of 
total activity scores revealed that the rats at PD60 were more active after amphetamine 
injection than their corresponding control group. B) Temporal profile of locomotor activity 
at PD60. C) Rats with prenatal amphetamine exposure were less active than control animals. 
Modified from Flores et al., 2011. 
 



















Fig. 3. Quantitative autoradiographic analysis of [3H]- SCH-23390/dopamine D1-like 
receptor binding, [3H]-spiperone/dopamine D2-like receptor binding, [3H]7-
OHDPAT/dopamine D3 receptor binding and [3H] WIN-35428/dopamine transporter 
binding in prenatal amphetamine exposure (PAE)- and prenatal vehicle exposure (PVE)-rats 
Dopamine (DA), Postnatal (PD), nucleus accumbens (NAcc), caudate–putamen (CPu), 
olfactory tubercle (OT) and the island of Calleja. (Modified from Flores et al., 2011).  
 


















Fig. 4. Photomicrograph showing representative Golgi-Cox-impregnated medium spiny 
neurons and spines dendritic from the nucleus accumbens. Neurons in the nucleus 
accumbens core (A) and shell (B). The spine density is higher at PD60 in the dendritic 
segments from the core (A2) and shell (B2) subregions of the NAc of rats prenatally exposed 
to amphetamine compared to their corresponding vehicle group. 
Cocaine and amphetamine may induce neural changes, including an increase in the density 
of spines on neuron dendrites in the NAc and PFC (Robinson and Kolb, 2004) associated 
with locomotor sensitization (Manev and Uz, 2009). More recently it has been suggested that 
cocaine-induced dendritic spine changes are correlated with the presence of DAT, because 
mice lacking DAT did not show an increase in dendritic spine density in the NAc (Martin et 
al., 211). In addition, the stereotypy induced by cocaine is also absent in this transgenic mice 
(Tilley and Gu, 2008). However, amphetamine and cocaine, although similar in many 
respects, do not produce identical patterns of structural plasticity when given to rats at 
different ages. In adult rats, several reports have demonstrated that cocaine increases spine 
density on the basilar dendrites of pyramidal neurons in the PFC, while amphetamine has 
either no effect or a weak effect on these dendrites. In contrast, in juvenile (P22–P34) rats, 
amphetamine increases spine density on the basilar dendrites of PFC (for review see 
Robinson and Kolb, 2011).  
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In conclusion, DAT is one of the principal mechanisms regulating DA neurotransmission via 
reuptake of synaptic DA. The psychostimulants amphetamine and cocaine alter DAT 
function and alter the lifetime of the DA after release. Exposure to amphetamine or cocaine 
produced persistent changes in the structure of dendrites and dendritic spines in brain 
regions such as the NAc and PFC, limbic structures related with the addictions. This 
structural plasticity associated with the use of the drugs of abuse results in a reorganization 
of synaptic connectivity in these neural systems, which may associate with addiction 
symptoms. Several reports suggest that cocaine abusers have an increase in DAT levels with 
a decrease in gray and white matter density (Gould et al., 2011), however, abstainers have 
significantly higher gray matter density and lower DAT levels than current cocaine users 
(Hanlon et al., 2011; Gould et al., 2011). Therefore, both, DAT levels and gray matter density 
in cocaine users reverse after prolonged abstinence (Volkow et al., 2001; Beverigde et al., 
2009; Hanlon et al., 2011). Interestingly, cocaine abstainers perform better cognitive test 
compared to current cocaine users (Hanlon et al., 2011). 
6. Treatment of addiction 
Despite intensive research and significant advances, drug addictions remain a substantial 
public health problem. Drug addictions have a high economical cost annually and impact 
not only the addicted individuals, but also their spouses, children, employers, and others. 
Thus, the development of improved prevention and treatment strategies is of importance 
(Potenza et al., 2011). Learning processes have been shown to play a major role in the 
maintenance of addictive behaviour (Everitt et al., 1999; Robbins & Everitt, 2002; Everitt & 
Robbins, 2005; Moreira & Lutz, 2008; Liu et al., 2010). Humans and animals rapidly learn 
cues and contexts that predict the availability of addictive drugs. Once learned, these cues 
and contexts initiate drug seeking, craving and relapse in both animal models and clinical 
studies (Von der Goltz & Kiefer, 2009; De Vries & Schoffelmeer, 2005; Micale et al., 2007). 
Evidence suggests that several types of neuroadaptation occur, including synapse-specific 
adaptations of the type thought to underlie specific long-term associative memory. Thus, 
understanding learning and memory processes in the addicted is an important key for 
understanding the persistence of addiction, and it is reasonable to hypothesize that the 
disruption of drug-related memories may help to prevent relapses (von der Goltz & Kiefer, 
2009). The study of structure-activity relationships of molecules which influence the 
cannabinoid system in the brain and body is crucial in the search of medical preparations 
with the therapeutic effects of the phytocannabinoids without the negative effects on 
cognitive function attributed to cannabis (see Fisar, 2009 for review).  
As discussed before, cannabinoid CB1Rs are novel targets for a new class of therapeutic 
agents used to treat drug addiction. Blockade of the CB1 receptor is particularly effective in 
reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced 
relapse in human addicts (See Gardner, 2002, 2005, 2011 for review). These relapse-
preventing properties are observed with different classes of abused drug (i.e. 
psychostimulants, opiates, nicotine and alcohol). In addition, recent evidence indicates a 
more general role of CB1 receptors in reward-related memories, which is consistent with the 
proposed role of endocannabinoids in memory-related plasticity. Relapse-preventing 
actions and inhibitory effects on weight gain were confirmed recently in clinical trials with 
the CB1 antagonist rimonabant (De Vries and Schoffelmeer, 2005). Preclinical results 
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provide support for the suggestion that targeting the endocannabinoid system may aid in 
the treatment of disorders associated with impaired extinction-like processes, such as post-
traumatic stress disorder (Abush and Akirav, 2010). Liu et al. (2010) provided evidence that 
NMDA receptor-dependent synaptic depression at VTA dopamine circuitry requires GluR2 
endocytosis, also suggest an essential contribution of such synaptic depression to 
cannabinoid-associated addictive learning, in addition to pointing to novel pharmacological 
strategies for the treatment of cannabis addiction. They found in rats that chronic 
cannabinoid exposure activates VTA CB1 receptors to induce transient neurotransmission 
depression at VTA local Glu-DA synapses through activation of NMDA receptors and 
subsequent endocytosis of AMPA receptor GluR2 subunits. A GluR2-derived peptide blocks 
cannabinoid-induced VTA synaptic depression and conditioned place preference, i.e., 
learning to associate drug exposure with environmental cues.  
6.1 Pharmacological treatments and targets 
Multiple pharmacological targets have been identified for the treatment of addictive 
disorders. ‘‘Classic’’ approaches tend to target the drug ‘‘reward’’ system, such as 
normalization of function through agonist approaches and negative reinforcement 
strategies. Agonist medications have their main impact on the same types of 
neurotransmitter receptors as those stimulated by abused substances. Most notably, 
dextroamphetamine has reduced drug use in short-term clinical trials in cocaine and 
methamphetamine users. The long-term safety and abuse liability of amphetamines as a 
treatment for cocaine addiction remains to be determined. Another example of an agonist 
approach for cocaine dependence is modafinil, a weak DAT inhibitor and increases synaptic 
DA levels, which has stimulant-like effects. On other hand, antagonists block the effects of 
drugs by either pharmacological or pharmacokinetic mechanisms. More recently, 
immunotherapies have been developed for the treatment of cocaine and methamphetamine 
addictions. The antibodies produced by immunotherapies sequester the drug in the 
circulation and reduce the amount of drug and the speed at which it reaches the brain. A 
potentially promising target for agonist and antagonist treatment of cocaine addiction is the 
D3 dopamine receptor. D3 partial agonists can act like agonists and stimulate DA receptors 
when endogenous levels of dopamine are low, as in cocaine withdrawal. An important 
limitation of vaccines is that the antibodies produced are specific for a given drug of abuse, a 
characteristic that will limit their clinical efficacy in polydrug abusers.  
Drug addiction is associated with adaptive changes in multiple neurotransmitter systems in 
the brain. These adaptive changes are thought to underlie the negative reinforcing effects of 
abstinence from drug use that are clinically observed as withdrawal symptoms, craving for 
drug use, and negative mood states like anhedonia and anxiety (Hasin et al., 2007; Treadway 
and Zald, 2011). Examples of medications targeting negative reinforcement of drugs include 
methadone or buprenorphine, drugs that relieve opioid withdrawal symptoms. Cocaine users 
with more severe withdrawal symptoms respond more favorably to propranolol, a beta-
adrenergic antagonist (Kampman et al., 2006). Several agents targeting glutamate system are 
also under investigation as potential treatment medications. Memantine, a noncompetitive 
NMDA glutamate receptor antagonist, may be efficacious and operate by reducing cognitive 
measures of compulsivity (Grant et al., 2010). However, clinical trials with an NMDA receptor 
antagonist have demonstrated negative findings for cocaine dependence (Bisaga et al., 2010). 
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Activation of cannabinoid receptors on synaptic terminals results in regulation of ion channels, 
neurotransmitter release and synaptic plasticity. Neuromodulation of synapses by the 
cannabinoids is proving to have a wide range of functional effects, making them potential 
targets as medical preparations in a variety of illnesses, including some mental disorders and 
neurodegenerative illnesses (see Fisar, 2009 for review).  
In conclusion, the review of existing evidences indicates that addictive drugs induce 
synaptic plasticity at DA system and produce changes in DA at different target structures of 
the brain, affecting glutamateric, GABAergic transmission and LTP and LTD processes 
(Figure 5). New research will without doubt shed light onto the mechanisms of addiction 






















Fig. 5. Addictive drug affects DA levels, glutamatergic and GABAergic transmission and 
LTP and LTD processes at different brain structures. DA: dopamine; CA1: CA1 region of the 
hippocampus; PFC, prefrontal cortex; NAc: accumbens nucleus; BLA: basolateral amygdala.  
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Activation of cannabinoid receptors on synaptic terminals results in regulation of ion channels, 
neurotransmitter release and synaptic plasticity. Neuromodulation of synapses by the 
cannabinoids is proving to have a wide range of functional effects, making them potential 
targets as medical preparations in a variety of illnesses, including some mental disorders and 
neurodegenerative illnesses (see Fisar, 2009 for review).  
In conclusion, the review of existing evidences indicates that addictive drugs induce 
synaptic plasticity at DA system and produce changes in DA at different target structures of 
the brain, affecting glutamateric, GABAergic transmission and LTP and LTD processes 
(Figure 5). New research will without doubt shed light onto the mechanisms of addiction 






















Fig. 5. Addictive drug affects DA levels, glutamatergic and GABAergic transmission and 
LTP and LTD processes at different brain structures. DA: dopamine; CA1: CA1 region of the 
hippocampus; PFC, prefrontal cortex; NAc: accumbens nucleus; BLA: basolateral amygdala.  
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1. Introduction  
The principal routes of cocaine administration are oral, intranasal, intravenous, and 
inhalation. The slang terms for these routes are, respectively, "chewing," "snorting," 
"mainlining," "injecting," and "smoking" (including freebase and crack cocaine). Cocaine use 
ranges from occasional use to repeated or compulsive use, with a variety of patterns 
between these extremes. There is no safe way to use cocaine. Any route of administration 
can lead to absorption of toxic amounts of cocaine, allowing to acute cardiovascular or 
cerebrovascular emergencies that could result in sudden death. Repeated cocaine use by any 
route of administration can produce addiction and other adverse health consequences. 
Those who snort or sniff cocaine through their noses suffer damage to their nasal and sinus 
passages. These include nasal crusting, nosebleeds, nasal congestion, irritation, facial pain 
caused by sinusitis and hoarseness. 
Cocaine addiction changes the responsiveness of the brain to various neurotransmitters or 
chemicals. The development of drug addiction involves persistent cellular and molecular 
changes in the Central Nervious System. The brain dopamine, GABA and glutamate 
systems play key roles in mediating drug-induced neuroadaptation. We show some 
physiological changes that can occur in some key pathways in which glutamate, dopamine 
and GABA receptors are involved. These chemical changes cause different effects in users, 
including: anxiety, confusion, dizziness, psychosis, headaches and nausea.  
Cocaine use and addiction affects the sympathetic nervous system (which controls 
automatic functions such as breathing, heartbeat, etc.). This system secretes adrenaline 
which raises ones heart rate, narrows blood vessels and significantly increases blood 
pressure. Chest pain, heart attacks and strokes are common side effects of cocaine use.  
The most widely studied neurobiological characteristic of cocaine addiction is the role 
played by dopamine transmission. It is clear that enhanced dopamine transmission in 
neurons projecting from the ventral mesencephalon to the limbic forebrain, including the 
medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), is the pharmacological 
target for cocaine-induced reinforcement and locomotor stimulation (O’Brien., 2001) 
However, persistence of the behavioral characteristics of cocaine addiction, such as paranoia 
(sensitization) and the propensity to relapse years after the acute rewarding effects of the 
drug have disappeared, indicates that there must also be neuronal substrates undergoing 
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which raises ones heart rate, narrows blood vessels and significantly increases blood 
pressure. Chest pain, heart attacks and strokes are common side effects of cocaine use.  
The most widely studied neurobiological characteristic of cocaine addiction is the role 
played by dopamine transmission. It is clear that enhanced dopamine transmission in 
neurons projecting from the ventral mesencephalon to the limbic forebrain, including the 
medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), is the pharmacological 
target for cocaine-induced reinforcement and locomotor stimulation (O’Brien., 2001) 
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(sensitization) and the propensity to relapse years after the acute rewarding effects of the 
drug have disappeared, indicates that there must also be neuronal substrates undergoing 
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long-term neuroplastic changes. Although studies have endeavored to identify enduring 
changes in dopamine transmission that might underlie behavioral sensitization and the 
reinstatement of drug-seeking (relapse), the results have not been entirely consistent with an 
obligatory role for dopamine. 
Addiction can be viewed as a form of drug-induced neural plasticity. One of the best-
established molecular mechanisms of addiction is up-regulation of the cAMP second 
messenger pathway, which occurs in many neuronal cell types in response to chronic 
administration of opiates or other drugs of abuse. This up-regulation and the resulting 
activation of the transcription factor CREB appear to mediate aspects of tolerance and 
dependence. In contrast, induction of another transcription factor, termed 1FosB, exerts the 
opposite effect and may contribute to sensitized responses to drug exposure. Knowledge of 
these mechanisms could lead to more effective treatments for addictive disorders. 
2. The neurobiology of cocaine addiction 
Dopamine acts as a modulator for many nerve cells throughout the brain. Dopamine is 
responsible for keeping those cells operating at the appropriate levels of activity to accomplish 
our needs and aims (Nestler., 2005). Whenever we need to mobilize our muscles or mind to 
work harder or faster, dopamine drives some of the involved brain cells to step up to the 
challenge (Nestler., 2005).  The targets in brain and other organs are shown in figure 1. 
 
Fig. 1. Cocaine and receptors associated with its toxicity. Continuous lines show the main 
target organs affected; dashed lines represent the secondary neurotransmitters associated. 
(Adapted from Nestler., 2005) 
Dopamine is originated in dopaminergic neurons and launch them into their surroundings. 
Some of the free-floating dopamine molecules latch onto receptor proteins on neighboring 
cells. Once attached, dopamine stimulates the receptors to alter electrical impulses in the 
receiving cells and thereby alter the cells’ function.  To keep the receiving cells in each brain 
region functioning at appropriate intensities for current demands the dopaminergic cells 
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further regulate the amount of dopamine available to stimulate the receptors by pulling 
some previously released dopamine molecules back into themselves (Nestler., 2005). 
One of the most addictive drugs is cocaine. Cocaine can act mainly on the mesoaccumbens 
dopamine (DA) pathway of the midbrain, extending from the ventral tegumental area 
(VTA) to the nucleus accumbens (NAc).  This pathway is also known as the reward pathway 
as it is the area of the brain that is activated when someone has a pleasurable experience 
such as eating, sex, or receiving praise. Cocaine interferes with the dopamine control 
mechanism: It ties up the dopamine transporter. As a result, with cocaine on board, 
dopamine molecules that otherwise would be picked up remain in action. Dopamine builds 
up and overactivates the receiving cells. However, DA is not the only system affected by 
cocaine. Glutamate and neurotransmission mediated for this aminoacid is also modified and 
has an importantt role in the  mechanism  of this drug addiction. 
 
Fig. 2. The potential mechanisms regulating glutamatergic transmission in the NAc that are 
involved in the reinstatement of drug-seeking behavior. The cocaine-induced changes in 
extrasynaptic glutamate release outlined below are postulated to increase the signal-to-noise 
ratio of synaptically released glutamate, thereby facilitating drug-seeking. 1. Homer protein 
is reduced in the nucleus accumbens, causing a reduction in signaling via mGluR1 receptors 
through inositol trisphosphate (IP3) receptor regulation of internal calcium (Ca) stores. 2. 
Because glutamate release stimulated by mGluR1 receptors results from activation of the 
cystine/glutamate exchanger, it is proposed that down regulated mGluR1 signaling may 
mediate the reduced activity of the cystine/glutamate exchanger produced by chronic 
cocaine administration. 3. The reduced heteroexchange of extracellular cystine (C) for 
intracellular glutamate (E) in glia results in reduced basal extracellular glutamate and 
reduced tone on mGluR2/3 presynaptic autoreceptors. 4. This reduced tone, accompanied 
by mGluR2/3 residing in a more phosphorylated (desensitized) state, results in reduced 





































Addictions – From Pathophysiology to Treatment 
 
104 
long-term neuroplastic changes. Although studies have endeavored to identify enduring 
changes in dopamine transmission that might underlie behavioral sensitization and the 
reinstatement of drug-seeking (relapse), the results have not been entirely consistent with an 
obligatory role for dopamine. 
Addiction can be viewed as a form of drug-induced neural plasticity. One of the best-
established molecular mechanisms of addiction is up-regulation of the cAMP second 
messenger pathway, which occurs in many neuronal cell types in response to chronic 
administration of opiates or other drugs of abuse. This up-regulation and the resulting 
activation of the transcription factor CREB appear to mediate aspects of tolerance and 
dependence. In contrast, induction of another transcription factor, termed 1FosB, exerts the 
opposite effect and may contribute to sensitized responses to drug exposure. Knowledge of 
these mechanisms could lead to more effective treatments for addictive disorders. 
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work harder or faster, dopamine drives some of the involved brain cells to step up to the 
challenge (Nestler., 2005).  The targets in brain and other organs are shown in figure 1. 
 
Fig. 1. Cocaine and receptors associated with its toxicity. Continuous lines show the main 
target organs affected; dashed lines represent the secondary neurotransmitters associated. 
(Adapted from Nestler., 2005) 
Dopamine is originated in dopaminergic neurons and launch them into their surroundings. 
Some of the free-floating dopamine molecules latch onto receptor proteins on neighboring 
cells. Once attached, dopamine stimulates the receptors to alter electrical impulses in the 
receiving cells and thereby alter the cells’ function.  To keep the receiving cells in each brain 
region functioning at appropriate intensities for current demands the dopaminergic cells 
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The way in which this sequence of adaptations could synergize to dysregulate presynaptic 
glutamate transmission in cocaine addiction is illustrated in Figure 2. This hypothetical 
model describes how reduced Homer1bc could account for reduced activity of the cystine-
glutamate exchanger and the accompanying reduced basal levels of extracellular glutamate. 
The reduced levels of glutamate, combined with desensitization of the mGluR2/3 receptor, 
results in a loss of regulatory feedback on synaptic glutamate release. Thus, lower basal 
levels of glutamate, combined with increased release of synaptic glutamate in response to 
activation of prefrontal cortical afferents to the NAc, results in an amplified signal and 
behavioral drive to engage drug seeking (e.g. to relapse). In addition to adaptations in 
presynaptic and possibly glial release of glutamate that regulate the expression of 
sensitization and/or reinstatement  a variety of changes in postsynaptic glutamate 
transmission have been documented in the NAc. Interestingly, although presynaptic release 
of glutamate was augmented by withdrawal from repeated cocaine, most data indicate a 
reduction in postsynaptic responses to glutamate (Kalivas., 2004). 
3. Brain changes during cocaine addiction 
Animal studies of cocaine´s action have focused on a set of subcortical gray matter of some 
structures as paralimbic cortices, that are involved in the mediation of reward and 
reinforcement, most notably the ventral tegmental area of the midbrain, the nucleus 
accumbens, the amygdala, and regions of the prefrontal cortex (Makris et al., 2004). Existing 
studies of brain structure in cocaine users have reported abnormalities only in brain regions 
connected to the amygdala, such as the orbitofrontal and anterior cingulate cortex (Franklin 
et al., 2002; Matochik et al., 2003). Markis et al., (2004) sought to evaluate the hypothesis that 
topological and volumetric abnormalities may exist in the amygdala of cocaine-dependent 
subjects that may represent a predisposition to cocaine addiction, or an adaptation to 
protracted exposure to the drug. Amygdala volume and topology were assessed by 
segmentation-based morphometric analysis, and absolute quantitative volumetric measures 
were performed. It was observed that amygdala volume of cocaine-dependent subjects was 
significantly smaller than the one of matched controls. 
The amygdala volumes of cocaine-dependent subjects were similar for each hemisphere, 
whereas those of their matched controls had clear laterality differences. In addition, 
amygdala volume in addicts did not correlate with (1) measures of anxiety or depression, (2) 
any measure of the amount of cocaine use, or (3) age at which cocaine use began (Makris et 
al., 2004) 
Barrós-Loscertales et al., (2011) reported reduced gray matter (GM) volume in the striatum 
and in the supramarginal gyrus. Likewise, another set of cortical and subcortical structures, 
such as the amygdala, the insula and dorsolateral prefrontal cortex, were seen to have 
volume reductions related to years of cocaine exposure (Barrós-Loscertales et al., 2011). All 
these structural changes associated with cocaine addiction seem to merge in the striato-
cortico-limbic circuitry linked not only to addiction, but also to the wider set of disinhibitory 
disorders (Barrós-Loscertales et al., 2011). Although causal relationships are very difficult to 
determine in human studies, the significant relationship between years of use and reduced 
GM volumes are consistent with these volumetric effects arising from the cumulative 
exposure to cocaine or the concomitant lifestyle (e.g., stress) that accompanies prolonged 
drug use (Yücel et al., 2008). 
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In other aspects, Ersche et al., (2011) found some differences between healthy and cocaine 
users, specially in the gray matter abundance in some regions of the brain. There was 
widespread significant loss of grey matter in orbitofrontal cortex bilaterally in the cocaine 
user group. Grey matter volume was also abnormally reduced in the insula, the medial 
frontal and anterior cingulate cortex, temporoparietal cortex and the cerebellum. In contrast 
to this extensive system of decreased cortical grey matter volume, cocaine users also showed 
a significant increase of grey matter volume mainly localized to basal ganglia structures 
(including putamen, caudate nucleus and pallidum), and cerebellum (figure 3).  
 
Fig. 3. Whole-brain maps of significant differences in grey matter volume between healthy 
volunteers and cocaine users. Voxels coloured blue indicate brain areas in which cocaine 
users have reduced grey matter volume compared with healthy volunteers, and voxels 
coloured red indicate brain areas in which cocaine users have abnormally increased grey 
matter volume. These results were generated by permutation testing of voxel cluster 
statistics with cluster-wise P50.001, at which level we expect less than one false positive 
cluster per map. The statistical results are overlaid on the FSL MNI152 standard T1 image 
and the numbers beneath each section of the image refer to its position (mm) relative to the 
intercommissural plane in standard stereotactic space. L = left; R = right. (Ersche et al., 2011) 
In addition, it has been found that the caudate enlargement in cocaine users was associated 
with significant attentional impairments, whereas the reduction in grey matter in the 
orbitofrontal cortex was associated with cocaine-related compulsivity. The abnormal 
changes in grey matter in the striatum and in the orbitofrontal cortex were both related to 
the duration of cocaine abuse (Ersche et al., 2011). 
 
Addictions – From Pathophysiology to Treatment 
 
106 
The way in which this sequence of adaptations could synergize to dysregulate presynaptic 
glutamate transmission in cocaine addiction is illustrated in Figure 2. This hypothetical 
model describes how reduced Homer1bc could account for reduced activity of the cystine-
glutamate exchanger and the accompanying reduced basal levels of extracellular glutamate. 
The reduced levels of glutamate, combined with desensitization of the mGluR2/3 receptor, 
results in a loss of regulatory feedback on synaptic glutamate release. Thus, lower basal 
levels of glutamate, combined with increased release of synaptic glutamate in response to 
activation of prefrontal cortical afferents to the NAc, results in an amplified signal and 
behavioral drive to engage drug seeking (e.g. to relapse). In addition to adaptations in 
presynaptic and possibly glial release of glutamate that regulate the expression of 
sensitization and/or reinstatement  a variety of changes in postsynaptic glutamate 
transmission have been documented in the NAc. Interestingly, although presynaptic release 
of glutamate was augmented by withdrawal from repeated cocaine, most data indicate a 
reduction in postsynaptic responses to glutamate (Kalivas., 2004). 
3. Brain changes during cocaine addiction 
Animal studies of cocaine´s action have focused on a set of subcortical gray matter of some 
structures as paralimbic cortices, that are involved in the mediation of reward and 
reinforcement, most notably the ventral tegmental area of the midbrain, the nucleus 
accumbens, the amygdala, and regions of the prefrontal cortex (Makris et al., 2004). Existing 
studies of brain structure in cocaine users have reported abnormalities only in brain regions 
connected to the amygdala, such as the orbitofrontal and anterior cingulate cortex (Franklin 
et al., 2002; Matochik et al., 2003). Markis et al., (2004) sought to evaluate the hypothesis that 
topological and volumetric abnormalities may exist in the amygdala of cocaine-dependent 
subjects that may represent a predisposition to cocaine addiction, or an adaptation to 
protracted exposure to the drug. Amygdala volume and topology were assessed by 
segmentation-based morphometric analysis, and absolute quantitative volumetric measures 
were performed. It was observed that amygdala volume of cocaine-dependent subjects was 
significantly smaller than the one of matched controls. 
The amygdala volumes of cocaine-dependent subjects were similar for each hemisphere, 
whereas those of their matched controls had clear laterality differences. In addition, 
amygdala volume in addicts did not correlate with (1) measures of anxiety or depression, (2) 
any measure of the amount of cocaine use, or (3) age at which cocaine use began (Makris et 
al., 2004) 
Barrós-Loscertales et al., (2011) reported reduced gray matter (GM) volume in the striatum 
and in the supramarginal gyrus. Likewise, another set of cortical and subcortical structures, 
such as the amygdala, the insula and dorsolateral prefrontal cortex, were seen to have 
volume reductions related to years of cocaine exposure (Barrós-Loscertales et al., 2011). All 
these structural changes associated with cocaine addiction seem to merge in the striato-
cortico-limbic circuitry linked not only to addiction, but also to the wider set of disinhibitory 
disorders (Barrós-Loscertales et al., 2011). Although causal relationships are very difficult to 
determine in human studies, the significant relationship between years of use and reduced 
GM volumes are consistent with these volumetric effects arising from the cumulative 
exposure to cocaine or the concomitant lifestyle (e.g., stress) that accompanies prolonged 
drug use (Yücel et al., 2008). 
 
Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission 
 
107 
In other aspects, Ersche et al., (2011) found some differences between healthy and cocaine 
users, specially in the gray matter abundance in some regions of the brain. There was 
widespread significant loss of grey matter in orbitofrontal cortex bilaterally in the cocaine 
user group. Grey matter volume was also abnormally reduced in the insula, the medial 
frontal and anterior cingulate cortex, temporoparietal cortex and the cerebellum. In contrast 
to this extensive system of decreased cortical grey matter volume, cocaine users also showed 
a significant increase of grey matter volume mainly localized to basal ganglia structures 
(including putamen, caudate nucleus and pallidum), and cerebellum (figure 3).  
 
Fig. 3. Whole-brain maps of significant differences in grey matter volume between healthy 
volunteers and cocaine users. Voxels coloured blue indicate brain areas in which cocaine 
users have reduced grey matter volume compared with healthy volunteers, and voxels 
coloured red indicate brain areas in which cocaine users have abnormally increased grey 
matter volume. These results were generated by permutation testing of voxel cluster 
statistics with cluster-wise P50.001, at which level we expect less than one false positive 
cluster per map. The statistical results are overlaid on the FSL MNI152 standard T1 image 
and the numbers beneath each section of the image refer to its position (mm) relative to the 
intercommissural plane in standard stereotactic space. L = left; R = right. (Ersche et al., 2011) 
In addition, it has been found that the caudate enlargement in cocaine users was associated 
with significant attentional impairments, whereas the reduction in grey matter in the 
orbitofrontal cortex was associated with cocaine-related compulsivity. The abnormal 
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the duration of cocaine abuse (Ersche et al., 2011). 
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In another interesting description, Ersche et al., (2011) showed some maps of brain regions 
demonstrating significant association between grey matter volume and measures of 
duration of cocaine use, compulsivity and impulsivity in the group of cocaine users (figure 
4). This study allow see that is possible find some positive and negative correlations 
between grey matter and duration of cocaine use, or compulsive cocaine taking or 
impulsivity in cocaine users.  
 
Fig. 4. Maps of brain regions. Regions where grey matter volume correlated significantly 
with the duration of cocaine use in drug users are indicated in orange. Regions that 
correlated significantly with compulsive cocaine-taking are coloured in green. Regions 
where grey matter volume correlated significantly with the inattention component of 
impulsivity in cocaine users are indicated in red (if the correlation was positive) and blue (if 
the correlation was negative). The scatter plots beneath each section of the brain image show 
the correlation between these measures and the total grey matter volume for each drug user. 
The numbers above each section of the image refer to its plane position (mm) relative to the 
origin in MNI stereotactic space. L = left; R = right (Ersche et al., 2011). 
In addition, there are differences between the cocaine-dependent and healthy groups. For 
example, the cocaine users had higher depressive scores than the healthy people, and fewer 
years in formal education (11.5 compared to 12.3 years). Most of the cocaine users also had 
nicotine dependence (83%), some also had alcohol dependence (27%), cannabis dependence 
(18%) and heroin dependence (7%). These factors may also have been related to the brain 
differences seen, rather than just the cocaine use. Morever, Ersche et al., (2011), noted that 
impulsivity is a complex trait and that the measures they used would not have captured all 
aspects of it.  
4. The signaling pathways involved in cocaine addiction 
The drugs of abuse differ greatly in their chemical structure, they act on their own unique 
target that are mostly proteins involved in synaptic transmission, although different drugs 
affect different neurotransmitter systems (Nestler, E., 2004). 
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All addictive drugs facilitate dopamine transmission. The dopamine projection to the 
prefrontal cortex (PFC), nucleus accumbens (NAc) and amygdala is a primary site of 
pharmacological action by cocaine, as well as a site where addictive behaviors such as 
relapse and sensitization can be initiated (Berridge and Robinson., 1998). The regions of the 
prefrontal cortex most clearly tied to addiction in both neuroimaging studies in addicts and 
lesion/pharmacological studies in animal models of addiction (rats) are the anterior 
cingulate/prelimbic cortex and the ventral orbital cortex (Neisewander et al., 2000; 
Goldstein and Volkow., 2002; Kalivas., 2004). 
The NAc is composed of two compartments termed the core and the shell (Zahm and Brog., 
1992) and, although the shell is more clearly associated with dopamine-dependent reward, 
the core has been linked to the enduring cellular changes elicited by repeated use of 
addictive drugs (Di Ciano and Everitt., 2001; Kalivas and McFarland., 2003). The projections 
from the amygdala and prefrontal cortex to the nucleus accumbens are glutamatergic, as are 
the reciprocal connections between the basolateral amygdala and prefrontal cortex (figure 
5). The prefrontal cortex also sends glutamatergic efferents to the dopamine cell body region 
in the ventral tegmental area (VTA). This circuit has primary output through co-localized γ-
amino butyric acid (GABA)ergic and peptidergic neurons in the NAc that project to the 
ventral pallidum (PV) and ventral tegmental area (Kalivas., 2004). 
The changes in the NAc, influenced by activation of dopamine receptors, are critically 
involved in behavioral adaptations (Marinelli and White., 2000). Natural rewards, but also 
drugs of abuse, increase VTA release of dopamine in downstream structures such as the 
NAc (Di Chiara, 2002; Schultz., 2002). However, an essential difference between natural 
rewards and drugs of abuse is that, over time, the dopamine response to the natural 
rewards, but not drugs of abuse, diminishes (Kalivas and O'Brien., 2008). Additionally, the 
amount of dopamine released following administration of a drug of abuse, particularly 
cocaine, typically exceeds what occurs following exposure to a natural reward. Thus, the 
repeated large release of dopamine is believed to be critical in the development of addiction, 
as it alters and modifies structures and their connections (Uys and LaLumiere,. 2008). 
 
Fig. 5. The schematic diagram identify the critical structures involved in drug reward and 
relapse to cocaine seeking.  VTA, Ventral tegmental area; PFC, Prefrontal cortex; NAc, 
Nucleus accumbens; VP, Ventral pallidum. 
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The VTA–NAc, so called mesolimbic, pathway seems to be a site where virtually all drugs of 
abuse converge to produce their acute reward signals. Two major mechanisms are involved: 
first, all drugs of abuse increase dopamine-mediated transmission in the NAc, although by 
very different mechanisms; second, some drugs also act directly on NAc neurons by 
dopamine-independent mechanisms (Everitt and Wolf., 2002).  
An interesting point is the intracellular event precipitated by stimulation of dopamine 
receptors as a result of repeated use of cocaine. In dopamine D1 receptor stimulation of 
cAMP-dependent protein kinase (or PKA) and subsequent changes in protein function and 
gene expression in the NAc and VTA appear critical to establishing sensitization (Nestler., 
2001). The most well-characterized effect of increased cAMP-dependent protein kinase 
activity is the induction of cAMP response element and the subsequent change in ∆FosB and 
cyclin-dependent kinase 5 (Nestler et al., 2001; Lu et al., 2003). In addition to the immediate 
consequences of dopamine receptor signaling, calcium/calmodulin and ras/mitogen-
activated protein kinase activity in the ventral tegmental area are critical for the 
development of sensitization (figure 6).  The dopamine D1 receptor stimulation–dependent 
activation of L-type Ca2+ channels and CaMKII facilitates the reinstatement of cocaine 
seeking by promoting the transport of GluA1-containing AMPA receptors in the NAc shell 
to the plasma membrane. The CaMKII activity in the NAc shell may be an essential link 
between dopamine and glutamate systems involved in the neuronal plasticity underlying 
cocaine craving and relapse (figure 6). (Wolf et al., 2004; Boehm and Malinow., 2005; 
Schmidt and Pierce., 2010). 
 
Fig. 6. Pathway between NAc shell dopamine and glutamate systems, via L-type Ca2+ 
channels and Ca2+/calmodulin kinase II (CaMKII), which is proposed to underlie the 
reinstatement of cocaine seeking. (Adapted from Schmidt and Pierce., 2010).  
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In contrast to dopamine, glutamate transmission appears to be a primary contributor in the 
majority of examples of enduring neuroplasticity in the brain, and the development and 
expression of cocaine addiction is no exception (Winder et al., 2002).  The activation of 
glutamatergic efferents from the amygdala and prefrontal cortex is critical in the expression 
of addictive behaviors. 
Cocaine indirectly influences glutamate transmission in the limbic system, including the 
NAc, producing persistent changes in neuronal function that can alter the behavioral effects 
that generate this drug. (Gass and Olive., 2008; Uys and LaLumiere., 2008; Thomas et al., 
2008). Thus, maladaptive forms of neuroplasticity in the NAc contribute to cocaine-seeking 
behavior, and reversing these cocaine-induced neuroadaptations in glutamatergic 
transmission may prevent relapse of cocaine taking. 
The interaction between glutamate and dopamine in VTA and NAc is rather complex, but in 
simplified terms, glutamatergic input to the VTA increases the activity of dopaminergic cells 
and enhances dopamine release in the NAc (Tzschentke., 2001). At the level of the NAc, 
glutamate also facilitates dopaminergic transmission, presumably by presynaptically 
influencing dopamine release (Floresco et al., 1998; Tzschentke and Schmidt., 2003). 
5. The role of glutamate, and GABA receptors in cocaine addiction 
The glutamate as neurotransmitter interacts with specific ionotropic glutamate receptors 
(iGluR) or metabotropic glutamate receptors (mGluR) (Dingledine et al., 1999; Cull-Candy et 
al., 2001). The ionotropic family of glutamate receptors consists of three subfamilies of 
tetrameric receptors; N-methyl-D-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid receptors (AMPAR), and kainate receptors. Agonist 
binding induces a conformation change in NMDA, AMPA, and kainate receptors that 
increases the probability of channel opening. Different subunit compositions of ionotropic 
glutamate receptors produce functionally diverse NMDA, AMPA, and kainate receptors 
that are expressed differently throughout the brain (Dingledine et al., 1999). 
The latter are the G protein-coupled receptor. Through various G proteins, they connect to 
multiple second messenger systems. There are three functional groups of mGluRs (group I–
III) classified from eight subtypes (mGluR1–8) (Conn and Pin., 1997). Group I mGluRs 
(mGluR1/5 subtypes) are positively coupled to phospholipase Cβ1 through Gαq proteins. 
Activation of mGluR1/5 increases phosphoinositol hydrolysis, resulting in intracellular Ca2+ 
release and protein kinase C (PKC) activation (Conn and Pin, 1997). Both group II 
(mGluR2/3) and group III (mGluR4/6/7/8) receptors are negatively coupled to adenylyl 
cyclase through Gαi/o proteins. Their activation reduces cAMP formation and inhibits 
protein kinase A (PKA).  
Group I mGlu receptors can also couple Homer proteins through a Homer-phosphatidyl-
inositol 3-kinase enhancer (PIKE) adaptor complex (Szumlinski et al., 2008). This is 
particularly important for mGlu receptor trafficking into and out of the synapse and also to 
functionally connect mGlu to iGlu receptors.  
5.1 Ionotropic receptors and cocaine 
The glutamate neurotransmission in the NAc core is necessary for cocaine-induced 
behaviors, which are regulated by AMPA receptors (Pierce et al., 1996). In addition, chronic 
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Fig. 6. Pathway between NAc shell dopamine and glutamate systems, via L-type Ca2+ 
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reinstatement of cocaine seeking. (Adapted from Schmidt and Pierce., 2010).  
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In contrast to dopamine, glutamate transmission appears to be a primary contributor in the 
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cocaine treatment changes iGluR’s in both the PFC and NAc. In cocaine sensitized rats, there 
is an increase in GluN2B receptors in the NAc shell and decreased Tyr1472 phosphorylation 
in the NAc core with an increase in GluA1 Ser845 phosphorylation in the PFC, NAc shell 
and core (Zhang et al., 2007). Interestingly, glutamate receptor trafficking may be highly 
relevant for cocaine-induced neuroplasticity (Lau and Zukin., 2007). 
Dopamine D1 receptor stimulation of rat PFC cortical neurons increases surface expression 
of GluA1-containing AMPA receptors through a protein kinase A-dependent mechanism 
(Sun et al., 2005). Cocaine self-administration increases synaptic GluA2-lacking AMPA 
receptors in the NAc after withdrawal (Conrad et al., 2008). Likewise when sensitized 
animals are re-exposed to cocaine after 10–14 days of withdrawal, both AMPAR surface 
expression and AMPA/NMDA ratio were shown to be decreased 24 h later (Boudreau et al., 
2007; Ferrario et al., 2010; Kourrich et al., 2007; Thomas et al., 2001). GluA2-lacking AMPA 
receptors may therefore be a novel target for treating cocaine addiction. 
The effect of repeated cocaine exposure on the cellular distribution of AMPARs is of 
functional significance because it has been shown that drug seeking requires AMPAR 
transmission in the NAc (Cornish and Kalivas, 2000; Di Ciano and Everitt, 2001) and that 
enhanced AMPAR transmission in the NAc is associated with enhanced drug seeking 
(Anderson et al., 2008; Conrad et al., 2008; Suto et al., 2004; Wolf and Ferrario, 2010). 
Carrie et al., (2011) showed effects of a single cocaine exposure in rats and the difference 
from those previously reported after repeated cocaine administration. They further 
suggested that cocaine exerts these effects by influencing neuronal circuits rather than 
simply stimulating NAc DA transmission. 
Cocaine injection administered to rats pretreated with repeated cocaine injections results in 
increased glutamate release in the NAc core (McFarland et al., 2003; Pierce et al., 1996; 
Hotsenpiller et al., 2001). There are different neuroadaptations in the accumbens core and 
the accumbens shell. When cocaine is injected during withdrawal from repeated cocaine 
exposure, occurs that cocaine decreased presynaptic glutamate immunoreactivity in the 
accumbens core, but not the accumbens shell (Kozell et al., 2003, 2004). Similarly, cocaine–
induced reinstatement of drug seeking was associated with increased glutamate release in 
the core of the nucleus accumbens, an effect that is attenuated by pharmacological 
inactivation of the medial prefrontal cortex (mPFC) (McFarland et al., 2003). Then, the 
administration of an AMPA receptor antagonist into the NAc blocked the reinstatement of 
cocaine seeking induced by administration of cocaine directly into the mPFC (Park et al., 
2002). The activation of the glutamatergic projection  from the mPFC to the NAc promotes 
cocaine seeking (Park et al., 2002)., a finding supported by brain imaging studies of human 
cocaine addicts, which demonstrate that cocaine craving is associated with metabolic 
activation of the mPFC (Volkow et al., 2005). These findings also demonstrate that 
stimulation of AMPA glutamate receptors in the NAc  plays a critical role in cocaine seeking 
(Schmidt and Pierce., 2010).  
Has been established an association (correlation) between AMPAR phosphorylation and 
enduring behavioral plasticity (behavioral sensitization and more significantly drug-seeking 
behavior), although a causal link between them remains to be proven experimentally (Mao 
et al., 2011). S845/S831 phosphorylation is likely to be up-regulated to increase surface 
AMPAR expression  thereby enhancing AMPAR transmission related to behavioral 
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plasticity (Boudreau and Wolf, 2005; Conrad et al., 2008). However, self-administration of 
cocaine induced lesser S845 phosphorylation in the striatum as compared to acute cocaine 
injection, establishing a tolerance of S845 phosphorylation in response to chronic cocaine 
(Edwards et al., 2007). This tolerance may reflect a down-regulated GluA1 function in 
accumbens neurons and may contribute to cocaine sensitization and cocaine-seeking 
behavior (Sutton et al., 2003; Bachtell et al., 2008). These imply a phosphorylation-dependent 
mechanism for AMPAR plasticity and drug-seeking (Mao et al., 2011).  
In terms of NMDA receptors there is evidence that links post-translational modifications of 
glutamate receptors to excitatory synaptic plasticity and drug-seeking behavior (Di Ciano, 
Everitt, 2001). Generally, modification processes of striatal glutamate receptors are sensitive 
to addictive drugs such as cocaine.  
Dopamine D2 receptors are involved in the regulation of NMDA receptor phosphorylation 
(Liu et al., 2006). A single dose of cocaine induced a heteroreceptor complex formation 
between D2 receptors and GluN2B-containing NMDA receptor in D2 receptor-bearing 
striatopallidal neurons. The interaction of D2 receptors with GluN2B disrupted the 
association of CaMKII with GluN2B, thereby reducing phosphorylation at the CaMKII-
sensitive site S1303 and inhibiting NMDA receptor currents. Behaviorally, this 
phosphorylation, involving D2–GluN2B interaction, suppressed the inhibitory indirect 
pathway to promote a full motor response to cocaine. Chronic cocaine reduced GluN1 S896 
phosphorylation in the rat frontal cortex at 24 h, although not 14 days after of withdrawal 
(Loftis and Janowsky, 2002). However, acute, repeated, and self-administration of cocaine 
increased GluN1 S897 phosphorylation in the rat striatum (Edwards et al., 2007). Then the 
fact that S897 is a sensitive site modified by cocaine can show the importance of post-
translational modifications in NMDA receptor plasticity and drug craving (Mao et al., 2011; 
Hemby et al., 2005).  
5.2 Metabotropic receptors and cocaine 
An acute injection of cocaine did not alter the total accumbal expression of mGluR5 protein 
but was enough to reduce surface expression of mGluR5 in the nucleus accumbens, 
suggesting that trafficking of mGluRs plays a critical role in cocaine-induced synaptic 
plasticity (Fourgeaud et al., 2004). There is evidence that indicates that mGluR2/3 and 
mGluR5 proteins are redistributed to the synaptosomal membrane fraction after a period of 
extended, but not acute, forced abstinence (Ghasemzadeh et al., 2009).  
In fact, mGluR2/3s have already been demonstrated to play a key role in the excessive 
glutamate release believed to promote drug-seeking (Kalivas, 2004). Acute and chronic 
cocaine treatment alter the normal function, expression or traficking of group I metabotropic 
receptors in the NAc of rats (Mitrano et al., 2008). A single injection of cocaine decreases the 
proportion of plasma membrane-bound mGluR1a in the NAc shell dendrites 45 minutes 
after the injection, while chronic cocaine treatment decreased mGluR1a in the NAc core 
dendrites. This is in contrast to acute and chronic cocaine treatment having no effect on the 
localization of mGluR5 receptors (Mitrano et al., 2008).  Another study found a decrease in 
mGluR1a in the NAc shell of chronic cocaine treated rats (Ary and Szumlinski., 2007; Uys 
and LaLumiere., 2008). Mice lacking mGluR5 receptors do not self-administer cocaine or 
show an increase in locomotor activity after cocaine treatment, despite having a similar 
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increase in dopamine levels in the NAc as compared to wild-type mice (Chiamulera et al., 
2001). Activation of the perisynaptic group II mGluR receptors, mGluR2/3, decreases 
presynaptic glutamate release in the NAc (Xi et al., 2002; Moran et al., 2005) 
Likewise the cocaine-induced plasticity in excitatory synapses within the NAc initiates 
adaptive changes in neuronal ensembles that lead to drug-seeking behavior and alters 
subsequent physiological responses to cocaine, including increased trafficking and surface 
expression of AMPA receptors, during protracted withdrawal (Schmidt and Pierce., 2010). 
Glutamate receptors antagonists produce undesirable side effects on neurological functions. 
Therefore, modulation, rather than blockade, of glutamatergic transmission would be more 
advantageous. Accordingly, glutamate transmission-modulating agents have emerged as 
possible therapeutic compounds in preclinical and clinical studies (Kalivas, 2004). 
5.3 GABA in cocaine addiction 
GABA is an inhibitory neurotransmitter that is found primarily in the brain. As mentioned 
previously, the VTA plays a role in the reinforcing effects of most drugs of abuse, including 
cocaine, and consists of both dopaminergic and GABAergic cell bodies along with afferent 
terminals containing a variety of neurotransmitters. Then GABA acts as the primary 
inhibitory neurotransmitter in the VTA, and the GABAergic environment in the VTA has 
been understudied in the realm of cocaine abuse. High GABA levels result in low levels of 
dopamine. However cocaine diminishes transmission through of type a GABA-A receptor 
on dopaminergic cells in the VTA, and stimulation of other GABA-B receptor, instead, can 
counteract the reinforcing properties of cocaine.  
The activation of GABA-A and GABA-B receptors inhibit VTA neurons, reduce dopamine 
release, and reduce cocaine-induced increases in extracellular dopamine (Klitenick et al., 
1992; Fadda et al., 2003). GABA-A receptors are also located on GABAergic interneurons 
presynaptic to dopaminergic VTA neurons, and activation of these receptors would be 
predicted to inhibit GABAergic interneurons, disinhibit VTA neurons, enhance dopamine 
release, and enhance cocaine-induced increases in extracellular dopamine (Klitenick et al., 
1992; Xi and Stein, 1998). Now, given the interactions between GABA and dopaminergic 
systems, GABAergic ligands may be useful for modifying some of the abuse-related effects 
of cocaine. Then the use of an among mechanistically diverse GABA agonists, high-efficacy 
GABA-A modulators may be the most effective for modifying the abuse-related effects of 
cocaine (Barrett et al., 2005). 
On the other hand, acute cocaine toxicity is frequently associated with seizures. The 
mechanisms underlying the convulsant effect of cocaine are not well understood. 
Previously, studies have shown that cocaine depresses whole-cell current evoked by 
gamma-aminobutyric acid (GABA) in hippocampal neurons freshly isolated from rats. 
Cocaine's effect was voltage-independent and concentration-dependent. Ye and Ren, (2006), 
suggest that cocaine induces an increase from intracellular calcium [Ca]i, which stimulates 
phosphatase activity and thus leads to dephosphorylation of GABA receptors. This 
dephosphorylation-mediated disinhibitory action may play a role in cocaine-induced 
convulsant states. 
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6. Therapeutical targets for cocaine addiction 
Studying the pathways involved in cocaine addiction, it is possible to know that 
pharmaceutical industries are hardly working on pharmacotherapies to treat this addiction 
and that must be directed toward the molecular transductors of abnormalities found in 
cocaine users. In the present section, we´ll show some of the most used pharmacotherapies 
and the usual targets that are regulated for them. In general, we can say that most of those 
therapies have been used firstly in other pathologies and assayed in cocaine addiction 
according to their action mode or target. 
Topiramate: is a sulphamatefructopyranose derivative, thought to antagonize a drug’s 
rewarding effects by inhibiting mesocorticolimbic dopamine release via the gamma 
aminobutyric acid (GABA) activity and inhibition of glutamate function after drug intake. 
Through this activity, topiramate may decrease extracellular release of dopamine in the VTA 
projecting to the nucleus accumbens. This action may mediate drug-seeking behaviors and 
craving by reducing the rewarding effects associated with drug use (Johnson et al., 2004). 
Disulfiram: inhibits plasma and microsomal carboxylesterases and plasma cholinesterase 
that inactivate cocaine systemically thereby increasing blood levels of cocaine without any 
cardiovascular toxicity. Another important role is that disulfiram chelates copper, and since 
copper is essential in the function of the dopamine beta-hydroxylase enzyme, disulfiram 
inhibits the conversion of dopamine to norepinephrine. Dopamine betahydroxylase 
inhibition by disulfiram leads to decreases in peripheral and central norepinephrine and 
increases in dopamine levels. This effect is believed to contribute to disulfiram’s efficacy in 
treating cocaine addiction (McCance-Katz et al., 1998) 
Ondansetron: Post-synaptic 5-HT3 receptors are located densely on the terminals of 
corticomesolimbic dopamine containing neurons, where they promote DA release. A 
primary effect of ondansetron a 5-HT3 antagonist is to decrease dopamine release, especially 
under suprabasal conditions in these regions (Haile et al., 2009) 
Baclofen: is a GABA B receptor agonist used to reduce muscle spasticity in different 
neurological diseases. It is believed to modulate cocaine-induced dopamine release in the 
nucleus accumbens. In animal studies baclofen was found to reduce cocaine self-
administration, reinstatement, and cocaine seeking behaviors in rats suggesting its potential 
utility as a medication for treatment of cocaine addiction. In humans, an open label study 
found that baclofen 20 taken three times daily significantly reduced cocaine craving in 
cocaine-dependent subjects. However, this trial had a sample size of 10 and did not have a 
placebo arm. An analysis of the same data found that baclofen significantly reduced cocaine 
use in the subgroup of patients with the heaviest cocaine use only (Fadda et al., 2003) 
Modafinil: a functional stimulant, is FDA approved for the treatment of narcolepsy and 
idiopathic hypersomnia. The mechanisms underlying modafinil’s therapeutic actions 
remain unknown. It is believed to occupy both the dopamine and norepinephrine 
transporters consistent with a stimulant like effect. In addition, modafinil appears to 
increase release of the excitatory neurotransmitter glutamate, and decrease the inhibitory 
neurotransmitter GABA. Modafinil is usually well tolerated, although up to 3% of patients 
on modafinil experienced cardiovascular side-effects such as hypertension, tachycardia, and 
palpitations. Because of its stimulant-like activity, modafinil was suggested and later tested 
as a treatment for cocaine dependence. It was believed to diminish not only the symptoms 
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placebo arm. An analysis of the same data found that baclofen significantly reduced cocaine 
use in the subgroup of patients with the heaviest cocaine use only (Fadda et al., 2003) 
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remain unknown. It is believed to occupy both the dopamine and norepinephrine 
transporters consistent with a stimulant like effect. In addition, modafinil appears to 
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on modafinil experienced cardiovascular side-effects such as hypertension, tachycardia, and 
palpitations. Because of its stimulant-like activity, modafinil was suggested and later tested 
as a treatment for cocaine dependence. It was believed to diminish not only the symptoms 
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of cocaine withdrawal, but also act as a “substitution treatment” for cocaine (Ballon and 
Feifel., 2006). 
Naltrexone: (NTX) has long been available as an orally available antagonist at opioid receptors, 
with a relative selectivity for the μ-opioid receptor at lower doses. It was originally studied as 
a potential treatment for opiate dependence, where it seems to be effective in special cases, but 
not across the broad range of patients. NTX taps into known EtOH actions in a seemingly 
logical manner. EtOH administration leads to release of endogenous opioid peptides, and one 
of the downstream effects of this is to activate mesolimbic dopamine (DA) release. This in turn 
contributes to acute positive reinforcing properties of drugs of abuse (Kreek et al., 2002). 
Consistant with this chain of events, μ-receptor null-mutant mice do not self-administer EtOH 
(Roberts et al., 2000; Heilis and  Egli., 2006). 
Other medications that interact with GABA- or glutamate-mediated neuronal systems have 
been tried as potential treatment for cocaine dependence. While there is preclinical evidence 
that acamprosate can inhibit conditioned place preference to cocaine and attenuates both 
drug and cue-induced reinstatement of cocaine-seeking behavior there is to date, no clinical 
trial testing its utility in treating humans with cocaine dependence. Gabapentin is another 
gabanergic drug used to treat both epilepsy and neuropathic pain. Its exact pharmacological 
mechanism remains unclear. Gabapentin has showed some promising results in an open-
label study and case series suggesting that it might have utility in the treatment of cocaine 
dependence. There are encouraging preclinical data that support the utility of vigabatrin as 
a treatment agent for cocaine dependence. Vigabatrin is another anticonvulsant that 
increases GABA neurotransmission but this time by inhibiting GABA transaminase. It is a 
drug with great potentials but needs to be tested in adequately powered placebo controlled 
randomized studies. Tiagabine is yet another anticonvulsant that increases GABA 
neurotransmission by blocking the presynaptic reuptake of GABA. In 2 randomized clinical 
trials involving cocaine dependent patients who were maintained on methadone, tiagabine 
(12-24 mg/day) was found to decrease cocaine use compared with placebo (Bowers et al., 
2007; Gonzalez et al., 2003) . 
Finally, the use of stimulants has been tried for the treatment of cocaine dependence under 
the premise of a drug substitution for a drug with slower onset formulation and less abuse 
liability. Methylphenidate, a dopamine and nerepinephrine reuptake inhibitor used to treat 
attention deficit hyperactivity disorders (ADHD) was found to be no better than placebo in 
the treatment of cocaine dependent patients without comorbid ADHD. However when used 
in a population with dual diagnosis of cocaine dependence and ADHD, results from clinical 
trials were mixed. While a controlled clinical trial using immediate release methylphenidate 
(90 mg/day) found no difference between the active drug and placebo groups, another trial 
using sustained release methylphenidate (60 mg/day), found significant improvement in 
ADHAD symptoms that were associated with decrease in cocaine use compared with 
placebo. Though medications such as those that facilitate gabaergic function, modulate 
dopaminergic function or act as an agonist replacement therapy show promise in treating 
cocaine dependence, there are certain drawbacks (Levin et al., 2007).  
Other authors (Heilis and Egli., 2006) have organized medication used in cocaine addiction 
in three different groups. The medications described in past paragraphs are classified in the 
“first wave: currently available treatments” and “second wave: the near future”. Those 
medications have been used in mixes between them and have shown interesting results. 
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Table 1 summarizes some aspects related to treatment and targets of first, and second wave 
medications. 
 
Medication Group (wave) Target, mechanism References 
Disulfiram First 
Blocking aldehyde dehydrogenase 
(alcohol treatment), and dopamine 
beta-hydroxylase (cocaine 
dependence) 
Carroll et al., 2004 
Naltrexone 
(NTX) First Antagonist at opioid receptors Kirchmayer et al., 2000 
Acamprosate 
(ACM) First 
Glutamate antagonist, attenuates 
NMDA signaling through 
spermidine site and actions at 
metabotropic glutamate receptors 
Spanagel & 
Zieglgansberger, 1997; 
Harris et al., 2002. 
NTX and 
ACM mixed First 
Opioid receptors, NMDA 
receptors and metabotropic 
receptors 
Rist et al., 2005; Spanagel & 
Mann, 2005. 
Ondansetron Second Serotonin receptors Higgins et al., 1992; Meert, 1993; Tomkins et al., 1995. 
Baclofen Second 
Agonist at GABA-B receptor. 
Treatment when in detected 
additional alcohol dependence 
Stromberg, 2004. 
Topiramate Second 
Proposed effects: blockade of 
voltage dependent sodium 
channels, antagonism of kainite 
receptors and potentiation of 
GABA signaling through 
increased GABA availability 
Zona et al., 1997; Gryder & 
Rogawski, 2003; 
Kaminski et al., 2004, White 
et al.,1997 
Table 1. Medications used in cocaine dependence, showing its classification and possible 
mechanism (or target) of action. The main use of those medications is in alcohol dependence 
treatment but they have shown good results in other dependences as cocaine addiction 
(adapted from Heilis and Egli., 2006) 
The third wave medications in cocaine addiction have been used with promising results. 
The development of pharmacotherapy for cocaine addiction is based on previous strategies 
designed to alleviate other chemical dependencies such as alcoholism and opiate addiction, 
focusing on the neurobiological and the behavioral bases of addiction. To date, however, no 
pharmacotherapy has been approved by the U.S. Food and Drug Administration for cocaine 
dependence, but two major classes of medications have been investigated: (1) dopaminergic 
agents and (2) antidepressants. Studies have been relatively brief for both types of agents 
and have focused on abstinence initiation rather than on relapse prevention. In addition to 
dopaminergic agents and antidepressants, other compounds such as calcium channel 
blockers, have been examined as potential treatments of cocaine dependence (figure 7) 
(Carrera et al., 2004)  
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In the first group, some dopaminergic agents have been used based on the theory that 
chronic cocaine use reduces the efficiency of central DA neurotransmission, several 
dopaminergic compounds, including amantadine, bromocriptine, mazindol, and 
methylphenidate, have been examined as treatments for cocaine abuse. Investigators hoped 
that these dopaminergic agents, which have a fast onset of action, would correct the DA 
dysregulation and alleviate the withdrawal symptoms that often follow cessation of 
stimulant use. 
 
Fig. 7. Classification of medications used for cocaine addiction, based on target and 
mechanism of action (based on Carrera et al., 2004). 
Large array of cocaine analogues and other dopamine uptake inhibitors (see Table 2) 
including analogues of WIN-35,065, GBR-12909, nomifensine, and benztropine have been 
developed in the last years. The largest class of compound studies is the class of 3-
phenyltropane analogues, of which many hundreds have been made and tested. The 
analogues RTI-112 and PTT are in preclinical evaluation. Like cocaine, RTI-112 and PTT both 
have good affinity for all three monoamine transporters, but in contrast to cocaine they enter 
the brain slowly and are long-lasting. A number of other 3-phenyltropanes are potent and 
selective for the dopamine transporter relative to inhibition of serotonin and norepinephrine 
transporters, are long-lasting, and also enter the brain more slowly than cocaine, for 
example, RTI-113 and RTI-177 (Carrera et al., 2004). 
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The effect of inhibiting neurotransmitter uptake is to stimulate neurotransmitter receptors; 
thus the use of direct receptor agonists as substitute agonist medications also has been 
suggested. Data on dopamine receptor agonists have been extensively reviewed. Animal 
studies indicate that dopamine receptor agonists such as apomorphine and bromocriptine 
maintain self-administration in rodents. 
 
Compound CNS target 
RTI-113, RTI-177, GBR-12909 DA uptake inhibitors (selective for DAT) 
Mazindol, methyl phenidate, 
nomifensine, benztropine DA uptake inhibitors (not selective) 
Apomorphine, bromocriptine, 
SKF38393, quinpirole DA receptor agonists and partial agonist 
Desipramine Antagonist of cocaine binding that spare DA uptake 
Fluoxetine, alaproclate 5HT uptake inhibitors 
Quipazine 5HT receptor agonist 
Ketanserin, ritanserin, 
ondansetron Calcium channel blockers 
Table 2. List of some compounds that have been used as pharmacotherapy in cocaine 
addiction and target identified in Central Nervous System (adapted from Carrera et al., 
2004) 
The second class of medications used to treat cocaine dependence, antidepressants, are 
thought to down regulate synaptic catecholamine receptors, and this action is opposite to 
the presynaptic up-regulation caused by chronic stimulant use. Although antidepressants 
have a relatively benign side-effect profile, good patient compliance rates, and lack of abuse 
liability, they have a delayed onset of action ranging from 10 to 20 days. Therefore, the 
physician may consider beginning antidepressant treatment during early withdrawal and 
continuing for weeks or longer as clinically indicated. The tricyclic antidepressant 
desipramine has been studied most extensively as a treatment of cocaine dependence. Early 
studies of desipramine to treat cocaine dependence showed positive results but placebo-
controlled trials have not produced impressive findings. A meta-analysis of placebo-
controlled studies by Levin and Lehman showed that although desipramine did not 
improve retention in treatment, it did produce greater cocaine abstinence relative to placebo. 
However, treatment with desipramine has induced “early tricyclic jitteriness syndrome” 
and cocaine craving, as well as relapse to cocaine use in some patients. Therefore, 
desipramine as pharmacotherapy would hold serious clinical caveats. Additional studies 
have focused on the involvement of the 5HT3 receptor subtype in the neuropharmacology 
of cocaine, but the results obtained are somewhat inconsistent. Several 5HT3-selective 
antagonists, including MDL-72222 and ondansetron were reported to attenuate cocaine-
induced locomotor activityin rodents. However, ondansetron failed to block the reinforcing 
or discriminative-stimulus effects of cocaine in rodents. Several other antidepressants, 
including fluoxetine, sertraline, and trazodone, that work predominantly through 
serotonergic mechanisms also have been used as pharmacotherapy for cocaine dependence. 
Although some reports indicated that treatment with fluoxetine reduced cocaine craving 
and use in cocaine-abusing heroin addicts, other investigators have not found fluoxetine to 
be effective in attenuating cocaine use and withdrawal symptoms. Bupropion, a “second-
 
Addictions – From Pathophysiology to Treatment 
 
118 
In the first group, some dopaminergic agents have been used based on the theory that 
chronic cocaine use reduces the efficiency of central DA neurotransmission, several 
dopaminergic compounds, including amantadine, bromocriptine, mazindol, and 
methylphenidate, have been examined as treatments for cocaine abuse. Investigators hoped 
that these dopaminergic agents, which have a fast onset of action, would correct the DA 
dysregulation and alleviate the withdrawal symptoms that often follow cessation of 
stimulant use. 
 
Fig. 7. Classification of medications used for cocaine addiction, based on target and 
mechanism of action (based on Carrera et al., 2004). 
Large array of cocaine analogues and other dopamine uptake inhibitors (see Table 2) 
including analogues of WIN-35,065, GBR-12909, nomifensine, and benztropine have been 
developed in the last years. The largest class of compound studies is the class of 3-
phenyltropane analogues, of which many hundreds have been made and tested. The 
analogues RTI-112 and PTT are in preclinical evaluation. Like cocaine, RTI-112 and PTT both 
have good affinity for all three monoamine transporters, but in contrast to cocaine they enter 
the brain slowly and are long-lasting. A number of other 3-phenyltropanes are potent and 
selective for the dopamine transporter relative to inhibition of serotonin and norepinephrine 
transporters, are long-lasting, and also enter the brain more slowly than cocaine, for 
example, RTI-113 and RTI-177 (Carrera et al., 2004). 
 
Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission 
 
119 
The effect of inhibiting neurotransmitter uptake is to stimulate neurotransmitter receptors; 
thus the use of direct receptor agonists as substitute agonist medications also has been 
suggested. Data on dopamine receptor agonists have been extensively reviewed. Animal 
studies indicate that dopamine receptor agonists such as apomorphine and bromocriptine 
maintain self-administration in rodents. 
 
Compound CNS target 
RTI-113, RTI-177, GBR-12909 DA uptake inhibitors (selective for DAT) 
Mazindol, methyl phenidate, 
nomifensine, benztropine DA uptake inhibitors (not selective) 
Apomorphine, bromocriptine, 
SKF38393, quinpirole DA receptor agonists and partial agonist 
Desipramine Antagonist of cocaine binding that spare DA uptake 
Fluoxetine, alaproclate 5HT uptake inhibitors 
Quipazine 5HT receptor agonist 
Ketanserin, ritanserin, 
ondansetron Calcium channel blockers 
Table 2. List of some compounds that have been used as pharmacotherapy in cocaine 
addiction and target identified in Central Nervous System (adapted from Carrera et al., 
2004) 
The second class of medications used to treat cocaine dependence, antidepressants, are 
thought to down regulate synaptic catecholamine receptors, and this action is opposite to 
the presynaptic up-regulation caused by chronic stimulant use. Although antidepressants 
have a relatively benign side-effect profile, good patient compliance rates, and lack of abuse 
liability, they have a delayed onset of action ranging from 10 to 20 days. Therefore, the 
physician may consider beginning antidepressant treatment during early withdrawal and 
continuing for weeks or longer as clinically indicated. The tricyclic antidepressant 
desipramine has been studied most extensively as a treatment of cocaine dependence. Early 
studies of desipramine to treat cocaine dependence showed positive results but placebo-
controlled trials have not produced impressive findings. A meta-analysis of placebo-
controlled studies by Levin and Lehman showed that although desipramine did not 
improve retention in treatment, it did produce greater cocaine abstinence relative to placebo. 
However, treatment with desipramine has induced “early tricyclic jitteriness syndrome” 
and cocaine craving, as well as relapse to cocaine use in some patients. Therefore, 
desipramine as pharmacotherapy would hold serious clinical caveats. Additional studies 
have focused on the involvement of the 5HT3 receptor subtype in the neuropharmacology 
of cocaine, but the results obtained are somewhat inconsistent. Several 5HT3-selective 
antagonists, including MDL-72222 and ondansetron were reported to attenuate cocaine-
induced locomotor activityin rodents. However, ondansetron failed to block the reinforcing 
or discriminative-stimulus effects of cocaine in rodents. Several other antidepressants, 
including fluoxetine, sertraline, and trazodone, that work predominantly through 
serotonergic mechanisms also have been used as pharmacotherapy for cocaine dependence. 
Although some reports indicated that treatment with fluoxetine reduced cocaine craving 
and use in cocaine-abusing heroin addicts, other investigators have not found fluoxetine to 
be effective in attenuating cocaine use and withdrawal symptoms. Bupropion, a “second-
 
Addictions – From Pathophysiology to Treatment 
 
120 
generation” antidepressant, has been studied as pharmacotherapy for cocaine dependence 
(Heilis and Egli., 2006; Carrera et al., 2004) 
Various studies suggest that L-type calcium channel blockers potentially reduce the 
rewarding effects of cocaine. One such compound, the L-type calcium channel blocker 
isradipine (Fig. 7), attenuated the cocaine induced dopamine release in the striatum of rats. 
Another report described isradipine-induced attenuation of condition place preference and 
the discriminative stimulus properties of cocaine. Also, pretreatment with isradipine 
resulted in a dose-dependent decrease in intravenous cocaine self-administration. Because 
of the antihypertensive quality of calcium channel blockers, the potential increase in cardiac 
output in patients with normal ventricular function could complicate their use as 
pharmacotherapies for cocaine abuse (Carrera et al., 2004) 
Notwithstanding the impressive amount of research effort in this area, a large number of 
studies using dopaminergic drugs have failed to yield encouraging results. To date, no 
pharmacotherapeutic agent of this type used on an experimental basis has been shown 
effectiveness that would merit medical implementation. 
7. Perspectives 
The fact that GABA and glutamate are so widely present makes it likely that they will be 
altered during drug addiction. This fact also makes it difficult to treat addiction with drug 
therapy. Say that a drug affects GABA and glutamate in way that relieves craving. Because 
GABA and glutamate are so widely present, these drugs could produce a mess of side 
effects as well. If we had drugs that could selectively stimulate or block certain receptors, 
then we could treat addiction and avoid doing people more harm than good. 
Treatment studies should continue the present emphases on (1) identifying and 
systematically testing pharmacological agents that may be useful in achieving abstinence 
from cocaine and reducing the likelihood of relapse; (2) characterizing and understanding 
the processes and outcomes of existing treatments by using field studies with outcomes 
studied over a 1-year post treatment period and longer; and (3) testing the efficacy of 
specific psychosocial interventions such as psychotherapies, behavioral treatments, and 
relapse prevention strategies. The need for theory-based treatment approaches should be 
recognized. Promising pharmacotherapies also should be field tested in clinical programs to 
understand issues related to compliance with medication regimens. 
Recent efforts to discover new pharmacs have been oriented to get a vaccine for cocaine 
addiction. However, to improve existing treatment, there should be a systematic effort to 
integrate research and treatment. Research should develop and test criteria for client-
treatment matching so that the most cost-effective treatments can be provided for cocaine 
dependent users. Additional research should focus on better understanding motivation as a 
factor for increasing the retention of cocaine users in treatment. This focus would include 
use of motivational incentives to enter and remaining treatment. There is a need to better 
understand the role of self-help in treating cocaine users. 
Additional studies for the current cocaine vaccine are planned to confirm and extend the 
discussed outpatient studies, and there are ongoing developmental studies of alternative 
adjuvants and vaccine constructs which will likely improve the quantity and quality of 
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antibodies produced, as well as the proportion of high response subjects. Such results would 
lead to clinical application of these vaccines for in the treatment of cocaine abusers. Better 
vaccines or newer methods will not be the end of the game for treating substance abuse, 
however. The motivated cocaine addict will need other interventions such as therapy and 
rehabilitation programs in order to overcome this seductive addiction. Anti-drug programs 
in schools should be strengthened, as cocaine addiction often starts before age 20. The 
criminal justice system should reconsider the wholesale incarceration of cocaine users, and 
offer help rather than punishment. Let us hope that in the years ahead anti-cocaine 
vaccination will be one of numerous arrows in our therapeutic quiver to combat drug 
addiction (Kinsey et al., 2010). 
Incorporation of technology into treatment methods is also being explored. Computer-
assisted therapies may offer more consistent and convenient delivery of instruction and 
reinforcement in conjunction with CBT. An additional and innovative approach, to be used 
with a structured treatment program, is the administration of a therapeutic cocaine vaccine. 
The vaccine is shown to inhibit the cocaine ‘high’ through antibodies binding to cocaine in 
the circulation and inhibiting entry to the brain. However, it does not stop drug cravings.  In 
addition, recent findings suggest that only those subjects who attain high (> 43 ug/L) IgG 
anticocaine antibody levels benefited from significantly reduced cocaine use. Unfortunately, 
only 38% of the vaccinated subjects achieved such high IgG levels. Psychosocial therapy is 
still essential in medication and vaccine studies because the underlying issues of the 
dependence and use behavior must be addressed or individuals may relapse or resort to 
misusing another drug. The intent of the vaccine is to immunize motivated patients as part 
of a comprehensive recovery program and to inhibit the reinforcing activity of cocaine and 
decrease the likelihood of relapse (Penberthy et al., 2010). 
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vaccines or newer methods will not be the end of the game for treating substance abuse, 
however. The motivated cocaine addict will need other interventions such as therapy and 
rehabilitation programs in order to overcome this seductive addiction. Anti-drug programs 
in schools should be strengthened, as cocaine addiction often starts before age 20. The 
criminal justice system should reconsider the wholesale incarceration of cocaine users, and 
offer help rather than punishment. Let us hope that in the years ahead anti-cocaine 
vaccination will be one of numerous arrows in our therapeutic quiver to combat drug 
addiction (Kinsey et al., 2010). 
Incorporation of technology into treatment methods is also being explored. Computer-
assisted therapies may offer more consistent and convenient delivery of instruction and 
reinforcement in conjunction with CBT. An additional and innovative approach, to be used 
with a structured treatment program, is the administration of a therapeutic cocaine vaccine. 
The vaccine is shown to inhibit the cocaine ‘high’ through antibodies binding to cocaine in 
the circulation and inhibiting entry to the brain. However, it does not stop drug cravings.  In 
addition, recent findings suggest that only those subjects who attain high (> 43 ug/L) IgG 
anticocaine antibody levels benefited from significantly reduced cocaine use. Unfortunately, 
only 38% of the vaccinated subjects achieved such high IgG levels. Psychosocial therapy is 
still essential in medication and vaccine studies because the underlying issues of the 
dependence and use behavior must be addressed or individuals may relapse or resort to 
misusing another drug. The intent of the vaccine is to immunize motivated patients as part 
of a comprehensive recovery program and to inhibit the reinforcing activity of cocaine and 
decrease the likelihood of relapse (Penberthy et al., 2010). 
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1. Introduction 
Understanding the mechanisms of drug dependence has been the goal of a large number of 
neuroscientists, pharmacologists and clinicians who carried out research with the hope of 
individuating and proposing an efficacious therapy for this disorder (Sofuoglu, 2010; 
Kalivas and Volkow, 2011). Unfortunately, although huge efforts, drug dependence is still a 
relevant health, social and economical problem (Popova et al., 2012; Hiscock et al., 2011; 
Shorter and Kosten, 2011). Treatments for drug abuse are for the most part ineffective 
because the molecular and cellular mechanisms through which drugs of abuse alter 
neuronal circuitry are still unexplained and above all, because drugs of abuse determine a 
global alteration of cerebral functions that govern behaviour through decision formation, 
making therefore unfocused the identification of a pharmacological target (Volkow et al., 
2011; Schultz 2011). One of the first strategies pursued in drug dependence therapy was 
directed to removal of pleasure associated with drug taking, but the compliance with the 
treatment has been always limited, although it could improve when it was supported by 
psychology based motivational therapy as in alcohol dependence (Krampe and Ehrenreich, 
2010; Simkin and Grenoble, 2010). On the other hand it is not infrequent that heavy smokers 
or heavy drinkers stop suddenly dependence just because their will overcome year-long 
habits. Decision making is a process based on the interaction between prefrontal cortex 
(PFC) and subcortical regions involved in reward and motivation, therefore it is likely that 
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addicted subjects. This interaction has been elegantly discussed by Kennerley and Walton 
(2011) by comparing the functional correspondence between neurophysiological and 
neuropsychological studies to help define the roles of different PFC areas in supporting 
optimal decision making. The following brief overview on PFC is not intended to be 
exhaustive, as far as regards discussion of cognitive and executive functions of sub areas of 
PFC, but it will address specific features of PFC areas in which catecholamine transmission 
plays relevant role in drug addiction.  
Dopamine transmission in PFC is directly involved in cognitive processes (Seamans and 
Yang, 2004), in the regulation of emotions (Sullivan, 2004), in working memory (Khan and 
Muly 2011), as well as in executive functions such as motor planning, inhibitory response 
control and sustained attention (Fibiger and Phillips, 1988; Granon et al., 2000; Robbins, 
2002). The association of PFC functions with impulse control is supported by the evidence 
that damage to the ventromedial PFC causes persistent motivational impulsivity associated 
with affective instability, reduced capability for decision making, poor executive planning 
and general apathy towards social life (Damasio et al., 1994). In general damage of PFC 
function in humans can therefore affect one or more of the above functions producing 
personal and social difficulties as observed in disorders such as Alzheimer’s disease 
(Melrose et al., 2011), schizophrenia (Arnsten, 2011), and Parkinson’s disease (Luft and 
Schwarz, 2009). Loss of PFC function can be also generated by traumas (Bechara and Van 
Der Linden, 2005), or can result from drug addiction (Koob and Volkow, 2010; Van den 
Oever et al., 2010). Moreover, PFC functional or anatomical abnormalities are frequently 
found in individuals with drug abuse disorders (Liu et al., 1998a and 1998b; Franklin et al., 
2002) and at the same time PFC is thought to have an important role in the onset and in the 
progression of psychiatric disorders associated with poor decision making such as 
schizophrenia (Arnsten, 2004), attention deficit/hyperactivity disorder (ADHD) (Sullivan 
and Brake, 2003) and depression (Davidson et al., 2002). Also, clinical studies report that 
when traumatic brain injury damages the PFC it often facilitate the emergence of drug use 
disorders (Ommaya et al., 1996, Delmonico et al., 1998).  
The knowledge on PFC functions in mammals has been accumulated through research on 
different species but anatomy differences between primates and rodents is object of 
discussion when comparing experimental evidence on PFC function. In particular the 
dorsolateral PFC of mammals is thought to be involved in working memory, in attention 
processes, in reasoning-based decision making and in the timing of behavioural 
organization (Curtis and Lee, 2010; Arnsten, 2011). The prominent role of PFC 
catecholamine transmission in motivation is also supported by its anatomical and functional 
connection with other important areas of the brain, such as the nucleus accumbens (NAcc) 
(Di Chiara et al., 2011), and the ventral tegmental area (Omelchenko and Sesack, 2007) (Fig. 
1). Chambers et al. (2003) provided an interesting definition for the role of the PFC: - It plays 
a determining role in the representation, execution and inhibition of motivational drives by 
influencing patterns of neural ensemble firing in the NAcc and poor PFC function could 
increase the probability of performing inappropriate motivated drives viewed clinically as 
impulsive. This view may acquire increasing relevance by integrating it in a scenario in 
which neural transmission in the NAcc is considered a common molecular pathway for 
addiction (Nestler, 2005; Di Chiara et al., 2004). Furthermore, one of the primary outputs of 
the accumbens is the gabaergic innervation (Fig. 2) directed to the ventral pallidum that in 
turn innervate the mediodorsal thalamic nucleus by GABA neurons. Mediodorsal thalamus 
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in turn sends and excitatory output to the prelimbic and infralimbic PFC (O’Donnel et al., 
1997). The PFC in primates receives the projection from the medio-dorsal nucleus of the 
thalamus that innervates the dorsolateral, medial and orbital cortices (Vertes, 2006) but in 
general, the thalamic innervation of PFC is a part of a loop which includes cortical thalamic 
glutamatergic excitatory projection that has a role in working memory (Watanabe and 
Funahashi, 2012) and is involved in the reward circuit (Haber and Knutoson, 2010).  
Recent reviews suggest that the medial PFC in rat is functionally equivalent to the medial 
PFC of primates (Brown and Bowman 2002; Wilson et al. 2010). It has also been suggested 
that the rat PFC is not differentiated and therefore can subserve cognitive function localized 
in the dorsolateral PFC of primates as discussed elegantly by Brown and Bowman, (2002). 
These authors recognised that behavioural deficits following PFC damage in rats could 
reflect impaired behavioural flexibility similar to that reported in primates (De Bruin et al., 
1994; Joel et al., 2005) and although the ability of shifting attention from one complex 
stimulus to another can be characterized by different abstraction level among different 
species, mammals could share executive processing mechanisms [selective attention, 
working memory, updating (manipulating the contents of working memory)] and rerouting 
attention (Shimamura, 2000; Brown and Bowman 2002). Due to the complexity of reciprocal 
neurotransmitter relationship in PFC, this chapter will mainly consider the role of dopamine 
and norepinephine in the PFC and their relationship with the effects of drugs of abuse and 
therapy of addiction. This choice is based on the important role of dopaminergic 
transmission in the effects of drugs of abuse and on the modulation of cognitive control (van 
Schouwenburg et al., 2010).  
3. Dopamine in the prefrontal cortex: innervation, receptors and functions  
The PFC receives multiple ascending innervations (Fig. 1 and Fig. 2). Whereas Acetylcholine 
(Ach) and serotonin (5-HT), contact widely all the subregions of PFC, dopamine 
innervations are more localized (e.g., prelimbic and infralimbic cortex) although they have a 
discrete grade of overlapping with norepinephrine innervation (Del Campo et al., 2011). The 
PFC is reciprocally connected with the VTA by dopaminergic afferents and glutamatergic 
efferents. Dopaminergic innervation of the PFC is predominantly provided by VTA 
dopamine cells sublocated in the parabrachialis pigmentosus nucleus which projects to 
cortical deep layers that contain the highest density of dopamine D1 and D2 receptors 
(Oades and Halliday, 1987). The main target of these innervations are the dendritic spines of 
pyramidal cells that project to GABA neurons of the NAcc which in turn complete a circuit 
by projecting back to VTA cells (Omelchenko and Sesack, 2007). A small population of PFC 
neurons that project to the VTA form synaptic contact with dopamine neurons that project 
onto the PFC, and a second population synapse onto GABA neurons that project to the 
nucleus accumbens, however no synaptic contact was found between PFC neurons and 
dopamine neurons that project to the NAcc (Carr and Sesack, 2000b). Lastly, to emphasize 
the complexity of the circuits in which the PFC is involved, it is important to underline that 
the majority of PFC terminals within the VTA area appear to target dopamine and GABA 
neurons that project onto target sites different from PFC and NAcc (Carr and Sesack, 2000a). 
Among them, some innervate ventral pallidum (Papp et al., 2012) and others, such as the 
putative gabaergic cells of the rostral linear nucleus that innervate the mediodorsal thalamic 
nucleus may have relevance in reward mechanism (Del Fava et al., 2007). Efferent 
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projections from VTA to hippocampus influence spatial working memory performance 
(Martig and Mizumori, 2011). Dopamine innervation of PFC is functionally inhibitory either 
by direct action on pyramidal cells or via GABA interneurons (Grobin, and Deutch, 1998) 
reducing glutamatergic excitatory output to NAcc and VTA. Therefore, an increase in 
dopamine stimulation of PFC conversely attenuates dopamine activity in striatal and limibic 
terminal regions (Karreman and Moghaddam, 1996) and attenuates the motor stimulatory 
effects of systemically administered stimulants such as amphetamine and cocaine (Karler et 
al., 1998).  
 
Fig. 1. Schematic representation of few major sites of interaction between prefrontal cortex 
(PFC) glutamate neurons, ventral tegmental area (VTA) dopamine and GABA neurons, and 
nucleus accumbens (NAcc) GABA neurons. Dendrites are occasionally represented for 
drawing clarity.  
 




Fig. 2. Schematic representation of several major sites of interaction between prefrontal 
cortex (PFC) and thalamus (Th), hippocampus (Hi), amygdala (Amy), ventral tegmental 
area (VTA), dorsal raphe (DR), basal forebrain cholinergic system (BFCS), locus coeruleus 
(LC) globus pallidus (GP). Glutamate (Glu), Dopamine (DA), GABA, Acetylcholine (Ach), 
Norepinephrine (NA), and Serotonin (5-HT) neurons and axons are represented. The 
detailed connection represented in Fig. 1 have been omitted for drawing clarity.  
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Dopamine is a model of slow synaptic transmission; therefore it does not mediate fast 
synaptic transmission but instead modulates the response of other systems. The majority of 
D1 and D2 type receptors in the medial PFC appear to be located on pyramidal cells with 
the density of D2, apparently considerably lower than that of D1 (see the review by 
Tzschentke, 2001). Although both receptors are also present in GABAergic interneurons, the 
D4 subtype in particular (Ariano et al., 1997; Defagot et al., 1997a and 1997b) appears to be 
located on GABAergic interneurons rather than on pyramidal cells (Mrzljak et al., 1996). It is 
interesting to note that in the same postsynaptic pyramidal cell of the mPFC, dopaminergic 
terminals are localized in close opposition to each other with glutamatergic terminal 
originating in both the mediodorsal thalamus and the controlateral medial PFC. The former 
is not affected by VTA activation which instead inhibits the excitation of pyramidal cells 
generated by the input from recurrent collaterals of efferent glutamatergic output 
(Tzschentke, 2001). By acting on D1 receptors and through cAMP for the activation of cAMP 
sensitive protein kinase, dopamine determines an increase in the phosphorylation of DARP-
32 and an inhibition of phosphatase 1 modulating mechanisms that involve ion channel and 
transcription factors (Greengard, 2001). D1 receptor optimal stimulation is essential to 
working memory process (Williams and Goldman-Rakic, 1995) and therefore either an 
increase or a decrease of the transmission leads to an inverted U response (Desimone, 1995). 
The involvement of dopamine activity through D1 receptor in cognitive function has a 
strong impact in schizophrenia research because of the importance of cognitive impairment 
in this disorder (Barch and Ceaser, 2012).  
Although the result of dopamine interaction on pyramidal cells is complex and is influenced 
by a number of factors (e.g. dopamine concentration, receptor interaction, direct or indirect 
effect, depolarization status of the cells), dopamine generally, as also described in the 
previous paragraph, inhibits the activity of pyramidal cells in the medial PFC (see 
Tzschentke, 2001 for a review). The direct dopamine action on pyramidal cells (Geijo-
Barrietos and Pastore, 1995; Gulledge and Jaffe, 1998) or the indirect action by a stimulation 
of the GABA interneurons may in turn inhibit pyramidal cells (Mercuri et al., 1985; Penit-
Soria et al., 1987; Pirot et al., 1992). This latter action appears to be mediated through D2 
receptors (Retaux et al., 1991; Grobin and Deutch, 1998). On the other hand, pyramidal cells 
respond more to NMDA stimulation through D1 receptors in the presence of a low 
concentration of dopamine, whereas a high concentration would instead reduce this 
response (Zheng et al., 1999) by acting through D2 receptors. The role of D1/5 receptor is 
also crucial in suppressing the sustained neuronal firing that takes place during working 
memory activity (Vijayraghavan et al., 2007). This property is displayed by D1/5 dopamine 
receptor agonists, which have been found to cause a decrease in extracellular glutamate in 
PFC in vivo (Abekawa et al. 2000; Harte and O’Connor 2004). Interestingly D1/5 dopamine 
receptor agonists are also effective in normalizing aberrant network activity induced by 
both hallucinogens and minimal GABAA antagonism, although clinical efficacy remains to 
be determined (Aghajanan, 2009). The close relationship between dopamine and glutamate 
is functionally expressed at NAcc level where medial PFC efferents terminate in close 
opposition to dopamine terminals originating in the VTA, often in the same spine of 
GABAergic accumbal cells (Bouyer et al, 1984; Sesack and Pickel, 1992). It is interesting to 
note that only about 30-40 % of the VTA projection to PFC is dopaminergic, while the rest is 
likely to be an inhibitory GABAergic innervation (Carr and Sesack 2000a). Of further 
relevance is that PFC glutamate innervations of the NAcc is part of the motivational circuit 
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completed by accumbal GABA neurons projecting onto the ventral globus pallidus, by 
pallidal GABA neurons that project to the thalamus and lastly by thalamic glutamate 
neurons that project back to the PFC (see Chambers et al., 2003, for a review). Hence, PFC 
and NAcc work together to produce a behavioral output resulting from brain activity that 
processes input information concerning the internal status of the individual and the external 
environment (Dorman and Gaudiano, 1998). Considering that firing patterns in both the 
NAcc and PFC are influenced by glutamatergic input from the hippocampus and amygdala 
(Aggleton, 2011; Miller et al., 2010), it may be suggested that abnormalities in these distal 
structures may produce both psychiatric disorders as well as higher vulnerability to drug 
addiction (Chambers et al., 2001). As far as regards dopamine transmission in the PFC it is 
necessary to remind that dopamine could be captured by norepinephrine reuptake system 
(Carboni et al., 1990; Carboni et al., 2006)  
4. Noradrenaline in the prefrontal cortex: Innervation, receptors and 
interactions  
The long established observation that catecholamine depletion in PFC can be considered as 
destructive as tissue ablation (Brozoski et al., 1979) confirms the prominent role of 
catecholamine innervation in the PFC. The noradrenergic system that originates in the locus 
coeruleus and in other small nuclei in the medulla and the pons has the peculiar feature of 
projecting onto the entire neuraxis, although it originates in a relatively small group of cells. 
This extensive, irradiating anatomical arrangement allows the noradrenergic system to 
potentially influence all brain activity. In particular, noradrenaline innervations of PFC depend 
on neurons located in the locus coeruleus (Foote et al., 1983; Bjorklund and Lindvall, 1986) that 
project to dendrites of both pyramidal cells and interneurons. An interesting feature of locus 
coeruleus noradrenergic innervation of the cerebral cortex is that individual locus coeruleus 
neurons simultaneously innervate functionally and cyto-architectonically distinct cortical 
regions. In fact, locus coeruleus neurons arborize more extensively in the anterior-to-posterior 
axis of the cortex and exhibit relatively minimal medial-to-lateral collateralization (Swanson, 
1976; Aoki et al., 1998). Individual locus coeruleus cells were also shown to innervate both 
superficial and deep layers of a cortical region (Loughlin et al., 1982). Furthermore, the PFC 
projects back to the locus coeruleus thereby completing a circuitry which plays a role in 
relevant brain activity, i.e. maintaining vigilance (reviewed by Aston Jones, 1985) or 
modulating the behavioural response to stress (Morilak et. al., 2005). Functionally, the 
noradrenergic system can be viewed as a modulatory system because it can increase the 
“signal to noise ratio” of responses evoked by other neurotransmitters that excite or inhibit 
target cells (Woodward et al., 1991). Modulatory actions of this type can be mediated through 
either α or β noradrenergic receptors (Waterhouse et al., 1991; Woodward et al., 1991). This 
modulatory type action is also supported by the fact that in the monkey PFC noradrenaline 
produces its effects predominantly through α2A adrenoceptors that occur in spines, localized 
discretely over postsynaptic membranes that are most likely PFC pyramidal cells (Aoki et al., 
1998). Yet α2A receptors are most prevalent along axons, and are found also in dendritic shafts 
and astrocytic processes that lack evident synaptic junction. This suggests that these receptors 
are activated by volume transmission (Aoki et al., 1998). In particular, axonal α2A 
adrenoceptors have a pre-terminal location; by closing voltage dependent Ca++ channels, they 
are probably able to reduce neurotransmitter release such as serotonin as well as 
noradrenaline release (Frankhuyzen and Mulder, 1980; Maura et al., 1982).  
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Dopamine is a model of slow synaptic transmission; therefore it does not mediate fast 
synaptic transmission but instead modulates the response of other systems. The majority of 
D1 and D2 type receptors in the medial PFC appear to be located on pyramidal cells with 
the density of D2, apparently considerably lower than that of D1 (see the review by 
Tzschentke, 2001). Although both receptors are also present in GABAergic interneurons, the 
D4 subtype in particular (Ariano et al., 1997; Defagot et al., 1997a and 1997b) appears to be 
located on GABAergic interneurons rather than on pyramidal cells (Mrzljak et al., 1996). It is 
interesting to note that in the same postsynaptic pyramidal cell of the mPFC, dopaminergic 
terminals are localized in close opposition to each other with glutamatergic terminal 
originating in both the mediodorsal thalamus and the controlateral medial PFC. The former 
is not affected by VTA activation which instead inhibits the excitation of pyramidal cells 
generated by the input from recurrent collaterals of efferent glutamatergic output 
(Tzschentke, 2001). By acting on D1 receptors and through cAMP for the activation of cAMP 
sensitive protein kinase, dopamine determines an increase in the phosphorylation of DARP-
32 and an inhibition of phosphatase 1 modulating mechanisms that involve ion channel and 
transcription factors (Greengard, 2001). D1 receptor optimal stimulation is essential to 
working memory process (Williams and Goldman-Rakic, 1995) and therefore either an 
increase or a decrease of the transmission leads to an inverted U response (Desimone, 1995). 
The involvement of dopamine activity through D1 receptor in cognitive function has a 
strong impact in schizophrenia research because of the importance of cognitive impairment 
in this disorder (Barch and Ceaser, 2012).  
Although the result of dopamine interaction on pyramidal cells is complex and is influenced 
by a number of factors (e.g. dopamine concentration, receptor interaction, direct or indirect 
effect, depolarization status of the cells), dopamine generally, as also described in the 
previous paragraph, inhibits the activity of pyramidal cells in the medial PFC (see 
Tzschentke, 2001 for a review). The direct dopamine action on pyramidal cells (Geijo-
Barrietos and Pastore, 1995; Gulledge and Jaffe, 1998) or the indirect action by a stimulation 
of the GABA interneurons may in turn inhibit pyramidal cells (Mercuri et al., 1985; Penit-
Soria et al., 1987; Pirot et al., 1992). This latter action appears to be mediated through D2 
receptors (Retaux et al., 1991; Grobin and Deutch, 1998). On the other hand, pyramidal cells 
respond more to NMDA stimulation through D1 receptors in the presence of a low 
concentration of dopamine, whereas a high concentration would instead reduce this 
response (Zheng et al., 1999) by acting through D2 receptors. The role of D1/5 receptor is 
also crucial in suppressing the sustained neuronal firing that takes place during working 
memory activity (Vijayraghavan et al., 2007). This property is displayed by D1/5 dopamine 
receptor agonists, which have been found to cause a decrease in extracellular glutamate in 
PFC in vivo (Abekawa et al. 2000; Harte and O’Connor 2004). Interestingly D1/5 dopamine 
receptor agonists are also effective in normalizing aberrant network activity induced by 
both hallucinogens and minimal GABAA antagonism, although clinical efficacy remains to 
be determined (Aghajanan, 2009). The close relationship between dopamine and glutamate 
is functionally expressed at NAcc level where medial PFC efferents terminate in close 
opposition to dopamine terminals originating in the VTA, often in the same spine of 
GABAergic accumbal cells (Bouyer et al, 1984; Sesack and Pickel, 1992). It is interesting to 
note that only about 30-40 % of the VTA projection to PFC is dopaminergic, while the rest is 
likely to be an inhibitory GABAergic innervation (Carr and Sesack 2000a). Of further 
relevance is that PFC glutamate innervations of the NAcc is part of the motivational circuit 
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completed by accumbal GABA neurons projecting onto the ventral globus pallidus, by 
pallidal GABA neurons that project to the thalamus and lastly by thalamic glutamate 
neurons that project back to the PFC (see Chambers et al., 2003, for a review). Hence, PFC 
and NAcc work together to produce a behavioral output resulting from brain activity that 
processes input information concerning the internal status of the individual and the external 
environment (Dorman and Gaudiano, 1998). Considering that firing patterns in both the 
NAcc and PFC are influenced by glutamatergic input from the hippocampus and amygdala 
(Aggleton, 2011; Miller et al., 2010), it may be suggested that abnormalities in these distal 
structures may produce both psychiatric disorders as well as higher vulnerability to drug 
addiction (Chambers et al., 2001). As far as regards dopamine transmission in the PFC it is 
necessary to remind that dopamine could be captured by norepinephrine reuptake system 
(Carboni et al., 1990; Carboni et al., 2006)  
4. Noradrenaline in the prefrontal cortex: Innervation, receptors and 
interactions  
The long established observation that catecholamine depletion in PFC can be considered as 
destructive as tissue ablation (Brozoski et al., 1979) confirms the prominent role of 
catecholamine innervation in the PFC. The noradrenergic system that originates in the locus 
coeruleus and in other small nuclei in the medulla and the pons has the peculiar feature of 
projecting onto the entire neuraxis, although it originates in a relatively small group of cells. 
This extensive, irradiating anatomical arrangement allows the noradrenergic system to 
potentially influence all brain activity. In particular, noradrenaline innervations of PFC depend 
on neurons located in the locus coeruleus (Foote et al., 1983; Bjorklund and Lindvall, 1986) that 
project to dendrites of both pyramidal cells and interneurons. An interesting feature of locus 
coeruleus noradrenergic innervation of the cerebral cortex is that individual locus coeruleus 
neurons simultaneously innervate functionally and cyto-architectonically distinct cortical 
regions. In fact, locus coeruleus neurons arborize more extensively in the anterior-to-posterior 
axis of the cortex and exhibit relatively minimal medial-to-lateral collateralization (Swanson, 
1976; Aoki et al., 1998). Individual locus coeruleus cells were also shown to innervate both 
superficial and deep layers of a cortical region (Loughlin et al., 1982). Furthermore, the PFC 
projects back to the locus coeruleus thereby completing a circuitry which plays a role in 
relevant brain activity, i.e. maintaining vigilance (reviewed by Aston Jones, 1985) or 
modulating the behavioural response to stress (Morilak et. al., 2005). Functionally, the 
noradrenergic system can be viewed as a modulatory system because it can increase the 
“signal to noise ratio” of responses evoked by other neurotransmitters that excite or inhibit 
target cells (Woodward et al., 1991). Modulatory actions of this type can be mediated through 
either α or β noradrenergic receptors (Waterhouse et al., 1991; Woodward et al., 1991). This 
modulatory type action is also supported by the fact that in the monkey PFC noradrenaline 
produces its effects predominantly through α2A adrenoceptors that occur in spines, localized 
discretely over postsynaptic membranes that are most likely PFC pyramidal cells (Aoki et al., 
1998). Yet α2A receptors are most prevalent along axons, and are found also in dendritic shafts 
and astrocytic processes that lack evident synaptic junction. This suggests that these receptors 
are activated by volume transmission (Aoki et al., 1998). In particular, axonal α2A 
adrenoceptors have a pre-terminal location; by closing voltage dependent Ca++ channels, they 
are probably able to reduce neurotransmitter release such as serotonin as well as 
noradrenaline release (Frankhuyzen and Mulder, 1980; Maura et al., 1982).  
 
Addictions – From Pathophysiology to Treatment 
 
136 
Moreover, it appears that noradrenaline receptors with different affinities may mediate 
responses triggered by different extracellular concentrations of this transmitter. As reviewed 
by Arnsten (2007), moderate levels of noradrenaline released during waking act on high 
affinity α2A adrenoceptors coupled with Gi proteins to inhibit cAMP signalling, whereas 
higher levels released during stress not only activate lower affinity β1 coupled to 
phosphatidyl inositol signalling but also low affinity β1 adrenoceptors coupled to Gs, to 
increase cAMP signalling (Arnsten, 2000). In general, the role of noradrenaline in the PFC 
can be seen as being an inhibitory action with a long onset and protracted effect, and can be 
defined as being neuromodulatory. By inhibiting ongoing background discharge, 
noradrenaline produces an increase in the signal–to-noise ratio that helps to filter irrelevant 
stimuli while enhancing behaviorally significant stimuli (Bjorklund and Lindvall, 1986). 
According to this view NA is crucial for many PFC functions mediated by α2A post synaptic 
adrenoceptors, such as working memory, attention regulation, planning and behavioural 
inhibition as suggested by experimental research on various mammals (Arnsten, 2006 and 
2009).  
Catecholamine transmission in PFC is also dependent on the location of receptors in the 
dendritic tree of pyramidal cells and may occur through both α2A adrenoceptors increasing 
delay-related firing for the preferred spatial direction or through D1 receptor decreasing 
delay-related firing for the nonpreferred direction (Vijayraghavan et al., 2007). 
Catecholamine transmission is thus essential for reducing the effect of distracting stimulus, 
or “noise” (Miller et al., 1996) and inhibiting inappropriate behaviours (Funahashi et al., 
1993 Arnsten, 2007). More recent data have indicated that both D1 and α2A adrenoceptors 
can either stimulate or reduce cAMP production respectively, i.e. may increase or reduce the 
probability of hyperpolarization-activated cyclic nucleotide gated cation channels opening 
(HCN) (Arnsten, 2007). Moreover, dopamine and NA can inhibit GABA interneurons in the 
PFC via D4 receptors for which noradrenaline has a high affinity (Wang et al., 2002).  
5. Addiction and prefrontal cortex function: Similarities and differences 
between humans and other mammals 
Addiction is the result of numerous factors and the PFC circuitry contributes to the 
expression of several behaviours that are associated with addiction (Goldstein and Volkow, 
2011; Heatherton and Wagner, 2011, George and Koob, 2010). A large majority of addicted 
subjects do not seek treatment, likely because they do not even recognize their condition as a 
disease that requires a therapeutic intervention (Goldstein et al. 2009). This condition is 
probably generated by viewing the abused substance as an essential ingredient of their life, 
regardless of the consequences of its use. The knowledge of mPFC role in drug dependence 
can be improved comparing the results of studies performed in animals with those 
performed in humans although the complexity of addiction behaviour suggests attention in 
comparing directly specific components of drug dependence (i.e. chronic drug exposure, 
drug abstinence, drug seeking, cue or drug induced relapse and stress induced relapse). 
Indeed, if drug addiction in humans can be considered a disorder of self-control because the 
reinforcing properties of drugs of abuse prevail on the conscious awareness of the negative 
consequences of addiction behaviour (Heatherton and Wagner, 2011), in animals drug self-
administration is supported mostly by the direct rewarding property of the drug (see 
O’Connor et al. 2011 for a critical evaluation). Therefore, if a man is conscious of the risk 
 
Role of Prefrontal Cortex Dopamine and Noradrenaline Circuitry in Addiction 
 
137 
associated with drug taking either as far as regards legal or health or social consequences, 
the same cannot apply to monkeys or rats.  
A second important difference among humans and animals deals with the beginning of 
drug taking. In man it is often the consequence of a complex psychological motivation in 
which expectations is a strong component (Berridge et al., 2009) while it is often a passive 
outcome in animals. Moreover, the consequences of drug taking may vary substantially 
depending on the age of the first experience. In fact drug taking can be started in 
adolescence, or at adult age and the consequences can be very different because the 
incomplete brain maturation at adolescence age can offer a fertile ground to the strong 
reinforcing properties of drugs of abuse (Casey and Jones, 2010). On the other hand, at adult 
age drug taking can be started to react to a stressful situation and although it may have 
multiple origin, it may offer again a common fertile ground because the altered status of 
brain circuitry. Now, if drug taking produces relevant changes in the mPFC of humans and 
animals, those changes are produced upon a rather different brain circuitry status and 
therefore the intrinsic rewarding effects in humans can be basically different from those 
produced in other mammals. When a drug of abuse is administered to animals, the effects 
observed are those produced on a brain circuitry ensemble that is in a balanced basal 
condition (unless specific treatments have been applied previously), therefore a great 
caution should be taken comparing those results to men.  
6. Drugs of abuse: Acute effects on prefrontal cortex dopamine and 
noradrenaline transmission 
Substantial evidence confirms the direct involvement of mPFC in addiction. Firing of mPFC 
neurons is strictly related to i.v. injections of cocaine and heroin (Chang et al., 1998), 
whereas 6-OH dopamine lesions of mPFC enhance cocaine self-administration (Schenk et 
al., 1991) and excitotoxic lesions of mPFC determine facilitation of cocaine self-
administration (Weissenborn et al., 1997). In particular mPFC has a critical role in drug 
seeking, craving and relapse either triggered by drugs or by stress or cues associated with 
drug taking either in humans or in animals (Kalivas et al, 2005; Kalivas and Volkow, 2005). 
Moreover image studies allowed to observe a reduction in blood flow and cellular 
metabolism in dorsal PFC of individuals who abused psychostimulants and opioids 
(Daglish et al., 2001; Bolla et al., 2003; Adinoff et al., 2012). On the contrary an increase has 
been observed when addicts are exposed to drug-associated cues (Goldstein and Volkow, 
2002; Langleben et al., 2008). Nevertheless a reduction in blood flow and cellular metabolism 
in ventral PFC has been observed in cocaine abusers upon exposition to cocaine related cues 
(Bonson et al., 2002). Taken together these data support the view that drug addiction 
increases the motivational value of drug-associated cues while, most likely, negatively 
affects the function of mPFC in reducing the value of natural reinforcers (see Van den Oever 
et al., 2010). 
Nevertheless, although the dorsal mPFC is critically involved in reinstatement of drug 
seeking behaviour after abstinence (Berglind et al., 2007) pharmacological inactivation of the 
dorsal mPFC had no effect on cocaine seeking induced by cocaine cues (Koya et al., 2009). 
Psychostimulants and other drugs that block dopamine or noradrenaline carrier increase 
directly extracellular concentration of these catecholamine in all brain areas innervated by 
dopamine and noradrenaline neurons (Carboni et al., 1989; Tanda et al., 1997; Carboni et al., 
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Moreover, it appears that noradrenaline receptors with different affinities may mediate 
responses triggered by different extracellular concentrations of this transmitter. As reviewed 
by Arnsten (2007), moderate levels of noradrenaline released during waking act on high 
affinity α2A adrenoceptors coupled with Gi proteins to inhibit cAMP signalling, whereas 
higher levels released during stress not only activate lower affinity β1 coupled to 
phosphatidyl inositol signalling but also low affinity β1 adrenoceptors coupled to Gs, to 
increase cAMP signalling (Arnsten, 2000). In general, the role of noradrenaline in the PFC 
can be seen as being an inhibitory action with a long onset and protracted effect, and can be 
defined as being neuromodulatory. By inhibiting ongoing background discharge, 
noradrenaline produces an increase in the signal–to-noise ratio that helps to filter irrelevant 
stimuli while enhancing behaviorally significant stimuli (Bjorklund and Lindvall, 1986). 
According to this view NA is crucial for many PFC functions mediated by α2A post synaptic 
adrenoceptors, such as working memory, attention regulation, planning and behavioural 
inhibition as suggested by experimental research on various mammals (Arnsten, 2006 and 
2009).  
Catecholamine transmission in PFC is also dependent on the location of receptors in the 
dendritic tree of pyramidal cells and may occur through both α2A adrenoceptors increasing 
delay-related firing for the preferred spatial direction or through D1 receptor decreasing 
delay-related firing for the nonpreferred direction (Vijayraghavan et al., 2007). 
Catecholamine transmission is thus essential for reducing the effect of distracting stimulus, 
or “noise” (Miller et al., 1996) and inhibiting inappropriate behaviours (Funahashi et al., 
1993 Arnsten, 2007). More recent data have indicated that both D1 and α2A adrenoceptors 
can either stimulate or reduce cAMP production respectively, i.e. may increase or reduce the 
probability of hyperpolarization-activated cyclic nucleotide gated cation channels opening 
(HCN) (Arnsten, 2007). Moreover, dopamine and NA can inhibit GABA interneurons in the 
PFC via D4 receptors for which noradrenaline has a high affinity (Wang et al., 2002).  
5. Addiction and prefrontal cortex function: Similarities and differences 
between humans and other mammals 
Addiction is the result of numerous factors and the PFC circuitry contributes to the 
expression of several behaviours that are associated with addiction (Goldstein and Volkow, 
2011; Heatherton and Wagner, 2011, George and Koob, 2010). A large majority of addicted 
subjects do not seek treatment, likely because they do not even recognize their condition as a 
disease that requires a therapeutic intervention (Goldstein et al. 2009). This condition is 
probably generated by viewing the abused substance as an essential ingredient of their life, 
regardless of the consequences of its use. The knowledge of mPFC role in drug dependence 
can be improved comparing the results of studies performed in animals with those 
performed in humans although the complexity of addiction behaviour suggests attention in 
comparing directly specific components of drug dependence (i.e. chronic drug exposure, 
drug abstinence, drug seeking, cue or drug induced relapse and stress induced relapse). 
Indeed, if drug addiction in humans can be considered a disorder of self-control because the 
reinforcing properties of drugs of abuse prevail on the conscious awareness of the negative 
consequences of addiction behaviour (Heatherton and Wagner, 2011), in animals drug self-
administration is supported mostly by the direct rewarding property of the drug (see 
O’Connor et al. 2011 for a critical evaluation). Therefore, if a man is conscious of the risk 
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associated with drug taking either as far as regards legal or health or social consequences, 
the same cannot apply to monkeys or rats.  
A second important difference among humans and animals deals with the beginning of 
drug taking. In man it is often the consequence of a complex psychological motivation in 
which expectations is a strong component (Berridge et al., 2009) while it is often a passive 
outcome in animals. Moreover, the consequences of drug taking may vary substantially 
depending on the age of the first experience. In fact drug taking can be started in 
adolescence, or at adult age and the consequences can be very different because the 
incomplete brain maturation at adolescence age can offer a fertile ground to the strong 
reinforcing properties of drugs of abuse (Casey and Jones, 2010). On the other hand, at adult 
age drug taking can be started to react to a stressful situation and although it may have 
multiple origin, it may offer again a common fertile ground because the altered status of 
brain circuitry. Now, if drug taking produces relevant changes in the mPFC of humans and 
animals, those changes are produced upon a rather different brain circuitry status and 
therefore the intrinsic rewarding effects in humans can be basically different from those 
produced in other mammals. When a drug of abuse is administered to animals, the effects 
observed are those produced on a brain circuitry ensemble that is in a balanced basal 
condition (unless specific treatments have been applied previously), therefore a great 
caution should be taken comparing those results to men.  
6. Drugs of abuse: Acute effects on prefrontal cortex dopamine and 
noradrenaline transmission 
Substantial evidence confirms the direct involvement of mPFC in addiction. Firing of mPFC 
neurons is strictly related to i.v. injections of cocaine and heroin (Chang et al., 1998), 
whereas 6-OH dopamine lesions of mPFC enhance cocaine self-administration (Schenk et 
al., 1991) and excitotoxic lesions of mPFC determine facilitation of cocaine self-
administration (Weissenborn et al., 1997). In particular mPFC has a critical role in drug 
seeking, craving and relapse either triggered by drugs or by stress or cues associated with 
drug taking either in humans or in animals (Kalivas et al, 2005; Kalivas and Volkow, 2005). 
Moreover image studies allowed to observe a reduction in blood flow and cellular 
metabolism in dorsal PFC of individuals who abused psychostimulants and opioids 
(Daglish et al., 2001; Bolla et al., 2003; Adinoff et al., 2012). On the contrary an increase has 
been observed when addicts are exposed to drug-associated cues (Goldstein and Volkow, 
2002; Langleben et al., 2008). Nevertheless a reduction in blood flow and cellular metabolism 
in ventral PFC has been observed in cocaine abusers upon exposition to cocaine related cues 
(Bonson et al., 2002). Taken together these data support the view that drug addiction 
increases the motivational value of drug-associated cues while, most likely, negatively 
affects the function of mPFC in reducing the value of natural reinforcers (see Van den Oever 
et al., 2010). 
Nevertheless, although the dorsal mPFC is critically involved in reinstatement of drug 
seeking behaviour after abstinence (Berglind et al., 2007) pharmacological inactivation of the 
dorsal mPFC had no effect on cocaine seeking induced by cocaine cues (Koya et al., 2009). 
Psychostimulants and other drugs that block dopamine or noradrenaline carrier increase 
directly extracellular concentration of these catecholamine in all brain areas innervated by 
dopamine and noradrenaline neurons (Carboni et al., 1989; Tanda et al., 1997; Carboni et al., 
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1990; Carboni et al., 2006) including the PFC. The increase in dopamine extracellular 
concentration can determine the inhibition of the firing of dopamine neurons through an 
action on D2 auto-receptors and in turn increase K+ conductance at cell body level (Mercuri 
et al., 1992). The simultaneous reduction of firing and increase of transmitter extracellular 
concentration at terminal level produced by psychostimulants and cocaine on catecholamine 
transmission in the mPFC cortex and other brain areas determines a complex effect on 
cognition, attention and learning circuitry. Indeed either an increase or a decrease in 
dopamine transmission in the mPFC may lead to dysfunctions in the ability to inhibit 
inappropriate actions or thoughts (Arnsten and Li, 2005).  
Investigations on the effects of non-psychostimulants substances of abuse on dopamine and 
norepinephrine transmission in the rat PFC have produced disaccording results. Devoto et 
al., (2002) have found that acute morphine reduced extracellular norepinephrine, and failed 
to modify extracellular dopamine level in the mPFC whereas the administration of 
naloxone, in morphine dependent rats, precipitated a typical abstinence syndrome 
associated with a concomitant dramatic increase of extracellular dopamine and 
noreadrenaline (by about 200 and 100%, respectively) in the PFC. The direct role of 
norepinephrine transmission in the effects of morphine was demonstrated by the alpha(2)-
adrenoceptor agonist clonidine that suppressed naloxone-precipitated abstinence symptoms 
and brought both noradrenaline and dopamine output in PFC to less than 50 % of basal 
levels (Devoto et al., 2002). In contrast it has been reported that morphine enhances 
norepinephrine and dopamine release in the mPFC and that norepinephrine transmission is 
necessary for morphine rewarding effects, reinstatement and mesoaccumbens dopamine 
release (Ventura et al., 2005). More recently it was found that the released levels of 
dopamine and its major metabolites in the anterior cingulate cortex were increased by either 
the electrical stimulation of VTA neurons or by microinjection of a selective μ-opioid 
receptor agonist, (D-Ala²,N-MePhe4,Gly5-ol) enkephalin (DAMGO), into the VTA (Narita et 
al., 2010).  
The ability of nicotine to stimulate dopamine and norepinephrine release in the mPFC has 
been also investigated to assess the involvement of PFC circuitry in the addiction 
mechanism of nicotine and to explore the potential of modulation of this transmission for 
cognition enhancement. At this regard Livingstone et al., (2010) reported that a selective 
alpha7 nicotinic acetylcholine receptors (nAChRs) agonist evoked dopamine overflow in the 
prefrontal cortex in vivo, and this effect was potentiated by PNU-120596, an allosteric 
modulator of alpha7 nACh receptor. Moreover, antagonists of NMDA and AMPA receptors 
blocked [3H]dopamine release from tissue prisms in vitro. On these bases the authors 
proposed that alpha7 nAChRs were present on glutamate terminals and could increase 
glutamate release that in turn coordinately could enhances dopamine release from 
neighboring buttons.  
The effect of other drugs of abuse such ethanol and cannabinoids on dopamine and 
noradrenaline transmission in the PFC received less attention although the effects of these 
drugs on cognition and mental health are well known. It has been found that posterior VTA 
dopamine neurons projecting to the ventral pallidum and mPFC are stimulated by local 
administration of ethanol and that these stimulating effects are mediated, at least in part, by 
5-HT(3)receptors (Ding et al., 2011). The presence of cannabinoid receptors in the PFC has 
been shown by neuroanatomical data suggesting that cortical norepinephrine release may 
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be modulated, in part, by CB1 receptors that are presynaptically distributed on 
noradrenergic axon terminals (Oropeza et al., 2006). Moreover, repeated treatment with 
delta-9-tetrahydrocannabinol (THC), the major psychoactive constituent of marijuana, or 
WIN 55,212-2 (WIN), a synthetic cannabinoid receptor agonist caused a persistent and 
selective reduction in mPFC dopamine turnover (Verrico et al., 2003). Thereby these 
evidences suggest that dopamine and norepinephrine transmission in the PFC are involved 
in the effects of many drugs of abuse, although their precise role is far to be clarified.  
7. Abstinence, dopamine and noradrenaline transmission in the PFC 
Although the intrinsic meaning of abstinence, as far as regards drug addiction, is referred to 
a drug free condition, the status of PFC during abstinence may vary depending on the time 
interval elapsed from the interruption of drug use. Abrupt drug removal can produce a 
rather similar abstinence syndrome as both men and rats will experience a neuro-
physiological adaptation to drug absence. This effect cannot be trivial considering the strong 
impact of drug effects on brain. Nevertheless once the acute abstinence has been overtaken, 
strong differences may be found between men and other mammals, in particular when 
abstinence is generated by a gradual quitting process in humans or extinction process in 
animals as in self-administration experiments. For instance, in these experiments, upon 
removal of the reinforcing drug, rats will soon experience the absence of drug effect. This 
condition will initially generate an enhanced activity at the operant administration 
mechanism (e.g. lever pressing, nose poke etc.) that will be followed by a reduction because 
operant activity becomes emptied of pleasurable consequences. This condition will activate 
a parsimonious process that drives rat behaviour to ignore the ineffective lever pressing 
with a come back to the routine cage activity. Thus, drug disappearance can be view as an 
uncontrollable variable and it is likely that rats will not go through the experience of 
choosing whether or not going back to the drug. Therefore, although it is hard to appraise in 
rats the role of memories associated with drug administration, we can suggest that medial 
PFC circuitry will respond to drug removal through adapting progressive changes, thus 
generating the relative abstinence condition.  
On the other hand in man, abstinence is a multiple component condition in which the lack 
drug effects is strictly associated with an internal struggle between the desire of the reward 
associated with drug taking and the evaluation of the consequences of that behaviour in 
terms of money, social life and health involvement (e.g. smoking, cocaine use). It is therefore 
likely that mPFC circuitry response to abstinence in man will be unique, although it is 
obviously dependent on the abused drug and on plenty of other environmental factors such 
as recreational habits, family or economic problems or other stress related conditions. 
Therefore, craving for drugs is characterized in animals by an initial stereotyped search for 
drug, that ends relatively quickly with the reaching of a relatively stable brain circuitry 
equilibrium. Instead in man, mPFC brain circuitry reaches only a pseudo-equilibrium to 
which contribute the lack of drug effects and its desire (in common with animals), together 
with of the effort of self-controlling environmental stimuli that often were those that 
generated drug addiction. In this scenario the result of the exposition to cues associated with 
drug taking can trigger relapse either in animals or humans, but again involvement of 
mPFC circuitry can be completely different. The role of PFC in extinction has been recently 
investigated in humans and animals though the circuitry involved is poorly understood (See 
the recent review by Millan et al., 2011).  
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1990; Carboni et al., 2006) including the PFC. The increase in dopamine extracellular 
concentration can determine the inhibition of the firing of dopamine neurons through an 
action on D2 auto-receptors and in turn increase K+ conductance at cell body level (Mercuri 
et al., 1992). The simultaneous reduction of firing and increase of transmitter extracellular 
concentration at terminal level produced by psychostimulants and cocaine on catecholamine 
transmission in the mPFC cortex and other brain areas determines a complex effect on 
cognition, attention and learning circuitry. Indeed either an increase or a decrease in 
dopamine transmission in the mPFC may lead to dysfunctions in the ability to inhibit 
inappropriate actions or thoughts (Arnsten and Li, 2005).  
Investigations on the effects of non-psychostimulants substances of abuse on dopamine and 
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al., (2002) have found that acute morphine reduced extracellular norepinephrine, and failed 
to modify extracellular dopamine level in the mPFC whereas the administration of 
naloxone, in morphine dependent rats, precipitated a typical abstinence syndrome 
associated with a concomitant dramatic increase of extracellular dopamine and 
noreadrenaline (by about 200 and 100%, respectively) in the PFC. The direct role of 
norepinephrine transmission in the effects of morphine was demonstrated by the alpha(2)-
adrenoceptor agonist clonidine that suppressed naloxone-precipitated abstinence symptoms 
and brought both noradrenaline and dopamine output in PFC to less than 50 % of basal 
levels (Devoto et al., 2002). In contrast it has been reported that morphine enhances 
norepinephrine and dopamine release in the mPFC and that norepinephrine transmission is 
necessary for morphine rewarding effects, reinstatement and mesoaccumbens dopamine 
release (Ventura et al., 2005). More recently it was found that the released levels of 
dopamine and its major metabolites in the anterior cingulate cortex were increased by either 
the electrical stimulation of VTA neurons or by microinjection of a selective μ-opioid 
receptor agonist, (D-Ala²,N-MePhe4,Gly5-ol) enkephalin (DAMGO), into the VTA (Narita et 
al., 2010).  
The ability of nicotine to stimulate dopamine and norepinephrine release in the mPFC has 
been also investigated to assess the involvement of PFC circuitry in the addiction 
mechanism of nicotine and to explore the potential of modulation of this transmission for 
cognition enhancement. At this regard Livingstone et al., (2010) reported that a selective 
alpha7 nicotinic acetylcholine receptors (nAChRs) agonist evoked dopamine overflow in the 
prefrontal cortex in vivo, and this effect was potentiated by PNU-120596, an allosteric 
modulator of alpha7 nACh receptor. Moreover, antagonists of NMDA and AMPA receptors 
blocked [3H]dopamine release from tissue prisms in vitro. On these bases the authors 
proposed that alpha7 nAChRs were present on glutamate terminals and could increase 
glutamate release that in turn coordinately could enhances dopamine release from 
neighboring buttons.  
The effect of other drugs of abuse such ethanol and cannabinoids on dopamine and 
noradrenaline transmission in the PFC received less attention although the effects of these 
drugs on cognition and mental health are well known. It has been found that posterior VTA 
dopamine neurons projecting to the ventral pallidum and mPFC are stimulated by local 
administration of ethanol and that these stimulating effects are mediated, at least in part, by 
5-HT(3)receptors (Ding et al., 2011). The presence of cannabinoid receptors in the PFC has 
been shown by neuroanatomical data suggesting that cortical norepinephrine release may 
 
Role of Prefrontal Cortex Dopamine and Noradrenaline Circuitry in Addiction 
 
139 
be modulated, in part, by CB1 receptors that are presynaptically distributed on 
noradrenergic axon terminals (Oropeza et al., 2006). Moreover, repeated treatment with 
delta-9-tetrahydrocannabinol (THC), the major psychoactive constituent of marijuana, or 
WIN 55,212-2 (WIN), a synthetic cannabinoid receptor agonist caused a persistent and 
selective reduction in mPFC dopamine turnover (Verrico et al., 2003). Thereby these 
evidences suggest that dopamine and norepinephrine transmission in the PFC are involved 
in the effects of many drugs of abuse, although their precise role is far to be clarified.  
7. Abstinence, dopamine and noradrenaline transmission in the PFC 
Although the intrinsic meaning of abstinence, as far as regards drug addiction, is referred to 
a drug free condition, the status of PFC during abstinence may vary depending on the time 
interval elapsed from the interruption of drug use. Abrupt drug removal can produce a 
rather similar abstinence syndrome as both men and rats will experience a neuro-
physiological adaptation to drug absence. This effect cannot be trivial considering the strong 
impact of drug effects on brain. Nevertheless once the acute abstinence has been overtaken, 
strong differences may be found between men and other mammals, in particular when 
abstinence is generated by a gradual quitting process in humans or extinction process in 
animals as in self-administration experiments. For instance, in these experiments, upon 
removal of the reinforcing drug, rats will soon experience the absence of drug effect. This 
condition will initially generate an enhanced activity at the operant administration 
mechanism (e.g. lever pressing, nose poke etc.) that will be followed by a reduction because 
operant activity becomes emptied of pleasurable consequences. This condition will activate 
a parsimonious process that drives rat behaviour to ignore the ineffective lever pressing 
with a come back to the routine cage activity. Thus, drug disappearance can be view as an 
uncontrollable variable and it is likely that rats will not go through the experience of 
choosing whether or not going back to the drug. Therefore, although it is hard to appraise in 
rats the role of memories associated with drug administration, we can suggest that medial 
PFC circuitry will respond to drug removal through adapting progressive changes, thus 
generating the relative abstinence condition.  
On the other hand in man, abstinence is a multiple component condition in which the lack 
drug effects is strictly associated with an internal struggle between the desire of the reward 
associated with drug taking and the evaluation of the consequences of that behaviour in 
terms of money, social life and health involvement (e.g. smoking, cocaine use). It is therefore 
likely that mPFC circuitry response to abstinence in man will be unique, although it is 
obviously dependent on the abused drug and on plenty of other environmental factors such 
as recreational habits, family or economic problems or other stress related conditions. 
Therefore, craving for drugs is characterized in animals by an initial stereotyped search for 
drug, that ends relatively quickly with the reaching of a relatively stable brain circuitry 
equilibrium. Instead in man, mPFC brain circuitry reaches only a pseudo-equilibrium to 
which contribute the lack of drug effects and its desire (in common with animals), together 
with of the effort of self-controlling environmental stimuli that often were those that 
generated drug addiction. In this scenario the result of the exposition to cues associated with 
drug taking can trigger relapse either in animals or humans, but again involvement of 
mPFC circuitry can be completely different. The role of PFC in extinction has been recently 
investigated in humans and animals though the circuitry involved is poorly understood (See 
the recent review by Millan et al., 2011).  
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Here we will briefly discuss mPFC changes related to immediate abstinence generated from 
drug withdrawal. For instance interruption of nicotine exposure in humans, determines a 
rather fast appearance of withdrawal syndrome that is characterized by depressed mood, 
irritability, mild cognitive deficits accompanied by other peripheral physiological symptoms 
(Shiffman et al., 2004). We observed that either mecamylamine or naloxone determine the 
precipitation of an abstinence syndrome in rats carrying an osmotic minipump that 
continuously delivers nicotine (Carboni et al., 2000). This syndrome was characterized by 
physical abstinence signs appearing to be dissociated from dopamine extracellular 
concentration. Mecamylamine decreased dopamine in the NAcc while increasing it the 
mPFC whereas naloxone did not (Carboni et al., 2000). Interestingly withdrawal from a 
schedule of increasing doses of morphine or the administration of naloxone determined an 
increase in the extracellular concentration of dopamine mPFC (Bassareo et al., 1995). 
Preclinical research in animal models have also shown that early nicotine withdrawal is 
characterized by decreased function of presynaptic inhibitory metabotropic glutamate 2/3 
receptors (Markou, 2008). At the same time it has been observed an increased expression of 
postsynaptic glutamate receptor subunits in limbic and frontal brain sites. This increase may 
explain why a protracted abstinence may be associated with increased glutamate response 
to stimuli associated with nicotine administration (as reviewed by Markou, 2008).  
As far as regards cocaine addiction it has been reported (Kalivas et al., 2005) that enhanced 
D1 activity would lead to an increased inhibitory state of the PFC during withdrawal, so 
that only particularly strong stimuli, such as those associated with drug consumption, 
would be able to activate and guide behaviour. Moreover repeated cocaine administration 
change functional properties of the D1 receptors in the PFC through an enhancement of the 
activity of the G protein signalling 3 (AGS3), coupled to D1 receptors, whereas the G protein 
activity coupled to D2 was reduced following cocaine withdrawal (Bowers et al., 2004). 
These alterations in the mPFC may determine alteration of prefrontal glutamatergic 
innervation of the accumbens promoting the compulsive character of drug seeking in 
addicts by decreasing the value of natural rewards, diminishing cognitive control (choice), 
and enhancing glutamatergic drive in response to drug-associated stimuli. 
8. Relapse, dopamine and noradrenaline transmission in the prefrontal cortex  
The relapse to drug use is a major problem in drug addiction therapy. Essentially, relapse 
can be categorized in three major types: drug induced relapse, reinstatement of self-
administration behaviour upon exposition to drug related cues and stress induced relapse 
(Stewart, 2003; Crombag et al., 2008; Van den Oever et al., 2010). Drug-induced relapse 
could be associated with similar processes in humans and animals and will determine the 
resumption of drug intake behaviour, whereas cue-induced relapse may engage different 
brain circuitry depending on the involvement of self-control mechanisms. If a rat will just 
start pressing a lever, a man, who probably went through a strong involving process to 
achieve drug taking interruption, will go through a complex decision making process (e.g. a 
man will evaluate the strong effect of the cue and only when self control processes will be 
defeated will resume drug taking; alternatively he can resume drug taking without craving, 
or even he can rationally decide to take the drug because he has the conviction to be able to 
control drug taking). Thus, it is likely that reinstatement in man involves a more complex 
mPFC circuitry than in other mammals. Nevertheless one of the major determinants of 
reinstatement to cocaine use among human addicts is acute re-exposure to the drug, which 
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often precipitates cocaine craving and relapse (Cromabag et al., 2008; Volkow et al., 2010). 
As far as regards animal studies, it has been reported that the mPFC plays a major role 
during reinstatement, either because its direct role in cognition or because its connections 
with subcortical areas (Kalivas et al., 2005; Crombag et al., 2008; Van den Oever et al., 2010). 
Projections from the mPFC to the NAcc are stratified in a dorso-ventral pattern with the 
dorsal mPFC projecting predominantly to the NAcc core and the ventral mPFC projecting to 
the NAcc shell (Heidbreder and Groenewegen, 2003; Voorn et al., 2004). These anatomical 
features have been used to assume that during reinstatement the increase in extracellular 
glutamate in the NAcc core is associated with an increased excitatory activity of pyramidal 
neurons of dorsal mPFC that in turn may drive heroin (LaLumiere and Kalivas, 2008) or 
cocaine seeking behaviour in rats (Mac Farland et al., 2003).  
On the other hand, glutamatergic projections from the ventral mPFC to the NAcc shell have 
been found to suppress conditioned drug seeking after extinction learning (Peters et al., 2009) 
whereas interruption of this neuronal link or pharmacological inactivation of the NAcc shell 
produce resumption of drug craving (Peters et al., 2008; Fuchs et al., 2008). At this regard it has 
been proposed that the mPFC regulates the expression of both fear and drug memories after 
extinction, through divergent projections to the amygdala and nucleus accumbens, 
respectively. Therefore a common neural circuit for extinction of fear and drug memories 
would suggest shared mechanisms and treatment strategies across both domains (Peters et al., 
2009). These experimental evidences support the view of mPFC neurons controlling drug 
craving whereas its suppression may occur through two separate but balanced pathways by 
acting directly in the two NAcc sub-regions. This view has been contradicted by numerous 
studies (for a review see Van den Oever et al., 2010) and therefore it can be suggested that 
drug dependence in rats cannot be the product of a single neuronal pathway 
VTA dopaminergic neurons that innervate the dorsal mPFC have been reported to be 
involved in the initiation of drug seeking responses (for a review see Crombag et al., 2008 
and Van den Over et al., 2010). In particular dopamine administration into the dorsal mPFC 
has been shown to be sufficient to elicit a reinstatement of self-administration behavior 
(McFarland and Kalivas, 2001), whereas microinjections of the D1/D2 antagonist 
fluphenazine into the dorsal PFC but not into the NAcc core or ventral pallidum, prevented 
cocaine induced reinstatement (McFarland and Kalivas 2001). A role for dopamine 
transmission in reinstatement is also supported by the findings of Park and coworkers (Park 
et al., 2002). These authors showed that intra-mPFC administration of the dopamine 
antagonist flupentixol blocked cocaine reinstatement triggered by systemic cocaine 
administration in rats that were first trained to self-administer cocaine intravenously and 
later underwent through extinction by substitution of cocaine (i.v.) with saline (Park et al., 
2002). These authors also showed that reinstatement of cocaine seeking behavior could be 
induced by intra-mPFC cocaine and could be blocked by local administration of the AMPA 
receptor antagonist CNQX into NAcc shell or the border with the core (Park et al., 2002). 
Interestingly, it has been recently reported that the infralimbic mPFC, and specifically its 
glutamatergic and beta-adrenergic systems, regulates the consolidation of extinction of 
cocaine self-administration. Therefore the transmission at level of infralimbic cortex can be 
manipulated to influence the retention of extinction (LaLumiere and Kalivas, 2008).  
Moreover, a role for dopamine transmission in the mPFC has been also proposed in cue and 
in stress induced reinstatement of self-administration behavior. In fact intracranial infusion 
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Here we will briefly discuss mPFC changes related to immediate abstinence generated from 
drug withdrawal. For instance interruption of nicotine exposure in humans, determines a 
rather fast appearance of withdrawal syndrome that is characterized by depressed mood, 
irritability, mild cognitive deficits accompanied by other peripheral physiological symptoms 
(Shiffman et al., 2004). We observed that either mecamylamine or naloxone determine the 
precipitation of an abstinence syndrome in rats carrying an osmotic minipump that 
continuously delivers nicotine (Carboni et al., 2000). This syndrome was characterized by 
physical abstinence signs appearing to be dissociated from dopamine extracellular 
concentration. Mecamylamine decreased dopamine in the NAcc while increasing it the 
mPFC whereas naloxone did not (Carboni et al., 2000). Interestingly withdrawal from a 
schedule of increasing doses of morphine or the administration of naloxone determined an 
increase in the extracellular concentration of dopamine mPFC (Bassareo et al., 1995). 
Preclinical research in animal models have also shown that early nicotine withdrawal is 
characterized by decreased function of presynaptic inhibitory metabotropic glutamate 2/3 
receptors (Markou, 2008). At the same time it has been observed an increased expression of 
postsynaptic glutamate receptor subunits in limbic and frontal brain sites. This increase may 
explain why a protracted abstinence may be associated with increased glutamate response 
to stimuli associated with nicotine administration (as reviewed by Markou, 2008).  
As far as regards cocaine addiction it has been reported (Kalivas et al., 2005) that enhanced 
D1 activity would lead to an increased inhibitory state of the PFC during withdrawal, so 
that only particularly strong stimuli, such as those associated with drug consumption, 
would be able to activate and guide behaviour. Moreover repeated cocaine administration 
change functional properties of the D1 receptors in the PFC through an enhancement of the 
activity of the G protein signalling 3 (AGS3), coupled to D1 receptors, whereas the G protein 
activity coupled to D2 was reduced following cocaine withdrawal (Bowers et al., 2004). 
These alterations in the mPFC may determine alteration of prefrontal glutamatergic 
innervation of the accumbens promoting the compulsive character of drug seeking in 
addicts by decreasing the value of natural rewards, diminishing cognitive control (choice), 
and enhancing glutamatergic drive in response to drug-associated stimuli. 
8. Relapse, dopamine and noradrenaline transmission in the prefrontal cortex  
The relapse to drug use is a major problem in drug addiction therapy. Essentially, relapse 
can be categorized in three major types: drug induced relapse, reinstatement of self-
administration behaviour upon exposition to drug related cues and stress induced relapse 
(Stewart, 2003; Crombag et al., 2008; Van den Oever et al., 2010). Drug-induced relapse 
could be associated with similar processes in humans and animals and will determine the 
resumption of drug intake behaviour, whereas cue-induced relapse may engage different 
brain circuitry depending on the involvement of self-control mechanisms. If a rat will just 
start pressing a lever, a man, who probably went through a strong involving process to 
achieve drug taking interruption, will go through a complex decision making process (e.g. a 
man will evaluate the strong effect of the cue and only when self control processes will be 
defeated will resume drug taking; alternatively he can resume drug taking without craving, 
or even he can rationally decide to take the drug because he has the conviction to be able to 
control drug taking). Thus, it is likely that reinstatement in man involves a more complex 
mPFC circuitry than in other mammals. Nevertheless one of the major determinants of 
reinstatement to cocaine use among human addicts is acute re-exposure to the drug, which 
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often precipitates cocaine craving and relapse (Cromabag et al., 2008; Volkow et al., 2010). 
As far as regards animal studies, it has been reported that the mPFC plays a major role 
during reinstatement, either because its direct role in cognition or because its connections 
with subcortical areas (Kalivas et al., 2005; Crombag et al., 2008; Van den Oever et al., 2010). 
Projections from the mPFC to the NAcc are stratified in a dorso-ventral pattern with the 
dorsal mPFC projecting predominantly to the NAcc core and the ventral mPFC projecting to 
the NAcc shell (Heidbreder and Groenewegen, 2003; Voorn et al., 2004). These anatomical 
features have been used to assume that during reinstatement the increase in extracellular 
glutamate in the NAcc core is associated with an increased excitatory activity of pyramidal 
neurons of dorsal mPFC that in turn may drive heroin (LaLumiere and Kalivas, 2008) or 
cocaine seeking behaviour in rats (Mac Farland et al., 2003).  
On the other hand, glutamatergic projections from the ventral mPFC to the NAcc shell have 
been found to suppress conditioned drug seeking after extinction learning (Peters et al., 2009) 
whereas interruption of this neuronal link or pharmacological inactivation of the NAcc shell 
produce resumption of drug craving (Peters et al., 2008; Fuchs et al., 2008). At this regard it has 
been proposed that the mPFC regulates the expression of both fear and drug memories after 
extinction, through divergent projections to the amygdala and nucleus accumbens, 
respectively. Therefore a common neural circuit for extinction of fear and drug memories 
would suggest shared mechanisms and treatment strategies across both domains (Peters et al., 
2009). These experimental evidences support the view of mPFC neurons controlling drug 
craving whereas its suppression may occur through two separate but balanced pathways by 
acting directly in the two NAcc sub-regions. This view has been contradicted by numerous 
studies (for a review see Van den Oever et al., 2010) and therefore it can be suggested that 
drug dependence in rats cannot be the product of a single neuronal pathway 
VTA dopaminergic neurons that innervate the dorsal mPFC have been reported to be 
involved in the initiation of drug seeking responses (for a review see Crombag et al., 2008 
and Van den Over et al., 2010). In particular dopamine administration into the dorsal mPFC 
has been shown to be sufficient to elicit a reinstatement of self-administration behavior 
(McFarland and Kalivas, 2001), whereas microinjections of the D1/D2 antagonist 
fluphenazine into the dorsal PFC but not into the NAcc core or ventral pallidum, prevented 
cocaine induced reinstatement (McFarland and Kalivas 2001). A role for dopamine 
transmission in reinstatement is also supported by the findings of Park and coworkers (Park 
et al., 2002). These authors showed that intra-mPFC administration of the dopamine 
antagonist flupentixol blocked cocaine reinstatement triggered by systemic cocaine 
administration in rats that were first trained to self-administer cocaine intravenously and 
later underwent through extinction by substitution of cocaine (i.v.) with saline (Park et al., 
2002). These authors also showed that reinstatement of cocaine seeking behavior could be 
induced by intra-mPFC cocaine and could be blocked by local administration of the AMPA 
receptor antagonist CNQX into NAcc shell or the border with the core (Park et al., 2002). 
Interestingly, it has been recently reported that the infralimbic mPFC, and specifically its 
glutamatergic and beta-adrenergic systems, regulates the consolidation of extinction of 
cocaine self-administration. Therefore the transmission at level of infralimbic cortex can be 
manipulated to influence the retention of extinction (LaLumiere and Kalivas, 2008).  
Moreover, a role for dopamine transmission in the mPFC has been also proposed in cue and 
in stress induced reinstatement of self-administration behavior. In fact intracranial infusion 
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of the dopamine D1 receptor antagonist, SCH 23390 into the prelimbic cortex potently, and 
dose dependently, attenuated heroin-seeking in response to either cue presentations or a 
priming dose of heroin, confirming that dopamine D1 receptors regulate prefrontal cortex 
pathways necessary for the reinstatement of heroin-seeking in rats (See, 2009). In addition 
systemic blockade of D1 receptors prevents an increase in Fos expression in the dorsal mPFC 
(Ciccocioppo et al., 2001) suggesting an increase in dopamine transmission in this area during 
reinstatement. Moreover the role of the mPFC and in particular the involvement of dopamine 
transmission in stress induced reinstatement of cocaine seeking have been investigated in rats 
(Capriles et al., 2003). These authors have shown that inactivation of prelimbic cortex by 
tetrodotoxin blocked reinstatement of cocaine seeking induced by either foot shock or by 
cocaine priming, whereas the effects of tetrodotoxin injections in the orbitofrontal cortex (OFC) 
were mixed. Moreover, Capriles and coworkers found that infusion of the D1 dopamine 
antagonist SCH23390 into either the prelimbic or into the OFC blocked foot-shock induced 
reinstatement. These results suggest that the prelimbic and the orbitofrontal cortices form part 
of the circuitry mediating the effects of foot shock stress in reinstatement of drug seeking and 
that the prelimbic region may be a common pathway for cue, drug and foot-shock stress-
induced reinstatement of drug seeking (Capriles et al., 2003). Nevertheless, the dichotomy in 
mPFC function, attributing to dorsal mPFC (prelimbic, cingulate subregions) promotion of 
drug seeking and to ventral mPFC (infralimbic) inhibition of drug seeking in cocaine-
experienced rats (Peters et al., 2009), has been challenged by studies on heroin self-
administration suggesting that heroin seeking is promoted by a minority of selectively 
activated ventral mPFC neurons (Bossert et al., 2011). These authors thus suggested that 
different brain mechanisms mediate heroin and cocaine relapse in the rat model.  
9. Genetic variation, catecholamine transmission in the prefrontal cortex and 
predisposition to addictions 
Dopamine neurons projecting to the PFC possess an interesting feature as compared with 
other systems. In fact they have a higher baseline rate firing and a higher rate of dopamine 
turnover. This feature renders them very sensitive to alteration in dopamine synthesis and 
metabolism either underlained by gene variation or induced by drugs of abuse (Bannon et 
al., 1981; Hallman, 1984; Garris et al., 1993; Garris and Wightman, 1994; Cass and Gerhardt, 
1995). Improved performances in cognitive tasks requiring working memory and inhibition 
have been observed in subjects that carry variations in the catechol-O-methyltransferase 
(COMT) gene (Dumontheil et al., 2011). COMT degrades the catecholamine 
neurotransmitters dopamine, epinephrine, and norepinephrine. A functional polymorphism 
in the COMT gene (val158met) accounts for a four-fold variation in enzyme activity (Heinz 
and Smolka, 2006). The low activity met158 allele causes approximately 75 % reduction in 
dopamine methylation and increased dopamine function. This has been associated with 
improved working memory, executive functioning, and attention control, but is also linked 
to a higher risk of anxiety-related behaviours. The latter, in turn, may be related to an 
excessive activation of the HPA axis and relative responses due to elevated noradrenaline 
transmission in the PFC (Heinz and Smolka, 2006). On the other hand, limbic and prefrontal 
activation elicited by unpleasant stimuli in subjects with more met158 alleles might contribute 
to the observed lower emotional resilience against negative mood states (Smolka, et al., 
2005). The increase in dopamine function is particularly relevant in areas such as the 
prefrontal cortex because it contains significantly less dopamine transporter (Sesack et al., 
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1998; Lammel et al., 2008), and because dopamine clearance (approx. 60 %) is carried out by 
the COMT enzyme, unlike in other dopamine areas such as the striatum where dopamine is 
cleared promptly by the reuptake system (Karoum et al., 1994). 
Furthermore, Adele Diamond (2007) makes an interesting observation on the difference 
found between males and females. COMT activity in females is in fact roughly 30 % lower, 
due probably to estrogen activity (Cohn and Axelrod, 1971; Boudikova et al., 1990). This 
gender variation may render females able to better perform cognitive tasks because of the 
more elevated dopamine function in the PFC whereas they perform worse under even 
minor stress. On the other hand there is also substantial evidence that males perform better 
or no worse if slightly stressed (Shors and Miesegaes, 2002; Shors and Leuner, 2003; Shansky 
et al., 2004). This observation fits well with the above reported characteristics of the PFC 
dopamine function being highly sensitive to stress (Thierry et al., 1972; Reinhard et al., 1982; 
Roth et al., 1988; Deutch and Roth, 1990; Arnsten and Goldman-Rakic 1998; Arnsten, 1999 
and 2000). Thus, as reported by Diamond (2007), cognitive functioning in men would benefit 
from the expression of COMT variation with reduced activity whereas females would 
instead benefit from the expression of a faster-acting valine version of the COMT enzyme 
that would moderate excess dopamine functioning in the PFC. Altered activity of COMT, 
which has a primary role in the degradation of dopamine in the frontal cortex (Karoum et 
al., 1994), might thus also be involved in the magnification of the reinforcing properties of 
drugs of abuse. Considering that the increase of extracellular dopamine and norepinephrine 
in PFC is a peculiar effect of drugs such as amphetamine and cocaine one can wonder if 
subjects that carry variations in the catechol-O-methyltransferase (COMT) gene are 
predisposed to psychostimulant addiction. Genetic studies suggest that while occasional use 
of drugs of abuse is predominantly linked to environmental or familiar factors, over 60 % of 
the cocaine users inherited their vulnerability to heavy use and dependence (Kendler et al., 
2000; Kendler and Prescott, 1998).  
Nevertheless there are no convincing studies that correlate cocaine addiction with variation 
of genes related to dopaminergic system such as the genes DRD2, COMT, SLC6A3 (coding 
for the dopamine transporter DAT) and DBH (coding for the dopamine beta hydroxylase). 
However an interesting hypothesis (Brousse et al., 2010) suggested that individuals carrying 
genetic variation of the DBH gene, that has particularly been linked with the psychotic 
effects caused by cocaine, could be predisposed to cocaine-induced psychosis making the 
development of cocaine addiction less probable. This can also apply to mutations of the 
Val158Met of the gene COMT, TaqI A of the gene DRD2 and VNTR 9 repeat of the DAT. On 
the other hand Hosak et al., (2006) found that consumers of methamphetamine carrying the 
Met allele of the COMT gene Val158Met polymorphism showed higher novelty seeking 
scores. This polymorphism is associated with low COMT enzyme activity and high 
endogenous dopamine synaptic levels in the PFC. According to the authors this leads to a 
decrease in dopaminergic neurotransmission in the NAcc and a need to stimulate it through 
novelty seeking behaviour or psychostimulant use.  
10. Prefrontal cortex dopamine transmission in adolescence and drug 
addiction  
Adolescence (see chapter XX) is a crucial developmental period of life in which physical and 
psychological remarkable changes occurring after puberty, model the personality to allow 
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of the dopamine D1 receptor antagonist, SCH 23390 into the prelimbic cortex potently, and 
dose dependently, attenuated heroin-seeking in response to either cue presentations or a 
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reinstatement. These results suggest that the prelimbic and the orbitofrontal cortices form part 
of the circuitry mediating the effects of foot shock stress in reinstatement of drug seeking and 
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activated ventral mPFC neurons (Bossert et al., 2011). These authors thus suggested that 
different brain mechanisms mediate heroin and cocaine relapse in the rat model.  
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metabolism either underlained by gene variation or induced by drugs of abuse (Bannon et 
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1995). Improved performances in cognitive tasks requiring working memory and inhibition 
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(COMT) gene (Dumontheil et al., 2011). COMT degrades the catecholamine 
neurotransmitters dopamine, epinephrine, and norepinephrine. A functional polymorphism 
in the COMT gene (val158met) accounts for a four-fold variation in enzyme activity (Heinz 
and Smolka, 2006). The low activity met158 allele causes approximately 75 % reduction in 
dopamine methylation and increased dopamine function. This has been associated with 
improved working memory, executive functioning, and attention control, but is also linked 
to a higher risk of anxiety-related behaviours. The latter, in turn, may be related to an 
excessive activation of the HPA axis and relative responses due to elevated noradrenaline 
transmission in the PFC (Heinz and Smolka, 2006). On the other hand, limbic and prefrontal 
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prefrontal cortex because it contains significantly less dopamine transporter (Sesack et al., 
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1998; Lammel et al., 2008), and because dopamine clearance (approx. 60 %) is carried out by 
the COMT enzyme, unlike in other dopamine areas such as the striatum where dopamine is 
cleared promptly by the reuptake system (Karoum et al., 1994). 
Furthermore, Adele Diamond (2007) makes an interesting observation on the difference 
found between males and females. COMT activity in females is in fact roughly 30 % lower, 
due probably to estrogen activity (Cohn and Axelrod, 1971; Boudikova et al., 1990). This 
gender variation may render females able to better perform cognitive tasks because of the 
more elevated dopamine function in the PFC whereas they perform worse under even 
minor stress. On the other hand there is also substantial evidence that males perform better 
or no worse if slightly stressed (Shors and Miesegaes, 2002; Shors and Leuner, 2003; Shansky 
et al., 2004). This observation fits well with the above reported characteristics of the PFC 
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subjects that carry variations in the catechol-O-methyltransferase (COMT) gene are 
predisposed to psychostimulant addiction. Genetic studies suggest that while occasional use 
of drugs of abuse is predominantly linked to environmental or familiar factors, over 60 % of 
the cocaine users inherited their vulnerability to heavy use and dependence (Kendler et al., 
2000; Kendler and Prescott, 1998).  
Nevertheless there are no convincing studies that correlate cocaine addiction with variation 
of genes related to dopaminergic system such as the genes DRD2, COMT, SLC6A3 (coding 
for the dopamine transporter DAT) and DBH (coding for the dopamine beta hydroxylase). 
However an interesting hypothesis (Brousse et al., 2010) suggested that individuals carrying 
genetic variation of the DBH gene, that has particularly been linked with the psychotic 
effects caused by cocaine, could be predisposed to cocaine-induced psychosis making the 
development of cocaine addiction less probable. This can also apply to mutations of the 
Val158Met of the gene COMT, TaqI A of the gene DRD2 and VNTR 9 repeat of the DAT. On 
the other hand Hosak et al., (2006) found that consumers of methamphetamine carrying the 
Met allele of the COMT gene Val158Met polymorphism showed higher novelty seeking 
scores. This polymorphism is associated with low COMT enzyme activity and high 
endogenous dopamine synaptic levels in the PFC. According to the authors this leads to a 
decrease in dopaminergic neurotransmission in the NAcc and a need to stimulate it through 
novelty seeking behaviour or psychostimulant use.  
10. Prefrontal cortex dopamine transmission in adolescence and drug 
addiction  
Adolescence (see chapter XX) is a crucial developmental period of life in which physical and 
psychological remarkable changes occurring after puberty, model the personality to allow 
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the assumption of adult roles and responsibilities (Dahl, 2004a and 2004b; Steinberg, 2008). 
In this scenario PFC represents a crucial brain area because its function in expressing a 
specific behaviour. This may be the outcome of multiple interactions such as those between 
the hormonal triggered desires, and the representation of increasingly complex and distant 
social goals. The shaping of this objective in turn will be influenced by the social and family 
environment. Therefore the maturation of PFC occurring in adolescence may definitively 
shape the adult personality and at the same time, dysfunctions happening in this process 
may constitute a milieu necessary and often sufficient for developing psychiatric disorders 
such as schizophrenia and depression or for predisposing individuals to a high vulnerability 
to drug addiction (see Davey, et al., 2008). 
The PFC has a prominent role in controlling impulsiveness (Fineberg et al., 2010) and in 
adolescence it is likely that this control is insufficient due to incomplete maturation of 
cognitive function. Accordingly, working memory, abstract thinking and complex problem 
solving improve during adolescence to peak at late adolescence (Feinberg, 1983; Woo et al., 
1997; Williams et al., 1999). These acquired abilities are supported by distinct developmental 
changes occurring in the PFC during adolescence and involve changes in densities of 
dendritic processes and synapses, increased myelination, increased neuronal membrane 
synthesis and in turn, increase in white matter (Paus et al., 1999; Giedd et al., 1999a, 1999b). 
Among these changes, synaptic pruning has been considered a way to reduce energy use 
through a selective reduction of synaptic contacts that are not necessary to sustain a 
particular ability; in humans PFC synaptic density, after reaching a maximum at the age of 5 
years, diminishes by about 35 % by late adolescence (Lewis, 1997). This synapse reduction 
involves mostly local PFC circuits (Woo et al., 1997) and both excitatory and inhibitory 
inputs are implicated (Anderson et al., 1995). During the pruning that occurs in adolescence 
there is a prevalent reduction of the excitatory stimulation that reaches the PFC (Rakic et al., 
1994). In particular synapse elimination of presumed glutamatergic inputs occurs in PFC. 
Binding to NMDA receptors in rat brain peaks at 28 post natal day (PND) whereas a 
successive reduction leads to a 33 % reduction by the 60 PND (Insel et al., 1990).  
On the contrary, dopamine functional activity in the PFC increases in adolescence, peaking 
to levels much higher than those seen in adulthood (for a review see Lewis et al., 1998). In 
rats, dopamine innervation is maximum at 35 PND in superficial layers and at 60 PND in 
deeper layers (Kalsbeek et al., 1988); moreover, the density of DAT, often used as an index of 
dopamine innervation in the PFC, is about 70 % of adult levels in weaning rats. On the other 
hand the increase in dopamine fiber density observed in development may be associated to 
a decline in synthesis and turnover; in fact synthesis peaks at PND 30 and then declines in 
late adolescence (Andersen, et al., 1997). Adolescence has a peculiar feature from an 
energetically point of view. In fact cortex energy consumption in humans peaks at 3-4 years 
and is maintained up to the age of 20, to progressively decline in later life (Chugani et al., 
1987). In general synaptic pruning and myelination can be considered parallel processes that 
apparently have the role of strengthening regularly used innervations rendering them able 
to fire in a more concerted pattern (Lewis, 1997; Miller, 1996). At the same time infrequently 
used innervations are eliminated (Rutherford et al., 1998). Furthermore dopamine 
modulation of fast-spiking interneurons changes dramatically during adolescence (PND 45-
50 in rats) with D2 agonists switching from being mildly inhibitory in prepubertal rats to 
strongly excitatory in young adult rats. In vivo recordings in adult rats reveal that deep-
layer pyramidal neurons respond to endogenous DA release with suppression of firing 
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while interneurons are activated (Tseng and O’Donnell, 2007; Gruber et al., 2010). Thus the 
increase in dopamine functional activity that peaks in adolescence together with the 
reduction of excitatory innervation are two delicate processes which reduce the activity of 
pyramidal cells. Therefore either a deficiency in excitatory reduction or a defective increased 
inhibitory activity may lead to an excessive pyramidal cell activity that in turn may be 
reflected by the onset of a psychiatric disorder or drug abuse.  
Substantial evidence points to the higher risk of drug exposure in adolescence (Barron et al., 
2005; Crews and Hodge, 2007; Schramm-Sapyta et al., 2009). In particular alcohol 
consumption during adolescence causes diffuse brain alterations and greatly increases the 
likelihood that an alcohol use disorder will develop later in life (Nixon and McClain, 2010). 
Diffusion tensor imaging studies have shown that adolescent binge drinking damages white 
matter tracts throughout the brain, including main hippocampus efferent fibers and those 
interconnecting the PFC (McQueeny et al., 2009; Jacobus et al., 2009). Adolescents respond to 
the effects of alcohol distinctly from adults in fact they are less sensitive to negative effects 
of alcohol, they do no perceive cues that may suggest reduction of intake, but are more 
sensitive to positive effects such as those related to social interaction, which may serve to 
reinforce or promote excessive intake (Spear et al., 2005). Adolescence is also critical for 
cannabis abuse, indeed it is widely reported that cannabis use during adolescence increases 
the risk of developing psychotic disorders later in life (Bossong and Niesink, 2010, Malone et 
al, 2010). However, although the neurobiological processes underlying this relationship are 
unknown, alteration of PFC circuitry is more than likely. Very recently it was found that 
marijuana users had decreased cortical thickness in right caudal middle frontal, bilateral 
insula and bilateral superior frontal cortices (Lopez-Larson, 2011). These results suggest that 
age of regular use may be associated with altered PFC gray matter development in 
adolescents. According to the authors of this study reduced insular cortical thickness may be 
used as a biological marker for ascertain increased risk of substance dependence (Lopez-
Larson, 2011). An interesting comparison in adolescent alcohol and marijuana users has 
been proposed by evaluating participants who performed a verbal paired associates 
encoding task during functional magnetic resonance imaging (fMRI) scanning. The results 
of this study suggested that adolescent substance users demonstrated altered fMRI response 
relative to non-using controls, yet binge drinking appeared to be associated with more 
differences in activation than marijuana use (Schweinsburg et al., 2011). Alcohol and 
marijuana may have interactive effects that alter these differences, particularly in prefrontal 
brain regions (Schweinsburg et al., 2011).  
As far as regards cocaine effects, rats with adolescent-onset cocaine self-administration 
experience were more impaired in an OFC-related learning task than rats with adult-onset 
cocaine self-administration experience (Harvey et al., 2009). Treatment with cocaine during 
adolescence also caused acute alterations in the expression of genes encoding cell adhesion 
molecules and transcription factors within the PFC. In particular, a decrease in histone 
methylation was observed and this effect may indicate a role for chromatin remodelling in 
gene expression patterns. These findings allowed the authors to suggest that exposure to 
cocaine during adolescence has extensive molecular and behavioural effects in the rat PFC. 
These consequences develop over time and endure long after drug administration has 
ceased (Black et al., 2006). Smoking and nicotine exposure during adolescence is a very 
relevant heath problem because the higher dependence developed in individuals who start 
smoking early (see O’Dell, 2009 for review). Early tobacco use is facilitated by the legal 
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the assumption of adult roles and responsibilities (Dahl, 2004a and 2004b; Steinberg, 2008). 
In this scenario PFC represents a crucial brain area because its function in expressing a 
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involves mostly local PFC circuits (Woo et al., 1997) and both excitatory and inhibitory 
inputs are implicated (Anderson et al., 1995). During the pruning that occurs in adolescence 
there is a prevalent reduction of the excitatory stimulation that reaches the PFC (Rakic et al., 
1994). In particular synapse elimination of presumed glutamatergic inputs occurs in PFC. 
Binding to NMDA receptors in rat brain peaks at 28 post natal day (PND) whereas a 
successive reduction leads to a 33 % reduction by the 60 PND (Insel et al., 1990).  
On the contrary, dopamine functional activity in the PFC increases in adolescence, peaking 
to levels much higher than those seen in adulthood (for a review see Lewis et al., 1998). In 
rats, dopamine innervation is maximum at 35 PND in superficial layers and at 60 PND in 
deeper layers (Kalsbeek et al., 1988); moreover, the density of DAT, often used as an index of 
dopamine innervation in the PFC, is about 70 % of adult levels in weaning rats. On the other 
hand the increase in dopamine fiber density observed in development may be associated to 
a decline in synthesis and turnover; in fact synthesis peaks at PND 30 and then declines in 
late adolescence (Andersen, et al., 1997). Adolescence has a peculiar feature from an 
energetically point of view. In fact cortex energy consumption in humans peaks at 3-4 years 
and is maintained up to the age of 20, to progressively decline in later life (Chugani et al., 
1987). In general synaptic pruning and myelination can be considered parallel processes that 
apparently have the role of strengthening regularly used innervations rendering them able 
to fire in a more concerted pattern (Lewis, 1997; Miller, 1996). At the same time infrequently 
used innervations are eliminated (Rutherford et al., 1998). Furthermore dopamine 
modulation of fast-spiking interneurons changes dramatically during adolescence (PND 45-
50 in rats) with D2 agonists switching from being mildly inhibitory in prepubertal rats to 
strongly excitatory in young adult rats. In vivo recordings in adult rats reveal that deep-
layer pyramidal neurons respond to endogenous DA release with suppression of firing 
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while interneurons are activated (Tseng and O’Donnell, 2007; Gruber et al., 2010). Thus the 
increase in dopamine functional activity that peaks in adolescence together with the 
reduction of excitatory innervation are two delicate processes which reduce the activity of 
pyramidal cells. Therefore either a deficiency in excitatory reduction or a defective increased 
inhibitory activity may lead to an excessive pyramidal cell activity that in turn may be 
reflected by the onset of a psychiatric disorder or drug abuse.  
Substantial evidence points to the higher risk of drug exposure in adolescence (Barron et al., 
2005; Crews and Hodge, 2007; Schramm-Sapyta et al., 2009). In particular alcohol 
consumption during adolescence causes diffuse brain alterations and greatly increases the 
likelihood that an alcohol use disorder will develop later in life (Nixon and McClain, 2010). 
Diffusion tensor imaging studies have shown that adolescent binge drinking damages white 
matter tracts throughout the brain, including main hippocampus efferent fibers and those 
interconnecting the PFC (McQueeny et al., 2009; Jacobus et al., 2009). Adolescents respond to 
the effects of alcohol distinctly from adults in fact they are less sensitive to negative effects 
of alcohol, they do no perceive cues that may suggest reduction of intake, but are more 
sensitive to positive effects such as those related to social interaction, which may serve to 
reinforce or promote excessive intake (Spear et al., 2005). Adolescence is also critical for 
cannabis abuse, indeed it is widely reported that cannabis use during adolescence increases 
the risk of developing psychotic disorders later in life (Bossong and Niesink, 2010, Malone et 
al, 2010). However, although the neurobiological processes underlying this relationship are 
unknown, alteration of PFC circuitry is more than likely. Very recently it was found that 
marijuana users had decreased cortical thickness in right caudal middle frontal, bilateral 
insula and bilateral superior frontal cortices (Lopez-Larson, 2011). These results suggest that 
age of regular use may be associated with altered PFC gray matter development in 
adolescents. According to the authors of this study reduced insular cortical thickness may be 
used as a biological marker for ascertain increased risk of substance dependence (Lopez-
Larson, 2011). An interesting comparison in adolescent alcohol and marijuana users has 
been proposed by evaluating participants who performed a verbal paired associates 
encoding task during functional magnetic resonance imaging (fMRI) scanning. The results 
of this study suggested that adolescent substance users demonstrated altered fMRI response 
relative to non-using controls, yet binge drinking appeared to be associated with more 
differences in activation than marijuana use (Schweinsburg et al., 2011). Alcohol and 
marijuana may have interactive effects that alter these differences, particularly in prefrontal 
brain regions (Schweinsburg et al., 2011).  
As far as regards cocaine effects, rats with adolescent-onset cocaine self-administration 
experience were more impaired in an OFC-related learning task than rats with adult-onset 
cocaine self-administration experience (Harvey et al., 2009). Treatment with cocaine during 
adolescence also caused acute alterations in the expression of genes encoding cell adhesion 
molecules and transcription factors within the PFC. In particular, a decrease in histone 
methylation was observed and this effect may indicate a role for chromatin remodelling in 
gene expression patterns. These findings allowed the authors to suggest that exposure to 
cocaine during adolescence has extensive molecular and behavioural effects in the rat PFC. 
These consequences develop over time and endure long after drug administration has 
ceased (Black et al., 2006). Smoking and nicotine exposure during adolescence is a very 
relevant heath problem because the higher dependence developed in individuals who start 
smoking early (see O’Dell, 2009 for review). Early tobacco use is facilitated by the legal 
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possibility to purchase tobacco in most of the western countries. Besides other health 
consequences, tobacco smoking and nicotine exposure during adolescence interfere with 
PFC development and leads to cognitive impairments in later life with enduring attentional 
disturbances (Cunotte et al., 2009). Among molecular alteration, early nicotine exposure 
determines reduced mGluR2 protein and function on presynaptic terminals of PFC 
glutamatergic synapses. Interestingly restoring mGluR2 activity in vivo by local infusion of 
a group II mGluR agonist in adult rats that received nicotine as adolescents rescued 
attentional disturbances (Counotte et al., 2011).  
Among others, novelty directed behavior is highly expressed in adolescence. It may 
represent a strong risk for the use of addictive drugs and consequently for the developing of 
drug dependence. Novelty directed behavior can be observed in periadolescent rats, in fact 
they show a strong exploratory behavior in a novel open field. Although it is not clear the 
role of dopamine and norepinephrine transmission in this behavior, periadolescent rats 
show hypo-responsivity to dopamine agonists and hypersensitivity to antagonist action 
suggesting that their dopamine transmission is hyperactive as compared with adult rats 
(Spear and Brake, 1983). Moreover the response of adolescent animals to amphetamine (an 
indirect dopamine and noradrenaline agonist) supports the peculiarity of catecholamine 
transmission in adolescence (Mathews and McCormick, 2011). Paradoxically amphetamine 
reduces novelty preference when adolescent mice are paired with a novel environment 
while it increases novelty preference when this test is performed in normal adult mice 
(Adriani et al., 1998). Thus we can hypothesize that typical adolescent behaviors such as 
novelty seeking, impulsivity and risk taking are the result of a natural drive that emerges in 
adolescence possibly linked to the need of spreading individuals of a species in a territory. It 
may be likely that this behaviour could be maintained by an overactive excitatory 
transmission in the prefrontal cortex and in subcortical areas that are balanced by an 
increasing active inhibitory catecholamine transmission. On the other hand catecholamine 
innervations reaching their maximal inhibitory activity at the end of adolescence, may have 
a role in stabilizing those brain processes that have been developed in adolescence and will 
be then acquired as behaviour reference in adult life.  
As far as nicotine effect in adolescents, we observed that nicotine-stimulated dopamine 
release was higher in the mPFC of adolescent rats as compared with adults (Carboni et al., 
2010). These results suggest that the higher response observed in adolescents might be 
correlated to their higher sensitivity to the effects of nicotine. This trait might have a 
contributory role in the strong nicotine addiction that is observed in smokers who start 
nicotine abuse during adolescence (see the review of O’Dell, 2009). In fact, although nicotine 
abuse has much in common with other drugs of abuse in that it increases dopamine output 
in the NAcc shell (Di Chiara, 2000) or in other brain areas (Carboni et al., 2000), its ability to 
determine a higher increase of dopamine in the PFC of adolescents could potentially be 
correlated to the alteration of the brain maturation process that occurs in adolescent smokers 
(Carboni et al., 2010). Consequently this feature may alter the PFC’s role in the ability to 
establish a rational evaluation of smoking even during adult age. We also observed that 
nicotine increased noradrenaline release in the PFC (Carboni et al., 2010) thus suggesting 
that this increase may have a role in the nicotine enhancement of cognition (see the review 
of Poorthuis et al., 2009). Furthermore local infusion of nicotine in the prelimbic mPFC can 
increase mPFC glutamate extracellular concentration supporting the role of nAChRs in 
modulating thalamocortical input to the PFC (Gioanni et al., 1999). These findings therefore 
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suggest that such a mechanism may be relevant to the cognitive effects of nicotine and 
nicotinic agonists. 
11. Role of stress (prenatal, adolescent and adult) on prefrontal cortex 
function and drug addiction  
Acute stress modulates the neuronal activity of brain regions such as mPFC (Hains and 
Arnsten, 2008), amygdala (Goldstein et al., 1996), hippocampus (Belujon and Grace 2011) , 
OFC (Capriles et al., 2003), insula, and striatum (Koob, 2009) that are also areas of the brain 
involved in regulation of appetitive behaviors, such as feeding and drug taking (Marchant et 
al., 2012). These areas share common a consistent dopaminergic innervation pointing to a 
role of dopamine in stress-induced reinstatement of drug taking (Erblich et al., 2004; 
Shaham and Stewart, 1995; Shaham et al., 2003). The preclinical early work of Piazza and 
collaborators has shown a clear relationship between drugs of abuse, stress and 
glucocorticoids levels (Piazza et al., 1996), although most of their work was focused on sub-
cortical areas. They have indeed shown that drugs of abuse acutely activate the 
hypothalamic-pituitary-adrenal (HPA) axis and that drug dependence was characterized by 
a dysregulation of HPA axis (Piazza and Le Moal, 1996). Moreover they showed that 
stressors facilitate the acquisition of cocaine and amphetamine self-administration (Piazza 
and Le Moal, 1998). Stress plays and important role in drug addiction either by triggering 
relapse in abstinent addicts, or by altering PFC function thus predisposing for drug use and 
abuse (Stewart, 2003; George and Koob, 2010; Van den Oever et al., 2010). Human studies 
suggested that the incapacity to resist to drug cues, such as the sight of drug, can also be 
amplified by stress (Swan et al., 1988; Breese et al., 2011; Potenza et al., 2012). Although 
moderate stress can have a positive value on cognition, strong or repeated stress will either 
be deleterious for cognitive functions or may be a determining factor in vulnerability to 
mental illness and drug addiction, likely through an alteration of catecholamine 
transmission in the PFC (Holmes and Welman 2009, George and Koob, 2010; Goldstein and 
Volkow, 2011). Indeed, it has recently been reported (Radley et al., 2008) that selectively 
ablating noradrenergic input into the rat medial PFC attenuates the effects of stress in the 
paraventricular hypothalamic nucleus, as well as the HPA axis secretory responses, while 
stress-induced Fos expression in dorsal medial PFC was enhanced and was negatively 
correlated with stress-induced paraventricular hypothalamic nucleus activation. These 
observations identify the locus coeruleus as an upstream component of a circuitry providing 
for dorsal medial PFC modulation of emotional stress-induced HPA activation. Since 
noradrenergic projection, and its innervations of the prefrontal cortex play an important role in 
the modulation of working memory and attention, it may be likely that noradrenaline release 
in the medial PFC could modulate stress response, depending on the evaluation and 
comparison of environmental stimuli with past experience in mounting adequate 
behaviourally adaptive responses to emotional stress and environmental challenge in general.  
Further, the artificial activation of catecholamine transmission in the PFC, such as that 
produced by amphetamine administration, similarly to stress, can have beneficial or a 
deleterious effects on cognition depending on the dose and on basal dopamine and 
noradrenaline transmission. The ability of stress to alter neuronal function has been 
investigated in 15 smokers undergoing functional magnetic resonance imaging who were 
exposed to a psychosocial stressor, followed by smoking drug cues (Dagher et al., 2009). The 
 
Addictions – From Pathophysiology to Treatment 
 
146 
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(Carboni et al., 2010). Consequently this feature may alter the PFC’s role in the ability to 
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that this increase may have a role in the nicotine enhancement of cognition (see the review 
of Poorthuis et al., 2009). Furthermore local infusion of nicotine in the prelimbic mPFC can 
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suggest that such a mechanism may be relevant to the cognitive effects of nicotine and 
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correlated with stress-induced paraventricular hypothalamic nucleus activation. These 
observations identify the locus coeruleus as an upstream component of a circuitry providing 
for dorsal medial PFC modulation of emotional stress-induced HPA activation. Since 
noradrenergic projection, and its innervations of the prefrontal cortex play an important role in 
the modulation of working memory and attention, it may be likely that noradrenaline release 
in the medial PFC could modulate stress response, depending on the evaluation and 
comparison of environmental stimuli with past experience in mounting adequate 
behaviourally adaptive responses to emotional stress and environmental challenge in general.  
Further, the artificial activation of catecholamine transmission in the PFC, such as that 
produced by amphetamine administration, similarly to stress, can have beneficial or a 
deleterious effects on cognition depending on the dose and on basal dopamine and 
noradrenaline transmission. The ability of stress to alter neuronal function has been 
investigated in 15 smokers undergoing functional magnetic resonance imaging who were 
exposed to a psychosocial stressor, followed by smoking drug cues (Dagher et al., 2009). The 
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results allowed to observe a significant change in neural activity during stress with an 
increased neural response to drug cues in the medial prefrontal cortex, posterior cingulate 
cortex, dorsomedial thalamus, medial temporal lobe, caudate nucleus, and primary and 
association visual areas. A stress-induced limbic deactivation that predicted subsequent 
neural cue-reactivity was also observed. The authors thus suggested that stress increases the 
incentive salience of drug cues (Dagher et al., 2009). The role of mPFC in the ability of stress 
to enhance the reinforcing properties of morphine has been recently investigated (Rozeske et 
al., 2009). The results obtained show that escapable stress activates the ventral regions of the 
mPFC while inescapable stress does not. On the other hand inescapable stress potentiates 
morphine-conditioned place preference while escapable stress does not. Moreover these 
effects are modulated by intra-mPFCv microinjection of the GABAA agonist muscimol 1 h 
before stress session (Rozeske et al., 2009). 
It was early reported that the adult offspring of stressed pregnant rats exhibited higher 
locomotor response to novelty and to an injection of amphetamine but also a higher level of 
amphetamine self-administration, suggesting that prenatal stress (PNS) could determine an 
individual predisposition to drug self-administration (Deminiére et al., 1992). The effect of 
PNS was also observed to elevate active lever responding in rats either during extinction or 
in cocaine-primed reinstatement, but not during self-administration or in conditioned-cued 
reinstatement, thus suggesting that early environmental factors contribute to an individual's 
initial responsiveness to cocaine and propensity to relapse to cocaine-seeking (Kipping et al., 
2008). We recently investigated in rats the effect of PNS on dopamine and noradrenaline 
transmission in the mPFC (Carboni et al., 2010) and in the NAcc shell (Silvagni et al., 2008). 
We observed that PNS did not change dopamine but decreased noradrenaline basal output 
in the PFC of both adolescents and adult rats (Carboni et al, 2010). Moreover we observed 
that PNS decreased amphetamine stimulated dopamine output and increased 
amphetamine-stimulated noradrenaline output. PNS decreased nicotine-stimulated 
noradrenaline (but not dopamine output) in adults, though not in adolescents (Carboni et 
al., 2010). These data support a contributing role of PNS in the development of psychiatric 
disorders and that its effect may augment drug addiction vulnerability. 
12. Areas of prefrontal cortex, decision making and drug addiction.  
Preclinical and human studies have provided unequivocal evidence that drug addiction 
involves many subregions of the PFC. Nevertheless the correspondence between these 
subregions among rodents and primates has been long debated (Brown and Bowman, 2002). 
Moreover it is claimed that PFC function is more than the sum of the functions of individual 
PFC sub-regions (Wilson et al., 2010). An exhaustive review of PFC dysfunction in addiction 
has been recently provided (Goldstein and Volkow, 2011). In this section we will briefly 
consider some preclinical and human studies on the involvement of the OFC in addiction 
because this PFC sub region has recently received much attention in drug addiction 
(Shoenbaum et al., 2006). The orbitofrontal area is interconnected in both rat and primates 
with mediodorsal talamus, the basolateral amigdala and NAcc, and has been proposed to 
use associative information handled by this circuitry to guide behaviour on the basis of the 
expected outcome of a specific action (See the review of Shoenbaum et al., 2006 for specific 
anatomical location and relationship with other brain areas). In particular this area is 
activated in humans during anticipation of expected outcomes and therefore can allow 
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prediction of reward or punishment using this information to guide decisions (Arana et al., 
2003). Rats with OFC lesions fail to behave correctly in reinforcing devaluation tasks where 
they have to make decisions on the basis of outcome expectancies (Gallagher et al., 1999). As 
far as regards addicted they may suffer of OFC circuitry alteration because, often under the 
control of drug-associated cues, they are unable to control drug-seeking behaviour despite 
they are aware of adverse consequences associated with their compulsive and impulsive 
behaviour and despite a stated desire to stop. The alteration of OFC have been detected by 
imaging studies of addicts and in particular it has been observed a reduction in OFC 
activation during acute withdrawal whereas an over-activation of OFC associated with high 
level of craving has been observed in addicts exposed to drug-related cues (see the review of 
Dom et al., 2005). Furthermore, in addicts are observed impairments of OFC-dependent 
behaviours that strongly parallel those that are observed in individuals carrying OFC 
damage (Grant et al., 2000).  
Nevertheless in humans it is difficult to state that functional deficits at the level of OFC are 
due to drug exposure because it could be attributable to pre-existing condition. At this 
regard Volkow and collaborators proposed an interesting hypothesis (Volkow et al., 2009). 
They suggested an association between an impairment of the OFC and other PFC areas 
involved in addiction, and a decrease of striatal dopamine D2 receptors availability. This 
condition would render subjects more vulnerable to drug addiction (Volkow et al., 2009). 
Further, a study done in subjects who have a high risk for alcoholism but were not 
alcoholics showed higher than normal striatal D2 receptor levels and a normal metabolism 
in OFC, anterior cingulate cortex and dorsolateral PFC (Volkow et al., 2006). On this basis 
the authors proposed that normal PFC function may have protected these subjects from 
alcohol abuse. A further recent evolution of this hypothesis suggested that OFC and 
cingulate function are involved in individual positive emotionality which in turn is a 
defence against drug of abuse vulnerability (Volkow et al., 2011). Nevertheless these 
stimulating hypotheses have to be evaluated taking into account that dopoamine D2 
availability does not distinguish between an increase in the released dopamine or in a 
decrease of receptors. On the other hand rats trained to self-administer amphetamine show 
a long term (one month) reduction of dendritic spine density specifically in the OFC 
whereas spine density was increased in the medium spiny neurons of the NAcc and in 
pyramidal neurons of the mPFC (Crombag et al., 2005). Moreover others have reported an 
increase of dendritic spine density in the medial PFC and in the NAcc after treatment with 
psychostimulant (Robinson and Kolb, 1999). It has been reported that chronic cocaine use 
causes long lasting impairment in OFC function as established by studies on reversal 
learning in animals, thus suggesting that this damage is expressed by the inability of using 
the value of predicted outcome to guide behavior (Shoenbaum et al., 2004, 2006 and 2009). 
The results of these experiments allowed Shoenbaum et al. (2006) to claim that “cocaine use 
can drive to the loss of outcome expectancies making addicts to continue to seek drugs 
despite the almost inevitable negative consequences of such behaviour concluding that 
changes in the OFC-dependent signal would by themselves contribute powerfully to a 
transition from normal goal-directed behaviour to compulsive habitual responding”.  
Moreover a dysregulation of the ventral, dorsomedial and dorsolateral striatal systems has 
been hypothesized to play a fundamental role in the transition from voluntary drug use to 
more habitual and compulsive drug use (Everitt and Robbins, 2005; Belin and Everitt, 2008). 
These sub cortical areas are strictly connected with PFC regions and in particular the NAcc 
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prediction of reward or punishment using this information to guide decisions (Arana et al., 
2003). Rats with OFC lesions fail to behave correctly in reinforcing devaluation tasks where 
they have to make decisions on the basis of outcome expectancies (Gallagher et al., 1999). As 
far as regards addicted they may suffer of OFC circuitry alteration because, often under the 
control of drug-associated cues, they are unable to control drug-seeking behaviour despite 
they are aware of adverse consequences associated with their compulsive and impulsive 
behaviour and despite a stated desire to stop. The alteration of OFC have been detected by 
imaging studies of addicts and in particular it has been observed a reduction in OFC 
activation during acute withdrawal whereas an over-activation of OFC associated with high 
level of craving has been observed in addicts exposed to drug-related cues (see the review of 
Dom et al., 2005). Furthermore, in addicts are observed impairments of OFC-dependent 
behaviours that strongly parallel those that are observed in individuals carrying OFC 
damage (Grant et al., 2000).  
Nevertheless in humans it is difficult to state that functional deficits at the level of OFC are 
due to drug exposure because it could be attributable to pre-existing condition. At this 
regard Volkow and collaborators proposed an interesting hypothesis (Volkow et al., 2009). 
They suggested an association between an impairment of the OFC and other PFC areas 
involved in addiction, and a decrease of striatal dopamine D2 receptors availability. This 
condition would render subjects more vulnerable to drug addiction (Volkow et al., 2009). 
Further, a study done in subjects who have a high risk for alcoholism but were not 
alcoholics showed higher than normal striatal D2 receptor levels and a normal metabolism 
in OFC, anterior cingulate cortex and dorsolateral PFC (Volkow et al., 2006). On this basis 
the authors proposed that normal PFC function may have protected these subjects from 
alcohol abuse. A further recent evolution of this hypothesis suggested that OFC and 
cingulate function are involved in individual positive emotionality which in turn is a 
defence against drug of abuse vulnerability (Volkow et al., 2011). Nevertheless these 
stimulating hypotheses have to be evaluated taking into account that dopoamine D2 
availability does not distinguish between an increase in the released dopamine or in a 
decrease of receptors. On the other hand rats trained to self-administer amphetamine show 
a long term (one month) reduction of dendritic spine density specifically in the OFC 
whereas spine density was increased in the medium spiny neurons of the NAcc and in 
pyramidal neurons of the mPFC (Crombag et al., 2005). Moreover others have reported an 
increase of dendritic spine density in the medial PFC and in the NAcc after treatment with 
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learning in animals, thus suggesting that this damage is expressed by the inability of using 
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The results of these experiments allowed Shoenbaum et al. (2006) to claim that “cocaine use 
can drive to the loss of outcome expectancies making addicts to continue to seek drugs 
despite the almost inevitable negative consequences of such behaviour concluding that 
changes in the OFC-dependent signal would by themselves contribute powerfully to a 
transition from normal goal-directed behaviour to compulsive habitual responding”.  
Moreover a dysregulation of the ventral, dorsomedial and dorsolateral striatal systems has 
been hypothesized to play a fundamental role in the transition from voluntary drug use to 
more habitual and compulsive drug use (Everitt and Robbins, 2005; Belin and Everitt, 2008). 
These sub cortical areas are strictly connected with PFC regions and in particular the NAcc 
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shell receives glutamatergic inputs from the ventromedial PFC and insular cortex, the NAcc 
core receives glutamatergic inputs from the dorsomedial PFC, insular cortex and OFC 
whereas the dorsomedial and the dorsolateral striatum receive glutamatergic inputs from 
the OFC, the anterior cingulate cortex and the sensory and motor cortices (Reynolds and 
Zahm, 2005; Gabbott et al., 2005). Therefore it is objectively possible that the dysfunction in 
the cortical areas observed after chronic cocaine use (Shoenbaum et al., 2006 and 2009) are a 
consequence of a complex neural adaptative response that occurs during the transition from 
voluntary drug use to a more habitual and compulsive drug use. This transition has been 
hypothesized to be mediated at neural level through a shift from PFC to striatal control over 
drug seeking and drug taking (Everitt and Robbins, 2005). Nevertheless a recent review of 
neuroimaging studies have revealed a generalized PFC dysfunction in drug addicted 
individuals and although the activity of PFC regions is highly integrated and plastic, pre-
existing dysfunction of specific PFC regions may confer individual vulnerability to drug 
addiction (Goldstein and Volkow, 2011).  
13. Addiction a disorder of awareness, motivation, or self-control  
Addiction may be considered the product of an imbalance between two separate, but 
interacting, neural systems: an immediate one that generates decision making, based on the 
impulsivity-related amygdala system for signalling pain or pleasure of immediate prospects 
and a reflective one, based on PFC circuitry for elaborating the value of signalling pain or 
pleasure of future prospects (Bechara, 2005). The capacity of controlling behavior is 
challenged by the ability of cues associated with reinforcing activities (food, sex, drugs of 
abuse, pleasure) of activating circuitry in which dopamine release in the NAcc has a 
fundamental value (Schultz, 2010). On the other hand self-control efforts involve increased 
activity in regions of the PFC regulating emotions and cognition (i.e. dorsolateral and 
ventrolateral PFC) and a reduced activity in regions associated with reward processing and 
craving. These brain areas include the ventral striatum, subgenual cingulate, amygdala, 
ventral tegmental area and OFC as observed in neuroimaging studies in cocaine users 
(Volkow et al., 2010) or smokers (Kober et al., 2010) when they are required to inhibit 
craving. In smokers a decrease in craving correlated with a decrease in ventral striatum 
activity and an increase in dorsolateral prefrontal cortex activity, with ventral striatal 
activity fully mediating the relationship between lateral prefrontal cortex and reported 
craving (Kober et al., 2010).  
Interestingly, the activation of similar regions was seen in healthy volunteers who were 
requested to control response to cues associated with monetary rewards (Delgado et al., 
2008). Therefore, emotional and cognitive processes that influence decision-making and 
which may also lead to impulsive behavior or motivational disturbances such as food abuse, 
drug addiction, excessive spending, risky sexual behavior, may be indicative of an abnormal 
functioning of PFC or subcortical ventral striatal regions as observed in neuroimaging 
studies (Breiter et al., 2001). A further feature of PFC role in cognition deals with the 
overlapping dopamine and ACh innervations in the PFC. It suggests that all the cognitive 
processes in which are involved these two transmitters may occur involving local 
mechanisms (Briand et al., 2007). In particular it is of relevance that dopamine agonists 
increase Ach release and social cognition in rats (Di Cara et al., 2006). Several authors 
suggested that dopaminergic modulation of PFC cholinergic output is mediated primarily 
through activation of D1 and D5 type receptors (see Briand et al., 2007 for a review).  
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Moreover the importance of PFC in expressing self-control is supported by the fact that 
failure occurs when frontal executive control is compromised such as following alcohol 
consumption or injury (Crews and Boettinger, 2009) as reported in patients with frontal lobe 
damage (Sellito et al., 2010) and in subjects who were subjected to transient disruption of 
functions in the lateral PFC by repetitive transcranial magnetic stimulation in lateral PFC 
(Figner et al., 2010). The lateral PFC is considered the area which activity allows self-control 
as proposed by the top-down model although two types of subcortical activities could be 
distinguished: one related to drug addiction that involves primarily the control of PFC over 
NAcc and one related to amygdala that controls the emotions. Therefore PFC could be 
associated with long term outcomes whereas sub-cortical activity is associated with more 
immediate outcomes. The prevalence of subcortical areas in managing drug taking is gained 
progressively during drug taking experience. At this regard Belin and Everett (2010) have 
proposed the incentive habit hypothesis. According to these authors drug seeking habits 
progressively dominate goal directed drug seeking behavior that in turn ca be highly 
influenced by Pavlovian incentive mechanisms. This process in humans may crucially affect 
the transition from drug use to drug abuse, involves a strong emotional component but the 
outcome of this process likely depends on the individual resilience of neuronal circuit to 
resist to the neurochemical insult of the drug abused. In fact drug addiction depending on 
the situation can involve a strong component of emotion (Burke et al., 2008; Heatherton and 
Wagner, 2011; Artiges et al., 2009). The similarity between the control over drug addiction 
and over emotion share many commonalities although reactivity to emotion may involve an 
immediate response while drug addiction control is the result of a complex outcome of brain 
elaborating activity. According to a simplified point of view addiction is the result of a 
hypersensitivity of the brain reward systems that escapes the control from PFC regions 
(Bechara, 2005; Koob et al. 2008). In fact it has been reported that during alcohol intoxication, 
together with a shift toward right versus left brain metabolic laterality, can be observed a 
shift in the predominance of activity from cortical to limbic brain regions (Volkow et al., 
2008). The widespread nature of these brain changes may contribute to the marked 
disruption of behaviour, mood, cognition and motor activity induced by alcohol (Volkow et 
al., 2008) or other drugs of abuse (Goldstein and Volkow, 2011) and can cause degeneration 
in cortical areas deputed to controlling impulsivity in case of heavy alcohol use (Crews and 
Bottinger, 2009).  
14. Concluding remarks 
In summary it has been proposed that according to the theory of top-down control, the PFC 
and in particular the lateral PFC is responsible for controlling different domains of behavior 
(Cohen and Lieberman, 2010) regardless their content that may vary depending on the 
subcortical area involved. It may range from food intake, to drug addiction behaviour up to 
control of emotions and may explain why the effect of resource depletion are no tied to any 
one self-regulatory domain, as discussed by Heatherton and Wagner (2010). Among PFC 
areas many are definitively involved in drug addiction as well as in self-control and decision 
making. Nevertheless an interesting observation suggested that the PFC is involved in 
cognitive functions exceeding the sum of specific functions attributed to its subregions 
(Wilson et al., 2010). Thus if behaviour and decision making are considered as an overall 
result of PFC activity it is interesting to investigate the reason why self-control fails in drug 
addicts. Thus it could be hypothesized as mentioned before, that chronic exposure to a drug 
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Moreover the importance of PFC in expressing self-control is supported by the fact that 
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addicts. Thus it could be hypothesized as mentioned before, that chronic exposure to a drug 
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of abuse could disrupt the balance between cortical and sub-cortical activities but it is less 
clear why some people start taking drugs of abuse. Do they miss an unspecified activity in 
brain (genetic theory) or is the environment (psychological pressure and need to emulate 
companion behaviour to be accepted in the group), or is the sum of each factor to push to 
drug use. Fortunately, in the case of prevalence of the second factor drug taking may not 
necessarily lead to drug abuse. Considering that an optimal therapy for drug addiction is far 
to be proposed it remains to pursue prevention by involving young subject, and especially 
those at risk for drug use and abuse with involving activities in order to occupy brain 
activities in thoughts that are far from drug taking.  Nevertheless drug therapy aimed at 
controlling drug taking impulse could be directed on improving the awareness of the 
consequences associated with pleasure directed behaviours and the capacity to take 
decisions directed to break the vicious circle of drug dependence.  
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of abuse could disrupt the balance between cortical and sub-cortical activities but it is less 
clear why some people start taking drugs of abuse. Do they miss an unspecified activity in 
brain (genetic theory) or is the environment (psychological pressure and need to emulate 
companion behaviour to be accepted in the group), or is the sum of each factor to push to 
drug use. Fortunately, in the case of prevalence of the second factor drug taking may not 
necessarily lead to drug abuse. Considering that an optimal therapy for drug addiction is far 
to be proposed it remains to pursue prevention by involving young subject, and especially 
those at risk for drug use and abuse with involving activities in order to occupy brain 
activities in thoughts that are far from drug taking.  Nevertheless drug therapy aimed at 
controlling drug taking impulse could be directed on improving the awareness of the 
consequences associated with pleasure directed behaviours and the capacity to take 
decisions directed to break the vicious circle of drug dependence.  
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1. Introduction 
The World Health Organization (WHO) estimates that there are about 2 billion people world-
wide who consume alcoholic beverages (WHO, 2004). Alcohol use is related to a wide range of 
physical, mental, and social detriments. Additionally, alcohol affects almost every organ in the 
human body as well as the central nervous system (CNS) (Spanagel, 2009). There are several 
theories as to how alcohol affects the CNS. They are classified into two main groups depending 
on the primary target of ethanol. These two groups are lipid and protein theories (Goldstein, 
1986). Before the 1990s, different lipid theories postulated that alcohol acted via some 
perturbation of the membrane lipids in CNS neurons. In particular, the effects on membrane 
fluidity and the disordering of the bulk lipid phase of membranes were originally attractive 
hypotheses for alcohol action. However, recently the protein hypothesis has become the 
predominant theory (Lovinger, 1997). This hypothesis predicts that alcohol acts specifically on 
membrane proteins such as receptors and ion channels. The main reason for a shift towards the 
protein theory originates from evidence that alcohol, at concentrations in the 10–20 mM range, 
directly interferes with the function of several ion channels (K+, Ca2+) and receptors (Lovinger 
et al., 1989). These ethanol effects are mediated through a number of neural transmitter systems 
including γ-aminobutyric acid (GABA) and glutamate (Takadera et al., 2008; Murail et al., 2011).  
The GABA receptor is involved in GABA signalling and the ionotropic glutamate receptor 
complex activated by N-methyl-D-aspartate (iGluR-NMDA) is involved in glutamate 
signalling. The GABA and NMDA receptors have competing roles in neural excitability and 
transmission. Activation of GABA receptors results in a decrease in neural activity. In contrast, 
activation of iGluR-NMDA results in an increase in neural activity. Alcohol has been shown to 
have opposite effects on these two types of receptors. Alcohol administration leads to increases 
in GABA receptor activity and decreases in iGluR-NMDA activity (Suzdak et al., 1986; Tsai et 
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al., 1995). The GABA receptor is a key inhibitory neurotransmitter receptor in the CNS (Figure 
1). There are two types of GABA receptors. The GABAA receptor is a ligand-gated ion channel 
receptor and the GABAB receptor is a G coupled-protein receptor. Both are associated with the 
influx of chloride ions into the cell upon activation by GABA. Under normal conditions GABA 
binds to the GABA receptor and the chloride channel opens (Figure 1). This allows negatively 
charged chloride ions to enter the cell and inhibit neuronal cell activity. The GABA receptor is 
affected by low concentrations of alcohol (Suzdak et al., 1986). Also, ethanol has been shown to 
reduce the number of GABAA-receptor sub-units, and GABA receptor polymorphisms have 
been associated with several alcoholic phenotypes (Mihic et al., 1997; Sander et al., 1999). The 
effects of alcohol are not limited to the modulation of GABA receptor activity; they also 
modulate iGluR-NMDA activity.  
 
Fig. 1. The GABA receptor composition and potential GABA binding sites. Adapted from 
Belelli, 2005.  
Most GABA receptors are believed to assemble as pentamers with two α subunits, two β 
subunits, and one γ subunit. The figure shows the influx of Cl- ions into the cell during 
GABA activation of the GABA receptor. The GABA molecules bind to interfaces between 
the α and β subunits. 
The iGluR-NMDA is one of the most active molecules in the central nervous system that is 
involved in learning and memory. It has been extensively studied during the last 30 years. 
iGluR-NMDA function is inhibited by ethanol in a concentration-dependent manner over 
the range of 5–50 mM. This is also the concentration range that produces intoxication and 
that is linearly related to the intoxication potency (Ron, 2004). This suggests that ethanol-
induced inhibition of responses to the iGluR-NMDA activation may contribute to the neural 
and the cognitive impairments associated with alcohol intoxication. However, the 
mechanism(s) of ethanol interference on NMDA receptor function remains in question.  
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The iGluR-NMDA is a ligand-gated ion channel with a heteromeric assembly of GluN1, 
GluN2 (A-D), and GluN3 subunits. The GluN1 and GluN2 subunits contain the co-agonist 
and agonist binding sites for glycine and glutamate respectively. The GluN3 subunit has 
some modulatory functions on channel activity especially under pathological conditions 
(Paoletti, 2011; Traynelis et al., 2010). Electrophysiological studies demonstrated ethanol 
interactions with domains that influence channel activity. This suggested that residues 
within the transmembrane (TMD) domains were involved. In the search for these possible 
binding sites of alcohol in the iGluR-NMDA, several putative binding sites were discovered. 
Utilizing site-directed mutagenesis, several studies reported putative binding sites in the 
TM3 and TM4 domains of the GluN1 and GluN2 subunits, respectively. Furthermore, the 
substitution of an alanine for a phenylalanine residue in the TM3 domain of the GluN1 
subunit strongly reduced ethanol sensitivity in recombinant iGluR-NMDAs (Ren et al., 2003, 
Ren et al., 2008). 
The iGluR-NMDA functions as a modulator of synaptic response and a molecular 
coincidence detector. At resting membrane potentials, iGluR-NMDAs are inactive. This is 
due to a voltage-dependent block of the channel pore by magnesium ions. This prevents ion 
flow. For example, the depolarization of the post-synaptic cell occurs through a train of 
impulses arriving at the pre-synaptic terminal. These impulses sustain the activation of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. AMPA receptors 
are a non-NMDA-type ionotropic transmembrane receptor for glutamate. This 
depolarization caused by the influx of sodium ions into the post-synaptic cell leads to the 
repulsion of magnesium ions in the iGluR-NMDAs. This repulsion of magnesium ions 
releases the channel inhibition and allows for iGluR-NMDA activation. However, this is not 
the only factor necessary for iGluR-NMDA channel function. Other factors include the 
agonist (glutamate) and the co-agonist (glycine) that allows the channel to open. Unlike 
GluA2-containing AMPA receptors, NMDA receptors are permeable to calcium ions as well 
as being permeable to other ions such as sodium and potassium. Therefore, iGluR-NMDA 
activation leads to a calcium influx into the post-synaptic cell. This event is important in the 
activation of a number of signaling cascades. Depending on the specific impulse received, 
the iGluR-NMDA is responsible for a wide range of post-synaptic functions that are 
involved in physiological processes such as long-term potentiation (LTP) and synaptic 
plasticity (Van Dongen, 2009). These processes have essential functions in learning and 
memory (Traynelis et al., 2010). In addition, the iGluR-NMDA is involved in different 
neurodegenerative diseases such as Alzheimer’s, Huntington’s, and Parkinson’s (Ułas et al., 
1994; Hallett et al., 2005; Levine et al., 2010; Saft et al., 2010). It is also involved in psychiatric 
disorders and pathophysiological conditions such as neuropathic pain (Javitt & Zukin, 1991; 
Collins et al., 2010). Recently, the iGluR-NMDA has been proposed as an important factor 
that can be altered in several addictions such as drug and alcohol addiction. 
Ethanol inhibits iGluR-NMDA activity at very low concentrations that are typically found 
during alcohol dependence and abuse (Vengeliene et al., 2005). Several studies have 
investigated the direct involvement of the N-methyl D-aspartate receptor subtype 2B 
(NR2B)-containing iGluR-NMDA in ethanol dependence. Narita et al. demonstrated that the 
protein levels of NR2B subunits in the limbic forebrain but not the cerebral cortex were 
significantly increased during chronic ethanol dependence in mice. These findings suggest 
that the up-regulation of NR2B subunits during chronic ethanol exposure may be implicated 
in the initial development of physical dependence on ethanol (Narita et al., 2007). Sheela et 
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al. reported that NR2B mRNA was significantly elevated in cultured mouse cortical neurons 
during chronic ethanol exposure (intermittent and non-intermittent) and remained elevated 
5 days after withdrawal (Sheela et al., 2006). Studies such as these and others demonstrate 
that ethanol is a potent inhibitor of the iGluR-NMDA in a number of brain regions 
(Lovinger, et al., 1989; Lovinger, 1995; Weitlauf & Woodward, 2008). The ability of ethanol 
to inhibit responses to the iGluR-NMDA is dependent on the subunit combination of the 
iGluR-NMDA. The N-methyl D-aspartate receptor subtypes 1/2A (NR1/NR2A) and 1/2B 
(NR1/NR2B) combinations are preferentially sensitive to ethanol inhibition (Otton et al., 
2009).  
Structural information about the putative alcohol-binding sites on proteins such as the 
iGluR-NMDA continues to be discovered (Peoples & Weight, 1992; Mirshahi & Woodward, 
1995). The functional impact of these binding sites also remains to be elucidated. 
Substitution studies have shown that a complete substitution for ethanol is exerted by 
iGluR-NMDA antagonists and certain GABA-mimetic drugs acting through different sites 
within the GABAA receptor complex. It has been consistently shown in mice, rats, and 
monkeys that noncompetitive antagonists of the iGluR-NMDA such as dizocilpine (MK-
801), phencyclidine (PCP), ketamine, or memantine (which all act as an ion channel 
blockers) result in a generalized ethanol response. However, competitive iGluR-NMDA 
antagonists have often shown only partial substitution for ethanol. Moreover, it has been 
demonstrated that ketamine produced dose-related ethanol-like subjective effects in 
detoxified alcoholics. This suggests that NMDA receptors mediate the subjective effects, at 
least in part, of ethanol in humans (Ren et al., 2003). 
In recent years the iGluR-NMDA has emerged as one of the most important and relevant 
molecules in all neural processes and a key structure in all excitable tissues. The iGluR-
NMDA participates in almost all physiological, pathological, and pharmacological processes 
of the postsynaptic neural membrane. In addition, the iGluR-NMDA is a major target of 
alcohol (ethanol) in the brain and has been implicated in acute tolerance, long-term 
facilitation (LTF), sensitization, dependence, withdrawal, and craving (Nagy & László, 2002; 
Trujillo & Akil, 1995; De Witte, 2004). This chapter’s focus is to present in a coherent and 
comprehensive approach as to why the iGluR-NMDA is one of the most important 
therapeutic targets in alcohol addiction. It will provide important information for 
understanding the effects produced by ethanol on the iGluR-NMDA such as the signaling 
pathways involved and the physiological consequences. It will also summarize information 
regarding the potential use of different iGluR-NMDA modulators as therapeutic treatments 
for the adverse effects of alcoholism. In addition, the review will summarize key results 
obtained from preclinical research such as in vivo animal models, in vitro cellular models, 
and ex vivo organotypic/acute brain slice models that are currently used to investigate CNS 
addictions.  
2. Structural and functional aspects of the iGluR-NMDA  
The iGluR-NMDA is a post-synaptic receptor involved in most neural functions that include 
fundamental processes such as learning, memory, and possibly consciousness (Lebel et al., 
2006; Lareo & Corredor, 2007). The NMDARs are heteromeric complexes composed of three 
major types of subunits: NR1, with eight isoforms generated by the alternative splicing of 
the Grin1 gene (Perez-Otano et al., 2001); four NR2 subunits (A–D) generated by the genes 
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Grin2A–D (Sun et al., 2000); and two NR3 subunits generated by the genes Grin3A and 
Grin3B (Andersson et al., 2001). The stoichiometry of the NMDAR remains unknown. It is 
also not clear whether the NMDAR is a trimeric, tetrameric, or pentameric subunit complex 
(Ferrer-Montiel & Montal, 1996; Laube et al., 1998; Rosenmund et al., 1998; Hawkins et al., 
1999; Nusser, 2000). However, it is known that the various cellular, biophysical, and 
pharmacological properties of NMDARs are dependent on the splice variants and the 
composition of these subunits within the receptor complex (Cull-Candy & Leszkiewicz, 
2004; Paoletti & Neyton, 2007). The NMDAR is differentially distributed throughout the 
CNS and has been shown to mediate the fast synaptic action of the major excitatory 
neurotransmitter L-glutamate (Cochilla & Alfors, 1999; Nusser, 2000). These receptors are 
multimodulated. Glycine, polyamines (spermine and spermidine), histamine, and cations 
can act as positive modulators (McBain & Mayer, 1994; Hirai et al., 1996; Kashiwagi et al., 
1997; Paoletti et al., 1997). The NMDA receptors are coupled to high conductance cationic 
channels that are permeable to Ca+2, K+, and Na+ ions (Cushing et al., 1999).  
NMDAR subunits contain a long extracellular N-terminal domain, three true 
transmembrane segments, a re-entrant pore loop, and an intracellular C-terminal domain of 
variable length (Mayer, 2005). The C-terminus of both NR1 and NR2 subunits interact with 
several intracellular scaffolding proteins and are subject to phosphorylation. As such, they 
are involved in the regulation of receptor trafficking and function (Salter & Kalia, 2004; Lau 
& Zukin, 2007). Glutamate, an agonist, binds to the NR2 subunits while the co-agonist 
glycine binds to the NR1 subunit. The N-terminal domain of the NR2 subunit is subject to 
allosteric inhibition by compounds such as ifenprodil and zinc (Figure 2) (Perin-Dureau et 
al., 2002; Hatton & Paoletti, 2005). Synaptic NMDA receptors are localized in the post-
synaptic density where they are structurally organized into large macromolecular 
complexes that interact with signaling molecules such as kinases and phosphatases. They 
also interact with other transmembrane proteins such as adhesion proteins and 
metabotropic glutamate receptors (mGluRs) (Husi et al., 2000). Membrane export and 
synaptic insertion of NMDA receptors involves intrinsic trafficking signals specific for each 
subunit, splice variant, and complex interaction between NMDA receptors and a variety of 
interacting proteins. These interacting proteins include the post-synaptic density protein 
(PSD95), Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein 
(zo-1) also known collectively as PDZ-domain proteins. Membrane insertion and regulated 
endocytosis of NMDA receptors are also tightly controlled by phosphorylation events (Chen 
& Roche, 2007; Lau & Zukin, 2007). The synaptic activity of NMDARs influence the number 
and the subunit composition of other synaptic membrane receptors (Zhou &  Baudry, 2006; 
Lau & Zukin, 2007).  
The NMDAR requires simultaneous activation by glutamate and glycine for channel 
opening (Dingledine et al., 1999). Ion passage also requires depolarization because 
magnesium directly blocks the ion channel in a voltage-dependent manner. Although the 
physiological significance remains unknown, the receptor is also modulated by polyamines 
such as spermine and spermidine in a biphasic manner (Figure 2) (Lynch & Guttmann, 
2002). At low micromolar concentrations, polyamines promote channel opening by 
increasing the affinity of the receptor for glycine as well as by removing tonic proton 
inhibition (Dingledine et al., 1999). In contrast, polyamines at high concentrations that are 
probably not achievable in vivo block the channel in a voltage dependent manner. Three 
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opening (Dingledine et al., 1999). Ion passage also requires depolarization because 
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other types of endogenous compounds (zinc, redox modulators, and nitric oxide) also 
inhibit the NMDA receptor allosterically through different sites (Lynch & Guttmann, 2002). 
Several compounds such as haloperidol, amitriptyline, and amantidine have been 
characterized for their ability to inhibit NMDA receptors. These diverse pharmacological 
antagonists produce different effects when given to animals which suggest that the NMDA 
receptor population within the brain is heterogeneous.  
2.1 NMDA receptor complexes: Structure and function 
The NMDA type of glutamate receptor is thought to play a role in long-term potentiation, 
memory formation, and controlling brain development (MacDonald et al., 2006; Ewald & 
Cline, 2009; Vastagh et al., 2012). NMDA receptor-mediated neurotoxicity is implicated in 
neurodegeneration associated with epilepsy, ischemia, Huntington’s chorea, Alzheimer’s 
disease, and AIDS encephalopathy (Durand et al., 1993; Reyes et al., 2006). 
Three gene families encoding NMDA receptor subunits have been identified in rat brain. 
One family is composed of the NR1 gene. The NR1 gene encodes RNA that undergoes 
alternate splicing to yield at least eight receptor variants. These variants arise from the 
splicing of three alternative exons which have been designated as N1, C1, and C2. Exon 
N1 encodes 21 amino acids that can be inserted into the N-terminal domain. Exons C1 and 
C2 are adjacent and encode the last portion of the C-terminal domain. Exon C1 encodes 37 
amino acids and exon C2 encodes 38 amino acids before reaching a stop codon followed 
by an additional 239 nucleotides from the 3’ non-coding region. The splicing out of exon 
C2 removes the first stop codon. This yields an open reading frame that encodes an 
unrelated sequence C2’ which consists of 22 amino acids before a second stop codon is 
reached. The NR1 subunit is essential for channel activity and has glycosylated and de-
glycosylated functionally active forms (Reyes et al., 2006). 
There are four subtypes (A–D) of the NR2 subunit which bind glutamate (Figure 2). These 
subunits confer the majority of pharmacological and biophysical properties associated with 
NMDA receptor (NMDAR) subtypes (Chen & Wyllie, 2006). Since the cloning of NMDAR 
subunits, the identification of many native NMDARs has been elucidated by comparing the 
properties of native receptors with those of known recombinant subunit compositions. 
These studies determined that NR2A and NR2B-containing NMDARs are widely expressed 
throughout the CNS while NR2C-containing NMDARs are mainly expressed in the 
cerebellum. Expression levels of NR2D subunits peak around the first week of postnatal 
development and are thought to be retained in certain neurons that express receptors with 
properties indistinguishable from recombinant receptors containing only NR1 and NR2D 
subunits (Monyer et al., 1992; Momiyama et al., 1996; Misra et al., 2000). Activation of 
NR1/NR2D NMDARs at synaptic sites are thought to produce long lasting synaptic events 
since recombinant forms deactivate with a time constant of several seconds following rapid 
synaptic-like glutamate application (Vicini et al., 1998; Wyllie et al., 1998; Wyllie, 2008). The 
NR2 subunits contain divergent sequences that regulate unique protein-protein interactions 
and distinct receptor trafficking properties. For example, the NR2A and NR2B intracellular 
C-terminal domains contain trafficking motifs that regulate NMDAR endocytosis and 
intracellular trafficking (Tang et al., 2010).  
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Fig. 2. NMDA receptor composition and potential ligand binding sites.  
Most NMDARs are believed to assemble as tetramers that associate two NR1 and two 
NR2 subunits in a "dimer of dimers" quaternary structure. The diagram shows an 
assembly with the heterodimer NR1/NR2. For clarity, only one of the two NR1/NR2 
heterodimers is shown. The extracellular region is composed of the N-terminal domain 
(NTD) and ligand binding domain (LBD). Allosteric modulators such as zinc interact with 
the NTD. Competitive agonists such as glycine, glutamate, and polyamines interact with 
the LBD. The intermembrane region is composed of the Pore Domain (PD). The Mg 2+ ion 
is the endogenous pore blocker of the PD. The intracellular region is composed of the C-
terminal domain (CTD). The CTD is involved in receptor trafficking and cell signaling 
processes.  
The successful cloning of NR3, the third subunit of the NMDA receptor, has taken the 
complexity of NMDA receptors to a new level. NR3 subunits have been identified in rat 
brains in two variants known as NR3A and NR3B (Méndez et al., 2008; Ciabarra et al., 
1995; Sucher et al., 1995). The NR3 subunits have been reported in GenBank as L34938 and 
U29873, respectively. NR3A has 27% similarity to the other NMDA receptor subunits and 
23% similarity to other non-NMDA receptor proteins. Despite this low homology, NR3A 
was grouped under the NMDA receptor because the CTD and the region upstream of M1 
are structurally related to other NMDA receptor subunits (Ciabarra et al., 1995; Moreno et 
al., 2010; Vargas et al., 2010). The NR3B subunit was initially discovered in 1995. Its 
complete characterization was published later by other groups (Forcina et al., 1995; 
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subunits, the identification of many native NMDARs has been elucidated by comparing the 
properties of native receptors with those of known recombinant subunit compositions. 
These studies determined that NR2A and NR2B-containing NMDARs are widely expressed 
throughout the CNS while NR2C-containing NMDARs are mainly expressed in the 
cerebellum. Expression levels of NR2D subunits peak around the first week of postnatal 
development and are thought to be retained in certain neurons that express receptors with 
properties indistinguishable from recombinant receptors containing only NR1 and NR2D 
subunits (Monyer et al., 1992; Momiyama et al., 1996; Misra et al., 2000). Activation of 
NR1/NR2D NMDARs at synaptic sites are thought to produce long lasting synaptic events 
since recombinant forms deactivate with a time constant of several seconds following rapid 
synaptic-like glutamate application (Vicini et al., 1998; Wyllie et al., 1998; Wyllie, 2008). The 
NR2 subunits contain divergent sequences that regulate unique protein-protein interactions 
and distinct receptor trafficking properties. For example, the NR2A and NR2B intracellular 
C-terminal domains contain trafficking motifs that regulate NMDAR endocytosis and 
intracellular trafficking (Tang et al., 2010).  
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Sevarino et al., 1996; Matsuda et al., 2003; Méndez, 2008). NR3B is also the most similar to 
NR3A with 47% similarity in amino acid sequence, but it has only 17-21% similarity to 
NR1 and NR2. There is greater similarity between NR3 and NR1 than with NR2 
(Andersson et al., 2001). The mouse homolog of NR3B has 1003 residues whereas the rat 
homolog is one residue shorter (Chatterton et al., 2002; Nishi et al., 2001; Low & Wee, 
2010). NR3 subunits have been reported to be expressed differentially in space and in 
time. Méndez et al. reported that the NR3A subunit is expressed in different proportions 
between 1 day postnatal and adult rats, while NR3B has the same expression at both age 
groups (Méndez et al., 2008). 
The "dimer of dimers" quaternary structure of the NMDAR contains at least 2 glutamate 
binding sites and 2 glycine-binding sites (Figure 2). NMDARs can also assemble with 2 
different NR1 splice isoforms and 2 different NR2 subunits. Studies on the AMPA receptor 
(AMPAR), another member of the ionotropic glutamate receptor family, have given insights 
into the structure of the NMDA receptor. Crystallographic analyses coupled with 
electrophysiologic studies indicate a tetrameric structure similar to AMPARs. In the 
NMDAR, regions of NR2 and NR1 subunits are necessary for transmitting allosteric signals 
between the glutamate and glycine-binding sites that are analogous to the areas of dimer 
interactions in AMPARs. This suggests that the NMDARs have similar dimer-dimer 
interactions. Therefore, collected research suggests that functional NMDAR complexes are 
tetramers of 2 NR1 and 2 NR2 subunits with an evolutionary link between glutamate 
receptors and potassium channels (Figure 2). The actual process of assembly of the 
individual subunits into the functional channel has not been well characterized. However, 
critical residues in this process are known to be located in the N-terminal domain of the 
NMDAR (Prybylowski & Wenthold, 2004). 
2.2 Stoichiometry 
The stoichiometry of NMDA receptors has not been completely established, but the 
consensus is that they are mostly tetramers composed of two NR1 subunits and two NR2 
subunits (Paoletti & Neyton, 2007; Ulbrich & Isacoff, 2008) (Figure 3). NMDARs assemble 
from two glycine-binding NR1 subunits with two glutamate-binding NR2 subunits to form 
glutamate-gated excitatory receptors that mediate synaptic transmission and plasticity 
(Figure 2, 3). The role of glycine-binding NR3 subunits is less clear. In Xenopus laevis oocytes, 
two NR3 subunits co-assemble with two NR1 subunits to form a glycine-gated receptor; 
such a receptor has yet to be found in mammalian cells. The NR1, NR2, and NR3 appear to 
co-assemble into tri-heteromeric receptors in neurons, but it is not clear whether this occurs 
in oocytes (Figure 3). To test the rules that govern subunit assembly in NMDA receptors, 
Ulbrich and Isacoff developed a single-molecule fluorescence co-localization method. They 
found that NR1, NR2, and NR3 follow an exclusion rule that yields separate populations of 
NR1/NR2 and NR1/NR3 receptors on the surface of oocytes. In contrast, co-expression of 
NR1, NR3A, and NR3B yields tri-heteromeric receptors with a fixed stoichiometry of two 
NR1 subunits with one NR3A subunit and one NR3B subunit (Figure 3). Therefore, at least 
part of the regulation of subunit stoichiometry appears to be caused by internal retention. 
Cell-to-cell differences in these rules may help sculpt distinct physiological properties 
(Ulbrich & Isacoff, 2008). 
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Fig. 3. The different assembly scenarios for NMDA receptors:  
Scenario (i) is a 2:2 stoichiometric assembly where two NR1 (orange) and two NR2 (blue) 
subunits co-assemble. Scenario (ii) is a 1:1 stoichiometric assembly where two NR1 (light 
blue) subunits assemble with one NR2 (blue) and one NR3 (orange) subunit. Scenario (iii) is 
a random assembly where two NR1 (light blue) subunits assemble randomly with two NR2 
(blue) or two NR3 (orange) subunits, or one NR2 (blue) and one NR3 (orange) subunit. 
Scenario (iv) is an exclusion rule where two NR1 (light blue) subunits assemble with either 
two NR2 (blue) or two NR3 (orange) subunits but never form a tri-heteromeric receptor 
(adapted from Ulbrich & Isacoff, 2008). 
3. The impact of alcohol on the NMDA receptor  
Alcohol has a complex pharmacology that acts by disrupting distinct receptor or effector 
proteins via direct or indirect interactions (protein theory). At very high concentrations, it 
might even change the composition of lipids in the surrounding membrane (lipid theory). 
At concentrations in the 5–20 mM range, (which constitutes the legal intoxication range for 
driving in many countries) alcohol directly interferes with and/or influences the function of 
several membrane receptors. Lovinger et al. showed that NMDA function was inhibited by 
alcohol in a concentration dependent manner in the range of 5-50 mM. The amplitude of the 
NMDA-activated current was reduced 61% by 50 mM alcohol (Lovinger et al., 1989). Also, 
the potency of several alcohols to inhibit the NMDA-activated current is linearly related to 
their intoxicating potency. This suggests that alcohol-induced inhibition of NMDA receptor 
activation may contribute to the neural and cognitive impairments associated with 
intoxication. Several other ionotropic receptors have also been characterized as primary 
targets of alcohol. These other ionotropic receptors include GABAA and glycine receptors 
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Sevarino et al., 1996; Matsuda et al., 2003; Méndez, 2008). NR3B is also the most similar to 
NR3A with 47% similarity in amino acid sequence, but it has only 17-21% similarity to 
NR1 and NR2. There is greater similarity between NR3 and NR1 than with NR2 
(Andersson et al., 2001). The mouse homolog of NR3B has 1003 residues whereas the rat 
homolog is one residue shorter (Chatterton et al., 2002; Nishi et al., 2001; Low & Wee, 
2010). NR3 subunits have been reported to be expressed differentially in space and in 
time. Méndez et al. reported that the NR3A subunit is expressed in different proportions 
between 1 day postnatal and adult rats, while NR3B has the same expression at both age 
groups (Méndez et al., 2008). 
The "dimer of dimers" quaternary structure of the NMDAR contains at least 2 glutamate 
binding sites and 2 glycine-binding sites (Figure 2). NMDARs can also assemble with 2 
different NR1 splice isoforms and 2 different NR2 subunits. Studies on the AMPA receptor 
(AMPAR), another member of the ionotropic glutamate receptor family, have given insights 
into the structure of the NMDA receptor. Crystallographic analyses coupled with 
electrophysiologic studies indicate a tetrameric structure similar to AMPARs. In the 
NMDAR, regions of NR2 and NR1 subunits are necessary for transmitting allosteric signals 
between the glutamate and glycine-binding sites that are analogous to the areas of dimer 
interactions in AMPARs. This suggests that the NMDARs have similar dimer-dimer 
interactions. Therefore, collected research suggests that functional NMDAR complexes are 
tetramers of 2 NR1 and 2 NR2 subunits with an evolutionary link between glutamate 
receptors and potassium channels (Figure 2). The actual process of assembly of the 
individual subunits into the functional channel has not been well characterized. However, 
critical residues in this process are known to be located in the N-terminal domain of the 
NMDAR (Prybylowski & Wenthold, 2004). 
2.2 Stoichiometry 
The stoichiometry of NMDA receptors has not been completely established, but the 
consensus is that they are mostly tetramers composed of two NR1 subunits and two NR2 
subunits (Paoletti & Neyton, 2007; Ulbrich & Isacoff, 2008) (Figure 3). NMDARs assemble 
from two glycine-binding NR1 subunits with two glutamate-binding NR2 subunits to form 
glutamate-gated excitatory receptors that mediate synaptic transmission and plasticity 
(Figure 2, 3). The role of glycine-binding NR3 subunits is less clear. In Xenopus laevis oocytes, 
two NR3 subunits co-assemble with two NR1 subunits to form a glycine-gated receptor; 
such a receptor has yet to be found in mammalian cells. The NR1, NR2, and NR3 appear to 
co-assemble into tri-heteromeric receptors in neurons, but it is not clear whether this occurs 
in oocytes (Figure 3). To test the rules that govern subunit assembly in NMDA receptors, 
Ulbrich and Isacoff developed a single-molecule fluorescence co-localization method. They 
found that NR1, NR2, and NR3 follow an exclusion rule that yields separate populations of 
NR1/NR2 and NR1/NR3 receptors on the surface of oocytes. In contrast, co-expression of 
NR1, NR3A, and NR3B yields tri-heteromeric receptors with a fixed stoichiometry of two 
NR1 subunits with one NR3A subunit and one NR3B subunit (Figure 3). Therefore, at least 
part of the regulation of subunit stoichiometry appears to be caused by internal retention. 
Cell-to-cell differences in these rules may help sculpt distinct physiological properties 
(Ulbrich & Isacoff, 2008). 
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Fig. 3. The different assembly scenarios for NMDA receptors:  
Scenario (i) is a 2:2 stoichiometric assembly where two NR1 (orange) and two NR2 (blue) 
subunits co-assemble. Scenario (ii) is a 1:1 stoichiometric assembly where two NR1 (light 
blue) subunits assemble with one NR2 (blue) and one NR3 (orange) subunit. Scenario (iii) is 
a random assembly where two NR1 (light blue) subunits assemble randomly with two NR2 
(blue) or two NR3 (orange) subunits, or one NR2 (blue) and one NR3 (orange) subunit. 
Scenario (iv) is an exclusion rule where two NR1 (light blue) subunits assemble with either 
two NR2 (blue) or two NR3 (orange) subunits but never form a tri-heteromeric receptor 
(adapted from Ulbrich & Isacoff, 2008). 
3. The impact of alcohol on the NMDA receptor  
Alcohol has a complex pharmacology that acts by disrupting distinct receptor or effector 
proteins via direct or indirect interactions (protein theory). At very high concentrations, it 
might even change the composition of lipids in the surrounding membrane (lipid theory). 
At concentrations in the 5–20 mM range, (which constitutes the legal intoxication range for 
driving in many countries) alcohol directly interferes with and/or influences the function of 
several membrane receptors. Lovinger et al. showed that NMDA function was inhibited by 
alcohol in a concentration dependent manner in the range of 5-50 mM. The amplitude of the 
NMDA-activated current was reduced 61% by 50 mM alcohol (Lovinger et al., 1989). Also, 
the potency of several alcohols to inhibit the NMDA-activated current is linearly related to 
their intoxicating potency. This suggests that alcohol-induced inhibition of NMDA receptor 
activation may contribute to the neural and cognitive impairments associated with 
intoxication. Several other ionotropic receptors have also been characterized as primary 
targets of alcohol. These other ionotropic receptors include GABAA and glycine receptors 
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that have their functions enhanced by alcohol (Mihic, 1999). Alcohol has also been shown to 
potentiate the function of other non-ionotropic receptors such as neuronal nicotinic ACh 
receptor (nAChR) and 5-hydroxytryptamine 3 (5-HT3) that is also known as serotonin 
(Lovinger, 1999; Narahashi et al., 1999).  
The influence of alcohol on ionotropic receptors depends on the alcohol concentration and 
receptor subunit composition. For example, NMDA receptors composed of either 
NR1/NR2A or NR1/NR2B subunit complexes are more sensitive to alcohol’s inhibitory 
effects than those composed of NR1/NR2C or NR1/NR2D subunit complexes (Kalluri et al., 
1998; Allgaier, 2002). Another example is GABAA. GABAA receptors are composed of α, β, γ, 
and δ subunits. Most subunit compositions of GABAA receptors are deficient in δ subunits 
and only display responses to alcohol at high concentrations (460 mM). However, GABAA 
receptors containing δ subunits are affected by very low concentrations (1–3 mM) of alcohol. 
Also in α4βδ subunit complexes, GABAA receptors containing the β3 subunit have been 
found to be almost 10 times more sensitive to alcohol than receptors containing the β2 
subunit (Wallner et al., 2003). 
In summary, despite the generally held view that alcohol is a non-specific pharmacological 
compound recent studies demonstrate that it specifically targets certain receptors such as 
NMDA, GABA, 5-HT3, and nAChRs. Concentrations as low as 1 mM produce alterations in 
the function of these ionotropic receptors. The complex interaction of alcohol on these 
receptors is generally characterized by the inhibition of NMDA receptors and by the 
inhibition of GABA receptors. This complex interaction of alcohol with different receptors is 
responsible for the psychotropic effects seen with alcohol consumption. These pathways 
involved in the effects of alcohol on the brain continue to be elucidated. 
3.1 The stages of alcohol effects and NMDAR function 
The effects of alcohol can be categorized into several stages. These stages are referred to as 
initiation of alcohol consumption (acute alcohol effects), maintenance of alcohol 
consumption (chronic alcohol effects and loss of control), craving and alcohol seeking 
(withdrawal), and relapse to alcohol use (compulsive alcohol consumption) (Wolffgramm et 
al., 2000; Heyne et al., 1998; Heyne et al., 2000; Ferko, 1994). The glutamatergic system which 
is a fast-signaling system important for information processing has been shown to play a 
pivotal role in these stages. The glutamatergic system is composed of at least three major 
types of glutamate receptors: the AMPA receptor, the NMDA receptor, and the kainate 
receptor. The NMDA receptor has been demonstrated to have major influence in the first 
and last stages of alcohol effects and minor or no influence in the middle stages. The AMPA 
receptor has been shown to have a major influence in the craving and reinstating of alcohol 
seeking stage (middle stage).  
In the initiation of alcohol consumption stage, glutamate has been shown to enhance the 
central depressant action of alcohol because glutamate can alter the alcohol induced loss of 
righting reflex (LORR) (Petrakis et al., 2004). NMDARs are associated with decreases in 
LORR response time and are primary targets of alcohol. This suggests that altered NMDAR 
function contributes to the initial pathophysiological response during acute alcohol 
exposure (Ge et al., 2007). Accordingly, NMDAR antagonists are capable of preventing 
initial alcohol responses. This was shown by the elimination of alcohol-induced conditioned 
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place preference in rats during administration of dizocilpine (a non-competitive NMDAR 
antagonist). It was also shown by the attenuation of alcohol self-administration in a free-
choice operant task with administration of 2-amino-5-phosphopentanoic acid (a competitive 
NMDAR antagonist) microinjections (Biala & Kotlinska, 1999; Rassnick et al., 1992).  
Nitric oxide (NO) production has also been correlated to the initiation of alcohol 
consumption stage. The glutamatergic/NMDA receptor system is closely linked to NO 
production. NO is an intracellular and extracellular messenger which is produced by nitric 
oxide synthase (NOS) (Bredt et al., 1990). The stimulation of NMDARs leads to a calcium 
influx within the cell and the binding of calcium to calmodulin activates neuronal NOS 
(nNOS) activity (Spanagel et al., 2002). Other studies have also implicated NOS activity in 
the modulation of alcohol mediated effects on the CNS (Spanagel et al., 2002; Deng & 
Deitrich, 2007). Alcohol has been shown to increase inducible NOS (iNOS) activity in glial 
cells and inhibit nNOS activity in neurons. The link between the NMDA receptor system 
and NO production implies that both iNOS and nNOS activity within the brain may also be 
involved in the modulation of acute alcohol effects. NOS activity has also been implicated in 
the maintenance of alcohol consumption stage (Deng & Deitrich, 2007). 
In the maintenance of alcohol consumption stage, adaptive responses occur such as changes 
in the number and/or affinity of synaptic glutamate receptors or their subunits (Henniger et 
al., 2003; Vengeliene et al., 2008). These adaptive responses act to counterbalance the acute 
inhibitory effect of alcohol on iGluR-NMDA function (Nagy et al., 2003; Wu et al., 2010). 
However, studies suggest that iGluR-NMDA has no influence during this stage. For 
example, NR2A subunit deletion in mice does not affect voluntary alcohol intake (Boyce-
Rustay & Holmes, 2006). Also studies utilizing knockout mice (GluR1 and GluR3 deletions) 
did not have any effect on either home cage alcohol drinking or operant self-administration 
(Cowen et al., 2003; Sanchis-Segura & Spanagel, 2006). In contrast, two studies did report 
that antagonists against the non-ionotropic receptor mGluR5 were capable of reducing 
alcohol-reinforced responding in mice and alcohol-preferring P/Fawn-Hooded rats (Cowen 
et al., 2005; Schroeder et al., 2005). This suggests a role for non-ionotropic receptors during 
this stage of alcohol effects. 
In the craving and alcohol seeking stage, adaptive responses in the glutamatergic system 
cause hyper-excitability in the Central Nervous System (CNS) during withdrawal or 
conditioned withdrawal. Animal studies have shown that the overactivation of glutamate 
receptors contributes to the generation of hyper-excitability (Grant et al., 1990; Gulya et al., 
1991; Davidson et al., 1995; Grant, 1999). Human studies have supported this hyper-
excitability by demonstrating that excitatory neurotransmitters were elevated in the 
cerebrospinal fluid of alcohol-dependent patients (Tsai & Coyle, 1998). These adaptive 
responses may represent one mechanism that causes alcohol cravings (Gass & Olive, 2008). 
Both NMDA receptors and non-NMDA ionotropic glutamate receptors such as AMPA 
receptors have major roles during this stage (Bachteler et al., 2005; Sanchis-Segura et al., 
2006). More specifically, as in the previous stage, mGluRs have also been implicated in this 
alcohol-craving/seeking behavior. For example, mGluR5 receptor antagonists have been 
effective in attenuating alcohol cravings (Bäckström et al., 2004). In regards to the NMDA 
receptor, ethanol withdrawal has been shown to potentiate NMDA-induced damage to the 
hippocampus by increases in mRNA expression of the NR2 subunit which is correlated with 
withdrawal seizures (Davidson et al., 1993; Follesa & Ticku, 1996). Also, the competitive 
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that have their functions enhanced by alcohol (Mihic, 1999). Alcohol has also been shown to 
potentiate the function of other non-ionotropic receptors such as neuronal nicotinic ACh 
receptor (nAChR) and 5-hydroxytryptamine 3 (5-HT3) that is also known as serotonin 
(Lovinger, 1999; Narahashi et al., 1999).  
The influence of alcohol on ionotropic receptors depends on the alcohol concentration and 
receptor subunit composition. For example, NMDA receptors composed of either 
NR1/NR2A or NR1/NR2B subunit complexes are more sensitive to alcohol’s inhibitory 
effects than those composed of NR1/NR2C or NR1/NR2D subunit complexes (Kalluri et al., 
1998; Allgaier, 2002). Another example is GABAA. GABAA receptors are composed of α, β, γ, 
and δ subunits. Most subunit compositions of GABAA receptors are deficient in δ subunits 
and only display responses to alcohol at high concentrations (460 mM). However, GABAA 
receptors containing δ subunits are affected by very low concentrations (1–3 mM) of alcohol. 
Also in α4βδ subunit complexes, GABAA receptors containing the β3 subunit have been 
found to be almost 10 times more sensitive to alcohol than receptors containing the β2 
subunit (Wallner et al., 2003). 
In summary, despite the generally held view that alcohol is a non-specific pharmacological 
compound recent studies demonstrate that it specifically targets certain receptors such as 
NMDA, GABA, 5-HT3, and nAChRs. Concentrations as low as 1 mM produce alterations in 
the function of these ionotropic receptors. The complex interaction of alcohol on these 
receptors is generally characterized by the inhibition of NMDA receptors and by the 
inhibition of GABA receptors. This complex interaction of alcohol with different receptors is 
responsible for the psychotropic effects seen with alcohol consumption. These pathways 
involved in the effects of alcohol on the brain continue to be elucidated. 
3.1 The stages of alcohol effects and NMDAR function 
The effects of alcohol can be categorized into several stages. These stages are referred to as 
initiation of alcohol consumption (acute alcohol effects), maintenance of alcohol 
consumption (chronic alcohol effects and loss of control), craving and alcohol seeking 
(withdrawal), and relapse to alcohol use (compulsive alcohol consumption) (Wolffgramm et 
al., 2000; Heyne et al., 1998; Heyne et al., 2000; Ferko, 1994). The glutamatergic system which 
is a fast-signaling system important for information processing has been shown to play a 
pivotal role in these stages. The glutamatergic system is composed of at least three major 
types of glutamate receptors: the AMPA receptor, the NMDA receptor, and the kainate 
receptor. The NMDA receptor has been demonstrated to have major influence in the first 
and last stages of alcohol effects and minor or no influence in the middle stages. The AMPA 
receptor has been shown to have a major influence in the craving and reinstating of alcohol 
seeking stage (middle stage).  
In the initiation of alcohol consumption stage, glutamate has been shown to enhance the 
central depressant action of alcohol because glutamate can alter the alcohol induced loss of 
righting reflex (LORR) (Petrakis et al., 2004). NMDARs are associated with decreases in 
LORR response time and are primary targets of alcohol. This suggests that altered NMDAR 
function contributes to the initial pathophysiological response during acute alcohol 
exposure (Ge et al., 2007). Accordingly, NMDAR antagonists are capable of preventing 
initial alcohol responses. This was shown by the elimination of alcohol-induced conditioned 
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place preference in rats during administration of dizocilpine (a non-competitive NMDAR 
antagonist). It was also shown by the attenuation of alcohol self-administration in a free-
choice operant task with administration of 2-amino-5-phosphopentanoic acid (a competitive 
NMDAR antagonist) microinjections (Biala & Kotlinska, 1999; Rassnick et al., 1992).  
Nitric oxide (NO) production has also been correlated to the initiation of alcohol 
consumption stage. The glutamatergic/NMDA receptor system is closely linked to NO 
production. NO is an intracellular and extracellular messenger which is produced by nitric 
oxide synthase (NOS) (Bredt et al., 1990). The stimulation of NMDARs leads to a calcium 
influx within the cell and the binding of calcium to calmodulin activates neuronal NOS 
(nNOS) activity (Spanagel et al., 2002). Other studies have also implicated NOS activity in 
the modulation of alcohol mediated effects on the CNS (Spanagel et al., 2002; Deng & 
Deitrich, 2007). Alcohol has been shown to increase inducible NOS (iNOS) activity in glial 
cells and inhibit nNOS activity in neurons. The link between the NMDA receptor system 
and NO production implies that both iNOS and nNOS activity within the brain may also be 
involved in the modulation of acute alcohol effects. NOS activity has also been implicated in 
the maintenance of alcohol consumption stage (Deng & Deitrich, 2007). 
In the maintenance of alcohol consumption stage, adaptive responses occur such as changes 
in the number and/or affinity of synaptic glutamate receptors or their subunits (Henniger et 
al., 2003; Vengeliene et al., 2008). These adaptive responses act to counterbalance the acute 
inhibitory effect of alcohol on iGluR-NMDA function (Nagy et al., 2003; Wu et al., 2010). 
However, studies suggest that iGluR-NMDA has no influence during this stage. For 
example, NR2A subunit deletion in mice does not affect voluntary alcohol intake (Boyce-
Rustay & Holmes, 2006). Also studies utilizing knockout mice (GluR1 and GluR3 deletions) 
did not have any effect on either home cage alcohol drinking or operant self-administration 
(Cowen et al., 2003; Sanchis-Segura & Spanagel, 2006). In contrast, two studies did report 
that antagonists against the non-ionotropic receptor mGluR5 were capable of reducing 
alcohol-reinforced responding in mice and alcohol-preferring P/Fawn-Hooded rats (Cowen 
et al., 2005; Schroeder et al., 2005). This suggests a role for non-ionotropic receptors during 
this stage of alcohol effects. 
In the craving and alcohol seeking stage, adaptive responses in the glutamatergic system 
cause hyper-excitability in the Central Nervous System (CNS) during withdrawal or 
conditioned withdrawal. Animal studies have shown that the overactivation of glutamate 
receptors contributes to the generation of hyper-excitability (Grant et al., 1990; Gulya et al., 
1991; Davidson et al., 1995; Grant, 1999). Human studies have supported this hyper-
excitability by demonstrating that excitatory neurotransmitters were elevated in the 
cerebrospinal fluid of alcohol-dependent patients (Tsai & Coyle, 1998). These adaptive 
responses may represent one mechanism that causes alcohol cravings (Gass & Olive, 2008). 
Both NMDA receptors and non-NMDA ionotropic glutamate receptors such as AMPA 
receptors have major roles during this stage (Bachteler et al., 2005; Sanchis-Segura et al., 
2006). More specifically, as in the previous stage, mGluRs have also been implicated in this 
alcohol-craving/seeking behavior. For example, mGluR5 receptor antagonists have been 
effective in attenuating alcohol cravings (Bäckström et al., 2004). In regards to the NMDA 
receptor, ethanol withdrawal has been shown to potentiate NMDA-induced damage to the 
hippocampus by increases in mRNA expression of the NR2 subunit which is correlated with 
withdrawal seizures (Davidson et al., 1993; Follesa & Ticku, 1996). Also, the competitive 
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NMDA receptor antagonist, CGP-39551, is a potent inhibitor of withdrawal seizures and 
hyperexcitability (Liljequist, 1991; Ripley & Little, 1995).  
In the last stage, relapse to alcohol use, one major hypothesis proposes that the 
glutamatergic system is critically involved (Gass & Olive, 2008). Several studies have 
demonstrated a major role for the NMDA receptors during this stage. For example, the 
clinical drug acamprosate, known to attenuate hyper-glutamatergic activity, was capable of 
reducing the alcohol deprivation effect (ADE) in Wistar rats under home cage and operant 
conditions (Spanagel  et al., 1996; Spanagel et al., 2005; Heyser et al., 1998). Furthermore, 
Hölter et al. demonstrated that chronic treatment with a non-competitive NMDA receptor 
antagonist selectively abolished the increased alcohol intake during the ADE (Hölter et al., 
2000). Similarly, reduction of relapse-like alcohol drinking after a deprivation phase was 
reported during the administration of competitive and non-competitive antagonists of the 
NMDA receptor (Vengeliene et al., 2005). 
3.2 Acute and chronic alcohol exposure 
Acute and chronic effects of alcohol exposure on NMDARs have been observed in 
hippocampal brain slices in which resistance develops 5-15 min after exposure to ethanol (100 
mM) (Miyakawa et al., 1997; Yaka et al., 2003; Nelson et al., 2005). However, the mechanisms 
of this resistance are not fully understood. Wu et al. proposes that time and dose dependent 
effects of ethanol produce adaptive changes in the NMDAR which may also occur during 
exposure to ethanol in ex vivo conditions. These changes may be the basis for the functional 
adaptation of these receptors to alcohol exposure (Wu et al., 2011). It has been shown that 
changes in the process of adaptation can also occur as a result of NMDAR overexpression, or 
by other signaling mechanisms that are mediated by selective dephosphorylation of the 
NMDAR after acute or chronic alcohol exposure (Roberto et al., 2004; Lack et al., 2007; Clapp et 
al., 2010; Wu et al., 2011). 
The NMDAR is considered one of the primary molecular targets of ethanol in the brain. 
Ethanol inhibits NMDAR function via a non-competitive mechanism and induces the 
dephosphorylation of NR2 subunits (Wirkner et al., 2000; Suvarna et al., 2005; Wang et al., 
2007). For example, NR2A and NR2B in hippocampal and cortical brain slices were 
characterized after acute ethanol exposure. They exhibited a decrease in tyrosine 
phosphorylation levels. Both the inhibition of NMDAR function and the decrease in tyrosine 
phosphorylation of NR2 subunits produced by acute ethanol exposure were blocked by 
protein tyrosine phosphatases (PTP) inhibitors (Alvestad et al., 2003; Ferrani-Kile et al., 
2003). This suggests that ethanol’s inhibition of NMDAR function is a result of a decrease in 
tyrosine phosphorylation of NMDARs by ethanol enhancement of PTP activity (Mahadev & 
Vemuri, 1999).  
NMDARs have also been strongly implicated in synaptic development and cellular models 
of learning and memory such as long-term potentiation (LTP) and long-term depression 
(LTD) (Medina et al., 2001; Malenka & Bear, 2004). It has been shown that ethanol inhibits 
the induction of several forms of neural plasticity such as LTP in the hippocampus, dorsal 
striatum, and bed nucleus of the stria terminalis while enhancing LTD in the hippocampus 
(Blitzer et al., 1990; Morrisett et al., 1993; Pyapali et al., 1999; Hendricson et al., 2002; 
Weitlauf et al., 2004; Hendricson et al., 2007; Yin et al., 2007). Such mechanisms of synaptic 
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plasticity could subsequently lead to the reorganization of neural circuitry by altering gene 
and protein expression of neuronal receptors such as NMDAR. LTP and LTD have thus 
become important candidate mechanisms for alcohol induced alterations of neural circuit 
function in alcohol addiction (Hyman & Malenka, 2001). These studies have proposed the 
intriguing possibility that disruptions and subsequent adaptive changes in glutamate 
signaling through NMDARs may contribute to adaptations in brain function. These 
adaptions in return may produce ethanol tolerance and/or dependence similar to processes 
involved in experience-dependent plasticity. 
The ability of ethanol to inhibit NMDAR function is dependent on various factors including 
the NR1 splice variant that is co-assembled with NR2 subunits (Jin & Woodward, 2006). 
While homomeric NR1 subunits form an active ion channel that conducts Na+ and Ca2+ 
currents, the incorporation of NR2 subunits allows this channel to be modulated by the Src 
family of kinases (SFKs), phosphatases, and other small molecules such as ethanol. 
Therefore, NMDAR complexes containing subunits NR1/NR2A or NR1/NR2B are more 
sensitive to the inhibitory effects of alcohol than complexes that contain the subunits 
NR1/NR2D or NR1/NR2C. Additionally, given the differential distribution of NMDAR 
subunits in the brain, alcohol affects certain brain regions more than others. For example, 
the NR1/NR2B subtype that is mainly expressed in forebrain regions is more sensitive to 
the inhibitory effects of ethanol (Allgaier, 2002; Smothers et al., 2001; Popp, 1998).  
Recently, it has been found that acute ethanol exposure inhibits NMDAR function by 
modifying STriatal enriched protein tyrosine phosphatase (STEP) activity. STEP is a brain-
specific protein that is thought to play a critical role in synaptic plasticity (Fitzpatrick & 
Lombroso, 2011). The genetic deletion of STEP61, the active form of STEP within the brain, 
leads to marked attenuation of acute ethanol inhibition of NMDAR currents. Also, STEP61 
negatively regulates Fyn and p38 mitogen-activated protein kinase (p38 MAPK). Both of 
these proteins are members of the NMDAR super molecular complex. The adaptation of 
NMDAR responses to acute alcohol is associated with 1) a partial inactivation of STEP61, 2) 
an activation of p38 MAPK, and 3) a requirement for NR2B activity. Together this data 
indicates that altered STEP61 and p38 MAPK signaling contributes to the modulation of 
ethanol inhibition of NMDAR activity in brain neurons (Wu et al., 2011).  
The functional activity of the NMDAR is increased by SFKs, but its activity is also regulated 
by protein tyrosine phosphatases (Pelkey et al., 2002; Salter & Kalia, 2004; Snyder et al., 2005; 
Paul et al., 2007). STEP61 co-immunoprecipitates with NMDARs suggesting a strong 
physical association between these two molecules as a signaling unit (Pelkey et al., 2002; 
Braithwaite et al., 2006; Xu et al., 2009). Inhibition of STEP61, the only actively expressed 
isoform of STEP in the hippocampus, has been shown to enhance NMDAR function and to 
attenuate ethanol inhibition of the NMDA receptor (Pelkey et al., 2002; Hicklin et al., 2011). 
Acute ethanol exposure has been shown to decrease phosphorylation at the tyrosine (Y) 
1472 phosphorylation site of the NR2B subunit without altering its protein levels (Alvestad 
et al., 2003; Wu et al., 2010). Y-1472 is a site in the C-terminal tail of the NR2B subunit where 
STEP61 has been shown to interact. This suggests that acute ethanol treatment activates 
STEP61 which is involved in the dephosphorylation of the Y-1472 site (Paul et al., 2007; 
Braithwaite et al., 2006). In accordance, several studies have also shown that the inhibition of 
NMDAR currents by the action of ethanol requires the participation of STEP61. When 
STEP61 activity is repressed, ethanol‘s ability to inhibit NMDAR current is attenuated 
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NMDA receptor antagonist, CGP-39551, is a potent inhibitor of withdrawal seizures and 
hyperexcitability (Liljequist, 1991; Ripley & Little, 1995).  
In the last stage, relapse to alcohol use, one major hypothesis proposes that the 
glutamatergic system is critically involved (Gass & Olive, 2008). Several studies have 
demonstrated a major role for the NMDA receptors during this stage. For example, the 
clinical drug acamprosate, known to attenuate hyper-glutamatergic activity, was capable of 
reducing the alcohol deprivation effect (ADE) in Wistar rats under home cage and operant 
conditions (Spanagel  et al., 1996; Spanagel et al., 2005; Heyser et al., 1998). Furthermore, 
Hölter et al. demonstrated that chronic treatment with a non-competitive NMDA receptor 
antagonist selectively abolished the increased alcohol intake during the ADE (Hölter et al., 
2000). Similarly, reduction of relapse-like alcohol drinking after a deprivation phase was 
reported during the administration of competitive and non-competitive antagonists of the 
NMDA receptor (Vengeliene et al., 2005). 
3.2 Acute and chronic alcohol exposure 
Acute and chronic effects of alcohol exposure on NMDARs have been observed in 
hippocampal brain slices in which resistance develops 5-15 min after exposure to ethanol (100 
mM) (Miyakawa et al., 1997; Yaka et al., 2003; Nelson et al., 2005). However, the mechanisms 
of this resistance are not fully understood. Wu et al. proposes that time and dose dependent 
effects of ethanol produce adaptive changes in the NMDAR which may also occur during 
exposure to ethanol in ex vivo conditions. These changes may be the basis for the functional 
adaptation of these receptors to alcohol exposure (Wu et al., 2011). It has been shown that 
changes in the process of adaptation can also occur as a result of NMDAR overexpression, or 
by other signaling mechanisms that are mediated by selective dephosphorylation of the 
NMDAR after acute or chronic alcohol exposure (Roberto et al., 2004; Lack et al., 2007; Clapp et 
al., 2010; Wu et al., 2011). 
The NMDAR is considered one of the primary molecular targets of ethanol in the brain. 
Ethanol inhibits NMDAR function via a non-competitive mechanism and induces the 
dephosphorylation of NR2 subunits (Wirkner et al., 2000; Suvarna et al., 2005; Wang et al., 
2007). For example, NR2A and NR2B in hippocampal and cortical brain slices were 
characterized after acute ethanol exposure. They exhibited a decrease in tyrosine 
phosphorylation levels. Both the inhibition of NMDAR function and the decrease in tyrosine 
phosphorylation of NR2 subunits produced by acute ethanol exposure were blocked by 
protein tyrosine phosphatases (PTP) inhibitors (Alvestad et al., 2003; Ferrani-Kile et al., 
2003). This suggests that ethanol’s inhibition of NMDAR function is a result of a decrease in 
tyrosine phosphorylation of NMDARs by ethanol enhancement of PTP activity (Mahadev & 
Vemuri, 1999).  
NMDARs have also been strongly implicated in synaptic development and cellular models 
of learning and memory such as long-term potentiation (LTP) and long-term depression 
(LTD) (Medina et al., 2001; Malenka & Bear, 2004). It has been shown that ethanol inhibits 
the induction of several forms of neural plasticity such as LTP in the hippocampus, dorsal 
striatum, and bed nucleus of the stria terminalis while enhancing LTD in the hippocampus 
(Blitzer et al., 1990; Morrisett et al., 1993; Pyapali et al., 1999; Hendricson et al., 2002; 
Weitlauf et al., 2004; Hendricson et al., 2007; Yin et al., 2007). Such mechanisms of synaptic 
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plasticity could subsequently lead to the reorganization of neural circuitry by altering gene 
and protein expression of neuronal receptors such as NMDAR. LTP and LTD have thus 
become important candidate mechanisms for alcohol induced alterations of neural circuit 
function in alcohol addiction (Hyman & Malenka, 2001). These studies have proposed the 
intriguing possibility that disruptions and subsequent adaptive changes in glutamate 
signaling through NMDARs may contribute to adaptations in brain function. These 
adaptions in return may produce ethanol tolerance and/or dependence similar to processes 
involved in experience-dependent plasticity. 
The ability of ethanol to inhibit NMDAR function is dependent on various factors including 
the NR1 splice variant that is co-assembled with NR2 subunits (Jin & Woodward, 2006). 
While homomeric NR1 subunits form an active ion channel that conducts Na+ and Ca2+ 
currents, the incorporation of NR2 subunits allows this channel to be modulated by the Src 
family of kinases (SFKs), phosphatases, and other small molecules such as ethanol. 
Therefore, NMDAR complexes containing subunits NR1/NR2A or NR1/NR2B are more 
sensitive to the inhibitory effects of alcohol than complexes that contain the subunits 
NR1/NR2D or NR1/NR2C. Additionally, given the differential distribution of NMDAR 
subunits in the brain, alcohol affects certain brain regions more than others. For example, 
the NR1/NR2B subtype that is mainly expressed in forebrain regions is more sensitive to 
the inhibitory effects of ethanol (Allgaier, 2002; Smothers et al., 2001; Popp, 1998).  
Recently, it has been found that acute ethanol exposure inhibits NMDAR function by 
modifying STriatal enriched protein tyrosine phosphatase (STEP) activity. STEP is a brain-
specific protein that is thought to play a critical role in synaptic plasticity (Fitzpatrick & 
Lombroso, 2011). The genetic deletion of STEP61, the active form of STEP within the brain, 
leads to marked attenuation of acute ethanol inhibition of NMDAR currents. Also, STEP61 
negatively regulates Fyn and p38 mitogen-activated protein kinase (p38 MAPK). Both of 
these proteins are members of the NMDAR super molecular complex. The adaptation of 
NMDAR responses to acute alcohol is associated with 1) a partial inactivation of STEP61, 2) 
an activation of p38 MAPK, and 3) a requirement for NR2B activity. Together this data 
indicates that altered STEP61 and p38 MAPK signaling contributes to the modulation of 
ethanol inhibition of NMDAR activity in brain neurons (Wu et al., 2011).  
The functional activity of the NMDAR is increased by SFKs, but its activity is also regulated 
by protein tyrosine phosphatases (Pelkey et al., 2002; Salter & Kalia, 2004; Snyder et al., 2005; 
Paul et al., 2007). STEP61 co-immunoprecipitates with NMDARs suggesting a strong 
physical association between these two molecules as a signaling unit (Pelkey et al., 2002; 
Braithwaite et al., 2006; Xu et al., 2009). Inhibition of STEP61, the only actively expressed 
isoform of STEP in the hippocampus, has been shown to enhance NMDAR function and to 
attenuate ethanol inhibition of the NMDA receptor (Pelkey et al., 2002; Hicklin et al., 2011). 
Acute ethanol exposure has been shown to decrease phosphorylation at the tyrosine (Y) 
1472 phosphorylation site of the NR2B subunit without altering its protein levels (Alvestad 
et al., 2003; Wu et al., 2010). Y-1472 is a site in the C-terminal tail of the NR2B subunit where 
STEP61 has been shown to interact. This suggests that acute ethanol treatment activates 
STEP61 which is involved in the dephosphorylation of the Y-1472 site (Paul et al., 2007; 
Braithwaite et al., 2006). In accordance, several studies have also shown that the inhibition of 
NMDAR currents by the action of ethanol requires the participation of STEP61. When 
STEP61 activity is repressed, ethanol‘s ability to inhibit NMDAR current is attenuated 
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(Alvestad et al., 2003; Wu et al., 2010; Hicklin et al., 2011). During the adaptive response 
increased levels of STEP33 and phospho-p38 mitogen-activate protein kinase (pp38 MAPK) 
along with decreased levels of STEP61 were correlated with the failure of acute alcohol 
exposure to inhibit NMDAR currents (Wu et al., 2010; Wu et al., 2011). STEP33 is produced 
by the cleavage of STEP61. This cleavage process may be one of the mechanisms involved in 
the partial inhibition of STEP61 during the adaptive phase of alcohol exposure. Studies such 
as these have suggested that the adaptive resistance of NMDAR currents to acute ethanol 
inhibition likely involves NR2B subunit activity. 
The mechanism of resistance to acute and chronic alcohol exposure during the adaptive 
response is not well understood. Several studies have reported increases in the expression 
level of several subunits of the NMDAR such as NR1, NR2A, and NR2B during the adaptive 
phase under chronic alcohol exposure conditions (Snell et al., 1996; Roberto et al., 2004; 
Roberto et al., 2006; Lack et al., 2007). Other studies have reported increases in the 
accumulation of synaptic NMDARs during this phase as well (Carpenter-Hyland et al., 
2004; Clapp et al., 2010). For example, hippocampal neurons exposed to ethanol chronically 
for 7 days demonstrated an increase and accumulation of synaptic NMDARs that was 
quickly reversed once ethanol exposure ceased (Clapp et al., 2010). This suggests that 
alcohol inhibition of NMDAR activity regulates the expression and accumulation of 
NMDARs. In contrast, other studies reported no changes in the expression levels of the 
NMDAR or its subunits. Instead these studies showed an increased inhibition of NMDAR 
activity using NR2B antagonists and concluded that resistance may be attributed to 
increases in NR2B activity (Ferreira et al., 2001; Wu et al., 2010). Even though increases in 
NR2B activity have not been directly verified, increases in STEP33 and pp38 as mentioned 
previously are characteristic of excessive NMDAR activation (Floyd et al., 2003; 
Hardingham, 2009; Xu et al., 2009).  
Other mechanisms involved in the adaptive response have been proposed but proven to be 
untrue. For example, several studies proposed that tolerance could occur in presynaptic 
neurons, postsynaptic neurons, or both (Wu et al., 2001). Thus, the inhibitory actions of 
ethanol on postsynaptic glutamate receptors could be counteracted by an increase in 
presynaptic glutamate release. This hypothesis was tested via a paired pulse facilitation 
(PPF) experiment. The PPF ratio proves to be inversely proportional to the amount of 
neurotransmitter release in neurons (Dobrunz & Stevens, 1997; Dittman et al., 2000; Wu et 
al., 2001). No significant effects of chronic ethanol in the PPF ratio were seen. This suggested 
that chronic ethanol did not significantly alter the pre-synaptic mechanisms of NMDA 
neurotransmission. Another group of studies proposed that alterations in the Mg2+ blockade 
were responsible for the alcohol resistance seen during the adaptive phase. However, acute 
ethanol inhibition of NMDAR currents did not significantly differ in low Mg2+ and control 
Mg2+ conditions. This demonstrated that alterations in the Mg2+ blockade were unlikely to 
be responsible for this adaptive response as well (Alvestad et al., 2003; Hicklin et al., 2011; 
Wu et al., 2011).  
Studies in humans have shown that individuals with low initial sensitivity (high resistance) 
to acute ethanol effects on cognition are at greater risk for becoming alcohol dependent 
(Schuckit & Smith, 2001). However, other studies have shown that those individuals that 
develop greater acute ethanol tolerance (low initial resistance) also have a greater risk for 
alcohol dependence (Newlin & Renton, 2010). Even though the underlying mechanisms for 
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alcohol dependence are not clear, the general consensus is that STEP61 and p38 MAPK 
activities have critical roles in the modulation of acute and chronic alcohol exposure. These 
studies also suggest that NR2B subunit antagonists are likely to be effective in regulating the 
acquisition of functional tolerance to the acute and chronic inhibitory effects of ethanol.  
3.3 Mechanisms of alcohol-induced brain damage 
The mechanisms of alcohol-induced brain damage and abstinence-induced regeneration are 
complex (Crews et al., 1998; Farber et al., 2004). The extent of neurodegeneration and 
potential regeneration varies by brain region and is dependent on many factors including 
pattern of intake (Crews & Nixon, 2009). Alcoholics display cycles of excessive ethanol 
intake, abstinence, and relapse behavior. For example, Bell et al showed that high alcohol 
drinking rats consumed significantly more alcohol upon re-exposure than control rats after a 
period of alcohol abstinence (Bell et al., 2008). Another studied showed that repeated alcohol 
deprivation cycles increased the severity of relapse within rats (Rodd et al., 2008). These 
studies suggest a strong correlation between abstinence and relapse that perpetuate the 
detrimental cycle of alcohol consumption. 
Chronic exposure to ethanol causes an adaptive increase in NMDA receptor sensitivity both 
in vivo and in vitro. This leads to an increased vulnerability to the glutamate-induced 
cytotoxic response (excitotoxicity) (Dodd et al., 2000). This sensitization of neuronal cells is 
one of the most important factors in the mechanism underlying ethanol-induced brain 
damage. Increased calcium influx through NMDA receptors, as a result of hyper-sensitivity, 
is tightly coupled to the increase in calcium influx within the mitochondria. This results in 
the increased production of reactive oxygen species and oxidative damage that eventually 
attenuates mitochondrial function. Primary inhibition of the mitochondrial respiratory chain 
can also indirectly induce further NMDA receptor stimulation and damage (Matsumoto et 
al., 2001).  
Various studies show the effect of alcohol on the induction of brain damage. Cell culture 
models in vitro suggest that chronic ethanol intake inhibits the NMDARs which over time 
results in a hyper-sensitivity that is alleviated by alcohol withdrawal (Chandler et al., 1993; 
Chandler et al., 2006, Chandler et al., 1999). These studies suggest that neurotoxicity occurs 
through NMDARs during withdrawal (Butler et al., 2008; Smith et al., 2008). However, other 
studies in vivo using different NMDAR antagonists such as MK801 (dizocilpine), 
memantine, and DNQX failed to reduce binge ethanol neurotoxicity. Surprisingly, some 
doses even increased neurodegeneration (Collins et al., 2010; Corso et al., 1998; Crews et al., 
2004; Hamelink et al., 2005). These studies suggest that the mechanism of ethanol-induced 
brain damage is not glutamate excitotoxicity. Therefore, ethanol-induced brain damage in 
the binge model occurs during intoxication. Other studies also support the hypothesis that 
alcohol-induced neurodegeneration occurs primarily during intoxication and is related to 
increased oxidative stress and pro-inflammatory signaling (Qin et al., 2008). Abstinence after 
binge ethanol intoxication results in brain cell genesis that could contribute to the return to 
normal brain function and structure found in abstinent humans (Crews & Nixon, 2009).  
Additionally, transcription factors such as the cAMP responsive element-binding protein 
(CREB) and the nuclear factor κB (NF-κB) regulate the gene expression that increases 
plasticity and survival of damaged neurons (Walton & Dragunow, 2000; Mabuchi et al., 
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(Alvestad et al., 2003; Wu et al., 2010; Hicklin et al., 2011). During the adaptive response 
increased levels of STEP33 and phospho-p38 mitogen-activate protein kinase (pp38 MAPK) 
along with decreased levels of STEP61 were correlated with the failure of acute alcohol 
exposure to inhibit NMDAR currents (Wu et al., 2010; Wu et al., 2011). STEP33 is produced 
by the cleavage of STEP61. This cleavage process may be one of the mechanisms involved in 
the partial inhibition of STEP61 during the adaptive phase of alcohol exposure. Studies such 
as these have suggested that the adaptive resistance of NMDAR currents to acute ethanol 
inhibition likely involves NR2B subunit activity. 
The mechanism of resistance to acute and chronic alcohol exposure during the adaptive 
response is not well understood. Several studies have reported increases in the expression 
level of several subunits of the NMDAR such as NR1, NR2A, and NR2B during the adaptive 
phase under chronic alcohol exposure conditions (Snell et al., 1996; Roberto et al., 2004; 
Roberto et al., 2006; Lack et al., 2007). Other studies have reported increases in the 
accumulation of synaptic NMDARs during this phase as well (Carpenter-Hyland et al., 
2004; Clapp et al., 2010). For example, hippocampal neurons exposed to ethanol chronically 
for 7 days demonstrated an increase and accumulation of synaptic NMDARs that was 
quickly reversed once ethanol exposure ceased (Clapp et al., 2010). This suggests that 
alcohol inhibition of NMDAR activity regulates the expression and accumulation of 
NMDARs. In contrast, other studies reported no changes in the expression levels of the 
NMDAR or its subunits. Instead these studies showed an increased inhibition of NMDAR 
activity using NR2B antagonists and concluded that resistance may be attributed to 
increases in NR2B activity (Ferreira et al., 2001; Wu et al., 2010). Even though increases in 
NR2B activity have not been directly verified, increases in STEP33 and pp38 as mentioned 
previously are characteristic of excessive NMDAR activation (Floyd et al., 2003; 
Hardingham, 2009; Xu et al., 2009).  
Other mechanisms involved in the adaptive response have been proposed but proven to be 
untrue. For example, several studies proposed that tolerance could occur in presynaptic 
neurons, postsynaptic neurons, or both (Wu et al., 2001). Thus, the inhibitory actions of 
ethanol on postsynaptic glutamate receptors could be counteracted by an increase in 
presynaptic glutamate release. This hypothesis was tested via a paired pulse facilitation 
(PPF) experiment. The PPF ratio proves to be inversely proportional to the amount of 
neurotransmitter release in neurons (Dobrunz & Stevens, 1997; Dittman et al., 2000; Wu et 
al., 2001). No significant effects of chronic ethanol in the PPF ratio were seen. This suggested 
that chronic ethanol did not significantly alter the pre-synaptic mechanisms of NMDA 
neurotransmission. Another group of studies proposed that alterations in the Mg2+ blockade 
were responsible for the alcohol resistance seen during the adaptive phase. However, acute 
ethanol inhibition of NMDAR currents did not significantly differ in low Mg2+ and control 
Mg2+ conditions. This demonstrated that alterations in the Mg2+ blockade were unlikely to 
be responsible for this adaptive response as well (Alvestad et al., 2003; Hicklin et al., 2011; 
Wu et al., 2011).  
Studies in humans have shown that individuals with low initial sensitivity (high resistance) 
to acute ethanol effects on cognition are at greater risk for becoming alcohol dependent 
(Schuckit & Smith, 2001). However, other studies have shown that those individuals that 
develop greater acute ethanol tolerance (low initial resistance) also have a greater risk for 
alcohol dependence (Newlin & Renton, 2010). Even though the underlying mechanisms for 
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alcohol dependence are not clear, the general consensus is that STEP61 and p38 MAPK 
activities have critical roles in the modulation of acute and chronic alcohol exposure. These 
studies also suggest that NR2B subunit antagonists are likely to be effective in regulating the 
acquisition of functional tolerance to the acute and chronic inhibitory effects of ethanol.  
3.3 Mechanisms of alcohol-induced brain damage 
The mechanisms of alcohol-induced brain damage and abstinence-induced regeneration are 
complex (Crews et al., 1998; Farber et al., 2004). The extent of neurodegeneration and 
potential regeneration varies by brain region and is dependent on many factors including 
pattern of intake (Crews & Nixon, 2009). Alcoholics display cycles of excessive ethanol 
intake, abstinence, and relapse behavior. For example, Bell et al showed that high alcohol 
drinking rats consumed significantly more alcohol upon re-exposure than control rats after a 
period of alcohol abstinence (Bell et al., 2008). Another studied showed that repeated alcohol 
deprivation cycles increased the severity of relapse within rats (Rodd et al., 2008). These 
studies suggest a strong correlation between abstinence and relapse that perpetuate the 
detrimental cycle of alcohol consumption. 
Chronic exposure to ethanol causes an adaptive increase in NMDA receptor sensitivity both 
in vivo and in vitro. This leads to an increased vulnerability to the glutamate-induced 
cytotoxic response (excitotoxicity) (Dodd et al., 2000). This sensitization of neuronal cells is 
one of the most important factors in the mechanism underlying ethanol-induced brain 
damage. Increased calcium influx through NMDA receptors, as a result of hyper-sensitivity, 
is tightly coupled to the increase in calcium influx within the mitochondria. This results in 
the increased production of reactive oxygen species and oxidative damage that eventually 
attenuates mitochondrial function. Primary inhibition of the mitochondrial respiratory chain 
can also indirectly induce further NMDA receptor stimulation and damage (Matsumoto et 
al., 2001).  
Various studies show the effect of alcohol on the induction of brain damage. Cell culture 
models in vitro suggest that chronic ethanol intake inhibits the NMDARs which over time 
results in a hyper-sensitivity that is alleviated by alcohol withdrawal (Chandler et al., 1993; 
Chandler et al., 2006, Chandler et al., 1999). These studies suggest that neurotoxicity occurs 
through NMDARs during withdrawal (Butler et al., 2008; Smith et al., 2008). However, other 
studies in vivo using different NMDAR antagonists such as MK801 (dizocilpine), 
memantine, and DNQX failed to reduce binge ethanol neurotoxicity. Surprisingly, some 
doses even increased neurodegeneration (Collins et al., 2010; Corso et al., 1998; Crews et al., 
2004; Hamelink et al., 2005). These studies suggest that the mechanism of ethanol-induced 
brain damage is not glutamate excitotoxicity. Therefore, ethanol-induced brain damage in 
the binge model occurs during intoxication. Other studies also support the hypothesis that 
alcohol-induced neurodegeneration occurs primarily during intoxication and is related to 
increased oxidative stress and pro-inflammatory signaling (Qin et al., 2008). Abstinence after 
binge ethanol intoxication results in brain cell genesis that could contribute to the return to 
normal brain function and structure found in abstinent humans (Crews & Nixon, 2009).  
Additionally, transcription factors such as the cAMP responsive element-binding protein 
(CREB) and the nuclear factor κB (NF-κB) regulate the gene expression that increases 
plasticity and survival of damaged neurons (Walton & Dragunow, 2000; Mabuchi et al., 
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2001; Hara et al., 2003). In the presence of ethanol changes can be seen in DNA binding 
protein activities such as increased DNA binding by NF-κB and reduced DNA binding by 
CREB. NMDAR activation by synaptic glutamate release is associated with decreased DNA 
binding by CREB as a result of a decrease in CREB phosphorylation (pCREB) (Papadia & 
Hardingham, 2007). This decrease in pCREB has also been observed in an in vivo model of 
alcohol consumption where rats were treated with ethanol. Therefore, pCREB is reduced 
during intoxication (Bison & Crews, 2003). NMDAR inhibition is caused by saturation with 
ethanol and is expected to enhance neurodegeneration and inhibit neurogenesis. During 
ethanol withdrawal there is a notable increase in pCREB, 3 days post-withdrawal, which is 
consistent with the neurogenesis observed (Bison & Crews, 2003). Therefore, it is possible 
that during abstinence NMDAR activity recovers leading to an increase in the pCREB 
activated transcription of genes involved in plasticity, cell growth, cell proliferation, and 
neurogenesis. However, oxidative stress and pro-inflammatory cytokines could attenuate 
the regeneration process due to imbalances generated by brain cell damage (Collins & 
Neafsey, 2011; Qin et al., 2008). 
3.3.1 Alcoholic neurodegeneration and glial cells 
Studies in nonhuman primate adolescents show alcohol-induced changes during 
neurogenesis in the hippocampus. Alcohol significantly reduced the number of different 
neural progenitor cell types 1, 2a, and 2b as well as glial progenitor cells (Taffe et al., 2010). 
This suggests that alcohol interferes with the division and migration of progenitor cells in 
the hippocampus preneuronal region. Thus, the effect of alcohol decreases neurogenesis and 
increases degeneration. These results demonstrate that the neurogenic niche of the 
hippocampus during adolescence is very vulnerable to alcohol. It also demonstrates that 
alcohol decreases the turnover of neurons in the hippocampus by altering the process of 
neural development. This effect diminishes slowly and can be seen two months after alcohol 
abstinence. These findings could explain the deficit in the hippocampus associated with 
cognitive tasks that may be associated with increased DNA binding of NF-kB and reduced 
DNA binding of CREB (Fulton et al., 2009, Taffe et al., 2010). 
Alcohol-related neuronal loss has been documented in specific regions of the cerebral cortex 
(superior frontal association cortex), hypothalamus, and cerebellum (Harper et al., 2003; 
Baker et al., 1999). Glial cells, also contribute to neurodegeneration because astroglial 
degeneration has been reported during ethanol exposure (Miguel-Hidalgo et al., 2006, 
Miguel-Hidalgo & Rajkowska, 2003). Glial cells are non-neuronal cells that provide physical 
and functional support for neurons and are essential for normal neuronal cell function. The 
loss of glial cells results in a deficiency of metabolic and trophic support for neuronal cells. 
For example, loss of glial cells leads to the inactivation of neurotransmitters such as 
glutamate and loss of ionic homeostasis, particularly K+ (Bezzi & Volterra, 2001; Volterra & 
Meldolesi, 2005; Obara et al., 2008). This loss directly enhances the deleterious effects of 
ethanol on neurons. An increase in the glial fibrillary acidic protein (GFAP), a glial-specific 
cell marker, has been reported after brain injury which suggests activation of glial 
proliferation in response to damage (Eng et al., 1992; Norton et al., 1992). Studies have 
demonstrated reduced glial cell proliferation and reduced expression of GFAP by ethanol 
exposure in astrocyte cultures (Crews et al., 2004; Guerri & Renau-Piqueras, 1997). In 
addition, acute alcohol exposure or acute alcohol-induced brain damage results in gliosis 
(enlargement and increased proliferation of astrocytes) and increases in GFAP levels (Crews 
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et al., 2004; Evrard et al., 2006). In contrast, chronic ethanol exposure results in decreased 
levels of GFAP (Duvernoy et al., 1981; Franke et al., 1997; Miguel-Hidalgo, 2005; 
Udomuksorn et al., 2011).  
Postmortem studies in patients with alcohol dependence showed low glial densities in the 
Pre-Frontal Cortex (PFC). However, in these patients glutamine sythetase (GS) levels as well 
as GFAP levels were significantly higher (Miguel-Hidalgo et al., 2010). One hypothesis for 
this activation of astrocytes in alcoholism involving increased GS/GFAP expression may be 
due to the repeated acute exposure to alcohol or to periods of withdrawal that defines 
alcoholism. This augmentation of GS expression in astrocytes of alcoholics is supported by 
augmented GS immunoreactivity detected in the PFC of alcohol-consuming rats three days 
after withdrawal from alcohol (Miguel-Hidalgo, 2005). In this animal model, the GS 
immunoreactivity was significantly correlated with the amount of ethanol ingested in the 
days before withdrawal. It has been suggested that astrocytes play a critical role in 
controlling glutamatergic activity and take up most of the synaptically released glutamate 
that terminates neurotransmitter activity. Glutamate can then be delivered to neurons via 
the glutamate–glutamine cycle (Danbolt, 2001). Therefore, changes in the glial expression of 
GS/GFAP suggest an impairment of certain aspects of glutamatergic processing during 
alcohol exposure and withdrawal. Further research should determine whether the 
morphological plasticity and GS/GFAP expression are induced more readily in chronic 
alcoholics despite a paradoxical association of chronic alcohol intake with low glial or 
astrocyte density (Korbo, 1999; Miguel-Hidalgo et al., 2002; Miguel-Hidalgo et al., 2006). 
3.4 Clinical studies: The role of NMDA receptor antagonists ketamine and memantine 
Several studies have suggested that NMDA receptor antagonists are an effective method of 
treatment for alcohol disorders. Ketamine, a NMDA receptor antagonist, has been evaluated 
in subjects with a strong family history of ethanol dependence versus subjects with no such 
family history (Petrakis, 2004). This study demonstrated that during ketamine infusion 
individuals with a family history of ethanol dependence showed an attenuated response in 
terms of perceptual alterations and dysphoric mood relative to those without such a family 
history. This study reaffirms NMDAR dysfunction as an important contributing factor of 
alcohol dependence. Another study by Phelps et al. investigated whether a family history of 
alcohol dependence influences ketamine's initial antidepressant effect. The study reported 
that subjects with a family history of alcohol dependence showed significantly greater 
improvement in MADRS (Montgomery-Asberg Depression Rating Scale) scores compared 
with subjects who had no family history of alcohol dependence. The study concluded that a 
family history of alcohol dependence appears to predict a rapid initial anti-depressant 
response to NMDA receptor antagonists (Phelps, 2009). The precise reasons underlying the 
better response of the family history of alcohol dependence (FHP) group to ketamine 
remains unknown but reaffirms NMDARs association with LTD. Another study compared 
the ethanol-related effects of ketamine and thiophental on both NMDA and GABAA 
receptor activity. This study reported that the ethanol-like effects of ketamine were greater 
than that of thiopental (Dickerson, 2008). The results obtained are important because 
ketamine (a NMDAR antagonist) produced alcohol alterations in perception that were not 
produced by thiopental (a GABAA receptor agonist). This also reaffirms the role of the 
NMDAR in alcohol dependence. 
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2001; Hara et al., 2003). In the presence of ethanol changes can be seen in DNA binding 
protein activities such as increased DNA binding by NF-κB and reduced DNA binding by 
CREB. NMDAR activation by synaptic glutamate release is associated with decreased DNA 
binding by CREB as a result of a decrease in CREB phosphorylation (pCREB) (Papadia & 
Hardingham, 2007). This decrease in pCREB has also been observed in an in vivo model of 
alcohol consumption where rats were treated with ethanol. Therefore, pCREB is reduced 
during intoxication (Bison & Crews, 2003). NMDAR inhibition is caused by saturation with 
ethanol and is expected to enhance neurodegeneration and inhibit neurogenesis. During 
ethanol withdrawal there is a notable increase in pCREB, 3 days post-withdrawal, which is 
consistent with the neurogenesis observed (Bison & Crews, 2003). Therefore, it is possible 
that during abstinence NMDAR activity recovers leading to an increase in the pCREB 
activated transcription of genes involved in plasticity, cell growth, cell proliferation, and 
neurogenesis. However, oxidative stress and pro-inflammatory cytokines could attenuate 
the regeneration process due to imbalances generated by brain cell damage (Collins & 
Neafsey, 2011; Qin et al., 2008). 
3.3.1 Alcoholic neurodegeneration and glial cells 
Studies in nonhuman primate adolescents show alcohol-induced changes during 
neurogenesis in the hippocampus. Alcohol significantly reduced the number of different 
neural progenitor cell types 1, 2a, and 2b as well as glial progenitor cells (Taffe et al., 2010). 
This suggests that alcohol interferes with the division and migration of progenitor cells in 
the hippocampus preneuronal region. Thus, the effect of alcohol decreases neurogenesis and 
increases degeneration. These results demonstrate that the neurogenic niche of the 
hippocampus during adolescence is very vulnerable to alcohol. It also demonstrates that 
alcohol decreases the turnover of neurons in the hippocampus by altering the process of 
neural development. This effect diminishes slowly and can be seen two months after alcohol 
abstinence. These findings could explain the deficit in the hippocampus associated with 
cognitive tasks that may be associated with increased DNA binding of NF-kB and reduced 
DNA binding of CREB (Fulton et al., 2009, Taffe et al., 2010). 
Alcohol-related neuronal loss has been documented in specific regions of the cerebral cortex 
(superior frontal association cortex), hypothalamus, and cerebellum (Harper et al., 2003; 
Baker et al., 1999). Glial cells, also contribute to neurodegeneration because astroglial 
degeneration has been reported during ethanol exposure (Miguel-Hidalgo et al., 2006, 
Miguel-Hidalgo & Rajkowska, 2003). Glial cells are non-neuronal cells that provide physical 
and functional support for neurons and are essential for normal neuronal cell function. The 
loss of glial cells results in a deficiency of metabolic and trophic support for neuronal cells. 
For example, loss of glial cells leads to the inactivation of neurotransmitters such as 
glutamate and loss of ionic homeostasis, particularly K+ (Bezzi & Volterra, 2001; Volterra & 
Meldolesi, 2005; Obara et al., 2008). This loss directly enhances the deleterious effects of 
ethanol on neurons. An increase in the glial fibrillary acidic protein (GFAP), a glial-specific 
cell marker, has been reported after brain injury which suggests activation of glial 
proliferation in response to damage (Eng et al., 1992; Norton et al., 1992). Studies have 
demonstrated reduced glial cell proliferation and reduced expression of GFAP by ethanol 
exposure in astrocyte cultures (Crews et al., 2004; Guerri & Renau-Piqueras, 1997). In 
addition, acute alcohol exposure or acute alcohol-induced brain damage results in gliosis 
(enlargement and increased proliferation of astrocytes) and increases in GFAP levels (Crews 
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et al., 2004; Evrard et al., 2006). In contrast, chronic ethanol exposure results in decreased 
levels of GFAP (Duvernoy et al., 1981; Franke et al., 1997; Miguel-Hidalgo, 2005; 
Udomuksorn et al., 2011).  
Postmortem studies in patients with alcohol dependence showed low glial densities in the 
Pre-Frontal Cortex (PFC). However, in these patients glutamine sythetase (GS) levels as well 
as GFAP levels were significantly higher (Miguel-Hidalgo et al., 2010). One hypothesis for 
this activation of astrocytes in alcoholism involving increased GS/GFAP expression may be 
due to the repeated acute exposure to alcohol or to periods of withdrawal that defines 
alcoholism. This augmentation of GS expression in astrocytes of alcoholics is supported by 
augmented GS immunoreactivity detected in the PFC of alcohol-consuming rats three days 
after withdrawal from alcohol (Miguel-Hidalgo, 2005). In this animal model, the GS 
immunoreactivity was significantly correlated with the amount of ethanol ingested in the 
days before withdrawal. It has been suggested that astrocytes play a critical role in 
controlling glutamatergic activity and take up most of the synaptically released glutamate 
that terminates neurotransmitter activity. Glutamate can then be delivered to neurons via 
the glutamate–glutamine cycle (Danbolt, 2001). Therefore, changes in the glial expression of 
GS/GFAP suggest an impairment of certain aspects of glutamatergic processing during 
alcohol exposure and withdrawal. Further research should determine whether the 
morphological plasticity and GS/GFAP expression are induced more readily in chronic 
alcoholics despite a paradoxical association of chronic alcohol intake with low glial or 
astrocyte density (Korbo, 1999; Miguel-Hidalgo et al., 2002; Miguel-Hidalgo et al., 2006). 
3.4 Clinical studies: The role of NMDA receptor antagonists ketamine and memantine 
Several studies have suggested that NMDA receptor antagonists are an effective method of 
treatment for alcohol disorders. Ketamine, a NMDA receptor antagonist, has been evaluated 
in subjects with a strong family history of ethanol dependence versus subjects with no such 
family history (Petrakis, 2004). This study demonstrated that during ketamine infusion 
individuals with a family history of ethanol dependence showed an attenuated response in 
terms of perceptual alterations and dysphoric mood relative to those without such a family 
history. This study reaffirms NMDAR dysfunction as an important contributing factor of 
alcohol dependence. Another study by Phelps et al. investigated whether a family history of 
alcohol dependence influences ketamine's initial antidepressant effect. The study reported 
that subjects with a family history of alcohol dependence showed significantly greater 
improvement in MADRS (Montgomery-Asberg Depression Rating Scale) scores compared 
with subjects who had no family history of alcohol dependence. The study concluded that a 
family history of alcohol dependence appears to predict a rapid initial anti-depressant 
response to NMDA receptor antagonists (Phelps, 2009). The precise reasons underlying the 
better response of the family history of alcohol dependence (FHP) group to ketamine 
remains unknown but reaffirms NMDARs association with LTD. Another study compared 
the ethanol-related effects of ketamine and thiophental on both NMDA and GABAA 
receptor activity. This study reported that the ethanol-like effects of ketamine were greater 
than that of thiopental (Dickerson, 2008). The results obtained are important because 
ketamine (a NMDAR antagonist) produced alcohol alterations in perception that were not 
produced by thiopental (a GABAA receptor agonist). This also reaffirms the role of the 
NMDAR in alcohol dependence. 
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Memantine, another NMDAR antagonist, also has been evaluated in clinical trials for the 
treatment of alcoholism. The first study was conducted by Bisagra et al. by evaluating the 
acute effects of memantine on the subjective, physiological, and performance effects of 
alcohol in moderate (10–30 drinks per week) alcohol drinkers. This study reported that pre-
treatment with memantine attenuated the craving for alcohol before alcohol administration 
but not after alcohol was given. It demonstrated that memantine increased the dissociative 
effects of alcohol without altering its sedative, stimulant, and overall intoxicating effects. It 
reported that memantine had no effect on alcohol-induced impairment in performance, 
physiological changes, or pharmacokinetics. This study also showed that memantine 
increased subjective reports of dissociation, confusion, stimulation, and impaired motor 
coordination on the balance task (Bisaga & Evans, 2004). Due to the high comorbidity shared 
between alcoholism and depression Muhonen et al. also evaluated memantine as well as 
escitalopram, a selective serotonin reuptake inhibitor (SSRI), for the treatment of comorbid 
with alcohol dependence. This study reported that both treatments significantly reduced the 
baseline level of depression and anxiety according to Montgomery-Asberg Depression 
Rating Scale (MADRS) and Hamilton Rating Scale for Anxiety (HAM-A). This evidence 
provides safety and potential efficacy of memantine and escitalopram for major depressive 
disorder in patients with comorbid alcohol dependence (Muhonen, 2008). 
4. Conclusion 
Approximately 2 billion people world-wide consume alcoholic beverages. Alcohol use is 
related to a wide range of physical, mental, and social detriments. Additionally, alcohol 
affects almost every organ in the human body as well as the central nervous system. The 
protein theory is the generally accepted theory on how alcohol affects the CNS. This theory 
proposes that alcohol acts specifically on membrane protein receptors such as the iGluR-
NMDA. The iGluR-NMDA is one of the most active molecules in the central nervous system 
and has been shown to be directly inhibited in a non-competitive manner by alcohol. It is a 
post-synaptic receptor critical in most neural activities such as learning and memory. 
NMDARs are hetermeric complexes composed of three major types of subunits NR1, NR2, 
and NR3. Alcohol effects on the NMDAR are dependent on the NMDAR subunit 
composition as well as alcohol concentration. The major effects of alcohol on the NMDAR 
activity are thought to be conferred by alcohol’s direct interaction with the NR2 subunits of 
the NMDA receptor. The effects of alcohol can be categorized into several stages. These 
stages are referred to as initiation of alcohol consumption, maintenance of alcohol 
consumption, craving and reinstating of alcohol seeking, and relapse to alcohol use. A 
combination of ionotropic receptors such as NMDAR, non-ionotropic receptors, and other 
receptors of the glutamatergic system are intimately involved in the acquisition of alcohol 
dependence. The NMDAR has a critical role in the stages of initiation of alcohol 
consumption and relapse to alcohol use. In response to the NMDA receptors role in alcohol 
addiction several NMDAR antagonists have been used in clinical trials to alleviate alcohol 
dependence. These antagonists include ketamine and memantine. Both have been shown to 
be successful in alleviating some of the symptoms of alcohol dependence. Future research 
should focus on the continued characterization of the NMDAR structure as well as its 
structural variation in different tissue compartments within the brain. Also, further studies 
are needed to elucidate the interactions of alcohol on specific NMDAR subunits and 
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characterize their effects on NMDAR activity. This will be crucial in developing novel 
therapeutic targets against alcohol addiction.  
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1. Introduction 
Human drug addictions are chronic medical disorders characterized by tolerance and 
dependence to the abused substance, incentive sensitization, loss of control over drug use 
that becomes compulsive, relapse (Belin & Everitt, 2010), and in some cases high mortality. 
A large body of research has established that the majority of drugs leading to addiction 
stimulate dopamine release through the meso-cortico-limbic circuit in laboratory animals 
and humans (e.g. see Badiani et al., 2011). Brain neuroadaptations along the reward system 
are a focus of current research, especially those induced in the prefrontal cortex of human 
addicts (Goldstein & Volkow, 2011). These persistent neuroplastic events appear to be major 
causes for compulsive drug-seeking behavior despite the negative effects (e.g., 
neurotoxicity) induced by drugs of abuse in humans (Nutt et al., 2007). 
It is generally accepted that some addictive drugs can induce cell death in the human brain, 
following observations that neurons and astrocytes die when exposed to drugs of abuse 
(Cunha-Oliveira et al., 2008; Büttner, 2011). Neurotoxicity and neuroplasticity acting 
together in the addicted brain might explain the dampened cognition and the reinforced 
behaviors driving to drug consumption. The best-studied cell-killing machinery is the so-
called programmed cell death or apoptosis (Galluzzi et al., 2011). In vivo studies have 
reported controversial data for drugs of abuse regulating the apoptotic machinery in the 
brain (Tegeder & Geisslinger, 2004). Moreover, other findings have revealed important roles 
of pro-apoptotic proteins in the molecular mechanisms mediating synaptic and structural 
plasticity in the brain (Gilman & Mattson, 2002). Indeed, proteins belonging to the extrinsic 
apoptotic pathway have gained special interest in the study of neuroplastic machinery for 
their functional duality, promoting either apoptosis or cell survival and differentiation (Park 
et al., 2005; Tourneur and Chiocchia, 2010). Thus, Fas-associated death domain (FADD) 
protein is the most proximal adaptor molecule that mediates the signaling of death receptors 
belonging to the tumor necrosis factor receptor superfamily (TNFRSF), such as Fas or 
TNFRSF6 receptor (Tourneur and Chiocchia, 2010). Although the main role of FADD 
adaptor is to engage cell death through the extrinsic apoptotic pathway (Galluzzi et al., 
2011), it also mediates non-apoptotic actions in cell systems in vitro (Park et al., 2005) and 
has a critical role in embryogenesis (Imtiyaz et al., 2009). In the CNS, Fas receptor 
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dysregulation is associated with a number of disease states, including neurodegenerative 
disorders (Sharma et al., 2000). Fas stimulation can also promote neurite outgrowth and 
neuronal branching, which suggests the induction of neuroplastic responses in neurons 
(Lambert et al., 2003; Reich et al., 2008). Notably, FADD can translocate to the nucleus, a 
process favoured by its phosphorylation, and regulate nuclear factors, possibly altering the 
genetic profile of the cell, and promoting differentiation, neuroplasticity, and/or other 
anti/non-apoptotic actions. 
All these features made of FADD an intriguing molecule for the study of brain neurotoxicity 
and/or neuroplasticity induced by drugs of abuse. This chapter reviews current evidence on 
the new roles of brain FADD in the complex neurobiology of drug addiction. After a brief 
overview on Fas/FADD complex and specific features of FADD protein, the involvement of 
multifunctional FADD and associated signalling in the acute and chronic effects of opiates, 
cocaine and cannabinoids are summarized from biochemical and behavioral studies 
performed in rat, mouse and human brains. 
2. Relevant features of FADD protein 
2.1 Fas/FADD complex: Pro-apoptotic function 
In the standard model of Fas-mediated cell death (binding of FasL resulting in receptor 
trimerization; Algeciras-Schimnich et al., 2002), Fas and FADD are bound through 
homotypic death domain (DD) interactions (Fas/FADD complex) (Fig. 1A). Then FADD can 
recruit death effector domain (DED)-containing initiator pro-caspase 8 (and other molecules 
such as FLIP and PEA-15) to form a death inducing signalling complex (DISC), which finally 
promotes the activation of death-effector caspases (mainly caspase-3) with the final cleavage 
of downstream vital cellular substrates. Recently, two models of Fas/FADD-DISC (Scott et 
al., 2009; Wang et al., 2010) and a likely 5 Fas:5 FADD stoichiometry (Fig. 1A; Wang et al., 
2010) have been proposed based on the crystal structures of the proteins. Therefore, FADD  
 
Fig. 1. (A) Fas/FADD-DISC complex. (B) FADD protein structure and domains (DD and 
DED). NLS: nuclear localization signals; NES: nuclear export signals. FLIP: FADD-like 
interleukin-1β-converting enzyme-inhibitory protein; PEA-15: phosphoprotein enriched in 
astrocytes of 15 kDa. 
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can form functional homo-oligomers of high molecular mass (oligomeric signalling 
complexes) which have been shown to increase the efficiency of Fas apoptotic signalling in 
normal and cancer cells (Sandu et al., 2006). Cell death in the CNS shares the same basic 
mechanisms operating in peripheral cells. Thus, brain apoptosis can be initiated through the 
extrinsic (Fas receptor) and intrinsic (mitochondrial) pathways, which converge to the 
activation of executioner caspases (Sastry and Rao, 2000). 
2.2 FADD phosphorylation: Nuclear localization and functional implications 
The structure of FADD displays, outside its C-terminal DD region (Fig. 1B), a single serine 
phosphorylation site (p-Ser191 in mouse, p-Ser194 in human; p-Ser194 or p-Ser195 in rat; 
Zhang et al., 2004; García-Fuster et al., 2008a). This phosphorylation of FADD, mainly 
mediated by casein kinase 1α (CK1α), is essential for the non-apoptotic actions of  
this multifunctional protein, such as the regulation of cell growth and differentiation 
(Alappat et al., 2005). 
Although FADD was initially thought to be a cytoplasmic protein, it contains nuclear 
localization and export signals (NLS/NES; Fig. 1B) that allow its nuclear translocation 
(Gómez-Angelats and Cidlowski, 2003). Some studies have even reported that FADD is 
predominantly stored in the nucleus of resting cells, being redistributed to the cytoplasm 
upon Fas receptor activation (Föger et al., 2009). In any case, p-FADD is the main protein 
species translocated to the nucleus (Screaton et al., 2003). Nuclear p-FADD is involved in the 
anti-apoptotic actions of the molecule through the modulation of critical factors (Screaton et 
al., 2003; Alappat et al., 2005). 
2.3 FADD adaptor in the brain: Immunodetection of protein forms and regional 
distribution 
In rat, mouse and human brain tissue, various commercially available antibodies tested 
against FADD (up to seven) readily immunolabeled a ≈51-kDa band corresponding to its 
dimeric form (Fig. 2A, left panel). To a lesser extent, these antibodies also reacted against the 
monomeric (≈20-23 kDa) and other FADD species of higher magnitude (≈92-116 kDa) 
(García-Fuster et al., 2008a). In contrast, different antibodies against p-FADD recognized 92-
116-kDa bands corresponding to oligomeric p-FADD species (Fig. 2A, right panel). 
Noteworthy, these higher FADD structures fit well with the recently proposed pentameric 
model of DISC association (see Fig. 1A; Wang et al., 2010). In addition, some of these 
antibodies immunodetected the monomeric p-FADD species (García-Fuster et al., 2008a; 
Ramos-Miguel et al., 2009) (Fig. 2A, right panel). The ability of these phospho-directed 
antibodies to label p-FADD species was challenged with the alkaline phosphatase assay, 
which demonstrated the specificity of these antibodies to bind to the p-sites of the protein 
(Fig. 2A, right panel). Therefore, in brain tissue, it is likely that non-p-FADD is more stable 
as a dimer, and its phosphorylation switches FADD self-associative properties. Thus, these 
FADD (dimers) and p-FADD (monomers and oligomers) forms were initially selected to 
assess the role of multifunctional FADD protein in the molecular mechanisms of drug 
addiction. To note that some p-FADD species (e.g. ≈45 kDa form; Fig. 2A. right) most 
probably represent degradation products of higher mass p-oligomers. These and other 
technical issues are largely discussed in previous reports (García-Fuster et al., 2008a). 
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Fig. 2. (A/B) Immunodetection of FADD protein forms (arrow heads: monomeric, dimeric and 
oligomeric nonphosphorylated and phosphorylated species) in brain total homogenate (RB: rat 
cortex; MB: mouse cortex; HB: human cortex; C: rat striatum, control sample; AP: alkaline 
phosphatase; IC: inhibited control, alkaline phosphatase plus sodium pyrophosphate) and 
subcellular compartments (rat cortex; F1: cytosol; F2: membranes; F3: nucleus; F4: 
cytoskeleton), in which the acute effect of sufentanil (S: 0.015 mg/kg, s.c., 30 min) on p-FADD 
is shown (C: control saline). Protein sizes (kDa) as visualized in Western blots. (Modified from 
García-Fuster et al., 2007a, 2008a). (C) Detection of FADD mRNA in rat brain (anatomical level: 
Bregma -3.60 mm) by in situ hybridization. Note that FADD mRNA (antisense probe) showed 
very low expression in the brain, except for hippocampal regions and cortex (see García-Fuster 
et al., 2009). To verify specificity of binding a sense control probe was hybridized in test tissue. 
(Modified from García-Fuster et al., 2006). (D) Regional distribution of FADD protein forms in 
the rat brain (FC: frontal cortex, region of reference; PC: parietal cortex; ST: corpus striatum; 
HC: hippocampus; TH: thalamus; CB: cerebellum). 
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FADD is expressed in neurons and glial cells (Hartmann et al., 2002; Bi et al., 2008; Tewari et 
al., 2008). FADD mRNA expression is homogeneous along the brain tissue, as visualized by 
in situ hybridization (Fig. 2C), with slight increased labeling in cortical areas and 
hippocampus. However, the distribution of FADD protein (monomeric and dimeric species) 
in rat brain regions is uneven, with a greater content in the cerebral cortex than in 
cerebellum (Fig. 2D, left). In contrast, p-FADD (monomeric and oligomeric p-species) is 
highly expressed in cerebellum (Fig. 2D, right). Thus, the ratio of p-FADD to FADD 
(monomeric species) was much greater in the cerebellum (CB: 22.4) than in cortical areas 
(FC: 0.91; PC: 1.58) (Fig. 2D). Subcortical regions also display high p-FADD/FADD ratios 
(ST: 5.87; HC: 5.61; TH: 4.98) (Fig. 2D). The physiological relevance of the marked variation 
of p-FADD/FADD ratio across brain regions remains to be determined. To note that FADD 
and p-FADD are well expressed in brain regions (e.g., the frontal cortex and corpus 
striatum) more closely associated with the behavioral effects of drug of abuse (Fig. 2D). In 
the human brain, a dynamic relationship between monomeric and oligomeric p-FADD 
forms has been observed (Ramos-Miguel et al., 2009). Notably, some opiate and cannabinoid 
drugs, but not cocaine, have been shown to induce the interconversion between FADD and 
p-FADD (increasing the ratio p-FADD/FADD), which may favor the induction of non-
apoptotic (neuroplastic) actions (see below and Fig. 6). 
At the subcelullar level, FADD and p-FADD (rat, mouse and human brains) are expressed in 
cytosol and nucleus, and to a lesser extent in membranes (García-Fuster et al., 2007a, 2008a; 
Ramos-Miguel et al., 2009; Álvaro-Bartolomé et al., 2010) (Fig. 2B and 11D). To note that the 
monomeric form of p-FADD is particularly well expressed in the nucleus (Fig. 2B) (Ramos- 
Miguel et al., 2009). Nuclear p-FADD has been reported to play important roles in the 
molecular mechanisms of opiate addiction in humans (Ramos-Miguel et al., 2009), possibly 
by regulating nuclear factors such as methyl-CpG binding domain protein 4 (Screaton et al., 
2003) and nuclear factor kappaB (Schinske et al., 2011). 
2.4 FADD adaptor: Apoptotic and non-apoptotic signalling pathways 
Besides the role of FADD in the cascades of apoptotic signaling in drug addiction (García-
Fuster et al., 2007a, 2008b; Ramos-Miguel et al., 2009; Álvaro-Bartolomé et al., 2011), several 
pathways have been postulated to link FADD with some forms of behavioral plasticity 
induced by drugs of abuse, especially heroin/morphine (Ramos-Miguel et al., 2009, 2010, 
2011) and cocaine (García-Fuster et al., 2009, 2011; Álvaro-Bartolomé et al., 2011) (Fig. 3).  
These signalling pathways involve, inter alia, the extracellular signal-regulated kinase (ERK), 
the kinase Akt1 or protein kinase B (PKB), and phosphoprotein enriched in astrocytes of 15 
kDa (PEA-15), which interactions with FADD are discussed below (see section 3.3) in the 
context of the acute/chronic effects of opiates, cocaine and cannabinoids (Fig. 3). 
3. Role of FADD adaptor in opiate addiction 
Opiate addiction is associated with various forms of neurotoxicity, which can result in serious 
brain dysfunction in most subjects (Yücel et al., 2007; Bütnner, 2011). Moreover, heroin addicts 
often develop severe immunodeficiencies that could be the result of apoptotic cell death in the 
immune system (Kreek, 1990; Govitrapong et al., 1998). In fact, morphine was reported to 
increase, through a naloxone-sensitive mechanism, the expression of Fas receptor mRNA in 
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cytoskeleton), in which the acute effect of sufentanil (S: 0.015 mg/kg, s.c., 30 min) on p-FADD 
is shown (C: control saline). Protein sizes (kDa) as visualized in Western blots. (Modified from 
García-Fuster et al., 2007a, 2008a). (C) Detection of FADD mRNA in rat brain (anatomical level: 
Bregma -3.60 mm) by in situ hybridization. Note that FADD mRNA (antisense probe) showed 
very low expression in the brain, except for hippocampal regions and cortex (see García-Fuster 
et al., 2009). To verify specificity of binding a sense control probe was hybridized in test tissue. 
(Modified from García-Fuster et al., 2006). (D) Regional distribution of FADD protein forms in 
the rat brain (FC: frontal cortex, region of reference; PC: parietal cortex; ST: corpus striatum; 
HC: hippocampus; TH: thalamus; CB: cerebellum). 
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mouse splenocytes and in human blood lymphocytes (Yin et al., 1999). However, the possibility 
of opiate-induced cell death in the mature brain, including the brains of human addicts, still is a 
debated issue (Boronat et al., 2001; Tegeder and Geisslinger, 2004; Liao et al., 2005; Cunha-
Oliveira et al., 2008; García-Fuster et al., 2008b; Tramullas et al., 2008; Zhang et al., 2008). 
 
Fig. 3. Schematic diagram illustrating the complex interactions between the multifunctional 
protein FADD (pro-apoptotic, anti-apoptotic and/or neuroplastic actions) and pro-survival 
MAP kinases (MEK-ERK) and Akt1/PEA-15 signalling in opiate, cocaine and cannabinoid 
addiction. See the main text for specific details and comments.  
3.1 Regulation of basal Fas/FADD complex by opioid receptors: Anti-apoptotic  
δ-opioid receptor tone 
A relevant interaction between the opioid system and Fas/FADD complex in the brain was  
disclosed using gene-targeted mice lacking μ-, δ-, or κ-opioid receptors (García-Fuster et al., 
2007b). Thus, wild-type (WT) and knock-out (KO) mice were compared to investigate the 
existence of endogenous opioid tones regulating the basal contents of Fas receptor and 
FADD adaptor in the brain.  
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The results indicated that μ- and κ-receptors do not exert a significant tonic control on 
Fas/FADD complex expression levels in the mouse brain (i.e., no major target changes in μ- 
and κ-KO mice). In δ-KO mice, however, Fas aggregates (Fas forms triggering receptor 
signalling) and FADD adaptor were markedly increased in the cortex (Fig. 4) and corpus 
striatum. Moreover, the basal content of monomeric p-FADD (the FADD species implicated 
in non-apoptotic signals) was also up-regulated in the cortices of δ-KO mice, which is in line 
with the observed increase of FADD in these animals (Fig. 4). In this context, it is worth 
mentioning that inhibitory δ-opioid receptors possess a high level of constitutive (ligand-
independent) activity (Costa and Herz, 1989; Neilan et al., 1999), which could control the 
basal level of some associated signalling molecules such as the Fas/FADD complex.  
 
Fig. 4. Fas receptor aggregates, FADD adaptor, and p-FADD (monomeric and oligomeric 
forms) in the cerebral cortex of WT mice and δ-opioid receptor KO mice. *At least p<0.05 
versus WT. (Modified from García-Fuster et al., 2007b). 
Taken together, the findings in δ-KO mice strongly suggest that the functioning of pro-
apoptotic Fas/FADD complex in vivo is partly under an inhibitory tonic control of brain δ-
opioid receptors (i.e., removal of a negative endogenous opioid tone results in Fas/FADD 
up-regulation; see Fig. 3) (García-Fuster et al., 2007b). The anti-apoptotic δ-opioid receptor 
tone on Fas/FADD complex could play an important role in the neuroprotection afforded 
by δ-opioid receptor agonists (Narita et al., 2006). 
3.2 Acute, chronic and withdrawal effects of opiate drugs on FADD and associated 
signalling in the brain 
Acute and chronic treatments of rats with various opiate drugs (heroin, morphine, SNC-80, 
U-50488-H, pentazocine), as well as the induction of opiate withdrawal states, were initially 
shown to result in increases or decreases of various Fas receptor forms in the brain (Boronat 
et al., 2001q; García-Fuster et al., 2003, 2004). Thus, heroin/morphine addiction in rats was 
associated with up-regulation of both native and aggregated forms, thereby suggesting the 
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induction of pro-apoptotic actions in the brain (García-Fuster et al., 2003, 2004). In contrast, 
similar treatments with morphine and selective μ-(fentanyl, sufentanil), δ-(SNC-80) and κ-
(U-50488-H) opioid receptor agonists were associated with receptor-specific reductions of 
FADD, except for the chronic treatments that show tachyphylaxis to the acute drug effects in 
the brain (Fig. 5) (García-Fuster et al., 2007a).  
 
Fig. 5. Acute (Ac), chronic (Chr) and spontaneous (+SW) or antagonist precipitated 
(naltrindole, Ntl; nor-binaltorphimine, Nbt) withdrawal effects of μ-(morphine), δ-(SNC-80) 
and κ-(U50488H) opioid receptor agonists on FADD and p-FADD in rat brain cortex. *At 
least p<0.05 versus control (C). (Modified from García-Fuster et al., 2007a, 2008a). 
As a matter of fact, the modulation of FADD by opiate drugs is opposite to that of Fas 
receptor, which suggests that possible apoptotic signals engaged by Fas activation would 
be offset by a lesser signal transduction through FADD adaptor. Indeed, μ/δ-opiate 
agonists increased the content of p-FADD in the brain (Fig. 5; see also Fig. 2B for the acute 
effect of sufentanil on p-FADD in subcellular compartments), which suggests the 
induction of non-apoptotic (neuroplastic) effects by these drugs (see Fig. 3) (García-Fuster 
et al., 2007a, 2008a). On the other hand, SNC-80-induced down-regulation of FADD in rat 
brain (cortex and striatum) was blunted after the inhibition of the MEK-ERK pathway in 
vivo, which demonstrates the direct involvement of this anti-apoptotic signalling in FADD 
regulation (García-Fuster et al., 2007a). On the other hand, the molecular mechanism by 
which seven transmembrane (7TM) receptors interact with FADD (i.e., G protein 
dependent or independent process; see Fig. 3) remains to be fully determined (see García-
Fuster et al., 2008a). 
Remarkably, morphine, sufentanil and SNC-80 (acute, chronic and/or withdrawal effects) 
up-regulated the content of p-FADD with a concomitant decrease of total FADD in rat brain 
cortex (Fig. 6A), indicating that these drugs promote an increase in the ratio of p-FADD to 
FADD  (a proposed index of non-apoptotic activity). The inverse relationship between p-
FADD and FADD is likely to be due to changes in the phosphorylation status, possibly 
mediated by CK1α, of the adaptor molecule induced by opiate drugs (García-Fuster et al., 
2008a; Ramos-Miguel et al., 2009). These findings support the concept of an interconversion 
between non-phosphorylated FADD and phosphorylated FADD after exposure to opiate 
drugs, which appears to be a relevant molecular mechanism in morphine-induced 
neuroplasticity (see below). A similar inverse correlation between p-FADD and FADD has 
been observed for the acute effects of the CB1 receptor agonist WIN55212-2 (Fig. 6B), but not 
for the psychostimulant cocaine (Fig. 6C). 
 




Fig. 6. Inverse correlation between the contents of p-FADD and FADD in rat or mouse brain 
cortex (each point corresponds to an animal). (A) Opiate agonists: effects of acute (30 and 
100 mg/kg) and chronic (10-100 mg/kg; 6 days) morphine, and spontaneous morphine 
withdrawal (1-3 days); effects of acute sufentanil (15-30 mg/kg); effects of acute SNC-80 (10-
30 mg/kg). (B) CB1 receptor agonist: effects of acute WIN55212-2 (0.5-8 mg/kg). (C) Effects 
of acute cocaine (3-30 mg/kg). (Modified from García-Fuster et al., 2008a, 2009; Álvaro-
Bartolomé et al., 2010). 
3.3 FADD phosphorylation correlates with morphine-evoked behaviors 
Recent findings have revealed a direct role of p-FADD in the molecular mechanisms leading 
to the expression of unconditioned morphine-induced psychomotor sensitization (Ramos-
Miguel et al., 2010) and to the expression of spontaneous morphine abstinence syndrome 
(Ramos-Miguel et al., 2011) in rats. 
To develop sensitization to morphine (Ramos-Miguel et al., 2010), rats were subjected to a 
standard treatment protocol (Fig. 7A, left) in which they received saline (controls) or 
morphine (10 mg/kg/day) for 5 days in absence of environmental cues. After 3 (day 8 of the 
treatment; Fig. 7A) or 14 days of spontaneous saline/morphine withdrawal (SW3 and SW14, 
respectively), all rats received a morphine challenge (10 mg/kg) to assess the expression of 
locomotor sensitization, which was observed at SW3 (Fig. 7A) but not at SW14 (Ramos-
Miguel et al., 2010). In parallel to morphine-induced behavioral sensitization, striatal FADD 
was modulated at SW3, but not at SW14. Thus, p-FADD was up-regulated (Fig. 7A, right) 
whereas FADD content was decreased (not shown) at SW3. Therefore, the ratio p-
FADD/FADD (a postulated marker of neuroplasticity) was increased (2.6-fold) in rat 
striatum. Similarly, ERK activity was also enhanced in the same striatal samples (Fig. 7A, 
right). Notably, inhibition of MEK-ERK signalling attenuated the expression of morphine-
induced psychomotor sensitization and fully prevented the up-regulation of p-FADD at 
SW3 (Fig. 7A). The Akt1/PEA-15 pathway, which may link ERK and FADD functions (see 
Fig. 3), was also activated at SW3, being dependent on the integrity of MEK-ERK signalling 
(Fig. 7A, right). Taken together, these findings reveal a major role of p-FADD, interacting 
with MEK/ERK and Akt1/PEA-15, in mediating the short-lasting expression of 
unconditioned psychomotor sensitization induced by morphine in rats. 
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Fig. 7. (A) FADD phosphorylation and expression of unconditioned morphine-induced 
psychomotor sensitization. Note that day 8 of the treatment corresponds to SW3 (see text). 
(B) FADD phosphorylation and intensity of spontaneous morphine abstinence syndrome. 
BL, baseline; SL327, an inhibitor of MEK in vivo; EEDQ, an alkylating of α2-adrenoceptors. 
*At least p<0.05 versus controls, †at least p<0.05 versus morphine-treated rats. (Modified 
from Ramos-Miguel et al., 2010, 2011). 
To explore the role of FADD in the mechanisms of morphine-induced physical dependence, 
the regulation of cortical p-FADD was investigated during the development of spontaneous 
opiate withdrawal (SW) in morphine-dependent rats (10-100 mg/kg for 6 days) (Ramos-
Miguel et al., 2011). Notably, cortical p-FADD mirrored the time course of morphine SW (12-
96 h; peak at 24 h) (Fig. 7B, left), which resulted in a striking correlation between p-FADD 
and the intensity of morphine abstinence (Fig. 7B, right). On the other hand, the 
involvement of α2-adrenoceptors in opiate addiction is well-known, and the stimulation of 
these inhibitory receptors induces anti-withdrawal effects in morphine-dependent animals 
and in human addicts. Interestingly, the inactivation of brain α2-adrenoceptors (EEDQ at 
SW12) (Fig. 7B, left) further enhanced morphine abstinence intensity and cortical p-FADD 
content at SW24 (Fig. 7B, right and middle panels). The disruption of ERK signalling (SL 327 
 
Role of Multifunctional FADD (Fas-Associated Death Domain) Adaptor in Drug Addiction 
 
211 
at SW4 and SW8) did not alter morphine abstinence at SW12, but did attenuate the 
behavioral syndrome at SW24 (Fig. 7B, left). ERK inhibition, however, did not prevent the 
up-regulation of p-FADD at SW12 and SW24 (Fig. 7B, middle panel). Taken together, these 
findings reveal that cortical p-FADD, mainly through an interaction with α2-adrenoceptors, 
plays a functional role in the behavioral expression of morphine abstinence in rats.  
Together, these studies indicate that relevant behavioral adaptations induced by repeated 
morphine exposure in rats correlate with an increased p-FADD/FADD ratio in the cerebral 
cortex, which strongly suggests that multifunctional FADD is involved in the complex 
molecular mechanisms of opiate-induced neuroplasticity. 
3.4 Regulation of apoptotic pathways and associated signalling in brains of opiate 
addicts: p-FADD and neuroplasticity 
Recent studies have investigated the role of Fas receptor, FADD adaptor and its 
phosphorylation, other pro- and anti-apoptotic proteins, and FADD-associated signalling 
pathways, in postmortem brains of long-term opiate addicts (García-Fuster et al., 2008b; 
Ramos-Miguel et al., 2009). The prefrontal cortex (Brodmann’s area 9, middle frontal gyrus; 
PFC/BA9) was the region selected for examination because it is directly related with the 
mesocorticolimbic dopaminergic system and the rewarding and addictive properties of 
opiates and other drugs of abuse. 
First, the hypothesis was tested that human opiate addiction is associated with an increased 
cell death in the brain (García-Fuster et al., 2008b). In a well-characterized cohort (n=48) of 
heroin or methadone abusers (including the assessment of opiates and metabolites in blood, 
urine, and hair samples), the content of Fas receptor in PFC/BA9 did not differ from that in 
age-, gender-, and postmortem delay-matched controls (Fig. 8A). In contrast, FADD adaptor 
was down-regulated in the same brain samples of short- and long-term opiate addicts (Fig. 
8A). Furthermore, initiator caspase-8 was not altered, but FLIPL content, a dominant 
inhibitor of caspase-8, was increased in long-term opiate addicts. 
 
Fig. 8. (A) Contents of Fas receptor aggregates, FADD adaptor, and p-FADD in the prefrontal 
cortex/Brodmann’s area 9 (PFC/BA 9; total homogenate samples) of short- and long-term 
opiate abusers. (B) Subcellular content (increases or decreases in cytosol and nucleus) of p-
FADD and CK1α in the PFC/BA9 of long-term (LT) opiate addicts. *At least p<0.05 versus 
matched controls. (Modified from García-Fuster et al., 2008b; Ramos-Miguel et al., 2009). 
 




Fig. 7. (A) FADD phosphorylation and expression of unconditioned morphine-induced 
psychomotor sensitization. Note that day 8 of the treatment corresponds to SW3 (see text). 
(B) FADD phosphorylation and intensity of spontaneous morphine abstinence syndrome. 
BL, baseline; SL327, an inhibitor of MEK in vivo; EEDQ, an alkylating of α2-adrenoceptors. 
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In the intrinsic mitochondrial pathway, pro-apoptotic Bax and AIF (apoptosis-inducing 
factor) were unchanged, cytochrome c (a potent caspase-3 activator) was reduced, and anti-
apoptotic Bcl-2 augmented in long-term opiate addicts. Importantly, the content of 
executioner caspase-3/active fragments and the pattern of cleavage of nuclear PARP-1 
(poly-(ADP-ribose)-polymerase-1), a hallmark of apoptosis, were very similar in opiate 
addicts and control subjects. 
Taken together, these findings indicate that the molecular machineries of canonical 
apoptotic pathways are not abnormally activated enough in the PFC/BA9 of opiate abusers 
to suggest higher rates of cell death in this brain region. Instead, the long-term adaptations 
of FADD and cytochrome c (down-regulation) and those of FLIPL and Bcl-2 (up-regulation) 
could be related to the induction of non-apoptotic actions including phenomena of 
neuroplasticity in brains of opiate addicts. 
Therefore, the role of p-FADD and FADD-associated signalling pathways involved in 
neuroplasticity was investigated (Ramos-Miguel et al., 2009) in the same cohort and brain 
region of opiate abusers (García-Fuster et al., 2008b). In these subjects, the content of 
monomeric, but not oligomeric, p-FADD was markedly increased in the PFC/BA9 of short- 
and long-term opiate abusers (Fig. 8A, total homogenate samples). At the subcellular level 
(PFC/BA9), long-term opiate addiction was associated with up-regulation of monomeric p-
FADD and down-regulation of oligomeric p-FADD in the nucleus (Fig. 8B). In the cytosol, in 
contrast, oligomeric p-FADD was increased (Fig. 8B). Along this line, CK1α, the enzyme that 
mediates p-FADD, was found co-localized with FADD in cytosol and nucleus (Fig. 8B). 
These findings appear to indicate that FADD is phosphorylated (and oligomerized) in the 
cytosol of cortical cells (PFC/BA9), and translocates to the nucleus, where it is 
disaggregated to monomers to develop its nuclear functions (see Fig. 3). 
In long-term opiate addicts, on the other hand, marked down-regulation of ERK1/2, 
JNK1/2 (c-Jun N-terminal Kinase), PEA-15 and Akt1 signalling were observed in the 
PFC/BA9 (total homogenate and subcellular compartments) (Ferrer-Alcón et al., 2004; 
Ramos-Miguel et al., 2009). Remarkably, down-regulation of ERK1/2 and Akt1 in the PFC of 
chronic opiate addicts could also play a major role in the induction of tolerance to opiate 
reward (Ramos-Miguel et al., 2009). A complex cross-talk between FADD/p-FADD and 
Akt1/PEA-15 and ERK1/2 signalling would take place in the brain to finally result in the 
induction of neuroplasticity without an abnormal rate of cell death in the PFC/BA9 of 
chronic opiate addicts (see Fig. 3). 
Taken together, the results of these studies (García-Fuster et al., 2008b; Ramos-Miguel et al., 
2009) clearly indicate that opiate addiction in humans is associated with an altered balance 
between p-FADD (content increased) and FADD (content decreased) in brain, which may 
favor the neuroplastic actions of FADD adaptor (ratio p-FADD/FADD: a 3.3-fold increase 
over matched controls). In fact, relevant roles of p-FADD in modulating morphine-induced 
behavioral plasticity have been demonstrated in the rat brain (see subheading 3.3.).  
4. Role of FADD adaptor in cocaine addiction 
Cocaine and/or its oxidative metabolites (e.g. norcocaine) can induce various forms of 
neurotoxicity (Büttner, 2011), including apoptotic effects in both cultured cells (Xiao et al., 
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2000; Cunha-Oliveira et al., 2008) and the developing brain (Novikova et al., 2005). 
However, the aberrant activation of several cell death mechanisms by cocaine, including 
those mediated by the Fas/FADD complex, in the adult rat brain remains inconclusive 
(Dietrich et al, 2005; García-Fuster et al., 2009). Nevertheless, self-exposure to cocaine in 
humans was recently shown to enhance the degradation of a DNA-repairing enzyme in the 
PFC/BA9 of long-term addicts, which is compatible with the induction of aberrant cell 
death by the psychostimulant (Álvaro-Bartolomé et al., 2011). 
4.1 Acute, chronic and withdrawal effects of cocaine on FADD and associated 
signalling in the brain 
Acute treatments of rats with cocaine (7.5-30 mg/kg) modulated FADD protein forms in 
brain cortex, increasing the content of FADD and moderately decreasing that of p-FADD 
with the lower doses (Fig. 9A) (García-Fuster et al., 2009; Álvaro-Bartolomé et al., 2011). In 
contrast to opiate and cannabinoid drugs, cortical FADD and p-FADD do not correlate 
after acute cocaine (Fig. 6C), suggesting that psychostimulants favours the expression of 
pro-apoptotic FADD form (increased). Acute cocaine increased FADD in all subcellular 
compartments where it was expressed, with the greater effects in the cytosol and  
nucleus (García-Fuster et al., 2009). Dopamine D2 receptors were involved in FADD 
activation by cocaine as pretreatment with raclopride, a D2-type receptor antagonist, fully 
prevented the acute cocaine-induced increase of FADD in rat brain cortex (Fig. 9B). 
Pretreatment with a D1-type receptor antagonist (SCH-23390) did not block the acute 
effect of cocaine on FADD (Fig. 9B). In fact, SCH-23390 by itself increased cortical FADD 
(Fig. 9B), an effect possibly mediated by its agonistic properties at 5-HT1c/2c receptors 
(García-Fuster et al., 2009). 
A non-contingent experimenter-administered regimen of chronic cocaine in rats (15 or 40 
mg/kg, for 6-7 days), known to induce behavioral sensitization, induced tachyphylaxis to 
the acute modulatory effect of the psychostimulant on cortical FADD (Fig. 9C). Cocaine 
withdrawal (1-7 days) was associated with a transient reduction in cortical FADD, which 
was significant 3 days after discontinuation of the chronic treatment (Fig. 9C) (García-Fuster 
et al., 2009; Álvaro-Bartolomé et al., 2011). It is worth noting that there was a positive 
correlation between FADD protein and the levels of FADD mRNA in rat brain cortex 
(r=0.43; n=29; p<0.05, see García-Fuster et al., 2009). 
Acute cocaine (20 mg/kg) stimulated p-Thr34 DARPP-32 (dopamine- and cAMP-
regulated phosphoprotein of 32 kDa) in rat brain cortex, consistent with the engagement 
of dopamine signalling. Chronic cocaine (40 mg/kg for 6 days) and cocaine withdrawal (3 
days), however, were not associated with activation of cortical p-DARPP-32 
(tachyphylaxis after the repeated treatment). Interestingly, chronic cocaine and 
abstinence, but not acute cocaine, increased the content of t-DARPP (a truncated 30 kDa 
isoform of DARPP-32 with striking anti-apoptotic actions; El-Rifai et al., 2002) in rat brain 
cortex. Moreover, acute cocaine, but not the chronic/abstinence treatments, stimulated 
Akt1 in rat brain cortex. Neither treatment with cocaine (acute, chronic, and abstinence) 
altered the basal stimulation of anti-apoptotic PEA-15 and pro-apoptotic JNK1/2 
signaling (Álvaro-Bartolomé et al., 2011). 
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In the intrinsic mitochondrial pathway, pro-apoptotic Bax and AIF (apoptosis-inducing 
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Fig. 9. (A) Acute dose-response effects of cocaine (7.5-30 mg/kg) on FADD and p-FADD in 
rat brain cortex. (B) FADD is modulated by acute cocaine (Coc, 7.5 mg/kg) through the 
activation of dopamine D2 receptors in rat cortex. Rac: raclopride (0.5 mg/kg), SCH: SCH-
23390 (0.5 mg/kg). (C) Non-contingent chronic cocaine (Chr, 15 mg/kg for 7 days) and 
spontaneous withdrawal (+SW) time course effects on cortical FADD and p-FADD. (D) 
Effects of spontaneous withdrawal (+SW) following contingent cocaine self-administration 
(Coc SA) on hippocampal FADD protein and mRNA. (E) Basal cortical differences in FADD 
and p-FADD in bred low-responder (bLR) and high-responder (bHR) rats. (F) Individual 
differences in locomotor response to novelty correlated (Pearson's r) with basal contents of 
FADD and p-FADD in rat cortex; non-parametric analysis (Spearman's ρ) also resulted in 
significant correlations for FADD (ρ=0.85; p<0.003; n=10) and p-FADD (ρ=-0.70; p<0.05; 
n=10) (open circle: bLR rats; closed circles: bHR rats). *At least p<0.05 versus control (C) or 
bLR rats. (Modified from García-Fuster et al., 2009, 2011; Álvaro-Bartolomé et al., 2011).  
It is unlikely that cocaine-induced up-regulation of pro-apoptotic FADD in rat brain (Fig. 
9A) could result in the induction of aberrant cell death. In fact, neither acute and chronic 
cocaine treatments nor cocaine spontaneous withdrawal altered the content of Fas receptor 
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forms or mitochondrial cytochrome c (a potent caspase-3 activator) and AIF (a 
mitochondrial mediator of caspase-independent apoptosis) in rat cortex (Álvaro-Bartolomé 
et al., 2011). Moreover, none of these cocaine treatments altered the pattern of cleavage of 
nuclear PARP-1 in rat brain cortex (García-Fuster et al., 2009; Álvaro-Bartolomé et al., 2011). 
A recent study has examined how a contingent extended daily access to cocaine self-
administration impacts the hippocampus at the cellular and molecular levels, and how these 
alterations can change over the course of cocaine withdrawal (García-Fuster et al., 2011). 
This animal model has good validity in that it results in the escalation of drug intake (as 
controlled by the animal, see Ahmed and Koob, 1998) and in cognitive deficits (Briand et al., 
2008) similar to those seen in human addicts. Moreover, hippocampal plasticity likely plays 
an important role in addiction-related behaviors. For example, suppression of hippocampal 
neurogenesis enhanced resistance to extinction of drug-seeking behavior (Noonan et al., 
2010). The results of this study indicated that 5-hour of extended daily access to cocaine for 
14 days elicits a profound increase in drug intake from the first self-administration session 
to the last (García-Fuster et al., 2011), providing a model to study the hippocampal 
adaptations associated with cocaine withdrawal after abuse of the psychostimulant. This 
cocaine paradigm led to alterations of hippocampal cell fate regulation (in various 
hippocampal subregions) during the course of withdrawal (1, 14 and 28 days) with 
significant changes observed at 14 days (García-Fuster et al., 2011). Notably, FADD adaptor 
(protein and mRNA; Fig. 9D) was increased in the hippocampus of rats with impaired cell 
proliferation rates (Ki-67+ mitotic progenitor cells and NeuroD+ neural progenitor cells). 
The increase in hippocampal FADD (14 days of cocaine withdrawal) did not parallel 
changes in apoptotic cell death, as measured by cleavage of nuclear PARP-1 (García-Fuster 
et al., 2011). These data suggest that FADD adaptor is an important hippocampal cell fate 
regulator during cocaine withdrawal in rats. 
4.2 Relevance of FADD in novelty-seeking behaviour and cocaine abuse 
Selectively breeding for divergence in locomotor reactivity to a novel environment (bred 
high-responder (bHR) and low-responder (bLR) lines of Sprague-Dawley rats) has been 
shown to display reliable differences across multiple behavioural and neurochemical 
dimensions (Stead et al., 2006). For example, bHR compared to bLR rats have shown an 
increased behavioural sensitization to cocaine (García-Fuster et al., 2010) and a greater initial 
propensity to self-administer cocaine (Davis et al., 2008). Interestingly, bHR and bLR rats 
showed significant basal differences in cortical FADD (higher content in bHR) and p-FADD 
(lower content in bHR) (Fig. 9E) (García-Fuster et al., 2009). However, bHR/bLR rats 
showed similar levels of basal nuclear PARP-1 cleavage, indicating similar rates of basal 
induction of cell death in the cortex (García-Fuster et al., 2009). Moreover, locomotion in a 
novel environment (bLR versus bHR) correlated with the basal content of cortical FADD 
(positive relation) and p-FADD (inverse relation) (Fig. 9F, n=10). Similarly to the acute, 
chronic and withdrawal cocaine effects observed in commercially purchased Sprague-
Dawley rats (see Fig. 9A/C), the basal differences observed between bHR and bLR rats were 
maintained post-cocaine (i.e., increased FADD after acute cocaine with a reversal following 
3 days of withdrawal) for both phenotypes (García-Fuster et al., 2009). These results suggest 
that FADD signalling could represent a molecular correlate for the bHR and/or bLR 
phenotype and therefore the initial propensity to initiate cocaine use (Belin et al., 2008). 
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4.3 Regulation of apoptotic pathways and associated signalling in brains of cocaine 
addicts: Increased degradation of nuclear PARP-1 
In a recent study (Álvaro-Bartolomé et al., 2011), the hypothesis was tested that cocaine 
addiction in humans results in abnormal activation of canonical (extrinsic and intrinsic) 
apoptotic pathways leading to increased cell death in the brain (Fig. 10). 
 
Fig. 10. (A) Contents of apoptotic proteins of the intrinsic (Fas receptor, FADD adaptor and 
p-FADD) and intrinsic (cytochrome c, caspase-3 and AIF) pathways, as well as the cleavage 
of nuclear PARP-1 in the prefrontal cortex/Brodmann’s area 9 (PFC/BA9; total homogenate 
samples) of cocaine abusers. (B) Subcellular content of AIF and PARP-1 (F1: cytosol; F2: 
membranes; F3: nucleus) in the PFC/BA9 of a representative chronic cocaine addict. *At 
least p<0.05 versus matched controls. (Modified from Álvaro-Bartolomé et al., 2011). 
In a small (n=10) and well-characterized cohort of “pure” cocaine abusers (including the 
assessment of cocaine and metabolites in blood, urine, and hair samples), Fas aggregates 
and FADD adaptor were down-regulated in the PFC/BA9 (Fig. 10A), which was associated 
with a modest increase in p-FADD/FADD ratio. Moreover, mitochondrial cytochrome c was 
also reduced, but not caspase-3 or AIF (Fig. 10A) (AIF, however, was increased in the 
nuclear fraction, Fig. 10B). Importantly, the proteolytic cleavage of nuclear PARP-1 (ratio of 
85 kDa fragment to 116 kDa PARP-1) was augmented in the same brain samples of cocaine 
addicts (Fig. 10A), including an increase in the cortical nuclear fraction (Fig. 10B). In chronic 
cocaine abusers (PFC/BA9), several signalling molecules associated with cocaine/dopamine 
and/or apoptotic pathways (Akt1, PEA-15, JNK1/2) were found unaltered, with the 
exception of DARPP-32 and anti-apoptotic t-DARPP whose contents were decreased. 
These findings indicate that cocaine addiction in humans is not associated with abnormal 
upregulation of major components of the extrinsic and intrinsic apoptotic machineries in the 
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PFC/BA9. On the contrary, the downregulation of Fas–FADD receptor complex and 
cytochrome c could reflect the induction of contraregulatory adaptations or non-apoptotic 
(neuroplastic) actions induced by the repeated abuse of the psychostimulant. In any case, 
the enhanced degradation of nuclear PARP-1 (Fig. 10B), a hallmark of apoptosis, clearly 
indicates the possibility of aberrant cell death in brains of chronic cocaine addicts. The 
molecular mechanism appears to involve the induction of oxidative stress by cocaine 
metabolites (norcocaine and derivatives) and the activation of the mitochondrial death 
effector AIF after its translocation to the nucleus (Fig. 10B) (Álvaro-Bartolomé et al., 2011), 
where it interact with PARP-1 and induces chromatin condensation and large-scale DNA 
fragmentation (Strosznajder et al., 2010). This particular (caspase-independent) cell death 
subroutine, involving the nuclear interaction of AIF and PARP-1, has been named 
parthanatos and has a role in multiple pathophysiological conditions (Galluzzi et al., 2011), 
which could include the induction of neurotoxic effects in the brain of human cocaine 
addicts (see Fig. 3). 
5. Role of FADD adaptor in the neurobiology of the cannabinoid system  
Among the many effects induced by natural and synthetic cannabinoids (Pertwee, 1997), 
their beneficial or deleterious actions on neuronal survival remain a controversial topic 
(Guzmán et al., 2002; Álvaro-Bartolomé et al., 2010). Although cannabinoids can induce pro-
apoptotic activity in several cellular models (Maccarrone and Finazzi-Agró, 2003), recent 
evidence also demonstrates that these compounds, acting through cannabinoid CB1 
(Aguado et al., 2007) or CB2 receptors (Viscomi et al., 2009) can also protect neurons from 
death. It is conceivable therefore that the neuroprotection induced by some cannabinoids in 
vivo could be the result of a favorable balance between the relative activation of anti- and 
pro-apoptotic signalling pathways in the brain. 
5.1 Regulation of basal Fas/FADD complex by cannabinoid receptors: Pro-apoptotic 
CB1 receptor tone 
CB1 receptors are highly expressed in the CNS (Howlett et al., 2002) and display a high level 
of constitutive activity (Gifford and Ashby, 1996). This contrasts with brain CB2 receptors, 
which pharmacological activation has been questioned in conscious rats (Chin et al., 2008) 
and, therefore, the presence of any receptor constitutive activity is uncertain. Similarly to δ-
opioid receptors (see Fig. 4; García-Fuster et al., 2007b), the remarkable constitutive activity 
of CB1 receptors was also postulated to be involved in the tonic control of pro-apoptotic 
Fas/FADD complex. This possibility was investigated using gene-targeted mice lacking CB1 
or CB2 receptors (Álvaro-Bartolomé et al., 2010). 
In brain regions of CB1-KO mice (cerebral cortex, corpus striatum and cerebellum), the 
content of Fas receptor and/or FADD was reduced (Fig. 11A), suggesting that 
endocannabinoids acting on CB1 receptors stimulate the expression of pro-apoptotic 
Fas/FADD complex. In these mice, non-apoptotic p-FADD and p-FADD/FADD ratio are 
increased (Fig. 11A), indicating that CB1 receptors tonically inhibit the phosphorylation of 
brain FADD, which could also favour the induction of pro-apoptotic actions. In brain 
regions of CB2-KO mice, in contrast, the changes of Fas receptor, FADD and p-FADD 
(somehow opposite to those observed in CB1-KO mice) did not indicate that CB2 receptors 
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cytochrome c could reflect the induction of contraregulatory adaptations or non-apoptotic 
(neuroplastic) actions induced by the repeated abuse of the psychostimulant. In any case, 
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metabolites (norcocaine and derivatives) and the activation of the mitochondrial death 
effector AIF after its translocation to the nucleus (Fig. 10B) (Álvaro-Bartolomé et al., 2011), 
where it interact with PARP-1 and induces chromatin condensation and large-scale DNA 
fragmentation (Strosznajder et al., 2010). This particular (caspase-independent) cell death 
subroutine, involving the nuclear interaction of AIF and PARP-1, has been named 
parthanatos and has a role in multiple pathophysiological conditions (Galluzzi et al., 2011), 
which could include the induction of neurotoxic effects in the brain of human cocaine 
addicts (see Fig. 3). 
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evidence also demonstrates that these compounds, acting through cannabinoid CB1 
(Aguado et al., 2007) or CB2 receptors (Viscomi et al., 2009) can also protect neurons from 
death. It is conceivable therefore that the neuroprotection induced by some cannabinoids in 
vivo could be the result of a favorable balance between the relative activation of anti- and 
pro-apoptotic signalling pathways in the brain. 
5.1 Regulation of basal Fas/FADD complex by cannabinoid receptors: Pro-apoptotic 
CB1 receptor tone 
CB1 receptors are highly expressed in the CNS (Howlett et al., 2002) and display a high level 
of constitutive activity (Gifford and Ashby, 1996). This contrasts with brain CB2 receptors, 
which pharmacological activation has been questioned in conscious rats (Chin et al., 2008) 
and, therefore, the presence of any receptor constitutive activity is uncertain. Similarly to δ-
opioid receptors (see Fig. 4; García-Fuster et al., 2007b), the remarkable constitutive activity 
of CB1 receptors was also postulated to be involved in the tonic control of pro-apoptotic 
Fas/FADD complex. This possibility was investigated using gene-targeted mice lacking CB1 
or CB2 receptors (Álvaro-Bartolomé et al., 2010). 
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content of Fas receptor and/or FADD was reduced (Fig. 11A), suggesting that 
endocannabinoids acting on CB1 receptors stimulate the expression of pro-apoptotic 
Fas/FADD complex. In these mice, non-apoptotic p-FADD and p-FADD/FADD ratio are 
increased (Fig. 11A), indicating that CB1 receptors tonically inhibit the phosphorylation of 
brain FADD, which could also favour the induction of pro-apoptotic actions. In brain 
regions of CB2-KO mice, in contrast, the changes of Fas receptor, FADD and p-FADD 
(somehow opposite to those observed in CB1-KO mice) did not indicate that CB2 receptors 
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are involved in the tonic regulation of Fas/FADD complex. The alterations of Fas/FADD in 
brains of CB1 and CB2 receptors KO mice did not appear to result in an increased cell death 
because the pattern of cleavage of nuclear PARP-1 was very similar to that measured in WT 
mice (Álvaro-Bartolomé et al., 2010). 
 
Fig. 11. (A) Fas receptor aggregates, FADD adaptor, and p-FADD in the cerebral cortex of 
WT mice and cannabinoid CB1 receptor KO mice. (B) Acute (dose-response) effects of the 
CB1 receptor agonist WIN55212-2 on the content of FADD and p-FADD in mouse brain 
cortex. (C) Acute (Ac, 8 mg/kg), chronic (Chr, 1-8 mg/kg, increasing doses for 5 days) and 
withdrawal effects (SR, 10 mg/kg; precipitated with the antagonist SR141716A or 
rimonabant) of WIN55212-2 on FADD and p-FADD content in mouse brain cortex. (D) 
Effects of WIN55212-2 (8 mg/kg) on the content of FADD and p-FADD at the subcellular 
level (F1: cytosol; F2: membranes; F3: nucleus; F4: cytoskeleton). *At least p<0.05 versus WT 
or control (C). (Modified from Álvaro-Bartolomé et al., 2010). 
Therefore, CB1 receptors appear to exert a tonic activation of Fas/FADD complex in brain 
(Fig. 11A) that is opposite to that induced by δ-opioid receptors (inhibitory tonic control; 
Fig. 4). Given the interactions between cannabinoids and opiates (Bushlin et al., 2010), and 
particularly between CB1 receptors and δ-opioid receptors (Urigüen et al., 2005), the 
opposite tonic control of these inhibitory receptors on pro-apoptotic Fas/FADD complex 
could be of relevance in drug mechanisms leading to neuronal cell death or 
neuroprotection. 
5.2 Acute, chronic and withdrawal effects of cannabinoid drugs on FADD and 
associated signalling in the brain 
Acute treatment of mice with the CB1 receptor agonist WIN55212-2 (0.5, 1 and 8 mg/kg) 
did not alter the content of Fas receptor forms in the cerebral cortex. However, a low dose 
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of WIN55212-2 (0.5 mg/kg) increased FADD, whereas higher doses of the agonist (1 and 8 
mg/kg) decreased FADD content in mouse brain cortex (Fig. 11B). WIN55212-2 also 
induced bell-shaped dose effects on p-FADD, but in the opposite direction (Fig. 11B). 
Pretreatment of mice with the antagonist rimonabant prevented the opposite effects of 
WIN55212-2 on FADD and p-FADD, indicating a CB1 receptor-related mechanism. At the 
subcellular level, WIN55212-2 increased p-FADD in the cytosol and membranes, and to a 
lesser extent in the nucleus (Fig. 11D right). In contrast, WIN55212-2 decreased FADD in 
membranes and nucleus, and increased its content in cytosol (Fig. 11D left). WIN55212-2 
also increased CK1α in cytosol, which was coincident with the marked enhancement of p-
FADD in this compartment (Fig. 11D right). In marked contrast to the activation CB1 
receptors, high doses of the CB2 receptor agonist JWH133 were not associated with 
significant changes of Fas receptor forms, FADD or p-FADD in mouse brain cortex 
(Álvaro-Bartolomé et al., 2010). 
These data indicate that the activation of CB1 receptors decreases (lower dose) or increases 
(higher doses) the ratio of cortical p-FADD/FADD (an index of non-apoptotic activity). 
Interestingly, and as observed for opiate drugs, acute WIN55212-2 treatment induced 
opposite changes on p-FADD and FADD (Fig. 6B), and this interconversion of FADD forms 
associated with the activation of CB1 receptors could be important in the actions of 
cannabinoids in the brain. For example and consistent with the findings observed in the 
cerebral cortex of CB1 receptor KO mice (Fig. 11A: decreased FADD and increased p-FADD), 
a low dose of WIN55212-2 (0.5 mg/kg) increased FADD and decreased p-FADD in mouse 
brain cortex (Fig. 11B). This opposite regulation of FADD forms is also consistent with the 
existence of a pro-apoptotic CB1 receptor tone. However, the selective CB1 receptor 
antagonist/inverse agonist rimonabant (10 mg/kg) did not alter FADD or p-FADD in brains 
of mice, suggesting that the receptor tonic control on this system is moderate (Álvaro-
Bartolomé et al., 2010). 
It is noteworthy that chronic WIN55212-2 administration (1-8 mg/kg for 5 days) also 
resulted in down-regulation of FADD and up-regulation of p-FADD in mouse brain cortex 
(Fig. 11C), which indicates a sustained attenuation of apoptotic signalling in spite of the 
induction of some tolerance (tachyphylaxis) upon the repeated stimulation of CB1 receptors. 
Rimonabant-precipitated WIN55212-2 withdrawal did not cause a rebound of FADD or p-
FADD over control values (Fig. 11C). Along this line, the acute and chronic treatments of 
mice with WIN55212-2, as well as rimonabant-precipitated withdrawal, did not alter the 
contents of mitochondrial cytochrome c, AIF, or the cleavage of nuclear PARP-1 in the 
cerebral cortex. These negative findings further discount the induction of cell death after the 
activation of CB1 receptors in the mouse brain. 
On the other hand, acute, but not chronic, treatment with WIN55212-2 markedly stimulated 
the activation of anti-apoptotic ERK1/2 and Akt1/PEA-15, as well as pro-apoptotic JNK1/2 
and p38 MAPK in the mouse cerebral cortex. This suggests that the acute neuroprotection in 
vivo induced by some cannabinoids could be the result of a favorable balance between the 
relative activation of anti- and pro-apoptotic signalling pathways. In contrast to FADD and 
p-FADD, the lack of a sustained stimulation of anti- and pro-apoptotic cascades upon 
chronic WIN55212-2 treatment probably reflects the rapid induction of CB1 receptor 
desensitization in the regulation of these systems (Álvaro-Bartolomé et al., 2010). 
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The current findings indicate that the chronic stimulation of CB1 receptors is associated with 
a marked downregulation of brain FADD, a major pro-apoptotic molecule of the extrinsic 
cell death pathway. This may represent a relevant molecular mechanism to explain, in part, 
the neuroprotective effects induced by natural and synthetic cannabinoids (Guzmán et al., 
2002). In addition, the chronic stimulation of CB1 receptors is also associated with up-
regulation of p-FADD, the protein form that mediates non-apoptotic actions including brain 
plasticity (see Fig. 3). The link between CB1 receptors and the multifunctional FADD 
adaptor provides new insights into the complex neurobiology of the cannabinoid system. 
6. General conclusions 
The modulation of FADD adaptor by drugs of abuse is a new and relevant molecular 
process in the complex neurobiology of addictions. The regulation of FADD and associated 
signalling by opiate drugs (heroin/methadone) and the psychostimulant cocaine can lead to 
neurotoxicity and/or neuroplasticity in brains of human addicts. The ratio of p-Ser194 
FADD (anti-apoptotic form) to FADD (pro-apoptotic form) appears to represent a novel 
marker of cortical plasticity. 
In the prefrontal cortex of long-term opiate addicts, the observed down-regulation of FADD 
(i.e. attenuation of Fas signals), the up-regulation of FLIPL and Bcl-2 (greater anti-apoptotic 
effects), the increased Bcl-2/Bax ratio (positive balance for cell survival), the reduction of 
cytochrome c (lesser activation of other pro-apoptotic factors), the lack of abnormal caspase-
3 activation, and the normal pattern of nuclear PARP-1 cleavage (Fig. 3) clearly indicate the 
absence of aberrant cell death. In contrast, p-FADD and p-FADD/FADD ratio are increased 
in brains of opiate addicts, which suggests the induction of neuroplastic actions. In fact, 
other studies in laboratory rats have shown that the behavioural response to morphine-
induced psychomotor sensitization, as well as the severity of opiate abstinence syndrome 
(two well-known neuroplastic responses) correlated with increased p-FADD and reduced 
FADD in the brain, which further supports the role of p-FADD/FADD ratio as a marker of 
neuronal plasticity. 
In the prefrontal cortex of long-term cocaine addicts, Fas/FADD receptor complex and 
mitochrondrial cytochrome c are down-regulated, suggesting contraregulatory adaptations 
or non-apoptotic actions (Fig. 3). Importantly, however, the degradation of nuclear PARP-1 
is increased in the absence of caspase-3 activation. This type of caspase-independent cell 
death (named parthanatos) involves the induction of oxidative stress by cocaine metabolites 
(norcocaine and derivatives) and the nuclear translocation of the mitochondrial death 
effector AIF (Fig. 3). Therefore, cocaine addiction in humans appears to be associated with 
aberrant cell death in the brain. However, p-FADD/FADD ratio is also increased which also 
suggest the induction of neuroplastic changes in brains of cocaine addicts. In fact, other 
studies in laboratory rats have shown that p-FADD and FADD in the cortex represent a 
molecular correlate of the initial brain plasticity that might predispose to some facets of 
addictive-like behaviours such as locomotor response to novelty. 
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effector AIF (Fig. 3). Therefore, cocaine addiction in humans appears to be associated with 
aberrant cell death in the brain. However, p-FADD/FADD ratio is also increased which also 
suggest the induction of neuroplastic changes in brains of cocaine addicts. In fact, other 
studies in laboratory rats have shown that p-FADD and FADD in the cortex represent a 
molecular correlate of the initial brain plasticity that might predispose to some facets of 
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1. Introduction 
1.1 Drug and polydrug use among adolescents 
The 2010 Monitoring the Future survey conducted by the US government raises concerns 
about an increase in drug use among teenagers, particularly those of a younger age. A 
similar trend has been reflected by European surveys, such as the 2010 Annual report on the 
state of the drugs problem in Europe, EMCDDA. According to this study, commissioned by 
the European Council, the use of multiple substances — polydrug use — is widespread and 
represents a major challenge. A recent survey by the Spanish government (EDADES 
2009/2010) revealed that approximately 50% of drug users consumed two or more 
substances simultaneously. The objective of users is to increase or reverse the effects of the 
different drugs taken, but greater health risks and problems and a poor treatment response 
are also inherent in polydrug consumption. Almost all patterns of polydrug use include 
alcohol, and the use of amphetamines or ecstasy among frequent or heavy alcohol 
consumers is much higher than the average. A study by the Spanish government (Encuesta 
Estatal sobre uso de drogas en estudiantes de enseñanzas secundarias, ESTUDES, 2008) 
revealed that Spanish students between 14-18 years old who used drugs generally 
consumed more than one drug at the same time. 96.2% of students who had taken ecstasy in 
the previous year had simultaneously consumed alcohol and 86.1% had simultaneously 
consumed cannabis. An association between consumption of stimulants and hallucinogen 
drugs was also reported. For example, among students who had used ecstasy in the 
previous year, 71.4% had also consumed cocaine, while 38.5% of those who had used 
cocaine in the same period had also consumed ecstasy.  
2. The adolescent brain 
Adolescence is the period of gradual physiological, cognitive, behavioural and psychosocial 
transition from childhood to adulthood (Pickles et al., 1998) during which individuals 
experience physical changes, new interests, greater independence and heightened 
responsibility.  Since adolescence is a process, it is difficult to characterize its ontogenetic 
time course, and no single event signals its onset or termination. In humans, adolescence is 
often considered to begin with the onset of the biological changes associated with puberty 
(the period during which an individual becomes sexually mature), although the timing of 
puberty within the adolescent period varies notably among humans. Adolescence ends 
when the individual assumes adult social roles, with a change in the sleep pattern having 
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been proposed as a physiological marker of its termination (Abbott, 2005). The adolescent 
age span in humans is commonly considered to be from 12 to 18 years, although the entire 
second decade is sometimes considered adolescence, with up to 25 years being considered 
late adolescence (Baumrind, 1987).  
Adolescent subjects exhibit certain characteristic behaviours (some of which are common 
among adolescents across species), including hyperphagia, shorter periods of sleep, 
increases in peer-directed social interactions and affiliation with peers, an increase in the 
number of conflicts with parents, egocentrism, a lack of ‘common sense’ in decision-making, 
rigidity in reasoning, impulsivity, including a preference for actions that offer immediate 
rewards (cognitive impulsivity), reduced self-control, enhanced novelty-seeking and risk-
taking behaviours (Spear, 2011a; Sturman & Moghaddam, 2011). All of these behaviours can 
lead to a higher incidence of risky behaviours such as misconduct at school, drink driving, 
unsafe sex, use of illegal drugs, and antisocial behaviours (Doremus-Fitzwater et al., 2010; 
Eaton et al., 2010; Spear, 2011b). Although cognitive control improves throughout 
adolescence (Luna et al., 2010), youths show differences in cognitive strategies in relation to 
adults. According to the “fuzzy trace theory” adolescents process the risk and benefits of 
choices more explicitly than adults, which, paradoxically, leads to greater risk-taking (Rivers 
et al., 2008). The characteristic irresponsibility of adolescents may be due to differences in 
the way in which they experience risk and reward, especially under conditions of 
heightened emotional arousal (Sturman & Moghaddam, 2011). Thus, the risk-taking 
behaviour of adolescents is probably related to the fact that their decision-making capacity 
is more vulnerable to disruption by stress. Adolescence is generally considered to be a 
stressful stage of life, and individuals are more likely to perceive events as stressful at this 
age, with adolescents exhibiting higher rates of depressed mood, sleep problems, emotional 
instability, anxiety and self-consciousness (Buchanan et al., 1992). Moreover, some aspects of 
neurobehavioural and hormonal responses to stressors also vary when adolescents are 
compared to younger or older individuals (Allen & Matthews, 1997). Similarly, behavioural 
experiments in laboratory animals have revealed that adolescents are more disrupted by 
stressors than younger or older counterparts and that they differ behaviourally and 
physiologically in their response to stressors when compared to animals of other ages 
(Buwalda et al., 2011; Stone & Quartermain, 1998; Vázquez, 1998). For example, the rise in 
plasma corticosterone levels induced by restraint stress is prolonged in adolescent rats in 
comparison with adult animals. Moreover, while adult male rats, which are repeatedly 
exposed to daily restraint stress, show a clear habituation in their neuroendocrine response, 
adolescent male rats actually exhibit a facilitation of this response (Romeo, 2010). 
The characteristic behaviour of adolescence can be explained in neurobiological terms 
(Brenhouse & Andersen, 2011; Casey et al., 2011; Sturman & Moghaddam, 2011). Indeed, the 
features of an adolescent brain predispose individuals to behaving in the way referred to 
above. Maturational alterations of the brain contribute to these age-specific behavioural 
characteristics, including the increase in risk-taking and propensity to use drugs of abuse 
(Doremus-Fitzwater et al., 2010). Recent research has demonstrated the importance of 
gonadal hormones for neurobehavioural maturation during adolescence in laboratory 
animals and an association between gonadal hormones and adolescent behaviour/mood in 
humans (see Vigil et al., 2011, for review). Adolescence represents a stage of development of 
the nervous system (as does embryonic development) in which steroid hormones trigger 
various organizational phenomena related to structural brain circuit remodelling: 
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myelination, apoptosis, neural pruning, and dendritic spine remodelling, thus determining 
the adult behavioural response to steroids or sensory stimuli (Vigil et al., 2011).  
The adolescent brain undergoes dramatic changes in gross morphology. During this phase 
there is a massive loss of gray matter and synapses in neocortical brain regions (Gogtay et 
al., 2004), and the most characteristic ontogenetic change, which occurs across a variety of 
species, is an alteration of the prefrontal cortex. Throughout human adolescence there is a 
marked increase in hemispheric asymmetry and in the degree to which the two cerebral 
hemispheres can process information independently (Merola & Liederman, 1985). In the 
primate cortex, the density of receptors of different neurotransmitter systems (dopamine, 
serotonine, acetylcholine, and GABA) decreases as adolescence progresses (Lidow et al., 
1991; Brenhouse & Andersen, 2011). Most of the synapses that undergo pruning during 
adolescence are excitatory, which results in a decline in N-methyl-D-aspartate (NMDA) 
receptors and the extension of glutaminergic excitatory stimulation to the cortex (Insel et al., 
1990). There is a body of evidence to show that the balance of excitatory and inhibitory 
neurotransmission varies between adolescents and adults, suggesting that the increased 
inhibition associated with development of the prefrontal cortex promotes greater neural 
coordination (Sturman & Moghaddam, 2011). 
Maturational changes are also evident during adolescence in limbic regions such as the 
hippocampus (Insel et al., 1990; Wolfer and Lipp, 1995), and gray matter reductions also take 
place in the striatum and other subcortical structures (Sowell et al., 2002). Conversely, white 
matter increases in cortical and subcortical fiber tracts (Paus et al., 2001) and in circuits 
connecting the amygdala and striatum with the prefrontal cortex (Asato et al 2010). A decrease 
is observed in glutamate receptors in the hippocampus (Insel et al., 1990) and DA receptors in 
the striatum (Seeman et al., 1987; Teicher et al, 1995). Cannabinoid binding peaks in the limbic 
forebrain of rats during adolescence before declining to adult levels (Rodriguez de Fonseca et 
al., 1993). Experimental evidence supports a shift during adolescence from a relative balance 
between subcortical and cortical DA systems toward a greater predominance of cortical DA. In 
contrast to this enhanced DA tone in the prefrontal cortex during adolescence, DA activity in 
the accumbens and other subcortical DA terminal regions seems to be less noticeable in 
adolescents than in adults (Andersen & Gazzara, 1993). Basal levels of synaptic DA are lower 
during this phase of development, although adolescents show a greater and faster increase in 
drug-induced DA release (Badanich et al. 2006; Laviola et al. 2001). Consistent with this, 
adolescents are generally subject to a less positive impact from stimuli with moderate to low 
incentive value, and thus seek additional appetitive reinforcers (Spear, 2000).  
Neuroimaging studies have shown variations in human adolescent functional activity in 
different forebrain regions, including the amygdala, orbitofrontal cortex and striatum (Bjork 
et al., 2010). For example, the amygdala and accumbens of adolescents exhibit more activity 
than those of adults (Ernst et al., 2002). Similarly, in comparison to adults, adolescents show 
a lower response to reward in the lateral orbitofrontal cortex and a higher activity in the 
nucleus accumbens (Galvan et al., 2006). Neural coordination within and between brain 
regions as well as processing efficiency are reduced in adolescents due to a less-effective 
information transfer between regions, incomplete myelination, and imbalances in neuronal 
inhibition/excitation within critical brain regions (Sturman & Moghaddan, 2011). Human 
and animal studies have revealed a differential development of subcortical limbic systems 
related to top-down control systems during adolescent brain development, with subcortical 
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forebrain of rats during adolescence before declining to adult levels (Rodriguez de Fonseca et 
al., 1993). Experimental evidence supports a shift during adolescence from a relative balance 
between subcortical and cortical DA systems toward a greater predominance of cortical DA. In 
contrast to this enhanced DA tone in the prefrontal cortex during adolescence, DA activity in 
the accumbens and other subcortical DA terminal regions seems to be less noticeable in 
adolescents than in adults (Andersen & Gazzara, 1993). Basal levels of synaptic DA are lower 
during this phase of development, although adolescents show a greater and faster increase in 
drug-induced DA release (Badanich et al. 2006; Laviola et al. 2001). Consistent with this, 
adolescents are generally subject to a less positive impact from stimuli with moderate to low 
incentive value, and thus seek additional appetitive reinforcers (Spear, 2000).  
Neuroimaging studies have shown variations in human adolescent functional activity in 
different forebrain regions, including the amygdala, orbitofrontal cortex and striatum (Bjork 
et al., 2010). For example, the amygdala and accumbens of adolescents exhibit more activity 
than those of adults (Ernst et al., 2002). Similarly, in comparison to adults, adolescents show 
a lower response to reward in the lateral orbitofrontal cortex and a higher activity in the 
nucleus accumbens (Galvan et al., 2006). Neural coordination within and between brain 
regions as well as processing efficiency are reduced in adolescents due to a less-effective 
information transfer between regions, incomplete myelination, and imbalances in neuronal 
inhibition/excitation within critical brain regions (Sturman & Moghaddan, 2011). Human 
and animal studies have revealed a differential development of subcortical limbic systems 
related to top-down control systems during adolescent brain development, with subcortical 
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limbic systems developing earlier than control systems. It has been proposed that the 
mechanisms underlying adolescent changes in behaviour (impulsiveness, risky choices, 
drug taking, etc.) could underlie an imbalance between an increased sensitivity to 
motivational cues and immature cognitive control (Casey et al., 2011). In summary, 
immature neuronal processing in the prefrontal cortex and other cortical and subcortical 
regions, and their interaction, lead to a behaviour that is biased toward risk and emotional 
reactivity during the adolescent period (Sturman & Moghaddan, 2011). 
 
Fig. 1. Neural circuit involved in motivated behaviour. Thick lines represent hyperactive 
brain areas or connections and faint and dashed lines represent brain areas that are more 
hypoactive in adolescent subjects than in adults. 
The adolescent brain operates in a promotivational state due to the combination of three 
factors: 
a. limited inhibitory capacity and poor regulatory control (due to the lack of cortical 
maturation)  
b. DA hyperactivity in the nucleus accumbens when processing appetitive stimuli 
c. Amygdala hyperactivity, which explains affective intensity and liability, and a weaker 
harm-avoidance system (Ernst et al., 2009). 
The relatively early development of bottom-up limbic regions (nucleus accumbens and 
amygdala), along with an immaturity of top-down regulatory systems (PFC), biases behavior 
toward risk-taking, risk-seeking, impulsive choice, sensation-seeking and novelty preference. 
3. Effects of drugs on adolescents 
In addition to increases in sensation- and novelty-seeking, drug use is more common during 
adolescence (2010 Annual report on the state of the drugs problem in Europe, EMCDDA; 
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Doremus-Fitzwater et al., 2010; Spear, 2011b). Youngsters differ from adults in their 
response to a variety of drugs (Schramm-Sapyta et al., 2009). These ontogenetic variations in 
drug responsiveness may be related with age differences in pharmacokinetics, particularly 
with respect to the functioning of the neural substrates upon which these drugs act, and also 
with social enhancement. As discussed previously, the neural systems involved in the 
effects exerted by drugs (mesolimbic DA system) differ considerably between adolescents 
and adults. These ontogenetic differences in drug responsiveness may have significant 
consequences for adolescents, who exhibit a reduced sensitivity to various drugs of abuse. 
This insensitivity can promote greater use per occasion in relation to more mature 
individuals (Schramm-Sapyta et al., 2009). After peer substance use, the next most powerful 
predictor of adolescent alcohol and drug use is perceived stress (Wagner et al., 1999). In 
animal models, stress has been shown to increase the rewarding effects of drugs of abuse 
(Piazza & LeMoal, 1998; Ribeiro Do Couto et al., 2006). On the other hand, experimental data 
suggest that drugs of abuse induce stronger effects in adolescents than in adults, although 
the literature is not conclusive regarding these differences (for review see Schramm-Sapyta 
et al., 2009). The developmental stage of adolescence can promote early experimentation 
with drugs, as addictive substances are generally more rewarding and less aversive 
(Schramm-Sapyta et al., 2009).  
Moreover, adolescent substance use disrupts the normal development of an adolescent 
brain. Exposure to drugs of abuse can induce neurobehavioural, neurochemical and 
neuroendocrinal effects in the adolescent rat brain, thereby affecting the growth process and 
systems involved in plasticity and cognition (Jain & Balhara, 2010). Since adolescents 
undergo structural and functional dynamic changes in brain areas implicated in the 
reinforcing properties of drugs of abuse (prefrontal cortex and ventral striatum) and habit 
formation (dorsal striatum), drug-taking during this period could increase susceptibility to 
drug dependence, although there is a lack of studies that demonstrate causality.  
4. Animal models of drug addiction 
The use of animal models to study drug addiction has the advantage of experimental control 
of variables (age of initial exposure, drug, dose, duration, timing of exposure, etc.) and has 
provided much valuable information. The main drawback to animal studies is that no 
model completely reproduces all the stages in the development of drug addiction. Results 
obtained with multiple behavioural and neurobiological models are necessary to achieve a 
deeper understanding of this disorder (Ahmed, 2010; Belin et al. 2010; Sanchis-Segura & 
Spanagel, 2006; Schramm-Sapyta et al., 2009; Shippenberg & Koob, 2002; Weiss, 2010). 
There are several animal models with a high predictive value, though most studies are 
performed with one of two paradigms: self-administration or conditioned place preference 
(CPP) (Aguilar et al., 2009). The most direct procedure for evaluating the reinforcing 
properties of a substance is self-administration (the animal works to obtain the substance: 
for example by pressing a lever), which assesses the intrinsic rewarding properties of a 
substance; and both oral and intravenous routes have been used to assess the relevance of 
age in voluntary intake. Animals that acquire drug-taking behaviour more quickly or 
indulge in it more frequently can be considered to resemble human drug addicts. However, 
drug taking, even when acquired quickly, is not equivalent to drug dependence (Ahmed, 
2010). Another shortcoming of the self-administration paradigm is the complexity of the 
 
Addictions – From Pathophysiology to Treatment 
 
230 
limbic systems developing earlier than control systems. It has been proposed that the 
mechanisms underlying adolescent changes in behaviour (impulsiveness, risky choices, 
drug taking, etc.) could underlie an imbalance between an increased sensitivity to 
motivational cues and immature cognitive control (Casey et al., 2011). In summary, 
immature neuronal processing in the prefrontal cortex and other cortical and subcortical 
regions, and their interaction, lead to a behaviour that is biased toward risk and emotional 
reactivity during the adolescent period (Sturman & Moghaddan, 2011). 
 
Fig. 1. Neural circuit involved in motivated behaviour. Thick lines represent hyperactive 
brain areas or connections and faint and dashed lines represent brain areas that are more 
hypoactive in adolescent subjects than in adults. 
The adolescent brain operates in a promotivational state due to the combination of three 
factors: 
a. limited inhibitory capacity and poor regulatory control (due to the lack of cortical 
maturation)  
b. DA hyperactivity in the nucleus accumbens when processing appetitive stimuli 
c. Amygdala hyperactivity, which explains affective intensity and liability, and a weaker 
harm-avoidance system (Ernst et al., 2009). 
The relatively early development of bottom-up limbic regions (nucleus accumbens and 
amygdala), along with an immaturity of top-down regulatory systems (PFC), biases behavior 
toward risk-taking, risk-seeking, impulsive choice, sensation-seeking and novelty preference. 
3. Effects of drugs on adolescents 
In addition to increases in sensation- and novelty-seeking, drug use is more common during 
adolescence (2010 Annual report on the state of the drugs problem in Europe, EMCDDA; 
 
Polydrug Use in Adolescence 
 
231 
Doremus-Fitzwater et al., 2010; Spear, 2011b). Youngsters differ from adults in their 
response to a variety of drugs (Schramm-Sapyta et al., 2009). These ontogenetic variations in 
drug responsiveness may be related with age differences in pharmacokinetics, particularly 
with respect to the functioning of the neural substrates upon which these drugs act, and also 
with social enhancement. As discussed previously, the neural systems involved in the 
effects exerted by drugs (mesolimbic DA system) differ considerably between adolescents 
and adults. These ontogenetic differences in drug responsiveness may have significant 
consequences for adolescents, who exhibit a reduced sensitivity to various drugs of abuse. 
This insensitivity can promote greater use per occasion in relation to more mature 
individuals (Schramm-Sapyta et al., 2009). After peer substance use, the next most powerful 
predictor of adolescent alcohol and drug use is perceived stress (Wagner et al., 1999). In 
animal models, stress has been shown to increase the rewarding effects of drugs of abuse 
(Piazza & LeMoal, 1998; Ribeiro Do Couto et al., 2006). On the other hand, experimental data 
suggest that drugs of abuse induce stronger effects in adolescents than in adults, although 
the literature is not conclusive regarding these differences (for review see Schramm-Sapyta 
et al., 2009). The developmental stage of adolescence can promote early experimentation 
with drugs, as addictive substances are generally more rewarding and less aversive 
(Schramm-Sapyta et al., 2009).  
Moreover, adolescent substance use disrupts the normal development of an adolescent 
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technique and the lack of a standardized procedure for evaluating substances with different 
potencies, reinforcement properties and pharmacokinetics. The choice of training substance, 
species and procedural parameters can radically affect the results obtained (Moser et al., 
2011). Variations of the self-administration model have been developed to study the main 
features of addiction. For example, the progressive ratio method designed by Hodos (1961), 
in which the sweetness and volume of a milk is varied in order to measure reward strength, 
has been used to assess motivation to seek a drug (Depoortere et al., 1993). On the other 
hand, extinction and reinstatement paradigms are employed to model relapse. Following  
acquisition of self-administration, animals undergo a process by which the response is 
extinguished and reinstatement is induced by drug priming, stress or drug-associated cues 
(Shaham et al., 2003; Epstein et al., 2006). Time-out and punished responding model 
compulsive use (Deroche-Gamonet et al., 2004; Vanderschuren and Everitt, 2004) and long-
access training schedules model high-level use (Knackstedt & Kalivas, 2007). Additionally, 
models of habitual drug-seeking have also been developed (Everitt et al., 2008). 
The CPP paradigm (in which rodents repeatedly exposed to a distinct environment in the 
presence of a positively reinforcing substance show preference for that environment) 
evaluates the conditioned rewarding properties of a substance, and is also frequently used 
due to its procedural simplicity and rapidity. This model is dose-sensitive, and drugs of 
abuse are typically rewarding at low to moderate doses and aversive at high doses. CPP is 
sensitive to a wide range of substances. In general, CPP is useful for measuring the level and 
persistence of drug-induced reward (Tzschentke, 1998), but not for modelling pathological 
drug-seeking or taking. For this reason, variations of this procedure (adding an extinction 
and reinstatement of the extinguished conditioned preference) have been developed to 
model addiction-like behaviours (Aguilar et al., 2009).  
Other animal models are employed to study motor behaviour, conditioned aversion, 
withdrawal, sensitization and compulsive drug-seeking (Belin et al., 2009; Schramm-Sapyta 
et al., 2009; Weiss, 2010). Most drugs of abuse stimulate locomotor behaviour through 
activation of the dopaminergic circuits that contribute to their reinforcing effects. At lower 
doses locomotor activity is generally increased, whereas at higher doses, locomotion falls 
and stereotypical behaviour can emerge. Conditioned place and taste aversion are designed 
to assess the aversive effects of drugs of abuse (which are assumed to discourage intake). 
Animals are trained to associate a place or a palatable flavour with the aversive sensations 
induced by a drug injected by the experimenter (generally lithium), which causes the place 
or flavour to be subsequently avoided. These tests measure the use-limiting effects of drugs 
of abuse but do not model pathological drug-seeking or taking (Schramm-Sapyta et al., 
2009), since experimenter-delivered injections greatly differ from volitional intake even for 
the aversive effects of the drug (Galici et al., 2000).  
Withdrawal is a constellation of affective and physiological changes that occurs after 
cessation of intake of some drugs of abuse and is used to evaluate dependence. Symptoms 
generally reflect the reversal of initial drug effects, although they vary with the drug, 
duration and extent of exposure. This, together with the kind of observations made and the 
choice of end points, can obstruct the interpretation of withdrawal effects (Moser et al., 
2011). In the case of ethanol or opioids, withdrawal effects (including autonomic and 
behavioural activation) can be easily quantified in animal models. Withdrawal from 
psychostimulants and most other drugs of abuse results in a generalized “negative 
 
Polydrug Use in Adolescence 
 
233 
motivational state” which can be assessed using an intracranial self-stimulation procedure 
(Bauzo & Bruijnzeel, 2012) or an anxiety-like state which can be assessed using many 
models, including the social interaction test and elevated plus maze (Hall et al. 2010). 
Repeated exposure to any of the aforementioned drugs can lead to a phenomenon called 
sensitization, in which the ambulatory, stereotypic or rewarding effect of a repeated low 
dose is augmented. Sensitization reflects lasting neuroplastic changes in response to 
repeated exposure, and is hypothesized to be a behavioural correlate of increased drug 
craving and development of dependence (Robinson and Berridge, 2008), though its 
relevance to drug dependence is debatable. However, since data from sensitization studies 
have led to the development of pharmacotherapies that have been tested in animal models 
of relapse and in human addicts, some authors support sensitisation as a useful model for 
determining the neural basis of addiction (Steketee & Kalivas, 2011). Compulsive drug-
seeking is analysed by the more complex methods of self-administration (progressive ratio, 
extinction, reinstatement, punishment, long-access, etc.), which tend to be more informative 
regarding vulnerability to addiction. However, it is difficult to employ these new techniques 
in developmental studies that aim to examine the behaviour of adolescent vs adult rodents, 
partly due to the prolonged duration of the experimental procedures. 
5. Animal models of adolescent polydrug consumption 
Recent advances in imaging have made it easier to study the human brain, but many 
questions about the effect of drugs in the adolescent brain require experimental 
manipulation in experimental animals in order to be answered. Given the across-species 
similarities in neurobehavioural features of adolescence, non-human animals undergoing 
this developmental transition can be used as models of human adolescence (Spear, 2000). 
There is growing evidence that adolescent humans and rodents experience many similar 
structural and functional changes in the brain as they progress towards adulthood. 
Behavioural changes characteristics of adolescence (increased social behaviour, novelty- and 
sensation-seeking, risk-taking, emotional instability and impulsivity) are also observed in 
rodents (Jain & Balhara, 2010). However, the use of adolescent rodent models does have 
some limitations. There are numerous areas of adolescent functioning in humans that cannot 
be addressed using animal models (peer pressure and self esteem, impact of parenting 
styles, obsession about weight, etc.). Moreover, the increases in adrenal 
hormones/neuroactive steroids during adrenarche in humans are generally not evident in 
other mammalian species. Furthermore, forebrain systems of rodents are less prominent 
than in humans, their social organization is simpler, and the time course of adolescence is 
briefer. The time frame of adolescence in non-human animals such as the rat is even more 
difficult to characterize than in humans. Among researchers who study adolescence in rats, 
opinions differ somewhat (Spear, 2000). The problem is further magnified by the limited 
amount of research to have focused on adolescence in laboratory animals. Animals of both 
genders exhibit neurobehavioural characteristics typical of adolescence during the period 
between postnatal days 28 and 42. According to hormonal, physical and social criteria, this 
development phase corresponds with age 12-18 in humans (Spear 2000). Moreover, different 
physiological changes (growth spurt, loss of excitatory input to prefrontal cortex, vaginal 
opening in females and increases in maturing spermatids in males) occur during this period. 
Indeed, some ontogenetic changes that signal the early onset of adolescence in female rats 
can emerge as early as 20 days of age, with later development taking place up until 55-60 
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technique and the lack of a standardized procedure for evaluating substances with different 
potencies, reinforcement properties and pharmacokinetics. The choice of training substance, 
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motivational state” which can be assessed using an intracranial self-stimulation procedure 
(Bauzo & Bruijnzeel, 2012) or an anxiety-like state which can be assessed using many 
models, including the social interaction test and elevated plus maze (Hall et al. 2010). 
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sensitization, in which the ambulatory, stereotypic or rewarding effect of a repeated low 
dose is augmented. Sensitization reflects lasting neuroplastic changes in response to 
repeated exposure, and is hypothesized to be a behavioural correlate of increased drug 
craving and development of dependence (Robinson and Berridge, 2008), though its 
relevance to drug dependence is debatable. However, since data from sensitization studies 
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styles, obsession about weight, etc.). Moreover, the increases in adrenal 
hormones/neuroactive steroids during adrenarche in humans are generally not evident in 
other mammalian species. Furthermore, forebrain systems of rodents are less prominent 
than in humans, their social organization is simpler, and the time course of adolescence is 
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between postnatal days 28 and 42. According to hormonal, physical and social criteria, this 
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physiological changes (growth spurt, loss of excitatory input to prefrontal cortex, vaginal 
opening in females and increases in maturing spermatids in males) occur during this period. 
Indeed, some ontogenetic changes that signal the early onset of adolescence in female rats 
can emerge as early as 20 days of age, with later development taking place up until 55-60 
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days of age in males. Taking into account the abovementioned limitations, adolescent rodent 
models can be considered to possess good face and construct validity, since there are strong 
similarities between human adolescents and various animal models of adolescence in terms 
of developmental history, behavioural traits and neural and hormonal characteristics (Spear, 
2011a). As more information is generated, stronger evidence of these forms of validity, and 
of predictive validity, will no doubt be obtained.  
Moreover, there are several methodological difficulties that are encountered when using 
experimental animals to model the complex pattern of drug abuse observed in humans. A 
polydrug animal model of drug abuse allows a situation that is closer to reality than the simple 
effect produced by one drug. However, a number of variables need to be taken into account 
when using such a model. Comparison of the studies published in the literature is difficult, 
since practically each one of them represents a different model of polydrug administration. 
This is to be expected given the high number of variables involved in this kind of study 
(Schensul et al., 2005). The first variable to bear in mind is the combination of drugs employed. 
In most studies only two drugs are employed; in many cases cocaine or alcohol. Another 
important aspect is the temporal pattern of drug administration employed. Until now, most 
studies have focused on acute administration (Braida & Sala, 2002; Daza-Losada et al., 2009a; 
Diller et al., 2007; Manzanedo et al., 2010; Robledo et al., 2007), though there is a growing 
number of studies employing repeated administration and studying long-term effects (Achat-
Mendes et al., 2003; Daza-Losada et al., 2008a, 2008b, 2009; Estelles et al., 2006; Jones et al., 
2010; Ribeiro Do Couto et al., 2011a, 2011b; Rodriguez-Arias et al., 2011). This is another point 
of discrepancy; some studies have measured effects after very short periods post-
administration (only 2 or 3 days), while others have assessed effects weeks or even months 
after the last administration. Finally, the effect under evaluation can vary considerably 
between purely physiological studies and those focusing exclusively on behavioural changes. 
All these discrepancies point to the fact that polydrug models simplify the complex reality of 
human consumption, in which each the pattern of drug use of each individual is unique.  
Most of the studies that have assessed polydrug use have employed adult animals and acute 
administration. Thus, it is necessary to design models of adolescent polydrug consumption 
that reflect the human reality, despite the intrinsic difficulties they may pose. Our research 
group has been working for several years in this field during which we have studied 
different drug combinations and different patterns of drug administration.  
The aim of the present chapter is to offer a detailed review of the experiments performed in 
this area. With this purpose in mind we will discuss not only the key results obtained in our 
experiments but also those of other studies of adolescent polydrug use. In an attempt to 
provide a clear overview of the evidence obtained to date, studies have been classified 
according to the pattern of drug administration employed. In this way, studies employing 
acute administration of drugs and studying immediate effects have been grouped together. 
Studies evaluating the binge pattern of drug administration, commonly employed by users 
of psychostimulants, constitute a second group. This section also represents a recently 
employed model developed with the aim of replicating the binge drinking that is so 
common among adolescents and young people of many cultures. Finally, we will discuss 
several studies in which a specific drug has triggered the reinstatement of drug-seeking 
behaviour of a different pharmacological kind of drug, known as the cross-reinstatement 
phenomenon and also the phenomenon of sensitization. 
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6. Principal results 
6.1 Acute polydrug studies 
6.1.1 MDMA plus cocaine 
Preclinical studies have until now focused mainly on the long-term consequences of drug 
pre-treatment in terms of subsequent changes in spontaneous behaviour or in the response 
to other drugs of abuse. For instance, a substantial number of studies have focused on the 
long-term consequences of MDMA pre-treatment on subsequent cocaine administration 
(Achat-Mendes et al., 2003; Åberg et al., 2007; Daza-Losada et al., 2008, 2009b). However, 
hardly any have examined the interactive profile of concomitant exposure to MDMA and 
cocaine. Diller and coworkers (2007) studied the effects of concurrent administration of 
MDMA and cocaine on CPP in adult rats, finding that both drugs induced CPP when 
administered alone. Co-administration, on the other hand, produced an antagonism, except 
when higher doses were employed. These results highlight how the neurochemical and 
behavioural effects of MDMA and cocaine consumed separately are dramatically altered 
when taken together. Based on the inverse relation between serotonin and DA activity (in 
general, decreases in serotonin neurotransmission produce an increase of DA function) (Di 
Giovanni et al., 2010), these authors speculated that cocaine had undermined MDMA-
mediated serotonin release more than MDMA-mediated DA release, thereby increasing the 
overall reward. 
In a more recent study, we focused on the interaction of acute MDMA and cocaine 
administration in adolescent mice (Daza-Losada et al., 2009a), studying the acute interaction 
of both drugs on motor activity, anxiety, memory and brain monoamines. One of the most 
important results of this study was that acutely administered cocaine plus MDMA induced 
an anxiolytic response in the elevated plus maze that was not present when the drugs were 
administered separately. Mice treated with cocaine and MDMA spent significantly more 
time in the open arms of the plus maze than controls or animals treated with just one of the 
drugs. This result was not due to an unspecific increase of motor activity, as no increase in 
the number of total or closed entries was observed in animals treated with both drugs. 
Although numerous studies have indicated that MDMA causes anxiety problems in drug 
users (for review see Baylen et al., 2006), our results revealed that MDMA alone does not 
exert a strong effect on levels of anxiety in adolescent mice. The few studies performed in 
the plus maze with mice have shown that acute MDMA administration induces anxiogenic 
or anxiolytic effects that vary depending on the dose employed (Navarro et al. 2002). 
Although all the available evidence supports an anxiogenic effect of acute cocaine 
administration in adult mice (Erhardt et al., 2006), cocaine did not affect the behaviours 
studied in the plus maze in our study. One possible explanation could be the different 
experimental conditions of the studies compared or a different dose-response curve to 
cocaine in adolescent versus adult mice. These results endorse the hypothesis that 
adolescent animals are more “protected” from adverse psychostimulant-related properties 
than older subjects (Laviola et al., 1999), and highlight the importance of employing 
adolescent animals in studies.  
Another important observation of our study was that an increase in DA turnover in the 
striatum was observed only when both drugs were administered together, due to a 
substantial increase in DOPAC concentration that was not accompanied by alterations of 
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after the last administration. Finally, the effect under evaluation can vary considerably 
between purely physiological studies and those focusing exclusively on behavioural changes. 
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human consumption, in which each the pattern of drug use of each individual is unique.  
Most of the studies that have assessed polydrug use have employed adult animals and acute 
administration. Thus, it is necessary to design models of adolescent polydrug consumption 
that reflect the human reality, despite the intrinsic difficulties they may pose. Our research 
group has been working for several years in this field during which we have studied 
different drug combinations and different patterns of drug administration.  
The aim of the present chapter is to offer a detailed review of the experiments performed in 
this area. With this purpose in mind we will discuss not only the key results obtained in our 
experiments but also those of other studies of adolescent polydrug use. In an attempt to 
provide a clear overview of the evidence obtained to date, studies have been classified 
according to the pattern of drug administration employed. In this way, studies employing 
acute administration of drugs and studying immediate effects have been grouped together. 
Studies evaluating the binge pattern of drug administration, commonly employed by users 
of psychostimulants, constitute a second group. This section also represents a recently 
employed model developed with the aim of replicating the binge drinking that is so 
common among adolescents and young people of many cultures. Finally, we will discuss 
several studies in which a specific drug has triggered the reinstatement of drug-seeking 
behaviour of a different pharmacological kind of drug, known as the cross-reinstatement 
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6.1 Acute polydrug studies 
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Preclinical studies have until now focused mainly on the long-term consequences of drug 
pre-treatment in terms of subsequent changes in spontaneous behaviour or in the response 
to other drugs of abuse. For instance, a substantial number of studies have focused on the 
long-term consequences of MDMA pre-treatment on subsequent cocaine administration 
(Achat-Mendes et al., 2003; Åberg et al., 2007; Daza-Losada et al., 2008, 2009b). However, 
hardly any have examined the interactive profile of concomitant exposure to MDMA and 
cocaine. Diller and coworkers (2007) studied the effects of concurrent administration of 
MDMA and cocaine on CPP in adult rats, finding that both drugs induced CPP when 
administered alone. Co-administration, on the other hand, produced an antagonism, except 
when higher doses were employed. These results highlight how the neurochemical and 
behavioural effects of MDMA and cocaine consumed separately are dramatically altered 
when taken together. Based on the inverse relation between serotonin and DA activity (in 
general, decreases in serotonin neurotransmission produce an increase of DA function) (Di 
Giovanni et al., 2010), these authors speculated that cocaine had undermined MDMA-
mediated serotonin release more than MDMA-mediated DA release, thereby increasing the 
overall reward. 
In a more recent study, we focused on the interaction of acute MDMA and cocaine 
administration in adolescent mice (Daza-Losada et al., 2009a), studying the acute interaction 
of both drugs on motor activity, anxiety, memory and brain monoamines. One of the most 
important results of this study was that acutely administered cocaine plus MDMA induced 
an anxiolytic response in the elevated plus maze that was not present when the drugs were 
administered separately. Mice treated with cocaine and MDMA spent significantly more 
time in the open arms of the plus maze than controls or animals treated with just one of the 
drugs. This result was not due to an unspecific increase of motor activity, as no increase in 
the number of total or closed entries was observed in animals treated with both drugs. 
Although numerous studies have indicated that MDMA causes anxiety problems in drug 
users (for review see Baylen et al., 2006), our results revealed that MDMA alone does not 
exert a strong effect on levels of anxiety in adolescent mice. The few studies performed in 
the plus maze with mice have shown that acute MDMA administration induces anxiogenic 
or anxiolytic effects that vary depending on the dose employed (Navarro et al. 2002). 
Although all the available evidence supports an anxiogenic effect of acute cocaine 
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Another important observation of our study was that an increase in DA turnover in the 
striatum was observed only when both drugs were administered together, due to a 
substantial increase in DOPAC concentration that was not accompanied by alterations of 
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DA levels. Neither serotonin nor its metabolites were altered in the striatum, but there was 
an increase in the concentration of serotonin in the cortex (total cortex, including the frontal 
cortex), which led to a decrease in its turnover. Although MDMA and cocaine act on the 
same neurotransmitter systems, the mechanisms involved differ, as do the effects produced. 
MDMA provokes an acute release of both serotonin and dopamine from nerve terminals 
(review in Colado et al., 2004) and is more potent in inhibiting serotonin and norepinephrine 
than dopamine transporters, while cocaine blocks these three monoamine transporters at 
similar concentrations (Han et al., 2006). One report suggested that serotonin plays a more 
prominent role in the psychotropic effects of MDMA than in those of cocaine (Itzhak et al., 
2006). As in our study, both drugs were administered together, cocaine appeared to block 
MDMA entry into the nerve terminals, thereby inhibiting MDMA-mediated monoamine 
release, which mainly affects serotonin. On the other hand, the reuptake-blocking effects of 
these compounds may have been an added factor that made DA more available to the 
synapse, which could have been responsible for the increase in dopaminergic turnover 
observed. This DA/serotoninergic balance, which occurred only in the groups treated with 
both drugs, could be, in part, responsible for the anxiolytic effect observed when cocaine 
and MDMA were administered together. Our results endorse the hypothesis of Diller and 
coworkers (2007), since we have observed an increase in DA turnover and lower levels of 
serotonin turnover in the striatum and cortex. These findings point to an increase in DA 
availability in conjunction with the release of serotonin in small amounts or at a slow rate, 
leading to a decrease in its turnover. These studies demonstrate that the combined use of 
MDMA and cocaine produces a specific neurochemical and behavioural profile different to 
that observed when each drug is administered alone.  
6.1.2 MDMA plus cannabinoids 
Several studies have highlighted that the prolonged combined use of MDMA and cannabis is 
associated with a variety of psychological problems, including elevated impulsiveness, anxiety 
and psychotic behaviour (Daumann et al., 2004). The cannabinoid system interacts with a 
variety of neurotransmitters, including DA and serotonin (Nakazi et al., 2000), and represents 
a common neurobiological substrate for the addictive properties of different drugs of abuse 
(Maldonado et al., 2006). In line with this, many of the physiological responses provoked by 
MDMA are modulated by the endocannabinoid system (Piomelli et al., 2005). 
Few studies have clarified the effects of exposure to cannabinoids on liability to MDMA 
abuse, and most of them suggest that cannabinoid agonists potentiate the rewarding effects 
of MDMA (Braida & Sala, 2002). However, studies performed recently have demonstrated 
that cannabinoid agonists modify sensitivity to the behavioural effects of MDMA in 
different ways (increase/decrease) depending on the dose employed. We have observed 
that a low dose of the specific CB1 agonist WIN 55212-2 increases the rewarding effects of an 
ineffective dose of MDMA administered during acquisition of the CPP. However, higher 
doses of the cannabinoid agonist weaken the preference induced by effective doses of 
MDMA (Manzanedo et al., 2010). Our results are in accordance with those of Robledo and 
co-workers (2007), who reported that a sub-threshold dose of THC produced CPP in mice 
when combined with a non-rewarding dose of MDMA but decreased the CPP induced by 
an effective dose of MDMA.  
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Cannabinoids participate in the regulation of DA synthesis, release and turnover (Gardner 
et al., 1998). The overlapping expression of cannabinoid and dopamine receptors in some 
brain areas such as the nucleus accumbens (Hermann et al., 2002) may represent a 
neuroanatomical substrate for such an interaction. At doses that neither WIN 55212-2 nor 
MDMA alter brain monamines, animals treated with both drugs exhibited decreases of 
striatal DA and serotonin in the cortex (Manzanedo et al., 2010). Despite the anti-
inflammatory and anti-oxidative properties of cannabinoids (Pazos et al., 2008; Aggarwal et 
al., 2009), animal studies have revealed that chronic administration of THC causes 
hippocampal damage (Fisk et al., 2006) and that exposure to low concentrations of 
cannabinoids over a prolonged period is likely to have a neurotoxic effect (Rubovitch et al., 
2002; Sarne & Keren, 2004). This evidence points to the capacity of cannabinoids to increase 
the neurotoxic potential of MDMA.  We must keep in mind that, due to the crucial role that 
the DA system plays in the reinforcing effects of drugs of abuse, the neurotoxic effect of 
MDMA on mice could modulate the response of lesioned brains to these drugs. For instance, 
mice pre-exposed to neurotoxic doses of MDMA exhibit a higher consumption of, and a 
preference for, EtOH than saline-treated animals (Izco et al. 2007). 
6.2 Binge pattern 
6.2.1 MDMA plus cocaine 
Epidemiological data reveal that the majority of MDMA users cease taking the drug 
spontaneously in their twenties (von Sydow et al., 2002), which highlights the relevance of 
using adolescent subjects in animal models. In addition to presenting a distinctive 
behavioural profile (Spear, 2000; Adriani & Laviola, 2003), young rats and mice are highly 
sensitive to the administration of psychostimulant agents (Laviola et al., 1999; Spear, 2000). 
Both MDMA and cocaine have been proved to induce long-term response after their 
consumption. MDMA users present weeks after discontinuation of intake, a reduced 
hormonal response to drug challenge and a combination of depressive pattern, dysphoria, 
high levels of aggressiveness and elevated scores of novelty-seeking behaviour (Gerra et al., 
1998). These long-term effects have also been described in mice and rats exposed to MDMA 
during adolescence, among which changes in social behaviour (Morley-Fletcher et al., 2002), 
motor activity (Balogh et al., 2004) and anxiety levels (Faria et al., 2006; Clemens et al., 2007) 
have been detected. On the other hand, cocaine administration also induces long-term 
effects in adolescent mice, which are expressed through increased flee and avoidance 
behaviour and fewer social contacts (Estelles et al., 2006). However, the long-lasting effect of 
the combination of two drugs taken during adolescence has received little attention. 
Furthermore, it should be taken into consideration that human MDMA and cocaine 
consumers commonly adhere to a binge pattern, which has been associated with a higher 
occurrence of stimulant-induced psychosis and addiction (Gawin, 1991; Segal & Kuczenski, 
1997; Belin et al., 2011). To explore these effects, we performed a series of studies using a 
model that mimics a binge pattern of MDMA and cocaine consumption. This model consists 
of two daily injections (at 8 am and 8 pm) of an identical dose of MDMA alone or plus 
cocaine, for 3 days (6 administrations), between postnatal day 28 and 30. Mice were 
evaluated three weeks after the last treatment, on postnatal day 51. MDMA administration 
decreased the concentration of striatal DA when administered at high doses (20 mg/kg) in 
agreement with previous reports (for review see Colado et al., 2004), but cocaine inhibited 
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DA levels. Neither serotonin nor its metabolites were altered in the striatum, but there was 
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prominent role in the psychotropic effects of MDMA than in those of cocaine (Itzhak et al., 
2006). As in our study, both drugs were administered together, cocaine appeared to block 
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observed. This DA/serotoninergic balance, which occurred only in the groups treated with 
both drugs, could be, in part, responsible for the anxiolytic effect observed when cocaine 
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this decrease in DA concentration three weeks later (Daza-Losada et al., 2008a). In 
accordance with these results, pretreatment with the dopamine uptake inhibitor GBR 12909 
prevented long-term loss in the striatal concentration of DA (O'Shea et al., 2001). This lack of 
neurotoxicity could have been due to the effect exerted on body temperature by the two 
drugs together, as cocaine is known to counteract the increase produced by neurotoxic doses 
of MDMA. Most evidence suggests that merely preventing MDMA-induced hyperthermia is 
enough to produce significant neuroprotection (Colado et al., 2001). Although a rise in 
temperature is an important element in MDMA-induced neurotoxicity, this phenomenon 
appears to involve more than MDMA metabolites, including dopamine deamination and/or 
autooxidation (Sprague & Nichols, 2005). As we administered both drugs together, it is also 
feasible that cocaine interfered with the dopamine uptake system by inhibiting the entry of 
MDMA into the nerve terminal. By affecting one or several of these processes, cocaine is 
capable of blocking dopamine neurodegeneration in the mouse brain. 
Since many MDMA users employ opiates in order to relieve the psychostimulant effects of 
ecstasy, it is of relevance to evaluate whether such individuals are subject to an increase in 
the well-known rewarding properties of morphine. We have observed that, following 
MDMA binges during adolescence, sensitivity to reinstatement of an extinguished 
preference is increased, as a morphine-induced preference was reinstated with lower 
priming doses in MDMA–treated mice than in non-treated animals (Daza-Losada et al., 
2008b). In the literature regarding learning, reinstatement refers to the recovery of a learned 
response when a subject is non-contingently exposed to either a conditioned or an 
unconditioned stimulus after extinction. This recovery of a learned response, which 
represents a return to drug seeking, occurs when rats or mice are exposed to drugs, drug 
cues or stressors following extinction. In the CPP version of the reinstatement model, an 
extinguished CPP is robustly reinstated by non-contingent administration of a priming dose 
of the drug (Aguilar et al., 2009). Contrasting results were obtained when adolescent mice 
were treated with cocaine alone or plus MDMA. These animals need higher priming doses 
of morphine than non-treated mice in order to reinstate the preference. The ability of 
repeated treatment with psychomotor stimulants to enhance the response to subsequent 
challenge by an opiate seems to be affected by the route and timing of administration of 
each drug. Prenatal treatment with cocaine decreases the rewarding actions of morphine in 
adult offspring (Estelles et al., 2006), while, in adult rats, doses of morphine that fail to 
produce CPP have been shown to induce a marked preference in those which have 
previously received cocaine (Shippenberg et al., 1998). However, when acute challenge with 
heroin takes place 3 weeks after daily systemic injections of cocaine, locomotor cross-
sensitization does not occur (DeVries et al., 1998). When cocaine is administered during 
gestational development, the development of brain reward systems can be altered, resulting 
in a long-term attenuation of the rewarding properties of morphine. Nevertheless, the 
possibility that such animals are unable to form the necessary association between a 
particular environment and morphine cannot be ruled out (Heyser et al., 1990; Inman-Wood 
et al., 2000). Additionally, prenatal exposure to cocaine can reduce the duration of 
pregnancy, gestational weight gain and food intake in the dams, factors that can contribute 
to an abnormal response to morphine. Finally, an association between prenatal cocaine 
exposure and the effect of altered maternal behaviour on later cognitive functions cannot be 
ruled out.  
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Thus, MDMA-treated mice are more vulnerable to relapse after receiving a priming 
administration of morphine, but this tendency is completely blocked in animals exposed to 
cocaine, in which an opposite effect is exhibited. Cocaine induces modifications in DA 
receptor function and transduction events mainly in the mesocorticolimbic dopamine 
pathway, where it induces an up-regulation of the cAMP-signalling pathway (Nestler, 2004) 
and augments the activity of the transcription factor cAMP response element-binding 
protein (CREB) (Walters et al., 2003). Increased CREB expression in the nucleus accumbens 
undermines the rewarding effects of both cocaine (Carlezon et al., 1998) and morphine 
(Barrot et al., 2002). In addition, repeated exposure to cocaine upregulates DYN/KOPr 
systems (Shippenberg et al., 2007).. This increase may initially serve as a homeostatic 
response that opposes the alteration in neurotransmission that occurs after exposure to this 
drug use. However, following the discontinuation of drug use, the unopposed actions of this 
system are likely to result in dysregulation of basal DA and glutamate transmission, thereby 
contributing to aberrant activity within the prefrontal-cortico-striatal loop (Shippenberg et 
al., 2007). These could represent some of the mechanisms responsible for the way in which 
cocaine affects the response of the dopaminergic system by altering the intensity of the 
response to priming.  
MDMA and cocaine are often first consumed at an early age, and the response to MDMA of 
users in their twenties can be affected by previous exposure to these or other drugs. 
Similarly to the observations reported with morphine, Achat-Mendes and co-workers (2003) 
found that a priming injection of cocaine after extinction reinstated a significantly higher 
CPP in mice previously exposed during adolescence to a comparable regimen of MDMA. 
Comparable results have been described in adolescent (Aberg et al., 2007) and adult rats 
(Horan et al., 2000). These results are also in accordance with the finding that the acquisition 
of cocaine self-administration is facilitated in rats pre-exposed to MDMA (Fletcher et al., 
2001). Concurring with these results, we have demonstrated that exposure to MDMA or 
cocaine binges during adolescence induces long-lasting changes that increase the reinforcing 
effects of MDMA (Daza-Losada et al., 2009b). We observed that only mice previously 
exposed to MDMA developed CPP after being conditioned with a sub-threshold dose of 
MDMA. On the other hand, although all the groups developed CPP after conditioning with 
10 mg/kg of MDMA, the extinguished preference was reinstated only in animals exposed to 
MDMA or cocaine during adolescence, in which it also took longer for the preference to be 
extinguished. Extinction provides a measurement of the motivational properties of drugs, 
which are evident in the persistence of drug-seeking behaviour in the absence of the drug 
(Aguilar et al., 2009). This is a powerful means of assessing the incentive motivational 
properties of drug-paired stimuli or non-contingent drug administration in the reinstating 
response (Pulvirenti, 2003). However, when the two drugs were administered together, 
cocaine blocked the increases that MDMA induced in sensitivity to the MDMA-induced 
CPP and in vulnerability to reinstatement of the preference. Once again, as the two drugs 
were administered simultaneously, the competition for the same molecular target could 
have affected their action, leading to a weaker effect.  
Most authors believe that increases in drug-induced CPP or self-administration observed in 
animals exposed to MDMA are due to the actions that MDMA exerts on the serotoninergic 
system (Horan et al. 2000; Fletcher et al. 2001). However, in many cases, it has been reported 
that the MDMA regimen employed did not induce dopaminergic or serotoninergic 
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that the MDMA regimen employed did not induce dopaminergic or serotoninergic 
 
Addictions – From Pathophysiology to Treatment 
 
240 
neurotoxicity, which was indeed the case in the studies mentioned above. None of the 
drugs, whether administered alone or together, induced significant changes in the 
concentration of these monoamines in the striatum, cortex or hippocampus 3 weeks later, at 
which time CPP was initiated (Daza-Losada et al. 2008b). Moreover, the chosen CPP 
schedule did not affect the concentration of monoamines (Daza-Losada et al. 2007). 
 
Fig. 2. Effects of MDMA or cocaine administration during adolescence on the acquisition 
and reinstatement of morphine or MDMA-induced CPP in adult mice. Bars represent mean 
(±SEM) time spent in the drug-paired compartment before conditioning session (□), after 
conditioning session (■), in the last extinction session (light grey), and in the reinstatement 
test (dark grey). During adolescence, mice were treated with six injections of physiological 
saline, 10 mg/kg of MDMA, or 25 mg/kg of cocaine. Three weeks later mice were 
conditioned with 40 mg/kg of morphine, or 10 mg/kg or 1.25 mg/kg of MDMA. After 
conditioning and extinction procedures, all animals received a priming injection of 50% of 
the drug dose administered during conditioning. In the subsequent reinstatement test, the 
priming doses employed were 25 and 12.5% that used during conditioning. MDMA 
exposure during adolescence increased the vulnerability to reinstatement of the 
extinguished preference induced by morphine and MDMA. This effect was also induced by 
administration of cocaine during adolescence. Pre-treatment with MDMA also increased its 
rewarding effects. * p< 0,05, **p<0.01, ***p<0.001 significant difference in time spent in Post-
C or Reinstatement tests vs. Pre-C session. Modified from Daza-Losada et al 2008b, 2009b). 
6.2.2 MDMA and ethanol binges 
Another drug often taken by adolescents in combination with ecstasy is alcohol (Riley et al., 
2001; Barrett et al., 2006). Physiological and behavioural studies in humans and rodents have 
demonstrated an interaction between these two drugs (Mohamed et al., 2009). In humans, 
ethanol enhances and prolongs the euphoria and feelings of well-being induced by MDMA 
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(Hernández-López et al., 2002), but moderates some of its physiological effects, such as fluid 
retention and hyperthermia (Dumont et al., 2010). In addition, animal models have 
demonstrated that the hyperpyretic effect of MDMA is modulated by Ethanol according to 
the moment of ethanol administration and ambient temperature (Cassel et al., 2004, 2005 
and 2007). 
Research has only recently begun to use animal models to evaluate ethanol–MDMA 
interactions. Ethanol was shown to increase MDMA concentrations not only in blood but 
also, and to a greater extent, in the striatum and cortex than in the hippocampus (Hamida et 
al. 2009). On the other hand, levels of alcohol dehydrogenase 2, which metabolizes ethanol 
to acetaldehyde, were found to be 35% lower in MDMA-treated rats than in controls (Upreti 
et al. 2009). EthOH significantly potentiates the MDMA-induced outflow of serotonin and 
DA in rat striatal slices (Riegert et al., 2008). EthOH also affects the neurotoxicity induced by 
MDMA, although discrepant results have been reported. In rats, EtOH treatment before 
MDMA administration enhances long-term neurotoxicity, while in mice, EtOH protects DA 
neurons from the toxic effects of MDMA when evaluated 72 h after the first injection 
(Johnson et al., 2004). At the behavioural level, EtOH administration potentiates MDMA-
induced hyperlocomotion in rats (Cassel, et al. 2004; Riegert, et al. 2008), and repeated co-
administration of the two drugs results in a pronounced sensitization of hyperactivity 
(Hamida et al., 2007, 2008). Recently, Jones and co-workers (2010) have reported CPP in rats 
that received MDMA plus ethOH but not in those administered just with one of these drugs. 
These results suggest that acute co-administration of EtOH plus MDMA potentiates the 
reinforcing effects of each drug alone. Moreover, administration of EtOH would appear to 
increase the risk of compulsive use of MDMA.  
A small number of studies have evaluated chronic exposure to both ethOH and MDMA, 
and none have explored this interaction in adolescent animals. Employing a model of binge 
drinking in which animals are treated during adolescence with intermittent doses of ethOH 
(a total of 16 doses administered intraperitoneally; two per day for two days, followed by a 
two-day interval without drugs), we aimed to imitate the pattern of weekend binge drinking 
that is currently so common among adolescents.  
Mice were injected twice per day on postnatal day 29, 30, 33, 34, 37, 38, 41, and 42 and with 
MDMA twice daily on postnatal day 33, 34, 41, and 42. The behavioural and neurochemical 
test took place three weeks after the last drug administration. Pascual and co-workers (2007) 
demonstrated that this pattern of ethOH administration during adolescence enhances neural 
cell death in several brain regions (neocortex, hippocampus, and cerebellum) and induces 
long-lasting neurobehavioural impairments in conditional discrimination learning as well as 
motor learning and discrimination between novel and familiar objects. We too have 
observed that exposure to ethOH during adolescence increases the anxiogenic response 
induced by MDMA in the elevated plus maze, with adult treated-mice spending less time in 
the open arms of the maze than non treated littermates. In addition, although ethOH 
undermines the hyperthermic response induced by MDMA, animals exposed to ethOH plus 
MDMA exhibit lower concentrations of DA in the striatum than those treated with MDMA 
only (Rodriguez-Arias et al., 2011). In the study in question, though ethanol efficiently 
decreased the hyperthermic response induced by MDMA, it did not protect mice treated 
with 20 mg/kg of MDMA and actually increased the toxic effect in those treated with 10 
mg/kg of MDMA, in which a hypothermic response was observed. This effect could be the 
 
Addictions – From Pathophysiology to Treatment 
 
240 
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result of binge pattern ethOH administration enhancing MDMA-induced long-term 
neurotoxicity through a mechanism that is unrelated to changes in acute hyperthermia and 
which is thought to involve hydroxyl radical formation (Izco et al., 2007). All the groups that 
presented reduced levels of striatal DA exhibited increased levels of anxiety. We have 
previously observed that adolescent mice treated with a schedule of MDMA that provoked 
a similar decrease in DA concentration without alterations in DOPAC levels behave 
normally in the elevated plus maze (Daza-Losada et al. 2008b). However, in our study, the 
decrease in DA was accompanied by a considerable decrease in DOPAC levels, which may 
have been responsible for the behavioural differences observed. Dopamine plays an 
important role in anxiety by modulating a cortical brake that the medial prefrontal cortex 
exerts on the anxiogenic output of the amygdala. It also has a considerable influence on the 
trafficking of impulses between the basolateral and central nuclei of the amygdala. Intra-
amygdaloid infusion of D1 agonists and antagonists elicits anxiogenic and anxiolytic effects, 
respectively, suggesting an anxiogenic role for D1 receptors in the amygdala. Analyses of 
the effects of D2 agonists and antagonists suggest that, depending on the model of anxiety 
in question, either anxiogenic or anxiolytic effects are elicited (de la Mora et al., 2010). 
 
Fig. 3. Effects of MDMA, cocaine or ethanol binge administration during adolescence on the 
striatal DA concentration three weeks after the last drug administration. Co-administration of 
cocaine counteracted the neurotoxic effect of binge administration of 20 mg/kg of MDMA. 
However, intermittent ethanol administration increased the dopaminergic decrease induced 
by a non-neurotoxic dose (10 mg/kg) of MDMA.  *** p<0.001 differences with respect to the 
saline group. Modified from Daza-Losada et al 2008a, and Rodriguez-Arias et al., 2011. 
In addition to inducing long-term consequences for the rewarding effects of drugs, any 
manipulation or intervention during adolescence can produce other changes, such as the 
reactivity of the HPA axis to different stressful situations. In a series of recent reports 
(Ribeiro do Couto et al., 2011a, 2011b), we observed that exposure during adolescence to 
intermittent injections of ethOH or MDMA modify the response of mice to MDMA 
administration in adulthood, in addition to previous reports that pointed out long-term 
behavioural (an increase in anxiety) and neurochemical (a rise in MDMA-induced 
neurotoxicity) effects (Rodriguez-Arias et al., 2011). Pre-exposure to ethOH, MDMA or both 
increased the rewarding effects of an ineffective dose of MDMA (1.25 mg/kg). Although 
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these pre-treatments did not affect acquisition of the CPP induced by higher doses, the 
preference was more persistent in mice pre-exposed to MDMA, ethOH or to both drugs. In 
addition, reinstatement of the extinguished preference was achieved with lower priming 
doses of MDMA in the groups pre-exposed to ethOH or MDMA (Ribeiro do Couto et al., 
2011a). These effects appear to be due to the changes in the rewarding effects of MDMA 
rather than unspecific effects such as changes in basal motor activity or stress levels. After 
conditioning adults mice with an effective (but non neurotoxic) dose of MDMA (10 mg/kg), 
we once again observed that MDMA or ethanol exposure during adolescence increased the 
time required to extinguish the preference induced by MDMA and that these effects were 
related with an increase in either brain monoamine or corticosterone levels in response to 
MDMA (Ribeiro do Couto et al., 2011b). Mice treated with ethanol after the priming 
injection presented a significant increase in striatal DA. It is possible that this stronger 
neurochemical response to the priming dose of MDMA increased the efficacy of 
conditioning, reflected in a greater resistance to extinction. Similarly, the administration of 
10 mg/kg of MDMA led to higher corticosterone values in mice exposed to MDMA during 
adolescence, while the response to low-mild stressors or to 5 mg/kg of MDMA did not 
differ, which could produce a stronger learning during conditioning. 
In these series of studies, the combination of intermittent administration of ethOH+MDMA 
did not produce synergistic effects at either behavioural or neurochemical levels. In fact, the 
combination of the two drugs would seem to counteract the behavioural and hormonal 
effects of MDMA observed when each is administered alone. These results are in line with 
the previously discussed observation that adolescent exposure to MDMA exerts more 
powerful and longer-lasting effects on an MDMA-induced CPP than exposure to 
cocaine+MDMA (Daza-Losada et al., 2009). In this case, it is possible that ethanol interferes 
with the metabolism of MDMA and with its penetration of, and/or elimination, from the 
brain, and that this is responsible for the lack of effects observed after co-administration. 
Evidence that ethanol increases brain and blood concentrations of MDMA (Johnson et al., 
2004) implies an enhanced MDMA-based neurotoxicity and an increased liability to abuse 
(Hamida et al., 2009). Since no neurotoxic effects were observed after any of the drug pre-
treatments measured in the first reinstatement test, our results could be explained by the 
fact that ethanol increases the concentration of MDMA in the brain. Indeed, we found that 
the rewarding effects of MDMA produced an inverted U-curve in function of dose, with 
high doses proving to be devoid of motivational effects (Daza-Losada et al., 2007). 
6.3 Cross-reinstatement and sensitization studies 
This last section is dedicated to other kinds of drug interaction, cross-reinstatement and 
sensitization phenomena. Cross-reinstatement can be defined as the reinstatement of 
extinguished drug-seeking by drugs other than the previously self-administered or 
conditioning drug. This phenomenon has been widely demonstrated in self-administration 
and CPP studies. Cross-reinstatement with drugs from different classes to that of the self-
administered drug has been demonstrated using the self-administration model. 
Cannabinoid agonists, DA agonists and re-uptake inhibitors and morphine, among others, 
produce reinstatement of cocaine-seeking after self-administration of cocaine has ended 
(reviewed by Shalev et al., 2002). Similarly, amphetamine and cocaine produce 
reinstatement of heroin self-administration (De Vries et al., 1998). Some studies have also 
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result of binge pattern ethOH administration enhancing MDMA-induced long-term 
neurotoxicity through a mechanism that is unrelated to changes in acute hyperthermia and 
which is thought to involve hydroxyl radical formation (Izco et al., 2007). All the groups that 
presented reduced levels of striatal DA exhibited increased levels of anxiety. We have 
previously observed that adolescent mice treated with a schedule of MDMA that provoked 
a similar decrease in DA concentration without alterations in DOPAC levels behave 
normally in the elevated plus maze (Daza-Losada et al. 2008b). However, in our study, the 
decrease in DA was accompanied by a considerable decrease in DOPAC levels, which may 
have been responsible for the behavioural differences observed. Dopamine plays an 
important role in anxiety by modulating a cortical brake that the medial prefrontal cortex 
exerts on the anxiogenic output of the amygdala. It also has a considerable influence on the 
trafficking of impulses between the basolateral and central nuclei of the amygdala. Intra-
amygdaloid infusion of D1 agonists and antagonists elicits anxiogenic and anxiolytic effects, 
respectively, suggesting an anxiogenic role for D1 receptors in the amygdala. Analyses of 
the effects of D2 agonists and antagonists suggest that, depending on the model of anxiety 
in question, either anxiogenic or anxiolytic effects are elicited (de la Mora et al., 2010). 
 
Fig. 3. Effects of MDMA, cocaine or ethanol binge administration during adolescence on the 
striatal DA concentration three weeks after the last drug administration. Co-administration of 
cocaine counteracted the neurotoxic effect of binge administration of 20 mg/kg of MDMA. 
However, intermittent ethanol administration increased the dopaminergic decrease induced 
by a non-neurotoxic dose (10 mg/kg) of MDMA.  *** p<0.001 differences with respect to the 
saline group. Modified from Daza-Losada et al 2008a, and Rodriguez-Arias et al., 2011. 
In addition to inducing long-term consequences for the rewarding effects of drugs, any 
manipulation or intervention during adolescence can produce other changes, such as the 
reactivity of the HPA axis to different stressful situations. In a series of recent reports 
(Ribeiro do Couto et al., 2011a, 2011b), we observed that exposure during adolescence to 
intermittent injections of ethOH or MDMA modify the response of mice to MDMA 
administration in adulthood, in addition to previous reports that pointed out long-term 
behavioural (an increase in anxiety) and neurochemical (a rise in MDMA-induced 
neurotoxicity) effects (Rodriguez-Arias et al., 2011). Pre-exposure to ethOH, MDMA or both 
increased the rewarding effects of an ineffective dose of MDMA (1.25 mg/kg). Although 
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these pre-treatments did not affect acquisition of the CPP induced by higher doses, the 
preference was more persistent in mice pre-exposed to MDMA, ethOH or to both drugs. In 
addition, reinstatement of the extinguished preference was achieved with lower priming 
doses of MDMA in the groups pre-exposed to ethOH or MDMA (Ribeiro do Couto et al., 
2011a). These effects appear to be due to the changes in the rewarding effects of MDMA 
rather than unspecific effects such as changes in basal motor activity or stress levels. After 
conditioning adults mice with an effective (but non neurotoxic) dose of MDMA (10 mg/kg), 
we once again observed that MDMA or ethanol exposure during adolescence increased the 
time required to extinguish the preference induced by MDMA and that these effects were 
related with an increase in either brain monoamine or corticosterone levels in response to 
MDMA (Ribeiro do Couto et al., 2011b). Mice treated with ethanol after the priming 
injection presented a significant increase in striatal DA. It is possible that this stronger 
neurochemical response to the priming dose of MDMA increased the efficacy of 
conditioning, reflected in a greater resistance to extinction. Similarly, the administration of 
10 mg/kg of MDMA led to higher corticosterone values in mice exposed to MDMA during 
adolescence, while the response to low-mild stressors or to 5 mg/kg of MDMA did not 
differ, which could produce a stronger learning during conditioning. 
In these series of studies, the combination of intermittent administration of ethOH+MDMA 
did not produce synergistic effects at either behavioural or neurochemical levels. In fact, the 
combination of the two drugs would seem to counteract the behavioural and hormonal 
effects of MDMA observed when each is administered alone. These results are in line with 
the previously discussed observation that adolescent exposure to MDMA exerts more 
powerful and longer-lasting effects on an MDMA-induced CPP than exposure to 
cocaine+MDMA (Daza-Losada et al., 2009). In this case, it is possible that ethanol interferes 
with the metabolism of MDMA and with its penetration of, and/or elimination, from the 
brain, and that this is responsible for the lack of effects observed after co-administration. 
Evidence that ethanol increases brain and blood concentrations of MDMA (Johnson et al., 
2004) implies an enhanced MDMA-based neurotoxicity and an increased liability to abuse 
(Hamida et al., 2009). Since no neurotoxic effects were observed after any of the drug pre-
treatments measured in the first reinstatement test, our results could be explained by the 
fact that ethanol increases the concentration of MDMA in the brain. Indeed, we found that 
the rewarding effects of MDMA produced an inverted U-curve in function of dose, with 
high doses proving to be devoid of motivational effects (Daza-Losada et al., 2007). 
6.3 Cross-reinstatement and sensitization studies 
This last section is dedicated to other kinds of drug interaction, cross-reinstatement and 
sensitization phenomena. Cross-reinstatement can be defined as the reinstatement of 
extinguished drug-seeking by drugs other than the previously self-administered or 
conditioning drug. This phenomenon has been widely demonstrated in self-administration 
and CPP studies. Cross-reinstatement with drugs from different classes to that of the self-
administered drug has been demonstrated using the self-administration model. 
Cannabinoid agonists, DA agonists and re-uptake inhibitors and morphine, among others, 
produce reinstatement of cocaine-seeking after self-administration of cocaine has ended 
(reviewed by Shalev et al., 2002). Similarly, amphetamine and cocaine produce 
reinstatement of heroin self-administration (De Vries et al., 1998). Some studies have also 
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demonstrated cross-reinstatement using the CPP paradigm. An extinguished cocaine-
induced CPP can be reinstated by a priming injection of related psychostimulants (Itzhak & 
Martin, 2002), and of other drugs of abuse of different pharmacological classes (Romieu et 
al., 2004). In the same way, we observed that a cocaine or amphetamine priming following 
extinction reinstated morphine-induced CPP (Ribeiro Do Couto et al., 2005). In a series of 
recent studies, we have also observed cross-reinstatement between cannabinoids and 
MDMA in adolescent animals. Extinguished MDMA-induced CPP was reinstated after a 
priming injection of the CB1 cannabinoid agonist WIN 55212-2, but this phenomenon only 
occurred in animals exposed to the cannabinoid agonist during adolescence (Rodríguez-
Arias et al., 2010). However, in mice conditioned with WIN 55212-2, a priming injection of 
MDMA was capable of reinstating the extinguished preference without pre-exposure 
(Manzanedo et al., 2010). Most authors agree that the mesocorticolimbic DA system is 
involved in cross-reinstatement. For instance, Wang et al. (2000) suggested that opiates and 
psychostimulants can all activate the mesolimbic DA system to release DA, which is a 
mechanism underlying the relapse to drug-seeking behaviour induced by morphine, cocaine 
or amphetamine. It is possible that one drug cross-primes the other via this common 
pathway, which is involved in incentive motivation and appetitive goal-directed behaviour 
(Wang et al., 2000). Such evidence of cross-reinstatement between drugs of different 
pharmacological classes has also been found in adolescents and suggests that, in drug-
abstinent individuals, exposure to an addictive drug can produce intense craving for the 
previously abused drug and thus lead to relapse to drug-taking and dependence.  
The repeated, intermittent administration of a variety of potentially addictive drugs 
produces persistent increases in their incentive motivational properties (Manzanedo et al., 
2004, 2005; Shippenberg & Heidbreder, 1995). Age-related differences in psychostimulant 
sensitization profiles have been described (Laviola et al., 1995, 1999), with adolescent rats 
proving to be less vulnerable to MDMA-induced sensitization, only developing this 
response to MDMA when administered with a high dose and within a narrow margin of 
time (Aberg et al., 2007). In a recent study, we have evaluated for the first time the effect of 
adolescent exposure to cannabinoids on the reinforcing effects of MDMA (Rodriguez-Arias 
et al., 2010). On postnatal day 27, animals received the first of five daily injections of the 
cannabinoid agonist WIN55212-2, and three days later the place conditioning procedure for 
MDMA was initiated. In mice pre-exposed to cannabinoids, sub-threshold doses of MDMA 
induced CPP and reinstatement of an extinguished preference. In the same way, delta-9-
tetrahydrocannabinol administration increased hedonic reactions to sucrose and the rise of 
dialysate DA in the shell of the NAc (de Luca et al., in press). These results endorse the 
gateway hypothesis, which is sustained by numerous epidemiological studies and suggests 
that prior exposure to cannabinoids encourages use of other illicit drugs such as 
psychostimulants (Lynskey et al., 2003). Few studies have tested this hypothesis in animal 
models, and those that have done so do not provide firm support for it. However, the 
adolescent brain is particularly sensitive to external and internal variables such as drug 
exposure, since this phase of development is characterized by active neural changes in, for 
example, synapse formation and elimination, in brain areas essential for behavioural and 
cognitive functions (Charmandari et al., 2003; Rice & Barone, 2000). Consequently, exposure 
to cannabis during the adolescent period may increase vulnerability to subsequent drug 
abuse disorders. 
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Authors Treatment employed Specie Age Behaviour studied/model employed Drugs of abuse Results
 Diller et al 2007 acute treatment rats adult MDMA- or cocaine-
induced CPP
MDMA and cocaine
Both drugs induced CPP when 
administered alone. Co-administration 
produced an antagonism, except at high 
doses 
Daza-Losada et al., 2009a acute treatment mice adolescent
Anxiety (EPM) and 
striatal monoamine levels MDMA and cocaine
Anxiolytic response in the elevated plus 
maze  and increased DA turnover in the 
striatum  only when the two drugs were 
administered together




Cannabinoid agonists potentiated the 
rewarding effects of MDMA 
Manzanedo et al., 2010 acute treatment mice adolescent MDMA- induced CPP MDMA and 
cannabinoid agonist
Low dose of the  CB1 agonist increased the 
rewarding effects of an ineffective dose of 
MDMA, but higher doses of the 
cannabinoid agonist weakened the 
preference induced by effective doses of 
MDMA 
Robledo et al (2007) acute treatment mice adult THC-induced CPP ∆9-THC and MDMA 
A sub-threshold dose of THC produced CPP 
in mice when combined with a non-
rewarding dose of MDMA, but decreased 
the CPP induced by an effective dose of 
MDMA
Daza-Losada et al., 2008a
MDMA and cocaine binge 
during adolescence mice adolescent Striatal monoamine levels  MDMA and cocaine
MDMA-induced long-lasting decreases in 
the concentration of striatal DA at high 
doses, but cocaine inhibited this effect 
Daza-Losada et al., 2008b
MDMA binge during 
adolescence mice adolescent Morphine-induced CPP MDMA and morphine
Sensitivity to reinstatement of an 
extinguished preference was increased in 
morphine-induced CPP
Estelles et al., 2006
Prenatal cocaine 
administration mice adult Morphine-induced CPP Cocaine and morphine
Prenatal treatment with cocaine decreased 
the rewarding actions of morphine in adult 
offspring 
Achat-Mendes et al., 2003 MDMA binge during 
adolescence
mice adolescent Cocaine-induced CPP Cocaine and MDMA
A priming injection of cocaine after 
extinction reinstated a significantly higher 
CPP in mice previously exposed to MDMA 
during adolescence
Daza-Losada et al., 2009b MDMA and cocaine binge 
during adolescence
mice adolescent MDMA- induced CPP Cocaine and MDMA
Only mice previously exposed to MDMA 
developed CPP after conditioning with a 
sub-threshold dose of MDMA. The 
extinguished preference was reinstated only 
in animals exposed to MDMA or cocaine 
during adolescence
Jones et al (2010) acute treatment rats adult
MDMA- and EtOH- 
induced CPP MDMA and EtOH
CPP was detected in rats that had received 
MDMA plus ethanol but not in those that 
had been administered just one of the drugs
Rodriguez-Arias et al., 2011 MDMA and EtOH binge 
during adolescence
mice adolescent Anxiety (EPM) and 
striatal monoamine levels
MDMA and EtOH
An increase was observed in the anxiogenic 
response induced by MDMA in adult mice 
treated with MDMA plus EtOH. EtOH 
increased the neurotoxic effect of MDMA
Ribeiro do Couto et al., 2011a, 2011b
MDMA and EtOH binge 
during adolescence mice adolescent MDMA-induced CPP MDMA and EtOH
Pre-exposure to EtOH, MDMA or both 
drugs increased the rewarding effects of an 
ineffective dose of MDMA. Reinstatement 
of the extinguished preference was achieved 
with lower priming doses of MDMA in the 
groups pre-exposed to ethanol or MDMA  
Table 1. Synthesis of the most relevant interactions observed in the different models 
explained within the text.  
7. Conclusion 
In conclusion, the risks associated with multi-drug exposure during adolescence are still 
unclear. The high frequency of the combined used of several drugs in human adolescent 
users demands an in-depth evaluation of their interaction. It is obvious that the developing 
brain is highly vulnerable to the damaging effects of drugs; effects that can be irreversible. 
Studies performed to date demonstrate that the combined use of drugs produces a specific 
neurochemical and behavioural profile which differs to that observed when each drug is 
administered alone. These kinds of studies are more complicated to perform than those 
employing only one drug and involve many more variables that need to be controlled. 
Nevertheless, despite their complexity and the limitations inherent in their design, each of 
these studies constitutes a piece of a giant jigsaw puzzle which, as it is gradually put 
together, provides an increasingly clearer image of the reality of drug use. 
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demonstrated cross-reinstatement using the CPP paradigm. An extinguished cocaine-
induced CPP can be reinstated by a priming injection of related psychostimulants (Itzhak & 
Martin, 2002), and of other drugs of abuse of different pharmacological classes (Romieu et 
al., 2004). In the same way, we observed that a cocaine or amphetamine priming following 
extinction reinstated morphine-induced CPP (Ribeiro Do Couto et al., 2005). In a series of 
recent studies, we have also observed cross-reinstatement between cannabinoids and 
MDMA in adolescent animals. Extinguished MDMA-induced CPP was reinstated after a 
priming injection of the CB1 cannabinoid agonist WIN 55212-2, but this phenomenon only 
occurred in animals exposed to the cannabinoid agonist during adolescence (Rodríguez-
Arias et al., 2010). However, in mice conditioned with WIN 55212-2, a priming injection of 
MDMA was capable of reinstating the extinguished preference without pre-exposure 
(Manzanedo et al., 2010). Most authors agree that the mesocorticolimbic DA system is 
involved in cross-reinstatement. For instance, Wang et al. (2000) suggested that opiates and 
psychostimulants can all activate the mesolimbic DA system to release DA, which is a 
mechanism underlying the relapse to drug-seeking behaviour induced by morphine, cocaine 
or amphetamine. It is possible that one drug cross-primes the other via this common 
pathway, which is involved in incentive motivation and appetitive goal-directed behaviour 
(Wang et al., 2000). Such evidence of cross-reinstatement between drugs of different 
pharmacological classes has also been found in adolescents and suggests that, in drug-
abstinent individuals, exposure to an addictive drug can produce intense craving for the 
previously abused drug and thus lead to relapse to drug-taking and dependence.  
The repeated, intermittent administration of a variety of potentially addictive drugs 
produces persistent increases in their incentive motivational properties (Manzanedo et al., 
2004, 2005; Shippenberg & Heidbreder, 1995). Age-related differences in psychostimulant 
sensitization profiles have been described (Laviola et al., 1995, 1999), with adolescent rats 
proving to be less vulnerable to MDMA-induced sensitization, only developing this 
response to MDMA when administered with a high dose and within a narrow margin of 
time (Aberg et al., 2007). In a recent study, we have evaluated for the first time the effect of 
adolescent exposure to cannabinoids on the reinforcing effects of MDMA (Rodriguez-Arias 
et al., 2010). On postnatal day 27, animals received the first of five daily injections of the 
cannabinoid agonist WIN55212-2, and three days later the place conditioning procedure for 
MDMA was initiated. In mice pre-exposed to cannabinoids, sub-threshold doses of MDMA 
induced CPP and reinstatement of an extinguished preference. In the same way, delta-9-
tetrahydrocannabinol administration increased hedonic reactions to sucrose and the rise of 
dialysate DA in the shell of the NAc (de Luca et al., in press). These results endorse the 
gateway hypothesis, which is sustained by numerous epidemiological studies and suggests 
that prior exposure to cannabinoids encourages use of other illicit drugs such as 
psychostimulants (Lynskey et al., 2003). Few studies have tested this hypothesis in animal 
models, and those that have done so do not provide firm support for it. However, the 
adolescent brain is particularly sensitive to external and internal variables such as drug 
exposure, since this phase of development is characterized by active neural changes in, for 
example, synapse formation and elimination, in brain areas essential for behavioural and 
cognitive functions (Charmandari et al., 2003; Rice & Barone, 2000). Consequently, exposure 
to cannabis during the adolescent period may increase vulnerability to subsequent drug 
abuse disorders. 
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 Diller et al 2007 acute treatment rats adult MDMA- or cocaine-
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MDMA and cocaine
Both drugs induced CPP when 
administered alone. Co-administration 
produced an antagonism, except at high 
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Anxiety (EPM) and 
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Anxiolytic response in the elevated plus 
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striatum  only when the two drugs were 
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Cannabinoid agonists potentiated the 
rewarding effects of MDMA 
Manzanedo et al., 2010 acute treatment mice adolescent MDMA- induced CPP MDMA and 
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Low dose of the  CB1 agonist increased the 
rewarding effects of an ineffective dose of 
MDMA, but higher doses of the 
cannabinoid agonist weakened the 
preference induced by effective doses of 
MDMA 
Robledo et al (2007) acute treatment mice adult THC-induced CPP ∆9-THC and MDMA 
A sub-threshold dose of THC produced CPP 
in mice when combined with a non-
rewarding dose of MDMA, but decreased 
the CPP induced by an effective dose of 
MDMA
Daza-Losada et al., 2008a
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during adolescence mice adolescent Striatal monoamine levels  MDMA and cocaine
MDMA-induced long-lasting decreases in 
the concentration of striatal DA at high 
doses, but cocaine inhibited this effect 
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MDMA binge during 
adolescence mice adolescent Morphine-induced CPP MDMA and morphine
Sensitivity to reinstatement of an 
extinguished preference was increased in 
morphine-induced CPP
Estelles et al., 2006
Prenatal cocaine 
administration mice adult Morphine-induced CPP Cocaine and morphine
Prenatal treatment with cocaine decreased 
the rewarding actions of morphine in adult 
offspring 
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mice adolescent Cocaine-induced CPP Cocaine and MDMA
A priming injection of cocaine after 
extinction reinstated a significantly higher 
CPP in mice previously exposed to MDMA 
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Daza-Losada et al., 2009b MDMA and cocaine binge 
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Only mice previously exposed to MDMA 
developed CPP after conditioning with a 
sub-threshold dose of MDMA. The 
extinguished preference was reinstated only 
in animals exposed to MDMA or cocaine 
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induced CPP MDMA and EtOH
CPP was detected in rats that had received 
MDMA plus ethanol but not in those that 
had been administered just one of the drugs
Rodriguez-Arias et al., 2011 MDMA and EtOH binge 
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MDMA and EtOH
An increase was observed in the anxiogenic 
response induced by MDMA in adult mice 
treated with MDMA plus EtOH. EtOH 
increased the neurotoxic effect of MDMA
Ribeiro do Couto et al., 2011a, 2011b
MDMA and EtOH binge 
during adolescence mice adolescent MDMA-induced CPP MDMA and EtOH
Pre-exposure to EtOH, MDMA or both 
drugs increased the rewarding effects of an 
ineffective dose of MDMA. Reinstatement 
of the extinguished preference was achieved 
with lower priming doses of MDMA in the 
groups pre-exposed to ethanol or MDMA  
Table 1. Synthesis of the most relevant interactions observed in the different models 
explained within the text.  
7. Conclusion 
In conclusion, the risks associated with multi-drug exposure during adolescence are still 
unclear. The high frequency of the combined used of several drugs in human adolescent 
users demands an in-depth evaluation of their interaction. It is obvious that the developing 
brain is highly vulnerable to the damaging effects of drugs; effects that can be irreversible. 
Studies performed to date demonstrate that the combined use of drugs produces a specific 
neurochemical and behavioural profile which differs to that observed when each drug is 
administered alone. These kinds of studies are more complicated to perform than those 
employing only one drug and involve many more variables that need to be controlled. 
Nevertheless, despite their complexity and the limitations inherent in their design, each of 
these studies constitutes a piece of a giant jigsaw puzzle which, as it is gradually put 
together, provides an increasingly clearer image of the reality of drug use. 
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This chapter will be dedicated to addressing various aspects of food addiction (where food 
is portrayed as being an addictive substance). It will encompass our group’s and colleagues’ 
newest neuroimaging research results and methods with respect to the findings of other 
researchers in the field. The chapter will attempt to elucidate the mechanisms of food 
addiction (FA) leading to obesity. It will begin with a brief introduction on the major points 
relating to obesity and FA. The first section will address the neurobiology and 
neurophysiology of addiction as well as the causes of obesity and its global impacts, 
concluding with therapeutic measures and future research.  
2. Food addiction and obesity: Health problems 
Obesity-related deaths rank second in the world (Mokdad et al., 2004). Obesity is linked 
with stroke, heart disease, diabetes mellitus, osteoarthritis, and certain cancers (Raman, 
2002). Developing countries have also been affected by this global epidemic (Zemmet, 2000). 
The number of adults over the age of 20 with a BMI over 30 has increased rapidly over the 
past 20 years (Pi-Sunyer, 2002). Although the etiology of obesity has been predominantly 
correlated with eating behavior, other factors such as individual preferences, mental 
disorders, genetic makeup, or addictive tendencies have been suggested to play 
contributing roles (von Deneen and Liu, 2011). Among some known etiological factors, the 
intrauterine environment plays a role in placing children at risk for becoming obese and 
having diabetes and high cholesterol levels (Blumenthal & Gold, 2010). McMillen et al. 
(2009) suggested that specific periods during pregnancy predisposed individuals to obesity, 
therefore maternal nutrition and perinatal lifestyle played a major role in fetal 
programming. Over-nutrition during pregnancy led to larger offspring or gestational 
diabetes associated with obesity, while breastfeeding could counter the effects of obesity 
(Martorell et al., 2001).  
New insights into the obesity issue involved developing an FA model that states food is 
eaten for pleasure and hedonistic intake of food can be linked with drug addiction and 
eating disorders.  
This section will assess childhood obesity etiology, metabolic syndrome, dietary and 
behavioral causes with a specific impetus on the Han Chinese population (von Deneen et al., 
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This section will assess childhood obesity etiology, metabolic syndrome, dietary and 
behavioral causes with a specific impetus on the Han Chinese population (von Deneen et al., 
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2011). Obesity particularly in China has led to worldwide attention and is becoming a 
pandemic disease resulting from a shift in energy balance caused by altered genes, a 
sedentary lifestyle, and neurohormonal imbalances as a result of Western influence. Obesity 
is spreading to low income and middle-income countries, such as China, as a result of novel 
dietary habits, promoting chronic diseases and premature mortality (Cecchini et al., 2010). 
Work-related activities declined, whereas leisure time is dominated by television/computer 
programs and other physically inactive pursuits (Popkin, 2001). The vicious obesity cycle 
begins with excess adipose leading to chronic low grade inflammation that results in insulin 
resistance (IR) along with hypertension, atherosclerosis, dyslipidemia and type 2 diabetes 
mellitus (T2DM), which are consistent findings of metabolic syndrome (MetS) (Achike et al., 
2011). Studies have shown that obesity can be linked to lower ghrelin concentrations in 
obese individuals (Groschl et al., 2005). As a result, ghrelin levels have been found to be 
negatively correlated with body fat and waist circumference (WC) (Fagerberg, Hulten & 
Hulthe, 2003).  
Metabolic syndrome (MetS) is defined as “a combination of clinical disorders that increase 
the risk for diabetes and cardiovascular disease, including atherosclerosis, stroke and 
hypertension” (Achike et al., 2011). The components of MetS include abdominal fat, 
atherogenic dyslipidemia, hypertension, pro-inflammatory state, pro-thrombic state and IR 
with or without glucose intolerance (Grundy et al., 2004). Obesity, dyslipidemia and 
hyperglycemia are all risk factors for colorectal cancer (Giovannucci, 2002). Increased 
plasma free fatty acids (FFA) in obese Chinese people acted as an important link between 
obesity and IR, and plasma FFA levels were negatively correlated with insulin sensitivity (Li 
et al., 2005). The Chinese were five times more likely to have a family history of T2DM than 
non-Chinese subjects (Xu et al., 2010). Finally, in middle-aged and elderly Chinese living in 
northeast China, there was a higher incidence of MetS and cardiovascular disease, especially 
atherosclerosis (Liu et al., 2010), which is increasing as influenced by a Westernized lifestyle 
(Mi et al., 2008). 
2.1 Social and cultural influence on obesity 
Parents and extended family members play a crucial role in shaping their children’s eating 
and exercise habits (Rhee, 2008). This is a global phenomenon, but the best example to 
describe the state the world is in with regards to obesity is China. Even though the Western 
world (first world countries) has had the greatest problems with obesity and FA, China is 
following in its footsteps. Approximately 22% of Chinese parents regarded their children as 
being underweight even if their children weren’t. Meanwhile, 23% of overweight children 
were perceived by their parents as being normal (Shi et al., 2007). Parental assessment of the 
weights of their children was associated with the physical appearance of the parents 
themselves (Huang, Becerra & Oda, 2007). Overweight daughters were more likely to be 
criticized by their mothers (Maynard et al., 2003). Chinese parents tended to misperceive 
their sons’ weights more than their daughters’. Mothers had a better ability to discriminate 
their children’s size. This gender difference could be related to social values and status 
(Campbell et al., 2006), hence exacerbating the obesity problem. For example, girls with slim 
and graceful bodies were deemed acceptable by Chinese society, while overweight boys 
were regarded as “strong and healthy” (Maynard et al., 2003). Parents’ and other family 
members’ ‘pressure to eat’ strategy was correlated with children’s caloric consumption 
(Drucker et al., 1999). Another important factor leading to childhood obesity is that a high 
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portion of Hong-Kong school children spend too many hours watching television (TV) and 
playing computer or video games (Kong & Chow, 2010). Overweight or obese adolescents 
had a tendency to view TV programs and become less physically active. In China, access to 
Westernized TV programming and food advertising has increased (Hong, 1998). 
Advertisements for food products, such as soft drinks and salty snacks, constituted more 
than 80% of commercials in China (Ji & McNeal, 2001). According to mothers surveyed in 
urban areas in China, many children have their own spending money, and they often use 
this money to buy snacks and beverages (Zhang & Harwood, 2004). Chinese parents stated 
that their children influenced most of their purchases, especially of snacks (McNeal & Yeh, 
1997). This can be witnessed in most Chinese cities with large supermarkets today. Food 
products and restaurant chains seen in TV programs and commercials provide food cues to 
children, thus enhancing the need to snack while watching TV (Coon et al., 2001). TV is 
present in almost every Chinese household, and TV advertising in China increasingly 
promotes high-calorie foods (Parvanta et al., 2010). Low-income families spend more hours 
watching TV than their counterparts (Livingstone, 2002). However, snacks seen on TV 
tended to be purchased more by those with higher incomes (Wang et al., 2008b). All in all, 
this evidence portrays that non-physical entertainment does play a major role in weight 
management in young people all over the world.  
China can be portrayed as a “double burden of malnutrition” where under-nutrition coexists 
with obesity (Popkin et al., 1995). The food selection and consumption in China has resulted in 
a diet that is more energy-dense and laden with saturated animal fat and processed sugars, 
and is low in complex carbohydrates, fiber, fresh fruits and vegetables (Zhai et al., 2009). 
Underprivileged individuals tend to stock up on non-nutritious, high-calorie foods as low-
budget staples, whereas nutrient-rich foods and high-quality diets are consumed by more 
affluent customers (Jones et al., 2007). In China, sugar-sweetened beverages (SSB) are a major 
food source with a high glycemic index (Murakami et al., 2006), thus are easily exploitable as a 
form of addictive substance. Another study found associations between frequent SSB intake 
and obesity predominantly in Chinese women, while lack of exercise, smoking, and high meat 
consumption increased the risk for greater weight gain in both genders (Ko et al., 2010). One 
study found that overweight children and adolescents consumed more energy, protein, and fat 
and ate fewer carbohydrates than did the controls (Guldan, 2010). They consumed less grain, 
fewer vegetables, more fruits, meats and cooking oil, eggs, fish, milk, and legumes. Those who 
ate at least 25g of cooking oil, 200g of meat, and 100g of dairy products had a higher chance of 
being overweight (Li et al., 2007).  
From a recent cross-sectional survey done in Jiangsu Province, researchers found that a 
higher socio-economic status and urban residency were associated with energy-dense foods 
such as animal and dairy products, soft drinks, Western food, and increased 
snacking/breakfast skipping behaviors (Shi et al., 2005). Rural and lower income students 
normally consumed rice porridge, a traditional, thin breakfast gruel. However, they also 
preferred hamburgers, ice cream, milk, fruits, chocolate, and SSB (Shi et al., 2005). The 
traditional Chinese high-glycemic diet consists of a variety of high-glycemic staple rice 
products such as boiled rice, rice congee, and glutinous rice which pose adverse 
cardiovascular and MetS risks (Ding & Malik, 2008). When the Chinese population was lean 
and active, this diet did not pose as much risk. However, China today has an obesity 
epidemic and a dietary transition shifting toward more processed foods such as SSB (Ding & 
Malik, 2008).  
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portion of Hong-Kong school children spend too many hours watching television (TV) and 
playing computer or video games (Kong & Chow, 2010). Overweight or obese adolescents 
had a tendency to view TV programs and become less physically active. In China, access to 
Westernized TV programming and food advertising has increased (Hong, 1998). 
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ate at least 25g of cooking oil, 200g of meat, and 100g of dairy products had a higher chance of 
being overweight (Li et al., 2007).  
From a recent cross-sectional survey done in Jiangsu Province, researchers found that a 
higher socio-economic status and urban residency were associated with energy-dense foods 
such as animal and dairy products, soft drinks, Western food, and increased 
snacking/breakfast skipping behaviors (Shi et al., 2005). Rural and lower income students 
normally consumed rice porridge, a traditional, thin breakfast gruel. However, they also 
preferred hamburgers, ice cream, milk, fruits, chocolate, and SSB (Shi et al., 2005). The 
traditional Chinese high-glycemic diet consists of a variety of high-glycemic staple rice 
products such as boiled rice, rice congee, and glutinous rice which pose adverse 
cardiovascular and MetS risks (Ding & Malik, 2008). When the Chinese population was lean 
and active, this diet did not pose as much risk. However, China today has an obesity 
epidemic and a dietary transition shifting toward more processed foods such as SSB (Ding & 
Malik, 2008).  
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The reason is that these foods are “appetizing, convenient and ready to eat, portable, 
affordable in single portions,” and widely marketed for the younger generation, allowing 
them to be addicted to these foods. These addictive substances include soft drinks, 
biscuits, snacks, and fast-food sandwiches (Guldan, 2010). Higher incomes in China allow 
families to purchase SSB, snacks, and fast food. Supermarkets are packed with highly-
processed, energy-dense, nutrient-poor, and lower-priced foods. Preferences include 
polished grains/white rice products, because Chinese consumers are unaware of the 
benefits from whole grains (Guldan, 2010). Another major dietary component is 
glutamate, which is a major taste ingredient of dietary protein described as ‘Umami’ 
(Kurihara & Kashiwayangani, 2000). Increasing concern with the rise of obesity in 
Westernized nations with the addition of monosodium glutamate (MSG) to commercially 
prepared foods is evident (Shi et al., 2010). There was a positive association between MSG 
consumption and the socio-economic status in rural China (Shi et al., 2010). Along those 
lines, Kazaks, Uyghurs and Mongolians are the major minorities in Xinjiang. The Kazaks 
have been reported to have hypertension (Jumabay et al., 2001), while obesity is common 
in the Uyghurs and Mongolians (Wang et al., 2006). Significant differences in mean blood 
pressure between Han, Kazaks, Uyghurs and Tibetan ethnic groups were deemed to be 
caused by different diet-related habits. It is well-known that alcohol, high-sodium foods 
and meat are traditionally popular among these groups, which are associated with 
surviving the cold weather in Xinjiang. Traditionally among Kazaks, Uyghurs and 
Mongolians in Xinjiang, alcohol consumption is paired with eating large amounts of 
animal fat or salty dishes, which could lead to an increase in fibrinogen levels. Males in 
particular traditionally drink spirits to deal with the cold. Additionally, salted milk tea is 
consumed in large amounts; vegetables are also rare in this region, hence they are not 
commonly consumed (Xi & Mi, 2009).  
Eating disorders ranged from 1.3% to 5.21% among young Chinese females (Fu et al., 2005). 
However, these data do not represent the entire population. Currently, there is little 
knowledge about weight control concerns and behaviors in China. Body mass index (BMI), 
dieting, and eating disorder symptoms are not clearly defined (Fan et al., 2010). Another 
important study of adolescents in China found a strong association between smoking and 
the belief that smoking was important in weight control (Ge et al., 1994).  
Overall, there are numerous problems arising from this epidemic such as psychosocial, 
emotional, neurological, cardiovascular, endocrine, musculoskeletal, gastrointestinal and 
pulmonary issues (Ebbeling, Pawlak & Ludwig, 2002). The costs of healthcare “associated 
with being overweight or obese projected exceed 850 billion dollars annually by 2030 in 
United States alone (Wang et al., 2008a).” As a result, this leads to a significant financial 
burden. 
3. Biology and neurobiology of food intake 
Food consumption is regulated via peripheral signals and central neuronal circuits (Wang et 
al., 2009) including the hypothalamus (HYP), amygdala (AMY), hippocampus (HIPP), insula, 
orbitofrontal cortex (OFC), and striatal brain regions (Dagher, 2009). These pathways regulate 
mechanisms of food reward, environmental stimuli perception, and integration of homeostasis 
of energy and gastrointestinal tract contents with food availability (Dagher, 2009). Most 
importantly, midbrain dopamine (DA) reward circuits motivate food ingestion and hedonistic 
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sensations resulting from eating (Dagher, 2009) as well as brain opioid peptides (Barbano et al., 
2005), which in turn work in tandem with other circuits responsible for enforcing feeding 
behaviors and weight regulation (Wang et al., 2009), as seen in Figure 1.  
 
Fig. 1. A generalized brain network for regulation of hunger as depicted from Dagher (2009). 
PFC, prefrontal cortex; OFC, orbitofrontal cortex; VTA, ventral tegmental area; DA, 
dopamine. 
The HYP and its circuits include orexin (ORX) and melanin concentrating hormone 
producing neurons in the lateral HYP as well as neuropeptide Y (NPY)/agouti related 
protein and alpha-melanocyte stimulating hormone producing neurons in the arcuate 
nucleus (ARC) known as the principal homeostatic brain regions responsible for 
regulating body weight (Wang et al., 2009). At the cellular level, important factors 
involved in communicating with the ARC in hunger regulation include ORX, melanin, 
NPY, and alpha-melanocyte-stimulating hormone (Wang et al., 2009). Ghrelin, leptin, 
insulin, and peptide YY all regulate hunger, satiety, and metabolism by stimulating 
neurons in the HYP (Wang et al., 2009). Ghrelin interacts with HYP depending on food 
intake, while leptin relays information to the HYP as well with regards to adipose storage 
(Wang et al., 2009). Insulin and peptide YY regulate metabolic changes (Wang et al., 2009). 
A useful summary of the neuropeptides that have the most dramatic influence on weight 
and eating regulation is listed in Table 1 and is also described in more detail by Wang et 
al. (2009).  
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Table 1. Neuropeptides That Regulate Food Intake (Sahu & Kalra, 1993) 
4. Food addiction: Failure in self-regulation 
Overeating and obesity are related to other substance addictions, not only in terms of 
overlapping neural substrates, but also in terms of genetic and environmental influences on 
eating behaviors and the implications that these influences have on treatment (Joranby, 
Pineda & Gold, 2005). The interaction between central satiety signals and reward responses 
to food stimuli with regards to failure in self-regulation will be discussed. 
There are two primary circuits depicting reward behavior. The first one is the connected 
regions of the prefrontal cortex and the AMY. The second one is the limbic system involving 
the AMY, HYP, septal nuclei, ventral striatum, and dopaminergic innervations (Augustine, 
1996). In most addictions, long-term is associated with drastic physiological alterations in 
the reward circuitry (Goldstein & Volkow, 2002) such as down-regulation of motivation, 
higher cognition and self-monitoring. Most importantly, emotions are correlated with the 
strength of the addiction (Shapira et al., 2003). One study found that hunger signals in the 
right OFC caused cravings and memories of food in fasting patients (Morris & Dolan, 2001). 
In more detail, those that fasted recognized previously viewed food faster. This is 
interesting because it implies dissociable roles of the OFC and left AMY in recognition of 
previously viewed food, while the nucleus accumbens (NAc) responds to internal reward 
(Morris & Dolan, 2001). 
4.1 Homeostatic substrates of over-eating 
Hyperphagia is primarily due to continuous stimulation of NPY receptors (Kalra & Kalra, 
1996). An imbalance of NPY signaling at a local level in the hypothalamus (ARC and 
paraventricular nucleus (PVN)) results in unregulated eating (Kalra & Kalra, 2004a). The 
neurotransmitter γ-aminobutyric acid (GABA) has also been known to enhance feeding 
behavior via its receptors, causing decreased melanocortin signaling to the PVN, which in 
turn results in hyperphagia (Cowley et al., 2001). Furthermore, it is possible that mutations 
or disturbances of α-melanocyte stimulating hormone (α-MSH) and other peptides involved 
in satiety can lead to hyperphagia and obesity (Kalra et al., 1999). Finally, in the case of 
abnormal hypothalamic function that accounts for a variety of eating disorders, it may lead 
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to hyperglycemia, which in turn causes other endocrine problems (Liu & Gold, 2003). This 
may be explained by one dietary example where fructose was consumed. Fructose promotes 
insulin production but blocks its release (Sato et al., 1996). Insulin is known to inhibit 
feeding by increasing leptin which in turn leads to weight gain (Saad et al., 1998).  
Hence, this would be a good model to explain why individuals with FA are obese and are 
more vulnerable to develop addiction-like behavior towards high carbohydrate foods 
containing high fructose corn syrup.  
From a neurohormonal perspective, glutamate is believed to be the neurotransmitter 
responsible for transmitting information between the areas depicted above, although the 
exact mechanism is still not understood (Swanson & Petrovich, 1998). It may be plausible 
that potential feeding mechanisms involve direct glutamatergic connections from the 
basolateral amygdala (BLA) to the lateral hypothalamic area (LHA), although the exact LHA 
neurons involved in this process remain unidentified. Nevertheless, it may be safe to 
assume that BLA outputs could influence LHA subsystems required for feeding initiation. 
For example, groups of LHA neurons express two recently discovered neuropeptides, 
melanin-concentrating hormone (MCH) and ORX, which are regulated by the hunger–
satiety state and are linked to initiation of feeding (Elmquist, Elias & Saper, 1999). There is 
still more information with regards to the interaction between ORX and FA that is outside 
the realm of this chapter, so refer to Kalra & Kalra (2004b). However, hunger caused by food 
cues is an adaptive mechanism for survival, but at the same time, learned cues can serve as a 
harmful force to promote overindulgence in food despite satiety. These particular learned 
cues can overcome specific satiety signals in order to promote continued eating (De Castro, 
1997). 
4.2 Metabolic substrates 
The gene-environment interaction, as part of the metabolic substrates contributing to 
obesity, is defined as “the response or the adaptation to an environmental agent, a behavior, 
or a change in behavior is conditional on the genotype of the individual” (Bouchard, 2009). 
For example, in Fujian province, the rate of obesity has increased due to poor nutrition 
before and during pregnancy, economic development, urbanization and improved living 
standards (McAuley et al., 2001). The genetic loci associated with obesity are: NEGR1, 
SEC16B-RASAL2, TMEM18, SFRS10-ETV5-DGKG, GNPDA2, NCR3-AIF1-BAT2, LGR4-
LIN7CBDNF, MTCH2, BCDIN3DFAIM2, SH2B1-ATP2A1, KCTD15, and FTO (fat mass and 
obesity associated) (Scuteri et al., 2007). The FTO gene is present in all tissues and encodes a 
non-heme (FeII)-dioxygenase that adapts to hypoxia, lipolysis, or DNA methylation (Gerken 
et al., 2007). This key protein may serve as a link between the central nervous system and 
energy homeostasis. FTO variants (rs8050136 and rs9939609) were associated with obesity 
and body mass index (BMI) in Hong Kong, Taiwan, and Singapore populations (Frayling et 
al., 2007). Further research needs to be done on obesity susceptibility genes for clinical 
applications. One study found a relationship between FTO SNP rs8050136 and BMI. It 
showed that the combined genetic risk of single-nucleotide polymorphisms (SNPs) may be 
useful in predicting obesity (Cheung et al., 2010). The A allele was indeed linked to obesity 
in Chinese adults (Li et al., 2010). Future studies need to be done if there is a link between 
FA and these obesity genes as well as with other addictions. For further discussion on this 
topic, please refer to these specific studies (Chen et al., 2009; Ruiz et al., 2010). 
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Prader-Willi syndrome (PWS) is the primary model for failure in self-regulation and the 
most important metabolic substrate with regards to hedonic food addiction (von Deneen, 
Gold & Liu, 2009). Our group has worked in both of these areas and believes that there are 
many shared neurohormonal pathways as well as distinct differences that may clue 
researchers in on why certain individuals overeat and become obese. Neuroimaging studies 
have shown that highly palatable food has characteristics similar to that of drugs of abuse. 
Many of the brain changes reported for hedonic eating and obesity are also seen in various 
forms of addictions (von Deneen et al., 2011). Most importantly, overeating and obesity may 
have an acquired drive such as for alcohol or drugs, and motivation and incentive craving, 
wanting, and liking occur after early and repeated exposures to stimuli. The acquired drive 
for great food and relative weakness of the satiety signal would cause an imbalance in drive 
and hunger centers of the HYP and their regulation. Prader-Willi may be a genetic model of 
the disease we are seeing on a daily basis. New hypotheses can yield new screening tests for 
new treatments. 
4.3 Increased drive 
Volkow & Fowler (2000) believe that reward circuits (NAc, AMY) have been central to drug 
addiction mechanisms, where the addictive state also involves disruption of circuits 
involved with compulsive behaviors and with increased drive. Intermittent activation of 
reward circuitry involving DA leads to dysfunction of the OFC via the striato-thalamo-
orbitofrontal circuit. The OFC is hypermetabolic in proportion to the intensity of the craving 
seen after last cocaine use or during drug-induced craving (Volkow & Fowler, 2000). Since 
the OFC is directly involved with drive and compulsive repetitive behaviors, abnormal 
activation in addicted individuals could explain compulsive drug use despite adverse 
reactions. This indicates that pleasure by itself cannot maintain compulsive substance abuse 
and drugs that could interfere with the activation of the striato-thalamo-orbitofrontal circuit 
could be beneficial in the treatment of drug addiction (Volkow & Fowler, 2000).  
Carbohydrates, as one of the most commonly abused food substances in FA, have been 
found to have an interesting psychological effect. For instance, women who craved and 
sought high-carbohydrate foods did so to alleviate negative feelings and emotions, showing 
that this food group depicts compulsive behavior (Corsica & Pelchat, 2010). More so, being 
chronically or acutely stressed led to consumption of high-fat or sugary foods, predisposing 
these individuals to bingeing and a failure in dieting (Dagher & Robbins, 2009; Dagher, 
2009). An interesting concept is the “refined food hypothesis” in which processed foods 
such as sugars, fat, salt, flour, and caffeine are the source of addiction (Ifland et al., 2009) as 
well as salty foods which mimic opiate agonists (Cocores & Gold, 2009). Finally, interesting 
findings have shown that motivation circuits relating to drinking alcohol and eating fat lead 
to the release of hypothalamic orexigenic peptides, such as ghrelin, which increase the 
consumption of these foods and raise triglyceride levels (Barson et al., 2009). In a study 
utilizing rats, the level of triglycerides predicted increased caloric consumption and 
orexigenic peptide expression following a high-fat meal (Karatayev et al., 2009).  
Drugs and food exert their reinforcing effects in part by increasing DA in limbic regions, 
which may explain how drug abuse/addiction relates to obesity (Volkow et al., 2008). 
Eating craved food and drug addiction result in reward circuitry activation involving DA 
pathways. However, these actions activate these pathways in different ways. FA affects 
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reward circuitry through endogenous opioids and cannabinoids, while drugs share the 
same circuitry through direct effects on DA neurons or via indirect effects through 
neurotransmitters (Volkow & Wise, 2005). Overstimulation of DA leads to more compulsive 
behavior and loss of control of food and drug intake due to increased availability of DAD2 
receptors in the striatum (Volkow & Li, 2004). However, FA can be considered more 
complex than drug abuse due to involvement of peripheral, endocrine and central pathways 
outside of the reward circuitry (Levine, Kotz & Gosnell, 2003).  
The fundamental idea of the reward system hypothesis is that there must be an explicit 
emotional state connected with the addiction, such as seen in PWS. The stronger the 
emotional link, the stronger the addiction. There exist a couple of primary circuits for the 
reward system. The first one involves a reciprocal connection between the prefrontal areas 
of the brain and the AMY. The second is the limbic system that links the AMY with the HYP 
and septal nuclei. The Papez limbic system also joins the HYP with the hippocampus and 
thalamus (Joranby, Pineda & Gold, 2005). Therefore, the reward system hypothesis states 
that appetizing food and addictive behaviors compete for reward regions such as the NAC . 
The act of overeating and obesity can lead to decreasing food reward and addiction (Kleiner 
et al., 2004). On the other hand, obesity is a “reward deficiency syndrome” (Blum et al., 
1996). Most importantly, increased activation in the somatic parietal areas in food addicted 
individuals suggests that enhanced activity in these regions involves sensory processing of 
food, making food even more rewarding (Wang et al., 2001), which is not typical in PWS 
cases. The reward hypothesis was best explained through sugar-dependent rat studies 
(Avena, Long & Hoebel, 2005; Rada, Avena & Hoebel, 2005; Avena, Rada & Hoebel, 2008). 
These rats had a disrupted Acetylcholine (ACh) response to hunger, ingested greater 
amounts of sugar, and produced more DA than control rats (Avena, Long & Hoebel, 2005). 
This may explain why PWS and obese individuals may be addicted to certain palatable 
foods that cause a delayed, prolonged increase in ACh levels. In drug addiction, the ventral 
striatum and midbrain were associated with immediate rewards and the hippocampus 
responded to reward consequences. The globus pallidus, thalamus, and subgenual cingulate 
were associated with immediate rewards, while the caudate, insula, and ventral prefrontal 
cortex (vPFC) responded to reward consequences (Elliott, Friston & Dolan, 2000). The 
mesolimbic reward system is a common pathway that food and drugs follow in order to 
reinforce craving behavior (Tartar, Ammerman & Ott, 1998). This pathway is also affected 
by PWS causing aberrant reward circuitry (James et al., 2007). We are still unable to 
differentiate the reward system mechanisms in PWS and other addictions.  
There are specific circuits and networks in the brain that regulate cravings, appetite, and 
cue-induced ingestion of addictive foods. The NAC and DA are specifically responsible for 
food reward and motivated eating (Cardinal et al., 2002). There are a variety of pathways 
that depict appetite and food craving regulation (Kalra & Kalra, 2004b). The ability of food-
related cues and a food-associated environment to induce eating in healthy humans can 
shed light on why PWS individuals overeat and become obese. In animal models, brain 
regions consisting of the BLA, medial prefrontal cortex (mPFC), and LHA act as a network 
to regulate eating by learned, motivational cues (Elmquist, Elias & Saper, 1999). The AMY 
has been shown to be crucial in cue-enhanced eating (Arana et al., 2003). The OFC is also 
involved in food-related cues (Arana et al., 2003). The mPFC regulates eating due to 
environmental cue pressure (O’Doherty, 2004). Activations of the AMY and medial OFC 
occur when food-deprived individuals are shown food items, and greater activations are 
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Prader-Willi syndrome (PWS) is the primary model for failure in self-regulation and the 
most important metabolic substrate with regards to hedonic food addiction (von Deneen, 
Gold & Liu, 2009). Our group has worked in both of these areas and believes that there are 
many shared neurohormonal pathways as well as distinct differences that may clue 
researchers in on why certain individuals overeat and become obese. Neuroimaging studies 
have shown that highly palatable food has characteristics similar to that of drugs of abuse. 
Many of the brain changes reported for hedonic eating and obesity are also seen in various 
forms of addictions (von Deneen et al., 2011). Most importantly, overeating and obesity may 
have an acquired drive such as for alcohol or drugs, and motivation and incentive craving, 
wanting, and liking occur after early and repeated exposures to stimuli. The acquired drive 
for great food and relative weakness of the satiety signal would cause an imbalance in drive 
and hunger centers of the HYP and their regulation. Prader-Willi may be a genetic model of 
the disease we are seeing on a daily basis. New hypotheses can yield new screening tests for 
new treatments. 
4.3 Increased drive 
Volkow & Fowler (2000) believe that reward circuits (NAc, AMY) have been central to drug 
addiction mechanisms, where the addictive state also involves disruption of circuits 
involved with compulsive behaviors and with increased drive. Intermittent activation of 
reward circuitry involving DA leads to dysfunction of the OFC via the striato-thalamo-
orbitofrontal circuit. The OFC is hypermetabolic in proportion to the intensity of the craving 
seen after last cocaine use or during drug-induced craving (Volkow & Fowler, 2000). Since 
the OFC is directly involved with drive and compulsive repetitive behaviors, abnormal 
activation in addicted individuals could explain compulsive drug use despite adverse 
reactions. This indicates that pleasure by itself cannot maintain compulsive substance abuse 
and drugs that could interfere with the activation of the striato-thalamo-orbitofrontal circuit 
could be beneficial in the treatment of drug addiction (Volkow & Fowler, 2000).  
Carbohydrates, as one of the most commonly abused food substances in FA, have been 
found to have an interesting psychological effect. For instance, women who craved and 
sought high-carbohydrate foods did so to alleviate negative feelings and emotions, showing 
that this food group depicts compulsive behavior (Corsica & Pelchat, 2010). More so, being 
chronically or acutely stressed led to consumption of high-fat or sugary foods, predisposing 
these individuals to bingeing and a failure in dieting (Dagher & Robbins, 2009; Dagher, 
2009). An interesting concept is the “refined food hypothesis” in which processed foods 
such as sugars, fat, salt, flour, and caffeine are the source of addiction (Ifland et al., 2009) as 
well as salty foods which mimic opiate agonists (Cocores & Gold, 2009). Finally, interesting 
findings have shown that motivation circuits relating to drinking alcohol and eating fat lead 
to the release of hypothalamic orexigenic peptides, such as ghrelin, which increase the 
consumption of these foods and raise triglyceride levels (Barson et al., 2009). In a study 
utilizing rats, the level of triglycerides predicted increased caloric consumption and 
orexigenic peptide expression following a high-fat meal (Karatayev et al., 2009).  
Drugs and food exert their reinforcing effects in part by increasing DA in limbic regions, 
which may explain how drug abuse/addiction relates to obesity (Volkow et al., 2008). 
Eating craved food and drug addiction result in reward circuitry activation involving DA 
pathways. However, these actions activate these pathways in different ways. FA affects 
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reward circuitry through endogenous opioids and cannabinoids, while drugs share the 
same circuitry through direct effects on DA neurons or via indirect effects through 
neurotransmitters (Volkow & Wise, 2005). Overstimulation of DA leads to more compulsive 
behavior and loss of control of food and drug intake due to increased availability of DAD2 
receptors in the striatum (Volkow & Li, 2004). However, FA can be considered more 
complex than drug abuse due to involvement of peripheral, endocrine and central pathways 
outside of the reward circuitry (Levine, Kotz & Gosnell, 2003).  
The fundamental idea of the reward system hypothesis is that there must be an explicit 
emotional state connected with the addiction, such as seen in PWS. The stronger the 
emotional link, the stronger the addiction. There exist a couple of primary circuits for the 
reward system. The first one involves a reciprocal connection between the prefrontal areas 
of the brain and the AMY. The second is the limbic system that links the AMY with the HYP 
and septal nuclei. The Papez limbic system also joins the HYP with the hippocampus and 
thalamus (Joranby, Pineda & Gold, 2005). Therefore, the reward system hypothesis states 
that appetizing food and addictive behaviors compete for reward regions such as the NAC . 
The act of overeating and obesity can lead to decreasing food reward and addiction (Kleiner 
et al., 2004). On the other hand, obesity is a “reward deficiency syndrome” (Blum et al., 
1996). Most importantly, increased activation in the somatic parietal areas in food addicted 
individuals suggests that enhanced activity in these regions involves sensory processing of 
food, making food even more rewarding (Wang et al., 2001), which is not typical in PWS 
cases. The reward hypothesis was best explained through sugar-dependent rat studies 
(Avena, Long & Hoebel, 2005; Rada, Avena & Hoebel, 2005; Avena, Rada & Hoebel, 2008). 
These rats had a disrupted Acetylcholine (ACh) response to hunger, ingested greater 
amounts of sugar, and produced more DA than control rats (Avena, Long & Hoebel, 2005). 
This may explain why PWS and obese individuals may be addicted to certain palatable 
foods that cause a delayed, prolonged increase in ACh levels. In drug addiction, the ventral 
striatum and midbrain were associated with immediate rewards and the hippocampus 
responded to reward consequences. The globus pallidus, thalamus, and subgenual cingulate 
were associated with immediate rewards, while the caudate, insula, and ventral prefrontal 
cortex (vPFC) responded to reward consequences (Elliott, Friston & Dolan, 2000). The 
mesolimbic reward system is a common pathway that food and drugs follow in order to 
reinforce craving behavior (Tartar, Ammerman & Ott, 1998). This pathway is also affected 
by PWS causing aberrant reward circuitry (James et al., 2007). We are still unable to 
differentiate the reward system mechanisms in PWS and other addictions.  
There are specific circuits and networks in the brain that regulate cravings, appetite, and 
cue-induced ingestion of addictive foods. The NAC and DA are specifically responsible for 
food reward and motivated eating (Cardinal et al., 2002). There are a variety of pathways 
that depict appetite and food craving regulation (Kalra & Kalra, 2004b). The ability of food-
related cues and a food-associated environment to induce eating in healthy humans can 
shed light on why PWS individuals overeat and become obese. In animal models, brain 
regions consisting of the BLA, medial prefrontal cortex (mPFC), and LHA act as a network 
to regulate eating by learned, motivational cues (Elmquist, Elias & Saper, 1999). The AMY 
has been shown to be crucial in cue-enhanced eating (Arana et al., 2003). The OFC is also 
involved in food-related cues (Arana et al., 2003). The mPFC regulates eating due to 
environmental cue pressure (O’Doherty, 2004). Activations of the AMY and medial OFC 
occur when food-deprived individuals are shown food items, and greater activations are 
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seen when food items are viewed (Arana et al., 2003). Our group has seen similar activations 
in PWS (James et al., 2007). The ventral mPFC has a significant role in appetite influenced by 
motivational cues, as reported by our group in PWS patients who had increased blood 
oxygen level-dependent (BOLD) responses in the ventral mPFC while viewing pictures of 
food (James et al., 2007). This would explain the excessive hunger due to increased reward 
values when viewing food, as well as the importance of the frontal cortex in its role in food 
responses. This data is also supported by findings of our group (James et al., 2002). 
Similarly, regions of the PFC may also participate in brain networks involved in cue-
induced drug cravings. Other regions overlapping the ventral mPFC are also activated by 
chocolate- and nicotine-associated contextual cues in rats (Schroeder, Binzak & Kelley, 2001). 
The ventral mPFC was correlated with decreased consumption of high caloric, sweet and 
fatty foods, as in the case of PWS. A dysfunctional ventral mPFC could mechanistically 
depict feeding behavior in PWS or obese humans relevant to overeating, appetite, cues and 
cravings (O’Doherty et al., 2000). This may be a key point as to why food addicted obese 
individuals continue to overeat despite satiety. In PWS patients, obsession and 
preoccupation with food, lack of satiation, and incessant food seeking are typical behaviors 
as compared to normal obese humans (Ogura et al., 2008). PWS adults show preference for 
sweet or high carbohydrate foods over any other type of food. This is sometimes the case in 
normal obese individuals (Ogura et al., 2008). PWS patients will often eat the most desirable 
foods first, such as sweet, high caloric foods, and the least preferred foods last. Oftentimes, 
this is a ritualistic procedure in which the PWS-afflicted individual will gather the food and 
line it up in order of preference and ingest it sequentially (Singh et al., 2008). PWS cases are 
most susceptible to visual cues, thus passing by a bakery or restaurant, or even seeing sweet 
or highly palatable foods on television, will cause an enormous increase in craving and 
appetite despite satiety as compared to normal obese people. PWS patients will often have 
tantrums and aberrant behavior after seeing or smelling delicious, inviting food (Singh et al., 
2008), which is highly uncommon in non-PWS individuals. In PWS, food cues (visual) have 
a very high emotional attachment and significance leading to bingeing episodes (Simmons, 
Martin & Barsalou, 2005). PWS is a biological model for hyperphagia and the reward system 
utilized to explain human obesity using functional magnetic resonance imaging (fMRI). 
Neuroimaging would be the most logical tool in precisely locating the brain regions 
responsible for controlling appetite and for being the reward centers specifically for FA 
(Tataranni & DelParigi, 2003). Using food-related pictures or other visual means to elicit 
brain responses has been a standard method of determining valid mechanisms that 
delineate the path to obesity (Jansen, 1998). Hence, the fMRI-supported hypothesis that PWS 
is a naturally occurring human model for FA or loss of control of eating or absence of satiety 
would be crucial for further studies. In the end, what remains is how logical and effective 
past, present, and future research can aid and treat abnormal eating behavior and brain 
responses to internal and external food cues in individuals afflicted with obesity. 
4.4 Increased incentive 
Compulsive drug-seeking and drug-taking behaviors are not always motivated by pleasure 
or by the desire to relieve withdrawal. The question remains, why do addicts compulsively 
seek drugs? Several groups have attempted to address this question by proposing the 
concept of “incentive–sensitization” (Robinson & Berridge, 1993; Berridge & Robinson, 
1995). The essential concepts of the incentive–sensitization theory are: (1) potentially 
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addictive drugs produce long-term adaptations in neural systems, hence altering the brain; 
(2) the brain systems that are altered are involved in the process of incentive motivation and 
reward; (3) the critical neuroadaptations for addiction hypersensitize these brain reward 
systems to drugs and drug-associated stimuli; and (4) the brain systems that become 
sensitized do not mediate the pleasurable effects of addictive substances, but instead they 
mediate a subcomponent of the reward system known as incentive salience or “wanting” 
(Robinson & Berridge, 1993; Berridge & Robinson, 1995; Berridge & Robinson, 1998).  
A study has shown that low D2 receptor availability places people at risk for FA and obesity 
(Allison et al., 1999). In morbidly obese individuals, prefrontal regions were responsible for 
the correlation between D2 receptor availability and glucose metabolism (Volkow et al., 
2008). Food cues increased striatal DA production which in turn caused increased hunger 
and craving for that particular food; this indicated regulation by the NAC (Volkow et al., 
2002). The four major circuits involved in drug and food addictions are reward/saliency, 
motivation/drive, learning/conditioning and inhibitory control/emotional 
regulation/executive function (Volkow et al., 2008). Disruption of these circuits leads to 
decreased motivation for good behavior and potentiates bad behavior that ends with 
negative results (weight gain in FA and drug overdose in substance abuse). This results in 
linking new memories of expected pleasurable responses when consuming the addictive 
substance or viewing similar stimuli (Volkow et al., 2008).  
4.5 Food addiction as an addiction 
Food addiction results from craving certain food or food-substances so as “to obtain a state 
of heightened pleasure, energy or excitement (Tartar, Ammerman & Ott, 1998).” It is 
important to understand the general pathophysiology of obesity in that metabolic 
alterations are not necessarily a cause of this disease, as seen in other eating disorders. 
Investigations into non-drug related addictions such as gambling, sex and food have 
provided insightful findings in understanding the neural mechanisms behind the addiction 
process (Comings et al., 2001; Bancroft & Vukadinovic, 2004; Petry, 2006; Warren & Gold, 
2007; Avena et al., 2008; Cocores & Gold, 2009; Blumenthal & Gold, 2010; Liu et al., 2010; 
Potenza et al., 2012) .  
FA is a chronic relapsing disorder associated with food cravings or food-related substances 
that lead to euphoria (Gold & Stembach, 1984) or amend negative emotions (Ifland et al., 
2009). As a result, the new DSM-V (http: //www.dsm5.org) will revise the category ‘Eating 
Disorders’ to ‘Eating and Feeding Disorders.’ Most food addicts crave carbohydrates or 
specific foods (Spring et al., 2008). FA is predominantly influenced by compulsive behavior 
instigated by emotional and environmental factors such as stress, pressure from family to be 
thinner, religious traditions, etc. (Gold, 1999). Most importantly, FA is related to drug 
addiction in that DA levels regulate this type of psychological dependence by activating DA 
pathways responsible for addictive behavior (Warren & Gold, 2007; Wang et al., 2009; 
Blumenthal & Gold, 2010). In one study, Wang et al. (2009) stated that drug addiction 
hijacks neurobiological pathways that regulate reward, motivation, decision-making, 
learning, and memory. Withdrawal results in anti-reward effects due to a loss of brain 
reward system function and stress when the addictive substance is not available (Dackis & 
O’Brien, 2005; Koob, 2009).  
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seen when food items are viewed (Arana et al., 2003). Our group has seen similar activations 
in PWS (James et al., 2007). The ventral mPFC has a significant role in appetite influenced by 
motivational cues, as reported by our group in PWS patients who had increased blood 
oxygen level-dependent (BOLD) responses in the ventral mPFC while viewing pictures of 
food (James et al., 2007). This would explain the excessive hunger due to increased reward 
values when viewing food, as well as the importance of the frontal cortex in its role in food 
responses. This data is also supported by findings of our group (James et al., 2002). 
Similarly, regions of the PFC may also participate in brain networks involved in cue-
induced drug cravings. Other regions overlapping the ventral mPFC are also activated by 
chocolate- and nicotine-associated contextual cues in rats (Schroeder, Binzak & Kelley, 2001). 
The ventral mPFC was correlated with decreased consumption of high caloric, sweet and 
fatty foods, as in the case of PWS. A dysfunctional ventral mPFC could mechanistically 
depict feeding behavior in PWS or obese humans relevant to overeating, appetite, cues and 
cravings (O’Doherty et al., 2000). This may be a key point as to why food addicted obese 
individuals continue to overeat despite satiety. In PWS patients, obsession and 
preoccupation with food, lack of satiation, and incessant food seeking are typical behaviors 
as compared to normal obese humans (Ogura et al., 2008). PWS adults show preference for 
sweet or high carbohydrate foods over any other type of food. This is sometimes the case in 
normal obese individuals (Ogura et al., 2008). PWS patients will often eat the most desirable 
foods first, such as sweet, high caloric foods, and the least preferred foods last. Oftentimes, 
this is a ritualistic procedure in which the PWS-afflicted individual will gather the food and 
line it up in order of preference and ingest it sequentially (Singh et al., 2008). PWS cases are 
most susceptible to visual cues, thus passing by a bakery or restaurant, or even seeing sweet 
or highly palatable foods on television, will cause an enormous increase in craving and 
appetite despite satiety as compared to normal obese people. PWS patients will often have 
tantrums and aberrant behavior after seeing or smelling delicious, inviting food (Singh et al., 
2008), which is highly uncommon in non-PWS individuals. In PWS, food cues (visual) have 
a very high emotional attachment and significance leading to bingeing episodes (Simmons, 
Martin & Barsalou, 2005). PWS is a biological model for hyperphagia and the reward system 
utilized to explain human obesity using functional magnetic resonance imaging (fMRI). 
Neuroimaging would be the most logical tool in precisely locating the brain regions 
responsible for controlling appetite and for being the reward centers specifically for FA 
(Tataranni & DelParigi, 2003). Using food-related pictures or other visual means to elicit 
brain responses has been a standard method of determining valid mechanisms that 
delineate the path to obesity (Jansen, 1998). Hence, the fMRI-supported hypothesis that PWS 
is a naturally occurring human model for FA or loss of control of eating or absence of satiety 
would be crucial for further studies. In the end, what remains is how logical and effective 
past, present, and future research can aid and treat abnormal eating behavior and brain 
responses to internal and external food cues in individuals afflicted with obesity. 
4.4 Increased incentive 
Compulsive drug-seeking and drug-taking behaviors are not always motivated by pleasure 
or by the desire to relieve withdrawal. The question remains, why do addicts compulsively 
seek drugs? Several groups have attempted to address this question by proposing the 
concept of “incentive–sensitization” (Robinson & Berridge, 1993; Berridge & Robinson, 
1995). The essential concepts of the incentive–sensitization theory are: (1) potentially 
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addictive drugs produce long-term adaptations in neural systems, hence altering the brain; 
(2) the brain systems that are altered are involved in the process of incentive motivation and 
reward; (3) the critical neuroadaptations for addiction hypersensitize these brain reward 
systems to drugs and drug-associated stimuli; and (4) the brain systems that become 
sensitized do not mediate the pleasurable effects of addictive substances, but instead they 
mediate a subcomponent of the reward system known as incentive salience or “wanting” 
(Robinson & Berridge, 1993; Berridge & Robinson, 1995; Berridge & Robinson, 1998).  
A study has shown that low D2 receptor availability places people at risk for FA and obesity 
(Allison et al., 1999). In morbidly obese individuals, prefrontal regions were responsible for 
the correlation between D2 receptor availability and glucose metabolism (Volkow et al., 
2008). Food cues increased striatal DA production which in turn caused increased hunger 
and craving for that particular food; this indicated regulation by the NAC (Volkow et al., 
2002). The four major circuits involved in drug and food addictions are reward/saliency, 
motivation/drive, learning/conditioning and inhibitory control/emotional 
regulation/executive function (Volkow et al., 2008). Disruption of these circuits leads to 
decreased motivation for good behavior and potentiates bad behavior that ends with 
negative results (weight gain in FA and drug overdose in substance abuse). This results in 
linking new memories of expected pleasurable responses when consuming the addictive 
substance or viewing similar stimuli (Volkow et al., 2008).  
4.5 Food addiction as an addiction 
Food addiction results from craving certain food or food-substances so as “to obtain a state 
of heightened pleasure, energy or excitement (Tartar, Ammerman & Ott, 1998).” It is 
important to understand the general pathophysiology of obesity in that metabolic 
alterations are not necessarily a cause of this disease, as seen in other eating disorders. 
Investigations into non-drug related addictions such as gambling, sex and food have 
provided insightful findings in understanding the neural mechanisms behind the addiction 
process (Comings et al., 2001; Bancroft & Vukadinovic, 2004; Petry, 2006; Warren & Gold, 
2007; Avena et al., 2008; Cocores & Gold, 2009; Blumenthal & Gold, 2010; Liu et al., 2010; 
Potenza et al., 2012) .  
FA is a chronic relapsing disorder associated with food cravings or food-related substances 
that lead to euphoria (Gold & Stembach, 1984) or amend negative emotions (Ifland et al., 
2009). As a result, the new DSM-V (http: //www.dsm5.org) will revise the category ‘Eating 
Disorders’ to ‘Eating and Feeding Disorders.’ Most food addicts crave carbohydrates or 
specific foods (Spring et al., 2008). FA is predominantly influenced by compulsive behavior 
instigated by emotional and environmental factors such as stress, pressure from family to be 
thinner, religious traditions, etc. (Gold, 1999). Most importantly, FA is related to drug 
addiction in that DA levels regulate this type of psychological dependence by activating DA 
pathways responsible for addictive behavior (Warren & Gold, 2007; Wang et al., 2009; 
Blumenthal & Gold, 2010). In one study, Wang et al. (2009) stated that drug addiction 
hijacks neurobiological pathways that regulate reward, motivation, decision-making, 
learning, and memory. Withdrawal results in anti-reward effects due to a loss of brain 
reward system function and stress when the addictive substance is not available (Dackis & 
O’Brien, 2005; Koob, 2009).  
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High-fat and high-sugar foods are being exploited by developed and developing countries 
(Davis & Carter, 2009) resulting in increased numbers of food addicts. These foods are 
linked to increasing neurochemicals such as DA (Liu et al., 2010), as demonstrated in animal 
studies (Rada & Hoebel, 2005), which can be applied to fMRI studies that have shown 
delayed satiety in obese people, meaning they consume more food despite being full than 
do normal individuals (Liu et al., 2000). Sugar craving caused a decrease in serotonin levels 
as well (Wurtman & Wurtman, 1995). As a result, FA is associated with the formation of 
pathological brain pathways that are reinforced by abnormal eating patterns and behaviors. 
Current research in FA and other disorders has shown that there were similar 
neurobiological pathways as those found in drug addiction (Berry & Mechoulam, 2002; 
Gearhardt et al., 2009a; Wang et al., 2009; Blumenthal & Gold, 2010). Animal studies 
attributed addiction to specific foods (Avena et al., 2004; Avena et al., 2005; Avena et al., 
2008), although humans have a tendency to respond to external food cues (Benarroch et 
al., 2007; James et al., 2007; von Deneen et al., 2009). Food and drugs cause DA to be 
released from dopaminergic neurons, originating from the mesencephalon and projecting 
to forebrain structures in the ventral striatum depending on the amount of reward 
obtained (Volkow et al., 2002; Volkow et al., 2008). Brain regions known to be associated 
with reward circuitry include the OFC, AMY, insula, striatum, anterior cingulate cortex 
(ACC), and dorsolateral prefrontal cortex (DLPFC) (McBride et al., 2006; Franklin et al., 
2007). FA can be diagnosed using the Yale Food Addiction Scale (YFAS) based on the 
Diagnostic Statistical Manual (DSM)-IV-TR substance dependence criteria. This would 
then allow direct comparison between FA and drug abuse (Gearhardt et al., 2009b). There 
are numerous current reviews that would be helpful references in explaining the 
neurobiology and neurophysiology of addiction (please see Detar, 2011; Avena et al., 
2102; Urban & Martinez, 2012).  
4.6 Neuroimaging of addiction: Main findings 
Most imaging projects studied DA involvement in the process of drug addiction because the 
ability of drugs of abuse to increase limbic DA is considered crucial for their reinforcing 
effects (Koob et al., 1994; Di Chiara, 1999). However, increased DA does not account for the 
process of addiction, since drugs of abuse increase DA in non-addicted as well as addicted 
subjects (Goldstein & Volkow, 2002). In the case of cocaine addiction, drug-induced DA 
increases and the intensity of self-reports of the drug’s reinforcing properties is smaller in 
addicted subjects (Volkow et al., 1997). This means DA involvement in drug addiction is 
likely to be mediated by changes in neurocircuitry modulated by DA, including the frontal 
cortex. Current structural/volumetric MRI studies depicted morphological changes in the 
frontal lobe in various forms of drug addiction (Goldstein & Volkow, 2002). In one study, 
frontal lobe volume losses were shown in cocaine-dependent subjects (Liu et al., 1998; 
Franklin et al., 2002), alcoholic subjects (Jernigan et al., 1991; Pfefferbaum et al., 1997), and 
heroin-dependent subjects (Liu et al., 1998). The latter study indicated there were negative 
correlations between normalized prefrontal volumes and prolonged cocaine or heroin use, 
meaning there was a cumulative effect of substance abuse on frontal volumes. DA 
activation, as seen during amphetamine administration, also prevented inhibition of the 
AMY by the medial prefrontal cortex (Rosenkranz & Grace, 2001). A similar process may be 
occurring in human drug addiction, in which prefrontal top-down processes are diminished 
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(see Miller & Cohen, 2001). Therefore, if the frontal cortex and its functions become down-
regulated in human drug addiction, the motivational, higher cognitive, and self-monitoring 
processes become affected (Goldstein & Volkow, 2002). 
5. Neuroimaging of food addiction: Main findings 
This section will briefly examine the neural correlates of addictive-like eating behavior using 
fMRI as compared to those with substance dependence (Gearhardt et al., 2011c). Other 
studies of interest relating to FA deal with the addiction potential of hyperpalatable foods 
(Gearhardt et al., 2011a), the public health and policy implications of FA (Gearhardt et al., 
2011b), the diagnostic criteria for FA (Gearhardt et al., 2009a), and the psychological 
correlates of obesity (Friedman & Brownell, 1995).  
Researchers may benefit from functional neuroimaging results depicting shared neural  
and hormonal pathways to determine similarities between substance abuse and hedonistic 
overeating, such as in FA and drug abuse individuals who continue to have cravings despite 
a dysfunctional satiety signal (Zhang et al., 2011). Functional neuroimaging studies  
have further revealed that good or great smelling, looking, tasting, and reinforcing food has 
characteristics similar to that of drugs of abuse (James et al., 2002; James et al., 2007). Many 
of the brain changes in fMRI studies showed that both food and drugs activated the  
AMY, insula, OFC, and striatum (Jonas & Gold, 1986; Matsuda et al., 1999). Food and  
drug cravings also showed signal activation in the HIPP, insula, and caudate (Matsuda et 
al., 1999).  
In Brownell’s group study (Gearhardt et al., 2011c), the relationship between high food 
addiction scores and blood oxygen level–dependent (BOLD) functional magnetic resonance 
imaging activation in response to receiving palatable food was evaluated. FA scores were 
positively correlated with activation in the ACC, medial OFC, and AMY when anticipating 
eating highly palatable food such as a chocolate milkshake. There was greater activation in 
the DLPFC and caudate when anticipating highly palatable food and decreased activation in 
the lateral OFC when eating palatable foods (Gearhardt et al., 2011c). These regions are 
associated with positive rewards from food cues (Rolls, 2000) and satiety (Small et al., 2001). 
Similar patterns of neural activation were seen in substance dependence (Gearhardt et al., 
2011c) in response to visual cues. Another interesting finding showed that the urge to cease 
consumption of a palatable food or drug is suppressed in the lateral OFC (Berridge & 
Kringelbach, 2008; Schoenbaum & Shaham, 2008). There has been some thought that food 
addicts eat compulsively but have compensatory behaviors to reduce weight (Fuhrer et al., 
2008). Recent functional neuroimaging studies have found abnormal brain activations in 
obese people. We found that before food intake, obese men had significantly increased 
baseline activity in the left putamen, left posterior insula, left medial temporal cortex and 
bilateral parietal cortex relative to lean men using a regional homogeneity (ReHo) analysis 
method. In this method, we measured temporal homogeneity of the regional BOLD signals. 
Decreased activity was also found in the medial orbitofrontal lobe, left DPFC, right inferior 
temporal lobe and right cerebellum in the obese subjects. After food intake, the obese men 
had remarkably elevated brain activity in the left putamen and bilateral parietal lobe, and 
reduced activity in the left superior frontal lobe and bilateral middle temporal lobe. These 
results indicated that, either before or after food intake, obese men might have a stronger 
desire to eat. This study provided strong evidence supporting the hypothesis that there is 
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High-fat and high-sugar foods are being exploited by developed and developing countries 
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(see Miller & Cohen, 2001). Therefore, if the frontal cortex and its functions become down-
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hypo-functioning reward circuitry in obese individuals, in which the prefrontal cortex may 
fail to inhibit the striatum and insula, and consequently lead to overeating and obesity.  
This study (Zhang et al., unpublished results) found a difference in BOLD activation 
between obese individuals versus controls especially in the left hemisphere as shown in 
Figure 2. It has been shown that a higher BMI was correlated with decreased gray matter in 
the left OFC and right cerebellum (Walther et al., 2010), indicating that obese individuals 
have limited inhibitions than controls (Baylis & Moore, 1994). In this study (Zhang et al., 
unpublished results), obese men had decreased neural activity in the left DLPFC prior to 
liquid ingestion, meaning they could not inhibit their hunger and found eating to be more 
desirable. The obese men also had higher activation in the left insula indicating that the 
insula could have affected satiety and eating (Zhang et al., unpublished results). 
Furthermore, greater ReHo activation in the bilateral parietal cortex in obese individuals 
showed that food was more palatable and enjoyable (Volkow, Fowler & Wang, 2004). 
Overall, it was found that the obese have hypo-functioning reward circuitry where the 
medial prefrontal cortex (MPFC) and left DLPFC fail to inhibit the left putamen and insula 
causing overeating (Zhang et al., unpublished results). fMRI was thus useful in determining 
the mechanisms of obesity with regards to neural activity.  
 
Fig. 2. A T-statistical difference map between obese subjects and controls before liquid 
ingestion (p<0.05, corrected). Warm and cold colors indicate obese subject-related ReHo 
increases and decreases, respectively (Zhang et al., unpublished).  
6. Food addiction versus drug addiction 
This section will introduce similarities and differences between food and drugs of abuse 
(Blumenthal & Gold, 2010). The DSM fifth edition has been prepared to address addiction with 
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new terminologies and approaches. For example, the term substance dependence was 
replaced with substance-use disorder. This is defined as ‘A maladaptive pattern of substance-
use leading to clinically significant impairment or distress, as manifested by two (or more) of 
the listed criteria occurring within a 12-month period (http://www.dsm5.org/ 
ProposedRevisions/Pages/Substance-RelatedDisorders.aspx).’ Substance-abuse disorder 
progresses from bingeing to withdrawal, and finally leading to craving the substance (Koob & 
Volkow, 2010). This cyclic behavior can be sustained and entertained by stress. Substance-use 
disorder stems from taking over neurobiological pathways regulating reward, motivation, 
decision-making, learning and memory in order to become responsive to the drug of choice 
(Everitt & Robbins, 2005; Wise, 2006; Belin et al., 2009; Hyman et al., 2009; Wang et al., 2009). 
Various neural networks, such as in the dorsolateral striatum, AMY, OFC and midbrain, 
regulate drug-seeking behavior which depends on feelings associated with using and craving 
that particular drug (Zapata et al., 2003; Belin & Everitt, 2008; Everitt et al., 2008; Koob, 2009). 
For a thorough review of this process and the neural structures involved, please see Robbins & 
Everitt (1999). Furthermore, DA seems to be the essential regulator of dependence, particularly 
in stimulants, while alcohol, opioids, and nicotine act upon opioid receptors (Koob & Volkow, 
2010). This can be seen in individuals with Parkinson’s disease who become addicted to 
dopamine-containing medications (Dagher & Robbins, 2009).  
A general figure (Figure 3) of the neurobiology of addiction is provided below. 
 
Fig. 3. Neurobiology of addiction that can be applied to food addiction as depicted by 
Dackis & O’Brien (2005). 
The figure clearly depicts how the cycle of drug addiction is positively reinforced by 
euphoria from drug intake and negatively reinforced during withdrawal, craving for the 
drug and hedonic dysregulation. This cycle becomes more uncontrollable as the brain 
becomes more addicted. Drug-related cues and stress increase this craving leading to a loss 
of control stemming from dysfunction of the prefrontal cortex. Neuronal mechanisms for 
these components of addiction have been delineated in animal models and human 
neuroimaging studies (Dackis & O’Brien, 2005). 
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Accumulating evidence has shown that there are many shared neural and hormonal 
pathways as well as distinct differences that may help researchers find why certain 
individuals overeat and become addicted. The FA criteria that provide this evidence are 
listed in Table 2 below. 
 
Tolerance Starting out with a single cookie, gradually 
increasing to several or a whole box 
Withdrawal symptoms Habitually eating to relieve depression, 
anxiety, and other emotional states; 
unpleasant physical sensations when 
cutting back on carbohydrates 
Taking in larger amounts or for a longer 
duration  
Intending to eat a single serving but 
instead eating a whole package; binges 
extending several hours  
Attempts to cut back Frequent attempts to eat ‘correctly’(e.g. 
avoid overeating or eating certain foods) 
Excessive time spent pursuing, using, or 
recovering from use 
Frequent thinking about food, planning 
intake, preparing, and/or resting or 
sleeping after excessive intake 
Reduction/discontinuation of important 
activities because of use 
Eating instead of spending time with 
friends; feeling too sick after overeating to 
do anything  
Continued use despite consequences Overeating in spite of overweight, physical 
illness, and/or distress about overeating 
Table 2. Food addiction characteristics compared with substance abuse criteria based on 
Ifland et al. (2009). 
Most importantly, overeating and obesity may have an acquired drive such as drug 
addiction with respect to motivation and incentive craving, wanting, and liking which occur 
after early and repeated exposures to stimuli. The acquired drive for great food and relative 
weakness of the satiety signal would cause an imbalance between the drive and 
hunger/reward centers in the brain described earlier and their regulation when conditioned 
via visual cues (Liu et al., 2010). As mentioned before, FA can be defined as a chronic 
relapsing problem caused by various fundamental factors that encourage craving for food or 
food-related substances so as “to obtain a state of heightened pleasure, energy, or 
excitement (Tartar, Ammerman & Ott, 1998).” An example of this would be carbohydrate 
cravers that have learned to consume high carbohydrate foods to improve their mood 
caused by a drop in serotonin levels (Spring et al., 2008). Most FA and eating disorders are 
the result of loss of control, impulsive and/or compulsive behavior stemming from 
emotional and environmental conditions and a psychological dependence on food. 
Abnormal eating behaviors along with other addictions affect the levels of DA in the 
mesolimbic dopaminergic system (Mogenson, 1982; Blum et al., 1996; Goldstein & Volkow, 
2002; Everitt & Robbins, 2005). FA is defined by a system as follows: bingeing consists of 
“unusually large bouts of intake” (Colantuoni et al., 2001); withdrawal is “indicated by signs 
of anxiety and behavioral depression” (Colantuoni et al., 2002); craving is “measured during 
sugar abstinence as enhanced by responding to sugar” (Avena, Long & Hoebel, 2005); and 
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cross-sensitization results “from sugar to drugs of abuse” (Avena et al., 2004). Furthermore, 
bingeing is also defined as “escalation of intake with a high proportion of intake at one time, 
usually after a period of voluntary abstinence or forced deprivation” (Avena, Rada & 
Hoebel, 2008). FA consists of sensitization and tolerance phases, which initiate addiction 
(Koob & Le Moal, 2005). Withdrawal resulting from the addictive food or foods has been 
known to be caused by alterations in the opioid system (Colantuoni et al., 2002). This phase 
consists of two parts, in which DA decreases and ACh is released from the NAC.  
When sugar was analyzed with regards to withdrawal symptoms, it was stated that it was 
capable of producing DA, ACh, and opioids similar to most narcotic substances (Avena, 
Rada & Hoebel, 2008). Withdrawal is marked by anxiety (File et al., 2004) and depression 
(Avena, Rada & Hoebel, 2008). For more information on using sugar as an addictive 
substance please refer to the following references (Colantuoni et al., 2001; Colantuoni et al., 
2002; Avena et al., 2004; Avena et al., 2005; Avena, Rada & Hoebel, 2008). Food craving can 
happen after a prolonged period of abstinence since “craving” is better defined by 
“increased efforts to obtain a substance of abuse or its associated cues as a result of 
dependence and abstinence” (Avena, Rada & Hoebel, 2008). Cross-sensitization is the last 
phase of FA and is predominantly defined as “an increased locomotor response to a 
different drug or substance” (Avena, Rada & Hoebel, 2008). All of these definitions play a 
major role in helping define and classify food (especially sugar) as a true addictive 
substance in comparison to the criteria for drug dependence as shown at least in rats 
(Haddock et al., 2000). People becoming addicted to food may be overweight and may 
possibly have leptin resistance as well that leads to overeating (Liu & Gold, 2003).  
Finally, the most problematic group for an increase in addictive behavior and obesity has 
been young adults and adolescents in the past 30 years (Dietz, 2001). One study showed that 
binge eating and drug abuse were linked (Ross & Ivis, 1999). Interestingly, those that 
smoked had an increased body mass index (BMI) than non-smokers, and they were also at a 
risk for gaining weight when not using drugs (Hodgkins et al., 2004). Therefore, it is 
reasonable to conclude that teenagers used food to replace the reinforcement behavior of 
drug addiction to compensate for the reward systems of the brain. Eating disorders are a 
form of addiction in a way that individuals are obsessed with body image and compulsively 
crave certain foods such as in binge eating. 
6.1 Intervention and prevention 
Besides altering the endocrine makeup of individuals affected by FA via drug therapies, 
alternative and complementary approaches could play a major role in the intervention and 
possible prevention of obesity. Decreasing access to highly palatable and addicting foods is 
necessary (and restriction to all foods and small inanimate objects for patients with PWS) 
(von Deneen, Gold & Liu, 2009). Management includes 24 hour or constant supervision, 
planned physical activities, a strict diet (≤ 1200 cal/day) divided into structured, portioned 
meals at set times, and a static, predictable way of life (Benarroch et al., 2007). Encouraging 
afflicted groups to exercise or do other enjoyable activities will discourage them from their 
usual eating behaviors, as well as maintaining a highly controlled eating environment and 
food regimen with strict, consistent and reinforced rules. There are two common types of 
non-medicinal methods to decreasing body weight and/or improving the health condition 
of the individual. The first one is the undieting approach which discourages the use of food 
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restriction or dieting due to its ineffectiveness and possible health risks (Foster, 2001). The 
second type is isolated dieting in which one consumes less of a particular type of food or 
food group such as seen in the Adkins diet where carbohydrates are almost completely 
eliminated from the diet. Experimental treatments in animals may have practical application 
in treatment and prevention of obesity. There is a possibility such drugs can be marketed for 
use in human medicine. Another suggested experimental treatment is the aid of central 
leptin gene therapy (Kalra & Kalra, 2002), where an injection of recombinant adeno-
associated virus vector encoding leptin into the HYP of prepubertal and adult rats resulted 
in weight gain and suppressed diet-induced obesity. The explanation was that it promoted 
loss of fatty deposits caused by a decrease in NPY and an increase in MCH and 
thermogenesis. This is a novel approach that may not be suitable for humans at this point. 
Indeed, disrupting NPYergic signaling at multiple loci without affecting normal 
hypothalamic function would be ideal, but more research needs to be done in this area 
(Kalra & Kalra, 2004a). Another experimental method is based on the theory that ACh 
inhibits feeding through the M1 receptors if a muscarinic agonist, arecholine, is injected into 
the NAC. This can be reversed by using an M1 antagonist pirenzapine (Rada & Hoebel, 
unpublished). Thus, it would be interesting to determine if arecholine would be a safe and 
effective method to prevent hyperphagia in individuals with FA and PWS patients. Some 
studies showed that taste aversion was a very useful therapy in which ACh levels were 
increased while decreasing DA levels (Mark et al., 1995). Others have found that baclofen, a 
GABA-B agonist, is useful for those that over-indulge on fatty foods (Buda-Levin, Wojnicki 
& Corwin, 2005). Other treatments utilized naloxone (an opioid antagonist) to block the 
opioid system, and rimonabant (a CB1 receptor antagonist) to block the cannabinoid system 
(Kenny, 2011); these systems have been shown to reinforce feeding behavior, and when used 
together, they act synergistically to treat obesity (Berry & Mechoulam, 2002). The still-
investigational drug is Lorcaserin, a combination of benzazepine and hydrochloride, two 
neurological agents. Lorcaserin is a selective 5-HT2C receptor agonist, working through the 
serotonin system, which regulates appetite, mood, and motor behavior. Two other 
investigational obesity drugs target the DA reward system-Contrave, which is a 
combination of bupropion and naltrexone, and Qnexa, which combines phentermine and 
topiramate (Solinas & Goldberg, 2005).  
7. Conclusion 
Obesity continues to place a tremendous burden on healthcare systems. Our current and 
future research on the neurobiological systems that motivate appetitive behavior strongly 
suggests that an acquired drive for highly energy-dense, reinforcing foods is contributing to 
weight gain. The limitations of current treatments compel healthcare professionals to 
develop more effective ways based on neurobiological addiction models to curb the obesity 
epidemic.  
Future studies should examine the relation between FA, hunger, and reward circuitry 
response with food intake and anticipated intake. The use of fMRI technology directly 
measures DA release or its receptors. It will be important to examine induced DA release 
and D2 receptor availability in those with FA. Other neurotransmitters are also likely to play 
an important role. Thus, future studies connecting FA and neural activation associated with 
these neurotransmitters will also be important. Understanding the mechanisms of hedonic 
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eating is essential for developing and implementing treatment and management strategies 
that address the root causes of obesity. In addition, cognitive factors such as social 
environment, emotional state, or intentional efforts to control consumption can also 
influence food intake. Most of what we know about these regulatory systems is derived 
from animal models, but our understanding of the control of eating behavior in humans is 
very limited. Consistent with the biological imperative to identify and consume food, 
neuroimaging studies have begun to document the responsiveness of the human brain to 
food cues such as odors and/or taste samples of food (Wang et al., 2004; Rosenbaum et al., 
2008). Future positron emission tomography (PET) and fMRI studies will provide 
neurobiological insights in brain alterations during addiction. fMRI is ideal for investigating 
activation in regions involved in a specific function, because scans can detect these 
simultaneously. It also provides temporal-spatial resolution and anatomical accuracy to be 
able to describe the interaction between major CNS components. This allows the monitoring 
of dynamic activities in the brain while processing visual cues (Zhang et al., 2011). Our 
group has future studies planned to determine brain responses when viewing photographs 
of food and non-food objects, where we will specifically examine brain regions important to 
the regulation of appetite and food intake in overweight and normal individuals. For 
example, one such fMRI study is to scan young healthy subjects of normal weight to 
measure different brain activation by visual images of highly rewarding-foods (high caloric 
foods such as hamburgers and chips) compared with images of non-rewarding objects 
during various physiological states; in particular, we are interested in effects of fast food-
branding on the brain and the effects in Chinese children with and without exposure to the 
Golden Arches (McDonald’s®) or the Kentucky Colonel (KFC®). The study tests the 
hypothesis of ‘food addiction’ that the fast food brands such as McDonald’s® may have 
reinforcing effects in the brain and such effects may be related to children’s drive to eat 
(Zhang et al., 2011). Using the Chinese population who has never been exposed to such food 
brands as controls (this CANNOT be done in the USA), this study would have a strong 
impact in the areas of addiction and obesity. Another research paradigm proposed is mostly 
based on a bottom-up approach to test the relationship between chronic subcutaneous 
recombinant leptin injections and weight loss (Benoit et al., 2004). fMRI techniques are 
powerful tools to probe leptin neurological function in modulation of human ingestive 
behavior and are ideal for investigating the concerted activity among the ensemble of 
regions involved in a specific function, because scans can detect all regions of brain 
activation simultaneously. Many recent studies have employed fMRI techniques to gain 
neuroanatomical insights into the effects of leptin in brain processing hunger, satiety and 
food reward in obese human subjects (Farooqi et al., 2007; Baicy et al., 2007). As a result, we 
propose to assess brain activation in response to acute subcutaneous leptin injection by 
examining the resting-state and exposure to stimuli consisting of food cues using an fMRI 
experiment (Zhang et al., 2011). We will also attempt to correlate the fMRI leptin brain 
response with weight gain based on a cafeteria diet. Positive results from this study will 
provide an invaluable diagnostic guideline for initiating early adulthood nutritional and 
behavioral intervention on an individualized basis to temper obesity development. This 
would constitute a realistic and meaningful cost-effective approach. An obesity-prevention 
strategy will help curb rising obesity treatment-related health expenditures. Positive study 
outcomes will also highlight a technological breakthrough for fMRI investigation of region-
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specific neural activity in an acutely stimulated brain reactive state rather than in a 
chronically adapted state following long-term drug treatment or other types of intervention. 
Thus, we hope to illuminate promising methods that use visual food cues to investigate 
mechanisms of human eating behavior, and to facilitate a more unified and reproducible 
approach to neuroimaging studies of FA and obesity. Results from this study can go far 
beyond obesity studies and could extend to the field of pharmacological research (Zhang et 
al., 2011). Furthermore, more research needs to be conducted world-wide especially in the 
Chinese population. Obesity in China is a multifactorial disease where intervention is not 
always clear-cut or applicable. For instance, specific gene therapy may be available in the 
future to prevent childhood and adulthood weight gain and endocrine disorders. Lifestyle 
and behavioral changes need to be addressed and applied to prevent unhealthy physiques. 
Alternative medicine intervention, such as acupuncture and Traditional Chinese Medicine 
remedies, may be most appropriate for this part of the world. Overall, obesity is preventable 
and now is the ideal time in implementing current scientific methods and techniques to 
battle this epidemic (von Deneen & Liu, 2011).  
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Department of Pharmacology, University of Murcia, Murcia, 
Spain 
1. Introduction 
The development of opioid addiction involves complex adaptive changes in opioid 
receptors and associated signalling systems, leading to neuronal plasticity in the brain 
regions projecting to different systems including the cardiovascular system. So, adaptive 
changes also occur in peripheral tissues and cells expressing opioid receptors, such as in the 
heart (Pugsley, 2002).  
The effects of drugs of abuse, especially cocaine, on the cardiovascular system, have been 
extensively documented in animal model and in human. There is emerging evidence that 
drug abuse might trigger a variety of cardiac disorders from arrhythmias to acute 
myocardial infarction, heart failure and even sudden cardiac death (Lippi et al., 2010). Thus, 
various types of cardiac arrhythmias have been described in heroin addicts. Moreover, street 
heroin addicts frequently die suddenly, and there is evidence that this is an arrhythmia-
related event (Nerantzis et al., 2011).  
The majority of studies dealing with morphine on the field of cardiology are oriented on 
clinical usage of this drug and current cardiovascular research has been limited to the 
evaluation of factors or pathways believed to contribute to its physiological actions, such as 
delta- and kappa-opioid receptors, cyclooxygenase-2, inducible nitric oxide synthase or 
reactive oxygen species (Huh et al., 2001; Wang et al., 2001; Jiang et al., 2006; Xu et al., 2011).  
Given the importance of morphine in clinical practice for the treatment of pain, investigation 
of its impact on the heart at the molecular levels requires more attention. Therefore, in this 
chapter we will discuss our recent discoveries about the implication of different molecular 
pathways in the cardiac adaptive changes that occur during morphine withdrawal.  
The noradrenergic pathways and the hypothalamo-pituitary-adrenocortical (HPA) axis, a 
system largely controlled by corticoticotropin-releasing factor (CRF) in the paraventricular 
nucleus (PVN) of the hypothalamus, comprise two major adaptation mechanisms to stress.  
Like stressors, morphine withdrawal activates HPA axis in rats, which results in neuronal 
activation of stress-related neurosecretory neurons in the parvocellular neurons of the PVN. 
The PVN is anatomically divided into three magnocellular and five parvocellular 
subdivisions. The parvocellular subdivisions comprise the dorsal, lateral, medial 
periventricular and anterior parvocellular subnuclei (fig. 1).  
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Fig. 1. Schematic illustrating the three main pathways by which the paraventricular nucleus 
of the hypothalamus (PVN) can influence sympathetic activity. Rostral ventrolateral 
medulla (RVLM), spinal intermediolateral cell column (IML). (Taken from Pyner, 2009). 
These regions project to autonomic nuclei in the brain stem and spinal cord and are 
responsible for the activation of the sympathetic nervous system including cardiovascular 
regulation (Sawchenko and Swanson, 1982). In addition, the PVN receives afferent 
projections from several limbic structures that are implicated in behavioural and 
cardiovascular control, such as the medial amygdale, the prefrontal cortex and the lateral 
septum (Ongur et al., 1998; Risold and Swanson, 1997). 
2. Hemodynamic variables during chronic morphine treatment and its 
withdrawal 
Previous studies have demonstrated that chronic μ-opiod receptor stimulation decreases 
muscle sympathetic nerve activity (Kienbaum et al., 2001; 2002), NA plasma concentration 
(Kienbaum et al., 2001) and dopamine turnover in the heart (Rabadán et al., 1997). 
According to these data, we have demonstrated that chronic morphine treatment decreases 
two baseline cardiovascular parameters, mean arterial blood pressure (MAP) and heart rate 
(HR). However, µ-opioid receptor blockade by naloxone unmasks these effects, resulting in 
markedly increases in both parameters (fig. 2 and 3). In agreement with these data, naloxone 
administration to patients with chronic opioid abuse or to morphine dependent rats results 
in markedly increased muscle sympathetic nerve activity, NA plasma concentrations (Peart 
and Gross, 2006),  NA and dopamine turnover (Almela et al., 2008; Milanés et al., 2000b) and 
total tyrosine hydroxylase (TH) expression (Almela et al., 2008). Altogether, these results 
suggest that an up-regulation of TH would be expected to increase the capacity of 
noradrenergic neurons to synthesize NA, which could contribute to the increase in NA 
turnover and in the hemodynamic changes seen in the heart during morphine withdrawal. 
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Fig. 2. Baseline mean arterial blood pressure (MAP) (mmHg) (A) in rats implanted with 
morphine or placebo pellets. Effects of naloxone (2 mg/kg s.c.) on changes in MAP (B). 
Naloxone was injected at time 0. Data are the mean±S.E.M. (n=5–7). ***P<0.001, **P<0.01, 
*P<0.05 versus placebo+naloxone. 
 
 
Fig. 3. Baseline heart rate (min−1) (A) in rats implanted with morphine or placebo pellets. 
Effects of naloxone (2 mg/kg s.c.) on changes in heart rate (B). Naloxone was injected at time 
0. Data are the mean±S.E.M. (n=5–7). ***P<0.001, **P<0.01, *P<0.05 versus 
placebo+naloxone. 
3. Evaluation of changes in pERK1/2 during morphine withdrawal 
Extracellular signal-regulated kinase (ERK), one member of mitogen-activated extracellular 
kinase (MAPK) family, transduces a broad range of extracellular stimuli into diverse 
intracellular responses. ERK signalling pathway could be important as regulator of cardiac 
function (Michel et al., 2001) and neuronal plasticity (Adams et al., 2002). Recently, several 
studies have shown that this pathway contributes to naloxone-precipitated withdrawal in 
morphine dependent rats (Ren et al., 2004; Almela et al., 2007, 2008, 2011). 
Our time course study showed that there was a significant elevation of phospho(p)ERK1 
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after naloxone administration to morphine dependent rats. We also studied the 
distribution of these proteins by immunohistochemical procedures and we observed 
high levels of pERK1/2 immunoreactivity in the right and left ventricle after naloxone 
administration to morphine-treated rats (fig. 5). The immunolabelling was mainly 
present in cytoplasmic compartments, suggesting a local activation of the protein. A 
nuclear staining was also observed in some myocytes, supporting a nuclear translocation 
of activated ERK proteins. These immunohistochemical results were consistent with 





Fig. 4. Western-blotting analysis of phospho(p)ERK1 and phospho(p)ERK2 in the right 
ventricle 30, 60, 90 and 120 min after saline (S) or naloxone (N) administration to placebo- 
(P) or morphine- (M) pretreated rats. The immunoreactivity corresponding to pERK1 or 
pERK2 is expressed as a percentage of that in the control group defined as 100% value. Data 
are the mean±S.E.M. (n=5–6). **P<0.01, *P<0.05 versus the placebo group injected with 
naloxone; +P<0.05 versus the dependent group injected with saline instead of naloxone; 
&&P<0.01, &P<0.05 versus the placebo group receiving saline. 
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Fig. 5. Immunohistochemical detection of phospho(p)ERK1/2 in the left ventricular wall. Rats 
were made dependent on morphine for 7 days and on day 8 were injected with naloxone (2 
mg/kg s.c.). 90 min after injections, rats were perfused and the right and left ventricle was 
processed for pERK1/2 immunohistochemistry. Scale bar 30 μm (a), 20 μm (b, c). 
4. Tyrosine hydroxylase phosphorylation  
TH, the rate limiting enzyme in the synthesis of catecholamines, plays important roles in the 
regulation of sympathetic nervous system and its impact on cardiac function (Rao et al., 2007). 
In particular, increases in the phosphorylation of Ser40 and Ser31 accelerate TH activity, 
thereby stimulating production of neurotransmitter in catecholamines terminals (Kumer and 
Vrana, 1996; Dunkley et al., 2004). TH expression is subjected to intricate regulation by a 
number of mechanisms, including transcriptional and post-transcriptional processes (Kumer 
and Vrana, 1996; Mallet, 1999). Short-term regulation of catecholamine biosynthesis occurs 
through the modulation of the state of phosphorylation of TH. TH phosphorylation and 
activation is the primary mechanism responsible for the maintenance of catecholamine levels 
in tissues after catecholamine secretion. TH can be phosphorylated at serine (Ser) residues 8, 
19, 31 and 40 by a variety of PKs (Campbell et al., 1986). PKA and PKC phosphorylate TH only 
at Ser40 (Roskoski et al., 1987; Funakoshi et al., 1991). ERK1 and ERK2 were shown to 
phosphorylate Ser31 in situ (Haycock et al., 1992). The phosphorylation of Ser40 increases the 
enzyme’s activity in vitro, in situ and in vivo. Phosphorylation at Ser31 also increases the 
activity but to a much lesser extent than Ser40 phosphorylation. The phosphorylation of TH at 
Ser19 or Ser8 has no direct effect on TH activity (Dunkley et al., 2004) (fig. 6). 
Previous studies have shown that naloxone-induced morphine withdrawal results in an 
increased NA turnover at heart level (Milanés et al., 2000a). This enhancement in NA 
turnover could be due to changes in the state of phosphorylation of TH, which are critically 
involved in the regulation of catecholamines synthesis and function. Therefore, we have 
studied the expression and phosphorylation at Ser31 and Ser40 during morphine 
withdrawal at different time points. Rats withdrawn from morphine presented an increase 
in total TH expression (fig. 7) and in TH phosphorylated at Ser31 (fig. 8) and Ser40 (fig. 9), 
together with an enhancement of TH activity (fig. 10). This activation of TH could be 
responsible for the increase in the hemodynamic parameters described above.  
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Fig. 6. The protein kinases (PK) and protein phosphatases (PP) capable of modulating 
tyrosine hydroxylase (TH) phosphorylation in vitro and in situ  
(Taken from Dunkley et al., 2004). 
 
Fig. 7. Western blotting analysis of TH immunoreactivity levels in the right and left ventricle 
60 or 90 min after saline (S) or naloxone (N) administration to placebo– (P) or morphine- (M) 
treated rats. The immunoreactivity corresponding to total TH is expressed as a percentage of 
that in the control group (P+S; defined as 100%). Data are the mean±S.E.M (n=4–6). **P<0.01, 
***P<0.001 versus the group receiving saline instead of naloxone; +P<0.05, ++P<0.01 versus 
the group pretreated with placebo instead of morphine.  
 


















Fig. 8. Western blotting analysis of phospho(p)Ser31TH in the right and left ventricle 60 or 
90 min after saline (S) or naloxone (N) administration to placebo- (P) or morphine- (M) 
treated rats. The immunoreactivity corresponding to pSer31TH is expressed as a percentage 
of that in the control group (P+S; defined as 100%). Data are the mean±S.E.M. (n=4–6). 
*P<0.05 versus the group receiving saline instead of naloxone; ++P<0.01, +P<0.05 versus the 
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Fig. 8. Western blotting analysis of phospho(p)Ser31TH in the right and left ventricle 60 or 
90 min after saline (S) or naloxone (N) administration to placebo- (P) or morphine- (M) 
treated rats. The immunoreactivity corresponding to pSer31TH is expressed as a percentage 
of that in the control group (P+S; defined as 100%). Data are the mean±S.E.M. (n=4–6). 
*P<0.05 versus the group receiving saline instead of naloxone; ++P<0.01, +P<0.05 versus the 
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Fig. 9. Western blotting analysis of phospho(p)Ser40 TH in the right and left ventricle 60 or 
90 min after saline (S) or naloxone (N) administration to placebo- (P) or morphine- (M) 
treated rats. The immunoreactivity corresponding to pSer40TH is expressed as a percentage 
of that in the control group (P+S; defined as 100%). Data are the mean±S.E.M. (n=4–6). 
*P<0.05 versus the group receiving saline instead of naloxone; +P<0.05 versus the group 
pretreated with placebo instead of morphine.  
 
Fig. 10. TH activity in right and left ventricle from placebo or morphine dependent rats 90 
min after s.c. administration of saline or naloxone. Data are the mean±S.E.M. (n=4–6). 
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5. Changes in c-Fos expression  
c-Fos immunoreactivity was examined by western blot and immunohistochemistry. Western 
blot analysis showed that after naloxone injection to rats chronically treated with morphine, 
there was a significant induction of c-Fos immunoreactivity in the right and left ventricle. 
Immunohistochemical analysis corroborated these results. Thus, rats dependent on 
morphine and given naloxone showed a significant induction of c-Fos immunoreactivity in 
the right ventricle, septum and left ventricle (fig. 11). This increase of c-Fos could contribute 
to activate TH synthesis through its activity on the AP-1 sequence present in the TH gene 
promoter region. 
 
Fig. 11. (a) Representative immunoblots of c-Fos in samples isolated from placebo (P) or 
morphine (M) dependent rats 90 min after s.c. administration of saline (S) or naloxone (N). 
For quantification, optical densities of c-Fos immunoreactive bands were measured, 
normalized to the background values, and expressed as percentage of controls, defined as 
100% value. Data are the mean±S.E.M. (n=4–6). +++P<0.001 versus M+S; ***P<0.001 versus 
P+N. (b) Photomicrographs of c-Fos immunoreactvity in the right and left ventricular wall 
and in the septum, after naloxone-precipitated withdrawal. Scale bar 58 μm.  
6. Implication of ERK and PKA in the cardiac adaptive changes observed 
during morphine withdrawal 
To assess the relative contribution of ERK and PKA to the regulation of c-Fos and TH, we 
examined morphine withdrawal-induced c-Fos expression in animals receiving SL327, a 
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*P<0.05 versus the group receiving saline instead of naloxone; +P<0.05 versus the group 
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Fig. 10. TH activity in right and left ventricle from placebo or morphine dependent rats 90 
min after s.c. administration of saline or naloxone. Data are the mean±S.E.M. (n=4–6). 
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6. Implication of ERK and PKA in the cardiac adaptive changes observed 
during morphine withdrawal 
To assess the relative contribution of ERK and PKA to the regulation of c-Fos and TH, we 
examined morphine withdrawal-induced c-Fos expression in animals receiving SL327, a 
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selective ERK inhibitor or HA-1004, a selective PKA inhibitor. SL327 administration before 
naloxone to rats chronically treated with morphine significantly diminished the increase in 




Fig. 12. Morphine withdrawal stimulates c-Fos expression in the right and left ventricle. 
Representative immunoblots of c-Fos in the right and left ventricle tissue isolated from 
placebo (P) or morphine (M) dependent rats, 90 min after s.c. administration of naloxone 
(Nx, N) in the absence (vehicle, veh, V, DMSO) or presence of SL327 (SL, 100 mg/kg) 1 h 
before naloxone. c-Fos immunoreactive bands were measured, normalized to the 
background values and expressed as percentages of controls. Data correspond to 
mean±S.E.M. (n=4). +++P<0.001, ++P<0.01 versus M+SL+N; ***P<0.001 versus P+V+N.  
However, chronic inhibition of PKA concurrently with morphine treatment did not modify 
c-Fos induction during morphine withdrawal (fig. 13). These results reveal that ERK but not 
PKA is an important pathway mediating c-Fos induction. However, previous results from 
our laboratory showed that inhibition of PKC also produced an inhibition of c-Fos 
expression in the heart (Almela et al., 2006) suggesting that the transcriptional regulation of 
c-Fos seems to be under a combined control of an ERK-dependent and-independent 
pathway. On the other hand, the expression of c-Fos, mainly due to phosphorylation of 
ERK1/2, was not antagonized by propranolol or prazosin (González-Cuello et al., 2004), 
suggesting that the activation of ERK and c-Fos expression is not due to an indirect 
mechanism via sympathetic activation. 
In addition, our results showed that SL327 blocks the increase in TH phosphorylated at 
Ser31 observed in the right and left ventricle after the injection of naloxone to morphine 
dependent rats (fig. 14). The only protein kinase reported to phosphorylate TH at Ser31 in 
vitro was ERK (Haycock et al., 1992; Lindgren et al., 2002). In situ phosphorylation of TH at 
Ser31 increases TH activity and catecholamine synthesis (Haycock, 1992). Given that TH is 
phosphorylated on a specific serine residue (Ser31) by the ERK, it is possible that activation 
of ERK1/2 in the heart provides a way in which TH is regulated under morphine 
dependence.   
 




Fig. 13. Western blotting analysis of c-Fos immunoreactivity levels in the right and left 
ventricle after naloxone-precipitated withdrawal in vehicle- (veh, V) infused rats and in 
animals chronically administered with HA-1004 (HA). Animals received s.c. implantation of 
placebo (pla, P) or morphine (mor, M) pellets for 7 days and concomitantly were infused 
with vehicle or HA-1004 (40 nmol/day). On day 8, rats were injected with saline (S) or 
naloxone (N, 5 mg/kg, s.c.) and were decapitated 90 min later. The immunoreactivity 
corresponding to c-Fos is expressed as a percentage of that in the control group (P+V+S; 
defined as 100% value). Data are the mean±SEM (n=4–6). ***p<0.001 versus the group 
receiving saline instead of naloxone; +++p<0.001 versus the group pretreated with placebo 




Fig. 14. Phospho(p)Ser31TH immunoblots in right and left ventricle from placebo or 
morphine dependent rats 90 min after s.c. administration of naloxone in the absence or 
presence of SL327 (SL, 100 mg/kg, i.p.), 1 h before naloxone. pSer31TH immunoreactive 
bands were measured, normalized to the background values and expressed as percentage of 
controls. Data are the mean±S.E.M. (n=4–6). ++P<0.01 versus the group pretreated with 
placebo instead of morphine; &&P<0.01 versus morphine+SL+naloxone. 
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Fig. 14. Phospho(p)Ser31TH immunoblots in right and left ventricle from placebo or 
morphine dependent rats 90 min after s.c. administration of naloxone in the absence or 
presence of SL327 (SL, 100 mg/kg, i.p.), 1 h before naloxone. pSer31TH immunoreactive 
bands were measured, normalized to the background values and expressed as percentage of 
controls. Data are the mean±S.E.M. (n=4–6). ++P<0.01 versus the group pretreated with 
placebo instead of morphine; &&P<0.01 versus morphine+SL+naloxone. 
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Similarly, HA-1004 blocked the enhancement of TH phosphorylated at Ser40 in the heart 
after morphine withdrawal (fig. 15), suggesting that different pathways are implicated in the 




Fig. 15. Western blotting analysis of phospho(p)Ser40TH in the right ventricle 60 min after 
saline (S) or naloxone (N) administration to placebo- (pla, P) or morphine- (mor, M) treated 
rats receiving vehicle (veh, V) or HA-1004 (HA). The immunoreactivity corresponding to 
pSer40TH is expressed as a percentage of that in the control group (P+V+S; defined as 
100%). Data are the mean±S.E.M. (n=4–6). *P<0.05 versus the group receiving saline instead 
of naloxone; +P<0.05 versus the group pretreated with placebo instead of morphine; &P<0.05 
versus the group receiving vehicle instead of HA-1004.  
7. Crosstalk between PKA and ERK 
It is now appreciated that crosstalk among various signal pathways plays an important role 
in activation of intracellular and intranuclear signal transduction cascades. In our study, 
chronic treatment with HA-1004 antagonized the increase in ERK1/2 phosphorylation 
observed during morphine withdrawal in the heart (fig. 16). These results suggest a 
crosstalk between PKA and ERK pathways.  
To assess the contribution of PKA to the regulation of TH, we examined TH phosphorylated 
at Ser31 during morphine withdrawal in animals receiving the selective inhibitor of PKA 
HA-1004. This inhibitor prevents the ability of naloxone-precipitated morphine withdrawal 
to increase TH phosphorylated at Ser31 levels in the right and left ventricle (fig. 17).  
Although the mechanism of crosstalk between PKA and ERK pathways has not yet been 
clarified, it is possible that PKA pathway facilitates MEK1/2 that activates the ERK1/2 
pathway (Obama et al., 2007; Stork and Schmitt, 2002). The activated ERK pathway increases 
the phosphorylation of proteins related to morphine dependence, including TH. Using 
phosphorylation state-specific antibodies directed toward TH at Ser31, we have shown that 
HA-1004 blocked the increase in the level of TH phosphorylation at Ser31 induced after 
naloxone injection to morphine dependent rats in the right and left ventricle. These data 
suggest that crosstalk between PKA and ERK pathways is a key regulatory design necessary 
to regulate the Ser31 phosphorylation of TH. 
 
Pathways Involved in the Cardiac Adaptive Changes Observed During Morphine Withdrawal 303 
 
 
Fig. 16. Western blotting analysis of phospho(p)ERK1 and phospho(p)ERK2 immunoreactivity 
levels in the right ventricle 60 min after saline (S) or naloxone (N) administration to placebo- 
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the control group (P+V+S; defined as 100% value). Data are the mean±S.E.M. (n=4-6). **P<0.01, 
*P<0.05 versus the dependent group receiving saline instead of naloxone. ++P<0.01, +P<0.05 
versus the group pretreated with placebo instead of morphine injected with naloxone. 
&&P<0.01, &P<0.05 versus the group receiving vehicle instead of HA.  
 
 
Fig. 17. Western blotting analysis of phospho(p)Ser31TH in the right and left ventricle 90 min 
after saline (S) or naloxone (N) administration to placebo- (pla, P) or morphine- (mor, M) 
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Fig. 17. Western blotting analysis of phospho(p)Ser31TH in the right and left ventricle 90 min 
after saline (S) or naloxone (N) administration to placebo- (pla, P) or morphine- (mor, M) 
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treated rats receiving vehicle (veh, V) or HA-1004 (HA). The immunoreactivity 
corresponding to pSer31TH is expressed as a percentage of that in the control group (P+V+S 
or P+HA+S; defined as 100% value). Data are the mean±S.E.M. (n=4–6). *p<0.05 versus the 
dependent group receiving saline instead of naloxone; ++P<0.01, +P<0.05 versus the group 
pretreated with placebo instead of morphine injected with naloxone. &&P<0.01 versus the 
group receiving vehicle instead of HA.  
8. Conclusion 
Naloxone administration after chronic morphine treatment, triggers neurochemical 
adaptations in the noradrenergic system and enhances PKA and ERK pathways. The 
functional consequences of this activation include an increase in TH activation and NA 
turnover and an enhancement in c-Fos expression. Many pathways implicated in the 
adaptive changes observed during withdrawal are subject to feedback mechanisms that 
can either amplify or suppress their own signalling and there is considerable signalling 
from one pathway to another, a phenomenon known as crosstalk. Consequently, the 
responses that cells mount to specific environmental conditions depend on the sum of the 
intensity and duration of signals from several pathways and how they interact with each 
other. Although the mechanism of crosstalk between PKA and ERK pathways has not yet 
been clarified, it is possible that PKA pathway facilitates MEK1/2 that activates the 
ERK1/2 pathway (Obama et al., 2007; Stork and Schmitt, 2002). The activated ERK 
pathway increases the phosphorylation of proteins related to morphine dependence, 
including TH. Our data suggest that crosstalk between PKA and ERK pathways is a key 
regulatory design necessary to regulate the phosphorylation of TH. These findings 
provide a new explanation to understand the complex mechanisms implicated in the 
adaptive changes observed during morphine withdrawal and could be useful for future 
treatment strategies. 
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pretreated with placebo instead of morphine injected with naloxone. &&P<0.01 versus the 
group receiving vehicle instead of HA.  
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1. Introduction 
Cocaine addiction continues to be an important public health problem in the United States 
and other countries. Acute cocaine produces potent rewarding and psychostimulant 
effects primarily by blocking dopamine (DA) transporters (DAT) in the brain's reward 
system – the mesocorticolimbic DA system. However, repeated use of cocaine leads to 
addiction, persistent craving and a high risk of relapse. To date, there are no proven 
pharmacotherapies for cocaine addiction. Recent progress in the neurobiology of drug 
dependence in preclinical animal models has lead to the discovery of various novel 
compounds that appear to be promising for the treatment of drug addiction. Some have 
been tested in controlled clinical trials and have produced encouraging results in reducing 
cocaine use and in increasing abstinence from relapse. In this review article, I will focus 
on those medication strategies that are well-studied in experimental animals and are 
currently under clinical trials for the treatment of addiction or for other diseases. These 
strategies include DAT-based agonist therapy, DA receptor-based antagonist therapy, 
glutamate-based therapy, GABA-based therapy and endocannabinoid-based therapy. For 
each treatment, I will first review the rationale and the underlying neurochemical 
mechanisms of the therapy, and then summarize the major findings of the drugs in each 
category at both preclinical and clinical levels.  
2. Dopamine transporter-based agonist therapies 
Rationale: The mesocorticolimbic DA system is thought to be critically involved in drug 
reward and addiction (Wise, 2005; Sulzer, 2011). This system originates from the DA 
neurons in the ventral tegmental area (VTA) in the midbrain and projects predominantly to 
the nucleus accumbens (NAc) and prefrontal cortex (PFC) in the forebrain (Figure 1). 
Almost all addictive drugs, such as cocaine, heroin, nicotine and alcohol, have been shown 
to increase extracellular DA in the NAc via different mechanisms (Wise, 2005; Sulzer, 2011). 
For example, cocaine elevates extracellular DA by blockade of DAT, while heroin increases 
extracellular DA by inhibition of GABA release in the VTA that disinhibits (activates) DA 
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neurons. Such an increase in NAc DA has been thought to underlie the euphoria associated 
with drug abuse. Based on this DA hypothesis, much attention in medication development 
for treatment of addiction has been focused on manipulation of DA transmission in the 
brain reward circuitry. One strategy is to target DAT (agonist therapy), and another is to 
target brain DA receptors (antagonist therapy) (Figure 2).  
 
Fig. 1. Schematic diagrams, illustrating the mesocorticolimbic DA reward system in human 
(A) and rat (B) brains. The mesocorticolimbic DA system originates in the midbrain ventral 
tegmental area (VTA) and projects predominantly to the nucleus accumbens (NAc) and 
prefrontal cortex (PFC). Dopaminergic afferents from the VTA and glutamatergic afferents 
from the PFC, hippocampus and amygdala synapse on NAc medium-spiny (GABAergic) 
neurons (MSN), which project to the VTA and the ventral pallidum (VP).   
Agonist or substitution therapies have been successful in the treatment of opioid (Mattick et 
al., 2009) and nicotine dependence (Xi et al., 2009; Xi, 2010). As such, drugs that block the 
DAT, but have lower addictive potential than cocaine, would have potential as ‘cocaine-like’ 
agonist therapies for the treatment of cocaine addiction. Indeed, this strategy has been at the 
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forefront of medication development for the treatment of cocaine addiction for more than a 
decade (Rothman and Baumann, 2006; Howell and Kimmel, 2008). To date, many DAT 
inhibitors have been developed, and several of them have been tested in human clinical 
trials (Newman and Kulkarni, 2002; Runyon and Carroll, 2006; Rothman et al., 2006, 2008). 
 
 
Fig. 2. Schematic diagram of the VTA-NAc-VP reward pathway, illustrating the actions of 
acute cocaine on extracellular DA, endocannabinoids (eCBs), glutamate and GABA in the 
NAc and VP, and the sites of action of various mechanism-based pharmacological agents in 
the brain reward system. Cocaine elevates extracellular DA in the NAc by blocking DAT on 
presynaptic DA terminals. DA activates postsynaptic DA receptors, in particular D2 and D3 
receptors, producing an overall inhibitory effect on NAc medium-spiny (GABAergic) 
neurons (MSN). In addition, activation of D2 receptors may also increase eCB release from 
MSNs, which subsequently activates cannabinoid CB1 receptors located on presynaptic 
glutamatergic terminals and GABAergic MSNs themselves, causing a reduction in 
glutamate release and in MSN excitability. Thus, increases in NAc DA and eCBs and a 
reduction in NAc glutamate release lead to a reduction in MSN excitability and GABA 
release in the VTA (not shown) and VP. Decreased GABA release in the VTA causes an 
increase in DA neuron activity (via a disinhibition mechanism) and DA release in the NAc. 
Based upon these neurochemical hypotheses, various pharmacological therapies have been 
proposed and tested in animal models of drug addiction to interfere with cocaine’s action. 
More details are discussed in the text of this review.  
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However, none have proven to be successful due to significant abuse liability by those 
compounds themselves and/or unwanted side-effects. Given the recent finding that 
rewarding and psychostimulant effects of the drugs are positively correlated with the speed 
of onset and offset of action on brain DA (Volkow et al., 1995; Kimmel et al., 2007; Xi and 
Gardner, 2008), it has been proposed that DAT inhibitors (Figure 2), in particular those with 
a slower-onset longer-acting profile than cocaine, would have lower addictive potential by 
themselves. In the following sections, we will review several DAT inhibitors with such a 
slow-onset long-action profile. 
2.1 GBR-12909  
Preclinical studies: GBR-12909 (Vanoxerine), a phenyl-substituted piperazine derivative, is a 
relatively slow-onset long-acting DAT inhibitor compared to cocaine (Howell and Wilcox, 
2001). To date, it is the most extensively studied DAT inhibitor proposed to be beneficial in 
the treatment of cocaine addiction (Rothman et al., 2008). GBR-12909 binds at the DAT site 
with high affinity, and selectively inhibits DA re-uptake. GBR-12909 can also compete with 
psychostimulants at the DAT site, thus blocking cocaine- or amphetamine-induced increases 
in extracellular DA. Compared to the same doses of cocaine, GBR-12909-induced increases 
in striatal DA and locomotion are relatively slow-onset and long-lasting (Baumann et al., 
1991, 1994; Kelley and Lang, 1989). Pretreatment with GBR-12909 significantly inhibits 
cocaine self-administration in rats and nonhuman primates at doses that have little or no 
effect on food self-administration (Glowa et al., 1995). Repeated treatment with low doses of 
GBR-12909 sustains the selective suppression of cocaine self-administration versus food self-
administration (Glowa et al., 1995). Further, a single injection of a slow-release formulation 
of GBR-12909 produced a prolonged (up to one month) suppression of cocaine self-
administration in nonhuman primates (Glowa et al., 1996). These findings support GBR-
12909 as a potential candidate for the treatment of cocaine addiction (Rothman et al., 2008).  
Clinical trials: GBR-12909 was investigated in clinical trials at NIDA and University of Texas 
from 2003 to 2008 (Table 1). However, the appearance of cardiovascular side-effects has 
prevented its further development as an anti-cocaine medicine at NIDA, NIH (Vocci and 
Elkashef, 2005).  
2.2 RTI-336 
Preclinical studies: RTI-336 is a novel DAT inhibitor of the 3-phenyltropane class and has a 
slower-onset (30 min vs. < 10 min) longer-acting (4 hrs vs. 1-2 hrs) profile than cocaine 
(Carroll et al., 2006; Kimmel et al., 2007). It has >1000- and >400-fold selectivity for  
DAT over serotonin transporter (SERT) and norepinepherine transporter (NET), respectively 
(Carroll et al., 2006). Pretreatment with RTI-336 produced a dose-dependent reduction in 
cocaine self-administration in both rats and nonhuman primates (Haile et al., 2005; Howell 
et al., 2007). The ED50 dose of RTI-336 for reducing cocaine self-administration resulted in 
approximately 90% DAT occupancy, suggesting that high levels of DAT occupancy by RTI-
336 are required to reduce cocaine self-administration. However, co-administration of the 
ED50 dose of RTI-336 with the SERT inhibitors fluoxetine or citalopram produced more 
robust reductions in cocaine self-administration in non-human primates than RTI-336 alone 
(Howell et al., 2007), suggesting that blockade of both DAT and SERT may be more effective 
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in attenuating cocaine’s reinforcing effects than selective blockade of DAT alone (Rothman 
et al., 2007). In addition, at the doses that effectively suppressed cocaine self-administration, 
RTI-336 also inhibited food-taking behavior (Howell et al., 2007). This differs from GBR-
12909, which selectively inhibits cocaine self-administration but not food-taking behavior. 
RTI-336, like many other DAT inhibitors, reliably maintained self-administration behavior 
in all non-human primates tested (Howell et al., 2007) and produced locomotor stimulating 
effects in mice and rats, suggesting abuse potential by itself. However, compared to cocaine, 
RTI-336 maintained lower rates of responding and lower progressive-ratio (PR) break-points 
in the self-administration paradigm. It also produced weaker locomotion hyperactivity and 
drug discriminative stimulus effects, and showed very low sensitization in locomotion 
(Carroll et al., 2006; Czoty et al., 2010). These data suggest that RTI-336 may have lower 
abuse potential than cocaine. 
Clinical trials: RTI-336 has been investigated in Phase I clinical trials at RTI International 
(NC, USA) and NIDA (MD, USA) since 2008 (Table 1). It was a double-blind, placebo-
controlled Phase I study to evaluate the safety, tolerability, and pharmacokinetics of RTI-336 
in healthy, male subjects. The study has been completed, but not yet reported. 
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Table 1. DAT- or DA-related drug candidates in clinical trials 
2.3 CTDP-31,345 
Based upon the above finding that a combination of DAT and SERT inhibitors appears to be 
more potent and effective than DAT inhibitor alone in attenuation of cocaine self-
administration (Howell et al., 2007), we studied slow-onset long-acting monamine transporter 
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(MAT) inhibitors that have higher affinity for both DAT and SERT over to NET. In addition, 
our interest in non-selective MAT inhibitors as potential anti-cocaine medications originally 
stems from the fact that cocaine is also a non-selective MAT inhibitor. Thus, it was 
hypothesized that a ‘cocaine-like’ MAT inhibitor with slow-onset and long-acting profiles 
would be able to substitute for cocaine for the treatment of cocaine dependence (Peng et al., 
2010c). CTDP-31,345 is such a MAT inhibitor with slow-onset (30-60 min) long-acting (at least 
6 hrs) (Peng et al., 2010c) and with higher selectivity for DAT and SERT over NET (Ki = 18, 23 
and 81 for DAT, SERT and NET, respectively) (Froimowitz et al., 2000). The “CTDP” 
terminology derives from the “Cocaine Treatment Discovery Program” of the NIDA 
Extramural Program. Structurally, it is a trans-aminotetralin derivative (Peng et al., 2010c). It is 
a prodrug, which is metabolized (N-demethylated) to CTDP-31,346, a slow-onset long-acting 
MAT inhibitor. Pretreatment with a single dose of CTDP-31,345 produced a dose-dependent 
long-term (24-48 h) reduction in cocaine self-administration in rats (Peng et al., 2010c). CTDP-
31,345 itself appears to have lower abuse liability than cocaine because it produces weaker 
brain-stimulation reward and maintains a lower rate of self-administration than cocaine (Peng 
et al., 2010c). In addition, systemic administration of CTDP-31,345 produces moderate, but 
long-lasting, increases in NAc DA, which may translate to decreases in drug craving and 
relapse by restoring reduced synaptic DA in brain reward circuits (Volkow et al., 1999). CTDP-
31,345 is not currently in clinical trials.  
2.4 Methylphenidate 
Preclinical studies: Methylphenidate is a FDA-approved DAT inhibitor for the treatment of 
attention deficit hyperactivity disorder (ADHD). It binds to presynaptic DAT and NET, but 
not to SERT, blocking DA and NE re-uptake and increasing synaptic DA and NE (Leonard 
et al., 2004). Methylphenidate is self-administered in rodents, and pretreatment with 
methylphenidate significantly shifts the cocaine self-administration dose-response curve to 
the left (Hiranita et al., 2009, 2011), suggesting that methylphenidate has cocaine-like abuse 
potential and produces additive effects in combination with cocaine.  
Clinical trials: ADHD has high comorbidity with cocaine-dependent patients as much as 30% 
in some studies (Schubiner et al., 2000). Because of this, its therapeutic effects for the 
treatment of cocaine addiction in this population have been recently evaluated in clinical 
trials (Table 1). Placebo-controlled studies produced mixed results with one study reporting 
no effect (Schubiner et al., 2002) while three studies demonstrating a significant reduction in 
both cocaine use and the positive subjective effects of cocaine compared to placebo 
(Winhusen et al., 2006; Collins et al., 2006; Levin et al., 2007). Because the half-life of 
methylphenidate is short (2-3 hrs in humans), the drug has been made available in 
sustained-release formulations in addition to the traditional immediate-release formulation. 
The sustained-release methylphenidate displayed much lower abuse potential than 
immediate-release, and appears to be more effective than immediate-release in decreasing 
cocaine use and the positive subjective effects (Arria and Wish, 2006; White et al., 2006).  
2.5 CTDP-32,476 
Based on the aforementioned findings of sustained-release methylphenidate in clinical trials, 
we have recently developed a series of methylphenidate analogs with slow-onset long-acting 
profiles as medication candidates for the treatment of cocaine addiction. CTDP-32,476 is a 
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representative compound in this drug category. Structurally, CTDP-32,476 is a metabolically 
stable methylphenidate analog, in which the metabolically unstable ester moiety of 
methylphenidate is removed from methylphenidate’s structure (Froimowitz et al. 2007). In 
vitro binding assays suggest that CTDP-32,476 is a selective DAT inhibitor with ~50-fold and 
~350-fold selectivity for DAT over NET and SERT (Ki= 16, 5900 and 840 nM for DAT, SERT 
and NET, respectively) (Froimowitz et al., 2007). Functional reuptake assays reveal that CTDP-
32,476 has IC50 values of 8.6, 490 and 120 nM for inhibition of DA, 5-HT and NE reuptake, 
respectively. In addition, it also displays approximately 30-fold higher affinity for the DAT 
than cocaine (Ki: 16 vs. 500 nM; IC50: 8.6 vs. 244 nM) (Froimowitz et al., 2007). Systemic 
administration of CTDP-32,476 produced a slow-onset (20-60 min) long-term (6-12 hrs) 
increase in locomotion and extracellular DA in the NAc (Xi et al., 2009). Pretreatment with 
CTDP-32,476 significantly and dose-dependently inhibited intravenous cocaine self-
administration under both FR and PR reinforcement, shifted the cocaine dose-response self-
administration curves downward and to the right, and attenuated cocaine-induced increases 
in locomotion and extracellular DA in the NAc (Xi et al., 2011a). These data suggest that 
pretreatment with CTDP-32,476 produced functional antagonism of cocaine’s action, likely by 
attenuating cocaine’s binding to DAT. CTDP-32,476 itself appears to have much lower 
addictive potential than cocaine. Drug naïve rats selectively self-administer cocaine, but not 
CTDP-32,476. In rats trained to self-administer cocaine, CTDP-32,476 maintained significantly 
lower rates of self-administration and lower PR break-points than cocaine. Taken together, 
these data suggest that CTDP-32,476 appears to be an excellent agonist therapy for cocaine 
dependence. CTDP-32,476 has not been tested in human clinical trials. 
2.6 Modafinil 
Preclinical studies: Modafinil is a wake-promoting drug used in the clinic for the treatment of 
narcolepsy and idiopathic hypersomnia (Wise et al., 2007). However, the neurochemical 
mechanisms underlying modafinil’s action are not fully understood. It is reported that 
modafinil increases extracellular levels of glutamate in numerous brain regions including 
striatum, thalamus, hippocampus, and hypothalamus (Ballon and Feifel, 2006; Wise et al., 
2007). In addition, it also inhibits brain GABA release (Ballon and Feifel, 2006). Recent 
studies suggest that modafinil is a DAT inhibitor in humans and primates (Madras et al., 
2006; Volkow et al., 2009). This is further supported by the findings that mice lacking DAT 
or DA (D1 and D2) receptors do not respond to the wake-promoting effects of modafinil (Qu 
et al., 2008; Wisor et al., 2001). In vivo microdialysis studies demonstrated that modafinil 
increases extracellular DA (Wisor et al., 2001; Ferraro et al., 1997; Murillo-Rodríguez et al., 
2007). Neuroimaging studies in both non-human primates and healthy human subjects 
demonstrated significant occupancy of DAT (and also NET) by intravenously-administered 
modafinil (Madras et al., 2006; Volkow et al., 2009). Consistent with these findings, 
modafinil has been shown to have weak cocaine-like discriminative and reinforcing effects 
in both rodents and non-human primates (Gold and Balster., 1996; Deroche-Gamonet et al., 
2002), and weak stimulant-like subjective effects in humans (Kruszewski, 2006; O'Brien et 
al., 2006). Based on these recent findings, modafinil is categorized as a DAT-based ‘agonist 
therapy’ for cocaine dependence.  
Clinical studies:  Dackis et al (2003) first reported that modafinil's stimulant-like activity may 
diminish the symptoms of cocaine withdrawal, including hypersomnia, lethargy, dysphoric 
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(MAT) inhibitors that have higher affinity for both DAT and SERT over to NET. In addition, 
our interest in non-selective MAT inhibitors as potential anti-cocaine medications originally 
stems from the fact that cocaine is also a non-selective MAT inhibitor. Thus, it was 
hypothesized that a ‘cocaine-like’ MAT inhibitor with slow-onset and long-acting profiles 
would be able to substitute for cocaine for the treatment of cocaine dependence (Peng et al., 
2010c). CTDP-31,345 is such a MAT inhibitor with slow-onset (30-60 min) long-acting (at least 
6 hrs) (Peng et al., 2010c) and with higher selectivity for DAT and SERT over NET (Ki = 18, 23 
and 81 for DAT, SERT and NET, respectively) (Froimowitz et al., 2000). The “CTDP” 
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Extramural Program. Structurally, it is a trans-aminotetralin derivative (Peng et al., 2010c). It is 
a prodrug, which is metabolized (N-demethylated) to CTDP-31,346, a slow-onset long-acting 
MAT inhibitor. Pretreatment with a single dose of CTDP-31,345 produced a dose-dependent 
long-term (24-48 h) reduction in cocaine self-administration in rats (Peng et al., 2010c). CTDP-
31,345 itself appears to have lower abuse liability than cocaine because it produces weaker 
brain-stimulation reward and maintains a lower rate of self-administration than cocaine (Peng 
et al., 2010c). In addition, systemic administration of CTDP-31,345 produces moderate, but 
long-lasting, increases in NAc DA, which may translate to decreases in drug craving and 
relapse by restoring reduced synaptic DA in brain reward circuits (Volkow et al., 1999). CTDP-
31,345 is not currently in clinical trials.  
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both cocaine use and the positive subjective effects of cocaine compared to placebo 
(Winhusen et al., 2006; Collins et al., 2006; Levin et al., 2007). Because the half-life of 
methylphenidate is short (2-3 hrs in humans), the drug has been made available in 
sustained-release formulations in addition to the traditional immediate-release formulation. 
The sustained-release methylphenidate displayed much lower abuse potential than 
immediate-release, and appears to be more effective than immediate-release in decreasing 
cocaine use and the positive subjective effects (Arria and Wish, 2006; White et al., 2006).  
2.5 CTDP-32,476 
Based on the aforementioned findings of sustained-release methylphenidate in clinical trials, 
we have recently developed a series of methylphenidate analogs with slow-onset long-acting 
profiles as medication candidates for the treatment of cocaine addiction. CTDP-32,476 is a 
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representative compound in this drug category. Structurally, CTDP-32,476 is a metabolically 
stable methylphenidate analog, in which the metabolically unstable ester moiety of 
methylphenidate is removed from methylphenidate’s structure (Froimowitz et al. 2007). In 
vitro binding assays suggest that CTDP-32,476 is a selective DAT inhibitor with ~50-fold and 
~350-fold selectivity for DAT over NET and SERT (Ki= 16, 5900 and 840 nM for DAT, SERT 
and NET, respectively) (Froimowitz et al., 2007). Functional reuptake assays reveal that CTDP-
32,476 has IC50 values of 8.6, 490 and 120 nM for inhibition of DA, 5-HT and NE reuptake, 
respectively. In addition, it also displays approximately 30-fold higher affinity for the DAT 
than cocaine (Ki: 16 vs. 500 nM; IC50: 8.6 vs. 244 nM) (Froimowitz et al., 2007). Systemic 
administration of CTDP-32,476 produced a slow-onset (20-60 min) long-term (6-12 hrs) 
increase in locomotion and extracellular DA in the NAc (Xi et al., 2009). Pretreatment with 
CTDP-32,476 significantly and dose-dependently inhibited intravenous cocaine self-
administration under both FR and PR reinforcement, shifted the cocaine dose-response self-
administration curves downward and to the right, and attenuated cocaine-induced increases 
in locomotion and extracellular DA in the NAc (Xi et al., 2011a). These data suggest that 
pretreatment with CTDP-32,476 produced functional antagonism of cocaine’s action, likely by 
attenuating cocaine’s binding to DAT. CTDP-32,476 itself appears to have much lower 
addictive potential than cocaine. Drug naïve rats selectively self-administer cocaine, but not 
CTDP-32,476. In rats trained to self-administer cocaine, CTDP-32,476 maintained significantly 
lower rates of self-administration and lower PR break-points than cocaine. Taken together, 
these data suggest that CTDP-32,476 appears to be an excellent agonist therapy for cocaine 
dependence. CTDP-32,476 has not been tested in human clinical trials. 
2.6 Modafinil 
Preclinical studies: Modafinil is a wake-promoting drug used in the clinic for the treatment of 
narcolepsy and idiopathic hypersomnia (Wise et al., 2007). However, the neurochemical 
mechanisms underlying modafinil’s action are not fully understood. It is reported that 
modafinil increases extracellular levels of glutamate in numerous brain regions including 
striatum, thalamus, hippocampus, and hypothalamus (Ballon and Feifel, 2006; Wise et al., 
2007). In addition, it also inhibits brain GABA release (Ballon and Feifel, 2006). Recent 
studies suggest that modafinil is a DAT inhibitor in humans and primates (Madras et al., 
2006; Volkow et al., 2009). This is further supported by the findings that mice lacking DAT 
or DA (D1 and D2) receptors do not respond to the wake-promoting effects of modafinil (Qu 
et al., 2008; Wisor et al., 2001). In vivo microdialysis studies demonstrated that modafinil 
increases extracellular DA (Wisor et al., 2001; Ferraro et al., 1997; Murillo-Rodríguez et al., 
2007). Neuroimaging studies in both non-human primates and healthy human subjects 
demonstrated significant occupancy of DAT (and also NET) by intravenously-administered 
modafinil (Madras et al., 2006; Volkow et al., 2009). Consistent with these findings, 
modafinil has been shown to have weak cocaine-like discriminative and reinforcing effects 
in both rodents and non-human primates (Gold and Balster., 1996; Deroche-Gamonet et al., 
2002), and weak stimulant-like subjective effects in humans (Kruszewski, 2006; O'Brien et 
al., 2006). Based on these recent findings, modafinil is categorized as a DAT-based ‘agonist 
therapy’ for cocaine dependence.  
Clinical studies:  Dackis et al (2003) first reported that modafinil's stimulant-like activity may 
diminish the symptoms of cocaine withdrawal, including hypersomnia, lethargy, dysphoric 
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mood, cognitive impairment, and increased appetite, thereby reducing the desire to use 
cocaine. The first randomized, double-blind clinical trial involved 62 cocaine-dependent 
outpatients who received either a single dose of modafinil or placebo daily for 8 weeks 
(Dackis et al., 2005). Patients treated with modafinil had significantly less cocaine use than 
patients treated with placebo (Hart et al., 2008). No significant adverse effects were noted. 
The therapeutic effects of modafinil in cocaine users have been supported by a recently 
completed multi-site, placebo-controlled clinical trial involving 210 cocaine-dependent 
outpatients (Anderson et al., 2009). Currently, more than 10 additional clinical trials are 
under way to further evaluate the efficacy of modafinil treatment for cocaine addiction 
(Table 1).  
2.7 Disulfiram  
Preclinical studies: Although disulfiram is not a DAT inhibitor, I list it under this treatment 
category because it elevates extracellular DA by inhibiting DA metabolism, producing 
effects similar to DAT inhibitors. In 1937, disulfiram was first reported as a potential 
treatment for alcoholism by Williams, a plant physician in a chemical company. 
Unexpectedly, Williams observed that after exposure to disulfram, his laboratory assistants 
could not drink alcohol in any form because alcohol produced a series of unwanted effects 
such as flushing, sweating, headaches, nausea, tachycardia, palpitations, arterial 
hypotension and hyperventilation (Williams, 1937). Since then, disulfiram has been used in 
the treatment of alcoholism for more than half a century (Suh et al., 2006; Barth and 
Malcolm, 2010). Disulfiram is an inhibitor of aldehyde dehydrogenase, the enzyme that 
transforms acetaldehyde into acetate during alcohol metabolism (Weinshenker, 2010). When 
a person drinks alcohol while taking disulfiram, the resulting acetylaldehyde accumulation 
causes an aversive reaction as described above, which discourages further drinking. In 
addition, disulfiram also inhibits dopamine-β-hydroxylase (DBH) (Weinshenker, 2010), the 
enzyme that transforms DA into norepinephrine. Such DBH inhibition would increase brain 
DA levels while decreasing brain NE release. This effect could be therapeutic for cocaine 
dependence since an increase in brain DA may be helpful in attenuating withdrawal 
syndromes and craving (Volkow et al., 1999), while a decrease in NE may be helpful in 
attenuating relapse to drug use (Smith and Aston-Jones, 2008; Weinshenker, 2010). In 
experimental animals, disulfram stimulates DA release and potentiates cocaine-induced 
increases in extracellular DA in the prefrontal cortex (Devoto et al., 2011). It also facilitates 
the development and expression of locomotor sensitization to cocaine in rats (Haile et al., 
2003). However, in animal models of relapse, pretreatment with disulfram attenuates 
cocaine-induced reinstatement of drug-seeking behaviour (Schroeder et al., 2010). 
Clinical trials:  The initial impetus for the use of disulfiram to treat cocaine dependence was 
the high rate of comorbidity between cocaine abuse and alcohol abuse (Gossop and Carroll, 
2006). Thus, it was hypothesized that a reduction in alcohol use would lead to secondary 
reduction in cocaine use. Additionally, abstinence from alcohol would prevent formation of 
cocaethylene, a metabolite formed when alcohol and cocaine are present together. 
Cocaethylene has pharmacological actions similar to cocaine and increases subjective 
euphoria and heart rate (Hart et al., 2000). Several short-term clinical trials in outpatients 
using both cocaine and alcohol showed that disulfiram, along with cognitive behavioural 
therapy (CBT), significantly reduced cocaine and alcohol use (Carroll et al., 1998; Higgins et 
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al., 1993; Grassi et al., 2007). In one study, the reduction in cocaine use was still present one 
year after treatment (Carroll et al., 2000). An 11-week, double-blind, placebo-controlled trial 
evaluated the efficacy of disulfiram, naltrexone and their combined treatment in 208 patients 
with concurrent cocaine and alcohol dependence. Patients taking disulfiram alone or in 
combination with naltrexone were more likely to achieve combined abstinence from cocaine 
and alcohol than placebo-treated patients (Pettinati et al., 2008). In several randomized, 
placebo-controlled trials, disulfiram seemed to directly reduce cocaine use rather than 
reducing it indirectly by reducing concurrent alcohol use (George et al., 2000; Petrakis et al., 
2000; Carroll et al., 2004). In addition, dilsufiram appears to be effective in attenuating 
cocaine use in comorbid cocaine- and opioid-dependent individuals (Oliveto et al., 2011). As 
a caveat, disulfiram is reported to inhibit cocaine metabolism, and therefore increases 
cocaine plasma levels in humans (Baker et al., 2006). Because of this, it should be used 
cautiously in comorbid cocaine and alcohol patients with severe cardiovascular diseases 
(Malcolm et al., 2008). 
3. Dopamine receptor-based antagonist therapies 
Rationale: Cocaine’s action is largely mediated by elevation of extracellular DA that activates 
postsynaptic DA receptors. Thus, blockade of DA receptors is a plausible therapeutic 
approach for cocaine addiction (Figure 2). There are five DA receptor subtypes identified in 
the brain that are classified as D1-like (D1, D5) and D2-like (D2, D3, D4) based on their 
pharmacological profile (Beaulieu and Gainetdinov, 2011). Although both D1 and D2 
receptor subtypes have been shown to play predominant roles in mediating actions of DA, 
clinical trials with selective D1 or D2 receptor antagonists for the treatment of cocaine 
addiction have failed due to ineffectiveness and/or unwanted side-effects such as sedation 
and extra pyramidal locomotor syndromes (see review by Platt et al., 2002; Gorelick et al., 
2004). In response, efforts have increased to develop relatively low selective D1/2 receptor 
antagonists or D3 receptor-based antagonist therapies for cocaine dependence.  
3.1 Levo-tetrahydropalmatine (l-THP) 
Preclinical studies: Tetrahydropalmatine (THP) is a tetrahydroprotoberberine (THPB) 
isoquinoline alkaloid and a primary active constituent of the herbal plant species Stephania 
rotunda Lour and Corydalis ambigua (Yanhusuo) (Jin et al., 1987). The levo-isomer of THP (l-
THP) has been shown to contribute to many of the therapeutic effects of these herbs such as 
sedative, neuroleptic and analgesic effects (Chu et al., 2008; Jin, 1987). Purified or synthetic l-
THP has been approved in China as a traditional sedative-analgesic agent for the treatment 
of chronic pain and anxious insomnia for more than 40 years. Pharmacologically, l-THP is a 
non-selective DA receptor antagonist with roughly 3-fold selectivity for D1 versus D2 
receptor and 10-fold selectivity for D1 versus D3 receptor (Ki = 124, 388, or 1420 nM for D1, 
D2, or D3 receptors, respectively) (Wang and Mantsch, 2012). In addition, it has moderate 
binding affinity to alpha (α1, α2A) adrenergic and 5-HT1A (Ki = 340 nM) receptors. Because 
cocaine is a non-selective MAT inhibitor, which increases brain DA, NE and 5-HT levels, it 
was hypothesized that blockade of multiple DA, adrenergic and 5-TH1A receptors by l-THP 
would functionally antagonize cocaine’s action (Mantsch et al., 2007; Xi et al., 2007). In 
support of this hypothesis, l-THP was found to significantly inhibit intravenous cocaine self-
administration under FR and PR reinforcement schedules (Mantsch et al., 2007, 2010; Xi et 
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mood, cognitive impairment, and increased appetite, thereby reducing the desire to use 
cocaine. The first randomized, double-blind clinical trial involved 62 cocaine-dependent 
outpatients who received either a single dose of modafinil or placebo daily for 8 weeks 
(Dackis et al., 2005). Patients treated with modafinil had significantly less cocaine use than 
patients treated with placebo (Hart et al., 2008). No significant adverse effects were noted. 
The therapeutic effects of modafinil in cocaine users have been supported by a recently 
completed multi-site, placebo-controlled clinical trial involving 210 cocaine-dependent 
outpatients (Anderson et al., 2009). Currently, more than 10 additional clinical trials are 
under way to further evaluate the efficacy of modafinil treatment for cocaine addiction 
(Table 1).  
2.7 Disulfiram  
Preclinical studies: Although disulfiram is not a DAT inhibitor, I list it under this treatment 
category because it elevates extracellular DA by inhibiting DA metabolism, producing 
effects similar to DAT inhibitors. In 1937, disulfiram was first reported as a potential 
treatment for alcoholism by Williams, a plant physician in a chemical company. 
Unexpectedly, Williams observed that after exposure to disulfram, his laboratory assistants 
could not drink alcohol in any form because alcohol produced a series of unwanted effects 
such as flushing, sweating, headaches, nausea, tachycardia, palpitations, arterial 
hypotension and hyperventilation (Williams, 1937). Since then, disulfiram has been used in 
the treatment of alcoholism for more than half a century (Suh et al., 2006; Barth and 
Malcolm, 2010). Disulfiram is an inhibitor of aldehyde dehydrogenase, the enzyme that 
transforms acetaldehyde into acetate during alcohol metabolism (Weinshenker, 2010). When 
a person drinks alcohol while taking disulfiram, the resulting acetylaldehyde accumulation 
causes an aversive reaction as described above, which discourages further drinking. In 
addition, disulfiram also inhibits dopamine-β-hydroxylase (DBH) (Weinshenker, 2010), the 
enzyme that transforms DA into norepinephrine. Such DBH inhibition would increase brain 
DA levels while decreasing brain NE release. This effect could be therapeutic for cocaine 
dependence since an increase in brain DA may be helpful in attenuating withdrawal 
syndromes and craving (Volkow et al., 1999), while a decrease in NE may be helpful in 
attenuating relapse to drug use (Smith and Aston-Jones, 2008; Weinshenker, 2010). In 
experimental animals, disulfram stimulates DA release and potentiates cocaine-induced 
increases in extracellular DA in the prefrontal cortex (Devoto et al., 2011). It also facilitates 
the development and expression of locomotor sensitization to cocaine in rats (Haile et al., 
2003). However, in animal models of relapse, pretreatment with disulfram attenuates 
cocaine-induced reinstatement of drug-seeking behaviour (Schroeder et al., 2010). 
Clinical trials:  The initial impetus for the use of disulfiram to treat cocaine dependence was 
the high rate of comorbidity between cocaine abuse and alcohol abuse (Gossop and Carroll, 
2006). Thus, it was hypothesized that a reduction in alcohol use would lead to secondary 
reduction in cocaine use. Additionally, abstinence from alcohol would prevent formation of 
cocaethylene, a metabolite formed when alcohol and cocaine are present together. 
Cocaethylene has pharmacological actions similar to cocaine and increases subjective 
euphoria and heart rate (Hart et al., 2000). Several short-term clinical trials in outpatients 
using both cocaine and alcohol showed that disulfiram, along with cognitive behavioural 
therapy (CBT), significantly reduced cocaine and alcohol use (Carroll et al., 1998; Higgins et 
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al., 1993; Grassi et al., 2007). In one study, the reduction in cocaine use was still present one 
year after treatment (Carroll et al., 2000). An 11-week, double-blind, placebo-controlled trial 
evaluated the efficacy of disulfiram, naltrexone and their combined treatment in 208 patients 
with concurrent cocaine and alcohol dependence. Patients taking disulfiram alone or in 
combination with naltrexone were more likely to achieve combined abstinence from cocaine 
and alcohol than placebo-treated patients (Pettinati et al., 2008). In several randomized, 
placebo-controlled trials, disulfiram seemed to directly reduce cocaine use rather than 
reducing it indirectly by reducing concurrent alcohol use (George et al., 2000; Petrakis et al., 
2000; Carroll et al., 2004). In addition, dilsufiram appears to be effective in attenuating 
cocaine use in comorbid cocaine- and opioid-dependent individuals (Oliveto et al., 2011). As 
a caveat, disulfiram is reported to inhibit cocaine metabolism, and therefore increases 
cocaine plasma levels in humans (Baker et al., 2006). Because of this, it should be used 
cautiously in comorbid cocaine and alcohol patients with severe cardiovascular diseases 
(Malcolm et al., 2008). 
3. Dopamine receptor-based antagonist therapies 
Rationale: Cocaine’s action is largely mediated by elevation of extracellular DA that activates 
postsynaptic DA receptors. Thus, blockade of DA receptors is a plausible therapeutic 
approach for cocaine addiction (Figure 2). There are five DA receptor subtypes identified in 
the brain that are classified as D1-like (D1, D5) and D2-like (D2, D3, D4) based on their 
pharmacological profile (Beaulieu and Gainetdinov, 2011). Although both D1 and D2 
receptor subtypes have been shown to play predominant roles in mediating actions of DA, 
clinical trials with selective D1 or D2 receptor antagonists for the treatment of cocaine 
addiction have failed due to ineffectiveness and/or unwanted side-effects such as sedation 
and extra pyramidal locomotor syndromes (see review by Platt et al., 2002; Gorelick et al., 
2004). In response, efforts have increased to develop relatively low selective D1/2 receptor 
antagonists or D3 receptor-based antagonist therapies for cocaine dependence.  
3.1 Levo-tetrahydropalmatine (l-THP) 
Preclinical studies: Tetrahydropalmatine (THP) is a tetrahydroprotoberberine (THPB) 
isoquinoline alkaloid and a primary active constituent of the herbal plant species Stephania 
rotunda Lour and Corydalis ambigua (Yanhusuo) (Jin et al., 1987). The levo-isomer of THP (l-
THP) has been shown to contribute to many of the therapeutic effects of these herbs such as 
sedative, neuroleptic and analgesic effects (Chu et al., 2008; Jin, 1987). Purified or synthetic l-
THP has been approved in China as a traditional sedative-analgesic agent for the treatment 
of chronic pain and anxious insomnia for more than 40 years. Pharmacologically, l-THP is a 
non-selective DA receptor antagonist with roughly 3-fold selectivity for D1 versus D2 
receptor and 10-fold selectivity for D1 versus D3 receptor (Ki = 124, 388, or 1420 nM for D1, 
D2, or D3 receptors, respectively) (Wang and Mantsch, 2012). In addition, it has moderate 
binding affinity to alpha (α1, α2A) adrenergic and 5-HT1A (Ki = 340 nM) receptors. Because 
cocaine is a non-selective MAT inhibitor, which increases brain DA, NE and 5-HT levels, it 
was hypothesized that blockade of multiple DA, adrenergic and 5-TH1A receptors by l-THP 
would functionally antagonize cocaine’s action (Mantsch et al., 2007; Xi et al., 2007). In 
support of this hypothesis, l-THP was found to significantly inhibit intravenous cocaine self-
administration under FR and PR reinforcement schedules (Mantsch et al., 2007, 2010; Xi et 
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al., 2007), cocaine-induced conditioned place preference (CPP) (Luo et al., 2003), cocaine-
enhanced electrical brain-stimulation reward (Xi et al., 2007), and cocaine-, cue- or stress-
induced reinstatement of drug-seeking behaviour in rats (Mantsch et al., 2007, 2010; 
Figueroa-Guzman et al., 2011). These anti-cocaine effects are unlikely due to l-THP-induced 
sedation or locomotor impairment, since the effective doses that decrease cocaine’s effects 
are much lower (3-10 fold) than those that produce locomotion inhibition (Xi et al., 2007). 
These data suggest that l-THP may have therapeutic potential for treatment of cocaine 
addiction in humans.  
Clinical studies: A pilot study examined the efficacy of l-THP in reducing craving and relapse 
in 120 heroin addicts (Yang et al., 2008). In this randomized, double-blind, placebo-
controlled study, patients received 4 weeks of l-THP treatment and three months follow-up 
after l-THP treatment. The results showed that l-THP significantly lowered opiate 
withdrawal symptoms and craving and increased abstinence rate. Another study examined 
the therapeutic effect of l-THP combined with methadone for heroin detoxification (Hu et 
al., 2006), and found that l-THP, combined with methadone, significantly elevated 
detoxification rate, lowered total amount of methadone and decreased time for the 
detoxification. L-THP is being investigated in human clinical trial for the treatment of 
cocaine addiction in University of Maryland, Baltimore (Table 2).  
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3.2 BP-897  
Preclinical studies: BP-897 is the first developed D3-selective partial agonist (Pilla et al., 1999) 
or antagonist (Wicke and Garcia-Ladona, 2001). A series of studies have assessed the 
efficacy of BP-897 in animal models of drug addiction (see reviews by Garcia-Ladona and 
Cox, 2003; Le Foll et al., 2005; Heidbreder et al., 2005). BP-897 produces a dose-dependent 
decrease in cocaine self-administration under second-order reinforcement, cocaine-induced 
CPP, cocaine’s discriminative stimulus properties, and cocaine- or cue-induced 
reinstatement of cocaine-seeking behaviour. These data support the potential use of BP-897 
in the treatment of cocaine addiction, particularly in relapse to drug-seeking behavior.  
Clinical trials: BP-897 entered Phase II clinical studies for the treatment of drug addiction in 
the early 2000s. However, the detailed results about its safety, pharmacokinetics and 
therapeutic efficay have not yet been reported.  
3.3 Cariprazine 
Preclinical studies: Cariprazine (RGH-188) is a novel D3 receptor partial agonist with 10-fold 
selectivity for D3 over D2 (Gründer, 2010; Kiss et al., 2010). It is also a weak 5-HT1A and 5-
HT5C partial agonist. Although limited preclinical data are available, the ‘concept-proven’ 
finding with BP-897 suggests that cariprazine might be similarly effective in attenuation of 
cocaine’s actions. 
Clinical studies: Cariprazine is currently in Phase III clinical trials for the treatment of 
schizophrenia and bipolar disorder (Table 2). Data from Phase II trials in patients with 
schizophrenia and bipolar mania indicate that the drug has antipsychotic and antimanic 
properties that are superior to placebo. The efficacy of cariprazine for treatment of cocaine 
addiction has not been evaluated.  
3.4 SB-277011A  
Preclinical studies: SB-277011A is the most well-characterized D3 receptor antagonist in 
preclinical animal models of drug addiction to date (Heidebreder et al., 2005; Heidbreder 
and Newman, 2010). SB-277011A has high affinity for human D3 receptor, and the 
selectivity for human and rat D3 over D2 receptor is 120 and 80, respectively (Reavill et al., 
2000). In experimental animals, SB-277011A significantly and dose-dependently attenuates 
cocaine-enhanced brain-stimulation reward (Vorel et al., 2002; Spiller et al., 2008), cocaine-
induced CPP (Vorel et al., 2002), cocaine self-administration under PR or FR10 (but not FR1 
or FR2) reinforcement (Xi et al., 2005), and reinstatement of drug-seeking behavior caused 
by cocaine priming, cue or footshock stress (Vorel et al., 2002; Xi et al., 2004b; Gilbert et al., 
2005). In addition, systemic administration or intracranial microinjections into the NAc or 
basolateral amygdala significantly and dose-dependently inhibited contextual cue-induced 
incubation of cocaine craving in rats (Xi et al., 2012). These data suggest that SB-277011A is a 
promising candidate in medication development for treatment of cocaine addiction.  
Clinical trials: Further development of SB-277011A as a medication for treatment of cocaine 
addiction has been halted by GlaxoSmithKline Pharmaceuticals, due to unexpected poor 
bioavailability (~2%) and a short half-life (<20 min) in primates (Austin et al., 2001; 
Remington and Kapue, 2001). Therefore, much effort has been made to develop other D3-
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al., 2007), cocaine-induced conditioned place preference (CPP) (Luo et al., 2003), cocaine-
enhanced electrical brain-stimulation reward (Xi et al., 2007), and cocaine-, cue- or stress-
induced reinstatement of drug-seeking behaviour in rats (Mantsch et al., 2007, 2010; 
Figueroa-Guzman et al., 2011). These anti-cocaine effects are unlikely due to l-THP-induced 
sedation or locomotor impairment, since the effective doses that decrease cocaine’s effects 
are much lower (3-10 fold) than those that produce locomotion inhibition (Xi et al., 2007). 
These data suggest that l-THP may have therapeutic potential for treatment of cocaine 
addiction in humans.  
Clinical studies: A pilot study examined the efficacy of l-THP in reducing craving and relapse 
in 120 heroin addicts (Yang et al., 2008). In this randomized, double-blind, placebo-
controlled study, patients received 4 weeks of l-THP treatment and three months follow-up 
after l-THP treatment. The results showed that l-THP significantly lowered opiate 
withdrawal symptoms and craving and increased abstinence rate. Another study examined 
the therapeutic effect of l-THP combined with methadone for heroin detoxification (Hu et 
al., 2006), and found that l-THP, combined with methadone, significantly elevated 
detoxification rate, lowered total amount of methadone and decreased time for the 
detoxification. L-THP is being investigated in human clinical trial for the treatment of 
cocaine addiction in University of Maryland, Baltimore (Table 2).  
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3.2 BP-897  
Preclinical studies: BP-897 is the first developed D3-selective partial agonist (Pilla et al., 1999) 
or antagonist (Wicke and Garcia-Ladona, 2001). A series of studies have assessed the 
efficacy of BP-897 in animal models of drug addiction (see reviews by Garcia-Ladona and 
Cox, 2003; Le Foll et al., 2005; Heidbreder et al., 2005). BP-897 produces a dose-dependent 
decrease in cocaine self-administration under second-order reinforcement, cocaine-induced 
CPP, cocaine’s discriminative stimulus properties, and cocaine- or cue-induced 
reinstatement of cocaine-seeking behaviour. These data support the potential use of BP-897 
in the treatment of cocaine addiction, particularly in relapse to drug-seeking behavior.  
Clinical trials: BP-897 entered Phase II clinical studies for the treatment of drug addiction in 
the early 2000s. However, the detailed results about its safety, pharmacokinetics and 
therapeutic efficay have not yet been reported.  
3.3 Cariprazine 
Preclinical studies: Cariprazine (RGH-188) is a novel D3 receptor partial agonist with 10-fold 
selectivity for D3 over D2 (Gründer, 2010; Kiss et al., 2010). It is also a weak 5-HT1A and 5-
HT5C partial agonist. Although limited preclinical data are available, the ‘concept-proven’ 
finding with BP-897 suggests that cariprazine might be similarly effective in attenuation of 
cocaine’s actions. 
Clinical studies: Cariprazine is currently in Phase III clinical trials for the treatment of 
schizophrenia and bipolar disorder (Table 2). Data from Phase II trials in patients with 
schizophrenia and bipolar mania indicate that the drug has antipsychotic and antimanic 
properties that are superior to placebo. The efficacy of cariprazine for treatment of cocaine 
addiction has not been evaluated.  
3.4 SB-277011A  
Preclinical studies: SB-277011A is the most well-characterized D3 receptor antagonist in 
preclinical animal models of drug addiction to date (Heidebreder et al., 2005; Heidbreder 
and Newman, 2010). SB-277011A has high affinity for human D3 receptor, and the 
selectivity for human and rat D3 over D2 receptor is 120 and 80, respectively (Reavill et al., 
2000). In experimental animals, SB-277011A significantly and dose-dependently attenuates 
cocaine-enhanced brain-stimulation reward (Vorel et al., 2002; Spiller et al., 2008), cocaine-
induced CPP (Vorel et al., 2002), cocaine self-administration under PR or FR10 (but not FR1 
or FR2) reinforcement (Xi et al., 2005), and reinstatement of drug-seeking behavior caused 
by cocaine priming, cue or footshock stress (Vorel et al., 2002; Xi et al., 2004b; Gilbert et al., 
2005). In addition, systemic administration or intracranial microinjections into the NAc or 
basolateral amygdala significantly and dose-dependently inhibited contextual cue-induced 
incubation of cocaine craving in rats (Xi et al., 2012). These data suggest that SB-277011A is a 
promising candidate in medication development for treatment of cocaine addiction.  
Clinical trials: Further development of SB-277011A as a medication for treatment of cocaine 
addiction has been halted by GlaxoSmithKline Pharmaceuticals, due to unexpected poor 
bioavailability (~2%) and a short half-life (<20 min) in primates (Austin et al., 2001; 
Remington and Kapue, 2001). Therefore, much effort has been made to develop other D3-
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selective antagonists with higher bioavailability and more promising pharmacotherapeutic 
profiles (Newman et al., 2005).   
3.5 GSK598809 and GSK618334 
Preclinical studies: Based on the results with SB-277011A, GSK is currently developing other 
D3 receptor antagonists, such as GSK618334 and GSK598809, for the treatment of substance 
abuse and addiction. GSK598809 is a novel, potent and selective DA D3 receptor antagonist 
(Searle et al., 2010). Functional assays showed that GSK598809 has >100-fold selectivity for 
D3 receptors over D2, histamine H1, muscarinic M1, M2, M3, M4, serotonin 5-HT1A, 5-HT1B 
and 5-HT1D receptors (te Beek et al., 2012). CPP experiments in animal models indicated that 
GSK598809 significantly reduced nicotine- and cocaine-seeking behaviour in a dose-
dependent manner (te Beek et al., 2012). In addition, GSK598809 significantly prevented 
relapse to nicotine-seeking behaviour, although no effect was observed on reducing alcohol 
consumption in rats.   
Clinical studies: GSK618334 is currently under Phase I and Phase II clinical trials (Table 2). A 
recent PET imaging study suggests that GSK598809 significantly and dose-dependently 
inhibits [11C]PHNO binding in D3-rich brain regions such as the ventral striatum, globus 
pallidus and substantia nigra (Searle et al., 2010). In healthy volunteers, single doses of 
GSK598809 were generally well tolerated. Plasma concentration of GSK598809 increased 
rapidly after oral administration (Tmax 2-3 hrs) and subsequently decreased in an apparent 
bi-exponential manner (terminal half-life of roughly 20 hrs). The CNS effects of GSK598809 
alone were limited to elevation of serum prolactin and a small decrease in adaptive tracking 
performance (te Beek et al., 2012).  GSK598809, at a dose (175 mg) that associated >90% D2/3 
receptor occupancy, appeared to have no overall effect on attention bias to food-related cues 
(as measured behaviorally) (Nathan et al., 2011), on subjective hunger or craving ratings and 
on brain response to food images (as measured by fMRI) in overweight and obese binge 
eating individuals (Dodds et al., 2012). These findings are consistent with previous findings 
in experimental animals demonstrating that SB-277011A or NGB-2904 have no significant 
effects on food-induced CPP and food-taking behavior (Vorel et al., 2002; Ross et al., 2007; 
Thanos et al., 2008). Contrary to the promising finding in experimental animals, a recent 
clinical trial with GSK598809 for the treatment of alcoholism demonstrated that it produces 
an additive, not an expected inhibitory, effect on alcohol intake (te Beek et al., 2012). 
GSK598809 is currently under Phase II clinic trial for treatment of nicotine dependence 
(http://clinicaltrials.gov/).  The effects of GSK598809 on cocaine dependence have not yet 
been evaluated.  
3.6 ABT-925 
ABT-925, also known as A-437203 or BSF-201640, is a selective D3 receptor antagonist 
developed by Abbott Laboratories. It has an approximately 100-fold selectivity for D3 versus 
D2 receptors (Geneste et al., 2006). Although the preclinical data for this compound are 
currently unavailable, proof-of-concept for D3 receptor antagonists in treatment of 
schizophrenia and drug abuse has been well-estabolished. In Phase I and Phase II clinical 
trials (Table 2), ABT-925 was safe and generally well tolerated up to the highest dose levels 
tested (600 mg single dose, 500 mg once daily for 7 days) (Day et al., 2010; Graff-Guerrero et 
al., 2010; Redden et al., 2011). However, a recent double-blind, placebo-controlled study for 
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the treatment of acute schizophrenia suggest that ABT-925, at 50-150 mg per day, did not 
produce statistically significant therapeutic effects compared to placebo (Redden et al., 
2011).  
3.7 NGB-2904 
NGB-2904 is another highly selective D3 receptor antagonist with >150-fold or 800-fold 
selectivity for primate or rat D3 over D2 receptors and 5000-fold selectivity for D3 over D1, 
D4, and D5 receptors (Yuan et al., 1998). Based upon its high selectivity for DA D3 receptors, 
we have recently evaluated the pharmacological effects in animal models of drug addiction. 
We found that systemic administration of NGB-2904 dose-dependently inhibits cocaine self-
administration under PR (but not FR2) reinforcement (Xi et al., 2006b), cocaine-enhanced 
electrical brain reward function (Xi et al., 2006b; Spiller et al., 2008), and cocaine- and 
cocaine cue-induced reinstatement of cocaine-seeking behavior (Gilbert et al., 2005; Xi et al., 
2006b). NGB-2904 alone neither produces dysphorigenic effects in brain-stimulation reward 
nor substitutes for cocaine in self-administration, suggesting that NGB-2904 itself has no 
abuse potential (Xi and Gardner, 2007). NGB-2904 is not currently under clinical trials, and 
detailed data regarding bioavailability and pharmacokinetic properties are presently 
unavailable.  
3.8 YQA-14 
YQA-14 is a novel D3 receptor antagonist developed recently (Song et al., 2012). 
Structurally, YQA-14 is a NGB-2904 analog. In vivo pharmacokinetic assays suggest that 
YQA-14 has improved oral bioavailability (>40%) and a longer half-life (>6 h in humans) 
compared to SB-277011A (~20 min in primates). In experimental animals, YQA-14 dose-
dependently inhibits cocaine self-administration under both FR2 and PR reinforcement 
schedules, cocaine-induced CPP, cocaine-enhanced brain-stimulation reward, and cocaine- 
or cue-induced reinstatement of drug-seeking behavior (Song et al., 2012). Strikingly, at the 
doses that inhibit cocaine’s actions, YQA-14 failed to alter oral sucrose self-administration 
and locomotor activity. YQA-14 is neither self-administered in drug-naïve rats nor 
substitutes for cocaine in maintenance of self-administration in rats previously trained for 
cocaine self-administration, suggesting that YQA-14 itself has no abuse liability. Deletion of 
DA D3 receptors in D3-knockout mice almost completely abolished the inhibitory effect by 
YQA-14 of cocaine self-administration, suggesting an effect mediated by blocking DA D3 
receptors in vivo (Song et al., 2012). YQA-14 is currently not under clinical trials.  
3.9 S33138 
Preclinical studies: S33138 is a preferential D3 versus D2 receptor (~25-fold selectivity) 
antagonist (Millan et al., 2008). It was hypothesized that blockade of D3 plus partial blockade 
of D2 receptors may produce additive anti-cocaine therapeutic effects, but have fewer 
unwanted side-effects such as sedation and extrapyramidal locomotor impairment due to 
partial blockade of D2 receptors (Peng et al., 2009). In experimental animals, we found that 
S33138 produced biphasic effects – low doses increase, while high doses inhibit, cocaine self-
administration under FR2 reinforcement. We interpret this increase in cocaine self-
administration as a compensatory response to a reduction in cocaine’s rewarding efficacy at 
low doses. In addition, S33138 also dose-dependently inhibits cocaine-enhanced brain-
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selective antagonists with higher bioavailability and more promising pharmacotherapeutic 
profiles (Newman et al., 2005).   
3.5 GSK598809 and GSK618334 
Preclinical studies: Based on the results with SB-277011A, GSK is currently developing other 
D3 receptor antagonists, such as GSK618334 and GSK598809, for the treatment of substance 
abuse and addiction. GSK598809 is a novel, potent and selective DA D3 receptor antagonist 
(Searle et al., 2010). Functional assays showed that GSK598809 has >100-fold selectivity for 
D3 receptors over D2, histamine H1, muscarinic M1, M2, M3, M4, serotonin 5-HT1A, 5-HT1B 
and 5-HT1D receptors (te Beek et al., 2012). CPP experiments in animal models indicated that 
GSK598809 significantly reduced nicotine- and cocaine-seeking behaviour in a dose-
dependent manner (te Beek et al., 2012). In addition, GSK598809 significantly prevented 
relapse to nicotine-seeking behaviour, although no effect was observed on reducing alcohol 
consumption in rats.   
Clinical studies: GSK618334 is currently under Phase I and Phase II clinical trials (Table 2). A 
recent PET imaging study suggests that GSK598809 significantly and dose-dependently 
inhibits [11C]PHNO binding in D3-rich brain regions such as the ventral striatum, globus 
pallidus and substantia nigra (Searle et al., 2010). In healthy volunteers, single doses of 
GSK598809 were generally well tolerated. Plasma concentration of GSK598809 increased 
rapidly after oral administration (Tmax 2-3 hrs) and subsequently decreased in an apparent 
bi-exponential manner (terminal half-life of roughly 20 hrs). The CNS effects of GSK598809 
alone were limited to elevation of serum prolactin and a small decrease in adaptive tracking 
performance (te Beek et al., 2012).  GSK598809, at a dose (175 mg) that associated >90% D2/3 
receptor occupancy, appeared to have no overall effect on attention bias to food-related cues 
(as measured behaviorally) (Nathan et al., 2011), on subjective hunger or craving ratings and 
on brain response to food images (as measured by fMRI) in overweight and obese binge 
eating individuals (Dodds et al., 2012). These findings are consistent with previous findings 
in experimental animals demonstrating that SB-277011A or NGB-2904 have no significant 
effects on food-induced CPP and food-taking behavior (Vorel et al., 2002; Ross et al., 2007; 
Thanos et al., 2008). Contrary to the promising finding in experimental animals, a recent 
clinical trial with GSK598809 for the treatment of alcoholism demonstrated that it produces 
an additive, not an expected inhibitory, effect on alcohol intake (te Beek et al., 2012). 
GSK598809 is currently under Phase II clinic trial for treatment of nicotine dependence 
(http://clinicaltrials.gov/).  The effects of GSK598809 on cocaine dependence have not yet 
been evaluated.  
3.6 ABT-925 
ABT-925, also known as A-437203 or BSF-201640, is a selective D3 receptor antagonist 
developed by Abbott Laboratories. It has an approximately 100-fold selectivity for D3 versus 
D2 receptors (Geneste et al., 2006). Although the preclinical data for this compound are 
currently unavailable, proof-of-concept for D3 receptor antagonists in treatment of 
schizophrenia and drug abuse has been well-estabolished. In Phase I and Phase II clinical 
trials (Table 2), ABT-925 was safe and generally well tolerated up to the highest dose levels 
tested (600 mg single dose, 500 mg once daily for 7 days) (Day et al., 2010; Graff-Guerrero et 
al., 2010; Redden et al., 2011). However, a recent double-blind, placebo-controlled study for 
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the treatment of acute schizophrenia suggest that ABT-925, at 50-150 mg per day, did not 
produce statistically significant therapeutic effects compared to placebo (Redden et al., 
2011).  
3.7 NGB-2904 
NGB-2904 is another highly selective D3 receptor antagonist with >150-fold or 800-fold 
selectivity for primate or rat D3 over D2 receptors and 5000-fold selectivity for D3 over D1, 
D4, and D5 receptors (Yuan et al., 1998). Based upon its high selectivity for DA D3 receptors, 
we have recently evaluated the pharmacological effects in animal models of drug addiction. 
We found that systemic administration of NGB-2904 dose-dependently inhibits cocaine self-
administration under PR (but not FR2) reinforcement (Xi et al., 2006b), cocaine-enhanced 
electrical brain reward function (Xi et al., 2006b; Spiller et al., 2008), and cocaine- and 
cocaine cue-induced reinstatement of cocaine-seeking behavior (Gilbert et al., 2005; Xi et al., 
2006b). NGB-2904 alone neither produces dysphorigenic effects in brain-stimulation reward 
nor substitutes for cocaine in self-administration, suggesting that NGB-2904 itself has no 
abuse potential (Xi and Gardner, 2007). NGB-2904 is not currently under clinical trials, and 
detailed data regarding bioavailability and pharmacokinetic properties are presently 
unavailable.  
3.8 YQA-14 
YQA-14 is a novel D3 receptor antagonist developed recently (Song et al., 2012). 
Structurally, YQA-14 is a NGB-2904 analog. In vivo pharmacokinetic assays suggest that 
YQA-14 has improved oral bioavailability (>40%) and a longer half-life (>6 h in humans) 
compared to SB-277011A (~20 min in primates). In experimental animals, YQA-14 dose-
dependently inhibits cocaine self-administration under both FR2 and PR reinforcement 
schedules, cocaine-induced CPP, cocaine-enhanced brain-stimulation reward, and cocaine- 
or cue-induced reinstatement of drug-seeking behavior (Song et al., 2012). Strikingly, at the 
doses that inhibit cocaine’s actions, YQA-14 failed to alter oral sucrose self-administration 
and locomotor activity. YQA-14 is neither self-administered in drug-naïve rats nor 
substitutes for cocaine in maintenance of self-administration in rats previously trained for 
cocaine self-administration, suggesting that YQA-14 itself has no abuse liability. Deletion of 
DA D3 receptors in D3-knockout mice almost completely abolished the inhibitory effect by 
YQA-14 of cocaine self-administration, suggesting an effect mediated by blocking DA D3 
receptors in vivo (Song et al., 2012). YQA-14 is currently not under clinical trials.  
3.9 S33138 
Preclinical studies: S33138 is a preferential D3 versus D2 receptor (~25-fold selectivity) 
antagonist (Millan et al., 2008). It was hypothesized that blockade of D3 plus partial blockade 
of D2 receptors may produce additive anti-cocaine therapeutic effects, but have fewer 
unwanted side-effects such as sedation and extrapyramidal locomotor impairment due to 
partial blockade of D2 receptors (Peng et al., 2009). In experimental animals, we found that 
S33138 produced biphasic effects – low doses increase, while high doses inhibit, cocaine self-
administration under FR2 reinforcement. We interpret this increase in cocaine self-
administration as a compensatory response to a reduction in cocaine’s rewarding efficacy at 
low doses. In addition, S33138 also dose-dependently inhibits cocaine-enhanced brain-
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stimulation reward and cocaine-induced reinstatement of drug-seeking behavior (Peng et al., 
2009). S33138, at low-to-moderate doses, has no effect on brain reward function by itself, while 
at high doses, produces an aversive-like effect as assessed by electrical brain-stimulation 
reward experiments, suggesting a D2 receptor-mediated effect at high doses. Further high 
doses of S33138 also inhibit oral sucrose self-administration, suggesting possible unwanted 
effects on nature reward at high doses.  
Clinical trials: S33138 is currently under clinical trials as an anti-psychotic agent for the 
treatment of schizophrenia and other psychiatric diseases (Millan and Brocco, 2008; 
Thomasson-Perret et al., 2008). The efficacy of S33138 for treatment of cocaine addiction has 
not been evaluated in human clinical trials.  
4. Glutamate-based medication strategies 
Rationale: L-glutamate is the major excitatory neurotransmitter in the brain and acts through 
two heterogeneous families of glutamate receptors: ionotropic (iGluR) and metabotropic 
(mGluR) glutamate receptors. While iGluRs (i.e. NMDA, AMPA and kainite) are ligand-
gated ion channels and responsible for fast excitatory neurotransmission, mGluRs (mGluR1-
8) are G-protein-coupled receptors linked to intracellular second messenger pathways. The 
eight subtypes of mGluRs have been classified into three groups on the basis of sequence 
similarities and pharmacological properties. Group I (mGluR1,5) receptors activate 
phospholipase C via Gq proteins, whereas group II (mGluR2,3) and group III (mGluR4,6,7,8) 
receptors inhibit adenylate cyclase via Gαi/o proteins (see review by Cartmell and Schoepp, 
2000). 
Although the role of glutamate in mediating cocaine’s rewarding effects remains unclear 
(see review by Xi and Gardner, 2008), growing evidence suggests that glutamate is critically 
involved in relapse to drug-seeking behavior (Figure 3) (Kalivas, 2009; Bowers et al., 2010). 
In brief, chronic cocaine produces a reduction in basal levels of extracellular glutamate or 
glutamate transmission in the NAc during cocaine withdrawal, while cocaine priming or re-
exposure to cocaine-associated cues stimulate glutamate release in both the VTA and NAc. 
These findings suggest that both a reduction in basal glutamate transmission and enhanced 
glutamate responding to cocaine or cocaine-associated cues may constitute a neurobiological 
substrate of relapse to drug-seeking behavior (Kalivas, 2009). Based on this hypothesis, a 
number of pharmacotherapeutic strategies have been proposed. These include, first, 
normalization (increase) of reduced basal glutamate neurotransmission during abstinence, 
and second, antagonism of enhanced glutamate responses to cocaine or cocaine-associated 
cues (Figure 3).  
4.1 N-acetylcysteine 
Preclinical studies: N-acetylcysteine (NAC) is a cystine prodrug. It is approved for the 
treatment of pulmonary complications of cystic fibrosis and paracetamol (acetaminophen) 
overdose. By providing a source of extracellular cysteine, which is converted to cystine, 
NAC can exchange extracellular cystine for intracellular glutamate. This restores 
(renormalizes) decreased basal levels of extracellular glutamate (Baker et al., 2003). The 
increased extracellular glutamate may subsequently attenuate cocaine-induced increases in 
glutamate release by activation of presynaptic mGluR2/3 receptors, and therefore inhibits 
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cocaine- or cocaine cue-induced reinstatement of drug-seeking behaviour (Figure 3). NAC 
did not decrease cocaine self-administration or acute cocaine-induced hyperactivity, while it 
decreased repeated cocaine-induced escalation of drug intake and behavioural sensitization 
(Madayag et al., 2007). In addition, repeated NAC treatments also attenuated cocaine-
induced increases in drug seeking in rats (Baker et al., 2003; Amen et al., 2010). Interestingly, 
NAC is also a prodrug for the synthesis of the endogenous antioxidant glutathione, and that 
NAC pretreatment protects animals from high dose methamphetamine- or amphetamine-
induced DA neurotoxicity and behavioural changes by lowering oxidative stress levels 
(Fukami et al., 2004; Achat-Mendes et al., 2007).  
Clinical trials: NAC is currently under clinical trials (Table 3). In double-blind, placebo-
controlled clinic trials, NAC was well tolerated and produced a significant reduction in 
cocaine-related withdrawal symptoms and/or cravings triggered by exposure to cocaine-
related cues or by an experimenter-delivered intravenous injection of cocaine (LaRowe et al., 
2006, 2007; Amen et al., 2010). A 4-week open-label clinical trial demonstrated that NAC 
significantly reduced cocaine use in 16 of 23 human cocaine-dependent subjects (Mardikian 
et al., 2007). More clinical trials are currently underway (http://clinicaltrials.gov/).  
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stimulation reward and cocaine-induced reinstatement of drug-seeking behavior (Peng et al., 
2009). S33138, at low-to-moderate doses, has no effect on brain reward function by itself, while 
at high doses, produces an aversive-like effect as assessed by electrical brain-stimulation 
reward experiments, suggesting a D2 receptor-mediated effect at high doses. Further high 
doses of S33138 also inhibit oral sucrose self-administration, suggesting possible unwanted 
effects on nature reward at high doses.  
Clinical trials: S33138 is currently under clinical trials as an anti-psychotic agent for the 
treatment of schizophrenia and other psychiatric diseases (Millan and Brocco, 2008; 
Thomasson-Perret et al., 2008). The efficacy of S33138 for treatment of cocaine addiction has 
not been evaluated in human clinical trials.  
4. Glutamate-based medication strategies 
Rationale: L-glutamate is the major excitatory neurotransmitter in the brain and acts through 
two heterogeneous families of glutamate receptors: ionotropic (iGluR) and metabotropic 
(mGluR) glutamate receptors. While iGluRs (i.e. NMDA, AMPA and kainite) are ligand-
gated ion channels and responsible for fast excitatory neurotransmission, mGluRs (mGluR1-
8) are G-protein-coupled receptors linked to intracellular second messenger pathways. The 
eight subtypes of mGluRs have been classified into three groups on the basis of sequence 
similarities and pharmacological properties. Group I (mGluR1,5) receptors activate 
phospholipase C via Gq proteins, whereas group II (mGluR2,3) and group III (mGluR4,6,7,8) 
receptors inhibit adenylate cyclase via Gαi/o proteins (see review by Cartmell and Schoepp, 
2000). 
Although the role of glutamate in mediating cocaine’s rewarding effects remains unclear 
(see review by Xi and Gardner, 2008), growing evidence suggests that glutamate is critically 
involved in relapse to drug-seeking behavior (Figure 3) (Kalivas, 2009; Bowers et al., 2010). 
In brief, chronic cocaine produces a reduction in basal levels of extracellular glutamate or 
glutamate transmission in the NAc during cocaine withdrawal, while cocaine priming or re-
exposure to cocaine-associated cues stimulate glutamate release in both the VTA and NAc. 
These findings suggest that both a reduction in basal glutamate transmission and enhanced 
glutamate responding to cocaine or cocaine-associated cues may constitute a neurobiological 
substrate of relapse to drug-seeking behavior (Kalivas, 2009). Based on this hypothesis, a 
number of pharmacotherapeutic strategies have been proposed. These include, first, 
normalization (increase) of reduced basal glutamate neurotransmission during abstinence, 
and second, antagonism of enhanced glutamate responses to cocaine or cocaine-associated 
cues (Figure 3).  
4.1 N-acetylcysteine 
Preclinical studies: N-acetylcysteine (NAC) is a cystine prodrug. It is approved for the 
treatment of pulmonary complications of cystic fibrosis and paracetamol (acetaminophen) 
overdose. By providing a source of extracellular cysteine, which is converted to cystine, 
NAC can exchange extracellular cystine for intracellular glutamate. This restores 
(renormalizes) decreased basal levels of extracellular glutamate (Baker et al., 2003). The 
increased extracellular glutamate may subsequently attenuate cocaine-induced increases in 
glutamate release by activation of presynaptic mGluR2/3 receptors, and therefore inhibits 
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cocaine- or cocaine cue-induced reinstatement of drug-seeking behaviour (Figure 3). NAC 
did not decrease cocaine self-administration or acute cocaine-induced hyperactivity, while it 
decreased repeated cocaine-induced escalation of drug intake and behavioural sensitization 
(Madayag et al., 2007). In addition, repeated NAC treatments also attenuated cocaine-
induced increases in drug seeking in rats (Baker et al., 2003; Amen et al., 2010). Interestingly, 
NAC is also a prodrug for the synthesis of the endogenous antioxidant glutathione, and that 
NAC pretreatment protects animals from high dose methamphetamine- or amphetamine-
induced DA neurotoxicity and behavioural changes by lowering oxidative stress levels 
(Fukami et al., 2004; Achat-Mendes et al., 2007).  
Clinical trials: NAC is currently under clinical trials (Table 3). In double-blind, placebo-
controlled clinic trials, NAC was well tolerated and produced a significant reduction in 
cocaine-related withdrawal symptoms and/or cravings triggered by exposure to cocaine-
related cues or by an experimenter-delivered intravenous injection of cocaine (LaRowe et al., 
2006, 2007; Amen et al., 2010). A 4-week open-label clinical trial demonstrated that NAC 
significantly reduced cocaine use in 16 of 23 human cocaine-dependent subjects (Mardikian 
et al., 2007). More clinical trials are currently underway (http://clinicaltrials.gov/).  
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Fig. 3. Schematic diagram of glutamatergic synaptic transmission in the NAc, illustrating 
that cocaine priming or re-exposuse to cocaine-associated cues evokes an increase in 
glutamate release and relapse to drug-seeking behaviour in rats. Various compounds that 
target CB1 and mGluRs may attenuate cocaine- or cue-induced increase in glutamate release 
or in postsynaptic glutamate receptor signalling, and therefore, inhibit relapse to drug-
seeking behaviour. 
4.2 MPEP  
Preclinical studies: MPEP is a selective mGluR5 negative allosteric modulator (NAM) or 
antagonist (Gasparini et al., 1999). The first study to examine the role of mGluR5 in drug 
addiction reported that deletion of mGluR5 subtype abolishes cocaine self-administration in 
mice, while systemic administration of MPEP significantly inhibited cocaine self-
administration in mice (Chiamulera et al., 2001). Since then, a large number of studies 
suggest that systemic administration of MPEP or its analog MTEP (a more selective mGluR5 
NAM) (Lea and Faden, 2006) significantly and dose-dependently inhibits cocaine self-
administration in rats (Xi et al., 2004a, 2004c; Tessari et al., 2004; Paterson and Markou, 2005; 
Kenny et al., 2005; Lee et al., 2005), cocaine-induced CPP (McGeehan and Olive, 2003; Herzig 
and Schmidt, 2004), cocaine-induced hyperactivity (McGeehan  et al., 2004), and cocaine-, 
cue- or stress-induced reinstatement of cocaine-seeking behaviour (Xi et al., 2004a, 2004c; 
Lee et al., 2005; Backstrom and Hyytia, 2006; Kumaresan et al., 2009; Martin-Fardon and 
Weiss, 2011; Wang et al., 2012). These data strongly suggest that mGluR5 antagonists may 
be promising in the treatment of cocaine addiction.  
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Clinical trials: MPEP and MTEP have not been tested in clinical trials. Relatively poor 
selectivity of MPEP for mGluR5 over other targets (NET, NR2B-containing NMDA receptor, 
monoamine oxidase A and mGluR4) may have prevented its use in human clinical trials.  
4.3 Fenobam 
Preclinical studies: Fenobam (McN-3377) was originally developed as a nonbenzodiazepine 
anxiolytic in the 1980s with an unknown molecular target until 2005 when it was reported 
that fenobam is a selective mGluR5 NAM or antagonist (Porter et al., 2005). Fenobam was 
reported to have improved mGluR5 selectivity compared to MPEP, as assessed by the use of 
mGluR5-KO mice, and rapidly penetrate brain-blood barrier to concentrate in the brain 
(Montana et al., 2009). Systemic administration of fenobam dose-dependently elevates 
stimulation threshold for brain-stimulation reward in rats, suggesting a reduction in brain 
reward function (Cleva et al., 2012). In addition, our pilot experimental data also suggest 
that oral administration of fenobam significantly inhibits cocaine self-administration and 
cocaine- or cue-, induced cocaine-seeking behaviour. 
Clinical trials: Fenobam was investigated in Phase II clinical trials in the 1980s for the 
treatment of anxiety and depression (Table 3). Earlier single- or double-blind, placebo-
controlled clinical trials demonstrated that fenobam was effective in attenuating severe 
anxiety with good safety profiles (Pecknold et al., 1982; Pecknold et al., 1980; Lapierre and 
Oyewumi, 1982). However, in another report, it was reported to be inactive and have 
psychostimulant effects by itself (Friedmann et al., 1980). At the time, fenobam was 
discontinued from further development as an anxiolytic.  In 2006, it was granted orphan 
drug designation by the FDA for clinical trials in the treatment of Fragile X syndrome, an 
inherited mental retardation disorder. The efficacy of fenobam in the treatment of cocaine 
addiction has not yet been evaluated. 
4.4 ADX10059 
ADX10059 is another novel mGluR5-selective NAM or antagonist with an IC50 of 17.1 nM at 
human mGluR5, showing good selectivity for mGluR5 over > 65 other receptors, 
transporters, ion channels and enzymes (Marin and Goadsby, 2010). Although limited 
preclinical data are available, it has been under Phase I and Phase II clinical trials for the 
treatment of gastro-oesophageal reflux disease (Zerbib et al., 2010, 2011) and migraine 
(Marin and Goadsby, 2010) (Table 3). To date, ADX10059 has been studied in at least 10 
clinical trials. However, Addex Pharmaceuticals announced the discontinuation of 
development of ADX10059 in December 2009 due to liver enzyme changes. The efficacy of 
ADX10059 in the treatment of cocaine addiction has not been evaluated.  
4.5 LY379268  
Preclinical studies:  LY379268 is a systemically effective mGluR2/3 orthosteric (competitive) 
agonist (Marek, 2004). The mGluR2/3 receptors have become attractive targets in medication 
development for the treatment of drug addiction because mGluR2/3 receptors function as 
glutamate autoreceptors, modulating presynaptic glutamate release (Xi et al., 2002a) (Figure 
3). In addition, mGluR2/3 modulates DA and other neurotransmitter release in the NAc. 
Since cocaine-induced increases in NAc DA and glutamate are critically involved in drug 
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target CB1 and mGluRs may attenuate cocaine- or cue-induced increase in glutamate release 
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4.2 MPEP  
Preclinical studies: MPEP is a selective mGluR5 negative allosteric modulator (NAM) or 
antagonist (Gasparini et al., 1999). The first study to examine the role of mGluR5 in drug 
addiction reported that deletion of mGluR5 subtype abolishes cocaine self-administration in 
mice, while systemic administration of MPEP significantly inhibited cocaine self-
administration in mice (Chiamulera et al., 2001). Since then, a large number of studies 
suggest that systemic administration of MPEP or its analog MTEP (a more selective mGluR5 
NAM) (Lea and Faden, 2006) significantly and dose-dependently inhibits cocaine self-
administration in rats (Xi et al., 2004a, 2004c; Tessari et al., 2004; Paterson and Markou, 2005; 
Kenny et al., 2005; Lee et al., 2005), cocaine-induced CPP (McGeehan and Olive, 2003; Herzig 
and Schmidt, 2004), cocaine-induced hyperactivity (McGeehan  et al., 2004), and cocaine-, 
cue- or stress-induced reinstatement of cocaine-seeking behaviour (Xi et al., 2004a, 2004c; 
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Weiss, 2011; Wang et al., 2012). These data strongly suggest that mGluR5 antagonists may 
be promising in the treatment of cocaine addiction.  
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Clinical trials: MPEP and MTEP have not been tested in clinical trials. Relatively poor 
selectivity of MPEP for mGluR5 over other targets (NET, NR2B-containing NMDA receptor, 
monoamine oxidase A and mGluR4) may have prevented its use in human clinical trials.  
4.3 Fenobam 
Preclinical studies: Fenobam (McN-3377) was originally developed as a nonbenzodiazepine 
anxiolytic in the 1980s with an unknown molecular target until 2005 when it was reported 
that fenobam is a selective mGluR5 NAM or antagonist (Porter et al., 2005). Fenobam was 
reported to have improved mGluR5 selectivity compared to MPEP, as assessed by the use of 
mGluR5-KO mice, and rapidly penetrate brain-blood barrier to concentrate in the brain 
(Montana et al., 2009). Systemic administration of fenobam dose-dependently elevates 
stimulation threshold for brain-stimulation reward in rats, suggesting a reduction in brain 
reward function (Cleva et al., 2012). In addition, our pilot experimental data also suggest 
that oral administration of fenobam significantly inhibits cocaine self-administration and 
cocaine- or cue-, induced cocaine-seeking behaviour. 
Clinical trials: Fenobam was investigated in Phase II clinical trials in the 1980s for the 
treatment of anxiety and depression (Table 3). Earlier single- or double-blind, placebo-
controlled clinical trials demonstrated that fenobam was effective in attenuating severe 
anxiety with good safety profiles (Pecknold et al., 1982; Pecknold et al., 1980; Lapierre and 
Oyewumi, 1982). However, in another report, it was reported to be inactive and have 
psychostimulant effects by itself (Friedmann et al., 1980). At the time, fenobam was 
discontinued from further development as an anxiolytic.  In 2006, it was granted orphan 
drug designation by the FDA for clinical trials in the treatment of Fragile X syndrome, an 
inherited mental retardation disorder. The efficacy of fenobam in the treatment of cocaine 
addiction has not yet been evaluated. 
4.4 ADX10059 
ADX10059 is another novel mGluR5-selective NAM or antagonist with an IC50 of 17.1 nM at 
human mGluR5, showing good selectivity for mGluR5 over > 65 other receptors, 
transporters, ion channels and enzymes (Marin and Goadsby, 2010). Although limited 
preclinical data are available, it has been under Phase I and Phase II clinical trials for the 
treatment of gastro-oesophageal reflux disease (Zerbib et al., 2010, 2011) and migraine 
(Marin and Goadsby, 2010) (Table 3). To date, ADX10059 has been studied in at least 10 
clinical trials. However, Addex Pharmaceuticals announced the discontinuation of 
development of ADX10059 in December 2009 due to liver enzyme changes. The efficacy of 
ADX10059 in the treatment of cocaine addiction has not been evaluated.  
4.5 LY379268  
Preclinical studies:  LY379268 is a systemically effective mGluR2/3 orthosteric (competitive) 
agonist (Marek, 2004). The mGluR2/3 receptors have become attractive targets in medication 
development for the treatment of drug addiction because mGluR2/3 receptors function as 
glutamate autoreceptors, modulating presynaptic glutamate release (Xi et al., 2002a) (Figure 
3). In addition, mGluR2/3 modulates DA and other neurotransmitter release in the NAc. 
Since cocaine-induced increases in NAc DA and glutamate are critically involved in drug 
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reward and relapse, it was proposed that mGluR2/3 agonists might be useful for the 
treatment of cocaine addiction (Xi et al., 2002a). Systemic administration of LY379268 
inhibits cocaine self-administration and cocaine cue-induced reinstatement of drug-seeking 
behaviour (Baptista et al., 2004; Peters and Kalivas, 2006). Microinjections of LY369268 into 
the NAc or central amygdala also inhibit cocaine- or food-triggered reinstatement of 
reward-seeking behaviour (Peters and Kalivas, 2006) or incubation of cocaine craving in rats 
(Lu et al., 2007). These data suggest that LY369268 may be useful for the treatment of cocaine 
addiction.  
Clinical studies: LY379268 is not currently under clinical trials. This may be related to its 
intrinsic competitive agonist properties that may produce unwanted side-effects by itself 
and/or reduce efficacy due to competitive binding inhibition by excessive glutamate release 
under pathological conditions. In contrast to LY379268, several other mGluR2/3 positive 
allosteric modulators (PAMs) are being investigated in Phase I and Phase II clinical trials for 
the treatment of schizophreria and anxiety (Mezler et al., 2010; Patil., et al., 2007). These 
compounds include AZD8529, LY404039, LY354740, and LY2140023 (Table 3). The potential 
effects of these mGluR2/3 agonists in treatment of cocaine addiction have not been 
evaluated. 
4.6 BINA  
Preclinical studies: Biphenylindanone A (BINA) is a selective mGluR2 PAM or agonist (Johnson 
et al., 2003; Galici et al., 2006).  Recent studies suggest that the pharmacological effects of 
LY379268 (a competitive mGluR2/3 orthosteric agonist) in animal models relevant to 
neuropsychiatric diseases could be mediated predominantly by activation of mGluR2, not 
mGluR3 receptor (Woolley et al., 2008), suggesting that mGluR2-selective agonists may 
produce similar therapeutic effects but have fewer unwanted effects than LY379268. Recently, 
Markou and her colleagues have compared the pharmacotherapeutic effects of BINA and 
LY379268 in animal models of drug addiction. They found that BINA selectively inhibits 
cocaine self-administration and cue-induced reinstatement of cocaine-seeking behaviour 
without affecting behaviours motivated by food reinforcement, while LY379268 nonselectively 
inhibits both cocaine- and food-taking and –seeking behaviour (Jin et al., 2010). These data 
suggest that selective mGluR2 PAMs (BINA) might have better therapeutic potential than dual 
mGluR2/3 agonists (LY379268) for the treatment of cocaine addiction. 
Clinical trials: BINA is currently not under clinical trials. However, other mGluR2 PAMs 
such as AZD71149, LY354740 and JNJ-40411813 are currently under clinical trials for safety 
and in vivo binding property in healthy volunteers (Table 3).  
4.7 2-PMPA and GPI-5693 
Preclinical studies: 2-PMPA and GPI-5693 (also called 2-MPPA) are inhibitors of NAALADase 
(N-acetylated-α-linked acidic dipeptidase, also called glutamate carboxypeptidase II, 
GCPII), an enzyme that hydrolyzes N-acetylaspartate-glutamate (NAAG) to N-
acetylaspartate (NAA) and glutamate (Neal et al., 2000, 2011). NAAG is an endogenous 
mGluR3 agonist, which negatively modulates the release of glutamate and other 
neurotransmitters (Neale et al., 2000, 2011). Given the important role of NAc glutamate in 
relapse to drug seeking as stated above, it was hypothesized that inhibition of NAALADase 
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by 2-PMPA and GPI-5693 would increase extracellular NAAG and decrease extracellular 
glutamate levels (due to decreased glutamate release from NAAG degradation), while the 
increase in NAAG would further inhibit glutamate release from neuronal terminals and/or 
glial cells by activating mGluR3 receptors (Xi et al., 2002a, 2010b). In addition, NAAG also 
inhibits DA release by activating mGluR3 receptors located on DA terminals in the NAc (Xi 
et al., 2010b). Thus, the endogenous NAALADase-NAAG-mGluR3 signal system may 
constitute a novel important target in medication development for the treatment of cocaine 
addiction. Earlier studies have shown that systemic administration of 2-PMPA inhibits 
cocaine-induced CPP (Slusher et al., 2001) and cocaine-induced behavioural sensitization 
(Shippenberg et al., 2000). Recently, we reported that systemic administration of 2-PMPA or 
GPI-5693 inhibited cocaine self-administration, cocaine-enhanced brain-stimulation reward, 
and cocaine-triggered reinstatement of drug-seeking behaviour (Xi et al., 2010a, 2010b; Peng 
et al., 2010b). This action was blocked by pretreatment with LY341495, a selective mGluR2/3 
antagonist. In addition, 2-PMPA dose-dependently attenuated cocaine-induced increases in 
extracellular DA and glutamate in the NAc (Xi et al., 2010a; 2010b). Taken together, these 
data suggest that inhibition of NAALADase by 2-PMPA or GPI-5693 produces an inhibitory 
effect on cocaine-taking and cocaine-seeking behaviour  
Clinical trials: GPI-5693 was investigated in a Phase I clinical trial for its safety, 
pharmacokinetics and efficacy for treatment of neuropathic pain (Table 3) (van der Post et 
al., 2005). It was reported to be safe and tolerable in healthy subjects.  
4.8 AMN082 
AMN082 is a novel systemically active mGluR7 PAM or agonist (Mitsukawa et al., 2005). 
The mGluR7 receptor subtype has attracted much attention in medication development for 
treatment of addiction for several reasons (Li et al., 2012). First, mGluR7 is the most 
abundant subtype of the group III mGluR subtypes in reward-related brain regions such as 
striatum, hippocampus and olfactory tubercles (Ferraguti and Shigemoto, 2006). Second, 
activation of group III mGluRs (including mGluR7) by L-AP4 inhibits DA and glutamate 
release in the NAc (Hu et al., 1999; Xi et al., 2003b). Third, it is the most conserved mGluR 
subtype across different mammalian species (Makoff et al., 1996), suggesting that selective 
mGluR7 ligands that are effective in experimental animals are more likely to be effective in 
humans. And fourth, the development of AMN082 has allowed us to explore the role of 
mGluR7 in drug reward and addiction.  
Based on the above, we and others have recently reported that systemic administration of 
AMN082 inhibits cocaine self-administration behaviour under both FR2 and PR 
reinforcement, cocaine-enhanced brain reward function, and cocaine-induced reinstatement 
of drug-seeking behaviour. In addition, AMN082 also decreases, while the selective mGluR7 
antagonist MMPIP increases, alcohol intake and preference (Salling et al., 2008; Bahi et al., 
2011). Importantly, the same doses of AMN082 neither alters locomotion or sucrose self-
administration (Li et al., 2010; Bahi et al., 2011; but see Salling et al., 2008) nor alters brain 
reward function (Li et al., 2008), suggesting that AMN082 produces therapeutic anti-cocaine 
effects without significant unwanted effects such as sedation, dysphoria or natural reward 
depression. Further mechanistic studies suggest that a NAc-VP GABAergic mechanism 
underlies its antagonism of cocaine reward (Li et al., 2008, 2009), while a glutamate-
mGluR2/3 mechanism underlies its antagonism of relapse to drug-seeking behaviour (Li et 
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reward and relapse, it was proposed that mGluR2/3 agonists might be useful for the 
treatment of cocaine addiction (Xi et al., 2002a). Systemic administration of LY379268 
inhibits cocaine self-administration and cocaine cue-induced reinstatement of drug-seeking 
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reward-seeking behaviour (Peters and Kalivas, 2006) or incubation of cocaine craving in rats 
(Lu et al., 2007). These data suggest that LY369268 may be useful for the treatment of cocaine 
addiction.  
Clinical studies: LY379268 is not currently under clinical trials. This may be related to its 
intrinsic competitive agonist properties that may produce unwanted side-effects by itself 
and/or reduce efficacy due to competitive binding inhibition by excessive glutamate release 
under pathological conditions. In contrast to LY379268, several other mGluR2/3 positive 
allosteric modulators (PAMs) are being investigated in Phase I and Phase II clinical trials for 
the treatment of schizophreria and anxiety (Mezler et al., 2010; Patil., et al., 2007). These 
compounds include AZD8529, LY404039, LY354740, and LY2140023 (Table 3). The potential 
effects of these mGluR2/3 agonists in treatment of cocaine addiction have not been 
evaluated. 
4.6 BINA  
Preclinical studies: Biphenylindanone A (BINA) is a selective mGluR2 PAM or agonist (Johnson 
et al., 2003; Galici et al., 2006).  Recent studies suggest that the pharmacological effects of 
LY379268 (a competitive mGluR2/3 orthosteric agonist) in animal models relevant to 
neuropsychiatric diseases could be mediated predominantly by activation of mGluR2, not 
mGluR3 receptor (Woolley et al., 2008), suggesting that mGluR2-selective agonists may 
produce similar therapeutic effects but have fewer unwanted effects than LY379268. Recently, 
Markou and her colleagues have compared the pharmacotherapeutic effects of BINA and 
LY379268 in animal models of drug addiction. They found that BINA selectively inhibits 
cocaine self-administration and cue-induced reinstatement of cocaine-seeking behaviour 
without affecting behaviours motivated by food reinforcement, while LY379268 nonselectively 
inhibits both cocaine- and food-taking and –seeking behaviour (Jin et al., 2010). These data 
suggest that selective mGluR2 PAMs (BINA) might have better therapeutic potential than dual 
mGluR2/3 agonists (LY379268) for the treatment of cocaine addiction. 
Clinical trials: BINA is currently not under clinical trials. However, other mGluR2 PAMs 
such as AZD71149, LY354740 and JNJ-40411813 are currently under clinical trials for safety 
and in vivo binding property in healthy volunteers (Table 3).  
4.7 2-PMPA and GPI-5693 
Preclinical studies: 2-PMPA and GPI-5693 (also called 2-MPPA) are inhibitors of NAALADase 
(N-acetylated-α-linked acidic dipeptidase, also called glutamate carboxypeptidase II, 
GCPII), an enzyme that hydrolyzes N-acetylaspartate-glutamate (NAAG) to N-
acetylaspartate (NAA) and glutamate (Neal et al., 2000, 2011). NAAG is an endogenous 
mGluR3 agonist, which negatively modulates the release of glutamate and other 
neurotransmitters (Neale et al., 2000, 2011). Given the important role of NAc glutamate in 
relapse to drug seeking as stated above, it was hypothesized that inhibition of NAALADase 
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by 2-PMPA and GPI-5693 would increase extracellular NAAG and decrease extracellular 
glutamate levels (due to decreased glutamate release from NAAG degradation), while the 
increase in NAAG would further inhibit glutamate release from neuronal terminals and/or 
glial cells by activating mGluR3 receptors (Xi et al., 2002a, 2010b). In addition, NAAG also 
inhibits DA release by activating mGluR3 receptors located on DA terminals in the NAc (Xi 
et al., 2010b). Thus, the endogenous NAALADase-NAAG-mGluR3 signal system may 
constitute a novel important target in medication development for the treatment of cocaine 
addiction. Earlier studies have shown that systemic administration of 2-PMPA inhibits 
cocaine-induced CPP (Slusher et al., 2001) and cocaine-induced behavioural sensitization 
(Shippenberg et al., 2000). Recently, we reported that systemic administration of 2-PMPA or 
GPI-5693 inhibited cocaine self-administration, cocaine-enhanced brain-stimulation reward, 
and cocaine-triggered reinstatement of drug-seeking behaviour (Xi et al., 2010a, 2010b; Peng 
et al., 2010b). This action was blocked by pretreatment with LY341495, a selective mGluR2/3 
antagonist. In addition, 2-PMPA dose-dependently attenuated cocaine-induced increases in 
extracellular DA and glutamate in the NAc (Xi et al., 2010a; 2010b). Taken together, these 
data suggest that inhibition of NAALADase by 2-PMPA or GPI-5693 produces an inhibitory 
effect on cocaine-taking and cocaine-seeking behaviour  
Clinical trials: GPI-5693 was investigated in a Phase I clinical trial for its safety, 
pharmacokinetics and efficacy for treatment of neuropathic pain (Table 3) (van der Post et 
al., 2005). It was reported to be safe and tolerable in healthy subjects.  
4.8 AMN082 
AMN082 is a novel systemically active mGluR7 PAM or agonist (Mitsukawa et al., 2005). 
The mGluR7 receptor subtype has attracted much attention in medication development for 
treatment of addiction for several reasons (Li et al., 2012). First, mGluR7 is the most 
abundant subtype of the group III mGluR subtypes in reward-related brain regions such as 
striatum, hippocampus and olfactory tubercles (Ferraguti and Shigemoto, 2006). Second, 
activation of group III mGluRs (including mGluR7) by L-AP4 inhibits DA and glutamate 
release in the NAc (Hu et al., 1999; Xi et al., 2003b). Third, it is the most conserved mGluR 
subtype across different mammalian species (Makoff et al., 1996), suggesting that selective 
mGluR7 ligands that are effective in experimental animals are more likely to be effective in 
humans. And fourth, the development of AMN082 has allowed us to explore the role of 
mGluR7 in drug reward and addiction.  
Based on the above, we and others have recently reported that systemic administration of 
AMN082 inhibits cocaine self-administration behaviour under both FR2 and PR 
reinforcement, cocaine-enhanced brain reward function, and cocaine-induced reinstatement 
of drug-seeking behaviour. In addition, AMN082 also decreases, while the selective mGluR7 
antagonist MMPIP increases, alcohol intake and preference (Salling et al., 2008; Bahi et al., 
2011). Importantly, the same doses of AMN082 neither alters locomotion or sucrose self-
administration (Li et al., 2010; Bahi et al., 2011; but see Salling et al., 2008) nor alters brain 
reward function (Li et al., 2008), suggesting that AMN082 produces therapeutic anti-cocaine 
effects without significant unwanted effects such as sedation, dysphoria or natural reward 
depression. Further mechanistic studies suggest that a NAc-VP GABAergic mechanism 
underlies its antagonism of cocaine reward (Li et al., 2008, 2009), while a glutamate-
mGluR2/3 mechanism underlies its antagonism of relapse to drug-seeking behaviour (Li et 
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al., 2008, 2010, 2012). Together, these preclinical data suggest a potential utility of AMN082 
in the treatment of cocaine addiction. AMN082 has not yet been tested in clinical trials. 
5. GABA-based medication strategies 
Rationale:  It is well known that the mesolimbic DA system is critically involved in drug 
reward and addiction. However, it remains unclear how increased NAc DA underlies these 
actions. Anatomically, the majority of neurons in the striatum are medium-spiny 
GABAergic output neurons, which receive DA projections from the VTA and glutamatergic 
projections predominantly from the prefrontal cortex, and project to the dorsal globus 
pallidus (from the dorsal striatum) and the ventral pallidum (VP) and VTA (from the ventral 
striatum, i.e. the NAc) (Bennett and Bolam, 1994; Groenewegen et al., 1996). Overall, DA 
produces a net inhibitory effect on striatal medium-spiny GABAergic neurons (Nicola and 
Malenka, 1997; Umemiya and Raymond, 1997), predominantly by activation of D2-like DA 
receptors (Centonze et al., 2002). Similarly, cocaine also produces an overall inhibitory effect 
on VTA GABAergic neurons (Cameron and Williams, 1994), striatal GABAergic neurons 
(Uchimura and North, 1990; White et al., 1993; Centonze et al., 2002; Schramm-Sapyta et al., 
2006), and GABA release in the VP (Tang et al., 2005; Li et al., 2010). Based on this, the NAc-
VP/VTA GABAergic projection constitutes common final pathway underlying drug reward 
and addiction (Figure 2). Thus, it has been hypothesized that a pharmacological strategy 
that enhances GABAergic transmission in the VTA and/or the VP would produce an 
inhibitory effect on cocaine- or DA-induced reductions in GABA release, therefore 
antagonizing cocaine’s rewarding effects. Based on this, several GABAergic compounds 
have been studied extensively in experimental animals.  
5.1 Gamma-vinyl GABA  
Preclinical studies: Gamma-vinyl GABA (GVG) (also called vigabatrin) is an irreversible 
GABA transaminase inhibitor.  GABA transaminase is an enzyme that breaks down GABA, 
causing an increase in brain GABA after GVG administration (Peng et al., 2010a). In the 
1990s, Dewey and colleagues first proposed that GVG might be useful for the treatment of 
drug addiction (Dewey et al., 1998). Since then, many preclinical studies appear to support 
this hypothesis (Xi and Gardner, 2008). Systemic administration of GVG inhibits cocaine 
self-administration, cocaine-enhanced brain-stimulation reward, cocaine-induced CPP and 
behavioural sensitization (see review by Xi and Gardner, 2008). Similarly, it also dose-
dependently inhibits cocaine-induced reinstatement of drug-seeking behaviour (Peng et al., 
2008). All these data support the use of GVG in the treatment of cocaine addiction.  
Clinical trials: GVG is currently under clinical trials for treatment of cocaine addiction (Table 
4). In three open-labeled studies, GVG was well-tolerated and produced a significant 
increase in cocaine abstinence rate (Brodie et al., 2003, 2005; Fechtner et al., 2006). In a more 
recent randomized, double-blind, placeto-controled trial, short-term GVG treatment 
significantly increased abstinence rate compared to placebo (Brodie et al., 2009). However, 
in another clinical trial for the treatment of methamphetamine dependence, GVG was not 
effective (De La Garza et al., 2009). GVG is not marketed in the USA because of concerns 
over ophthalmological side-effects, but none were observed during these short-term studies 
(Fechtner et al., 2006). More studies are underway to confirm its efficacy for cocaine 
dependence (http://clinicaltrials.gov).  
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Table 4. GABA receptor-based drug candidates in clinical trials 
5.2 Tiagabine 
Preclinical studies: Tiagabine is a selective type 1 GABA transporter (GAT1) inhibitor, which 
increases extracellular GABA levels (Eriksson et al., 1999). It has been approved as an 
antiepileptic medication (Schousboe et al., 2011). Preclinical studies suggest that tiagabine 
inhibited intravenous cocaine self-administration in rats (Filip et al., 2007) or baboons 
(Weerts et al., 2005), but had no significant effect on cocaine-induced reinstatement of drug-
seeking behaviour (Filip et al., 2007; Weerts et al., 2007). Our experimental data suggest that 
tiagabine, at much higher doses (10-20 mg/kg) than those used in the above-cited studies, 
selectively inhibited cocaine self-administration, but had no effect on cocaine-induced 
reinstatement of drug-seeking behaviour in rats (Yang et al., 2012). 
Clinical trials: The results of clinical trials with tiagabine are mixed. Two small-scale (45 and 
76 subjects, respectively) placebo-controlled clinical trials indicated that tiagabine produced 
a moderate reduction (~30%) in cocaine use in methadone-treated cocaine addicts (González 
et al., 2003, 2007), while other studies demonstrated that the same doses of tiagabine neither 
altered the acute effects of cocaine (Lile et al., 2004), nor lowered cocaine use in cocaine 
addicts (Winhusen et al., 2005; 2007).  
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al., 2008, 2010, 2012). Together, these preclinical data suggest a potential utility of AMN082 
in the treatment of cocaine addiction. AMN082 has not yet been tested in clinical trials. 
5. GABA-based medication strategies 
Rationale:  It is well known that the mesolimbic DA system is critically involved in drug 
reward and addiction. However, it remains unclear how increased NAc DA underlies these 
actions. Anatomically, the majority of neurons in the striatum are medium-spiny 
GABAergic output neurons, which receive DA projections from the VTA and glutamatergic 
projections predominantly from the prefrontal cortex, and project to the dorsal globus 
pallidus (from the dorsal striatum) and the ventral pallidum (VP) and VTA (from the ventral 
striatum, i.e. the NAc) (Bennett and Bolam, 1994; Groenewegen et al., 1996). Overall, DA 
produces a net inhibitory effect on striatal medium-spiny GABAergic neurons (Nicola and 
Malenka, 1997; Umemiya and Raymond, 1997), predominantly by activation of D2-like DA 
receptors (Centonze et al., 2002). Similarly, cocaine also produces an overall inhibitory effect 
on VTA GABAergic neurons (Cameron and Williams, 1994), striatal GABAergic neurons 
(Uchimura and North, 1990; White et al., 1993; Centonze et al., 2002; Schramm-Sapyta et al., 
2006), and GABA release in the VP (Tang et al., 2005; Li et al., 2010). Based on this, the NAc-
VP/VTA GABAergic projection constitutes common final pathway underlying drug reward 
and addiction (Figure 2). Thus, it has been hypothesized that a pharmacological strategy 
that enhances GABAergic transmission in the VTA and/or the VP would produce an 
inhibitory effect on cocaine- or DA-induced reductions in GABA release, therefore 
antagonizing cocaine’s rewarding effects. Based on this, several GABAergic compounds 
have been studied extensively in experimental animals.  
5.1 Gamma-vinyl GABA  
Preclinical studies: Gamma-vinyl GABA (GVG) (also called vigabatrin) is an irreversible 
GABA transaminase inhibitor.  GABA transaminase is an enzyme that breaks down GABA, 
causing an increase in brain GABA after GVG administration (Peng et al., 2010a). In the 
1990s, Dewey and colleagues first proposed that GVG might be useful for the treatment of 
drug addiction (Dewey et al., 1998). Since then, many preclinical studies appear to support 
this hypothesis (Xi and Gardner, 2008). Systemic administration of GVG inhibits cocaine 
self-administration, cocaine-enhanced brain-stimulation reward, cocaine-induced CPP and 
behavioural sensitization (see review by Xi and Gardner, 2008). Similarly, it also dose-
dependently inhibits cocaine-induced reinstatement of drug-seeking behaviour (Peng et al., 
2008). All these data support the use of GVG in the treatment of cocaine addiction.  
Clinical trials: GVG is currently under clinical trials for treatment of cocaine addiction (Table 
4). In three open-labeled studies, GVG was well-tolerated and produced a significant 
increase in cocaine abstinence rate (Brodie et al., 2003, 2005; Fechtner et al., 2006). In a more 
recent randomized, double-blind, placeto-controled trial, short-term GVG treatment 
significantly increased abstinence rate compared to placebo (Brodie et al., 2009). However, 
in another clinical trial for the treatment of methamphetamine dependence, GVG was not 
effective (De La Garza et al., 2009). GVG is not marketed in the USA because of concerns 
over ophthalmological side-effects, but none were observed during these short-term studies 
(Fechtner et al., 2006). More studies are underway to confirm its efficacy for cocaine 
dependence (http://clinicaltrials.gov).  
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Table 4. GABA receptor-based drug candidates in clinical trials 
5.2 Tiagabine 
Preclinical studies: Tiagabine is a selective type 1 GABA transporter (GAT1) inhibitor, which 
increases extracellular GABA levels (Eriksson et al., 1999). It has been approved as an 
antiepileptic medication (Schousboe et al., 2011). Preclinical studies suggest that tiagabine 
inhibited intravenous cocaine self-administration in rats (Filip et al., 2007) or baboons 
(Weerts et al., 2005), but had no significant effect on cocaine-induced reinstatement of drug-
seeking behaviour (Filip et al., 2007; Weerts et al., 2007). Our experimental data suggest that 
tiagabine, at much higher doses (10-20 mg/kg) than those used in the above-cited studies, 
selectively inhibited cocaine self-administration, but had no effect on cocaine-induced 
reinstatement of drug-seeking behaviour in rats (Yang et al., 2012). 
Clinical trials: The results of clinical trials with tiagabine are mixed. Two small-scale (45 and 
76 subjects, respectively) placebo-controlled clinical trials indicated that tiagabine produced 
a moderate reduction (~30%) in cocaine use in methadone-treated cocaine addicts (González 
et al., 2003, 2007), while other studies demonstrated that the same doses of tiagabine neither 
altered the acute effects of cocaine (Lile et al., 2004), nor lowered cocaine use in cocaine 
addicts (Winhusen et al., 2005; 2007).  
 




Preclinical studies: Topiramate is a positive modulator of GABAA receptors (acting at non-
benzodiazepine sites) and a licensed antiepileptic drug (Czuczwar and Patsalos, 2001). In 
addition, topiramate has other pharmacological actions, including antagonism of 
AMPA/kainate glutamate receptors, inhibition of voltage-gated sodium and calcium 
channels and inhibition of carbonic anhydrase (Johnson, 2005). In animal studies, topiramate 
was reported to inhibit cocaine self-administration and attenuate NAc DA response to 
cocaine or cocaine-associated cues (Johnson, 2005). 
Clinical studies: In a double-blind, placebo-controlled clinical trial (40 subjects), topiramate 
significantly increased abstinence rates compared to placebo (Kampman et al., 2004). A 
recent 12-week, open-label pilot study showed a significant reduction in craving intensity 
and duration in 25% of the sample group (Reis et al., 2008). Evidence for a beneficial role of 
topiramate in the treatment of cocaine dependence is promising but is limited by small 
sample sizes (Cubells, 2006; Minozzi et al., 2008). More studies are currently underway 
(Table 4). 
5.4 Baclofen 
Preclinical studies: Baclofen is a selective GABAB receptor agonist, licensed as an 
antispasmodic for patients with spinal cord injuries or multiple sclerosis. In rodents, 
pretreatment with baclofen dose-dependently attenuates cocaine self-administration under 
FR and PR reinforcement (Roberts et al., 1996; Brebner et al., 2000), cocaine-enhanced brain-
stimulation reward (Slattery et al., 2005), and cocaine-induced increases in NAc DA (Fadda 
et al., 2003). It also inhibited cocaine- or cue-induced cocaine-taking and cocaine-seeking 
behaviour (Di Ciano and Everitt, 2003; Campbell et al., 1999; Weerts et al., 2007).  
Clinical trials: In an initial open-label clinical trial, baclofen reduced self-reports of craving 
and cocaine use in 10 cocaine abusers (Ling et al., 1998). In a subsequent 16-week double-
blind study in 35 cocaine-dependent subjects, baclofen reduced cocaine use and increased 
the number of cocaine-free urines (Shoptaw et al., 2003), but did not alter cocaine craving. In 
a recent placebo-controlled, double-blind study, baclofen lowered cocaine intake, decreased 
cocaine craving, and attenuated cocaine’s cardiovascular effects in both cocaine- and opioid-
dependent subjects (Haney et al., 2006). However, a more recent large scale (160 cocaine 
addicts), double-blind, placebo-controlled clinical trial demonstrated that baclofen was not 
effective in attenuating cocaine use (Kahn et al., 2009). Thus, more studies are required to 
determine its efficacy in relapse prevention. 
5.5 Gabapentin 
Preclinical studies: Gabapentin is structurally analogous to GABA but, unlike the latter, it 
crosses the blood–brain barrier and can be administered systemically. Pharmacologically, 
gabapentin is a GABAmimetic drug that increases extracellular GABA levels, possibly by 
increasing the synthesis and nonvesicular release of GABA as well as by preventing GABA 
catabolism (Taylor et al., 1998). In addition, gabapentin also inhibits alpha2delta subunit-
composed voltage-dependent Ca++ channels (Gee et al., 1996). Early studies suggest that 
gabapentin (1-30 mg/kg, i.p.) significantly inhibited cocaine-induced hyperactivity and 
locomotor sensitization (Filip et al., 2006; but see Itzhak and Martin, 2000). However, other 
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studies demonstrate that gabapentin, at a broad dose range (10-200 mg/kg i.p.), neither 
inhibited cocaine self-administration nor altered cocaine-induced reinstatement of drug-
seeking behaviour in rats (Filip et al., 2007; Peng et al., 2008b). In vivo microdialysis studies 
demonstrate that gabapentin, at 100-200 mg/kg, produced a significant increase (~50 %) in 
extracellular GABA in the NAc, but failed to alter either basal or cocaine-enhanced NAc DA 
(Peng et al., 2008b). These data suggest that gabapentin is a weak GABA enhancer and may 
have limited potential in the treatment of cocaine addiction. 
Clinical trials: Early clinical studies and small-scale, open-label outpatient trials 
demonstrated that gabapentin reduced cocaine craving and use (Raby and Coomaraswamy, 
2004; Myrick et al., 2001; Hart et al., 2004, 2005). However, this finding was not repeated by 
larger-scale, double-blind, placebo-controlled clinical trials demonstrating that gabapentin, 
at doses up to 2400-3200 mg/day for 6-12 weeks, had no effect on abstinence rate, craving or 
subjective effects of cocaine (Bisaga et al., 2006; Berger et al., 2005; González et al., 2007; Hart 
et al., 2007). More clinical trials are currently under way to evaluate the effects of gabapentin 
or gabapentin combined with the antidepressant sertraline on cocaine or other addictive 
drug dependence (Table 4). 
6. Cannabinoid-based medication strategies 
Rationale: Marijuana is the most widely used illicit drug in the United States. Δ9-
tetrahydrocannabinol (Δ9-THC) is the major psychoactive ingredient in marijuana. Two 
major types of cannabinoid receptors, CB1 and CB2, have been cloned. Since CB1 receptors 
are found in both brain and peripheral tissues, whereas CB2 receptors are found 
predominantly in peripheral immune system, it is generally belived that the psychoactive 
effects of Δ9-THC or marijuana are mediated by activation of brain CB1, not CB2, receptors 
(Tanda and Goldberg, 2003). However, growing evidence suggests that functional CB2 
receptors are also found in the brain (Van Sickle et al., 2005; Gong et al., 2006; Xi et al., 2011), 
suggesting that brain CB2 receptors may be also involved in marijuana’s actions. 
As stated above, the mesolimbic DA and the downstream NAc-VP GABAergic transmission 
have been thought to underlie cocaine reward and addiction. Growing evidence suggests 
that similar mechanisms may also underlie the action produced by Δ9-THC or marijuana. It 
was reported that Δ9-THC elevates extracellular DA in the NAc (Chen et al., 1990; Tanda et 
al., 1997). This action could be mediated by a GABAergic mechanism, i.e., Δ9-THC may 
initially activate CB1 receptors located on VTA GABAergic interneurons and produce a 
decrease in GABA release, which subsequently disinhibits (or activates) VTA DA neurons 
(Figure 2) (Fernandez-Ruiz et al., 2010). In addition, CB1 receptors are also highly expressed 
on presynaptic glutamatergic terminals in the NAc (Lupica et al., 2004). Thus, activation of 
CB1 receptors located on glutamatergic terminals decreases glutamate inputs onto medium-
spiny GABAergic neurons in the NAc and decrease GABA release in their projection areas – 
the VP and VTA. Further, CB1 receptors are also expressed on striatal GABAergic neurons, 
and activation of the CB1 receptors produces a direct inhibitory effect on medium-spiny 
GABAergic neurons and decreases GABA release in the VP and the VTA (Maldonado et al., 
2011). Lastly, cocaine or DA has been shown to increase endocannabinoid release in the 
striatum (Giuffrida et al., 1999; Centonze et al., 2004; Caille et al., 2007), which subsequently 
increases endocannabinoid binding to CB1 receptors located on presynaptic glutamatergic 
terminals and postsynaptic GABAergic neurons (Figure 2). Taken together, activation of 
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effective in attenuating cocaine use (Kahn et al., 2009). Thus, more studies are required to 
determine its efficacy in relapse prevention. 
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Preclinical studies: Gabapentin is structurally analogous to GABA but, unlike the latter, it 
crosses the blood–brain barrier and can be administered systemically. Pharmacologically, 
gabapentin is a GABAmimetic drug that increases extracellular GABA levels, possibly by 
increasing the synthesis and nonvesicular release of GABA as well as by preventing GABA 
catabolism (Taylor et al., 1998). In addition, gabapentin also inhibits alpha2delta subunit-
composed voltage-dependent Ca++ channels (Gee et al., 1996). Early studies suggest that 
gabapentin (1-30 mg/kg, i.p.) significantly inhibited cocaine-induced hyperactivity and 
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studies demonstrate that gabapentin, at a broad dose range (10-200 mg/kg i.p.), neither 
inhibited cocaine self-administration nor altered cocaine-induced reinstatement of drug-
seeking behaviour in rats (Filip et al., 2007; Peng et al., 2008b). In vivo microdialysis studies 
demonstrate that gabapentin, at 100-200 mg/kg, produced a significant increase (~50 %) in 
extracellular GABA in the NAc, but failed to alter either basal or cocaine-enhanced NAc DA 
(Peng et al., 2008b). These data suggest that gabapentin is a weak GABA enhancer and may 
have limited potential in the treatment of cocaine addiction. 
Clinical trials: Early clinical studies and small-scale, open-label outpatient trials 
demonstrated that gabapentin reduced cocaine craving and use (Raby and Coomaraswamy, 
2004; Myrick et al., 2001; Hart et al., 2004, 2005). However, this finding was not repeated by 
larger-scale, double-blind, placebo-controlled clinical trials demonstrating that gabapentin, 
at doses up to 2400-3200 mg/day for 6-12 weeks, had no effect on abstinence rate, craving or 
subjective effects of cocaine (Bisaga et al., 2006; Berger et al., 2005; González et al., 2007; Hart 
et al., 2007). More clinical trials are currently under way to evaluate the effects of gabapentin 
or gabapentin combined with the antidepressant sertraline on cocaine or other addictive 
drug dependence (Table 4). 
6. Cannabinoid-based medication strategies 
Rationale: Marijuana is the most widely used illicit drug in the United States. Δ9-
tetrahydrocannabinol (Δ9-THC) is the major psychoactive ingredient in marijuana. Two 
major types of cannabinoid receptors, CB1 and CB2, have been cloned. Since CB1 receptors 
are found in both brain and peripheral tissues, whereas CB2 receptors are found 
predominantly in peripheral immune system, it is generally belived that the psychoactive 
effects of Δ9-THC or marijuana are mediated by activation of brain CB1, not CB2, receptors 
(Tanda and Goldberg, 2003). However, growing evidence suggests that functional CB2 
receptors are also found in the brain (Van Sickle et al., 2005; Gong et al., 2006; Xi et al., 2011), 
suggesting that brain CB2 receptors may be also involved in marijuana’s actions. 
As stated above, the mesolimbic DA and the downstream NAc-VP GABAergic transmission 
have been thought to underlie cocaine reward and addiction. Growing evidence suggests 
that similar mechanisms may also underlie the action produced by Δ9-THC or marijuana. It 
was reported that Δ9-THC elevates extracellular DA in the NAc (Chen et al., 1990; Tanda et 
al., 1997). This action could be mediated by a GABAergic mechanism, i.e., Δ9-THC may 
initially activate CB1 receptors located on VTA GABAergic interneurons and produce a 
decrease in GABA release, which subsequently disinhibits (or activates) VTA DA neurons 
(Figure 2) (Fernandez-Ruiz et al., 2010). In addition, CB1 receptors are also highly expressed 
on presynaptic glutamatergic terminals in the NAc (Lupica et al., 2004). Thus, activation of 
CB1 receptors located on glutamatergic terminals decreases glutamate inputs onto medium-
spiny GABAergic neurons in the NAc and decrease GABA release in their projection areas – 
the VP and VTA. Further, CB1 receptors are also expressed on striatal GABAergic neurons, 
and activation of the CB1 receptors produces a direct inhibitory effect on medium-spiny 
GABAergic neurons and decreases GABA release in the VP and the VTA (Maldonado et al., 
2011). Lastly, cocaine or DA has been shown to increase endocannabinoid release in the 
striatum (Giuffrida et al., 1999; Centonze et al., 2004; Caille et al., 2007), which subsequently 
increases endocannabinoid binding to CB1 receptors located on presynaptic glutamatergic 
terminals and postsynaptic GABAergic neurons (Figure 2). Taken together, activation of 
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CB1 receptors located on both GABAergic and glutamatergic neurons causes an increase in 
NAc DA and a decrease in GABA release in both the VTA and VP. This decrease in NAc-VP 
GABAergic transmission constitutes a final common pathway underlying drug reward and 
addiction. Accordingly, blockade of CB1 receptors in both the VTA and NAc would 
attenuate the actions of cocaine on NAc DA and VP GABA release, and therefore attenuate 
cocaine reward and addiction. 
6.1 SR141716A  
Preclinical studies: SR141716A (also called rimonabant) is the first developed CB1 receptor 
antagonist (also an inverse agonist) (Rinaldi-Carmona et al., 1994). SR141716A was reported 
to inhibit cocaine self-administration under PR reinforcement (Soria et al., 2005; Xi et al., 
2008), decrease cocaine-enhanced NAc DA (Cheer et al., 2007; Soria et al., 2005), and inhibit 
cocaine- and cue-induced reinstatement of drug-seeking behaviour (De Vries et al., 2001), 
while other studies suggest that it has no effect on cocaine self-administration under low FR 
reinforcement, cocaine-induced CPP, or cocaine-induced behavioural sensitization (Arnold, 
2005). These data suggest that SR141716A may have therapeutic effects in attenuating 
relapse to drug-seeking behaviour, but is limited in terms of attenuating cocaine’s acute 
rewarding effects (Beardsley and Thomas, 2005; Xi and Gardner, 2008).   
Clinical trials:  SR141716A was the first CB1 receptor antagonist to be approved for clinical 
trials for the treatment of obesity and cigarette smoking. However, there are some safety 
concerns with rimonabant – increased risk of anxiety, depression, and suicide tendency, 
which had led it to being withdrawn from the market in Europe and North America in 2008. 
Since then, many pharmaceutical companies (Sanofi-Aventis, Merck, Pfizer, Solvay) have 
announced that they will stop further clinical research on this class of drug.  
6.2 AM251 
Preclinical studies: AM251 is a more potent and selective CB1 receptor antagonist than 
SR141716A (Krishnamurthy et al., 2004). In animal models of drug addiction, AM251 
appears to be more potent and effective than SR141716A in attenuating cocaine’s action (Xi 
et al., 2006, 2008). For example, AM251 significantly and dose-dependently inhibited cocaine 
self-administration (under PR, but not FR reinforcement) (Xi et al., 2008), cocaine-enhanced 
brain-stimulation reward (Xi et al., 2008), and cocaine-induced behavioural sensitization 
(Corbille et al., 2007), as well as cocaine-triggered reinstatement of drug-seeking behaviour 
(Xi et al., 2006). Further, a glutamate-mGluR2/3 mechanism has been shown to underlie the 
antagonism of reinstatement of drug seeking (Xi et al., 2006). That is, blockade of CB1 
receptors by AM251 elevates extracellular glutamate in the NAc, which subsequently 
increased glutamate binding to presynaptic mGluR2/3 receptors, inhibiting cocaine-induced 
increases in glutamate release and relapse to drug-seeking behaviour (Xi et al., 2006) (Figure 
3). These findings suggest that AM251 may be more potent and effective than SR141716A for 
treatment of cocaine addiction.  
Clinical trials: Since the above mentioned side-effects of SR141716A have been linked to its 
inverse agonist property, it is generally believed that AM251, a CB1 receptor antagonist with 
similar inverse agonist property might have the same unwanted side-effects. It is not under 
clinical trials.  
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Preclinical studies: In addition to CB1 receptors, recent breakthrough findings suggest that brain 
CB2 receptors are also involved in drug reward and addiction (Onaivi et al., 2008; Xi et al., 
2011; Aracil-Fernández, et al., 2012). JWH133 and GW405833 are highly selective CB2 receptor 
agonists. We have recently reported that systemic, intranasal or intra-NAc administration of 
JWH133 or GW405833 significantly and dose-dependently inhibits cocaine self-administration, 
cocaine-induced increases in locomotion and extracellular DA in wild-type and CB1-KO mice, 
but not in CB2-KO mice. Similarly, overexpression of CB2 receptors in mouse brain decreases 
intravenous cocaine self-administration and cocaine-induced locomotor sensitization (Aracil-
Fernández, et al., 2012). These data suggest that CB2 receptor agonists may have therapeutic 
potential for the treatment of cocaine addiction (Figure 2) (Xi et al., 2011).   
Clinical trials: JWH133 and GW405833 are currently not under clinical trials. However, many 
other selective CB2 receptor agonists, such as cannabinor, GW842166, GRC-10693, LY-
2828360, ABT-521, and KHK-6188, are currently under Phase I and Phase II clinical trials 
for the treatment of pain or other diseases (Table 5). In addition, several dual CB1/CB2  
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CB1 receptors located on both GABAergic and glutamatergic neurons causes an increase in 
NAc DA and a decrease in GABA release in both the VTA and VP. This decrease in NAc-VP 
GABAergic transmission constitutes a final common pathway underlying drug reward and 
addiction. Accordingly, blockade of CB1 receptors in both the VTA and NAc would 
attenuate the actions of cocaine on NAc DA and VP GABA release, and therefore attenuate 
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cocaine- and cue-induced reinstatement of drug-seeking behaviour (De Vries et al., 2001), 
while other studies suggest that it has no effect on cocaine self-administration under low FR 
reinforcement, cocaine-induced CPP, or cocaine-induced behavioural sensitization (Arnold, 
2005). These data suggest that SR141716A may have therapeutic effects in attenuating 
relapse to drug-seeking behaviour, but is limited in terms of attenuating cocaine’s acute 
rewarding effects (Beardsley and Thomas, 2005; Xi and Gardner, 2008).   
Clinical trials:  SR141716A was the first CB1 receptor antagonist to be approved for clinical 
trials for the treatment of obesity and cigarette smoking. However, there are some safety 
concerns with rimonabant – increased risk of anxiety, depression, and suicide tendency, 
which had led it to being withdrawn from the market in Europe and North America in 2008. 
Since then, many pharmaceutical companies (Sanofi-Aventis, Merck, Pfizer, Solvay) have 
announced that they will stop further clinical research on this class of drug.  
6.2 AM251 
Preclinical studies: AM251 is a more potent and selective CB1 receptor antagonist than 
SR141716A (Krishnamurthy et al., 2004). In animal models of drug addiction, AM251 
appears to be more potent and effective than SR141716A in attenuating cocaine’s action (Xi 
et al., 2006, 2008). For example, AM251 significantly and dose-dependently inhibited cocaine 
self-administration (under PR, but not FR reinforcement) (Xi et al., 2008), cocaine-enhanced 
brain-stimulation reward (Xi et al., 2008), and cocaine-induced behavioural sensitization 
(Corbille et al., 2007), as well as cocaine-triggered reinstatement of drug-seeking behaviour 
(Xi et al., 2006). Further, a glutamate-mGluR2/3 mechanism has been shown to underlie the 
antagonism of reinstatement of drug seeking (Xi et al., 2006). That is, blockade of CB1 
receptors by AM251 elevates extracellular glutamate in the NAc, which subsequently 
increased glutamate binding to presynaptic mGluR2/3 receptors, inhibiting cocaine-induced 
increases in glutamate release and relapse to drug-seeking behaviour (Xi et al., 2006) (Figure 
3). These findings suggest that AM251 may be more potent and effective than SR141716A for 
treatment of cocaine addiction.  
Clinical trials: Since the above mentioned side-effects of SR141716A have been linked to its 
inverse agonist property, it is generally believed that AM251, a CB1 receptor antagonist with 
similar inverse agonist property might have the same unwanted side-effects. It is not under 
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receptor agonists such as Nabilone (a Δ9-THC analog), Marinol (Δ9-THC), Sativex (a mixture 
of THC and cannabidiol) have been approved for the treatment of pain and chemotherapy-
induced nausea and vomiting (Table 5). Based upon the recent findings that activation of 
CB2 receptors in primary afferents and spinal cord produces analgesic effects (Anand et al., 
2009; Beltramo, 2009), and that activation of CB2 receptors in the brainstem inhibits 
morphine-6-glucuronide–induced emesis (vomiting) (Van Sickle et al., 2005), it is likely that 
the therapeutic effects of these dual CB1/CB2 receptor agonists may at least in part be 
mediated by activation of brain CB2 receptors.   
7. Conclusion  
In this review article, I first briefly reviewed the neurochemical mechanisms underlying 
cocaine reward and addiction, and then provided the rationale for development of various 
pharmacological therapies for the treatment of cocaine addiction. Lastly, I summarized the 
major findings of multiple pharmacological agents in each drug catagory in animal models 
of drug addiction and the current status in clinical trials for the treatment of drug addiction 
and/or other neuropsychiatric diseases. In summary, the VTA-NAc-VP pathway, including 
the mesolimbic DA and the NAc-VP GABAergic transimission, appears to play a critical role 
in mediating cocaine’s rewarding effects (Figure 2), while a NAc glutamate-mGluR2/3 
mechanism plays an important role in controlling relapse to drug-seeking behaviour (Figure 
3). Accordingly, various pharmacological agents have been proposed and tested in animal 
models of drug addiction to interfere with the pharmacological actions produced by cocaine. 
Among those compounds discussed above, the DAT inhibitors (modafinil, RTI-335, 
CTDP31,345, CTDP-32,476), the DA receptor antagonists (l-THP, S33138, GSK598809, YQA-
14) and the glutamatergic ligands (NAC, MPEP, LY369268, 2-PMPA) appear to be promising 
in preclinical animal models of drug addiction. In addition, several compounds (such as 
modafinil, disulfram, topiramate) were initially found to be effective in humans with 
unknown mechanisms, while subsequent preclinical studies helped to uncover the 
mechanisms of the actions. Although many compounds are currently or at some point were, 
under clinical trials, most of them have been used to evaluate their safety and efficacy for 
other neuropsychiatric diseases such schizophrenia, anxiety, obesity or smoking, rather than 
for cocaine addiction. Clearly, more translational studies from preclinical research to human 
clinical trials are required to promote the medication discovery for the treatment of cocaine 
dependence.  
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Drug addiction is a chronic relapsing disorder characterized by compulsive use despite 
negative consequences and relapses even after years of abstinence (Leshner, 1997). Criteria 
put forth by the American Psychiatric Association (2000) for diagnosing drug addiction 
require at least three of the following symptoms associated with drug use: tolerance; 
withdrawal; a loss of control over drug intake; unsuccessful attempts to reduce intake; a 
significant amount of time spent acquiring, using, or recovering from the substance; reduced 
interest in social or work activities; and continued use despite awareness of adverse physical 
and psychological consequences (American Psychiatric Association, 2000). In the United 
States, 22.5 million people, or 8.9% of the population meets the criteria for substance 
dependence or abuse (Substance Abuse and Mental Health Services Administration, 2010), 
and in Europe, drug, and especially cocaine, use has been increasing over the last ten years 
in the general population, with a more pronounced trend in young individuals (EMCDDA, 
2009), suggesting that cocaine addiction may continue to spread in western countries. 
Worldwide estimates suggest more than 8% of the population have an alcohol use disorder 
and more than 2% have an illicit drug use disorder (World Health Organization, 2010). 
The prevalence of drug use despite obvious health and financial consequences is a testament 
to the tenacity of addiction as a brain disease affecting cognition, motivation and memory 
(Leshner, 1997). At the psychobiological level, addiction has been hypothesised to reflect the 
development of loss of executive control over aberrant incentive habits (Belin et al., 2009a, 
Belin & Everitt, 2010), resulting from drug-induced neuroplasticity processes in vulnerable 
subjects. These plasticity processes have been suggested to stem from the impact of drug 
action on the mesolimbic dopamine system, through which drug use can induce a host of 
changes in the brain resulting in significant neural reorganization (see Lüscher & Malenka, 
2011; Russo et al., 2010). Much of this reorganization is due to long term potentiation, or 
strengthening, of excitatory synapses as a result of drug use. As recently reviewed, the 
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dopamine signals from neurons originating in the ventral tegmental area (VTA) targeting the 
nucleus accumbens (NAc) in the ventral striatum modulate glutamate synaptic plasticity and 
are believed to be critically involved in the pathophysiology of addiction (Chen et al., 2010).  
In animal models using passive drug exposure, these neurons show an N-methyl-D-
aspartate (NMDA) receptor-dependent strengthening of excitatory synapses (long term 
potentiation) 24 hrs following an acute experimenter-administered injection of cocaine, 
amphetamine, nicotine, ethanol, and morphine (Saal et al., 2003; Ungless et al., 2001). 
Interestingly, this strengthening was not found with the non-abused psychoactive drugs, 
fluoxetine or carbamazepine, suggesting the role this plasticity may play in determining 
whether a drug is abused or not.  
Although of interest, these data capture neither the volitional aspect of drug use nor the 
instrumental nature of drug seeking and taking, thereby greatly limiting their translation to 
the pathophysiology of addiction (Belin et al., 2009b, Belin & Dalley, 2012). Therefore, in 
preclinical models, a more valid approach to the human drug administration situation is the 
self-administration paradigm in which – akin to the human experience – an animal, rather 
than the experimenter, voluntarily administers the drug through instrumental conditioning 
(see later).  
Following two weeks of cocaine self-administration, long term potentiation of glutamate 
function in DAergic VTA neurons is maintained even after 90 days of abstinence – an effect 
not found in a yoked, non-contingent control group receiving the same cocaine exposure 
(Chen et al., 2008). Similarly, measurements in the core of the NAc (NAcC) – where VTA 
projections are now known to co-release glutamate along with DA (Stuber et al., 2010) – 
following at least two weeks of cocaine self-administration, showed long-lasting resistance 
to the induction of long-term synaptic depression compared to yoked controls or controls 
lever pressing for food reinforcement. Finally, cocaine self-administration followed by either 
a 3-week abstinence period or 3 weeks of extinction training induced a state of long-term 
potentiation of glutamate synapses that was resistant to further potentiation (Moussawi et 
al., 2009). The resistance to further potentiation has been attributed to the prolonged 
expression of AMPA receptors that had been trafficked to the cell membranes during the 
drug exposure (Chen et al., 2010) and is indicative of long-lasting neural reorganization 
brought about by drug abuse. Combined, these data indicate that volitional administration 
of cocaine results in prolonged changes in NMDA receptor-dependent synaptic plasticity 
within the nucleus accumbens (Martin et al., 2006). 
This long-term strengthening of glutamatergic synapses within the brain reward circuitry as 
a result of chronic voluntary drug use is also related to dysregulation of glutamate 
homeostasis (for a review see Kalivas, 2009). Glutamate homeostasis refers to the balance 
between synaptic glutamate levels and extracellular, extrasynaptic glutamate levels that 
regulate stable neurotransmission (see Figure 1). If synaptic glutamate release is the key 
component of glutamate-induced excitatory synaptic transmission, extrasynaptic glutamate 
is vital for the negative feedback of glutamatergic transmission. This negative feedback is 
necessary for modulating and inhibiting further excitatory stimulation. Such feedback is 
supported by activation of extrasynaptically-localized Group II metabotropic glutamate 
autoreceptors (mGluR2/3 receptors) which results in a regulated reduction of vesicular 
neurotransmitter release whereby synaptic glutamate concentration is greatly decreased 
(Dietrich et al, 2002; Manzoni et al., 1997).  
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Extrasynaptic glutamate availability is primarily provided by the cystine/glutamate 
exchanger antiporter (system xc-) found on brain glial cell membranes (Baker et al., 2002). 
System xc- transports the extracellular cystine dimer into the astrocytes and intracellular 
glutamate out of the astrocytes and into the extracellular space in a 1:1 ratio, thereby 
enhancing extrasynaptic glutamate levels (Bannai, 1986). Glutamate availability inside the 
astrocytes is provided by the primary glial glutamate transporter, GLT-1 (Haugeto et al., 
1996), and these two systems work in concert to maintain homeostatic glutamate levels. 
Seven days of cocaine exposure (experimenter administered 15-30 mg/kg daily) followed by 
three weeks of abstinence, or self-administration (0.25 mg/kg in 2-hr sessions until 
responding stabilized to <10% variation) followed by extinction (until active lever pressing 
declined to at least 10% of self-administration levels) decrease basal levels of extracellular 
glutamate by ~50% within the NAcC. Extracellular glutamate levels are then elevated again  
into a range between about 160-600% of the withdrawal baseline following cocaine re-
exposure (e.g., Baker et al., 2003a; Baker et al., 2003b; McFarland et al., 2003; Pierce et al., 
1996). This dysregulation of glutamate homeostasis as a result of drug withdrawal has been 
suggested to be caused by an overall downregulation of system xc- and is in fact mimicked 
by blocking system xc- in the NAc (Baker et al., 2003b). Indeed, following chronic cocaine or 
nicotine self-administration, there is reduced NAc expression of both xCT, the light chain 
and catalytic subunit of the system xc- antiporter heterodimers, and GLT-1 (Knackstedt et 
al., 2009; 2010a), indicating these mechanisms are involved in the dysregulation of glutamate 
homeostasis and may impact the development and trajectory of addiction. 
 
 
Fig. 1. Actions of N-acetylcysteine on the cystine/glutamate exchanger (system xc-). 
Glutamate is packaged into presynaptic vesicles by vesicular glutamate transporters (vGluTs) 
[1]. Following release of glutamate into the synaptic cleft, glutamate binds to postsynaptic 
localized ionotropic receptors (iGluRs) such as the α-amino-3-hydroxy-5-methylisoxazole-4 
propionic acid (AMPA), N-methyl-D-aspartate (NMDA), and kainate receptors [2]. Excitatory 
amino acid transporters (EAATs) clear extracellular glutamate by taking it back up into cells. 
These transporters are localized on the presynaptic terminal [3] protecting extrasynaptic 
receptors from synaptic glutamate and synaptic receptors from extrasynaptic glutamate, and 
allow for re-packaging glutamate into vesicles. These transporters are also localized on 
astrocytes [4]. Once in the glial cell, glutamate can be transported into the extrasynaptic 
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environment by the cystine/glutamate exchanger (system xc-) in a 1:1 ratio [5]. Administration 
of NAC provides extra synaptic cysteine that is oxidized extracellularly into the cystine [6] 
required to enhance activation of the cystine/glutamate exchanger [7]. The enhanced xc- 
activation results in increased glutamate concentration in the extracellular space [8]. 
Intracellular cystine is rapidly reduced to cysteine where it is combined with intracellular 
glutamate (and glycine) in the synthesis of glutathione (GSH) which is then released from the 
astrocyte [9]. Extrasynaptic glutamate binds to and activates mGluR2/3 receptors [10] which 
negatively regulate adenylyl cyclase [11] thereby suppressing presynaptic glutamate release 
[12] and reducing postsynaptic iGluR activation [13]. 
2. Mechanisms of N-acetylcysteine action 
The cysteine prodrug and antioxidant precursor, N-acetylcysteine (NAC), has been in use in 
humans for many years, primarily as a treatment for acetaminophen/paracetamol overdose 
(Prescott et al., 1977; Scalley & Conner, 1978) and more recently as a mucolytic agent 
effective in chronic obstructive pulmonary disease (Decramer & Janssens, 2010; Kory et al., 
1968) and cystic fibrosis (Dauletbaev et al., 2009; Stamm & Docter, 1965). Further, an 
evaluation of the potential therapeutic use of NAC in a variety of psychiatric disorders has 
been recently reviewed (Dean et al., 2011). The aforementioned nature of the 
neurophysiological changes induced by drug use has also indicated a potential use for NAC 
treatment in addictions, prompting the initiation of thorough research into NAC as a 
treatment for addiction in both preclincal models of addiction and drug addicts  
In preclinical models of addiction, NAC appears to regulate the systems involved in 
glutamate homeostasis in the brain. Following 7 days of cocaine exposure and 21 
subsequent days of withdrawal, decreased basal extracellular glutamate levels in the NAc 
are recovered following an IP injection of NAC in rats (Baker et al., 2003a). Notably, 
inhibition of system xc- prevented the NAC-induced recovery of extracellular glutamate 
levels in this region, implicating the xc- system in the neurobiological mechanisms whereby  
NAC normalises cocaine-induced extracellular glutamate dysregulation (Baker et al., 2003a). 
Thus, NAC may induce a recovery of the downregulated xCT and GLT-1 function 
(Knackstedt et al., 2009; 2010a). Indeed, the recovery of an altered GLT-1 function allows for 
increased transport of glutamate into the astrocyte while the recovery of altered system xc- 
function by xCT recovery allows for increased export of glutamate back into the 
extrasynaptic space (see Figure 1). The resulting increase in extracellular glutamate then 
facilitates activation of extrasynaptic mGluR2/3 autoreceptors, ultimately reducing evoked 
synaptic glutamate release (Moran et al., 2005). This decrease in synaptic glutamate release 
as a downstream result of NAC administration is the mechanism by which NAC also 
restores the capacity to induce further long-term potentiation, since blockade of mGluR2/3 
receptors prevented this restoration (Moussawi et al., 2009). 
NAC is also a known precursor of the endogenous antioxidant, glutathione (GSH), the 
synthesis of which depends upon the rate-limiting activity of the xc- system. GSH is 
primarily produced within astrocytes using glutamate and cystine as substrates to generate 
γ-glutamylcysteine, which is then combined with glycine to create GSH (see Dringen & 
Hirrlinger, 2003). GSH is released from astrocytes into the extracellular space, where it is 
broken down by γ-glutamyltranspeptidase into glutamate and a cysteine-glycine dipeptide 
that is further hydrolyzed into the individual peptides. This reaction is the mechanism by 
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which astrocytes provide the precursors necessary for neuronal GSH production (Dringen & 
Hirrlinger, 2003). In addition to protecting brain cells from the oxidative stress, GSH has 
been shown to enhance responsivity of NMDA receptors to glutamatergic stimulation (see 
Janáky et al., 1999), suggesting some direct modulation of glutamatergic signalling as a 
result of NAC administration. The role of GSH in addiction has yet to be determined, and 
thus far, the effects of NAC as a pharmacotherapy for drug dependence appear to be 
primarily mediated via its actions on system xc- and GLT-1 (Knackstedt et al., 2009; 
Knackstedt et al., 2010a).  
3. N-acetylcysteine in animal models of self-administration, reinstatement, 
and relapse 
The study of the addictive properties of drugs in animals is largely based on variations of 
the self-administration procedure developed in rats by Weeks (1962; see Belin & Dalley 
2012; Panlilio & Goldberg, 2007). Although now conducted with many species, in its 
simplest and most common form, rats (or mice) are prepared with indwelling intravenous 
catheters that exit through a backmount to be attached to a tether hanging within a 
conditioning chamber. Tubing connecting the catheter to a syringe outside the chamber runs 
through the tether and provides the route by which drugs can be administered directly into 
the blood stream (see Figure 2).  
 
Fig. 2. Operant drug self-administration chamber and procedure. Operant chambers are 
typically equipped with two retractable levers (assigned as either ‘active’ or ‘inactive’) with 
a cue light above each. When a rat presses the active lever under an FR1 schedule, the 
resulting drug infusion is accompanied by the onset of the cue light associated with the 
active lever. 
When in the self-administration chamber, two levers are typically available – an ‘active’ and 
an ‘inactive’ lever. Under the most basic Fixed Ratio 1 (FR1) schedule of reinforcement, also 
called continuous reinforcement, a single press on the active lever results in a drug infusion 
often paired with a non-drug stimulus, such as a brief presentation of a light. The drug 
delivery reinforces the behavior, making it more likely the rat will press the active lever 
again (cf. Hall, 2002). Presses on the inactive lever have no consequence and are used as an 
index of general activity. This self-administration procedure is particularly useful in 
determining the abuse liability of psychoactive substances (for a review see O’Connor et al., 
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environment by the cystine/glutamate exchanger (system xc-) in a 1:1 ratio [5]. Administration 
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which astrocytes provide the precursors necessary for neuronal GSH production (Dringen & 
Hirrlinger, 2003). In addition to protecting brain cells from the oxidative stress, GSH has 
been shown to enhance responsivity of NMDA receptors to glutamatergic stimulation (see 
Janáky et al., 1999), suggesting some direct modulation of glutamatergic signalling as a 
result of NAC administration. The role of GSH in addiction has yet to be determined, and 
thus far, the effects of NAC as a pharmacotherapy for drug dependence appear to be 
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resulting drug infusion is accompanied by the onset of the cue light associated with the 
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When in the self-administration chamber, two levers are typically available – an ‘active’ and 
an ‘inactive’ lever. Under the most basic Fixed Ratio 1 (FR1) schedule of reinforcement, also 
called continuous reinforcement, a single press on the active lever results in a drug infusion 
often paired with a non-drug stimulus, such as a brief presentation of a light. The drug 
delivery reinforces the behavior, making it more likely the rat will press the active lever 
again (cf. Hall, 2002). Presses on the inactive lever have no consequence and are used as an 
index of general activity. This self-administration procedure is particularly useful in 
determining the abuse liability of psychoactive substances (for a review see O’Connor et al., 
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2011). The ability to self administer drugs for short periods of time daily (1-2 hrs per session) 
results in a stable drug intake over time, a so-called titration process that is suggested to 
reflect individual control of intake responding to optimal dosing (Wilson et al., 1971; 
Zimmer et al., 2011) around which blood levels fluctuate in the course of the self-
administration session.  
Pharmacological challenges during ongoing self-administration, following extinction or 
abstinence, or before relapse or reinstatement of self-administration (see later) have been 
useful in identifying potential targets for the development of pharmacotherapies for various 
forms of addictions (e.g., Schindler et al., 2011; Steensland et al., 2007). Such an approach is 
based on the common psychodynamic view of the addiction process of which the stages, 
namely development, maintenance, and relapse/reinstatement, are modelled in Figure 3. 
 
Fig. 3. Stages of the development and maintenance of addiction in humans and animal 
models. Stages of the addiction cycle that have been targeted with NAC treatment are 
regular drug use before the development of addiction as defined by the DSM-IV [1], thereby 
aiming at preventing the transition from controlled to compulsive drug use, the addiction 
stage (in animal models, when intake has escalated or become habitual) [2], following 
behavioral extinction of drug seeking predominately seen in animal models – human 
addicts rarely engage in extinction [3], at the time drug or a drug-associated cue is re-
introduced causing reinstatement [4], following short- or long-term abstinence from drug 
more typical for human addicts and increasingly modelled in animals [5], and at the return 
to the drug-seeking/taking context, resulting in relapse [4].  
A reasonable time point for targeting addiction is when the individual is still regularly 
engaged in drug use with the intended outcome of reducing intake and eventually stopping 
use altogether. Therefore, it is of interest to assess potential pharmacotherapies during the self-
administration phase. In a standard self-administration task, that is thought to model the stage 
in which humans engage in regular use but are not necessarily addicted (Figure 3, Stage 1), 
rats that had access to cocaine for 2 hrs under an FR1 schedule of reinforcement, and 
administered 60 mg/kg NAC before each daily training session displayed no differential 
intake as compared with vehicle-treated controls (Amen et al., 2011; Madayag et al., 2007).  
The efficacy of NAC on ongoing cocaine intake changes however, with increasing access to 
cocaine. Indeed, with long (e.g., ≥6 hrs) rather than short (e.g., 2 hrs) daily access to cocaine 
self-administration, rats no longer titrate intake, but instead tend to increase, or escalate, 
their intake across days (cf. Ahmed & Koob, 1998). This escalation of drug intake over time, 
associated with dysregulation of neural networks governing reward (for a review see Koob 
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& Kreek, 2007), has been suggested to reflect the loss of control over intake that characterises 
human drug addicts (Figure 3, Stage 2). In an experiment assessing the effects of NAC on 
cocaine escalation (Madayag et al., 2007), rats initially acquired cocaine (0.5 mg/kg) self-
administration in 2-hr sessions under an FR1 schedule of reinforcement until intake 
stabilized (<10% variation across ≥3 sessions). They were then shifted to 6-hr daily sessions 
for 11 days in which they were able to self-administer a higher dose of cocaine (1.0 mg/kg) 
and subsequently given either 60 mg/kg NAC or vehicle pre-treatment. Whereas saline-pre-
treated rats displayed typical escalation of their cocaine intake across sessions, NAC-
pretreated rats maintained a stable drug intake across days (Madayag et al., 2007). In a 
similar study, daily pretreatment with the higher dose of 90 mg/kg NAC appeared to 
reduce cocaine intake across the 12 sessions of long-access cocaine self-administration 
compared to saline pretreatment (Kau et al., 2008). Combined, the findings that NAC 
impacts escalation without affecting typical short-access drug self-administration suggests 
that loss of control over drug intake may be better reflective of dysregulated glutamate 
homeostasis.  
3.1 Treatment during reinstatement of drug seeking 
The ultimate goal of any addiction therapy is to achieve and maintain drug abstinence. 
This therapeutic goal is especially challenging due to the strong associations formed 
between the interoceptive drug experience and surrounding cues. Re-experiencing a drug 
or drug cue following a successful quit attempt can evoke and enhance drug craving (e.g., 
Niaura et al., 1988; O’Brien et al., 1992), thus increasing the likelihood of reinstatement of 
drug use, often resulting in relapse. As such, finding effective techniques that target the 
motivational impact of a ‘lapse’ in drug use (drug-induced reinstatement) or drug-related 
paraphernalia (cue-induced reinstatement) is of high therapeutic value for maintaining 
drug abstinence.  
From an experimental standpoint, when operant behavior no longer results in the delivery 
of the reinforcing outcome, extinction occurs, so that instrumental performance declines 
(Figure 3, Stage 3). Extinction of a behavior is a new learning process that exists alongside 
the old, previously learned, association (for a review see Bouton, 2002). This new learning is 
largely dependent on continued absence of the primary reinforcer while the manipulanda 
(i.e., levers) are still available to press. In humans, these sort of explicit extinction sessions 
are generally only provided within the context of cue-exposure therapy which aims at 
presenting inpatients with drug use paraphernalia in the absence of the drug (see Monti & 
MacKillop, 2007; Siegel & Ramos, 2002). Reinstatement of the previously extinguished 
behavior can therefore be evoked by presentation of the reinforcer (i.e., drug-induced 
reinstatement) or a conditioned stimulus (CS) associated with the reinforcer that had not 
presented during the extinction phase (i.e., cue-induced reinstatement; Figure 3, Stage 4; de 
Wit & Stewart, 1981).  
When an addict ‘lapses’, or uses once, following abstinence, he is at a much higher risk for 
re-engaging in regular use. Attenuating the effects of this drug-induced reinstatement may 
help prevent a ‘lapse’ in drug abstinence from turning into a full-blown relapse of addiction 
(e.g., Shadel et al., 2011; Witkiewitz & Masyn, 2008). In rats, cocaine exposure following 
extinction of self-administration is associated with a glutamate release from prefrontal 
projections into the NAcC (McFarland et al., 2003), and this release may provide the 
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2011). The ability to self administer drugs for short periods of time daily (1-2 hrs per session) 
results in a stable drug intake over time, a so-called titration process that is suggested to 
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& Kreek, 2007), has been suggested to reflect the loss of control over intake that characterises 
human drug addicts (Figure 3, Stage 2). In an experiment assessing the effects of NAC on 
cocaine escalation (Madayag et al., 2007), rats initially acquired cocaine (0.5 mg/kg) self-
administration in 2-hr sessions under an FR1 schedule of reinforcement until intake 
stabilized (<10% variation across ≥3 sessions). They were then shifted to 6-hr daily sessions 
for 11 days in which they were able to self-administer a higher dose of cocaine (1.0 mg/kg) 
and subsequently given either 60 mg/kg NAC or vehicle pre-treatment. Whereas saline-pre-
treated rats displayed typical escalation of their cocaine intake across sessions, NAC-
pretreated rats maintained a stable drug intake across days (Madayag et al., 2007). In a 
similar study, daily pretreatment with the higher dose of 90 mg/kg NAC appeared to 
reduce cocaine intake across the 12 sessions of long-access cocaine self-administration 
compared to saline pretreatment (Kau et al., 2008). Combined, the findings that NAC 
impacts escalation without affecting typical short-access drug self-administration suggests 
that loss of control over drug intake may be better reflective of dysregulated glutamate 
homeostasis.  
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between the interoceptive drug experience and surrounding cues. Re-experiencing a drug 
or drug cue following a successful quit attempt can evoke and enhance drug craving (e.g., 
Niaura et al., 1988; O’Brien et al., 1992), thus increasing the likelihood of reinstatement of 
drug use, often resulting in relapse. As such, finding effective techniques that target the 
motivational impact of a ‘lapse’ in drug use (drug-induced reinstatement) or drug-related 
paraphernalia (cue-induced reinstatement) is of high therapeutic value for maintaining 
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(Figure 3, Stage 3). Extinction of a behavior is a new learning process that exists alongside 
the old, previously learned, association (for a review see Bouton, 2002). This new learning is 
largely dependent on continued absence of the primary reinforcer while the manipulanda 
(i.e., levers) are still available to press. In humans, these sort of explicit extinction sessions 
are generally only provided within the context of cue-exposure therapy which aims at 
presenting inpatients with drug use paraphernalia in the absence of the drug (see Monti & 
MacKillop, 2007; Siegel & Ramos, 2002). Reinstatement of the previously extinguished 
behavior can therefore be evoked by presentation of the reinforcer (i.e., drug-induced 
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When an addict ‘lapses’, or uses once, following abstinence, he is at a much higher risk for 
re-engaging in regular use. Attenuating the effects of this drug-induced reinstatement may 
help prevent a ‘lapse’ in drug abstinence from turning into a full-blown relapse of addiction 
(e.g., Shadel et al., 2011; Witkiewitz & Masyn, 2008). In rats, cocaine exposure following 
extinction of self-administration is associated with a glutamate release from prefrontal 
projections into the NAcC (McFarland et al., 2003), and this release may provide the 
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mechanism that triggers reinstatement of drug seeking. Acute treatment with NAC has been 
shown to attenuate drug-induced reinstatement. In some of these experiments, rats were 
trained to self-administer cocaine in 2-hr or 6-hr daily sessions. During the subsequent 
extinction phase, instrumental responses were reinforced only with contingent presentations 
of the drug-associated light, and no cocaine was infused, so lever pressing progressively 
declined. For the drug-induced reinstatement test, rats were injected with a priming dose of 
cocaine, this pharmacological challenge resulted in a marked increased in the previously 
extinguished instrumental response, i.e., lever pressing. Pretreatment with 30, 60, or 600 
mg/kg NAC before cocaine re-exposure prevented reinstatement of cocaine-seeking 
behavior (Baker et al., 2003a; Baker et al., 2003b; Kau et al., 2008; Moran et al., 2005). 
Concurrent blockade of system xc- using (S)-4-carboxyphenylglycine (CPG) during the 
reinstatement test blocked the reinstatement-attenuating effects of NAC (Kau et al., 2008), 
thereby suggesting that NAC effects on cocaine-induced reinstatement are mediated 
through system xc-. Additionally, as measured by in vivo microdialysis during the 
reinstatement test, NAC administration restored the reduced extracellular glutamate levels 
that resulted from cocaine self-administration and withdrawal (Baker et al., 2003b). Further, 
concurrent blockade of mGluR2/3 autoreceptors also prevented the attenuating effects of 
NAC on cocaine-induced reinstatement (Moran et al., 2005) demonstrating that the effect of 
NAC restoration of extracellular glutamate on reinstatement may depend upon activation of 
the mGluR2/3 autoreceptors.  
The effects of NAC on drug-induced reinstatement have also been shown when NAC is 
administered prior to, but not explicitly during, the reinstatement test. In one such 
experiment, rats were trained to self-administer cocaine under short-access conditions and 
then underwent extinction followed by cocaine-primed reinstatement (Amen et al., 2011). 
Following the first test in which cocaine seeking was reinstated, rats were treated with 60 
mg/kg NAC for 7 days. The day following the seventh NAC treatment, rats were subjected 
to a second cocaine-primed reinstatement test. Rats that had received NAC treatment 
showed significantly reduced cocaine seeking compared to the rats that had received saline 
treatment during those 7 days (Amen et al., 2011). Although daily treatment with 60 mg/kg 
NAC before 2-hr cocaine self-administration sessions (see above) had no effect on amount of 
cocaine taken or subsequent extinction (without NAC pretreatment), cocaine-primed 
reinstatement was significantly reduced, even though it had been 2-3 weeks since last NAC 
treatment (Madayag et al., 2007). Similarly, 90 mg/kg NAC pretreatment throughout long-
access cocaine self-administration resulted in attenuated cocaine-primed reinstatement that 
was reversed by inhibition of system xc- following an extinction phase without NAC (Kau et 
al., 2008). These effects are indicative of the long-lasting protection of glutamate homeostasis 
as a result of NAC treatment. Indeed, concurrent microdialysis in the NAc immediately 
prior to the reinstatement test showed that there were lower extracellular basal glutamate 
levels in rats that had been pretreated with saline during the self-administration stage than 
in those that had been pretreated with NAC (Madayag et al., 2007). Once cocaine had been 
administered to induce reinstatement, the saline-pretreated group reached the level of 
extracellular glutamate that was shown at baseline by the NAC-pretreated group. These 
findings suggest that NAC administration during self-administration provided protection 
against the withdrawal-induced downregulation of extracellular glutamate in the NAc and 
subsequent cocaine-induced reinstatement. 
 
N-Acetylcysteine as a Treatment for Addiction 
 
363 
3.2 Treatment during extinction and reinstatement 
The effect of chronic NAC treatment during both extinction and subsequent reinstatement 
tests has also been evaluated (Figure 3, Stages 3 and 4). In one such study (Reichel et al., 
2011), rats were trained to self-administer cocaine (50 μg/infusion) under an FR1 schedule 
until they reached >10 infusions in two hours for twelve consecutive sessions. During the 
following twelve sessions, lever presses had no programmed consequences (i.e., extinction), 
and rats were given daily injections of 0, 60 or 100 mg/kg NAC. There was no effect of the 
lower 60 mg/kg dose of NAC on extinction responding. However, there was a significant 
enhancement of extinction (i.e., less active lever pressing) when rats were treated daily with 
100 mg/kg NAC (Moussawi et al., 2011; Reichel et al., 2011). This effect was also found 
during extinction of heroin self-administration for which daily administration of 100 mg/kg 
NAC resulted in enhanced extinction rate (Zhou & Kalivas, 2008). Although NAC treatment 
was ineffective when applied during acquisition of self-administration, it enhanced 
extinction learning. 
In each of these studies, two tests of reinstatement were then conducted: cue-induced 
reinstatement and cue+drug- or drug-induced reinstatement. Human addicts are 
particularly sensitive to cues that had previously been associated with drug use, and 
exposure to these cues following drug abstinence can reinstate drug seeking and taking 
behavior, resulting in relapse (see O’Brien et al., 1992; Taylor et al., 2009). Similarly, rats are 
also quite sensitive to the effects of re-presentation of these drug-associated CSs. As such, 
the impact of NAC treatment on cue-induced reinstatement of instrumental responding has 
recently begun to be assessed. For the cocaine self-administration group treated with the 
lower, 60 mg/kg, dose of NAC, there was a significant reduction in cue-induced 
reinstatement compared to saline controls, but no effect on cue+drug-induced reinstatement 
(Reichel et al., 2011). However, when NAC (100 mg/kg) was administered during extinction 
following either cocaine or heroin self administration, there was a significant reduction in 
both cue- and cue+drug- or drug-induced reinstatement. These results suggest that, 
compared to a conditioned stimulus, a higher treatment dose was necessary to disrupt the 
ability of an unconditioned drug stimulus+drug-associated CS compound to reinstate drug-
taking behavior (Moussawi et al., 2011; Reichel et al., 2011; Zhou & Kalivas, 2008). Notably, 
these effects on reinstatement lasted from two weeks (Moussawi et al., 2011; Reichel et al., 
2011) to 40 days (Zhou & Kalivas, 2008) following the last 100 mg/kg NAC treatment, 
indicating a long-term restoration of glutamate homeostasis in the NAcC brought about by 
the re-regulation induced by chronic NAC exposure (Moussawi et al., 2011). At the 
neurophysiological level, rats trained to self-administer cocaine that received saline (rather 
than NAC) during extinction showed reduced extrasynaptic glutamate levels in the NAcC 
compared to saline-yoked controls. In rats that received NAC during extinction, there was 
full recovery of the extrasynaptic glutamate levels two weeks following the last NAC 
injection – a time period corresponding to the behavioral effect on cue- and cue+drug-
induced reinstatement (Moussawi et al., 2011). Furthermore, administration of the 
mGluR2/3 antagonist, LY341495, into the NAcC prevented the attenuating effects of NAC 
on cue- and cue+drug-induced reinstatement of cocaine-seeking, again indicating the 
importance of presynaptic autoreceptors in maintaining glutamate homeostasis (Moussawi 
et al., 2011). 
 
Addictions – From Pathophysiology to Treatment 
 
362 
mechanism that triggers reinstatement of drug seeking. Acute treatment with NAC has been 
shown to attenuate drug-induced reinstatement. In some of these experiments, rats were 
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3.2 Treatment during extinction and reinstatement 
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during extinction of heroin self-administration for which daily administration of 100 mg/kg 
NAC resulted in enhanced extinction rate (Zhou & Kalivas, 2008). Although NAC treatment 
was ineffective when applied during acquisition of self-administration, it enhanced 
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on cue- and cue+drug-induced reinstatement of cocaine-seeking, again indicating the 
importance of presynaptic autoreceptors in maintaining glutamate homeostasis (Moussawi 
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3.3 Treatment during abstinence 
A key concern with the translational potential of the extinction-reinstatement model of drug 
dependence is that human users are not typically subjected to extinction of responding 
during presentation of drug-related cues unless they are patients in an explicit cue-exposure 
therapy session (cf. Monti & MacKillop, 2007). Rather, addicts undergo abstinence – a period 
in which they either voluntarily (i.e., independently, or by checking into a rehabilitation 
clinic) or forcibly (e.g., incarceration) abstain from drug use outside the drug-taking 
environment (Figure 3, Stage 5; Reichel & Bevins, 2009). Following the abstinence period, a 
person returns home where the associative strength of all the drug-associated cues is still 
fully intact, and no behavior has been extinguished, and ‘relapse’ of the addictive behavior 
often resumes.  
A rat model of ‘forced abstinence’ operationally uses the same drug self-administration 
protocols as the extinction-reinstatement model, but rather than undergoing an extinction 
phase in which responding diminishes with repeated non-reinforced lever pressing, the 
animal is typically left in its home cage for a specified period of time (e.g., 2 weeks) where it 
can undergo a treatment protocol before returning to the drug-associated conditioning 
chamber. Notably, extinction and abstinence following cocaine self-administration produce 
different patterns of protein expression in the NAc (Knackstedt et al., 2010b), warranting 
further investigation into the efficacy of potential pharmacotherapies in each model of 
addiction.  
The abstinence model has recently been used to assess the efficacy of NAC treatment 
following cocaine self-administration (Reichel et al., 2011). Rats were trained to self-
administer cocaine under an FR1 schedule until they reached >10 infusions in two hours for 
twelve consecutive sessions. During the subsequent two-week abstinence period, rats were 
given daily injections of 60 or 100 mg/kg NAC or saline. They were then tested for relapse 
to cocaine seeking by returning them to the self-administration environment and recording 
non-reinforced lever presses. Treatment with the lower, 60 mg/kg, dose of NAC during 
abstinence had no effect on relapse compared to saline, however, treatment with the higher 
100 mg/kg dose of NAC during abstinence significantly reduced cocaine-seeking during the 
relapse test (Reichel et al, 2011). During subsequent tests in which the drug-paired cue, and 
then the drug+cue, was presented, 100 mg/kg NAC treatment during abstinence 
maintained a significant effect on drug seeking. Finally, following a second phase of 
abstinence in which no NAC was administered, there was still a significant attenuation of 
drug seeking when rats were presented with the drug+cue in the self-administration 
chamber, again indicative of the long-term re-regulation of glutamate homeostasis provided 
by NAC administration. 
3.4 Treatment during habitual drug seeking 
Regular daily drug use is not limited to the taking of the drug. Rather, addicted individuals 
can invest countless hours ‘foraging’ for their next high. This foraging takes a person 
through multiple exposures to stimuli that are predictive of the impending drug experience. 
As such, not only can these drug-associated CSs reinstate drug-seeking behavior when 
presented following behavioral extinction but they can also serve as powerful conditioned 
 
N-Acetylcysteine as a Treatment for Addiction 
 
365 
reinforcers that drive and maintain continued drug foraging over long periods of time when 
presented contingently. This foraging can continue to persist even after the explicit drug-
taking behavior has been extinguished (Olmstead et al., 2001; Zapata et al., 2010), indicating 
a habitization of the drug-seeking behavior which may be a key characteristic in the 
transition from casual drug use to addiction (e.g., O’Brien et al., 1998, Everitt & Robbins 
2005, Belin et al., 2009a).  
Cocaine seeking (see Chapter 2) as opposed to mere cocaine taking, or self-administration, 
has been operationalized in primates (Goldberg, 1973) and then in rats (Arroyo et al., 1998) 
and humans (Panlilio et al., 2005) in the so-called second-order schedule of reinforcement. In 
this specialized model of self-administration, drug seeking is separated from the 
unconditioned effects of the drug. Cues associated with drug reinforcement function as 
conditioned reinforcers that maintain persistent, habitual, seeking responses across 
protracted periods of time without primary drug reinforcement (Everitt & Robbins, 2000; 
Schindler et al., 2002).  
In this procedure, rats are initially trained to self-administer drug under the FR1 schedule of 
reinforcement with a single lever press resulting in a drug infusion associated contingently 
with a 20-second cue light presentation. Following stabilization of responding, the response 
requirement is shifted across days to gradually move the behavior of the rat to what is 
known as a second-order schedule of reinforcement. There are several ways of increasing 
the response requirement (cf. Economidou et al., 2011; Vanderschuren et al., 2005, Belin & 
Everitt 2008), either by introducing ratio / ratio increments or fixed interval schedules with 
increasing interval durations across days. In the experiment in which NAC effect was 
measured on early and well-established cue-controlled cocaine seeking (Murray et al., 2012), 
rats were moved up through the following schedules: FR3; FR5(FR2:S); FR10(FR2:S); 
FR10(FR4:S); FR10(FR6:S); FR10(FR10:S); FI15(FR10:S). Under each of these schedules of 
cocaine reinforcement, completion of each unit schedule (given within the parentheses) 
resulted in a 1-second cue light presentation; cocaine infusions were delivered only upon 
completion of the first unit schedule according to the schedule outside the parentheses. 
Therefore, during the final second-order training schedule [i.e., FI15(FR10:S)], cocaine and 
the 20-second cue light were given on completion of the first FR10:S unit after the Fixed 
Interval 15-minute period had timed out. In these conditions instrumental responding is no 
longer under the control of the goal, from which it is now temporally distal, but instead 
becomes highly dependent upon contingent presentations of conditioned CSs, acting as 
conditioned reinforcers (cf. Arroyo et al., 1998). As shown in Figure 4, following acquisition 
of the second-order schedule, removal of CSs (i.e., 1-second light presentations provided 
under a FR10 schedule of reinforcement are removed, returning the animal to a strict FI15 
schedule of reinforcement) results in a decline in lever pressing across sessions in the first 
15-minute interval that is reversed when the unit schedule is returned (i.e., 1-second light 
presentations under FR10). By the time behavior has reached this stage of training, drug 
seeking during the first 15-min drug-free interval is maintained at very high rates and is 
thought to reflect cue-controlled habitual cocaine seeking which, at the neurobiological 
level, has been hypothesised to result of a gradual recruitment of dorsolateral  
striatal dopamine circuitry (Belin & Everitt, 2008; Ito et al., 2002; Murray et al., in press; 
Vanderschuren et al., 2005).  
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Fig. 4. Control of cocaine seeking by contingent presentations of conditioned reinforcers. 
Three consecutive days of conditioned reinforcer (1-s cocaine-associated light presentations) 
omission (CSO 1-3) are compared with performance on the session before conditioned 
reinforcer omission (Pre) and performance on the session when the reinforcer is returned 
(Post). * indicates significant difference from Pre, p<.05, **p<.01. Adapted from Arroyo et al 
(1998) with permission from Springer. 
Assessment of drug seeking before actual drug reinforcement can be conducted at both an 
early stage of acquisition and at a later, well-established stage. To assess drug seeking in the 
early stage when the behavior had only ever been reinforced under an FR1 schedule of 
reinforcement by the unconditioned drug stimulus with concurrent CS presentations, a 
switch in the contingency was instituted for a 15-min test session. This testing procedure 
allowed for measurement of drug seeking now reinforced by 1-sec cue light presentations. 
Cocaine was delivered only on the first lever press following the 15-min interval, and each 
test was immediately followed by an FR1 training session. The effects of acute NAC 
treatment on cocaine seeking during the early-stage tests are shown in Figure 5A. Drug 
seeking before the experience of unconditioned cocaine effects was reduced with 60 and 90 
mg/kg NAC treatment. 
After increasing the response requirements and at least 15 sessions of FI15(FR10:S) training, 
so that cocaine seeking maintained by regular contingent presentations of the drug-
associated conditioned reinforcer was well-established, conditions known to be associated 
with a shift in the locus of control over behavior from the ventral to the dorsolateral 
striatum (Vanderschuren et al., 2005; Belin & Everitt, 2008), the effect of NAC pre-treatment 
on cocaine seeking was measured once again (Figure 5B). At this stage, drug seeking was 
more sensitive to NAC treatment, with 30, 60, and 90 mg/kg disrupting the conditioned 
reinforcing effects of the cocaine-associated stimulus. The results of this experiment 
demonstrate that acute NAC treatment dose-dependently reduced cocaine seeking 
maintained by conditioned reinforcers both at an early stage of acquisition when drug 
seeking is considered to be goal-directed and following extensive training on the second-
order schedule, when drug seeking is considered to be habitual (Murray et al., 2012). These 
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findings demonstrate that NAC pretreatment may be an aid to establish abstinence by 
reducing cocaine seeking in individuals that actively seek cocaine on a daily basis, rather 
than only during relapse following an extinction or abstinence period.  
 
 
Fig. 5. Effects of NAC on cocaine seeking. Panel A depicts active (top) and inactive (bottom) 
lever presses during acute NAC treatment in the 15-min cocaine seeking test with 
contingent conditioned reinforcer presentations (FR1) at an early stage of self-
administration. Panel B depicts active (top) and inactive (bottom) lever presses during acute 
NAC treatment in the first 15-min cocaine seeking interval with contingent conditioned 
reinforcer presentations (FR10) during the late stage of cocaine self-administration. For both 
panels, * indicates significant difference from 0 mg/kg NAC, p<.05. Adapted from Murray 
et al. (2012) with permission from Wiley. 
4. N-acetylcysteine in humans: From acetaminophen overdose antidote to 
addictive and impulsive-compulsive spectrum disorders 
NAC, as an antioxidant and gluthatione precursor, has been used for more than 30 years 
in intravenous or oral protocols as an acetaminophen poisoning antidote. Within this 
framework, NAC has been shown to have low rates of adverse reactions which 
nevertheless include nausea, vomiting, as well as cutaneous and systemic anaphylactoid 
reactions. ECG abnormalities, status epilepticus and fatal reaction due to NAC overdose 
are rare, the latter having been observed only at doses 10 times greater than the 
recommended antidote dose (for review see Sandilands & Bateman, 2009). Atopy and 
asthma are major risk factors for developing adverse and anaphylactoid reactions to NAC 
(Schmidt & Dalhoff, 2001).  
Thanks to its antioxidant effect, NAC has dose-dependent protective effects against contrast-
induced nephrotoxicity (Briguori et al., 2011). NAC can also be used as both  a chelating 
agent for methylmercury (for review see Dodd et al., 2008) and a mucolytic and anti-
inflammatory agent, with controversial efficacy in patients with exacerbations of chronic 
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obstructive pulmonary disease (Decramer et al., 2005). Unlike orally-administered 
gluthatione and L-cysteine, NAC successfully crosses the blood-brain barrier, and permits 
restoration of glial and neuronal gluthatione levels, playing a role in the oxidative 
homeostasis in the brain, protecting neurons against oxidative stress. In addition, NAC 
treatment reduces levels of some pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) 
shown to be implicated in several psychiatric disorders, notably in depressive and bipolar 
disorders as well as in schizophrenia. NAC has been used to target the prefrontal 
glutamatergic dysfunction implicated in schizophrenia and impulsive-compulsive behaviors 
(for reviews see Dean et al., 2011; Sansone & Sansone, 2011). One of the first uses of NAC in 
psychiatry was a case-report of the amelioration of self-injurious behaviors and craving in a 
female patient suffering from Post-traumatic Stress Disorder and borderline personality 
disorder (Pittenger et al., 2005). There are to date very few rigorous studies assessing the 
efficacy of NAC in the treatment of addiction and impulsive-compulsive spectrum disorders 
(including behavioral addictions, impulse-control disorders and obsessive-compulsive and 
related disorders). Those available, despite limited statistical evidence (randomized studies 
with small size samples, non-randomized cohorts, or case reports), have provided consistent 
results, in that NAC was always reported to reduce drug use, craving or withdrawal 
symptoms during the treatment period, sometimes even resulting in a persistent effect on 
relapse after the end of the trials (Olive et al., 2012).  
4.1 NAC and cocaine dependence 
NAC treatment for addiction has been primarily studied in cocaine dependent patients, 
alongside the aforementioned publication of preclinical studies initiated by Kalivas’ team 
(Baker et al., 2003a; Baker et al., 2003b). In one such study, the safety and tolerability of NAC 
have been assessed in 13 otherwise-healthy, non-treatment-seeking, cocaine-dependent 
patients with a mean age of 37.1 ± 7.6. During the first hospitalization of the experiment, 
patients received either four treatments of NAC (600 mg per treatment; 2400 mg total) or 
placebo spaced 12 h apart. In a cross-over design, the opposite treatment (i.e., NAC or 
placebo) was given during a hospitalization during the second week. NAC treatment 
resulted in a significant reduction of withdrawal symptoms (assessed with the Cocaine 
Selective Severity Assessment, CSSA, a measure of cocaine abstinence signs and symptoms; 
Kampman et al., 1998) while placebo had no effect. The effect of NAC treatment was not 
restricted to withdrawal symptoms since it was also accompanied by an overall reduction in 
self-reported craving (five items, including desire to use, level of craving and other similar 
constructs, rated on ten-point Likert scales). In this study NAC was well tolerated during 
the treatment periods, with neither significant adverse effects nor with effects on primary 
biological parameters (renal and liver functions, complete blood count) between groups. In 
addition, at completion of the two-week follow-up period patients displayed a marked 
decrease both in days of cocaine use from 41% ± 7 (in the ninety days before study) to 27% ± 
7, and average daily dollar expenditure for cocaine from $30.31 ± 3.44 (in the ninety days 
before study) to $8.77 ± 2.52, suggesting that a brief NAC treatment, perhaps through 
promotion of reduced withdrawal symptoms and subjective craving, may have a prolonged 
efficacy even weeks after the end of the treatment (LaRowe et al., 2006). 
In addition to this clinical evaluation, at the end of the treatment period, the same patients 
were exposed to a cue-reactivity procedure to assess cocaine desire. During two sessions, 
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patients were semi-randomly presented cocaine-related, neutral, and affective (pleasant and 
unpleasant) slides. Cocaine-related slides produced greater skin conductance than either 
neutral or pleasant slides. NAC treatment did not modify physiological reactions to any of 
the slides viewed (i.e., skin conductance and heart rate measures). Cocaine slides evoked 
higher ratings of craving for, desire to use, and interest in, cocaine, as well as longer viewing 
times relative to neutral slides. NAC treatment resulted in lower motivation to use cocaine 
in comparison with placebo when viewing cocaine slides, characterized by a reduced desire 
to use, a reduced interest in cocaine, and less time viewing cocaine slides. Craving for 
cocaine was also reported to be lower in NAC- than in placebo-treated participants even 
though this difference did not reach statistical significance (LaRowe et al., 2007). 
In an independent laboratory study in 6 cocaine-dependent patients, with a mean age of 41.8 
± 7.4 and a mean age of drug-use onset of 18.3 ± 4.0, subjective ‘high’, ‘rush’, and craving for 
cocaine were assessed using a computerized version of a ten-point Likert scale. The patient 
had to use a joystick and move a tab along a horizontal bar with the anchors ‘Least Ever’ 
and ‘Most Ever’ at each extreme end, then push a button at the desired rating after viewing 
either a neutral or a cocaine video and after a 20 mg/kg IV cocaine infusion. This assessment 
was conducted the day before and after 3 days of NAC treatment (1200 mg or 2400 mg 
daily, TID). NAC treatment significantly reduced subjective craving induced by cocaine 
infusion, as measured before and after treatment. By contrast, NAC affected none of the 
subjective measures induced by cocaine videos, nor did it affect subjective feelings of high 
and rush induced by the cocaine infusion (Amen et al., 2011).  
Finally, in an open-label study, 23 cocaine-dependent patients, with a mean age of 40 ± 1.4 
and a mean lifetime of cocaine use of 13.3 ± 1.5 years, were treated for 4 weeks with three 
different doses of NAC (1200, 2400 or 3600 mg/day). In a subjective evaluation, the three 
doses of NAC decreased the mean number of days of use (from 8.3 ± 1.3 to 1.1 ± 1.4) and the 
dollar amount spent (from $1292.8 ± 508.6 to $52.2 ± 25.9) across the 28 days of treatment. 
This was in agreement with an objective evaluation revealing that urine drug screens were 
negative in two-thirds of the sample during treatment (without comparison with baseline 
due to a lack of significant sampling during this period). Cocaine abstinence symptoms 
(assessed with the CSSA) decreased during the treatment period. Retention in treatment was 
significantly better in the 2400 mg and the 3600 mg groups than in the 1200 mg group (88.9% 
and 83% respectively, vs. 37.5%). Adverse events were mild to moderate, including 
headache, pruritus and elevated blood pressure, but did not significantly differ among the 
treatment groups (Mardikian et al., 2007).  
These results indicate that administration of NAC (at daily doses of 2400 and 3600 mg) can 
be an effective treatment for relapse prevention in cocaine-dependent patients, due to its 
ability to decrease withdrawal symptoms and craving severity. The severity of the cocaine 
withdrawal symptomatology at treatment entry is negatively correlated with the treatment 
outcome and the duration of continuous abstinence from cocaine (Kampman et al., 2002). 
Furthermore, subjective and objective feelings of craving, even during experimental cue-
induced and cocaine-infusion procedures, which are predictors of early drug-use outcomes 
and rapid treatment attrition (Rohsenow et al., 2007), are reduced by NAC, a treatment that 
results in few mild-to-moderate side effects. Further studies with high-level evidence (i.e., 
randomized, double-blind, placebo-controlled, long-term studies) must be conducted in 
cocaine-dependent patients to determine the effective dosing ranges, the optimal duration of 
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treatment, and the indications of NAC as a treatment for cocaine withdrawal or as an anti-
addiction drug (used as an adjunct to psychotherapy to help patients in maintain 
abstinence). 
4.2 NAC and marijuana dependence 
In an open-label study, 24 cannabis-dependent subjects aged 18-21 were treated for 4 weeks 
with 1200 mg NAC twice daily (Gray et al., 2010). During the trial, the medication adherence 
was good (82.6% of scheduled doses), and adverse events were mild-to-moderate – none 
leading to discontinuation of the treatment. In a subjective evaluation at the fourth week of 
treatment, NAC significantly decreased the number of days per week cannabis was used, 
and showed a tendency to reduce the quantity of self-reported marijuana used per day (15.9 
± 2.4 vs. 11.9 ± 2.1 potency-adjusted ‘hits’). In an objective evaluation, the cannabinoid 
content of urine samples was not affected, but craving for marijuana, measured by the 
Marijuana Craving Questionnaire, was significantly reduced. These results show the 
potential promise for NAC treatment of cannabis abuse and dependence, especially 
provided that no effective treatments are available for this particularly vulnerable 
population. A double-blind placebo-controlled study evaluating the efficacy of NAC (1200 
mg twice daily for 8 weeks) combined with Contingency Management on marijuana use in a 
younger population (ages 13-21) is currently recruiting (NCT01005810). 
4.3 NAC and methamphetamine dependence 
In a small double-blind placebo-controlled study (Grant et al., 2010), 31 methamphetamine-
dependent patients, with a mean age of 36.8 ± 7.12 and a mean age of onset of drug use of 
24.3, were treated during 8 weeks with NAC (increased dose from 600 mg daily to 2400 mg 
daily every 2 weeks) and naltrexone (increased dose from 50 mg daily to 200 mg daily every 
2 weeks) or placebo. In a subjective evaluation, at the end of the study, NAC+naltrexone 
treatment decreased the mean number of days of use every two weeks from 8.1 ± 4.9 to 1.9 ± 
1.8 days in comparison with placebo (from 6.3 ± 4.6 to 2.3 ± 3.5 days). In an objective 
evaluation given at the end of the study however, positive urine drug screens did not differ 
between groups (46.2% vs. 35.3%). Concerning methamphetamine craving (assessed with 
the Penn Craving Scale: a self-report measure of frequency, intensity, and duration of 
craving, ability to resist taking drug, and an overall rating of craving for 
methamphetamine), NAC+naltrexone treatment did not result in significant improvement 
since there was no difference between the two groups in their decrease in total score at the 
end of the study (-43.6% vs. -37.7% for treated and placebo patients, respectively). Rates of 
adverse events (including nausea and lethargy) did not significantly differ between groups 
(57.1% vs. 41.2%). This preliminary 8-week study suggested that NAC+naltrexone treatment 
effectively reduced reported frequency of methamphetamine use even without affecting 
overall craving for the drug. 
4.4 NAC and nicotine dependence 
In a double-blind placebo-controlled study, 26 nicotine-dependent patients, with a mean age 
of 50, who had been smoking for an average of 33 years, were treated for 4 weeks with NAC 
(2400 mg daily) or placebo (Knackstedt et al., 2009). NAC treatment did not affect the 
objective measures related to nicotine dependence including carbon monoxide levels, or 
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craving for cigarettes (assesssed with the Questionnaire for Smoking Urges-Brief), nor did it 
affect withdrawal symptoms (assessed with the Minnesota Nicotine Withdrawal Scale). In a 
subjective evaluation, there was a trend towards an overall reduction in cigarette use during 
the study (main effect of time), but no group effect, indicating a lack of efficacy of that dose 
of NAC on tobacco use. In a separate double-blind placebo-controlled study, 22 students at 
least twenty years old smoking for an average of 6 years, received NAC (1800 mg twice 
daily) or placebo for 4 days (Schmaal et al., 2011). None of the subjects reported smoking 
during the 4 days of treatment. At the end of the experiment, NAC did not affect craving for 
cigarettes (assessed with the Questionnaire for Smoking Urges-Brief) or withdrawal 
symptoms (assessed with the Minnesota Nicotine Withdrawal Scale). However, compared 
to placebo, NAC reduced the subjective rewarding effect of a cigarette smoked at the end of 
the experiment, suggesting a potential preventative impact of the treatment on relapse. 
4.5 NAC and alcohol dependence 
NAC has just been evaluated for an 8-week treatment of alcohol dependence, but the results 
are not yet published (NCT00568087). NAC has only been fully assessed in humans for its 
antioxidant properties, with some results in combination with corticosteroids and enteral 
nutrition in the treatment of severe acute alcoholic hepatitis (for review see Reep and 
Soloway, 2011), while a recent study shows minimal benefits of the combination therapy by 
prednisolone plus NAC in terms of survival among patients with this indication (Nguyen-
Khac et al., 2011). Finally, preliminary findings in rats suggest NAC may also be helpful in 
the prevention of alcohol-induced heart disease (Seiva et al., 2009). Clearly, further work 
regarding the potential of NAC treatment for alcohol dependence needs to be conducted. 
4.6 NAC and opiates dependence 
To our knowledge, NAC has not yet been evaluated in the treatment of opiate dependence 
in humans. 
4.7 NAC and pathological gambling 
NAC treatment has been shown to reduce pathological gambling. In an open-label study 
(Grant et al., 2007), 27 subjects who engaged in pathological gambling, with a mean age of 
50.8 ± 12.1 and a mean age of onset of problem gambling of 37.1 ± 12.8, were treated for 8 
weeks with NAC (increased dose from 600 mg daily to 1800 mg daily every 2 weeks). 
Twenty-three patients (85.2%) completed the study for which the primary outcome was the 
effect of NAC treatment on the pathological gambling score, an adaptation of the Yale-
Brown Obsessive-Compulsive Scale (PG-YBOCS), measuring the severity and change in 
severity of pathological gambling symptoms (Pallanti et al., 2005). Of those that completed 
the study, 16 patients (69.6%) were responders on the PG-YBOCS, showing a 30% or greater 
reduction in total score at end-point compared with baseline. Ten patients reported total 
abstinence from gambling. The total score on the PG-YBOCS decreased during the treatment 
phase from 20.3 ± 4.1 to 11.8 ± 9.8. On the overall severity and change in clinical symptoms 
(assessed by the Clinical Global Impression-Improvement scale, a 7 point scale that requires 
the clinician to assess how much the patient's illness has improved or worsened relative to a 
baseline state at the beginning of the intervention), 59.3% of patients were ‘much’ or ‘very 
much’ improved at the end of the study. Urge, thought, and self-reported gambling 
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symptoms were improved after NAC treatment. In a second phase, 13 of the patients who 
completed the open-label study and were considered responders were included in a double-
blind placebo-controlled study with NAC treatment at the highest dose or placebo for 
another 6 weeks. At the end of the 6 weeks, 83.3% of active treatment patients vs. 28.6% of 
placebo patients still met responder criteria on the PG-YBOCS.  
4.8 NAC and impulsive-compulsive spectrum disorders 
Finally, NAC has been assessed in several impulsive-compulsive spectrum disorders other 
than addictions, including trichotillomania, obsessive-compulsive disorder (OCD), and nail-
biting in patients suffering from bipolar disorder. In a double-blind placebo-controlled 
study (Grant et al., 2009), 50 patients with trichotillomania (compulsive hair-pulling), with a 
mean age of 34.3 ± 12.1 and a mean age of onset of 12.1 ± 5.0 years, were treated for 12 weeks 
with NAC (1200 mg daily for 6 weeks, then 2400 mg daily) or placebo. Eighty-eight percent 
of all patients completed the study regardless the group assignment. In a subjective 
evaluation, NAC-treated patients, as compared to those treated with placebo, displayed 
significant reductions in the severity of trichotillomania symptoms according to the patient 
self-rating (using the Massachusetts General Hospital Hair Pulling Scale) and the physician-
assessment (with the Psychiatric Institute Trichotillomania Scale), associated with a 
significant improvement of the severity and the resistance and control dimensions of the 
disorder. On the severity and change in global clinical symptoms (assessed by the CGI-
improvement scale), 56% of NAC patients were ‘much’ or ‘very much’ improved at the end 
of the study compared with 16% of those taking placebo. In a report series, NAC used as an 
add-on therapy in the treatment of bipolar disorder was associated with a dramatic 
reduction in nail-biting behavior in three cases (Berk et al., 2009). NAC efficacy on this 
behavior may be due either to an anti-impulsive action of NAC or to an effect on anxiety or 
stress. In a case report, NAC has been used in conjunction with fluvoxamine (a serotonin-
reuptake inhibitor agent) treatment in a refractory OCD patient. During a total period of 12 
weeks, including 7 weeks at the total daily dose of 3000 mg, Y-BOCS scores decreased 
dramatically and the patient was able to resist her compulsive symptoms during the 
treatment period (Lafleur et al., 2006).  
These findings attest to the promise NAC treatment has for treating the behavioral 
symptoms of impulsive/compulsive disorders. Three double-blind placebo-controlled 
studies are currently being carried out, demonstrating the recent interest for NAC in the 
treatment of impulsive-compulsive spectrum disorders. The first one is evaluating the 
efficacy of NAC (3000 mg twice daily for 12 weeks) in adult Serotonin Reuptake Inhibitor-
refractory obsessive-compulsive disorder and depression (NCT00539513). The second one is 
evaluating the efficacy of NAC (1600 mg twice daily for 2 weeks then 2600 mg capsules 
twice daily for the remaining 10 weeks) for the treatment of pediatric obsessive-compulsive 
disorder (NCT01172275), and the third one is assessing the efficacy of NAC (from 1200 mg 
daily to 3000 mg daily, during 12 weeks) in pathologic skin picking (repetitive, ritualistic, or 
impulsive picking of otherwise normal skin leading to tissue damage, personal distress, and 
impaired functioning; NCT01063348). Moreover, NAC is currently being evaluated in a 
double-blind placebo-controlled study for children with Tourette syndrome (childhood-
onset neuropsychiatric disorder characterised by multiple and chronic motor and vocal tics; 
NCT01172288). 
 




In laboratory studies, NAC has been shown to prevent escalation of cocaine use during long 
access (6h/day) to the drug (an animal model of loss of control over drug intake, a hallmark 
feature of addiction) without affecting drug use during short access (1h and 2h/day). NAC 
also prevents relapse behaviors, reducing drug-associated cues-, cocaine-, and heroin-
priming-induced reinstatement after extinction and abstinence protocols (animal models of 
relapse, when a drug-addicted individual is exposed to different triggers of drug craving 
and relapse after a period of abstinence). Finally, NAC reduces cocaine seeking, when drug 
seeking has become habitual (an animal model of the daily behavior of drug foraging, as it 
can be seen in individuals who spend great deal of time in activities necessary to obtain and 
prepare the substance, rather than only during relapse following an extinction or abstinence 
period). These preclinical data resonate well with the human literature which shows overall 
promising results from clinical trials on drug addiction and impulsive-compulsive spectrum 
disorders. More specifically, the efficacy of NAC treatment for cocaine addiction appears 
relevant, with improvement of withdrawal symptoms, attenuation of subjective and 
objective craving for the drug (during laboratory experiments, NAC attenuates 
environmental and cocaine-induced urges to use), and persistent reduction in cocaine use 
even after the end of the treatment. Results in cannabis addiction are less marked but also 
hold promise, notably due to the absence of available treatment for addicted young adults, 
who are particularly vulnerable to the development of other, stronger, addictions and 
psychotic comorbid disorders (Gray et al., 2010). Promising but mitigated results in 
methamphetamine and nicotine addiction should make us remember that the pathology of 
addiction may be quite different across drugs of abuse and that a single pharmacotherapy 
may not be sufficient for all drugs (cf. Badiani et al., 2011). Even if the small sample size of 
these studies may have precluded the identification of statistically significant differences 
between groups, negative results may also be attributable to the implication of other 
biological and psychological factors in methamphetamine and nicotine dependence and 
craving. In particular, learned contextual associations and context-induced relapse 
(Crombag et al., 2008) may not be affected by NAC treatment. Indeed, interesting 
preliminary results in other behavioral disorders including pathological gambling and 
impulsive-compulsive disorders, which appear alleviated with NAC treatment, may suggest 
that NAC is not necessarily working to treat these behavioral disorders at the same level of 
the drug of abuse.  
At the neurobiological level this suggests that NAC-induced re-regulation of the 
homeostatic extrasynaptic glutamate levels in the brain may be affecting the behavioral 
component of ‘seeking’ – whether that be drug, a poker game, or the anxiety-alleviation 
provided by compulsive hair pulling. Preclinical studies using models in rats that 
specifically address the development of habitual drug seeking behavior, compulsive seeking 
and taking behavior, or addiction-like behavior (Belin et al., 2011) may help to elucidate the 
main psychological and associated neural substrate whereby NAC exerts its action and so in 
the different addictions, as it has been shown, for example, that opiate and stimulants 
addiction are behaviorally and neurobiologically distinct (for review see Badiani et al., 
2011). Studies evaluating the efficacy of NAC on neuropsychological processes that 
contribute to the development of drug addiction, (e.g., decision-making or impulsivity) may 
also prove useful. In humans, clinical studies should take interest in assessing efficacy of 
NAC as a cognitive enhancer (Brady et al., 2011), as it has been shown that improvement of 
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symptoms were improved after NAC treatment. In a second phase, 13 of the patients who 
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significant improvement of the severity and the resistance and control dimensions of the 
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evaluating the efficacy of NAC (1600 mg twice daily for 2 weeks then 2600 mg capsules 
twice daily for the remaining 10 weeks) for the treatment of pediatric obsessive-compulsive 
disorder (NCT01172275), and the third one is assessing the efficacy of NAC (from 1200 mg 
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hold promise, notably due to the absence of available treatment for addicted young adults, 
who are particularly vulnerable to the development of other, stronger, addictions and 
psychotic comorbid disorders (Gray et al., 2010). Promising but mitigated results in 
methamphetamine and nicotine addiction should make us remember that the pathology of 
addiction may be quite different across drugs of abuse and that a single pharmacotherapy 
may not be sufficient for all drugs (cf. Badiani et al., 2011). Even if the small sample size of 
these studies may have precluded the identification of statistically significant differences 
between groups, negative results may also be attributable to the implication of other 
biological and psychological factors in methamphetamine and nicotine dependence and 
craving. In particular, learned contextual associations and context-induced relapse 
(Crombag et al., 2008) may not be affected by NAC treatment. Indeed, interesting 
preliminary results in other behavioral disorders including pathological gambling and 
impulsive-compulsive disorders, which appear alleviated with NAC treatment, may suggest 
that NAC is not necessarily working to treat these behavioral disorders at the same level of 
the drug of abuse.  
At the neurobiological level this suggests that NAC-induced re-regulation of the 
homeostatic extrasynaptic glutamate levels in the brain may be affecting the behavioral 
component of ‘seeking’ – whether that be drug, a poker game, or the anxiety-alleviation 
provided by compulsive hair pulling. Preclinical studies using models in rats that 
specifically address the development of habitual drug seeking behavior, compulsive seeking 
and taking behavior, or addiction-like behavior (Belin et al., 2011) may help to elucidate the 
main psychological and associated neural substrate whereby NAC exerts its action and so in 
the different addictions, as it has been shown, for example, that opiate and stimulants 
addiction are behaviorally and neurobiologically distinct (for review see Badiani et al., 
2011). Studies evaluating the efficacy of NAC on neuropsychological processes that 
contribute to the development of drug addiction, (e.g., decision-making or impulsivity) may 
also prove useful. In humans, clinical studies should take interest in assessing efficacy of 
NAC as a cognitive enhancer (Brady et al., 2011), as it has been shown that improvement of 
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inhibitory control, attentional and decision-making processes may help individuals perform 
better in face of stressful and complex environmental situations. 
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Currently, the harmful use of alcohol and other drugs is recognized as a serious public 
health problem in many countries (WHO, 2002). However, it has not always been so. The 
reason is because, for quite a long time, the prevention and treatment related to the use of 
psychoactive substances were neglected in the context of public health policies, and 
delegated to other institutions such as justice and public safety. This fact gave rise to 
initiatives of total character attention1 and to therapeutic practices that aimed mainly at the 
abstention from psychoactive consumption. Hence, traditionally, the great majority of 
treatments offered to users of alcohol and other drugs was based on the abstinence proposal 
(Marlatt; Larimer & Witkiewitz, 2012). 
Nevertheless, a worldwide discussion about the difficulties that alcohol and other drug 
addicts have to drastically stop consuming such substances identified the need for the 
development of other treatment models as an alternative to the abstinence proposal (Brasil, 
2005; Paes, 2006). As a consequence, many countries all over the world  adopted the 
approach of harm reduction as the official strategy for prevention, treatment and education 
of people who use psychoactive substances in a harmful way (Brasil, 2001). 
Another existing perspective in the treatment of alcohol and other drug users is the 
psychoanalysis proposal (Director, 2005; Laxenaire, 2010; Loose, 2000; Valentine & Fraser, 
2008). Its main specificity lies in recognizing the different ways in which the subject relates 
to the toxic substances and consequently, understanding that drug use is anchored in the 
subjective dimension. Besides, psychoanalysis points to the fact that certain types of 
relationship to drugs can provide a kind of paradoxical and deadly satisfaction, called 
                                                                 
1 The term “initiatives of total character attention” is a mention to the term “total institutions”, coined 
by Erving Goffmann (1985/2001).  
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to the toxic substances and consequently, understanding that drug use is anchored in the 
subjective dimension. Besides, psychoanalysis points to the fact that certain types of 
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1 The term “initiatives of total character attention” is a mention to the term “total institutions”, coined 
by Erving Goffmann (1985/2001).  
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jouissance (enjoyment)2 (Lacan, 1969/1992; Laxenaire, 2010; Melman, 2000; Olievenstein, 
2002), which is articulated to the unconscious and the death drive. 
Thus, taking into consideration the abstinence proposal, the damage reduction proposal and 
the psychoanalytic proposal, this chapter will discuss the particular features of each one of 
these treatment models. Besides, it will also analyze the controversial and convergent points 
that exist among them, paying special attention to the debate between psychoanalysis and 
harm reduction.  Finally, the chapter will briefly consider how the treatments of drug users 
can be optimized, as the result of the ‘approximation’ between these proposals. 
2. The treatment proposals of drug use 
In order to start a discussion on the treatments offered to users of alcohol and other drugs, 
first it is necessary to emphasize the historical character of the phenomenon of psychoactive 
substance use. As several authors have pointed out, the human practice of drug 
consumption is universal and ancient. In fact, in nearly all civilizations and human societies, 
the consumption of drugs capable to promote changes in what are considered as the human 
beings’ states of consciousness has been a resource of great social and subjective importance 
(Mcrae, 2001; Seibel & Toscano Jr., 2001; Carneiro, 2006).  
Although this consumption was historically widespread, it is important to highlight that, 
until a certain moment in history, it was restricted to small groups and happened in 
connection to collective ceremonies and sacred rituals, according to socially shared norms 
and conventions, which gave a predominantly symbolic value to the use of these substances. 
For instance, some ancient people believed that the consumption of certain substances made 
it possible for the spiritual representatives of certain groups to incorporate supposedly 
supernatural powers. This association between psychoactive substances consumption and 
religion lasted for quite a long time, including the medieval period, when the use of drugs 
was condemned because it was considered a hedonistic and sinful behavior.    
However, this conception was strongly challenged from the seventeenth century on, with 
the development of medical studies, when certain vegetal products that have psychoactive 
effect started to be valued as a source of energy, stamina, humor and temper balance. As 
examples, we can mention the opium, originated from the poppy, which was for a long time 
prescribed as a painkiller, antitussive and antidiarrheal medication, and the marijuana, 
prescribed as a general sedative, for the specific treatment of rheumatism, neurosis, 
insomnia, headaches, diarrhea, seizures and anorexia as well as in the therapy of tetanus 
and cholera (Carneiro, 2006).  
Furthermore, with the isolation of the active principles of the psychoactive substances in the 
eighteenth century, trade was established and certain products started to be available to the 
general population. Simultaneously, there was the weakening of the socio-cultural 
regulation strategies for the use of these substances, as well as the rise of a number of social 
issues that contributed to the large dissemination of drugs consumption, both for 
therapeutic and recreational ends. This dissemination, in turn, revealed the capacity of these 
substances to cause physical and psychological dependence in some users.  
                                                                 
2 ‘Jouissance’ means ‘pleasure’ or ‘enjoyment’, but the terms in English lack the sexual connotation that 
the word has in French. Hence, in consonance with the majority of the English translations of Lacan’s 
works, the original term was adopted in this text. 
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Thereafter, the phenomenon of drug use was regarded both as a social and health problem, 
leading many scholars to devote themselves to the systematic investigation of the several 
types of addiction originated from the consumption of psychoactive substances. 
Consequently, especially from the nineteenth century on, the use of drugs has become the 
object of study in the field of psychiatry and started to be considered a psychopathology, 
and as such, it needed to be treated (Conte, 2000). This was the context in which several 
treatments for drug dependence appeared, which, in a first moment, focused mainly on the 
detoxification and/or the isolation of drug users. 
In a review of the existing treatments, it is noticeable that the field of drug addiction 
presents a great variety of offers. These offers can be classified as: medicamental treatments, 
with or without internment (especially through pharmacological interventions aimed at 
detoxification); non-medicamental treatments with internment (in therapeutic communities, 
recovery program farms, etc); non-medicamental treatments through the engagement in 
mutual help groups (such as Alcoholics Anonymous and Narcotics Anonymous, based on 
the Minnesota Method, also known as the Twelve-Step Model); cognitive-behavioral 
therapies (with emphasis on counseling techniques, motivational interviewing, relapse 
prevention and skill training); psychoanalysis (through individual and/or group 
psychotherapy care) and more recently, harm reduction (which provides services of drop-in, 
needle exchange, target delivery of healthcare, outreach and drug consumption rooms) 
(Stevens, Hallam & Trace, 2006).  
According to Queiroz (2001), except for psychoanalysis and harm reduction, the other 
treatments are predominantely grounded in the principle of abstinence. Hence, as 
previously mentioned, in the scope of drug addiction treatments at least three different 
proposals can be identified: abstinence, harm reduction and psychoanalysis.  
3. The proposal of treatments that aim at abstinence 
Considering that drug abuse treatments appeared mainly due to the recognition of drug 
addiction as a psychopathology by the psychiatry field, it is not difficult to understand why 
these treatments have been developed based on assumptions originated from psychiatry. 
Being a branch of medicine, initially psychiatry incorporated the hegemonic biomedical 
model and its strong emphasis on the organic and biological aspects of both physical and 
mental diseases (Pratta & Santos, 2009; Rothshild, 2010). Thus, due to the strong influence of 
the biomedical model on the psychiatry field, especially during the nineteenth and twentieth 
century, in many countries the treatments for drug use were led to adopt the same logic 
implemented in the therapies of other psychopathologies. 
Therefore, traditionally, these treatments had as their main feature the hospitalocentric 
model, with predominantly pharmacological therapies aiming at healing, which in general, 
in the case of psychoactive substance users, was considered equivalent to the abstention of 
drug use (Faria & Schneider, 2009; Rothschild, 2010; Valentine & Fraser, 2008). Although this 
fact was more evident in some countries, such as the USA, who have lived under the aegis 
of a real ‘war on drugs’, in a way it did have, and still has, effects upon how certain 
organizations around the world deal with the drug addiction phenomenon3 (Marlatt, 
                                                                 
3 An example of the influence of the prohibitionist concept on worldwide agencies were the three 
International Conventions organized by the UN Commission of Narcotic Drugs, that aimed at 
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Larimer & Witkiewitz, 2012). The concept underlying this type of this viewpoint about drug 
use was that drug addiction would be a neurochemical dysfunction caused by the use of 
drugs (Freda, 1989/1993; Khantzian, 1995; Olievenstein, 2002).  
In the mid-nineteenth century, a moral model of religious or spiritualist origin was added to 
this classic psychiatric view of psychopathology and treatment (Marlatt & Witkiewitz, 2010). 
This model proposed that drug use was the result of character deviation, and rehabilitation, 
correlated to abstinence, was of divine nature (Faria & Schneider, 2009; Stevens, Hallam & 
Trace, 2006). This moral model is still adopted by some therapeutic communities and by a 
great part of the self-help groups, which propose that chemical dependence is an incurable 
physical, mental and spiritual disease. 
In fact, according to Bastos (2009), there are still remaining practices of these ideas of 
morality in current treatment for drug users. Such practices determine that drug use 
treatments inserted into this logic take the strand of reward and punishment, to mould the 
drug users’ behavior into the one desired by the public health service, that usually is the 
abstinent behavior. This way, it is noticeable that both treatments, the one originated from 
the classic psychiatry and the one originated from the moral model, have as their common 
objective to make the user abandon the use of drugs and reach the goal of abstinence. 
In this sense, one may say that abstinence consists of a treatment proposal that is influenced by 
these two models, in that both establish the total abstention of consumption as the easiest way 
to avoid drug users to lose control in face of psychoactive substances. As a consequence, many 
countries that adopt abstinence based treatments (for examples, USA, Japan, Singapore, 
Malaysia, and others) favoring the therapeutic models based on the isolation of users (Alves, 
2009; Pratta & Santos, 2009). It is worth mentioning that this preference for treatments with 
internment reveals the influence of the asylum model in mental health, which has been 
sharply questioned by the anti-psychiatry movement4 (Marchant, 2010). 
Among other reasons, this preference comes from the belief that inpatient care allows for 
better surveillance and control of the users, which would assure the abstention of drug 
consumption, at least while under treatment. However, one of the main criticisms to 
treatments in closed institutions lies in the fact that the patient’s isolation from society 
creates an artificial environment which characteristics cannot be reproduced outside the 
institution’s walls. Hence, once the treatment ends, the patient’s reintegration to the family 
and social environment tends to be disturbing, favoring the occurrence of numerous 
relapses (Alves, 2009; Brasil, 2005; Marlatt; Larimer & Witkiewitz, 2012; Rothschild, 2010).  
This idea of making users’ access to psychoactive substances difficult is justified by the basic 
assumption that grounds the abstinence treatment proposal, which is that the drug makes 
the drug addict (Freda, 1989/1993). According to this viewpoint, drugs are seen as having a 
                                                                                                                            
implementing a common program to combat drugs in all its member states (Alves, 2009). In 1998, this 
same Organization devised an action plan, ratified in 2003, whose title was “A drug free world: We can 
do it,” establishing the year 2008 as the deadline to reach this goal in several countries. 
4 It is important to emphasize that, in some countries such as France and Switzerland, due to the 
influence of psychoanalysis, historically the psychiatric treatments were not so subordinated to the 
biomedical model. However, a steady increase of an organicist perspective in mental health has been 
perceived lately, even in these countries (Decker, 2008).  
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supposedly intrinsic power of getting subjects addicted to them. Thus, the idea conveyed is 
that anyone who uses drugs will compulsorily become, sooner or later, a drug addict. This is 
considered especially true in regard to those drugs viewed as more powerful, such as 
cocaine, heroin and crack. But in a way, this is a belief that is extended to the remaining 
psychoactive substances – mainly in cases in which the consumption of these drugs goes 
beyond the socially established standards. However, this viewpoint ends up favoring the 
pharmacological aspect of drugs, and ignoring the individual, subjective, social and cultural 
aspects implied by the phenomenon of drug abuse and addiction.  
Thus, in the perspective of treatments that aim uniquely and exclusively at abstinence, drug 
abuse is generally considered as a problem that concerns the disease, not the subject 
(Dufour, 2004; Olievenstein, 2002; Passos & Souza, 2011). By doing this, it is not taken into 
consideration the possibility that the use of drugs represents a way the subject found to deal 
with his/her conflicts and with the pain of existing, that is, the discontent that, in some 
measure, affects all human begins (Freud, 1930/1996)5. 
Therefore, in the abstinence proposal, it is assumed that the only means to prevent or treat 
drug addiction would be the non-use of drugs. This is one of the reasons why many drug 
addicts that are treated by the abstinence proposal say that they are permanently in 
recovery, regardless how long ago the last drug use was, and affirm that they are ‘clean just 
for today’. The explanation for this type of discourse is based on the fact that relapses are 
seen as a great threat in the horizon of those who undergo this model of treatment. And 
since relapses are considered the total treatment failure, abstinence is thus placed as the 
objective to be pursued daily and for the whole life. 
This conception favors the idea that once a drug addict, forever a drug addict. As a 
consequence, the abstinence proposal ends up promoting an imaginary collage of drug users 
to the signifiers ‘addict’, ‘toxicomaniac’, ‘sick’, etc. In turn, this collage makes it difficult for the 
user to get out of the subjective position of dependence on psychoactive substances. This is 
because the former user who structures his/her life around the abstinence from drugs 
continues to delegate to the drug a central role in his/her life, and to live under the aegis of an 
imperative: it is as if he/she had simply replaced the statement “I have to consume” for “I 
have to not consume”, thus remaining in the same subjective position of being subjected to 
toxic substances. In this case, the patient, whether using drugs or not, continues to use the 
resource to the toxic as a subterfuge to avoid confronting his/her psychic issues, so that 
his/her submission to the external imperative of abstinence ends up exempting him/her from 
the need to make his/her own choices and be responsible for them (Rothschild, 2010).  
Another criticism to drug treatments that aim exclusively at abstinence is the fact that they 
don’t generally consider the different modalities of drug use and consequently, the fact that 
                                                                 
5 The concept that drug use is tied to a subjective need of the user was strongly advocated by Khantzian 
(1995), who, from the perspective of ego psychology, proposed that the intoxication practices were a 
type of self-medication which the subject used in an attempt to better deal with his torments. However, 
the association between the use of certain substances and the existence of specific psychological 
problems, proposed by this author, did not resist empirical tests and clinical experience. On the other 
hand, the hypothesis of self-medication ended up contributing to the spread of the adoption of the 
psychoanalytical approach in the treatment of drug users, which will be explained in more detail in 
following sessions. 
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not every drug user becomes what is considered a drug addict. This view ignores that most 
users of drugs do so for recreational or occasional purposes, but never come to a 
dependency relationship with them (Araújo, 2007; Nery Filho & Torres, 2002; Rezende, 2000; 
Stevens, Hallam & Trace, 2006)6.  
Nevertheless, the differences among the types of drug consumption are acknowledged in 
several fields of knowledge. In this respect, the UNESCO, for example, distinguishes four 
types of drug users: the experimenter, who tries one or several types of drugs, but limits this 
contact to the first experience; the occasional user, who occasionally uses one or several drugs, 
but is not a drug dependent; the habitual user, that frequently uses drugs, but still functions 
socially; and the dependent user (also called a drug addict or toxicomaniac), who lives by and 
for the drugs, and has his/her social bonds severely hampered or even broken by them 
(Rezende, 2000). Hence, the definition of drug addiction does not include the modalities of 
drug use in which the subject, although he/she uses the drug, does not place it at the center 
and as a destructive element in his/her life, and manages to preserve the social ties. 
As a result of the various criticisms to the abstinence proposal, many authors have considered 
that, given the impossibility or great difficulty to maintain abstinence and eradicate drugs, the 
most interesting posture to be adopted is to try to manage the effects of drug use and minimize 
the damage caused by it, as proposed by the harm reduction strategy (Rezende, 1999; Queiroz, 
2001; Pratta & Santos, 2009). And in fact, although the zero-tolerance policy to drug use still 
prevails in some countries, many other, especially in the European Union, adopt the harm 
reduction approach in the prevention and treatment of drug addiction as well as in the 
problem arising from it (Marlatt & Witkiewitz, 2010; OEDT, 2011).   
4. The proposal of the harm reduction strategy 
Harm reduction7 is currently defined as a public health strategy that targets at reducing the 
damage caused to the individuals’ health and controlling the possible adverse consequences 
that result from the adoption of risk practices (Marlatt; Larimer & Witkiewitz, 2012). In the 
specific context of alcohol and other drugs, harm reduction implies a set of interventions 
with the purpose of preventing the negative consequences of the consumption of 
psychoactive substances, without the requirement of immediate and automatic abstinence.  
Among these interventions, it is worth of notice the distribution of syringes, needles and 
pipes, the presentation of educational lectures and the referral of users that are outside the 
health services to specialized institutions. Besides, the harm reduction approach is also 
dedicated to teach the patient the supposedly most efficient way to deal with the variety of 
risk factors that lead to the abuse of psychoactive substances, in order to help the patient to 
reach the goal he/she established for him/her, be it the total abstinence or moderate 
consumption. Hence, harm reduction presents an alternative perspective to treatments 
based on the abstinence logic, when it considers possible to prevent the negative effects of 
drug addiction without its compulsory interruption. 
                                                                 
6 According to the report published by the UM in 2007, approximately 200 million people use drugs 
worldwide, and only one-eighth of these have dependence problems. The remaining are occasional 
users (Araújo, 2007). 
7 In some places, the term harm reduction is replaced by risk reduction, and these two terms are often 
used as synonymous, although they are not.  
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The harm reduction approach, as a general guideline for action, was originated in England 
in 1926, through the development of the Rolleston Report (Stevens, Hallam & Trace, 2006). 
A ministerial committee chaired by the UK Ministry of Health established that the most 
adequate treatment for certain patients would be the maintenance of the use of certain 
substances, thereby regulating the right of British doctors to prescribe opiates to addicts of 
this type of drug. In the same Report, it was established that the criterion adopted for this 
prescription should be the need, after several failed attempts at abstinence, to manage the 
syndrome caused by the abstention of certain substances, besides the observation that the 
patient would not be able to lead a normal and productive life without a minimal dose of 
the drug administered regularly (Brasil, 2001). 
This procedure was known as substitution treatment, and until today is one of the harm 
reduction strategies used (Marlatt & Witkiewitz, 2010; Stevens, Hallam & Trace, 2006). It 
consists of changing the substance which the user is dependent on for another substance 
that will offer lower risk. The most common strategy is the substitution of heroin by 
methadone, a synthetic opioid agonist with long half-life, which is consumed orally, helps to 
relieve some of the heroin withdrawal symptoms, causes less organic and psychological 
damage and is considered a substance with lower addictive power. Although this model of 
treatment appeared in a context different from the current, it is still in use in several 
countries such as England, Holland, Croatia and Norway, among others, especially in the 
European Union (Alves, 2009; OEDT, 2011). 
Thus, the initial objectives of the harm reduction approach were to make it possible for users 
who were psychoactive dependents to lead a more stable and useful life, and to minimize 
the harmful health effects of drug use. However, after the 1980’s, with the spread of the 
HIV/AIDS virus due to the large contamination originated from the sharing of needles, the 
harm reduction strategies also aimed at preventing this contamination among the users of 
injectable drugs. 
As a consequence, due to some positive results obtained in the prevention of contamination 
in several countries such as Belgium, Australia, Germany, Switzerland, France and others 
(Brasil, 2001; Paes, 2006), many harm reduction programs appeared as public health 
strategies. Brazil was one of the countries that has most recently adopted this approach, 
when in 1994 the harm reduction model was embraced as the official policy by the Health 
Ministry (Brasil, 2005), resulting from the recognition of the harmful use of alcohol and 
other drugs as a serious public health problem. In addition, the observation that the majority 
of drug users are not capable or do not want to stop consuming such substances weighed 
heavily on this decision8. However, it is important to point out that despite all the incentives 
created by the Brazilian government, there has not yet been a significant adherence to this 
strategy that would allow for the institutionalization of the harm reduction policy in the 
entire public health system (Passos & Souza, 2011).  
From a public health perspective, the adoption of harm reduction as a strategy for the 
treatment of addiction to psychoactive substances aims to recover the users’ self-regulating 
                                                                 
8 One of the reasons why drug users do not want and/or do not manage to interrupt the consumption is 
the fact that they have already incorporated the drugs they use to their personal and relationships 
routine (Rothschield, 2010). Besides, in most cases, such substances are a source of jouissance, which 
they are not willing to do without (Laxenaire, 2010; Olievenstein, 2002).  
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not every drug user becomes what is considered a drug addict. This view ignores that most 
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4. The proposal of the harm reduction strategy 
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based on the abstinence logic, when it considers possible to prevent the negative effects of 
drug addiction without its compulsory interruption. 
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role and citizenship, while stimulating their inclusion and mobilization in the society, 
through the expansion of their social relationships and the increase of the chances within the 
society in which they live. Theoretically, the objectives of the harm reduction proposal can 
be reached through the adoption of certain strategies of action, namely those that seek to 
reach users who, due to their socio-economic characteristics (lack of permanent housing, 
close relationship with illegal practices, lack of health concerns, etc), are generally excluded 
from health services (Marlatt & Witkiewitz, 2010; Pinheiro, 2002; Stevens, Hallam & Trace, 
2006). Furthermore, there are other strategies that intend to promote drug users’ moderation 
of consumption, such as drug consumption rooms and target delivery of healthcare.  
As a consequence, the harm reduction proposes that, with the implementation of this new 
treatment model, users of alcohol and other drugs can receive counseling and adequate 
treatment in order to avoid the most serious consequences of drug abuse, such as deaths by 
overdose, organic damages and virus contamination. This way, there is the hope of 
contributing to a safer drug use and a global and less prejudicial understanding of this 
phenomenon.  
In fact, many authors argue that the treatment of drug users with the harm reduction 
approach is not only more efficient but also less costly, when compared to the abstinence 
model policies of drug use combat, because it contributes to decrease the number of deaths 
and illnesses associated to the use of drugs and to improve the social functioning of 
psychoactive substances users (Marlatt & Witkiewitz, 2010; OEDT, 2011; Stevens, Hallam & 
Trade, 2006). Nonetheless, this effectiveness is difficult to be supported by statistical data, 
partly because, although abstinence and harm reduction are grounded in apparently 
opposite philosophies, many drug users that start treatment with the objective of achieving 
abstinence end up redefining their goals during the process and begin to seek moderation in 
consumption (Neale, Nettleton & Pickering, 2010). From this perspective, in a number of 
health services, abstinence and harm reduction become part of the same treatment strategy, 
and can actually be used together (McKeganey, 2011). Besides, because studies on efficacy, 
effectiveness, and cost-effectiveness of the varied types of treatment have often employed 
methods and research designs of varied quality (such randomized controlled trials, clinical 
trials, case series, reviews, meta-analysis, etc), it is difficult to make a direct comparison of 
the different interventions. These are the reasons why there is a growing need for the 
development of more research focusing on these issues (CIAR, 2008).  
In spite of this, it is possible to state that, because it places lower demands, the harm 
reduction proposal seems more attractive to many users, and decreases the number of 
patients that give up treatment (Alves, 2009; Rothschild, 2010). In addition, some authors 
defend that the rampant increase in the consumption of illicit drugs and the growth of the 
progression from the use of least to most powerful drugs are less frequent in countries and 
areas that adopt the harm reduction perspective (Alves, 2006; OEDT, 2011). 
Especially because of these reasons, harm reduction is considered an “ethical landmark” in 
the field of prevention and treatment of disorders associated with the use of alcohol and 
other drugs. From this perspective, the proponents of harm reduction programs defend that 
this approach “recognizes each user in his/her singularities, designing with him/her the 
strategies to defend his/her life” (Brasil, 2005, p.42)9. 
                                                                 
9 All the translations from the Portuguese original versions were made by the author. 
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However, it is worth debating whether the ethic that the harm reduction strategy deals with 
actually takes into account the subjectivity of each user. Regarding this aspect, it is 
important to highlight that, in mental health practices based on harm reduction, the place 
occupied by the subjective aspects of the one who resorts to intoxication remains open to 
questioning. In this respect, it is valid to inquire whether this approach considers the 
dimension of jouissance coupled with the intoxication practices10.  
This issue deserves a thorough, deep discussion, to avoid falling in the empty promise of 
change, which will lead us to trade a practice that just considers the use of drugs as a 
disease, either physical or spiritual, for another practice that takes the drug use in its 
exclusively social dimension. Hence, it is important to note that drug addiction is a complex 
and multifaceted phenomenon. Thus, it is not possible to adopt a reductionist position, be it 
biological, moral, social or psychological, in relationship to it. This reservation derives from 
the assumption, advocated by some authors, that social inclusion and citizenship recovery 
in mental health, though important, tends to neglect the subjective nature entailed by the 
psychic suffering and the mode of jouissance of each subject (Kyrillos Neto, 2007; Rinaldi, 
Cabral & Castro, 2008). 
The request for the inclusion of the singularities and the listening of the patient in mental 
health practices is strongly considered by some psychoanalysts (Figueiredo & Tenório, 
2002; Valentine & Fraser, 2008), who, although recognizing the advances obtained by 
psychosocial rehabilitation, highlight that the emphasis on the citizen of rights can lead 
the current mental health practices to a new kind of subjective dismissal (Fernandes & 
Freitas, 2009). This is because there is a contemporary perspective in psychoanalysis that 
adverts that any rehabilitation proposal can only succeed if it follows the subject’s 
discourse, since the rehabilitation that denies the clinic will inevitably fall into the trap of 
re-education (Viganó, 1999). 
In this way, to psychoanalysis, the emphasis is placed on the subject, which makes the 
psychoanalytical practice different from the other approaches that are centered on the social 
determinants of the phenomena considered psychopathological, in spite of the agency and 
subjective choices (Valentine & Fraser, 2008). Thus, the psychoanalytical treatment focuses 
attention on what the patient says about him/herself, since the meaning of the symptoms, 
and consequently, the production of what Freud (1905/1996) called ‘talking cure’, will only 
be possible to emerge from the elements that the subject him/herself brings. Hence, the 
importance of psychoanalysis lies in the fact that this approach opens a space in which the 
patient’s talking can be listened to, interpreted and analyzed.  
5. The psychoanalysis proposal 
Thus, psychoanalysis also presents a specific proposal for treating users of alcohol and other 
drugs. This psychoanalytical proposal for the understanding and treatment of drug 
addictions was outlined along psychoanalysis’ own history. For, in this field, it was Freud 
who first became interested in this phenomenon, laying the conceptual foundations that 
                                                                 
10 It is important to emphasize that, from the psychoanalytical perspective, every type of drug use 
provides some kind of jouissance. However, in the case of drug addiction, the jouissance provided 
invades and dominates the user, in such a way that the subject remains subjected to the psychoactive 
substances.  
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made possible the subsequent development of psychoanalytical-based propositions on drug 
use such as the ones developed by Abraham (1908), Rado (1933), Krystal (1975), Lacan 
(1976), McDougall (1978), Wurmser (1995), Khantzian (1995), among others. Although all the 
theories formulated by these authors refer to the conceptual field of psychoanalysis, they are 
very different. Explaining each one of them is beyond the scope of this chapter, so the 
following considerations are embedded in the framework of Lacanian psychoanalysis, 
which stands out for having remained faithful to the Freudian doctrine and for being the 
only one that can explain why, in the use of drugs, pleasure and harm are inexorably 
interwoven (Loose, 2000).  
Nevertheless, it is important to highlight that, despite the existence of so many 
psychoanalytical readings on drug use, “the association between psychoanalysis and drug 
addiction is not common” (Laxenaire, 2010, p. 524). One reason is the fact that there is 
currently a strong demand for evidences of cost-effectiveness of the several existing 
treatments. And psychoanalysis is usually assessed as a long-term treatment, which proofs 
of efficacy are still insufficient (CIAR, 2008; Harrison et al, 2003). One of the main 
explanations for this assessment is the fact that psychoanalysis does not work on the same 
efficacy parameters that are adopted by other fields. Because the therapeutic efficacy is 
always related to a certain conception of cure and the psychoanalytical view of cure differs 
from the other fields, since psychoanalysis recognizes the existence of something incurable 
in the subject, and hence, is warned that it is not possible to ensure a full state of well-being, 
for suffering, to some extent, is at the core of human existence (Freud, 1930/1996; Lacan, 
1966/1998; Loose, 2000). Even so, many psychoanalysts have published works that 
demonstrate promising effects of the psychoanalytical treatment for drug addiction through 
the reports of clinical cases11 (Rothschield, 2010; Loose, 2000; Marlo & Kalinian, 2002).  
To start discussing the treatment proposal oriented by psychoanalysis, it is crucial to 
highlight that the psychoanalytical treatment operates under a view that is radically 
different from the therapeutic proposal originated in the medical-psychiatric field and from 
the one derived from the moral field as well (Silva, 2010). This is because psychoanalysis 
works with the notion of the subject of the unconscious, conceived as being beyond the 
individual and beyond the illness.  
The psychoanalytical concept of the unconscious refers to a psychic system that runs parallel 
to the conscious system, and that operates in a determined way, having an order and 
structure of its own (Fink, 1995). But, unlike the conscious system, the unconscious can only 
appear as a stumble, just in the gaps of the conscious manifestations, in what Lacan 
(1957/1999) coined as the formations of the unconscious: dreams, lapses, faulty actions 
(Freudian slips), jokes and symptoms, which reveal a meaning that so far had been hidden 
to the subject him/herself. By doing this, the unconscious indicates to the self the existence 
of an instance which is, at the same time, inside and conflicting with it. 
Whereas the consciousness operates in articulation with the reality principle, the 
unconscious operates in articulation with the pleasure principle, and, most importantly, 
                                                                 
11 This method of demonstration of results is justified because, as psychoanalysis emphasizes the 
singularity and the subject, it would be absolutely incoherent to expect that its efficiency could be 
demonstrated by statistical evidence. Hence, what can be expected from further research in this field are 
meta-analysis based studies that provide within-subject measures related to drug consumption, 
demonstrating the improvement of drug users that have undergone psychoanalytical treatment. 
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with the beyond pleasure principle. Whereas the reality principle, because it is articulated to 
the material reality, makes detours and delays in search of satisfaction, the pleasure 
principle seeks satisfaction in the shortest and most direct way (Freud, 1911/1996). The 
beyond pleasure principle, in turn, is articulated to the death drive, which Freud 
(1920/1996) defined as a certain tendency, inherent to all living beings, to seek the 
pacification of all the tensions – which ultimately can only be achieved with death. 
This is why, in psychoanalysis, the resource to intoxication is understood as a choice of the 
subject who, moved by the unconscious laws, searches actively for a jouissance that is 
extended towards death. To psychoanalysis, this search does not happen despite the subject, 
as other psychotherapeutic approaches propose. Yet, it is a choice12 made by the subject 
him/herself, but a choice that does not come from rational and logic elements alone, but 
also results from desires that many times escape rationality, since they resort to the 
unconscious and are articulated to the death drive. 
In fact, according to Laxenaire (2010), the unconscious search for death is well evidenced in 
drug addiction. Thus, one of the main particularities of the psychoanalytical proposal in 
comparison to the other treatment modalities lies on the emphasis given to the subjective 
structure at the expense of the pathological phenomenon. This is so much true that, while 
the medical-psychiatric diagnosis is most of the times phenomenological and based on a set 
of previously defined signs, the psychoanalytic diagnosis is structural and is from this 
structural diagnosis that the psychoanalytical treatment will develop. 
The structural diagnosis refers to the differentiation of the three clinical structures: neurosis, 
psychosis and perversion, which concern the mode of the resolution of the Oedipus 
Complex. This diagnosis results from the evaluation of the position assumed by the subject 
before the Other (Figueiredo & Tenório, 2002). This is explained by the fact that, to 
psychoanalysis, what marks out the structuring of the human psychism is the relationship 
with the Other, understood not as another person, but as the whole symbolic universe to 
which the individual finds him/herself referred to (the discourses, rituals, codes, beliefs, 
etc). Although this symbolic universe is initially transmitted by one primordial other (such 
as the mother or the one who is in charge of the child’s insertion in the world of language), 
in the Lacanian theory the Other represents the entire culture, and is considered an 
indispensable element for the human subject constitution, in that it makes it possible for the 
individual not to be a mere biological representative of the human species, but to become a 
being provided with thoughts and feelings, and inserted into social bonds (Lacan, 
1939/1985). From this perspective, every human subject is dependent on the Other, since no 
subject can engender him/herself on his/her own (Laxenaire, 2010).  
From this viewpoint, addiction would be a posterior dependence, but anchored exactly in 
the mode of relationship the subject established with the world around him/her (Laxenaire, 
                                                                 
12 The term choice is used by psychoanalysis not in the sense of a pondered decision, but as something 
that is chosen because it relates to what is most intimate to the subject, his/her unconscious. Hence, to 
psychoanalysis the choices are overdetermined by his/her psychic reality. In other words, 
psychoanalysis refers to choices that are not always rational, such as for example, the choice of abusive 
intoxication that many times threatens the subject. However, despite the sometimes hazardous effects 
caused by the subjective choices, psychoanalysis emphasizes how important it is for health 
professionals who work with drug addiction issues to keep alert to the fact that, in some way, users 
make the choice of intoxication. 
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11 This method of demonstration of results is justified because, as psychoanalysis emphasizes the 
singularity and the subject, it would be absolutely incoherent to expect that its efficiency could be 
demonstrated by statistical evidence. Hence, what can be expected from further research in this field are 
meta-analysis based studies that provide within-subject measures related to drug consumption, 
demonstrating the improvement of drug users that have undergone psychoanalytical treatment. 
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with the beyond pleasure principle. Whereas the reality principle, because it is articulated to 
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12 The term choice is used by psychoanalysis not in the sense of a pondered decision, but as something 
that is chosen because it relates to what is most intimate to the subject, his/her unconscious. Hence, to 
psychoanalysis the choices are overdetermined by his/her psychic reality. In other words, 
psychoanalysis refers to choices that are not always rational, such as for example, the choice of abusive 
intoxication that many times threatens the subject. However, despite the sometimes hazardous effects 
caused by the subjective choices, psychoanalysis emphasizes how important it is for health 
professionals who work with drug addiction issues to keep alert to the fact that, in some way, users 
make the choice of intoxication. 
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2010). This is why the structural diagnosis is of paramount importance in the 
psychoanalytical treatment of drug addiction, keeping in sight that it will enlighten the 
reasons why the inexorable dependence on the Other was transmuted into the dependence 
on a fixed object, which may give access to a kind of jouissance that is steady and repetitive, 
and to which the subject, from a certain moment on, becomes subordinated. 
Thus, psychoanalysis defends that if, in the beginning, the consumption of drugs has 
basically a recreational function, it is during its use that the drug, for some users, turns into 
a product that acquires a vital and indispensable role, configuring thereby an addiction. 
Several reasons converge to explain why addiction happens only in a subgroup of drug 
users. Among them are individual, social, economic, cultural and family factors. However, 
the psychoanalytical treatment emphasizes the subject that resorts to drugs, and 
consequently, to the particular function that drugs have in the psychism of each drug user 
and/or addict, and also highlights the importance of a diagnosis that differentiates between 
drug consumption and drug addiction. 
Hence, from a psychoanalytical perspective, “it is necessary to differentiate the simple uses 
of stupefiers from the imperative of treatment of the organism by a toxic drug, when this 
becomes the only means to shelter, on a daily basis, the body from an intolerable pain” 
(Kaufmann, 1996, p. 542). Thus, to psychoanalysis, drug addiction is defined as an “intense 
and exclusive relationship, in which the use of drugs has already been established as a 
function in the subject’s psychic life” (Conte, 2000, p. 11). 
For this reason, from a psychoanalytical viewpoint, the drug is not a problem in itself, since 
what can become problematic is certain types of drug use that some subjects make, which 
can turn into a form of the subject’s own destruction. This means that, in the 
psychoanalytical treatment of drug addiction, it is a matter of removing the biological 
characteristic from the drug (although not denying its existence), to give value to something 
else, converting it in something other than a simple object that produces psychological or 
physiological effects, which, by the way, can only be apprehended by the signifier, by what 
the patient reports. In this sense, if the treatment modalities based on abstinence claim that 
the drug makes the addict, to the extent that drugs are considered as having the supposedly 
intrinsic power to get the subjects addicted, psychoanalysis states that the drug addict 
makes the drug (Freda, 1989/1993), because it understands that this is a private relationship 
between the subject and the object, that grants to the latter the power to become a source of 
satisfaction which the subject himself cannot do without.  
From a psychoanalytical point of view, then, the addictions and the symptom have similar 
forming mechanisms, insofar as they both are a solution to an underlying conflict, but a 
solution that is not perfect, since it does not solve everything. But even being imperfect, it is 
a repeated solution, because there is something in it that the subject is not willing to give up, 
despite all the suffering that it brings (Loose, 2000). Hence, in the psychoanalytical treatment 
for drug addiction, it is understood that the subject’s choice to use drugs, the relapses and 
the excessive use of the psychoactive substance will only stop being an escape for the subject 
when the treatment enables him/her to find other forms of symbolization that allow 
him/her to abstain from drugs, in cases when this outcome is possible – for there are cases 
in which, due to a extremely unstable psychic configuration, the addiction is simply the one 
and only way the subject finds to manage to continue living. 
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Thus, in the psychoanalytical treatment, it is necessary to take into account the function and 
the meaning of the drug use to each subject, in order to make possible the identification of 
the relationship established between the subject and the drug. And to psychoanalysis, this 
identification is only viable when it comes from the knowledge produced by the subject 
him/herself during the treatment. According to this perspective, the role of the 
psychoanalyst in toxicomania treatments is to conduct a quality listening of the subject, 
enabling the emergence of the unsaid, of what is not obvious, of what is beyond the pleasure 
principle, which, by nature, point at the subject of the unconscious. In other words, if 
addictions result from the choice for a jouissance in the body, a jouissance that does not 
express itself through language, so the psychoanalytic treatment objective is to enable the 
subject to make a movement “from ad-diction to diction” (Loose, 2000, p. 80).  
According to Loose (2000), drugs and alcohol can only exert massive and extreme effects on 
the subject because they work pushing him/her out or against the language domain. In this 
sense, re-inserting him/her in the symbolic chain, in the diction domain, means going 
exactly in the opposite direction of the drug effects. Thus, the main difference from the 
psychoanalytical treatment is due to the ethic that guides psychoanalysis, which is radically 
different from any moralizing perspective. This is because, similarly to the medical-
psychiatric treatments, the treatments originated from the moral model assume to know, a 
priori, about the subject and what is supposed to be the best for him/her. This characteristic 
results from the fact that the moral model aims at responding to a social demand of 
standardization and adaptation of deviant behaviors, rather than fulfilling the users’ needs. 
Hence, the treatments based on this model end up promoting the subject’s orthopedic 
framing or re-education, to the extent that they intend to teach him/her what is considered 
as the adequate behavior, which is, in this case, the social ideology of sobriety and aims at a 
certain preservation of the other citizens’ life. 
Still in regard to the moral model of treatment, psychoanalysis advises that, when the 
professional embodies the position of knowing about the subject, there is no room for the 
subject to produce any knowledge about him/herself (Bastos, 2009). And in a context in 
which the subject is not given the means to produce his/her own knowledge, it is very likely 
that he/she will remain at the mercy of the professionals or institutions, being unable to 
make his/her own choices and/or to be responsible for them. Consequently, instead of 
becoming responsible, the subject under treatment remains in a state of tutelage, in which 
there is an attempt to remove all of his/her possible responses that do not conform to the 
expectations of the health professionals and institutions. In sum, the great contribution that 
psychoanalysis offers to the treatments of drug abuse and addiction is to call the attention to 
the fact that, if the subject choses his/her addiction as a solution that makes him/her suffer 
and at the same time brings him/her jouissance, then, only the subject him/herself is able to, 
through treatment, choose what to do with what affects his/her body and life so radically. 
6. Psychoanalysis and harm reduction: controversies and convergences 
Reviewing the literature, it is possible to confirm the extent to which psychoanalysis, while a 
specific field of knowledge, has long adopted a critical position with regard to the existing 
drug use treatments based on the mandatory abstinence (Conte, 2004; Melman, 2000; 
Queiroz, 2001; Rothschield, 2010). For this reason, in the first instance, it would be possible 
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to identify an approximation between psychoanalysis and harm reduction proposals, insofar 
as they both problematize the model of treatment guided by the logic of abstinence. 
In fact, according to Paes (2006), “the literature on drugs that has psychoanalytical basis has 
often been used by technicians who work on the training of harm reducers” (p. 129). Since 
the 1970s, there has been an increase in the number of professionals with a psychoanalytical 
focus, who offer chemical dependents a different kind of treatment and express serious 
criticism to the existent models of treatment (Paes, 2006). One of the main psychoanalysts 
that represent this viewpoint is the psychiatrist Claude Olievenstein, who, in the 1970s, 
founded the Centre Médical Marmottan, an institution for the treatment of drug addicts in 
Paris that became a benchmark and was inspirational for many treatment centers worldwide 
(Freda, 1989/1993; Marchant, 2010). 
Queiroz (2001) also believes that it is possible to consider an approximation between the 
psychoanalytical assumptions and the harm reduction approach, insofar as the programs 
that adopt the latter introduce the “dimension of the particularity of the subject” (p. 3) and 
therefore, acknowledges “drug users as particular subjects and citizens, who have the right 
to health and to a treatment that is in fact effective and produces meaning” (Queiroz, 2001). 
In this case, the production of meaning refers to the fact that both the harm reduction 
policies and the psychoanalytical approach grant drug users the right to use drugs, which 
makes possible for them to build significations for this use without necessarily having to 
interrupt it (Marchant, 2010; Rotschild, 2010). 
Adopting a similar perspective, Conte (2004) states that not only the harm reduction 
approach but also the advances achieved by the psychosocial rehabilitation paradigm do 
come close to psychoanalysis. According to the author, in both of them “there is the 
common refusal to flatten the subject to a passiveness that asks for social assistance or to a 
subject-body condition (organic and biologic) that asks for a “medicamental solution” 
(Conte, 2004, p.26). 
On the other hand, Conte (2004) warns that the principles that underlie the harm reduction 
proposals are not the same that guide psychoanalysis, and in this respect, adverts that “the 
differences are due to the ethic, the objectives of the interventions and those who they turn 
to” (p. 27). Hence, this proposal of conciliation between the singularity dimension, 
represented by the subject’s clinic and grounded in psychoanalysis, and the universal 
dimension, represented by the perspective of social rehabilitation and consequently, harm 
reduction, is not consensual. 
In this respect, Dufour (2004) presents a more critical position regarding the social emphasis 
given by some mental health policies, and advocates that “it is not about encouraging 
carelessness – as one is soon blamed when one shows the slightest reservation about the 
humanitarian conduct – but observing the effects, opposed to the desired ones, caused by 
the coercive kindness” (p.37). Therefore, the author indicates the existence of a certain 
amount of coercion in the psychosocial rehabilitation practices in mental health, and makes 
sure to explicitly include the harm reduction proposal under this view. 
When referring to the movement that he coined as “to limit the damage” or “reduce the 
harm”, Dufour (2004) states that: 
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the surprising fact in this type of proposal is that it does not take into consideration the opinion of the 
ones involved. It searches for their happiness and health, regardless of them. Some rebel against it. For 
example, a patient who lived with an HIV-positive woman used to say about precautions: ‘you know, 
for me, making plastified love is not my business’ (p.37). 
It is important to pinpoint that, as previously mentioned, because it is a public health 
strategy, harm reduction is inserted in the psychosocial rehabilitation logic. Then, the harm 
reduction objectives are to reduce the damage caused by the use of psychoactive substances, 
and promote the bio-psychosocial well being of the health service users, having for main 
focus of attention the citizen of universal rights. Therefore, harm reduction aims to provide 
a treatment for everyone, and is thus based on the principle of equal rights and connected to 
the universal dimension. This universalizing perspective in public health and in harm 
reduction may bring a number of complicating factors in regard to the possibility of 
approximation with psychoanalysis, which points to the singularity of each subject’s 
treatment. 
Henceforth, although psychoanalysis and harm reduction may initially come close, because 
they both oppose the abstinence model, the possibilities of convergence between these two 
fields need to be more deeply investigated. Whereas psychoanalysis adopts an ethic that 
foregrounds the subjective position and the modality of jouissance achieved by the 
intoxication practices, the harm reduction approach, being a public health strategy, 
advocates in its principles the bio-psychosocial well being of the health service users. 
7. Final considerations 
In the mental health field, it is possible to outline the existence of at least three prevalent 
models: the exclusively biomedical or pharmacological, the exclusively sociological and the 
subjective (Rigter at al, 2004; Kyrillos Neto, 2007). The exclusively organicist model has as its 
object the mental disorders, taken as a “biologizing degradation of nosology”, that ignores 
the subjective, political and social aspects of the psychic suffering, and has the purpose of 
treating them exclusively through the psychopharmaceutical sovereignty. In the specific 
context of alcohol and drug abuse, it would be possible to state that this model guides its 
treatments by abstinence, insofar as they do not consider the subjective and social issues that 
the use of psychoactive substances imply, and seem to give importance only to the 
neurochemical effects caused by toxic drugs. 
On the other hand, the exclusively sociological model takes as its object the man in his 
suffering existence, and is guided by the notion of individual originated from the liberal 
ideology and the human rights advocated by the constitution of the democratic regime. This 
model draws attention to the need for development and empowerment of individuals and 
communities so that, thereafter, they become able to have democratic participation in the 
actions devised to protect and promote their own health (Duggan, Cooper & Foster, 2002). It 
is possible to approximate this sociological model to some proposals derived from the 
psychosocial rehabilitation perspective, insofar as these place the emphasis on the citizen of 
universal rights and on the socio-political dimension. Thus, in the realm of the treatments 
offered to drug users, we can assume that this exclusively sociological model would be 
represented by the harm reduction approach.  
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foregrounds the subjective position and the modality of jouissance achieved by the 
intoxication practices, the harm reduction approach, being a public health strategy, 
advocates in its principles the bio-psychosocial well being of the health service users. 
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object the mental disorders, taken as a “biologizing degradation of nosology”, that ignores 
the subjective, political and social aspects of the psychic suffering, and has the purpose of 
treating them exclusively through the psychopharmaceutical sovereignty. In the specific 
context of alcohol and drug abuse, it would be possible to state that this model guides its 
treatments by abstinence, insofar as they do not consider the subjective and social issues that 
the use of psychoactive substances imply, and seem to give importance only to the 
neurochemical effects caused by toxic drugs. 
On the other hand, the exclusively sociological model takes as its object the man in his 
suffering existence, and is guided by the notion of individual originated from the liberal 
ideology and the human rights advocated by the constitution of the democratic regime. This 
model draws attention to the need for development and empowerment of individuals and 
communities so that, thereafter, they become able to have democratic participation in the 
actions devised to protect and promote their own health (Duggan, Cooper & Foster, 2002). It 
is possible to approximate this sociological model to some proposals derived from the 
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Finally, the subjective model has as its object the “subject of desire”, defined by Lacan 
(1969/1992) as constituted from its position before the Other. Among the existing proposals 
for the treatment of drug abuse, this subjective model is almost exclusively represented by 
psychoanalysis.  
According to Kyrillos Neto (2007), it is noticeable that, unfortunately, these three models are 
considered mutually exclusive in most health mental services. However, it is important to 
highlight that overcoming the impasses that arise daily in these services depends on an 
approach that does not rely only on the exclusive considerations of the social determinations 
nor on a purely clinical focus, but rather on the articulation of these important factors. 
Consequently, it is necessary that the harm reduction strategies, when proposed as a mental 
health policy, be able to reach these multiple sides that outline the complexity of the 
phenomenon of drug abuse and addiction. In this respect, psychoanalysis has great 
contributions to offer, since the psychoanalytical treatment aims at promoting the 
articulation between the universal aspect of the structure and the singular nature of the 
psychic reality of each individual, allowing the treatment of the universal (the structure) 
through the singular (the subject).  
Hence, despite the recognized need for more research in the field of treatments offered to 
drug users, it is important to ponder that any proposed treatment cannot leave out the 
consideration for the psychic aspects involved in the phenomenon of drug addiction (OEDT, 
2011). This is why current reports have demanded more studies analyzing the effects 
generated by the several types of existing psychological interventions, considering that, 
until now, the collected data are not sufficient to show evidence of the compared efficacy of 
each intervention. However, many studies suggest that such interventions are fundamental 
to act upon both the causes and the psychological consequences associated to drug use, 
especially when combined with other treatments, such as, for instance, the substitution 
treatments (CIAR, 2008; Marlatt; Larimer & Witkiewitz, 2012). And it is precisely in this 
context that psychoanalysis becomes a treatment proposal that, for placing the subject as the 
focus of any therapeutic action, presents itself as extremely promising. 
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“A living system, due to its circular organization, is an inductive system and functions 
always in a predictive manner; what occurred once will occur again. Its organization (both 
genetic and otherwise) is conservative and repeats only that which works.” 
Humberto Maturana 
1. Introduction 
Over the last few years cocaine use has spread considerably to all social levels. According to 
statistical data currently available, cocaine is the psychoactive substance most frequently 
used in Europe, after cannabis (European Monitoring Centre for Drugs and Drug Addiction 
[EMDDA], 2011). Italy is one of the European countries where such consumption is more 
frequent: about 7% of the population report to have used cocaine at least once in their 
lifetime (Presidenza del Consiglio dei Ministri, 2007). 
Cocaine is an alkaloid substance obtained from coca leaves, which acts on the central 
nervous system, especially on the dopamine system, compromising its functions. Cocaine 
use contributes to increased concentration of dopamine, a neurotransmitter that is present in 
different brain areas that governs cognition, emotional processes, motivation and associative 
processes related to feelings of pleasure. Normally, this neurotransmitter is released by 
neurons in response to a salient, pleasant stimuli, and then it is absorbed by the same cells 
that have produced it. Cocaine acts on these cells by blocking the recovery of dopamine, 
resulting in an accumulation of the neurotransmitter between synapses.  
Repeated cocaine use damages the normal communication between neurons, leading to 
alterations in brain circuits for pleasure that is thought to contribute to the development of 
dependence. In addition, the brain needs progressively higher doses of the psychoactive 
substance to achieve the same effects and it needs increasing use in order to achieve the same 
levels of pleasure originally experienced (National Institute on Drug Abuse [NIDA], 2008). 
The psychological effects of cocaine depend both on the amount consumed and on the route 
and modality of administration (Braglia et al., 2004): these effects consist mainly of 
sensations of euphoria, increased libido, reduction of hunger and thirst, and in the 
impression of increased perceptual abilities, but they may also generate panic attacks, mood 
disorders, paranoid ideation and induction of psychotic states with auditory, visual and 
tactile hallucinations (Braglia et al., 2004). Among the various routes of administration, the 
intravenous injection and the cocaine smoke are those causing a more rapid and intense 
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action, while sniffing cocaine determines longer lasting effects, up to 30 minutes versus the 
10 minutes of the smoke (NIDA, 2008). 
Based on currently available data, cocaine addiction is a complex phenomenon in which 
various factors interact; there are those that are dependent on the central nervous system 
and therefore biological and those that are related to a certain lifestyle that from the point of 
view of the cocaine addict would encourage new opportunities for social meetings, sexual 
gratification and friendship (Rigliano, 2004). 
2. Main therapeutic intervention protocols 
Despite the considerable and ever increasing spread of cocaine, therapeutic intervention 
protocols that exist today in Europe are unfortunately still being tested and often result from 
treatment of other forms of addiction, such as heroin (EMCDDA, 2007a).  
The pharmacological approach intervenes with the neurobiological systems involved in 
reinforcement and the long-term effects of drugs, thereby reducing the symptoms of 
abstinence. Most recently, some vaccines have also been developed based on the principle of 
using the properties of the immune system to counteract cocaine effects, preventing it from 
reaching the brain (Pirona & Hendrich, 2009). 
The pharmacological approach, although representing a significant step forward in the care 
and treatment of cocaine dependence, has not proven sufficient to effectively treat cocaine 
addiction. The reason for this is that cocaine addicts continue to remember the pleasurable 
effects and states of arousal produced by the substance, and the attempt to reduce any pre-
existing states of discomfort through the use of the psychoactive substance. Therefore, it is 
essential to integrate the pharmacological approach into a psychosocial and psychological 
treatment. 
Among the various psychological orientations that have been proposed, those which have 
demonstrated a good level of effectiveness are as follows: 
2.1 Cognitive Behavioural Therapy 
Cognitive Behavioural Therapy (CBT) (Carroll, 1998) that treats cocaine addiction as a 
problematic behaviour depending on cognitive and environmental factors. Treatment is 
usually delivered on an outpatient basis and it lasts from 12 to 16 sessions, usually over 12 
weeks. An individual format is preferred, because it makes possible to fit the treatment to 
the needs of each patient. 
According to CBT, the learning processes are important factors for the development and the 
maintenance of cocaine use, but the same processes may be useful for helping the patient 
stop his drug use. So, CBT tries to assist the patient to recognize the situations in which he 
most probably takes cocaine, to avoid these circumstances if it is possible and to manage the 
difficulties and the problematic behaviours related to the cocaine use. CBT has two 
important components: 
• functional analysis, that is, the identification of the patient’s thoughts, feelings and 
circumstances before and after cocaine use. The functional analysis is helpful to assess 
the factors, or high-risk situations, that are likely to lead to cocaine consumption and it 
can gives insights into some of the causes of this use; 
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• skills training, aimed at unlearning the patient’s habits associated with cocaine use and 
learning healthier skills and habits. At the beginning the skill training focuses on the 
practical and mental abilities which are useful to stop cocaine use. Then, the training is 
extended to other possible problems with which the patient may have difficulty facing 
(Carroll, 1998). 
So, CBT encourages subjects to assume alternative behaviours than those associated with 
substance use (EMCDDA, 2007a). 
2.2 Contingency Management Therapy 
Contingency Management Therapy (Petry, 2002), based upon the principles of behaviour 
modification. This consists of providing positive reinforcement (in the form of clinic 
privileges, vouchers or payment) when the patient achieves given behaviours or treatment 
goals. In particular, for cocaine users this reinforcement is related to the urine tests carried 
out periodically (Higgins et al., 2000). 
This therapy has four main values: 
• defining a target behaviour, that is, what outcome the patient has to achieve. For example, 
drug abstinence and undertaking clinic and social activities related to a drug-free lifestyle; 
• regular monitoring of target behaviour that has to be unequivocally assessed (for example, 
regular urine analysis would be undertaken to verify the patient’s abstinence); 
• reward contingent on achievement of target behaviour: at pre-established levels and 
frequencies, rewards are given to or retained by the patient depending on whether or 
not the target behaviours are achieved; 
• reinforcement by brief counselling to reinforce the positive effects of the rewards 
(Weaver et al., 2007). 
2.3 The Motivational Interview 
The Motivational Interview (MI) (Miller & Rollnick, 2002) approach is a client-centred, directive 
method aimed at understanding the motives the patients have for addressing their substance 
use problems, to gather the clinical information needed to plan their care and to build  
and reinforce their readiness for change. The MI approach consists of short-term intervention  
to help the person in the changing process towards a healthier lifestyle through the resolution  
of ambivalence, that is, the tendency to provide opposite emotional responses to cocaine. 
According to the MI, the patient can be in one of the following four stages of change: 
• pre-contemplation stage, in which the patient does not want to change his behaviour; 
• contemplation stage, when the patient would like to change, but he does not know how to 
do it; 
• preparation stage, in which the person shows explicitly the intention to change; 
• action stage, in which the patient realizes practical changes to feel better (Di Clemente & 
Velasquez, 2002). 
2.4 Modified Dynamic Group Therapy 
Modified Dynamic Group Therapy (MDGT) (Khantzian et al., 1990) aims to solve the 
problems of low self-esteem that lead the subjects to consume the substance. According to 
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this theory, low self-esteem produces a “psychological vulnerability” which can predispose 
a person to drug use and decrease impulse control. The purpose of MDGT consists of 
helping patients become aware of their psychological vulnerability. This approach has four 
main therapeutic focuses: 
• developing a better affective tolerance; 
• improving self-esteem; 
• improve interpersonal relationships; 
• development of appropriate strategies of “self-care”. 
MDGT lasts about 6 months and has 3 main stages: 
• during the first stage therapy consists of encouraging patients to address their 
vulnerability through better confidence resulting from the support of other members of 
the therapy and mutual listening; 
• in the middle stage the attention is on members’ attachment to the group, taken as a 
whole; 
• in the last stage the older members take on the role of “co-therapists” and explain 
aspects of MDGT to new members. 
So, the MDGT intervenes not only on drug use, but also in the self and on the relationship 
between some personality aspects and problems that can lead to relapse (Khantzian et al., 
1990). 
3. The interactional approach 
The Interactional Approach (IA) is a type of psychological intervention that includes specific 
therapeutic techniques and procedures for the treatment of cocaine addiction. 
Attempting to solve the problem of cocaine addiction, our research group has developed a 
short-term psychotherapeutic model, directed to increase the patient’s interpersonal and 
communicative skills, to improve emotional control and the use of meta-cognitive resources, 
to adopt a healthy lifestyle, leading eventually to reduced risk of relapse. The proposed 
outpatient treatment has led to good results both in terms of effectiveness and efficiency 
(Leonardi et al., 2006, 2009; Leonardi & Velicogna, 2009). 
At the basis of the psychological intervention there are studies on the processes of 
persuasive communication (Erickson et al., 1976; Erickson & Rossi, 1981), as well as 
theoretical models derived from constructivism (von Foerster, 1982; von Glasersfeld, 1984), 
the interactional approach (Jackson, 1961, 1965; Fisch et al., 1982; Watzlawick et al. 1967, 
1974, 1984, 1997) and those derived from action research (Lewin, 1946). 
Constructivism is a theoretical approach that challenges the idea that knowledge can be 
“objective”, arguing that each man builds his own reality through cognition, sensory 
perception and communication processes. What the person sees and knows is a construction 
based on his own experiences. Therefore, from a psychological point of view it becomes 
essential to try to understand the meaning that individuals attribute to their experiences, 
how they organize their knowledge and the expectations they have about what will happen 
to them. Other authors who have contributed to develop this approach were Maturana and 
Varela (1980), who studied the way in which living systems are regulated and organized in 
their environment. 
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The interactional model is applied to relational aspects and it is based on the concept that 
psychological disorders depend on the interaction between the subject and his own perception 
of reality: the aim of the therapy is to facilitate the change through appropriate strategies, so 
that individuals can look at their problems in a different way and take the best solutions.  
It often happens that just the attempted solutions1, implemented by the person, contribute to 
complicate the problem inadvertently, while with appropriate strategies it becomes possible 
to change the patient’s perceptive-reactive system, as well as his perspectives which are too 
rigid. The perceptive-reactive system is defined as the way a person constructs the three 
fundamental relationships: with himself, the others and the world. Thus, by intervening it is 
possible to change the processes of attribution of meaning to things over the perception of 
the problem (Nardone & Watzlawick, 1990). 
In accordance with Franz Alexander (Alexander & French, 1946), the change is due to the 
corrective emotional experience that helps to modify initially set perceptions and in doing so 
engaging a virtuous process of learning new skills and competencies in the social sphere. 
Therefore, the scope of the interactional and constructivist therapy is to get the patient to change 
his perceptive-reactive system, through the experimentation with new and different strategies. 
With regard to the interactional aspects, injunctive and evocative language is also really 
important: its aim is not to describe the surrounding reality, but to prescribe certain 
behaviours within a therapeutic relationship full of suggestion. Such injunctions can be very 
useful to interrupt the patient’s dysfunctional patterns. The injunctive and evocative language 
is used to persuade the other to engage in specific tasks. Through the execution of such tasks 
the patient may perceive reality in a different way (Watzlawick, 1978). 
Finally, our methodology of psychological treatment takes into consideration some aspects 
such as the neurological functional difference between the two hemispheres of the human 
brain. The left hemisphere uses a logical-analytical coding system and it specializes in the 
perception and in language, while the right one is involved in non-linguistic tasks such as 
recognition of their own and others‘ emotions or in activities that involve analogical 
processing such as the perception of images, configurations and contexts in their overview 
(Gazzaniga, 1972). The study of different functional specializations has been possible thanks 
to research on patients suffering from epilepsy and who had the corpus callosum surgically 
sectioned, a brain structure that represents the most important area linking the two 
hemispheres. Those studies revealed that the two hemispheres work in close synergy with 
each other, although responding to specific stimuli to their functional area, and that they are 
also highly integrated and complementary (Sperry, 1968).  
According to Watzlawick (1978), a specific language is able to communicate and influence 
each of the two hemispheres, in order to activate one at the expense of the other: for 
example, evocative language and hypnosis without trance2 (Erickson et al., 1976) are 
communicative modalities that can influence the right hemisphere. The purpose of these 
                                                                 
1 The attempted solutions are actions that a person does to try to solve his problem. If they do not lead to 
the resolution of the problem and if repeated, these solutions further complicate the situation 
preventing the change (Watzlawick et al., 1974). From the perspective of the therapist, the attempted 
solutions function as reducing complexity in the assessment of the clinical case examined.  
2 Without using formal hypnosis, Milton Erickson (Erickson et al., 1976) states that it is possible to 
realize a communicative exchange characterized by persuasion, control of attention and suggestion, 
which is able to bypass resistance to change. 
 
Addictions – From Pathophysiology to Treatment 406 
this theory, low self-esteem produces a “psychological vulnerability” which can predispose 
a person to drug use and decrease impulse control. The purpose of MDGT consists of 
helping patients become aware of their psychological vulnerability. This approach has four 
main therapeutic focuses: 
• developing a better affective tolerance; 
• improving self-esteem; 
• improve interpersonal relationships; 
• development of appropriate strategies of “self-care”. 
MDGT lasts about 6 months and has 3 main stages: 
• during the first stage therapy consists of encouraging patients to address their 
vulnerability through better confidence resulting from the support of other members of 
the therapy and mutual listening; 
• in the middle stage the attention is on members’ attachment to the group, taken as a 
whole; 
• in the last stage the older members take on the role of “co-therapists” and explain 
aspects of MDGT to new members. 
So, the MDGT intervenes not only on drug use, but also in the self and on the relationship 
between some personality aspects and problems that can lead to relapse (Khantzian et al., 
1990). 
3. The interactional approach 
The Interactional Approach (IA) is a type of psychological intervention that includes specific 
therapeutic techniques and procedures for the treatment of cocaine addiction. 
Attempting to solve the problem of cocaine addiction, our research group has developed a 
short-term psychotherapeutic model, directed to increase the patient’s interpersonal and 
communicative skills, to improve emotional control and the use of meta-cognitive resources, 
to adopt a healthy lifestyle, leading eventually to reduced risk of relapse. The proposed 
outpatient treatment has led to good results both in terms of effectiveness and efficiency 
(Leonardi et al., 2006, 2009; Leonardi & Velicogna, 2009). 
At the basis of the psychological intervention there are studies on the processes of 
persuasive communication (Erickson et al., 1976; Erickson & Rossi, 1981), as well as 
theoretical models derived from constructivism (von Foerster, 1982; von Glasersfeld, 1984), 
the interactional approach (Jackson, 1961, 1965; Fisch et al., 1982; Watzlawick et al. 1967, 
1974, 1984, 1997) and those derived from action research (Lewin, 1946). 
Constructivism is a theoretical approach that challenges the idea that knowledge can be 
“objective”, arguing that each man builds his own reality through cognition, sensory 
perception and communication processes. What the person sees and knows is a construction 
based on his own experiences. Therefore, from a psychological point of view it becomes 
essential to try to understand the meaning that individuals attribute to their experiences, 
how they organize their knowledge and the expectations they have about what will happen 
to them. Other authors who have contributed to develop this approach were Maturana and 
Varela (1980), who studied the way in which living systems are regulated and organized in 
their environment. 
 
The Interactional Approach in the Treatment of Cocaine Addicts 407 
The interactional model is applied to relational aspects and it is based on the concept that 
psychological disorders depend on the interaction between the subject and his own perception 
of reality: the aim of the therapy is to facilitate the change through appropriate strategies, so 
that individuals can look at their problems in a different way and take the best solutions.  
It often happens that just the attempted solutions1, implemented by the person, contribute to 
complicate the problem inadvertently, while with appropriate strategies it becomes possible 
to change the patient’s perceptive-reactive system, as well as his perspectives which are too 
rigid. The perceptive-reactive system is defined as the way a person constructs the three 
fundamental relationships: with himself, the others and the world. Thus, by intervening it is 
possible to change the processes of attribution of meaning to things over the perception of 
the problem (Nardone & Watzlawick, 1990). 
In accordance with Franz Alexander (Alexander & French, 1946), the change is due to the 
corrective emotional experience that helps to modify initially set perceptions and in doing so 
engaging a virtuous process of learning new skills and competencies in the social sphere. 
Therefore, the scope of the interactional and constructivist therapy is to get the patient to change 
his perceptive-reactive system, through the experimentation with new and different strategies. 
With regard to the interactional aspects, injunctive and evocative language is also really 
important: its aim is not to describe the surrounding reality, but to prescribe certain 
behaviours within a therapeutic relationship full of suggestion. Such injunctions can be very 
useful to interrupt the patient’s dysfunctional patterns. The injunctive and evocative language 
is used to persuade the other to engage in specific tasks. Through the execution of such tasks 
the patient may perceive reality in a different way (Watzlawick, 1978). 
Finally, our methodology of psychological treatment takes into consideration some aspects 
such as the neurological functional difference between the two hemispheres of the human 
brain. The left hemisphere uses a logical-analytical coding system and it specializes in the 
perception and in language, while the right one is involved in non-linguistic tasks such as 
recognition of their own and others‘ emotions or in activities that involve analogical 
processing such as the perception of images, configurations and contexts in their overview 
(Gazzaniga, 1972). The study of different functional specializations has been possible thanks 
to research on patients suffering from epilepsy and who had the corpus callosum surgically 
sectioned, a brain structure that represents the most important area linking the two 
hemispheres. Those studies revealed that the two hemispheres work in close synergy with 
each other, although responding to specific stimuli to their functional area, and that they are 
also highly integrated and complementary (Sperry, 1968).  
According to Watzlawick (1978), a specific language is able to communicate and influence 
each of the two hemispheres, in order to activate one at the expense of the other: for 
example, evocative language and hypnosis without trance2 (Erickson et al., 1976) are 
communicative modalities that can influence the right hemisphere. The purpose of these 
                                                                 
1 The attempted solutions are actions that a person does to try to solve his problem. If they do not lead to 
the resolution of the problem and if repeated, these solutions further complicate the situation 
preventing the change (Watzlawick et al., 1974). From the perspective of the therapist, the attempted 
solutions function as reducing complexity in the assessment of the clinical case examined.  
2 Without using formal hypnosis, Milton Erickson (Erickson et al., 1976) states that it is possible to 
realize a communicative exchange characterized by persuasion, control of attention and suggestion, 
which is able to bypass resistance to change. 
 
Addictions – From Pathophysiology to Treatment 408 
communicative approaches consists of evoking certain images in the patient, as with the 
storytelling of metaphors, aphorisms and anecdotes. As a point of fact, these communicative 
modalities serve to bypass the normal resistance to change and provide easier access to 
unconscious psychological resources (Erickson et al., 1976). 
In the therapeutic relationship, the use of suggestion, as well as the evocation of images, 
allows patients to gradually change their behaviours. 
The experience “on their skin” of such behaviours allows the persons to realize that new ways 
of handling their problems are possible. The cognitive restructuring of these new experiences 
contributes to maintaining over time the modifications that have progressively occurred. 
4. The five phases of the interactional model for the treatment of cocaine 
addiction 
Our model is applied to both individual and group therapy. It can be divided into five 
phases of intervention that are interconnected with many levels of communication: each of 
these five phases is characterized by specific objectives and the achievement of each one 
allows access to the next level (Leonardi et al. 2006, 2009; Leonardi & Velicogna, 2009). 
4.1 Evaluation-intervention 
The purpose of the first phase is to collect useful information to explain how cocaine 
addiction has been established, to evaluate the level of motivation and to begin 
simultaneously the intervention aimed at changing. 
Unlike what happens with other therapeutic approaches, such as Cognitive Behavioural 
Therapy (CBT) (Carroll, 1998), which uses more linear intervention strategies, our model 
consists of a sequence of self-corrective operations aimed at progressively increasing the 
effectiveness of care, which is accompanied by a circular type system of interaction with the 
patient. This happens from the first stage, in which there is no distinction between diagnosis 
and intervention. This distinction characterizes the traditional approach to the problem of 
cocaine addiction, where the time of diagnosis is considered free from possible 
communication influences. 
During this initial phase, the therapist: 
• investigates and assesses the overall situation; 
• recalls situations associated with cocaine use; 
• plans the most effective communication strategies to change the way the patient relates 
to the substance. 
After collecting information on a person’s life, the therapist identifies those elements that 
may have influenced the development of cocaine dependence (anamnesis). In parallel, he 
also seeks to assess the patient’s level of motivation to change, which generally falls into one 
of the following categories: 
• the person is motivated to seek help; 
• the person is slightly motivated to seek help and forced into treatment by the family; 
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• the person is not motivated to change at all. 
The elements of this scheme are additional to the already described usual resistance to 
change of the dysfunctional systems (Haley, 1963; Nardone, & Watzlawick, 1990). 
The start time of problematic cocaine use and whether it coincided with a traumatic event 
should be assessed carefully (Leonardi & Velicogna, 2009). 
It often happens that people who have occasionally used cocaine for fun or curiosity, 
increase their use considerably as a result of difficult situations that need to be addressed 
(such as bereavements, emotional loss, work problems, etc.), until the onset of a real 
physical and psychological dependence. Therefore, the therapist has to not only take care of 
the drug addiction behaviour, but he must attend also to the potential event that made 
things worse. Finding the possible reason that has contributed to the subsequent loss of 
control by the cocaine addict allows him to address the “real” problem that caused the 
suffering that he has tried to quell using cocaine (Leonardi & Velicogna, 2009). 
Another important factor to take into consideration concerns modes of taking cocaine 
(which can be sniffed, smoked or injected into veins), because the therapeutic intervention 
must be calibrated depending on the method of intake of the substance. For example, in the 
case of cocaine injected into veins, in our experience we are often in the presence of a former 
heroin consumer that, maybe after years of abstinence, has decided to switch to cocaine and 
this must be taken into account in the psychological intervention. In the case of smoked and 
sniffed cocaine the sensory, perceptive and imagination techniques change, although the 
process of therapeutic intervention is similar. 
During this first phase (see Table 1), the therapist adopts a style of communication aimed at 
increasing the level of the patient’s motivation to overcome his natural resistance to change: 
through questions that explore the problem, we aim to change both the perceptions and 
reactions to the substance.  
 
First phase of treatment First level of therapeutic communication 
• History and evaluation of general areas 





• Persuasive communication 
• Hypnosis without trance 
Table 1. The evaluation-intervention. 
For example, if a patient has just conjured up feelings of isolation and loneliness in relation 
to cocaine use, the therapist could explain this perception by means of a metaphor, 
comparing the patient to a person who is locked in by himself inside a cold and dark cell. 
This image evokes a painful sensation, but, at the same time, it produces a very refined 
restructuring because if a person has been able to enclose himself within a cell, he is also 
able to open it and to get out. As stated above, according to constructivist theory, the person 
may know and interact with the world around him through his own actions. Thus, an 
“objective” knowledge of reality is not possible, it depends upon the observer’s point of 
view. But often the person is not aware of that building process. Rather, for that person 
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The purpose of the first phase is to collect useful information to explain how cocaine 
addiction has been established, to evaluate the level of motivation and to begin 
simultaneously the intervention aimed at changing. 
Unlike what happens with other therapeutic approaches, such as Cognitive Behavioural 
Therapy (CBT) (Carroll, 1998), which uses more linear intervention strategies, our model 
consists of a sequence of self-corrective operations aimed at progressively increasing the 
effectiveness of care, which is accompanied by a circular type system of interaction with the 
patient. This happens from the first stage, in which there is no distinction between diagnosis 
and intervention. This distinction characterizes the traditional approach to the problem of 
cocaine addiction, where the time of diagnosis is considered free from possible 
communication influences. 
During this initial phase, the therapist: 
• investigates and assesses the overall situation; 
• recalls situations associated with cocaine use; 
• plans the most effective communication strategies to change the way the patient relates 
to the substance. 
After collecting information on a person’s life, the therapist identifies those elements that 
may have influenced the development of cocaine dependence (anamnesis). In parallel, he 
also seeks to assess the patient’s level of motivation to change, which generally falls into one 
of the following categories: 
• the person is motivated to seek help; 
• the person is slightly motivated to seek help and forced into treatment by the family; 
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• the person is not motivated to change at all. 
The elements of this scheme are additional to the already described usual resistance to 
change of the dysfunctional systems (Haley, 1963; Nardone, & Watzlawick, 1990). 
The start time of problematic cocaine use and whether it coincided with a traumatic event 
should be assessed carefully (Leonardi & Velicogna, 2009). 
It often happens that people who have occasionally used cocaine for fun or curiosity, 
increase their use considerably as a result of difficult situations that need to be addressed 
(such as bereavements, emotional loss, work problems, etc.), until the onset of a real 
physical and psychological dependence. Therefore, the therapist has to not only take care of 
the drug addiction behaviour, but he must attend also to the potential event that made 
things worse. Finding the possible reason that has contributed to the subsequent loss of 
control by the cocaine addict allows him to address the “real” problem that caused the 
suffering that he has tried to quell using cocaine (Leonardi & Velicogna, 2009). 
Another important factor to take into consideration concerns modes of taking cocaine 
(which can be sniffed, smoked or injected into veins), because the therapeutic intervention 
must be calibrated depending on the method of intake of the substance. For example, in the 
case of cocaine injected into veins, in our experience we are often in the presence of a former 
heroin consumer that, maybe after years of abstinence, has decided to switch to cocaine and 
this must be taken into account in the psychological intervention. In the case of smoked and 
sniffed cocaine the sensory, perceptive and imagination techniques change, although the 
process of therapeutic intervention is similar. 
During this first phase (see Table 1), the therapist adopts a style of communication aimed at 
increasing the level of the patient’s motivation to overcome his natural resistance to change: 
through questions that explore the problem, we aim to change both the perceptions and 
reactions to the substance.  
 
First phase of treatment First level of therapeutic communication 
• History and evaluation of general areas 





• Persuasive communication 
• Hypnosis without trance 
Table 1. The evaluation-intervention. 
For example, if a patient has just conjured up feelings of isolation and loneliness in relation 
to cocaine use, the therapist could explain this perception by means of a metaphor, 
comparing the patient to a person who is locked in by himself inside a cold and dark cell. 
This image evokes a painful sensation, but, at the same time, it produces a very refined 
restructuring because if a person has been able to enclose himself within a cell, he is also 
able to open it and to get out. As stated above, according to constructivist theory, the person 
may know and interact with the world around him through his own actions. Thus, an 
“objective” knowledge of reality is not possible, it depends upon the observer’s point of 
view. But often the person is not aware of that building process. Rather, for that person 
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knowledge has the value of “objective” truth and strongly influences his thoughts and 
actions (Nardone & Watzlawick, 1990). 
On the one hand the interactional intervention works on the problem, on the other it has the 
aim of helping the patient to gradually build a different reality (De Shazer, 1985). 
4.1.1 First clinical interviews 
The first clinical interviews with cocaine users are crucial in order to explore the ways to 
develop the treatment. They serve to gather a preliminary knowledge of the individual and 
to lay the groundwork for increasing motivation to change: the patient describes in detail his 
problematic situation, which is compounded by drug-induced automatisms and 
compulsions. 
Generally, people who seek psychological help for a problem of abuse and cocaine addiction 
have three levels of complexity that prevent the change: 
• at the first level there is the inevitable resistance that occurs in this clinical setting, 
(Mascetti & Strepparola, 2006); 
• at the second level lie the neurobiological modifications induced by cocaine use that 
render the brain less susceptible to changes (Shaham & Hope, 2005a; Edwards & Koob, 
2010); 
• finally, at the third level there is a lack of motivation of those who have been forced by 
family to undergo treatment. 
Because of these difficulties, which are added to by the specific problems due to cocaine use, 
in this preliminary stage the use of the persuasive communication mode reaches noteworthy 
levels. In fact, by only “capturing” the attention of the patient it is possible to change his 
behaviour first and then, subsequently, also his perceptive-reactive system. 
At this stage, the first question should be: “What is the problem?”. According to our model, 
this simple question already contains an initial restructuring message, since the patient is 
not considered as a chronically ill patient, but he is treated as an individual who has a 
problem which can still be given a solution. 
This is also the time to try to understand how the perceptive-reactive system works in 
relation to the problem of drug addiction. On the basis of our clinical experience gained over 
the years, we have found that cocaine users usually act like sensation seekers (Zuckerman, 
1979), that is as people who actively and constantly seek strong pleasurable experiences. 
Often, the first cocaine consumption happens randomly in a fun and entertaining context, 
such as in a club with friends. After a number of takings, which may vary from individual to 
individual, there is the loss of control leading to the emergence of a vicious circle which 
tends only to worsen (Serpelloni & Bertoncelli, 2006; Pavarin & Dionigi, 2009). 
It is of the utmost importance to ask the patient to relive those first experiences of use: this 
re-enactment aims to make the patient conscious of the act of taking cocaine so that it ceases 
to be a mainly automatic process. 
Generally, at the first interview the individual states that, after an initial phase characterized 
by extremely pleasurable sensations, side and opposite effects occurred (paradox effect). At 
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this stage the therapist adopts a communication style characterized by suggestion and 
persuasion, emphasizing that cocaine has caused unpleasant effects which are opposite to 
those originally experienced and it is now those unpleasant effects that the patient wants to 
stop as soon as possible (Leonardi & Velicogna, 2009). To do that the therapist may use an 
analogy such as that of the cage, already mentioned above, to get the best view of the 
situation and to evoke the unpleasant feelings associated with cocaine use. The therapist 
ends the sentence with a post-hypnotic message: “The more you use it, the more you feel 
sick and the more you feel sick, the more you would like to free yourself of it.” 
The next step is to survey the attempted solutions that the patient uses to address cocaine 
addiction.  Generally, there are three: 
• appeal to the patient’s willpower to resist the temptation to give in to drug use; 
• avoid risk situations; 
• try to not think about the substance. 
In order to achieve the goal of getting out of vicious circles established by the failed attempts 
to solve problems, the questions asked by the therapist act as keys that unlock the ability to 
change. For example, at this stage a question feature is: “Now that you have decided to 
change your ways by coming here, what would you do to implement this?”. This question 
prompts the person to feel as if he is actually changing and he is trying hard to do it, thus 
creating a prophecy that has a sensible hope of self-fulfilment3. 
Another category of questions is the one that puts the illusion of creating alternatives 
between two opposing choices. An example of this sequence of funnel-shaped questions 
could be the following: “Do you take more cocaine when you are with other persons or 
when you are alone?” If the answer is “alone”, the therapist continues asking if this taking is 
usually done at home or outside. In this way we proceed with other questions of the same 
type, until the therapist summarizes all the collected information into a single sentence 
which aims to make the patient relive the intense feeling of loneliness that the drug causes 
every time, thus using the patient’s arguments. 
Change can be induced by other tools, such as metaphors, analogies and citations, because 
they have the advantage over the hedges of the analytical processes (Watzlawick, 1980), as 
well as having a strong educational and evocative component. 
Towards the end of the first session, the therapist applies a therapeutic double bind4 (Bateson 
et al., 1956), thus constraining the individual to be even more motivated to change. An 
example of a double bind is when the therapist at the end of the interview states that 
“usually the treatment works, but I don’t know if it is so in your case. We’ll see...”. If the 
patient wants treatment to work, here he must commit to belonging to that category of 
people for whom the treatment was successful. 
                                                                 
3 The self-fulfilling prophecy is a prediction that, because it has been formulated, sooner or later it will be 
fulfilled. People who are convinced that a certain event will happen in the future, in the short or 
medium-term, tend to alter their behaviour in a way that ends in causing the events that they had 
expected (Watlawick et al., 1967). 
4 The concept of the therapeutic double bind was formulated by Bateson to describe a contradiction at the 
level of communication, both verbal and non-verbal. 
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knowledge has the value of “objective” truth and strongly influences his thoughts and 
actions (Nardone & Watzlawick, 1990). 
On the one hand the interactional intervention works on the problem, on the other it has the 
aim of helping the patient to gradually build a different reality (De Shazer, 1985). 
4.1.1 First clinical interviews 
The first clinical interviews with cocaine users are crucial in order to explore the ways to 
develop the treatment. They serve to gather a preliminary knowledge of the individual and 
to lay the groundwork for increasing motivation to change: the patient describes in detail his 
problematic situation, which is compounded by drug-induced automatisms and 
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Generally, people who seek psychological help for a problem of abuse and cocaine addiction 
have three levels of complexity that prevent the change: 
• at the first level there is the inevitable resistance that occurs in this clinical setting, 
(Mascetti & Strepparola, 2006); 
• at the second level lie the neurobiological modifications induced by cocaine use that 
render the brain less susceptible to changes (Shaham & Hope, 2005a; Edwards & Koob, 
2010); 
• finally, at the third level there is a lack of motivation of those who have been forced by 
family to undergo treatment. 
Because of these difficulties, which are added to by the specific problems due to cocaine use, 
in this preliminary stage the use of the persuasive communication mode reaches noteworthy 
levels. In fact, by only “capturing” the attention of the patient it is possible to change his 
behaviour first and then, subsequently, also his perceptive-reactive system. 
At this stage, the first question should be: “What is the problem?”. According to our model, 
this simple question already contains an initial restructuring message, since the patient is 
not considered as a chronically ill patient, but he is treated as an individual who has a 
problem which can still be given a solution. 
This is also the time to try to understand how the perceptive-reactive system works in 
relation to the problem of drug addiction. On the basis of our clinical experience gained over 
the years, we have found that cocaine users usually act like sensation seekers (Zuckerman, 
1979), that is as people who actively and constantly seek strong pleasurable experiences. 
Often, the first cocaine consumption happens randomly in a fun and entertaining context, 
such as in a club with friends. After a number of takings, which may vary from individual to 
individual, there is the loss of control leading to the emergence of a vicious circle which 
tends only to worsen (Serpelloni & Bertoncelli, 2006; Pavarin & Dionigi, 2009). 
It is of the utmost importance to ask the patient to relive those first experiences of use: this 
re-enactment aims to make the patient conscious of the act of taking cocaine so that it ceases 
to be a mainly automatic process. 
Generally, at the first interview the individual states that, after an initial phase characterized 
by extremely pleasurable sensations, side and opposite effects occurred (paradox effect). At 
 
The Interactional Approach in the Treatment of Cocaine Addicts 411 
this stage the therapist adopts a communication style characterized by suggestion and 
persuasion, emphasizing that cocaine has caused unpleasant effects which are opposite to 
those originally experienced and it is now those unpleasant effects that the patient wants to 
stop as soon as possible (Leonardi & Velicogna, 2009). To do that the therapist may use an 
analogy such as that of the cage, already mentioned above, to get the best view of the 
situation and to evoke the unpleasant feelings associated with cocaine use. The therapist 
ends the sentence with a post-hypnotic message: “The more you use it, the more you feel 
sick and the more you feel sick, the more you would like to free yourself of it.” 
The next step is to survey the attempted solutions that the patient uses to address cocaine 
addiction.  Generally, there are three: 
• appeal to the patient’s willpower to resist the temptation to give in to drug use; 
• avoid risk situations; 
• try to not think about the substance. 
In order to achieve the goal of getting out of vicious circles established by the failed attempts 
to solve problems, the questions asked by the therapist act as keys that unlock the ability to 
change. For example, at this stage a question feature is: “Now that you have decided to 
change your ways by coming here, what would you do to implement this?”. This question 
prompts the person to feel as if he is actually changing and he is trying hard to do it, thus 
creating a prophecy that has a sensible hope of self-fulfilment3. 
Another category of questions is the one that puts the illusion of creating alternatives 
between two opposing choices. An example of this sequence of funnel-shaped questions 
could be the following: “Do you take more cocaine when you are with other persons or 
when you are alone?” If the answer is “alone”, the therapist continues asking if this taking is 
usually done at home or outside. In this way we proceed with other questions of the same 
type, until the therapist summarizes all the collected information into a single sentence 
which aims to make the patient relive the intense feeling of loneliness that the drug causes 
every time, thus using the patient’s arguments. 
Change can be induced by other tools, such as metaphors, analogies and citations, because 
they have the advantage over the hedges of the analytical processes (Watzlawick, 1980), as 
well as having a strong educational and evocative component. 
Towards the end of the first session, the therapist applies a therapeutic double bind4 (Bateson 
et al., 1956), thus constraining the individual to be even more motivated to change. An 
example of a double bind is when the therapist at the end of the interview states that 
“usually the treatment works, but I don’t know if it is so in your case. We’ll see...”. If the 
patient wants treatment to work, here he must commit to belonging to that category of 
people for whom the treatment was successful. 
                                                                 
3 The self-fulfilling prophecy is a prediction that, because it has been formulated, sooner or later it will be 
fulfilled. People who are convinced that a certain event will happen in the future, in the short or 
medium-term, tend to alter their behaviour in a way that ends in causing the events that they had 
expected (Watlawick et al., 1967). 
4 The concept of the therapeutic double bind was formulated by Bateson to describe a contradiction at the 
level of communication, both verbal and non-verbal. 
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Finally, we give the prescriptions5, which can be direct or indirect behavioural injunctions 
formulated by means of a strongly suggestive language, so that the patient performs the 
task assigned between sessions. The behavioural prescriptions are intended to unhinge the 
attempted solutions used until then. 
4.1.2 Psychological assessment 
Although the interactional model is not planned to frame people by the diagnosis, however, 
our team has used a series of psychological assessment instruments to obtain statistically 
valid measures for research purposes.  
The assessment procedure aims to evaluate personality elements and those related to self-
esteem, cognitive processes and social skills. Therefore, diagnostic tools used in the research 
project investigate the relationship between behaviour, personality factors and attitudes. 
The survey instruments are: 
• the Eysenck Personality Questionnaire Revised Short Form (EPQ-RS) (Eysenck et al., 
1985), which measures some personality traits like introversion and extroversion; 
• the Parental Bonding Instrument (PBI) (Parker et al., 1979), which provides a reliable 
and valid evaluation about the relationship with both parents, especially with regard to 
the level of care received and the feelings of security; 
• the Basic Self-Esteem Scale (SE-BASIC) (Forsman et al., 2003), which consists of a rating 
scale of self-esteem in adulthood, seen as a stable personality trait over time and whose 
score is independent of the skills and feedback received from others. 
• other indices of cognitive and behavioural assessment that have been extrapolated 
during the psychological observation of patients, with particular reference to verbal and 
non-verbal communication factors. 
4.2 Motivational intervention 
In the second phase we address the problem of dependence, encouraging the patient to 
speak freely about the difficulties encountered in the relational and family field, which may 
have favoured the use of cocaine. This work is important not only because it allows defining 
the possible critical areas for the person, but also because it helps to shift attention from the 
main problem, cocaine, and it helps to decrease obsessive ideation about the dependence on 
the substance. 
In fact, two seemingly contradictory phenomena can be detected in the problem of cocaine 
addiction: obsessive ideation about the substance and mental dissociation that occurs during 
the use. To counter these two aspects of the problem, patients should be stimulated in 
sensory, perceptual and cognitive awareness (Main, 1991; Bara et al., 2005; Leonardi & 
Velicogna, 2009; Belin et al., 2011) of the occurrence of the abuse of cocaine. 
                                                                 
5 Direct prescriptions are clear instructions to carry out specific actions. They are aimed at the resolution 
of the problem or at reaching one of a series of goals on the road to change. Indirect prescriptions are 
behavioural injunctions whose real objectives are hidden. The therapist prescribes an action that will 
produce a different result from the one that was seemingly being specified (Nardone  & Watzlawick, 
1990). 
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To effectively achieve the treatment objectives, it is necessary to establish a relationship with 
the patient geared to the understanding of the problem and to mutual cooperation. The 
therapist must try to convey the message to the patient that he is not judging him by the fact 
of being dependent on a substance. In addition, rather than commiserate or treat him as an 
incompetent, the therapist encourages the patient to take responsibility and develop better 
decision-making capacity. Depending on different situations, the relationship with the 
patient can take directive or non-directive aspects.  
At this stage (see Table 2), we use specific intervention techniques to re-enact sensations and 
perceptions induced by cocaine on the imaginative level, thus increasing the patient’s 
capacity to recall the context in which the drug abuse developed and to prevent a possible 
relapse.  
 
Second phase of treatment Second level of therapeutic communication 
• Further evaluation-intervention 
• Intervention on the use of cocaine 
• Therapeutic capture 
• Sensory and perceptual intervention 
Table 2. The motivational intervention. 
A special technique was developed called the transformational re-enactment technique  
(Leonardi & Velicogna, 2009). This re-enactment is much more intense than just simple 
memory recalling, because it becomes possible to highlight the unpleasant moments 
connected with the use of the substance. 
Here now we provide an example of a case study to explain how this technique is 
structured, based on our previous publication (Leonardi & Velicogna, 2009, p. 48): 
(…) Gaetano, 35 years, has had a problem of cocaine addiction for about five years. He is a 
building contractor by profession, married and childless. In the past, he had abused heroin 
from the age of fifteen, but he was able to solve this problem after a period of one year in a 
drug rehabilitation centre. Abstinent for a long time, then he begins to take cocaine 
underestimating the risks and he loses control very quickly. 
During the motivational phase, the therapist applies the transformational re-enactment 
technique, asking the patient to recall a typical situation of cocaine abuse. Despite 
encountering some difficulties in the initial stage, the patient gradually achieves very 
satisfactory results: in fact, Gaetano claims to perceive a certain aversion in reviewing that 
situation, underlining that he had never thought previously about the specific moment of 
cocaine use. 
Continuing with the treatment, the therapist puts a new element in, representative 
configuration of use, which takes advantage of the discomfort the patient feels in “seeing” 
himself during the action of using cocaine (principle of use, Erickson et al., 1976). In fact, the 
patient tries to live again the moments immediately preceding the situation of abuse, during 
cocaine use and then after, as if he was reviewing them in front of a mirror. The effect 
obtained is very strong, because it completely changes the perception that the person had so 
far: whereas before the use was associated only with pleasure, now painful and negative 
feelings appear. Taking advantage of the difficulty of see himself, the therapist assists in 
leading to a greater fear in the patient, through the dual action to see the scene and to be 
able to review his actions. 
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Finally, we give the prescriptions5, which can be direct or indirect behavioural injunctions 
formulated by means of a strongly suggestive language, so that the patient performs the 
task assigned between sessions. The behavioural prescriptions are intended to unhinge the 
attempted solutions used until then. 
4.1.2 Psychological assessment 
Although the interactional model is not planned to frame people by the diagnosis, however, 
our team has used a series of psychological assessment instruments to obtain statistically 
valid measures for research purposes.  
The assessment procedure aims to evaluate personality elements and those related to self-
esteem, cognitive processes and social skills. Therefore, diagnostic tools used in the research 
project investigate the relationship between behaviour, personality factors and attitudes. 
The survey instruments are: 
• the Eysenck Personality Questionnaire Revised Short Form (EPQ-RS) (Eysenck et al., 
1985), which measures some personality traits like introversion and extroversion; 
• the Parental Bonding Instrument (PBI) (Parker et al., 1979), which provides a reliable 
and valid evaluation about the relationship with both parents, especially with regard to 
the level of care received and the feelings of security; 
• the Basic Self-Esteem Scale (SE-BASIC) (Forsman et al., 2003), which consists of a rating 
scale of self-esteem in adulthood, seen as a stable personality trait over time and whose 
score is independent of the skills and feedback received from others. 
• other indices of cognitive and behavioural assessment that have been extrapolated 
during the psychological observation of patients, with particular reference to verbal and 
non-verbal communication factors. 
4.2 Motivational intervention 
In the second phase we address the problem of dependence, encouraging the patient to 
speak freely about the difficulties encountered in the relational and family field, which may 
have favoured the use of cocaine. This work is important not only because it allows defining 
the possible critical areas for the person, but also because it helps to shift attention from the 
main problem, cocaine, and it helps to decrease obsessive ideation about the dependence on 
the substance. 
In fact, two seemingly contradictory phenomena can be detected in the problem of cocaine 
addiction: obsessive ideation about the substance and mental dissociation that occurs during 
the use. To counter these two aspects of the problem, patients should be stimulated in 
sensory, perceptual and cognitive awareness (Main, 1991; Bara et al., 2005; Leonardi & 
Velicogna, 2009; Belin et al., 2011) of the occurrence of the abuse of cocaine. 
                                                                 
5 Direct prescriptions are clear instructions to carry out specific actions. They are aimed at the resolution 
of the problem or at reaching one of a series of goals on the road to change. Indirect prescriptions are 
behavioural injunctions whose real objectives are hidden. The therapist prescribes an action that will 
produce a different result from the one that was seemingly being specified (Nardone  & Watzlawick, 
1990). 
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To effectively achieve the treatment objectives, it is necessary to establish a relationship with 
the patient geared to the understanding of the problem and to mutual cooperation. The 
therapist must try to convey the message to the patient that he is not judging him by the fact 
of being dependent on a substance. In addition, rather than commiserate or treat him as an 
incompetent, the therapist encourages the patient to take responsibility and develop better 
decision-making capacity. Depending on different situations, the relationship with the 
patient can take directive or non-directive aspects.  
At this stage (see Table 2), we use specific intervention techniques to re-enact sensations and 
perceptions induced by cocaine on the imaginative level, thus increasing the patient’s 
capacity to recall the context in which the drug abuse developed and to prevent a possible 
relapse.  
 
Second phase of treatment Second level of therapeutic communication 
• Further evaluation-intervention 
• Intervention on the use of cocaine 
• Therapeutic capture 
• Sensory and perceptual intervention 
Table 2. The motivational intervention. 
A special technique was developed called the transformational re-enactment technique  
(Leonardi & Velicogna, 2009). This re-enactment is much more intense than just simple 
memory recalling, because it becomes possible to highlight the unpleasant moments 
connected with the use of the substance. 
Here now we provide an example of a case study to explain how this technique is 
structured, based on our previous publication (Leonardi & Velicogna, 2009, p. 48): 
(…) Gaetano, 35 years, has had a problem of cocaine addiction for about five years. He is a 
building contractor by profession, married and childless. In the past, he had abused heroin 
from the age of fifteen, but he was able to solve this problem after a period of one year in a 
drug rehabilitation centre. Abstinent for a long time, then he begins to take cocaine 
underestimating the risks and he loses control very quickly. 
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configuration of use, which takes advantage of the discomfort the patient feels in “seeing” 
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patient tries to live again the moments immediately preceding the situation of abuse, during 
cocaine use and then after, as if he was reviewing them in front of a mirror. The effect 
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able to review his actions. 
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The next step was to create an alternative sequence in which Gaetano was able to avoid the 
situation of abuse, reviewing with satisfaction: him reducing the use until complete 
cessation and then focusing his attention on relationship problems and the lack of self-
esteem that had led him to cocaine addiction. 
Using the transformational re-enactment technique, the therapist achieves three different 
objectives: 
• to avoid automatisms. This technique allows the patient to review, at sensory and 
perceptual level, three fundamental aspects of cocaine consumption: what happens 
before, during and after use. It has, also, the prescription of the symptom6 function, 
because it forces the patient to re-think in detail something that until now escaped 
control: the dependence; 
• to insert in the patient’s memory of cocaine use minimal elements with an aversive 
content against the substance. Thus, the patient lives painful and unpleasant sensations 
at perceptual level, every time he thinks about the substance; 
• the modification of the patient’s mental patterns into more adaptive ones, so that he can 
imagine himself doing affirmative actions for his mental and physical health. 
Patients treated with this technique have gradually reduced cocaine use, often eventually 
complete cessation of using the drug, so that in a short time they were able to focus on their 
relationship problems and lack of self-esteem (Leonardi & Velicogna, 2009). 
4.3 Development and consolidation. 
The third stage is used to consolidate the results achieved in the previous two phases, 
proceeding in this way to restructure the cognitive level, in terms of less rigid alternatives in 
the perception of the reality. 
In this phase, which may occur during group or in individual sessions, we try to ensure that 
the patient thinks of new skills acquired through the therapeutic treatment. The course 
within a group has some advantages in terms of learning, because the person interacts with 
other individuals who share similar problems. Many circular exchanges occur in a group 
and they can improve the patient’s capacity to communicate with himself, the others and the 
world. So, the thought moves from the main problem: cocaine. In this way the mobilization 
of meta-cognitive resources helps to control the impulsivity that is typical of drug addicts 
and has been shown to contribute to compulsivity (Belin et al., 2008; Dalley et al., 2011). The 
ability of meta-communication (Sluzki, 1966; Watzlawick et al., 1967; Bateson, 1972; Belin et 
al., 2011) about cocaine addiction also helps the individual to reflect on interactions with his 
social environment. 
The development and consolidation phase (see Table 3) serves also to decrease the risk of 
relapse that may occur after several months or even years after cessation of use. Indeed, the 
prolonged use of cocaine produces changes at the neurobiological level (Huang et al., 2009; 
Dobi et al., 2011, for review see Belin et al., 2009), which likely involves the formation of a 
                                                                 
6 The prescription of the symptom is a type of paradoxical prescription. The patient has to perform 
voluntarily actions that were previously involuntary and uncontrollable, and that he had always tried 
to avoid. The voluntary performance of the symptom eliminates it, as it is no longer spontaneous and 
uncontrollable (Nardone & Watzlawick, 1990). 
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long-term memory trace (Lee & Dong, 2011) about the pleasurable effects caused by cocaine, 
even after a single exposure (Ungless et al., 2001). Thus, working on meta-cognition it 
becomes possible to act on the mechanisms of impulsivity that may promote relapse in 
cocaine addiction. 
 
Third phase of treatment Third level of therapeutic communication 
• Therapy admission 
• The seven therapeutic topics 
• Increased collaboration 
• Decrease in the evocative language 
Table 3. Development and consolidation. 
4.3.1 The seven learning topics 
The intervention we propose acts on the specific problem of addiction and on the possible 
situations that led to its appearance. For this reason, we use seven learning topics that are 
connected to each other and relate to many psychological areas. Considering and 
confronting each other about these topics we invite the patients to act in a more constructive 
way (O’Connell & Palmer, 2003). 
4.3.1.1 Choosing a healthy lifestyle 
The difficulties that a person normally encounters in the management of his lifestyle can be 
exacerbated by cocaine addiction (Serpelloni & Bertoncelli, 2006). At this phase, the focus of 
the therapy is on the possible choices which the patient can make to improve his own life. 
The purpose of this topic is to increase the ability to organize and direct daily activities 
towards healthier life choices. Adherence to more balanced rules of life, such as living by 
time schedules, eating a healthy diet and doing sport, allows individuals to build a healthier 
lifestyle. 
4.3.1.2 Avoidance of relapses 
Through group discussion assisted by the facilitator, we focus on the reasons that led to the 
patient using cocaine in the past. These may be different, such as difficulties in managing 
specific emotional states, the problems related to significant emotional relationships or risk 
underestimation in certain circumstances. 
Awareness of the factors that can lead to relapse may be increased through reflection on the 
choices made, on automatic thoughts7 and on emotional experiences occurring in certain 
circumstances. In accordance with the principle of use, we try to exploit even possible 
relapses in a positive way: instead of judging them as failures, they are redefined as 
opportunities to move on with greater and renewed commitment. According to Milton 
Erickson (Erickson et al., 1976), the principle of use is based on identifying the patient’s 
available resources, on the understanding of his belief system, on connecting the resources 
to deal with the problem and on conveying confidence to the patient about the fact that the 
present problems will soon be overcome. 
                                                                 
7 Automatic thoughts are ideas and unexpected images that the patient has when their beliefs related to 
addiction are activated. These thoughts may act to trigger and increase drug withdrawal (Newman & 
Ratto, 1999). Through repeated observations, the patient is able to consider objectively their automatic 
thoughts and recognize their possible unreliable and non-adaptive features. Beck (1975) calls this 
process distancing.  
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4.3.1.3 Increasing social skills 
Cocaine tends to alter the state of consciousness, distorting the perception and, therefore, it 
worsens the person’s ability to significantly relate to others. The experience of being part of 
a group is a powerful tool by which he constructs a network of shared meanings with other 
members. The facilitator helps group members to focus on the present moment, inviting 
them to feel the emotions that they are experiencing during the dialogue with others. 
4.3.1.4 Development of communication and meta-communication skills 
The communication can never be separated from the interactional aspects: the person learns 
to communicate through the discussions that take place in the group, drawing on the 
resources of the verbal and non-verbal sphere. The development of communication skills 
helps to contrast feelings of isolation that often accompany the experience of cocaine 
addiction. 
4.3.1.5 Increasing meta-cognitive resources 
Meta-cognition is the ability to reflect on your thought processes, because it is assumed that 
an increase of this ability may encourage the person to make global changes in his lifestyle 
and in the management of feelings evoked by the use of cocaine. The group facilitator 
invites the members to meta-communicate and reflect on their and others’ thinking, in order 
to stimulate greater awareness in emotion management. 
4.3.1.6 A more balanced emotion management 
Group members are instructed to recognize their own emotions and those of others: in other 
words, everyone is invited to wonder what he feels and what the others feel. To do this, the 
group members are invited to observe their sensations here and now and to realize the 
emotions of others. The same process can be referred also to remember particular events, 
such as the cocaine use situation. Observation and acceptance of their emotional states play 
important roles in the recognition of unpleasant emotions associated with the use of the 
substance.  
4.3.1.7 Increasing problem solving skills 
Increasing the capacity to solve problems effectively is obtained by assigning to the group 
members problem solving exercises to stimulate learning more appropriate strategies. This 
capacity can also improve the perceived sense of self-efficacy and thus the level of self-
esteem of the person. 
The self-efficacy refers to all the beliefs the person has about their ability to organize and 
execute the necessary actions to achieve their goals (Bandura, 1997). 
4.4 Gradual release 
Once you have completed the phase of development and consolidation, the next step 
requires the patient to acquire greater autonomy and self-confidence. The therapeutic 
session takes place during this phase with a collaborative attitude, in order to monitor any 
signs which could have anticipated the risk of relapse in cocaine addiction. At this stage, the 
patient has gained a greater autonomy and confidence in his ability to continue alone down 
the road of change. In this regard, it is interesting to focus on the concept of deutero-
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learning, introduced by Bateson (1972), to indicate the learning level higher than that of the 
basic stimulus-response scheme: briefly, it describes the process by which an individual 
“learns to learn”. 
This step is essential to encourage the patient to develop a greater degree of autonomy (see 
Table 4), as well as a greater sense of security, such as he becomes able to deal with various 
difficult situations. 
 
Fourth phase of treatment Fourth level of therapeutic communication 
• Increasing autonomy 
• Increased complexity of the arguments 
of the group 
• Deutero-learning 
• Demonstration-rational language 
• Perceptual and sensory forms of 
intervention 
Table 4. Gradual release. 
During this phase, the therapist also aims to improve the quality of inner dialogue, for 
example, through a specific training technique called inner conversation (Leonardi & 
Velicogna, 2009), whereby the patient imagines himself thinking as speaking aloud, focusing 
so that his linguistic performance is as correct as possible. This exercise leads to a 
progressive increase in reflective ability (self-regulation of thought) with a corresponding 
decrease in impulsivity, which is one of the reasons of possible relapse in cocaine use, as 
demonstrated by preclinical studies (Economidou et al., 2009). 
4.5 Follow-up 
After treatment, the phase of periodic review of results begins and it is realized by 
monitoring urine tests and follow-up interviews. This is the time (see Table 5) to understand 
whether or not the therapy has reached its objectives: the patient should become more 
cooperative towards the therapist, as well as more inclined to discuss any other issues that 
have occurred in other areas of his life. 
In order to avoid possible relapses, at this stage the therapist also uses training techniques 
and imaginative simulation procedures, similar to the transformational re-enactment 
technique described above. 
 
Fifth phase of treatment Fifth level of therapeutic communication 
• Verification, development and 
consolidation of achievements 
• Increased collaboration 
• Collaborative language 
Table 5. Follow-up. 
5. Evaluation of the effectiveness and efficiency of treatment 
Cocaine addiction is a highly complex field of study, in which communicative, interpersonal 
and neurobiological processes act. In order to collect data about the effectiveness (that means 
to cease cocaine use) and efficiency (to reach this goal as soon as possible) of the interactional 
approach, our research group has used both quantitative tools, such as urinary tests, and 
qualitative tools, such as self-evaluation questionnaires completed by the patients directly. 
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Through these evaluations indexes, given before, during and after treatment, we think it is 
possible to obtain a reliable evaluation of the treatment outcome. 
Data collected are used: 
• to assess whether treatment produces concrete results and if it responds adequately to 
the initial expectations; 
• to identify which aspects of the treatment are valid and which ones are ineffective and, 
therefore, modifiable;  
• to improve further those treatment components that have shown to be effective. 
One of the rules of scientific method is to never be satisfied with the results achieved, 
because in another context or with other patients the same results achieved in the past may 
not be obtained. So we need a constant monitoring of these activities, in order to modify 
certain aspects of the psychological intervention, if necessary. 
In a previous article (Leonardi et al., 2006), we underlined the importance of this circular 
deepening principle which derives from Lewin’s Action Research model (1946). According to 
this model, the research and intervention phases are interconnected and constantly 
changing thanks to a feedback mechanism. After theoretically defining the working 
hypotheses, the real finding phase, during which data are collected, follows. Through the 
analysis of these data it becomes possible to effectively coordinate the intervention. The 
evaluation of achievements generates new working hypotheses, thus determining the 
beginning of a circular process whereby it becomes possible to make corrections and 
changes to the treatment itself. 
This cycle also allows us to adjust the treatment to very different realities compared to the 
initial sample which has been processed. As Trombetta and Rosiello (2000) claimed, the 
circularity of this process is characterized by a collection of new material to be analysed, 
which is then used in constructing and implementing new strategies and action plans. 
The principle of circularity just described is consistent with systemic theory (von 
Bertanlaffy, 1971), which underlines the importance of feedback mechanisms that act 
through the different phases: in our case, these feedback processes concern the continuous 
analysis of clinical individual and group interviews, as well as observation of results 
achieved (urinary tests, remission of symptoms and change in behavioural style). 
Over the years, this circular process has meant continuous improvements to the treatment 
protocol, thus increasing the final effectiveness. 
The research process can be divided into three macro areas: 
• observation of individual and group interviews; 
• quantitative and qualitative monitoring of the results obtained, and the administration 
of cognitive and personality tests; 
• theoretical study in the field of general psychology and drug addiction. 
The evaluation of therapeutic work mainly consists of studying the interviews or the group 
meetings carried out, with particular reference to the interactional aspects which occur 
between the therapist and the patient. 
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As noted elsewhere (Leonardi et al., 2006), monitoring of the clinical situation through 
periodic urine tests represents an element of fundamental importance and is the primary 
tool to verify the abstinence from cocaine and thus, indirectly, to obtain an objective 
evaluation index on the effectiveness of treatment. 
According to our intervention protocol, urine tests should be carried out twice a week 
during treatment. These data provide an objective parameter for achieving and maintaining 
abstinence from cocaine, and they are also used to detect the possible occurrence of relapses. 
The statistical analysis of urine test results also allows the detection of the presence of some 
critical periods during the course of treatment, when abstinence from the drug is relatively 
more likely to be established (see Leonardi et al., 2006, for more details). 
To monitor the validity of the therapy we also use some subjective evaluation indices that refer 
to how the patients views the therapeutic activity, the skills that they believe they have 
acquired during the treatment and the personal areas where they would require further 
therapeutic intervention. These evaluations are obtained through semi-structured 
interviews. 
Finally, the study of general psychology and drug addiction literature has allowed 
expanding the existing knowledge, implementing it with new ways to observe and act on 
the person. The updating of bibliographic material is designed to deepen knowledge about 
the neurological, cognitive and social aspects related to the phenomenon of cocaine 
addiction. 
6. Conclusions 
Solving the problem of cocaine addiction presents considerable difficulties because of 
frequent relapses in the use of the substance. For this reason, a gradual change of subjective 
models for the construction of reality should also be combined with the psychological 
change, which begins to develop from the first session. 
The interactional model has allowed us to reach good levels of effectiveness and efficiency 
of treatment. For example, as reported in Leonardi et al. (2006), in a group of 22 subjects 
who finished the treatment successfully, 73% resulted in abstinence from cocaine after 12 
weeks. A 12 week outpatient study of Carroll et al. (1991), comparing the effectiveness of 
CBT with Interpersonal Psychotherapy or IPT (Klerman et al., 1984), reported that in a 
group of 42 subjects, 57% of the patients assigned to CBT and 33% of those assigned to IPT 
attained three or more continuous weeks of abstinence. 
Our results (see Leonardi et al., 2009, for more details) were achieved by continuous 
research and correction of what was not fully satisfactory for the purpose of the therapy. On 
the basis of the results and data collected over time, we have developed a specific protocol 
for dealing with the problem of cocaine addiction, characterized by the following principle: 
try constantly to adapt the treatment to changes occurring during the therapeutic work. 
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To monitor the validity of the therapy we also use some subjective evaluation indices that refer 
to how the patients views the therapeutic activity, the skills that they believe they have 
acquired during the treatment and the personal areas where they would require further 
therapeutic intervention. These evaluations are obtained through semi-structured 
interviews. 
Finally, the study of general psychology and drug addiction literature has allowed 
expanding the existing knowledge, implementing it with new ways to observe and act on 
the person. The updating of bibliographic material is designed to deepen knowledge about 
the neurological, cognitive and social aspects related to the phenomenon of cocaine 
addiction. 
6. Conclusions 
Solving the problem of cocaine addiction presents considerable difficulties because of 
frequent relapses in the use of the substance. For this reason, a gradual change of subjective 
models for the construction of reality should also be combined with the psychological 
change, which begins to develop from the first session. 
The interactional model has allowed us to reach good levels of effectiveness and efficiency 
of treatment. For example, as reported in Leonardi et al. (2006), in a group of 22 subjects 
who finished the treatment successfully, 73% resulted in abstinence from cocaine after 12 
weeks. A 12 week outpatient study of Carroll et al. (1991), comparing the effectiveness of 
CBT with Interpersonal Psychotherapy or IPT (Klerman et al., 1984), reported that in a 
group of 42 subjects, 57% of the patients assigned to CBT and 33% of those assigned to IPT 
attained three or more continuous weeks of abstinence. 
Our results (see Leonardi et al., 2009, for more details) were achieved by continuous 
research and correction of what was not fully satisfactory for the purpose of the therapy. On 
the basis of the results and data collected over time, we have developed a specific protocol 
for dealing with the problem of cocaine addiction, characterized by the following principle: 
try constantly to adapt the treatment to changes occurring during the therapeutic work. 
7. References 
Alexander, F. & French, T.M. (1946). Psychoanalytic Therapy: Principles and Applications, 
Ronald Press Company, New York. 
 
Addictions – From Pathophysiology to Treatment 420 
Bandura, A. (1997). Self-Efficacy: the exercise of control, W.H. Freeman & Company, ISBN 
978-0716726265, New York. 
Bara, G.B., Colle, L., Bosco & F.M. (2005). Metacognizione: aspetti rilevanti per la clinica, In: 
Bara, B.G. (Ed.), Nuovo manuale di Psicoterapia Cognitiva, Vol. I, Bollati 
Boringhieri, ISBN 978-8833957685, Torino. 
Bateson, G. (1972). Steps to an Ecology of Mind: Collected Essays in Anthropology, 
Psychiatry, Evolution, and Epistemology, University Of Chicago Press, ISBN 
0226039056, Chicago. 
Bateson, G., Jackson, D.D., Haley, J. & Weakland, J. (1956). Toward a Theory of 
Schizophrenia, Behavioural Science, 1(4): 251-264.  
Belin, D., Daniel, M.L., Lacoste, J., Belin-Rauscent, A., Bacconnier, M. & Jaafari, N. (2011). 
Insight: perspectives étiologiques et phénoménologiques dans la psychopathologie 
des désordres obsessionnels compulsifs. Annales Médico-psychologiques, revue 
psychiatrique, 169(7): 420-425. 
Belin, D., Mar, A., Dalley, J., Robbins, T. & Everitt, B. (2008). High Impulsivity Predicts the 
Switch to Compulsive Cocaine-Taking. Science, 320(5881):1352–1355. 
Belin, D., Jonkman, S., Dickinson, A., Robbins, T.W. & Everitt, B.J. (2009). Parallel and 
interactive learning processes within the basal ganglia: Relevance for the 
understanding of addiction, Behavioural Brain Research, 199(1):89–102. 
Bertalanffy, Von, L. (1969). General System Theory. Foundations, development, applications, 
George Braziller, ISBN 978-0807604533, New York. 
Beck, A.T. (1975). Cognitive Therapy and the Emotional Disorders, International 
Universities Press, ISBN 978-0823609901, New York. 
Braglia, D., Gerra, G., Mezzelani, P., Quaglio, G., Timpano, M.E., Zaimovic, A. & Zambelli., 
U. (2004). Cocaina: Farmacocinetica, abuso, dipendenza, detossificazione e 
trattamento. In: Trattato completo degli abusi e delle dipendenze, Nizzoli, U. & 
Pissacroia, M. (Eds.), Piccin, ISBN 978-8829916481, Padova. 
Carroll, K.M., Rounsaville, B.J. & Gawin F.H. (1991). A comparative trial of psychotherapies 
for ambulatory cocaine abusers: relapse prevention and interpersonal 
psychotherapy, The American Journal of Drug and Alcohol Abuse, 17(3):229-247. 
Carroll, K.M. (1998). A Cognitive-Behavioural Approach: Treating cocaine addiction, NIH 
Publication 98-4308, National Institute on Drug Abuse, Rockville, Retrieved from  
 archives.drugabuse.gov/TXManuals/CBT/CBT1.htm 
Childress, A.R., Mozley, P.D., McElgin, W., Fitzgerald, J., Reivich, M. & O’Brien, C.P. (1999). 
Limbic activation during cue-induced cocaine craving, American Journal of 
Psychiatry, 156: 11-18. 
Dalley, J.W., Everitt, B.J., Robbins, T.W. (2011) Impulsivity, compulsivity, and top-down 
cognitive control, Neuron, 69(4):680–694. 
De Shazer, S. (1985), Keys to Solutions in Brief Therapy, W.W. Norton & Company, ISBN  
978-0393700046, New York. 
Di Clemente, C.C., & Velasquez, M. (2002). Motivational Interviewing and the Stages  
of Change, In: Miller, W.R. & Rollnick, S. (Eds.), Motivational Interviewing: 
Preparing People to Change, The Guilford Press, ISBN 978-1572305632, New  
York. 
 
The Interactional Approach in the Treatment of Cocaine Addicts 421 
Dobi, A., Seabold, G.K., Christensen, C.H., Bock, R. & Alvarez, V.A. (2011). Cocaine-induced 
plasticity in the nucleus accumbens is cell-specific and develops without prolonged 
withdrawal, The Journal of Neuroscience, 31(5): 1895–1904. 
Economidou, D., Pelloux, Y., Robbin, T.W., Dalley, J.W. & Everitt, B.J. (2009). High 
impulsivity predicts relapse to cocaine-seeking after punishment-induced 
abstinence, Biological Psychiatry, 65(10): 851-856. 
Edwards, S. & Koob, G.F. (2010). Neurobiology of dysregulated motivational systems in 
drug addiction, Future Neurology, 5(3): 393-401. 
Erickson, M.H. & Rossi, E. (1981). Experiencing Hypnosis. Therapeutic Approaches to 
Altered States, Irvington Publishers, ISBN 0829002464, New York.  
Erickson, M.H., Rossi E. & Rossi S. (1976), Hypnotic Realities: The Induction of Clinical 
Hypnosis and Forms of Indirect Suggestion, Irvington Publishers, ISBN 978-
0829001129, New York. 
European Monitoring Centre for Drugs and Drug Addiction, (2007a), EMCDDA Literature 
reviews - Treatment of problem cocaine use: a review of the literature, European 




European Monitoring Centre for Drugs and Drug Addiction, (2011), 2011 Annual report on 
the state of the drugs problem in Europe, European Monitoring Centre for Drugs 
and Drug Addiction, ISBN 978-9291684700, Lisbon, Retrieved from 
http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR
2011_EN.pdf 
Eysenck, S.B.G., Eysenck, H.J. & Paul Barrett, P. (1985) A revised version of the psychoticism 
scale, Personality and Individual Differences, 6(1):21-29. 
Forsman, L., Johnson, M., Ugolini, V., Bruzzi, D. & Raboni, D., (2003), Basic SE. Basic self-
esteem scale. Valutazione dell’autostima di base negli adulti, Edizioni Erickson.  
ISBN 978-8879465304, Trento. 
Fisch, R., Weakland, J. & Segal, L. (1982). The Tactics of Change. Doing Therapy Briefly, 
Jossey-Bass, ISBN 978-0875895215, San Francisco.  
Foerster, Von, H. (1982). Observing systems, Intersystems Publications, ISBN 978-
0914105190 Seaside.  
Gazzaniga, M.S. (1972). One brain - two minds?, American Scientist, 60(3): 311-317. 
Glasersfeld, Von, E. (1984). An Introduction to Radical Constructivism, In: The invented 
reality: How do we know what we believe we know? (Contributions to 
Constructivism), Watzlawick, P. (ed.), pp. 17-40, W.W. Norton & Company,  ISBN 
978-0393017311, New York. 
Haley, J. (1963). Strategies of psychotherapy, Grune & Stratton, ISBN 0808901680, New York. 
Higgins, S.T., Wong, C.J., Badger, G.J., Odgen, D.E. & Dantona, R.L. (2000).  
Contingent reinforcement increases cocaine abstinence during outpatient treatment 
and 1 year of follow-up, Journal of Consulting and Clinical Psychology, 68(1): 64-72. 
Huang, Y.H., Lin, Y., Mu, P., Lee B.R., Brown T.E., Wayman, G., Marie, H., Liu, W., Yan, Z.,  
Sorg, B.A., Schlüter, O.M., Zukin, R.S., & Dong, Y. (2009). In vivo cocaine 
experience generates silent synapses, Neuron, 63(1): 40–47. 
 
Addictions – From Pathophysiology to Treatment 420 
Bandura, A. (1997). Self-Efficacy: the exercise of control, W.H. Freeman & Company, ISBN 
978-0716726265, New York. 
Bara, G.B., Colle, L., Bosco & F.M. (2005). Metacognizione: aspetti rilevanti per la clinica, In: 
Bara, B.G. (Ed.), Nuovo manuale di Psicoterapia Cognitiva, Vol. I, Bollati 
Boringhieri, ISBN 978-8833957685, Torino. 
Bateson, G. (1972). Steps to an Ecology of Mind: Collected Essays in Anthropology, 
Psychiatry, Evolution, and Epistemology, University Of Chicago Press, ISBN 
0226039056, Chicago. 
Bateson, G., Jackson, D.D., Haley, J. & Weakland, J. (1956). Toward a Theory of 
Schizophrenia, Behavioural Science, 1(4): 251-264.  
Belin, D., Daniel, M.L., Lacoste, J., Belin-Rauscent, A., Bacconnier, M. & Jaafari, N. (2011). 
Insight: perspectives étiologiques et phénoménologiques dans la psychopathologie 
des désordres obsessionnels compulsifs. Annales Médico-psychologiques, revue 
psychiatrique, 169(7): 420-425. 
Belin, D., Mar, A., Dalley, J., Robbins, T. & Everitt, B. (2008). High Impulsivity Predicts the 
Switch to Compulsive Cocaine-Taking. Science, 320(5881):1352–1355. 
Belin, D., Jonkman, S., Dickinson, A., Robbins, T.W. & Everitt, B.J. (2009). Parallel and 
interactive learning processes within the basal ganglia: Relevance for the 
understanding of addiction, Behavioural Brain Research, 199(1):89–102. 
Bertalanffy, Von, L. (1969). General System Theory. Foundations, development, applications, 
George Braziller, ISBN 978-0807604533, New York. 
Beck, A.T. (1975). Cognitive Therapy and the Emotional Disorders, International 
Universities Press, ISBN 978-0823609901, New York. 
Braglia, D., Gerra, G., Mezzelani, P., Quaglio, G., Timpano, M.E., Zaimovic, A. & Zambelli., 
U. (2004). Cocaina: Farmacocinetica, abuso, dipendenza, detossificazione e 
trattamento. In: Trattato completo degli abusi e delle dipendenze, Nizzoli, U. & 
Pissacroia, M. (Eds.), Piccin, ISBN 978-8829916481, Padova. 
Carroll, K.M., Rounsaville, B.J. & Gawin F.H. (1991). A comparative trial of psychotherapies 
for ambulatory cocaine abusers: relapse prevention and interpersonal 
psychotherapy, The American Journal of Drug and Alcohol Abuse, 17(3):229-247. 
Carroll, K.M. (1998). A Cognitive-Behavioural Approach: Treating cocaine addiction, NIH 
Publication 98-4308, National Institute on Drug Abuse, Rockville, Retrieved from  
 archives.drugabuse.gov/TXManuals/CBT/CBT1.htm 
Childress, A.R., Mozley, P.D., McElgin, W., Fitzgerald, J., Reivich, M. & O’Brien, C.P. (1999). 
Limbic activation during cue-induced cocaine craving, American Journal of 
Psychiatry, 156: 11-18. 
Dalley, J.W., Everitt, B.J., Robbins, T.W. (2011) Impulsivity, compulsivity, and top-down 
cognitive control, Neuron, 69(4):680–694. 
De Shazer, S. (1985), Keys to Solutions in Brief Therapy, W.W. Norton & Company, ISBN  
978-0393700046, New York. 
Di Clemente, C.C., & Velasquez, M. (2002). Motivational Interviewing and the Stages  
of Change, In: Miller, W.R. & Rollnick, S. (Eds.), Motivational Interviewing: 
Preparing People to Change, The Guilford Press, ISBN 978-1572305632, New  
York. 
 
The Interactional Approach in the Treatment of Cocaine Addicts 421 
Dobi, A., Seabold, G.K., Christensen, C.H., Bock, R. & Alvarez, V.A. (2011). Cocaine-induced 
plasticity in the nucleus accumbens is cell-specific and develops without prolonged 
withdrawal, The Journal of Neuroscience, 31(5): 1895–1904. 
Economidou, D., Pelloux, Y., Robbin, T.W., Dalley, J.W. & Everitt, B.J. (2009). High 
impulsivity predicts relapse to cocaine-seeking after punishment-induced 
abstinence, Biological Psychiatry, 65(10): 851-856. 
Edwards, S. & Koob, G.F. (2010). Neurobiology of dysregulated motivational systems in 
drug addiction, Future Neurology, 5(3): 393-401. 
Erickson, M.H. & Rossi, E. (1981). Experiencing Hypnosis. Therapeutic Approaches to 
Altered States, Irvington Publishers, ISBN 0829002464, New York.  
Erickson, M.H., Rossi E. & Rossi S. (1976), Hypnotic Realities: The Induction of Clinical 
Hypnosis and Forms of Indirect Suggestion, Irvington Publishers, ISBN 978-
0829001129, New York. 
European Monitoring Centre for Drugs and Drug Addiction, (2007a), EMCDDA Literature 
reviews - Treatment of problem cocaine use: a review of the literature, European 




European Monitoring Centre for Drugs and Drug Addiction, (2011), 2011 Annual report on 
the state of the drugs problem in Europe, European Monitoring Centre for Drugs 
and Drug Addiction, ISBN 978-9291684700, Lisbon, Retrieved from 
http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR
2011_EN.pdf 
Eysenck, S.B.G., Eysenck, H.J. & Paul Barrett, P. (1985) A revised version of the psychoticism 
scale, Personality and Individual Differences, 6(1):21-29. 
Forsman, L., Johnson, M., Ugolini, V., Bruzzi, D. & Raboni, D., (2003), Basic SE. Basic self-
esteem scale. Valutazione dell’autostima di base negli adulti, Edizioni Erickson.  
ISBN 978-8879465304, Trento. 
Fisch, R., Weakland, J. & Segal, L. (1982). The Tactics of Change. Doing Therapy Briefly, 
Jossey-Bass, ISBN 978-0875895215, San Francisco.  
Foerster, Von, H. (1982). Observing systems, Intersystems Publications, ISBN 978-
0914105190 Seaside.  
Gazzaniga, M.S. (1972). One brain - two minds?, American Scientist, 60(3): 311-317. 
Glasersfeld, Von, E. (1984). An Introduction to Radical Constructivism, In: The invented 
reality: How do we know what we believe we know? (Contributions to 
Constructivism), Watzlawick, P. (ed.), pp. 17-40, W.W. Norton & Company,  ISBN 
978-0393017311, New York. 
Haley, J. (1963). Strategies of psychotherapy, Grune & Stratton, ISBN 0808901680, New York. 
Higgins, S.T., Wong, C.J., Badger, G.J., Odgen, D.E. & Dantona, R.L. (2000).  
Contingent reinforcement increases cocaine abstinence during outpatient treatment 
and 1 year of follow-up, Journal of Consulting and Clinical Psychology, 68(1): 64-72. 
Huang, Y.H., Lin, Y., Mu, P., Lee B.R., Brown T.E., Wayman, G., Marie, H., Liu, W., Yan, Z.,  
Sorg, B.A., Schlüter, O.M., Zukin, R.S., & Dong, Y. (2009). In vivo cocaine 
experience generates silent synapses, Neuron, 63(1): 40–47. 
 
Addictions – From Pathophysiology to Treatment 422 
Jackson, D. (1961). Interactional psychotherapy, In: Contemporary Psychotherapies, Stein, 
M. (Ed.), pp. 256-271, The Free Press of Glencoe, New York. 
Jackson, D. (1965). The study of the family, Family Process, 4(1): 1-20.  
Khantzian, E.J., Halliday, K.S. & McAuliffe, W.E. (1990). Addiction and the vulnerable self: 
Modified Dynamic Group Therapy for drug abusers, Guilford Press, ISBN 978-
0898621723, New York. 
Klerman, G.L., Weissman, M.M., Rounsaville, B.J., & Chevron, E.S. (1984). Interpersonal 
Therapy of Depression, Basic Books, New York. 
Lee, B.R. & Dong, Y. (2011). Cocaine-induced metaplasticity in the nucleus accumbens: silent 
synapse and beyond, Neuropharmacology, 61(7): 1060–1069. 
Leonardi, A., Fioravanti, P., Scavelli, S. & Velicogna, F. (2006). Programma Conoscenza: 
trattamento psicoeducativo integrato ed evoluto per problemi di cocaina. In: 
Cocaina. Manuale di aggiornamento tecnico scientifico, Serpelloni G., Macchia T., 
Gerra G. (Eds.), Progetto “START” del Dipartimento Nazionale per le Politiche 
Antidroga, ISBN 978-8895149004, Retrieved from  
 http://iport.dronet.org/com/filedownloadlink/allegatoA.php?key=116&lingua=1 
Leonardi, A., Fioravanti, P., Scavelli, S. & Velicogna, F. (2009). Programma Conoscenza. 
Psycho-educational, integrated and evolved treatment for cocaine addiction. 
International Journal of Mental Health and Addiction, 7(4):513–529. 
Leonardi, A. & Velicogna, F. (2009). Cocaina: dipendenza e trattamento. Un modello di 
intervento psicologico, Franco Angeli, ISBN 987-8856812848, Milano. 
Lewin, K. (1946), Action Research and minority problems, Journal of Social Issues, 2(4):34-46.   
Main, M. (1991). Metacognitive knowledge, metacognitive monitoring and singular 
(coherent) vs. multiple (incoherent) models of attachment: findings and directions 
for future research, In: Parkes, C., Stevenson-Hinde, C.M & Marris, P.  
(Eds.), Attachment across the life cycle, Tavistock & Routledge, ISBN 0415056519, 
London. 
Mascetti, W. & Strepparola, G. (2006). I disturbi da uso di sostanze, In: Bara, B.G. (Ed.), 
Nuovo manuale di Psicoterapia Cognitiva, Vol. III, Bollati Boringhieri, ISBN 978-
8833957708, Torino. 
Maturana, H.R. & Varela, F.J. (1980). Autopoiesis and Cognition: the realization of the living, 
D. Reidel Publishing Company, ISBN 978-9027710161, Boston. 
Miller, W.R. & Rollnick, S. (2002), Motivational Interview: Preparing people to change, 
Guilford Press, ISBN 978-1572305632, New York. 
Nardone, G. & Watzlawick, P. (1990). L’arte del cambiamento, Ponte alle Grazie, ISBN 978-
8879284653, Firenze. 
National Institute on Drug Abuse, (2008). Cocaine, NIDA InfoFacts, Retrieved from 
http://www.nida.nih.gov/pdf/infofacts/Cocaine08.pdf 
Newman, C.F. & Ratto, C.L. (1999). Cognitive therapy of substance abuse. In: Comparative 
treatments of substance abuse, Dowd, E.T., Rugle, L. (Eds.), Springer Publishing 
Company, ISBN 0826112765, New York. 
O’Connell, B. & Palmer, S. (2003). Handbook of Solution-Focused Therapy, Sage 
Publications, ISBN 978-0761967842, London. 
Parker, G., Tupling, H., & Brown, L.B. (1979). A Parental Bonding Instrument, British Journal 
of Medical Psychology,  52(1):1-10. 
 
The Interactional Approach in the Treatment of Cocaine Addicts 423 
Pavarin, R.M. & Dionigi, A., (Eds.), (2009). Cocaina. Percezione del danno, comportamenti a 
rischio e significati, CLUEB , ISBN 978-8849133325, Bologna. 
Petry, N.M. (2002). Contingency management in addiction treatment, Psychiatric Times, 
19(2): 52-56. 
Pirona, A. & Hedrich, D. (2009). Treatment of cocaine use – a short update, European 
Monitoring Centre for Drugs and Drug Addiction, Retrieved from 
 http://www.emcdda.europa.eu/attachements.cfm/att_76877_EN_EMCDDA-
cocaine%20treatment-update.pdf 
Presidenza del Consiglio dei Ministri (Eds.). (2007). Relazione sullo stato delle 
tossicodipendenze in Italia anno 2007, Retrieved from 
 http://www.governo.it/GovernoInforma/Dossier/relazione_droga_2007/Relazio
ne_2007.pdf 
Rigliano, P. (2004). Piaceri drogati. Psicologia del consumo di droghe, Feltrinelli, ISBN 978-
8807817908, Milano. 
Serpelloni, G. & Bertoncelli, S. (2006). Cocaina: profili dei soggetti in base alle modalità 
d’uso, agli aspetti comportamentali e sociali, In: Cocaina. Manuale di 
aggiornamento tecnico scientifico, Serpelloni G., Macchia T., Gerra G. (Eds.), pp. 
637-653, Progetto “START” del Dipartimento Nazionale per le Politiche Antidroga, 
ISBN 978-8895149004, Retrieved from 
 http://iport.dronet.org/com/filedownloadlink/allegatoA.php?key=141&lingua=1 
Shaham, Y. & Hope, B.T. (2005a). The role of neuroadaptations in relapse in drug seeking, 
Nature Neuroscience, 8(11): 1437-1439. 
Sluzki, C. (1966). Seminario sobre metacomunicacion: nota, Acta Psiquiatrica y Psicologica de 
América Latina, 12:119. 
Sperry, R.W. (1968). Hemisphere deconnection and unity in conscious awareness, American 
Psychologist, 23(10): 723-733. 
Ungless, M.A., Whistler, J.L., Malenka, R.C. & Bonci, A. (2001). Single cocaine exposure in 
vivo induces long-term potentiation in dopamine neurons, Nature, 411(6837): 583-
587. 
Watzlawick, P. (1978). The Language of  Change: elements of therapeutic communication, 
Basic Books, ISBN 978-0465037926, New York. 
Watlawick, P. (Ed.)(1984). The invented reality. How do we know what we believe we 
know? (Contributions to Constructivism), W. W. Norton & Company, ISBN 978-
0393017311, New York. 
Watzlawick, P., Beavin, J. & Jackson, D. (1967). Pragmatics of human communication. A 
study of interactional patterns, pathologies and paradoxes, W. W. Norton & 
Company, ISBN 978-0393010091, New York. 
Watlawick, P. & Nardone, G. (1997). Terapia Breve Strategica, Raffaello Cortina Editore, 
ISBN 978-8870784718, Milano. 
Watlawick, P., Weakland, J., & Fisch, J. (1974). Change. Principles of problem resolution. W. 
W. Norton & Company, ISBN 978-0393011043, New York. 
Weaver, T., Hart, J., Fehler, J., Metrebian, N., D’Agostino, T. & Benn, P. (2007), Are 
contingency management principles being implemented in drug treatment in 
England?, National Treatment Agency for Substance Misuse, Retrieved from  
 
Addictions – From Pathophysiology to Treatment 422 
Jackson, D. (1961). Interactional psychotherapy, In: Contemporary Psychotherapies, Stein, 
M. (Ed.), pp. 256-271, The Free Press of Glencoe, New York. 
Jackson, D. (1965). The study of the family, Family Process, 4(1): 1-20.  
Khantzian, E.J., Halliday, K.S. & McAuliffe, W.E. (1990). Addiction and the vulnerable self: 
Modified Dynamic Group Therapy for drug abusers, Guilford Press, ISBN 978-
0898621723, New York. 
Klerman, G.L., Weissman, M.M., Rounsaville, B.J., & Chevron, E.S. (1984). Interpersonal 
Therapy of Depression, Basic Books, New York. 
Lee, B.R. & Dong, Y. (2011). Cocaine-induced metaplasticity in the nucleus accumbens: silent 
synapse and beyond, Neuropharmacology, 61(7): 1060–1069. 
Leonardi, A., Fioravanti, P., Scavelli, S. & Velicogna, F. (2006). Programma Conoscenza: 
trattamento psicoeducativo integrato ed evoluto per problemi di cocaina. In: 
Cocaina. Manuale di aggiornamento tecnico scientifico, Serpelloni G., Macchia T., 
Gerra G. (Eds.), Progetto “START” del Dipartimento Nazionale per le Politiche 
Antidroga, ISBN 978-8895149004, Retrieved from  
 http://iport.dronet.org/com/filedownloadlink/allegatoA.php?key=116&lingua=1 
Leonardi, A., Fioravanti, P., Scavelli, S. & Velicogna, F. (2009). Programma Conoscenza. 
Psycho-educational, integrated and evolved treatment for cocaine addiction. 
International Journal of Mental Health and Addiction, 7(4):513–529. 
Leonardi, A. & Velicogna, F. (2009). Cocaina: dipendenza e trattamento. Un modello di 
intervento psicologico, Franco Angeli, ISBN 987-8856812848, Milano. 
Lewin, K. (1946), Action Research and minority problems, Journal of Social Issues, 2(4):34-46.   
Main, M. (1991). Metacognitive knowledge, metacognitive monitoring and singular 
(coherent) vs. multiple (incoherent) models of attachment: findings and directions 
for future research, In: Parkes, C., Stevenson-Hinde, C.M & Marris, P.  
(Eds.), Attachment across the life cycle, Tavistock & Routledge, ISBN 0415056519, 
London. 
Mascetti, W. & Strepparola, G. (2006). I disturbi da uso di sostanze, In: Bara, B.G. (Ed.), 
Nuovo manuale di Psicoterapia Cognitiva, Vol. III, Bollati Boringhieri, ISBN 978-
8833957708, Torino. 
Maturana, H.R. & Varela, F.J. (1980). Autopoiesis and Cognition: the realization of the living, 
D. Reidel Publishing Company, ISBN 978-9027710161, Boston. 
Miller, W.R. & Rollnick, S. (2002), Motivational Interview: Preparing people to change, 
Guilford Press, ISBN 978-1572305632, New York. 
Nardone, G. & Watzlawick, P. (1990). L’arte del cambiamento, Ponte alle Grazie, ISBN 978-
8879284653, Firenze. 
National Institute on Drug Abuse, (2008). Cocaine, NIDA InfoFacts, Retrieved from 
http://www.nida.nih.gov/pdf/infofacts/Cocaine08.pdf 
Newman, C.F. & Ratto, C.L. (1999). Cognitive therapy of substance abuse. In: Comparative 
treatments of substance abuse, Dowd, E.T., Rugle, L. (Eds.), Springer Publishing 
Company, ISBN 0826112765, New York. 
O’Connell, B. & Palmer, S. (2003). Handbook of Solution-Focused Therapy, Sage 
Publications, ISBN 978-0761967842, London. 
Parker, G., Tupling, H., & Brown, L.B. (1979). A Parental Bonding Instrument, British Journal 
of Medical Psychology,  52(1):1-10. 
 
The Interactional Approach in the Treatment of Cocaine Addicts 423 
Pavarin, R.M. & Dionigi, A., (Eds.), (2009). Cocaina. Percezione del danno, comportamenti a 
rischio e significati, CLUEB , ISBN 978-8849133325, Bologna. 
Petry, N.M. (2002). Contingency management in addiction treatment, Psychiatric Times, 
19(2): 52-56. 
Pirona, A. & Hedrich, D. (2009). Treatment of cocaine use – a short update, European 
Monitoring Centre for Drugs and Drug Addiction, Retrieved from 
 http://www.emcdda.europa.eu/attachements.cfm/att_76877_EN_EMCDDA-
cocaine%20treatment-update.pdf 
Presidenza del Consiglio dei Ministri (Eds.). (2007). Relazione sullo stato delle 
tossicodipendenze in Italia anno 2007, Retrieved from 
 http://www.governo.it/GovernoInforma/Dossier/relazione_droga_2007/Relazio
ne_2007.pdf 
Rigliano, P. (2004). Piaceri drogati. Psicologia del consumo di droghe, Feltrinelli, ISBN 978-
8807817908, Milano. 
Serpelloni, G. & Bertoncelli, S. (2006). Cocaina: profili dei soggetti in base alle modalità 
d’uso, agli aspetti comportamentali e sociali, In: Cocaina. Manuale di 
aggiornamento tecnico scientifico, Serpelloni G., Macchia T., Gerra G. (Eds.), pp. 
637-653, Progetto “START” del Dipartimento Nazionale per le Politiche Antidroga, 
ISBN 978-8895149004, Retrieved from 
 http://iport.dronet.org/com/filedownloadlink/allegatoA.php?key=141&lingua=1 
Shaham, Y. & Hope, B.T. (2005a). The role of neuroadaptations in relapse in drug seeking, 
Nature Neuroscience, 8(11): 1437-1439. 
Sluzki, C. (1966). Seminario sobre metacomunicacion: nota, Acta Psiquiatrica y Psicologica de 
América Latina, 12:119. 
Sperry, R.W. (1968). Hemisphere deconnection and unity in conscious awareness, American 
Psychologist, 23(10): 723-733. 
Ungless, M.A., Whistler, J.L., Malenka, R.C. & Bonci, A. (2001). Single cocaine exposure in 
vivo induces long-term potentiation in dopamine neurons, Nature, 411(6837): 583-
587. 
Watzlawick, P. (1978). The Language of  Change: elements of therapeutic communication, 
Basic Books, ISBN 978-0465037926, New York. 
Watlawick, P. (Ed.)(1984). The invented reality. How do we know what we believe we 
know? (Contributions to Constructivism), W. W. Norton & Company, ISBN 978-
0393017311, New York. 
Watzlawick, P., Beavin, J. & Jackson, D. (1967). Pragmatics of human communication. A 
study of interactional patterns, pathologies and paradoxes, W. W. Norton & 
Company, ISBN 978-0393010091, New York. 
Watlawick, P. & Nardone, G. (1997). Terapia Breve Strategica, Raffaello Cortina Editore, 
ISBN 978-8870784718, Milano. 
Watlawick, P., Weakland, J., & Fisch, J. (1974). Change. Principles of problem resolution. W. 
W. Norton & Company, ISBN 978-0393011043, New York. 
Weaver, T., Hart, J., Fehler, J., Metrebian, N., D’Agostino, T. & Benn, P. (2007), Are 
contingency management principles being implemented in drug treatment in 
England?, National Treatment Agency for Substance Misuse, Retrieved from  
 
Addictions – From Pathophysiology to Treatment 424 
 http://www.drugsandalcohol.ie/11939/1/NTASM_rb33_contingency_manageme
nt_summary.pdf 
Zuckerman, M. (1979). Sensation seeking: beyond the optimal level of arousal, L. Erlbaum, 
ISBN 978-0470268513, Hillsdale. 
15 
Research and Intervention for Drug-Addicted 
Mothers and Their Children: New Perspectives 
Paolo Stocco1, Alessandra Simonelli2,  
Nicoletta Capra3 and Francesca De Palo2 
1Therapeutic Community “Villa Renata”, Venice, 
2Department of Developmental and Social Psychology, Padua University, 
3Mother-Child Therapeutic Community “Casa Aurora e Villa Emma,” Venice,  
Italy 
1. Introduction 
According to research carried out by the EMCDDA, drug-addicted women in Europe 
account for at least one quarter of the total European population consuming illicit 
substances (Emcdda, 2006a). A specific research platform entitled “Women and Drugs” was 
created within the context of the second European project “Democracies, Cities and Drugs.” 
This platform is focused on what characterizes and distinguishes female substance addiction 
from male substance addiction: its manifestation, its attributes, and the interventions or 
services which can be put into effect while devoting special attention and offering 
specialized care to this phenomenon. Our findings confirm that women substance users are 
exposed to a great number of risks such as medical, social, economic, familial and 
psychopathological risks requiring intervention through specific tools and aimed responses 
(see Brentari, Hernandez, Tripodi, 2011). The investigated factors included pregnancy, 
parenthood and the well-being as well as development of the child, while taking into 
account institutional and ethical reflections regarding this complex theme.  
The substance abuse phenomenon indeed affects a high number of fertile women. When 
drugs are consumed during pregnancy, they can have serious, direct and indirect effects on 
the postpartum development with subsequent effects on the child (OTIS, 2010). Substance 
abusing mothers represent an at-risk parenting situation which, in turn, profoundly 
influences the quality of the mother-child relationship. The awareness of these at-risk 
situations for children along with the widely accepted notion that ideally, children should 
always be raised by their mothers led to the introduction of residential treatment in Italy. 
These services deal with maternal pathologies and provide care and assistance for children; 
in fact, these therapeutic communities accommodate addicted mothers as well as their 
children.  
Up until recently, therapies for children (particularly medical ones) were administered by 
institutions outside of the community, while no therapeutic treatment was mandated for 
minors. The first therapeutic communities for drug addicted mothers and their children 
appeared in Europe in the early nineties. These institutions must provide assistance to 
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children and assure them the greatest possible social, psychological and physical well-being. 
In addition to the funds available for each mother, funds for each individual minor are 
made available on a daily basis. Our project: “Research and intervention on minors in 
communities for addicted mothers and their children: from at-risk parenting to child well-
being” was promoted within this specific intervention framework. The project aims to 
secure child well-being by assessing maternal parenting as well as by carrying out direct 
and indirect observations of the child, his/her caregivers and the caregiver-child 
relationship. At the same time, the most suitable intervention for each single subject is put 
into effect.  
2. Female substance addiction, pregnancy and parenthood 
As stated above, there is an ever increasing interest towards defining characteristics which 
are specifically related to substance abuse in the female population, with specific reference 
to the following two crucial aspects.  
a. general differences, in terms of individual and relational characteristics, life history and 
family history which single out addicted women as subjects with experiences of trauma, 
abandonment or neglect, from either a physical or psychological standpoint (Parsec 
Association, 2004; Stocco et Al., 2000, 2002; Studio VEdeTTE, 2007). These subjects 
suffer also for their specific medical problems (HIV, sexually transmitted pathologies, 
etc.), for their social situation (prostitution, access to the job market, etc.) and 
institutional difficulties (organization and access to services). From this point of view, 
the interest is to detect and realize any available data projections referring to female 
substance addiction and feasible interventions from the legislative and health 
perspective (Home Ministry Government, 2010).  
b. specific issues related to pregnancy and parenthood in substance abusing women from 
the medical-gynecological perspective, including all psychological aspects which might 
have an impact on the subsequent relationship with a child.  
2.1 Substance abuse 
All international data confirm a commonly shared view according to which male drug users 
outnumber women drug users by far (UNODC, 2004). However, recent research suggests 
that the gender gap may be narrowing, at least with reference to some types of drugs 
(EMCDDA 2006a). For example, for cannabis use and binge drinking, differences in drug 
use between men and women have substantially narrowed, at times showing an almost 
equal consumption between the genders. Another trend indicated a higher percentage of 
female rather than male students using tranquilizers or sedatives which are bought without 
prescription. Patterns of drug use based on gender differences are illustrated by the 
percentage of patients entering treatment services in Europe. The percentage of female 
patients is around 20% (EMCDDA 2005): among those receiving drug treatment, problems 
relating to amphetamine-type stimulant drugs (ATS) are most common among young 
people (under 20 years old), whereas problems relating to the use of sedatives or 
pharmaceutical drugs are most widespread among older patients (over 39 years old) 
(EMCDDA 2005). 
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With reference to intravenous drug use (IDU), the WHO reported a rapid increase in the rate 
of female IDUs in recent years, especially in Eastern Europe and Asia (Pinkham and 
Malinowska-Sempruch, 2007). According to available epidemiological data, women are 
more likely than men to abuse and become dependent on substances such as tranquilizers 
and sedatives when used without prescription (Simoni-Wastila et. al, 2004). It has also been 
shown that women typically become dependent on substances more quickly than men: this 
holds good for cannabis, cocaine and other stimulants, as well as opioids, inhalants and 
hallucinogens (UNODC, 2004).  
With respect to “binge drinking”1, an EMCDDA gender perspective report underlines that 
male predominance in general is lower in those countries where the prevalence of binge 
drinking is highest. Gender correlation with respect to cannabis use and binge drinking 
increases proportionally according to the increased use of those substances (EMCDDA, 
2006a). Other studies show that in recent years, risky alcohol consumption has increased 
among young girls and adolescents (Anderson, Baumberg, 2006; O.N.Da, 2008). 
Several studies suggest that women are more likely to use and abuse prescribed 
psychoactive drugs such as painkillers, sleeping pills and tranquillizers (EMCDDA, 2006a). 
This remark applies especially to opioids and depressants of the central nervous system. 
Sleeping-pill and anti-anxiety drug abuse is less visible than other, more common forms of 
addiction among women (PNS, 2008; Stocco, 2000). Actually, this seems related to the high 
incidence of depression or anxiety disorders in women (WHO, 2000). It is important to note 
that a lifetime prevalence of benzodiazepine use (for sleep or anxiety problems) without 
medical prescription among school students between the ages of 15 and 16 is significantly 
higher in females than in males (EMCDDA, 2006a).  
2.2 Mental health and dual diagnosis 
A high percentage of women substance users suffer from mental disorders. This specific 
type of diagnostic comorbidity, called dual diagnosis2 was defined as the co-existence, in one 
                                                                 
1 Binge drinking is defined as a dangerous practice of consuming large quantities of 
alcoholic beverages in a single session. More specifically, experts agree that binge drinking 
occurs when one consumes 5 or more alcoholic drinks within a couple of hours. 
2 The term “comorbidity” was introduced by Feinstein and further specified by Klerman 
(1990) who used it to denote two or more disorders occurring at the same time or in the life 
course of one and the same subject. Cloninger (1990) stated that comorbidity implied the 
likeliness for a subject with a specific index disorder to develop a second disorder. Finally, 
Golberg (1996) very interestingly pointed out that it was only possible to talk of comorbidity 
when the assessed disorders were clearly distinct entities: symptoms of interrelated 
domains should not be classified as comorbidity. This clarification must be kept in mind 
since comorbidity only occurs when two different disorder categories can be recognized and 
described: however, it cannot be considered irrelevant that a “disorder” should be 
accompanied by symptoms or clusters of symptoms belonging to domains that are to a 
greater or lesser extent interrelated with the psychopathological domain of the index 
disorder. Rather, this reveals a “specific vulnerability” for a psychopathological 
development of the interrelated domain to reach disorder level and, therefore, comorbid 
condition (Di Sciascio, Nardini, 2005). 
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and the same subject, of a disorder related to psychoactive substance abuse and another 
psychiatric disorder (World Health Organization, WHO, 1995). As far as addiction is 
concerned, co-morbidity refers to the co-presence of a serious mental disorder and a 
disorder caused by substance abuse/dependence when such causality can be demonstrated 
(De Leon, 1989; Buckley, Brady, Hermann, 2010; Bobes, Casas, Szerman, 2009).  
Dual diagnosis is more frequent among women than among men, particularly with regard 
to affective and anxiety disorders. Affective disorders (especially depression, moodiness and 
low self-esteem, loss of interest or pleasure in enjoyable activities) and anxiety disorders 
(excessive anxiety with physical and emotional effects such as apprehension, nervousness or 
fear) are common and serious pathologies to be treated in addicted women. A recent 
comprehensive study in United States confirmed that feelings of depression, hopelessness, 
sadness and suicidal ideation are more frequent in high school girls than in boys and that 
these feelings are more likely associated with a high risk for drinking and other drug use in 
girls (CASA 2003, cit. in Brady, Back, Greenfield, 2009). Also personality disorders (mostly 
Cluster B), posttraumatic stress disorders, suicide attempts and eating behavior disorders 
have to be treated in addict women. Schizophrenia and other psychotic symptoms are also 
frequent in women (Stocco et al., 2000, Instituto de la Mujer, 2007).  
Particularly, exposure to trauma is a very frequent condition in drug-addicted women and it 
is the environmental basis for a posttraumatic stress disorder: sexual assault is the most 
frequent type of trauma experienced by women, but all different kinds of abuse are suffered 
by women before or during drug addiction. All in all, women are four times more likely to 
develop this disorder than men after exposure to traumatic events (Ciechanowski, 2010; 
Instituto de la Mujer, 2007) 
Moreover, a lifetime prevalence of eating disorders (such as anorexia and bulimia) was 
found in women misusing substances: these disorders are thought to be behavioural 
patterns stemming from emotional conflicts that need to be solved so that the patient can 
develop a healthy relationship with food (Charles & Pull, 2004). Among psychiatric 
disorders, these are serious mental illnesses with a high incidence of co-morbidity and also 
with a high mortality rate (Ibidem). 
Causes for high co-morbidity between substance misuse and mental health issues are not 
known and prevalence varies among different populations. Etiological theories in dual 
diagnosis include factors that are common to both disorders: a substance use disorder 
secondary to mental illness; a mental illness secondary to substance use, as well as 
bidirectional models. Women have more difficulties than men when treated for dual 
pathologies: these difficulties are related to drug addiction and mental illness. Drug 
addiction damage in a woman’s body occurs earlier and more intensely than in men. 
Women seek treatment later than men, and addiction treatments do not often include a 
suitable program for dual diagnosis cases. In addition to this, women with mental illness 
usually suffer from some degree of impaired cognition. This makes them feel embarrassed, 
and contributes to a lack of compliance and difficulties when confronted with the need to 
change their lifestyle. Moreover, these women don’t seek specific services: on the contrary, 
they usually prefer to see general practitioners. Women typically don’t ask for mental or 
addiction treatments nor for social help. As a result, doctors that are unprepared to treat 
these cases may delay assistance (Instituto de la Mujer, 2007). 
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Finally, reference should be made to the co-dependence phenomenon (also called bi-
dependence): more often than not, drug-addicted women experience problematic 
relationships with multi-problematic partners who also have drug- or alcohol-addiction 
problems (Moral Jiménez & Sirvent Ruiz, 2007).  
2.3 Medical implications 
Drug use, particularly intravenous drug use (IDU) remains one of the major risk factors for 
acquiring blood-borne infections for both men and women. With reference to the risk of 
infections related to sharing needles and other drug paraphernalia, it has been 
demonstrated that a significant number of women begin using drugs in the context of a 
sexual relationship (Unodc, 2004; Price & Simmel, 2002). Women are also more likely than 
men to borrow or share injection equipment, particularly with their sexual partners. They 
also often rely on men to acquire and inject them with drugs (Doherty et al. 2000; Vidal-
Trecan at al, 1998, Pinkham et al. 2007). Women share needles with more people in their 
social network than men do (Sherman et al. 2001). This leads to an increased risk for 
acquiring blood-borne infections, particularly HIV and hepatitis C, which is generally very 
high among intravenous drug users. 
Biological and social factors contribute to the increase of women drug users’ risks for HIV. 
The overall data available for 25 European countries in 2005 showed that 35% of newly 
diagnosed cases of HIV were among women, reaching 41% in Eastern Europe, where the 
epidemic was mainly concentrated among IV drug users (Euro-HIV, 2007). Studies in nine 
EU countries showed that the average HIV prevalence was more than 50 percent higher 
among women IV drug users than among their male counterparts (EMCDDA, 2006). The 
correlation of IV drug use, sex work and unsafe sexual practices led to a significantly 
increased risk of HIV infection among women (UNODC, 2004).  
Risk behaviour for infections needs to be considered not only with reference to HIV, but also 
to other blood-borne diseases such as Hepatitis C and B. Hepatitis C is the most common 
infectious disease among IV drug users, since it is transmitted through the sharing of 
needles, syringes and, unlike HIV, other injection-related equipment (Eurasian Harm 
Reduction Network (2007b). In 2006, the EMCDDA reported that median sero-prevalence of 
hepatitis C virus (HCV) is quite similar in male and female IV drug users: 58.1 % in males 
and 56.4 % in females. It is generally understood that it is more difficult to acquire HCV 
through sexual transmission than it is to acquire HIV. Infection among IV drug users will 
therefore be almost exclusively the result of sharing syringes and other injecting 
paraphernalia (EMCDDA, 2006).  
2.4 Gender violence and social conditions  
Neglect and abuse in childhood are common trends in the personal backgrounds of many 
female substance users.  
European data estimates that one in five women experiences some form of physical or 
sexual violence (European Women’s Lobby, 2001; Stocco, Llopis et al., 2000). In England and 
Wales alone, there were over 1 million female victims of domestic violence between 2009-
2010. In the same area, every year over 300,000 women are sexually assaulted and 60,000 
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Finally, reference should be made to the co-dependence phenomenon (also called bi-
dependence): more often than not, drug-addicted women experience problematic 
relationships with multi-problematic partners who also have drug- or alcohol-addiction 
problems (Moral Jiménez & Sirvent Ruiz, 2007).  
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men to borrow or share injection equipment, particularly with their sexual partners. They 
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Trecan at al, 1998, Pinkham et al. 2007). Women share needles with more people in their 
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diagnosed cases of HIV were among women, reaching 41% in Eastern Europe, where the 
epidemic was mainly concentrated among IV drug users (Euro-HIV, 2007). Studies in nine 
EU countries showed that the average HIV prevalence was more than 50 percent higher 
among women IV drug users than among their male counterparts (EMCDDA, 2006). The 
correlation of IV drug use, sex work and unsafe sexual practices led to a significantly 
increased risk of HIV infection among women (UNODC, 2004).  
Risk behaviour for infections needs to be considered not only with reference to HIV, but also 
to other blood-borne diseases such as Hepatitis C and B. Hepatitis C is the most common 
infectious disease among IV drug users, since it is transmitted through the sharing of 
needles, syringes and, unlike HIV, other injection-related equipment (Eurasian Harm 
Reduction Network (2007b). In 2006, the EMCDDA reported that median sero-prevalence of 
hepatitis C virus (HCV) is quite similar in male and female IV drug users: 58.1 % in males 
and 56.4 % in females. It is generally understood that it is more difficult to acquire HCV 
through sexual transmission than it is to acquire HIV. Infection among IV drug users will 
therefore be almost exclusively the result of sharing syringes and other injecting 
paraphernalia (EMCDDA, 2006).  
2.4 Gender violence and social conditions  
Neglect and abuse in childhood are common trends in the personal backgrounds of many 
female substance users.  
European data estimates that one in five women experiences some form of physical or 
sexual violence (European Women’s Lobby, 2001; Stocco, Llopis et al., 2000). In England and 
Wales alone, there were over 1 million female victims of domestic violence between 2009-
2010. In the same area, every year over 300,000 women are sexually assaulted and 60,000 
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women are raped. Overall in the UK, more than one in four women experience domestic 
abuse during their lifetime (Home Minister Government, 2010)3. 
These women tend to define their substance use as the best coping mechanism available to 
them. Parental negligence and lack of attention in addition to the trauma of physical or 
sexual abuse make women more vulnerable to developing problems with substance abuse. 
In the absence of adequate support, such conditions can become a descending spiral 
(EMCDDA, 2009). 
The link between substance use and gender violence/domestic abuse is complex. There is 
no reliable evidence of a cause-effect link between the two. However, where problems with 
substance use exist, domestic abuse is often present as well. Physical or sexual abuse on 
women is often perpetrated by a male partner or other male family members. Studies show 
that women with substance use problems are more likely than men to have experienced 
physical and/or sexual abuse (UNODC, 2004). A history of violence can have an impact on 
a woman’s experience with substance abuse and mental health problems. Women who use 
substances are also more likely to live in environments where violence or sexual abuse is a 
common pattern: a study by Vogt (1998) and Zenken et Al. (2003) found that a significant 
background variable for female drug addiction are past experiences of violence, especially 
sexual exploitation. In line with this view, some Italian research studies have shown that 
about 50 % of young female drug users with anti-social behaviour and one-third of female 
psychiatric patients were victims of untreated sexual abuse during childhood (Gelinas, 1983; 
Malacrea, 2006). 
Social, physical and psychological deprivations expose women to the influence and 
exploitation of male partners. Substance use can also drive women into sex work as a source 
of income (EMCDDA, 2009). 
2.5 Pregnancy and parenthood 
Women drug users who become pregnant form an additional sub-group requiring specific 
attention and care, both for them and for their babies (EMCDDA, 2006a). Drug use is 
associated with direct and indirect complications throughout pregnancy, postnatal 
morbidity and developmental delays (Hunter and Powis 1996): for instance, within the 
groups studied by Aronica et al. (1987) and by Palmieri (1991), 50% of the subjects were 
pregnant women with one or more children. Alleged reproduction difficulties in this 
population were attributed both to neuroendocrine alterations induced by substances such 
as heroin and opioids and to an irregular and inconstant lifestyle, alimentary deficits and 
poor hygienic, sanitary habits (Genazzani, 1987). However, neither of the two classes of 
factors seem to significantly reduce the chances for these subjects to bear children (Ibidem).  
These women usually report deep feelings of anguish and dismay which build up their 
inner world, always suspended between impotence and manipulative, boundless 
omnipotence. Actually, addicted women often wish to get pregnant and bear a child as a 
form of vital defense or a redemption experience, even though this idealized view does not 
prevent the emergence of phases of anguish which are tied to the clashing of evidence 
against the ever incumbent denial of the event (Tempesta, et al., 1987). Evidence of this 
                                                                 
3 Figures from 2009/10 British Crime Survey data http://rds.homeoffice.gov.uk/rds/  
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denial can be found in the failed acknowledgement of a delayed period as a “sign” of 
pregnancy, the delay with which they finally resolve to taking a pregnancy test and, later 
on, their carelessness towards the fetus’ needs (Tempesta et al., 1987). Moreover, these 
women often keep on using drugs during pregnancy while keeping their lifestyle 
unchanged for as long as possible, in homage to drug addiction homeostasis (Di Cagno et 
al., 1985). Even when drug consumption is discontinued during pregnancy, it is often 
resumed after delivery or during the postpartum period in an attempt to feel up to the new 
task and soothe the sense of guilt and failure. 
In fact, for an addicted woman, delivery may imply having to cruelly realize what she 
was not able to do for her child and her negligence towards him/her: when real life needs 
become too hard, either because of the child’s or the mother’s difficulties or else for lack of 
a support network, the dream embodied in the fetus/child is shattered and heavy, 
depressive feelings may ensue which, up to that point, had been kept at bay by a 
megalomaniac investment on the child and on an idealized maternal image (De Zordo, 
1997; Tempesta, et al., 1987).  
No matter whether these women remain abstinent or else resume drug consumption, their 
difficulties in carrying out parenting functions emerge fairly early. Generally speaking, these 
mothers seem to find it difficult to build and maintain gratifying interpersonal relationships 
(with their partners and their families of origin), they tend to adopt a lifestyle leading to 
isolation and, above all, they have trouble in recognizing and satisfying their children’s needs 
(Fiks, Johnson, Rosen, 1985). Their more or less conscious inadequacy in performing the 
parenting function has been suggested to derives from their early feelings and experiences: 
affective deprivation, losses, separations, lack of affective continuity in their families of origin 
(Johnson, Cohen, Brown, et al., 1999; Ravndal, Lauritzen, Frank, Jansson, Larsson, 2001). This 
inadequacy seems to be at the root of their educational style which is often characterized by an 
authoritarian overinvolment of the child: any external influence is rejected with a tendency to 
isolation, while the child is urged to become independent as quickly as possible and 
communication is controlled and avoided (Wellisch, Steinberg, 1980). Moreover, ambivalence 
seems to be a complex and typical feature of the relationships these mothers build with their 
children: they often expect them to take their mothers’ expectations and wishes on themselves 
and consequently, they induce a role reversal and a process whereby these children are forced 
to think and act like adults, something they also experimented during their infantile past 
(Malagoli Togliatti, Mazzoni, 1993).  
Finally, becoming a mother to a newborn does not coincide with a renewed motivation  
to seek counselling and/or treatment, rather, it strictly depends on a wide range of variables 
(McMahon, Luthar, 2000): according to the data available in the literature, mothers seem to 
be more prone to entering a detoxification and drug treatment when they are in young  
age, have more than one child, have got financial and legal problems, have suffered  
physical mistreatment and, above all, when they join advanced therapeutic programs 
(Grella et Al., 2006). 
3. Children of drug-addicted mothers 
It is indisputable that the development of children born from drug-addicted parents is 
highly at risk already before their birth, because the interaction of personal, relational and 
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psychiatric patients were victims of untreated sexual abuse during childhood (Gelinas, 1983; 
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Social, physical and psychological deprivations expose women to the influence and 
exploitation of male partners. Substance use can also drive women into sex work as a source 
of income (EMCDDA, 2009). 
2.5 Pregnancy and parenthood 
Women drug users who become pregnant form an additional sub-group requiring specific 
attention and care, both for them and for their babies (EMCDDA, 2006a). Drug use is 
associated with direct and indirect complications throughout pregnancy, postnatal 
morbidity and developmental delays (Hunter and Powis 1996): for instance, within the 
groups studied by Aronica et al. (1987) and by Palmieri (1991), 50% of the subjects were 
pregnant women with one or more children. Alleged reproduction difficulties in this 
population were attributed both to neuroendocrine alterations induced by substances such 
as heroin and opioids and to an irregular and inconstant lifestyle, alimentary deficits and 
poor hygienic, sanitary habits (Genazzani, 1987). However, neither of the two classes of 
factors seem to significantly reduce the chances for these subjects to bear children (Ibidem).  
These women usually report deep feelings of anguish and dismay which build up their 
inner world, always suspended between impotence and manipulative, boundless 
omnipotence. Actually, addicted women often wish to get pregnant and bear a child as a 
form of vital defense or a redemption experience, even though this idealized view does not 
prevent the emergence of phases of anguish which are tied to the clashing of evidence 
against the ever incumbent denial of the event (Tempesta, et al., 1987). Evidence of this 
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denial can be found in the failed acknowledgement of a delayed period as a “sign” of 
pregnancy, the delay with which they finally resolve to taking a pregnancy test and, later 
on, their carelessness towards the fetus’ needs (Tempesta et al., 1987). Moreover, these 
women often keep on using drugs during pregnancy while keeping their lifestyle 
unchanged for as long as possible, in homage to drug addiction homeostasis (Di Cagno et 
al., 1985). Even when drug consumption is discontinued during pregnancy, it is often 
resumed after delivery or during the postpartum period in an attempt to feel up to the new 
task and soothe the sense of guilt and failure. 
In fact, for an addicted woman, delivery may imply having to cruelly realize what she 
was not able to do for her child and her negligence towards him/her: when real life needs 
become too hard, either because of the child’s or the mother’s difficulties or else for lack of 
a support network, the dream embodied in the fetus/child is shattered and heavy, 
depressive feelings may ensue which, up to that point, had been kept at bay by a 
megalomaniac investment on the child and on an idealized maternal image (De Zordo, 
1997; Tempesta, et al., 1987).  
No matter whether these women remain abstinent or else resume drug consumption, their 
difficulties in carrying out parenting functions emerge fairly early. Generally speaking, these 
mothers seem to find it difficult to build and maintain gratifying interpersonal relationships 
(with their partners and their families of origin), they tend to adopt a lifestyle leading to 
isolation and, above all, they have trouble in recognizing and satisfying their children’s needs 
(Fiks, Johnson, Rosen, 1985). Their more or less conscious inadequacy in performing the 
parenting function has been suggested to derives from their early feelings and experiences: 
affective deprivation, losses, separations, lack of affective continuity in their families of origin 
(Johnson, Cohen, Brown, et al., 1999; Ravndal, Lauritzen, Frank, Jansson, Larsson, 2001). This 
inadequacy seems to be at the root of their educational style which is often characterized by an 
authoritarian overinvolment of the child: any external influence is rejected with a tendency to 
isolation, while the child is urged to become independent as quickly as possible and 
communication is controlled and avoided (Wellisch, Steinberg, 1980). Moreover, ambivalence 
seems to be a complex and typical feature of the relationships these mothers build with their 
children: they often expect them to take their mothers’ expectations and wishes on themselves 
and consequently, they induce a role reversal and a process whereby these children are forced 
to think and act like adults, something they also experimented during their infantile past 
(Malagoli Togliatti, Mazzoni, 1993).  
Finally, becoming a mother to a newborn does not coincide with a renewed motivation  
to seek counselling and/or treatment, rather, it strictly depends on a wide range of variables 
(McMahon, Luthar, 2000): according to the data available in the literature, mothers seem to 
be more prone to entering a detoxification and drug treatment when they are in young  
age, have more than one child, have got financial and legal problems, have suffered  
physical mistreatment and, above all, when they join advanced therapeutic programs 
(Grella et Al., 2006). 
3. Children of drug-addicted mothers 
It is indisputable that the development of children born from drug-addicted parents is 
highly at risk already before their birth, because the interaction of personal, relational and 
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social factors does not support the individual’s adjustment to his/her environment (see 
Nicolais, 2010). In this respect, Cicchetti and Rizley (1981) identify two categories of 
developmental risk factors: endogenous risk factors, such as physical or behavioral 
anomalies and psychological disorders, which make it difficult for the parent to take care of 
the child; exogenous risk factors, related to the environmental context in which the child is 
raised, such as features of his/her parents’ personal histories, their psychological 
characteristics as well as ecological aspects of his life context or the one of the whole family. 
Both categories have become the subject of interest in several studies on this special children 
population.  
3.1 Endogenous risk factors  
Many research studies on children of addicted mothers, originally from US, focused on the 
harmful effects on the fetus following exposure to psychotropic substances, since recent data 
indicate that around 5% of all pregnant women aged between 15 and 44 years use 
substances (Substance Abuse and Mental Health Service Administration, 2005) which leads 
to the birth of approx. 375,000 babies with withdrawal symptoms every year.  
In fact, psychoactive substances can have various harmful perinatal effects. Among others, 
the authors listed: rupture of the placenta and premature birth, low weight at birth and 
APGAR4 scores below normal, low cranial circumference, the occurrence of perinatal stroke, 
congenital deformities and neurobehavioral disorders in newborns who had been exposed 
to cocaine and heroin during pregnancy (Lutinger, Graham, Einarson, Karen, 1991; Mayes, 
Granger, Bornstein, Zuckermann, 1992; Zuckerman, Bresnahan, 1991; Zuckerman et al., 
1989). Moreover, the fetus can develop a dependency to the substances used by the mother: 
after delivery, when drug intake is abruptly discontinued, the baby runs the risk of 
undergoing real withdrawal crises (Foetal Drug Syndrome, FDS) which intensity may vary 
according to the used substance and its intake method (Finnegan, 1986; Zacchello, 
Giaquinto, 1997; Zuckerman, Brown, 1993).  
Finally, it must be pointed out that many of these children test HIV-positive at birth: in most 
cases, remission occurs during the first months of life but for some of them, it is indicative of 
infection. Similar data are reported also for other infective pathologies such as hepatitis, 
syphilis, toxoplasmosis, cytomegalovirus (Zacchello, Giaquinto, 1997). 
Later on, some studies report rhythm irregularities in the sleep-awake state and in food 
intake, as well as a tendency to hyperactivity (Zuckerman, 1994) already in early infancy. 
Learning difficulties, low attentive capacities and a higher degree of aggressiveness in 
                                                                 
4 Apgar: Abbreviation for the Apgar score, a practical method of evaluating the physical condition of a 
newborn infant shortly after birth. The Apgar score is a number arrived at by scoring the heart rate, 
respiratory effort, muscle tone, skin color, and response to a catheter in the nostril. Each of these signs 
can receive 0, 1, or 2 points. A perfect Apgar score of 10 means an infant is in the best possible 
condition. An infant with an Apgar score of 0-3 needs immediate intensive care. The Apgar score is 
measured routinely 60 seconds after delivery and then it is repeated after 5 minutes. In the event of a 
difficult resuscitation, the Apgar score may be done again at 10, 15, and 20 minutes. An Apgar score of 
0-3 at 20 minutes of age is predictive of high morbidity (disease) and mortality (death). 
<http://www.medterms.com/script/main/art.asp?articlekey=2302> 
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preschool and school age (Cavazzuti, Frigieri, Finelli, 1987; Fundaro, Salvataggio, 1987; 
Oloffson, Buckley, 1983; Sanderegger, Zimmermann, 1978; Wilson, McCreary, Kean, Baxter, 
1979) are also reported in these children, even if, compared to controls, neither differences in 
IQ levels nor alterations of intellectual functions are to be found (Azuma, Chasnoff, 1993). In 
this respect, Lester and Tronick (1994) offer an outlook on the effects of prenatal drug 
exposure which takes into consideration functional difficulties in the “4A” childhood areas 
(attention, arousal, affectivity and action). However, we should also remember the results of 
a research by Alessandri, Bendersky and Lewis (1998) revealing a correlation between the 
severity of the child’s developmental deficit and the amount of substance (in their specific 
research, heroin) consumed by the mother during pregnancy. The neurobehavioral 
vulnerability which is typical of children who were exposed to drugs in utero must, 
therefore, be considered within a wider context including relational and environmental 
aspects too, two factors which also have an influence upon child development immediately 
after birth. 
The clinical presentation of the "addicted babies" depends on the type of substances used by 
the mother during pregnancy, by value, frequency and time since last use / abuse. 
Substances commonly used by drug addicts are Alcohol, Nicotine, Marijuana, Tranquilizers, 
Cocaine and opioids in general, as well as 'heroin and methadone (Johnson & Kate, 2000; 
Lester & Barry, 2000). It was found that if the mother has made extensive use of drugs such 
as alcohol, hypnotics, or heroin–that could be considered "not exciting" the nervous system–
the infant will manifest respiratory depression problems immediately after birth. 
Expressions of neonatal abstinence syndrome could be constant irritability, tremors and 
stiffness of muscle tone. Other possible symptoms include: irritability of the nervous system, 
gastrointestinal disorders, vomiting, diarrhea, hysterical crying, sleep disturbances, rapid 
breathing.  
When we consider the effects of the substance exposure on the development of the child, the 
researches reveal that the global development is slowed and more in deficit at the cognitive 
level but not completely destroyed. In general, the child exposition to heroin and 
methadone during intrauterine development, is already evident after 48 hours of birth, 
while the exposure to the Alcohol leave marks immediate developing a real withdrawal 
syndrome. With reference to the specific symptoms related to different substances, many 
studies are interested to the exposure to Cocaine, that is a stimulant causing the blood 
vessels : this substance decreases the oxygen supply to the fetus and, consequently, the 
infant is at risk of suffocation. Also, the infants exposed to cocaine in the last gestational 
period reveal a state of reduced alertness and reduced responsiveness to external 
stimulation, when compared with controls.  
In the table below are classified as such direct effects, distinguishing them according to the 
type of substance used by the mother (Wright & Walker, 2001). 
3.2 Environmental factors: the attachment contribution  
In addition to the various aspects highlighted in the studies mentioned above, we should 
not forget the multiple postnatal factors which contribute to determine the developmental 
outcomes of children who were born from drug-addicted parents. 
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The effect of drugs on mother and baby 
Drug Antepartum Intrapartum Post-partum Long term 
Smoking Growth restriction Fetal Distress Increases in 
Infant deaths 
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Table 1. The effect of drugs on mother and baby. Source: Wright & Walker, 2001 
A large part of research in this domain have focused interest on the role of the quality of the 
proximal environmental factors on child development and well being; one of the most 
important factors that have an impact on child’s early development is the quality of 
interactions and relations between child and the significant adults who play a protective role 
for him (the mother and/or other caregivers). In this perspective, the “Attachment theory” 
(Bowlby, 1969-1980) has provided useful theoretical and methodological tools to study the 
affective-relational development during the first years of life both in normal as well as in 
“at-risk” populations, in order to study the role of the quality of early interactions on the 
child well being and adaptation to the context. 
According to this theoretical model, feeling safe and secure is the first and most important, 
early developmental task during the child’s first year of life and one major protection factor 
in the process of adjusting himself/herself to the environment. Various research studies 
investigated the parent and child role and how they influenced the quality of the attachment 
bond: however, the contribution of each of the two parties is still not clear.  
Van IJzendoorn, Goldberg, Kroonenberg, and Frenkel (1992) carried out a meta-analytical 
work on the influence of the child’s and/or the parents’ problems on the development of 
attachment during the first year of life. Attachment was assessed using the Strange Situation 
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Procedure5 (Ainsworth, Blehar, Waters, Wall, 1978): researchers found a lower percentage of 
Secure attachment (B) and an increase in the Disorganized/Disoriented (D) category among 
samples of mother-child dyads at risk which differentiated them from the distributions 
observed in the general population. Moreover, a prevalent influence of maternal problems 
and difficulties rather than of children’s endogenous risk factors came to light affecting the 
quality of infant-mother attachment. In fact, attachment distributions within groups of 
children of mistreating mothers (Carlson, Cicchetti, Barnett, Braunwald, 1989; Crittenden, 
1985; Schneider-Rosen, Braunwald, Carlson, Cicchetti, 1985), mentally disturbed mothers or 
drug addicted mothers (Rodnig, Beckwith, Howard, 1989) revealed high divergence when 
compared to normative samples, more so than in case of problems coming from the child’s 
side only. In fact, the child’s problems did not seem to jeopardize the process of creating a 
secure attachment bond with the mother (van JIzendoorn et al., 1992).  
Research studies with groups of parents suffering from psychiatric disorders, behavioral 
disorders or else mistreating their children seem to proceed along the same direction: once 
again, they reveal a high percentage of insecure attachment and, more specifically, 
entangled attachment (E) and unresolved attachment (U) tied to experiences of trauma and 
bereavement. These subjects seem to have difficulties in working through life experiences 
which they went through during childhood while their caregivers only proved to be 
scarcely adequate and supportive (van IJzendoorn, Bakermans-Kranenburg, 1996). 
Therefore, parents belonging to clinical populations do not seem to be emotionally secure, 
which represents a potential risk factor for their children, because of the process of 
intergenerational transmission of attachment, according to which the mother’s 
representational world has got a fundamental role in the co-construction of a bond with the 
                                                                 
5 The Strange Situation is a standardized observation procedure (Ainsworth et al., 1978; Ainsworth, 
Wittig, 1969) which aims at activating and intensifying the child’s attachment behavior towards his/her 
parent by exposing the child to a moderately, yet increasingly stressful situation. In fact, the Strange 
Situation takes place within a context – an observation laboratory – which is not familiar to the child: it 
foresees the presence of an unfamiliar adult and a series of two separations and reunions with the 
mother (or any other adult figure we might be interested in studying the child’s attachment relationship 
with). This procedure is applicable to children between 12 and 24 months of age: between two 
subsequent administrations, a time interval of at least 6 months must be respected, so that the child can 
forget the situation and the stressful feelings tied with it (Ainsworth, 1985; Ainsworth, Bell, Stayton, 
1971). The procedure is subdivided into eight short episodes, each of them lasting approximately three 
minutes and following one another according to a fixed order and a clearly stated consignment.  
The SSP coding is based on the observation of the overall organization of a child’s attachment behavior 
and foresees two assessment levels: the first one is based on graduated ordinal scales on a 7-point Likert 
scale (range 1 – 7), which refer to specific behavioral sequences the child can display in the various 
episodes. They can be applied to each procedure episode at 15-second intervals. The second level leads 
to the assignment of an attachment pattern according to four categories. It is based on the observation of 
the way in which the behavioral systems of attachment and exploration are organized during the whole 
procedure both towards the caregiver, as well as the stranger, while various stress elements are 
introduced, one after the other. The four categories are (Scheme 3): secure attachment (B) – research 
studies referring to “non-clinical” United States children show that between 54.9% and 67% of the 
population fall into this category; avoidant attachment (A) is observed in an average range of 20.5% - 
22.9% of the population. Resistant attachment (C) is less frequent among the population (7.5% -12.5%), 
while disorganized/disoriented attachment (D) is observed in 14.7% of the children (van IJzendoorn, 
Goldberg, Kroonenberg, Frenkel, 1992). 
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Table 1. The effect of drugs on mother and baby. Source: Wright & Walker, 2001 
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in the process of adjusting himself/herself to the environment. Various research studies 
investigated the parent and child role and how they influenced the quality of the attachment 
bond: however, the contribution of each of the two parties is still not clear.  
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child (Benoit, Parker, 1994; Fonagy, Steele, Steele, 1991; Ward, Carlson, 1995; van 
IJzendoorn, Bakermans-Kranenburg, 1997; Zeanah, 1992).  
4. Therapeutic communities and the intervention model in Italy: an overview 
In Europe, during the past years, referral to Juvenile Court was the most commonly applied 
procedure to drug-addicted mothers (Pomodoro, 1993, 1996). More often than not, these 
cases resulted in the suspension or revocation of parental rights, until the mother or both 
parents passed examinations which were required by the Court and administered by 
services in charge of evaluating and following the case. In case of substance addiction, a 
common solution during evaluation period was to separate the child from the mother (or 
both parents) and relocate him/her elsewhere, that is, for instance, at the grandparents’ 
home, or else, at other out-patients services’. The first TC for mothers and children were 
founded in Switzerland, Germany and Italy in the early 1990s, then also in Spain and 
Portugal. Further solutions included admitting the child to family crisis intervention homes 
or placing the child in an extra-familial home or elsewhere, depending on the resources 
available in the territory. As for Italy, the juvenile judges’ reluctance to place children in 
therapeutic communities – even though this would guarantee the presence of their mothers 
at their side – was justified by the fact that this environment – although run by professionals 
– did not seem to guarantee adequate attention to the child, nor did community workers 
seem to possess adequate training and the right methodological tools to operate for the well-
being of the child and the mother-child couple. Therefore, more often than not, judges 
would take steps towards a separation of the mother-child dyad. These measures clearly 
indicated a lack of alternative possibilities within the enlarged network of fostering services 
but also un underlying prejudice towards drug-addicted parents who were considered 
“irredeemable” with regard to their capability to offer adequate care and protection to their 
children, especially in the very first years of their lives (Pomodoro, 1993, 1996). Confiding 
the child to his/her grandparents in foster care has become the most frequently adopted 
measure when one or both parents are drug-addict, even though this measure is still 
considered controversial as for its outcomes (Cirillo, 1996; Ghezzi, 1996). More specifically, 
criticism is raised towards its generalized and almost automatic use: if it is true, on the one 
hand, that it can provide an answer to the child’s immediate need for protection, on the 
other hand it can turn into a very heavy obstacle against a possible recovery of the child’s 
parents (Cirillo et Al., 1996). For this reason – as well as many others - the need has arisen 
for new intervention paths to be sought and experimented. 
4.1 Therapeutic communities for drug-addicted women and their children 
Over the past twenty years, the Veneto region has radically modified the functions of 
therapeutic communities for addicted mothers and their children, rethinking assessment 
and intervention measures in case of female drug addiction while paying special attention to 
children’s well-being and to the results obtained in the short and long run. Communities for 
drug-addicted women and their children offer residential care to the mother-child dyad 
(sometimes to the father too) and provide a comprehensive rehabilitation program which 
takes place during a two-year stay. Many of these facilities are now present on the whole 
national territory: they greatly differ from each other in terms of constituent aspects which 
have now been included into a complex and articulated regulation that also leaves room for 
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autonomous regional organization and definition (available places, internal arrangement, 
monthly fee etc.). These facilities can accommodate up to 10-12 dyads: as for the children’s 
age, the range spans from few-months-old babies (but more and more often, pregnant 
women are admitted too) up to school age children. In the first place, communities give 
hospitality to drug-addicted women (already detoxified or on methadone therapy and 
followed by the “Ser.T.”, territorial services), who are offered a comprehensive 
rehabilitation path.  
One further aspect of paramount importance is that, within a mother-child therapeutic 
community, addicted mothers are offered parenting support. Admitting the mother-child 
dyad into the community means guaranteeing an adequate intervention for the adult, while 
providing a protective environment for the child. Indeed, many of the problems associated 
with child development when a mother suffers from addiction can be addressed more easily 
and eventually solved once these children are offered an appropriate and stable relational 
context (Chasnoff, 1992). Moreover, a direct admittance of the mother-child dyad satisfies 
the need to overcome barriers between generations, since both the addicted woman’s and 
her partner’s families of origin are often not willing to help looking after the child. 
Moreover, it has been demonstrated how implementing assistance tools for children and 
families with a family-based approach prevents treatment dropouts (McComish, et al., 2000; 
Grella, et al., 2000). In fact, a droupout risk exists from the very first moment addicted 
mothers enter a therapeutic community, which is for them a very difficult step to take. These 
mothers fear that they might be labeled as incapable of caring for their children and 
consequently, that they have to be separated from them (National Institute on Drug Abuse, 
1996; Stevens, et al., 1989). 
As for the intervention methods, a combined treatment (that is, for the parent and the child 
together) is carried out on an intensive basis (the dyads are in residential care): in other 
words, it is typical of these communities to offer a therapeutic rehabilitation program which 
is centered on the family-parent-child system taken as a whole (Meisels, Dichtelmiller, Fong-
Ruey Liaw, 1993). Usually, the mother is the primary focus of the intervention: however, 
special attention is given to the mother-child relationship too in all facilities offering support 
to the dyad. An intervention on the child is carried out only when it becomes clear that there 
is a need for it: in fact, in most cases, these children are physically and psychologically 
healthy but their caregiving environment reveals a symptomatology which must be tackled 
and solved. However, in recent times, greater and greater attention has been paid to 
ensuring the well-being of children living in therapeutic communities, since having a drug-
addicted parent is indeed considered as a sort of risk factor in relation to the child’s 
evolutionary path (Capra, 2011). The length of time mothers have to devote to their 
rehabilitation program actually affects children too. At a very early stage in their lives, when 
many new experiences should be made and new things should be learnt, they spend a long 
time at a therapeutic community’s. Actually, already during the gestation period, they were 
exposed to the drugs consumed by the mother and often had to endure their mother’s 
irregular alimentation and burdensome life rhythms. Even when delivery and the post 
partum period went well and without complications, during the first months of life most of 
these children experienced multiple separations from their mothers or closest caregivers, 
who were often scarcely respectful of their rhythms and needs. Others had to confront 
themselves with new people and environments: for instance, with specialized health care 
services, or else they had to meet social workers, psychologists or community workers. 
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As for the intervention methods, a combined treatment (that is, for the parent and the child 
together) is carried out on an intensive basis (the dyads are in residential care): in other 
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healthy but their caregiving environment reveals a symptomatology which must be tackled 
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evolutionary path (Capra, 2011). The length of time mothers have to devote to their 
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themselves with new people and environments: for instance, with specialized health care 
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Finally, some of them had to endure sudden changes in their daily life and moved to 
another house or a different town etc. Because of all this, one of the primary interventions in 
favor of children residing at a community’s is to offer them stable life conditions, deep 
affective experiences as well as sound routine practices. With reference to the last mentioned 
aspect, communities seem to work as a place of physical and psychological attachment 
within which it becomes possible to create new and adequate affective relationships: all this 
is made possible thanks to the ”holding” function supplied by the community as a context 
of early caregiving and a guarantee of protection from danger, as well as a secure base for 
the exploration of the environment. This concept of community allows us to consider it, all 
in all, as a parenting environment where the a growth towards motherhood can be followed 
and supported, where mothers are no longer blamed or punished for their inadequacy and 
difficulties but rather are offered a very important chance to experience regression to the 
role of daughters and children in need (who are taken care of by community workers, 
psychologists etc.). The chance to experience mixed feelings towards their institutional 
“parents” seems to make it possible for these women to trace down the relational and 
representational bonds which were cut short during their infancy and adolescence favoring 
a review of their own past which is very beneficial to the relationship with their children.  
5. A research and intervention project on minors in therapeutic communities 
for addicted mothers and children 
Until a few years ago, in Italy, communities for drug-addicted mothers and their children 
provided treatments to disintoxicate mothers and favour their rehabilitation into society, 
while also ensuring overall medical and social support for their children’s development, for 
whom no specialized health treatment was foreseen (in case of need, treatment would be 
carried out by facilities outside of the community). However, in the last few years, a radical 
and much needed-for reorganization has come into effect in the field of residential and 
semi-residential services for drug-addicts and alcohol-addicts. More specifically, during the 
years 2006-2007 in North-Eastern Italy, new service units have been defined for addiction 
treatment, among others: swift admission services, semi-residential services, residential 
services (type A – B – C), type C1 (for drug-addicted mothers with minor children) and C2 
(for drug-addicted minors). Moreover, requirements and standards authorizing socio-
sanitary and social facilities to offer assistance have been redefined so as to bestow them 
recognition at institutional level. Over the years, especially in the Veneto region, it became 
clear that it was necessary to better define professional competences together with the 
methodological and organizational pre-requisites which are at the root of the intervention 
procedures in these specialized services. Treatment paths and management procedures 
within these services were redefined, whereby treatment must include a parallel series of 
medical-pharmacological, psychological and socio-educational interventions which are 
offered not only to the mother, but to the child too. Therefore, since 2008, the mother-child 
dyad and the quality of the caregiving relationship which develops between the two in the 
course of time have acquired prominent focus in the assessments and interventions by 
professionals who work in this specific field. The combination of all these assessment 
procedures is extremely important in order to arrange the best therapeutic and 
rehabilitation path for the mother who, up to that point, had been considered the sole 
subject to be taken therapeutic charge of in the community.  
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However, when minors are sent to therapeutic communities together with their mothers, 
this usually happens following a decree by a tutelary judge of the juvenile court so as to 
make sure that they receive protection and their psycho-physical health condition is 
assessed. For this reason, it was necessary to reconsider all areas of competence within 
direct and indirect interventions in favour of minors. Following this path, as of 2010, new 
socio-sanitary services for children in therapeutic communities type C1 have received 
official recognition. They are conducted by health professionals and technicians and foresee 
individualized interventions (individual psychological support, psychomotility , pet 
therapy), group psychomotility, clinical observation and assessment of the father-child and 
mother-child relationship, neuropsychiatric observation and assessment, mother-child 
relationship supervision and relational psychotherapy. Therefore, nowadays, not only are 
mothers but also their children officially considered clients of a community, where they are 
offered specific interventions of socio-psycho-physical health care.  
It is not easy to combine clinical and rehabilitation activities with research. The authors have 
striven to set innovative research projects in motion which methodological principles are 
going to be described in the following pages. In so doing, we hope to stimulate cultural 
growth while improving care giving practices. The first, preliminary results are presented in 
this chapter.  
The project “Research and intervention on minors in communities for drug-addicted 
mothers and their children: from at-risk parenting to child wellbeing” is the result of joint 
work carried out by the Psychology Department of the University of Padua and two 
therapeutic communities for addicted mothers and their children, Villa Emma and Casa 
Aurora, located in Venice and its mainland (Mestre) and run by the social cooperative Villa 
Renata.  
The project provides a multi-method evaluation through a longitudinal approach aimed at 
programming and monitoring the interventions performed by parents while following the 
development of children living in therapeutic communities. Developmental risk factors 
and/or clinically relevant, real life symptoms are identified as they emerge. Our theoretical 
and methodological points of reference are based on the study of parenting and 
development according to the current, dynamic, multi-factor models of influence (Belsky, 
1984; Gabble, Belsky, Crnic 1992; De Palo, 2010).  
The setting of the project is the therapeutic community and its complex caregiving system. 
The focus of the assessment is set on three areas, each of which is investigated at different 
levels: (a) evaluation of the mother’s psychic condition, in terms of personality and 
individual characteristics, assessed through interviews (such as the Adult Attachment 
Interview6, SCID-II7), questionnaires and dynamic tests (Rorchach8); (b) evaluation of the 
                                                                 
6 The Adult Attachment Interview (AAI) developed by George, Kaplan and Main (1985) is a semi-
structured interview assessing attachment in adolescence and adult age. The interview includes a series 
of questions through which a subject is asked to recall his/her attachment history and attachment 
experiences with his/her caregivers during infancy. The AAI coding scheme foresees two distinct 
phases: a first phase during which text content and form are analyzed through Evaluation Scales (Scales 
of Subjective Experience and Scales of the State of Mind) and a second phase during which the 
interview is analyzed as a whole in order to formulate a categorical classification of the subject’s 
attachment.  
 
Addictions – From Pathophysiology to Treatment 438 
Finally, some of them had to endure sudden changes in their daily life and moved to 
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of early caregiving and a guarantee of protection from danger, as well as a secure base for 
the exploration of the environment. This concept of community allows us to consider it, all 
in all, as a parenting environment where the a growth towards motherhood can be followed 
and supported, where mothers are no longer blamed or punished for their inadequacy and 
difficulties but rather are offered a very important chance to experience regression to the 
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psychologists etc.). The chance to experience mixed feelings towards their institutional 
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However, when minors are sent to therapeutic communities together with their mothers, 
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The project “Research and intervention on minors in communities for drug-addicted 
mothers and their children: from at-risk parenting to child wellbeing” is the result of joint 
work carried out by the Psychology Department of the University of Padua and two 
therapeutic communities for addicted mothers and their children, Villa Emma and Casa 
Aurora, located in Venice and its mainland (Mestre) and run by the social cooperative Villa 
Renata.  
The project provides a multi-method evaluation through a longitudinal approach aimed at 
programming and monitoring the interventions performed by parents while following the 
development of children living in therapeutic communities. Developmental risk factors 
and/or clinically relevant, real life symptoms are identified as they emerge. Our theoretical 
and methodological points of reference are based on the study of parenting and 
development according to the current, dynamic, multi-factor models of influence (Belsky, 
1984; Gabble, Belsky, Crnic 1992; De Palo, 2010).  
The setting of the project is the therapeutic community and its complex caregiving system. 
The focus of the assessment is set on three areas, each of which is investigated at different 
levels: (a) evaluation of the mother’s psychic condition, in terms of personality and 
individual characteristics, assessed through interviews (such as the Adult Attachment 
Interview6, SCID-II7), questionnaires and dynamic tests (Rorchach8); (b) evaluation of the 
                                                                 
6 The Adult Attachment Interview (AAI) developed by George, Kaplan and Main (1985) is a semi-
structured interview assessing attachment in adolescence and adult age. The interview includes a series 
of questions through which a subject is asked to recall his/her attachment history and attachment 
experiences with his/her caregivers during infancy. The AAI coding scheme foresees two distinct 
phases: a first phase during which text content and form are analyzed through Evaluation Scales (Scales 
of Subjective Experience and Scales of the State of Mind) and a second phase during which the 
interview is analyzed as a whole in order to formulate a categorical classification of the subject’s 
attachment.  
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mother’s parenting capabilities as well as those of the father’s (if present), through the 
observation of their interactions with the child both in daily routine exchanges and/or in 
structured settings (Attachment Q-Sort9, Lausanne Trilogue Play10, Emotional Availability 
Scales11); (c) evaluation of the child’s development and adjustment through assessment 
measures for the developmental age (Vineland Scales12, Child Behavior Check List13, 
Attachment Story Completion Task14), aimed at identifying a developmental diagnosis 
according to the indications of the current 0-3 classification system for early infancy; (d) a 
comprehensive analysis of the progressive and current context of relations between 
caregiver and child, exploring limits and points of strength; (e) data obtained at various 
observational levels are shared by a professional team striving to achieve data integration so 
as to guarantee a very careful and comprehensive evaluation. Thanks to these organized 
data, it is possible to acquire a deeper knowledge and a better understanding of the  
                                                                                                                                                                   
7 The Structured Clinical Interview for DSM-III-R . The SCID-II (First, Gibbon, Spitzer, Williams, & 
Benjamin, 1997) allows diagnostic evaluations of a potential personality disorder such as the ones included 
on Axis II of DSM-IV, passive-aggressive and depressive disorders (Appendix B of DSM-IV) and 
unspecified personality disorder (UPD). The Italian version of the SCID for DSM-IV was published in 2003. 
8 The Rorschach Test (Rorschach, 1921) is a perception, projective, psycho-diagnostic instrument. It is 
composed of 10 standardized cards out of 23 (5 black and grey, 2 red and grey and 3 multi-coloured), 
each of them carrying a symmetric ink-blot. With this test, it is possible to observe both stable 
personality traits as well as a possible psychopathology or possible affective disorders. Moreover, this 
test offers very valuable information on the subject’s intelligence and cognitive processes. As for data 
analysis and interpretation, they are carried out both at quantitative and at qualitative level. 
9 The Attachment Q-Sort (Waters, & Deane, 1985) allows repeated data acquisition over one single week, 
so as to compare the attachment bonds created by the child with his/her caregivers, as well as a 
measurement of children’s attachment over a longer period of time (from 1 to 5 years). The AQS comprises 
90 items which describe a child’s attachment behaviours in his/her natural, everyday home environment. 
10 The Lausanne Trilogue Play (LTP, Fivaz-Depeursinge, Corboz-Warnery, 1999) is a semi-
standardized, laboratory, play procedure during which mother, father and child interact. This 
procedure allows observation and evaluation of the quality of interactions within the mother-father-
child family system during a play interaction where all three partners are involved at the same time. 
The coding scheme of the LTP procedure is made up of 10 scales, each of them defining an observation 
variable (Lavanchy, Cunnet, Favez, 2006). They are graduated on a 5-point Likert Scale (range 1 – 5) and 
coded for each of the four parts of the procedure. 
11 Emotional Availability Scales (EAS, Biringen Robison Emde, 1998 ) Interactive adult-child video-
recordings are observed and evaluated according to the adult’s sensitivity, his/her capacity to frame the 
environment, his/her non-intrusiveness and non-hostility. The child’s involvement and his/her replies 
to the adult are evaluated too. 
12 The Vineland scales allow measurement – by means of a semi-structured interview –of 4 main 
dimensions (scales) and 11 sub-dimensions (subscales). They can find application in various clinical, 
educational and research settings: they are particularly useful to observe adaptive behaviours and to 
investigate to what degree a disability, if present, can have an impact on the subject’s everyday 
performances.  
13 Child Behavior Check List Achenbach CBCL (1991, 1992) This scale allows to investigate social 
competencies and behavioural problems in children aged 18 months - 18 years. Its items favour a 
description of the child’s behavioural and emotional repertoire through the narratives supplied by 
parents, teachers and/or educators supporting the evaluation of a potentially problematic conduct as 
listed in the behavioural scales. 
14 The Attachment Story Completion Task (ASCT; Bretherton, Ridgeway, Cassidy, 1990) was designed 
to assess attachment style in preschool and school age. Five story stems referring to attachment-relevant 
family themes are presented to the child who is asked to complete them freely using a set of dolls and 
props.  
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Table 2. Phases of our research project: “A model of research and intervention on minors in 
communities for drug-addicted mothers and their children: from at-risk parenting to child 
wellbeing”. 
caregiver, the child and their relationship: these data also help professionals to more clearly 
identify the therapeutic and pedagogical objectives to be suggested to the dyad, which can 
then be supported and monitored over time. These objectives can be modified and re-
elaborated according to each individual project but also to the changes observed during the 
intervention. In fact, the same evaluation procedure is administered at different times 
during the mother-child residential period. It aims at monitoring the interventions and any 
possible change as well as identifying eventual aspects of danger and/or increased risk that 
may require the use of further community facilities. A continuous assessment of the 
intervention is a powerful instrument to reflect, both clinically and ethically, on the 
opportunity to go on providing care to mother-child pairs featuring elements of danger and 
pathology. This assessment also examines the presence of prejudicial clinical manifestations 
of the child and any developmental difficulties related to inadequate maternal care which 
can arise in spite of the protective and rehabilitative intervention provided by the 
community and its comprehensive setting. In 2010, we started gathering data which are 
presently being processed and which will be described in depth in this chapter.  
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6. Conclusions 
Our project started in 2009: the following, preliminary results are now available (De Palo, 
Simonelli, Capra, 2010). Twenty-four mothers took part to the program: they were evaluated 
according to the 1st phase protocol. The reported data refer to the first twelve of them, whom 
data have already been processed for. Generally speaking, 31 is their mean age: they entered 
the community at different times from 2007 to 2010. Most of them started consuming 
substances during pre-adolescence/adolescence (12-19 years).  
The first aspect refers to personality diagnosis: 10 subjects were diagnosed a structure of 
personality with borderline features (polydrug use of psychotropic substances with heroin 
as the main substance of abuse). This characteristic shows a clinically significant association 
with some other investigated aspects, particularly, with an insecure attachment style which 
is prevalent within the group and which seems to be rooted in experiences of traumatic 
and/or doleful events during these women’s infancy, especially physical and sexual abuse 
which most of them experienced in intra-familial environments. Moreover, their attachment 
style, which developed on the basis of their infantile experiences with their caregivers, is 
associated to disorganization characteristics and a difficulty to work through early 
experiences of loss or trauma. The educational style they experienced in their families of 
origin was predominantly coercive. To sum up, at exploratory level we can say that, in the 
mothers accommodated at the community, we notice associations between early traumatic 
events (coercive educational style and abuse) experienced within their families of origin, an 
insecure working-through of their own attachment history and borderline personality 
features. These results urge us towards a reflection on feasible intervention methods for 
patients presenting similar clinical pictures where drug-addiction almost seems just a 
symptom of a more complex pathology. At the same time, this reflection seems of 
paramount importance to globally re-think interventions in favor of minors living in the 
community: in fact, shouldn’t the fact of being born to mothers with similar characteristics 
be considered in itself a vulnerability factor which shall issue to psychopathology? 
We believe that a possible answer can be found within the described project, since the main 
objective of our research and intervention model is to observe the child’s level of 
development and the risk and protective factors characterizing his/her growth so as to plan 
taylor-made interventions to satisfy each single minor client’s needs and support each single 
mother-child relationship. Therefore, within the model we presented in this paper, attention 
is focused on the well-being of minors who were born to drug-addicted mothers. Reason for 
this choice is the unavoidable need to carefully and realistically consider the condition of 
these children: their drug-addicted mothers present an at-risk parenting function and are 
therefore supported by educators who play the role of more adequate, alternative 
caregivers. The “adolescent” aspect of drug-addicted women can be a major risk factor 
against the assumption of their parental role: these mothers are often envious of the 
therapeutic support which is given to the child and which develops in a situation of conflict 
between mother and child. Moreover, these patients often have great difficulties in 
acknowledging limits, even physical ones, between their child and themselves: these 
mothers often find it hard to distinguish themselves from their child, especially if it is a 
female child, and they mix up their thoughts, actions and feelings with those of their 
daughters. When they have a male child, they find it difficult to differentiate their sons from 
their own fathers or partners. Therefore, by choosing to set up a project on minors’ health, 
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all research objectives are focused on the viable, most adequate actions to be taken in order 
to achieve the set goal, that is, the well-being of children born to adults with parenting 
function at risk.  
To this extent, a parallel administration of evaluation measures both to the mother and to 
the educator makes it possible to investigate what is the latter’s (and the community’s) 
image of the child. Carefully monitoring the idea the community has of a child makes it 
possible to create a univocal perception of him/her which otherwise gets lost in the various 
circumstances characterizing the community environment. The attention educators 
continuously devote to the child is shared with the mother, with whom they strive to create 
a univocal, shared image of the minor. Actually, within a community for drug-addicted 
mothers and their children, both educators and the very treating team perform the function 
of secure base which neither the mother nor the child have found elsewhere: they offer an 
alternative and vicarious relational model both to women and their children. Since 
educators possess characteristics that are typical of early caregivers (closeness, continuous 
presence, responsiveness etc.), they often find themselves emotionally involved in the 
relationship with the child: for this reason, their continuous training and supervision aim at 
helping them to stick to their professional role, without wanting to replace the mother’s role.  
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circumstances characterizing the community environment. The attention educators 
continuously devote to the child is shared with the mother, with whom they strive to create 
a univocal, shared image of the minor. Actually, within a community for drug-addicted 
mothers and their children, both educators and the very treating team perform the function 
of secure base which neither the mother nor the child have found elsewhere: they offer an 
alternative and vicarious relational model both to women and their children. Since 
educators possess characteristics that are typical of early caregivers (closeness, continuous 
presence, responsiveness etc.), they often find themselves emotionally involved in the 
relationship with the child: for this reason, their continuous training and supervision aim at 
helping them to stick to their professional role, without wanting to replace the mother’s role.  
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HCV and Drug Use – What Can Be Learned  
from the Failure to Control This Epidemic? 
Philippe Chossegros 
         UHSI Lyon, Hospives Civils de Lyon,  
French National Coordination of Healthcare Networks, 
France 
1. Introduction 
Around 10 million intravenous drug addicts (IDUs) have been infected by the virus of 
hepatitis C (HCV) and around 1.2 million are HBsAg positive. Clear geographical 
differences exist in prevalence ranging in Western Europe between 37 and 98 % (1). At 
WHO’s 63rd World Health Assembly in May, 2010, a resolution was passed to establish 
“goals and strategies for disease control, increasing education and promoting screening 
and treatment of people infected with HBV and HCV”. In 2011, the WHO argued that 
injecting drug users (IDUs) are a key group that needs to be specifically targeted for 
prevention and treatment of viral hepatitis. At a time when a worldwide significant 
reduction in the HIV epidemic among drug users (DU) is observed, the spread of HCV 
infections is not controlled. If large variations are observed between countries and 
regions, prevalence of HCV infection of more than 70 % has been reported among recent-
onset DUs (2) and, in 2009, in a city, Vancouver, with one of the most diversified and 
publicized panel of care services for substance users, Grebely et al. could make the 
statement that “overall, the rate of new HCV seroconversions in this cohort in the study 
period was about 25 times the rate of HCV treatment uptake. There are extremely low 
rates of HCV treatment initiation and very limited effectiveness, despite a high prevalence 
of HCV infection in this large community-based cohort of inner city residents with access 
to universal healthcare”. It underlines the limits of the risk reduction policy which has 
been advocated and promoted for the last 20 years (3).  
This quasi universal observation may be explained by differences between the viral 
epidemics of HIV, HBV, HCV and HDV and between their local management. I will 
confront my own experience and what I have understood of this epidemic in France to a 
selection of the international literature to propose what, I believe, could improve the care 
not only of hepatitis but of DUs themselves.  
2. A scientific look at the HCV epidemic among DUs 
An attempt at understanding the HCV epidemic can be considered as an object of science 
and discussed as such.  
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2.1 What is known of HCV hepatitis? 
Our knowledge of HCV has grown tremendously since its discovery in 1988. However, gray 
areas persist. To develop effective control strategies, it is crucially important to determine 
how epidemiological significant organisms infect us, what is their natural history and what 
efficacy for its treatment. In most cases these evaluations are not easy.  
2.1.1 HCV transmission among DUs: A reappraisal 
In 2008, Rhodes et al. observed that “there was much confusion and uncertainty concerning 
HCV knowledge, including its medical and transmission risks” among drug injectors. Most 
IDUs viewed HCV prevalence as high and HCV transmission as an inevitable consequence 
of injecting, HCV risk was perceived as ubiquitous and unavoidable” (4). Is this confusion 
and uncertainty to be assigned to the messages they receive or our limited understanding of 
this disease and of its communication?  
2.1.1.1 Drug use and HCV: the mystery of the contamination of non injecting drug users 
(NIDU) 
The discovery of HCV followed a search for a viral cause of the remaining post-transfusion 
hepatitis after HBV had been excluded. Injections make a difference: 
• Blood borne transmission through syringe and needle sharing (NSS) has never been 
questioned and the evidence linking drug injection and NSS to HCV infections are 
overwhelming. However the level of infectivity of the HCV containing blood remaining 
in a needle or a syringe after injecting is not known. It is likely that the viral load will be 
a limiting factor and it is obvious that HCV is able to survive in the environment but we 
do not for how long? HCV infection is robustly associated with the duration of 
injections, the number of receptive injecting episodes and of needles and syringes 
exchanges (NSS), but despite these associations, IDUs may remain hepatitis free after 
years of risks and others may be contaminated after a unique exchange The observation 
of Smyth and al. that accidental and unnoticed sharing of injecting equipment may be 
an important contributor to an IDU’s increasing risk of infection over time (5) tallies 
with my own experience.  
• The incidence of contamination through other drug paraphernalia is still debated. 
Cross-sectional studies have given conflicting results, but cohort studies were able to 
show significant relations between HCV contamination and sharing drug cookers and 
filtration cottons among IDUs who did not share syringes (6,7). 
• Despite a much higher HCV prevalence (35.3 %) in non injecting drug users (NIDUs) 
than in non-drug users in some studies (8), the role of equipment (straws, bills, 
pipes,…) in HCV transmission remains unclear since statistical correlation has never 
been consistently found, since some misclassification of previous injectors could have 
occurred and since other possible modes of contamination such as tattooing or sexual 
transmission were often present (8). However, in some other studies, this prevalence 
was in the low range observed in individuals living in the same household as HCV 
carriers. Since it is obvious that every contact is not infectious, a comparison relating 
their number, the state of the nasal and buccal mucosa (cocaine, heroin) and the lips 
(crack) (9,10) at the time of sharing , as well as the HCV status of the DUS with whom 
the equipment was shared could help to understand the cause of these staggering 
discrepancies.  
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2.1.1.2 Possible modes of HCV contamination: blood but what else? 
An early assimilation to HBV and to HIV, led to the hypothesis that HCV was a sexually 
transmitted disease. In 1990, a study conducted in Barcelona, in an AIDS clinic, found that 
11 % of the partners of infected drug users and 16 % of the partners of infected homosexuals 
were seropositive for HCV (11). In 1999, using HCV genotypes, Neumayr et al., exploring 
heterosexual transmission of hepatitis C, finding no other cause of contamination concluded 
that sexual intercourse could be the cause of contamination in half of the cases (2,5 %) 
despite any significant relationship with any sexual practice (12). The same year, a 
metaanalysis computed an order of 1-3 % probability of being found infected among sexual 
partners of HCV carriers with no other known risk of contamination. The authors had no 
clue to counsel on their sexual practice viremic HCV carriers with a long term relationship 
who had not transmitted their infection (13). Overall, since the allocation of these 
contaminations to sexual intercourse was not significantly related with any history of 
particular sexual practice, room is left for other possible but never proven modes of 
contamination such as sharing razor or toothbrushes or, once every other suspected modes 
of contamination have been excluded, the mysterious “household” transmission (14).  
Recent studies rediscovered the risk of sexual transmission among men who have sex with 
men (MSM) with high-risk sexual behavior (15–17). The HIV epidemic with its mortality 
and its transient behavioral changes may have hidden its existence for a while, but a 
Canadian cohort study of HIV positive MSM was able to trace their first contaminations to 
1996, with an increase in the incidence of HCV contamination from 0.9 to 2.2 per 1000 
person-year to 23.4 and 51.1 % in 2007 which could be related to an increase in the HCV 
prevalence among MSM as well as an increased level of risks taken during sexual 
intercourse (18).  
Needles are used to perform tattoos and piercings. They are an obvious risk of transmission 
of HCV and they have been involved in small epidemics. Today, sterile material is used in 
professional parlors. Thus it is not surprising that non professional tattooing may be 
associated with a significant risk of HCV transmission among high-risk groups (19). 
However, like snorting drug, these contaminations, if possible, remain epidemiologically 
marginal when compared with NSS (20).  
2.1.1.3 New insights and new tools could change our understanding of the HCV epidemic 
•  A consensual belief that HCV antibodies can always be detected years after a 
contamination has been recently contradicted. If a previous contamination with HCV 
gives usually rise to antibody production (humoral response) 45–68 days after HCV 
infection, the presence of a cellular immunity in absence of antibodies has been known 
for more than 10 years but its epidemiological implication has been ignored until 
recently (21,22). The discovery that some acute HCV hepatitis could occur and be 
spontaneously cured without any detection of anti HCV through sequential studies of 
new expositions has confirmed this hypothesis. It was observed in as many as 33 % of 
RNA positive cases (23). HCV has also been found in the liver or lymphoid tissue 
despite the absence of detectable HCV RNA and, even, of HCV antibodies. These occult 
infections could be the cause of some cases of persistently elevated transaminases (24). 
However, the clinical meaning of these silent forms which include persistence of HCV 
in the tissue after clearance of HCV viremia is still a subject of debate (24,25). There was 
no difference in the prevalence of HCV markers between family members of patients 
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with my own experience.  
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Cross-sectional studies have given conflicting results, but cohort studies were able to 
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• Despite a much higher HCV prevalence (35.3 %) in non injecting drug users (NIDUs) 
than in non-drug users in some studies (8), the role of equipment (straws, bills, 
pipes,…) in HCV transmission remains unclear since statistical correlation has never 
been consistently found, since some misclassification of previous injectors could have 
occurred and since other possible modes of contamination such as tattooing or sexual 
transmission were often present (8). However, in some other studies, this prevalence 
was in the low range observed in individuals living in the same household as HCV 
carriers. Since it is obvious that every contact is not infectious, a comparison relating 
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with occult HCV infection and family members of patients with a chronic hepatitis C 
(26). 
Among IDUS different profiles have been described: but existing data are too scarce and 
sometimes contradictory to decide what is the real occurence of these evolutions:  
• In IDUs engaging in risky behaviors for years without being infected by HCV, the 
prevalence of HCV-specific T cell response was significantly higher than that of healthy 
controls in an English study (58/19 %, p=.004) (27). In another study, this response 
reached 62 % of at risk IDUs lacking antibodies (28). The authors report a 100 % positive 
response for subjects who indicated that they had shared syringes during the previous 6 
months as compared to 50 % who had not, implying a possible disappearance of 
cellular immunity with time.  
• The studies of reinfections occurring in IDUs followed up with repeated blood testing 
added a new understanding to the clearance of HCV infections: When the rate of NSS 
remains high and if the tests are repeated at short intervals, a significant incidence of 
reinfections is observed with a new clearance of HCV RNA observed in more than 40 % 
of the cases (29,30). It confirms the well known notion of an absence of a total protection 
by a previous immunization against HCV, as well as the possible immunity in some 
cases (31,32), but points out a high prevalence of repeated HCV clearance which was 
not known.  
• At last, genotyping HCV core sequences may identify phylogenic clusters and help to 
better understand HCV transmissions among IDUs and NIDUs (33). 
These notions could be of use to explain some of the confusing observation of dissimilar 
serological status among couples and IDUs with the same risky behaviors in the same 
neighborhood.  
2.1.2 The evolution of HCV chronic hepatitis: A lottery governed by genes?  
Currently, HCV, a positive-strand RNA virus distantly related to the Flaviviriadae family, is 
classified in 6 major genotypes and multiple subtypes. An excellent description of the 
disease can be found online in the 2004 EMCDDA monography (34).  
2.1.2.1 What prognosis for the HCV infections of IDUs? 
If some chronic HCV infections progress to cirrhosis, liver cancer and death, this evolution 
is still unpredictable:  
• It is assumed that, after an acute infection, 20 % of the subjects will clear spontaneously 
the virus. Using antibody screening followed by RNA amplification, 20 % of the cases 
occurring among IDUs following an acute infection resolve spontaneously (35,36) with 
a lower clearance rate in HIV infected and African-Americans (37). This prevalence of 
viral clearance is not significantly different from the general population. 
• Progression toward cirrhosis of HCV hepatitis has been studied by two meta-analysis, 
the second selecting DUs (38,39). The first concluded that cirrhotic progression was 
comprised between 7 and 18 % after an evolution of 20 years, the second was more 
precise with a progression rate of 14,8 % with a confidence interval of 7.5 to 25.5 %. 
Male sex and alcohol consumption added an additional 5 % each. However, when the 
original studies were independently considered the progression rate could vary from 
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0.3 to 34.9 %, and the computation was performed using the data of 47 papers selected 
out of 764 potentially relevant articles and 6 679 abstracts. Significant bias could explain 
these ranges such as a selection of symptomatic patients or the different proposal to 
perform liver biopsies and their acceptance. In my own series of 650 DUs recruited 
through my addiction network and in prison with liver biopsies proposed and 
performed (acceptance 98 %) whenever HCV RNA was present independently of the 
level of transaminases, after 20 years, the prevalence of cirrhosis was 10,5 % (alcoholics   
non alcoholics 3.6 %; alcoholics 12.5 %). In a study conducted in the general population 
in Italy, HCV infection was associated with a severe liver disease in less than 50 % of 
the cases (40). In these studies as well as in a study of DUs, a high daily intake of 
alcohol (3 or more drinks) explained most early progression to cirrhosis in DUs (36).  
• The prognosis of post-transfusional hepatitis mortality has been the first to be studied. 
They are characterized by their high rate of early death, their old age at contamination 
and the one-shot infection. It is believed that infections occurring at a younger age have a 
more benign evolution. Nurses infected by contaminated gammaglobulins had a 1 % 
prevalence of cirrhosis with no death after 25 years (41). This benign evolution has been 
confirmed by others (42). In 5 transfusion retrospective studies, 25 years after exposure 
all-cause mortality was not different between cases with an history of acute hepatitis and 
controls and the liver-related death significantly higher than controls was lower than 3 % 
(42). 16 years after contamination, a national cohort had no excess mortality compared to 
controls, but the risk of death directly from liver diseases was higher (Hazard ratio: 2.71, 
95% CI 1.09-6.75). An excessive alcoholic consumption was present in 30 % of those deaths 
(43) Progression after 20 years is “less” known but the overall mortality of HCV liver 
diseases is usually considered to be in a range of 20 to 30 %. The higher rate of death 
observed among veterans. infected by HCV by Butt et al in 2009 could be related to the 
presence of other comorbidities such as alcohol, tobacco, violence… since the cause of 
death was not recorded (44). However, modelisation of the impact of C hepatitis 
treatment on patients’ survival should consider the high rate of other causes of death 
among IDUs. They represent a significant proportion of infected people (44) : In a cohort 
of acute HCV hepatitis followed 25 years, if 8 % were cirrhotic, the death rate by overdose 
was eight times higher than the risk of dying of a liver disease (45) suicide, violence are 
common and, in older DUs, cardiovascular or pulmonary diseases compete with HIV and 
HCV (46–4).. In a more recent study conducted in of long-term heroin addicts in 
California, premature mortality was high, but “only” 14 % of the deaths were related to 
liver diseases (50).  
A search of prognosis markers of progression in hepatitis C has led to the identification of 
modifiable and non-modifiable factors which influence its evolution. An older age at 
infection, a longer evolution, being male or African-American (cancer), viral genotype 3 are 
non-modifiableOn the contrary, an alcohol consumption greater than 30-50 g/day, smoking 
(cancer), iron overload, coinfection in HBV and/or immunocompromised HIV positive 
patients, presence of a metabolic syndrome (obesity, steatosis, insulin resistance) can be 
acted upon to improve individual prognosis (51). More recently, a search for more accurate 
predictors of progression to cirrhosis led to genome-wide association studies (GWAS), 
screening the entire human genome. They identified single nucleotide polymorphisms 
(SNP) which are not often responsible for functional effects but serve as tag for the causal 
variant that is not genotyped: 
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in Italy, HCV infection was associated with a severe liver disease in less than 50 % of 
the cases (40). In these studies as well as in a study of DUs, a high daily intake of 
alcohol (3 or more drinks) explained most early progression to cirrhosis in DUs (36).  
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and the one-shot infection. It is believed that infections occurring at a younger age have a 
more benign evolution. Nurses infected by contaminated gammaglobulins had a 1 % 
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acted upon to improve individual prognosis (51). More recently, a search for more accurate 
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screening the entire human genome. They identified single nucleotide polymorphisms 
(SNP) which are not often responsible for functional effects but serve as tag for the causal 
variant that is not genotyped: 
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• The study of patients resistant to HCV infection has shown that multiple independent 
protective genetic factors could explain their diverse evolution: clearance of HCV 
remaining anti HCV positive (52,53) and “protection” against HCV without production 
of antibodies (53).  
• A link between fibrosis progression and genetic predisposition has been considered 
after the observation of familial clusters of HCV-related cirrhosis (54). An independent 
GWAS identified a genetic variant, already associated with alcoholic and non-alcoholic 
fatty liver disease (55), associated with steatosis and fibrosis severity in HCV related 
hepatitis (56). The screening of host genetic factors has led to a selection of seven single-
nucleotide polymorphisms used to compute a Cirrhosis Risk Score (CRS) which could 
be able to stratify patients’ cirrhosis risk prior to liver biopsy (57). This CRS was able to 
predict progression to cirrhosis in male patients at a F0 stage of fibrosis, result which 
could lead to treat them early without having to wait for the development of a 
significant liver disease. The prognosis value of the CRS held true even in patients who 
abused alcohol (58). 
2.1.2.2 Coinfections of HCV hepatitis with other viruses have worse disease progression 
and outcome  
Since high risk practices are common among IDUs, concomitant or successive 
contaminations by HBV, HCV and HDV, as well as HIV may be observed:  
• HBV is a partially double stranded, enveloped DNA virus of the Hepadna family and 
HDV is a defective RNA virus which requires the presence of an active HBV infection 
for its multiplication. The evolution of coinfections is dependent of the innate and 
adaptative immune host response. The results of their interactions are unforeseeable, 
but it seems that the newcomer will act as a dominant virus which can lead to the 
clearance of preexisting infections. Acute HBV, HDV or HCV coinfections or 
superinfection of HBV or HCV may be the cause of fulminant or subfulminant hepatitis. 
These interactions may also lead to occult, serologically silent HBV or HCV infections. 
Coinfections are believed to result in worse disease progression with a higher risk of 
cirrhosis and hepatocellular carcinoma when compared to HBV or HCV alone 
(46,59,60).  
• Up to one-third of HIV-infected patients are infected with hepatitis C virus. The 
advent of Highly Active Antiviral treatment (HAART) has transformed the  
prognosis of HIV infected patients with the occurrence of significant liver related 
death related to the prolongation of their life expectancy. A meta-analysis of 17 
studies including 3567 individuals confirmed that chronic hepatitis C outcomes are 
worse among coinfected individuals with a prevalence of cirrhosis of 49 % (40 to 59 
%), twice the rate observed in monoinfected patients (21 %; 16-28 %). This 
acceleration is mainly observed in immunocompomised patients and could be 
acccentuated by an immune reactivation occurring after the introduction of HAART. 
On the other hand, HAART might lessen progression of chronic liver disease and 
improve response to anti-HCV therapy without fully correcting the adverse effect of 
HIV infection on HCV prognosis (61-63) . If hepatic side effects of antiretroviral 
treatments are common, they do not seem to have a significant effect on the 
progression of liver fibrosis (64).   
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2.1.3 Hepatitis C management: Toward a potential Copernician revolution (at a price)  
2.1.3.1 Less invasive diagnosis tools 
Medical tools have also evolved with less invasive tests for the diagnosis and the follow-up 
of HCV hepatitis: 
• Individuals who perform a test are eager to know its result without waiting for days. 
Blood access of IDUs is often problematic. Rapid tests answer these problems. After HIV, 
they have become available for HCV diagnosis. They can be performed using saliva, 
whole blood, serum or plasma. The frame of their use is controversial. In France, they can 
only be used by healthcare professionals with a complementary traditional test as 
confirmation. In the United-states where HIV auto-tests are available, in a DTP 24 % of 
preferred to remain anonymous, preference which reached 38 % if the test was free (65).  
• To detect an ongoing infection, an amplification of the viral RNA is performed which is 
prone to contamination and false positive results. HCV core antigen detection, easily 
automated, and requiring less technical skill, has been advocated. Its limitations are 
noted in some HBV/HCV coinfections (66–68).  
• Liver biopsy is often believed to be dangerous and painful by some patients and most 
general practitioners becoming a barrier to the care of hepatitis C patients. Non invasive 
tests are proposed: either scores computed from the results of different blood tests or a 
measure of the elastance (fibroscan) of the liver. Diverse algorithms have been proposed 
to improve their results but they are today an indisputable alternative to liver biopsy 
even in HIV/HCV coinfected patients (69,70). The fibroscan does not need a blood 
sample and gives immediate results (71).  
2.1.3.2 Treat all, cure all? 
• For 10 years, the treatment of HCV hepatitis has been an association of a long lasting 
form of alpha interferon with ribavirine. It is able to reduce significantly HCV related 
mortality (71) Today, there is a clear-cut difference of the response rate to treatment 
between the types of HCV viruses. Among the 6 genotypes, 2 and 3 need only 6 months 
of treatment with 80 to 90 % sustained viral response (SVR) whereas, genotype 1 and 4 
usually need 12 months for a SVR of 50 %. Response rate of DUs are in the same range 
as the general population (72). Our finding of a significantly better SVR of genotype 1 
infected DUs treated by buprenorphine as compared to methadone remains to be 
explored in a prospective study exploring that difference (73). An “à la carte” 
adaptation of the duration of treatment has been proposed for genotype 1 following the 
time of RNA clearance at 4, 12 or 32 weeks followed by respective treatment duration of 
24, 48 or 72 weeks which has been confirmed for HIV/HCV coinfections (74,75). For 
patients with advanced diseases, treatment has been completed thanks to the use of 
growth factors which improved their tolerance (76)). 
• This individual response could be predicted before treatment prescription: A better 
knowledge of the immune response against hepatitis C gives a central role to regulatory 
T lymphocytes which are present in the necroinflammatory infiltrate of the liver. By 
studying a single nucleotide polymorphisms (SNPs) linked to the IFN-lambda 3 (IL28B) 
gene it is now possible to predict a better prognosis for patients infected with genotype 
1 with the CC genotype. They are more than twice as likely to respond to 48 weeks of 
treatment than non-CC genotypes (CT,TT) (77,78). This association has also been found 
in hepatitis C virus genotype 2 or 3 patients (79) and in HIV coinfected patients (80), but 
not in genotype 5 (81).  
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• The study of patients resistant to HCV infection has shown that multiple independent 
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2.1.3 Hepatitis C management: Toward a potential Copernician revolution (at a price)  
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treatment than non-CC genotypes (CT,TT) (77,78). This association has also been found 
in hepatitis C virus genotype 2 or 3 patients (79) and in HIV coinfected patients (80), but 
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• However, new drugs which have been specifically tailored to HCV will improve these 
results. The first antiproteases on the market, Telaprevir and boceprevir improved the 
SVR for genotype 1 from 50 to 70 % for naïve patients and improved significantly SVRs 
of previous relapsers or non-responders (82,83). Since these drugs are added to 
interferon/ribavirine side–effects are more frequent and severe with serious cutaneous 
reactions (telaprevir) or a need for more growth factors (boceprevir). Early responder 
could benefit of shorter treatments. Other drugs are in the pipeline which could still 
have better results. The combination of two antivirals to the association of 
interferon/ribavirine led to a 100 % viral response, 12 weeks after the completion of 
treatment in previous non responders of a classical bitherapy. In a near future, 
association of 2 antivirals tailored for HCV should be able to cure almost every infected 
patient. This improvement has a cost: A full treatment course of telaprevir (12 weeks 
fixed-duration) will cost £30 000, whereas a full treatment course of boceprevir will 
range from to €22 000 to €40 000 (84) which should be added to the €16 000 of 48 weeks 
of bitheray by interferon and vidarabine for a genotype 1 (for a genotype 2 or 3, 24 
weeks of a classic bitherapy are usually sufficient) and to the €1 000, annual cost of the 
care. The latest communications in international hepatology meetings promise a second 
generation of antivirals more effective with less side-effects which could be used in 
association without interferon and, in some cases, ribavriine in a near future. They 
should be able to cure almost all the hepatitis whatever their genotype. We do not know 
yet what will be their cost. 
• Among HCV/HIV coinfected DUS at risk for liver disease progression a combination of 
interferon and ribavirin, is not highly effective; it has lower rates of SVR than 
monoinfected patients, especially for coinfected patients with HCV genotype 1 and 
those of African descent. Direct-acting antivirals might overcome factors such as 
immunodeficiency that can reduce the efficacy of IFN with the additional problem of 
interaction with antiretrovirals which should lead to early treatment independent of the 
stage of the liver disease, before the introduction of an HIV antiviral treatment (85).  
• Most of the infectious epidemics observed in humans have been controlled by vaccination 
campaign. Novel vaccine candidates have been studied based on molecular technology 
such as recombinant proteins (E1 and/or E2 glycoprotein), poly peptides, virus-like 
particles, plasmid DNA and recombinant viral vectors which can be combined with novel 
adjuvants. Some of them have reached Phase I/II human clinical trials with, in some 
cases, production of robust antiviral immunity but the challenge is to move to test their 
efficacy in at-risk of infected population to prevent new infections. Their cost has led to 
preferential studies of their efficacy as adjuvant for existing treatment (86,87).  
2.1.4 Conclusion: DUs confusion and uncertainty are founded (they are not alone in 
that situation) 
We may know for certain that HCV infection follows conditions or practices causing blood 
transmission whether through contaminated needles or through mucosal traumatism 
and/or bleeding during hetero or homosexual intercourse. However, the studies of HCV 
transmission explore only the expected associations the researchers believe to be relevant. 
One must be cautious not to mix up low statistical significant association with causal 
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relationship and remember that our inability to explain some HCV contamination may be 
related to, until now, unknown or overlooked modes of contamination: Animal bites were 
found significantly related to HCV infections (88) and a model of transmission of HCV by 
biting arthropods could explain the maintenance of long-term endemic transmission of HCV 
in Africa and South-East Asia (89). The route of contamination of patients on hemodialysis 
has not yet been understood leading to a debate on the interest of their isolation (90).  
Today, our prevention messages are “simple”!!!: 
• Do not inject and if you do, never share syringes, needles or any injecting 
paraphernalia.  
• Never share bills and straws you use for sniffing or pipes you use to smoke cocaine. 
• Use condoms for every sexual intercourse. 
• Choose a reliable professional to perform your tattoos or piercings  
• Never share your toothbrush and your razor. 
• If, despite these counsels, you have taken some risks make a blood test. 
• If positive for HCV, ask to be treated. 
But, even if a DU could follow these very restricting recommendations, it is not possible to 
guarantee an absence of contamination. Confusion and indetermination are not gone. We 
are not on the eve of a simple training course for professionals as well as for the public at 
large which would explain hepatitis C and give coherent and always effective 
recommendations for prevention. We have to wait for effective vaccines. 
2.2 The epidemic of HCV hepatitis among DUs is not controlled 
More than 20 years after the discovery of the hepatitis C virus, much of the ongoing 
epidemic is attributable to unsafe drug injections. An evaluation of the drug consuming 
population and of the DUs infected with HCV is recognized as an arduous exercise. One can 
consider snapshots taken at one time or can study a trend in a cohort. Both approaches must 
consider the evolution of: 
• The population of DUs and the nature of drug consumption. Younger addicts cannot be 
treated as the older ones minus ten or twenty years. The French OFDT study “le matos” 
(the works), interviewing a panel of injectors, has been documenting these changes 
since the nineteen seventies. These different attitudes may coexist in different age 
groups (91). Despite globalization, each country and, even, each region, has its own 
history and market. I have described its course in France in a short overview in 2007 
(92). A series of publications relevant to the French drug consumption can be 
downloaded from the site of the Observatoire Français des Drogues et des 
Toxicomanies (OFDT) in free acess (http://www.ofdt.fr/ofdtdev/live/publi.html). 
• Illegal drugs’ use has cycles. Cocaine will succeed heroin, designer drugs will find a 
new public. A new drug is detected each week in the European market (93). Recently, 
high levels of amphetamine injection have been reported around the Baltic, as well as 
Slovakia and Hungary…. A tremendous growth of the drug business occurred since the 
beginning of a war on drugs and the repressive laws of the 1970s. It is related to the 
huge profitability of the trafficking and the increasing demand of new consumers for 
psychoactive drugs, licit or illicit. 
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2.2.1 How many (intravenous) drug users and what proportion is infected by HCV? 
Despite these recognized problems, figures are none the less produced: in counties of 
Western Europe, HCV prevalence among IDUs fall in a range comprised between 47.1 % 
(Austria) and Netherland (86.2 %) (94). The number of infected DUs in Western Europe 
could reach 727 500 (95% CI 497 000 – 1018 000).  
France is the only country were different approaches have been used at different times to 
estimate the number of DUs and of people infected by HCV. A comparison of their results 
gives an idea of the accuracy of these estimations: 
• The OFDT recently produced and discussed an estimation of the prevalence of problem 
drug users in France following a methodology shared by all the European countries: 5,4 
to 6,4 /1 000 hab 15-64 years old. This estimate is almost twice that of Germany but 
lower than Italy, Spain and UK which had the highest prevalence. It has certain limits 
which are listed in the publication with a rare honesty (95): 
• First, the changing definition of the subject of the estimate. In 1993, “heroin 
addicts” were, at least, 160 000. In 1995, the estimate was of 142-172 000 “opiate 
problem users”. In 2006, a new definition, taking into account the change in the 
drug market, considered “intravenous drug users or regular users of opiates, 
cocaine or amphetamines”, led to an increase of 44 %. The change in these 
estimates may be more related to a difference in definition than to a real change in 
the size of the population.  
• Second, the proposed estimate of 230 000 problem users (210 to 250 000) cannot 
hide the fact that the real range computed through the four different methods 
before its narrowing by the experts to a definite number, without convincing 
arguments explaining their choice, was 147 000 to 367 000.  
• Third, these approaches ignored the users who have not been and will not be in 
contact with one of the information sources used (arrest, treatment, health 
problems, death, etc.)”. For cocaine which is considered to be one of the most 
“addictive” drugs, no more than 20 % of users become addicted after 20 years of 
use, 80 % may not be accounted for by these evaluation (Wagner 2002). This 
statement is of importance, since this population is not negligible and can influence 
the evaluation of the number of patients infected by HCV through their drug use 
(96,97). In the nineties, most patients 30 to 40 years old, carriers of HCV, who came 
in our unit without any history of a possible contamination, confessed that 10 years 
before, on one or two “festive” occasions, they had injected drugs with friends and 
shared their syringes. They were not “addicts” and they did not consider 
themselves as such.  
• The Veille Sanitaire (VS), the French organization studying public health, conducted 4 
different surveys leading to four different results:,  
• Starting from HCV prevalence in the general population, two successive studies 
were conducted ten years apart (1994-2004) (98,99). Both addressed people covered 
by the French public welfare system (only 9 % of the recruited population agreed to 
make a test. They differed only by their scope. The second being much larger than 
the first. The interval of the first estimate was 500 000 to 600 000. Among IDUs, 
HCV prevalence was 78 %. Ten years later, what was presented as a more accurate 
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estimation of 367 000 was given with 65 % of viremic patients. The only 
explanation given to this spectacular decrease was the better methodology of the 
second study. Among the 0,38 % who recognized a previous history of injecting 
drugs, HCV prevalence was 55,5 % which would lead to a total of 150 000 French 
people with an history of at least one drug injectors in 2004, 82 500 of whom would 
be infected by HCV.  
• In 2003, the number of DUs infected by HCV and of the incidence of new 
contaminations started with an hypothesis of a number of active injectors ranging 
from 80 to 100 000, given, at the time, by the OFDT and a prevalence of 60 to 70 %. 
The proposed number of infected IDUs was 48 000 to 70 000 and the number of 
new infections ranged from 2 700 to 4 400 for an estimated yearly new 
contaminations of 11 % (100). 
• The fourth study was a cross-sectional multicenter survey of DUs having injected 
or snorted drugs at least once in their life conducted in 2004, the same year as the 
second population prevalence study (101). It was a two stage random survey of 
DUs selected to represent the diversity of drug use. Fingerprick blood samples 
were collected on blotting paper in 75 % of the screened population. The overall 
prevalence of HIV and HCV were respectively 10.8 (0.3 % under 30 years of age) 
and 59.8 % (NIDUs 27.9 %; IDUs 73,8 %; under 30 years 28%). In multivariate 
analysis, factors independently associated with HCV seropositivity were age over 
30, HIV seropositivity, having ever injected drugs, opiate substitution treatment 
(OST), crack use, and precarious housing. HIV seroprevalence was not related to an 
history of injecting, but increased with age with a geographic difference of 
prevalence.  
Contrary to the OFDT, no explanation was given of these discrepancies: a decrease of one 
third of the number of people infected by HCV between 1994 and 2004, and, the same year, 
2004, a discrepancy of 18.3 % between two estimations using different methodologies to 
assess HCV prevalence among IDUs.  
2.2.2 Is it possible to know HCV prevalence and incidence among DUs and what is the 
efficacy of harm reduction programmes? 
2.2.2.1 Cohorts the incidence and risk factors of new infections can only be studied in 
cohorts of IDUs initially seronegative 
Ideally, these cohorts should begin when IDUs start to inject and no drop out should occur 
or, at least, the drop outs should not differ from the rest of the cohort. Of course, these 
requirements are almost impossible to fulfill. In some cases, infection incidence rate was 
even computed from a retrospective selection of patients who had at least two serum 
samples available and found initially seronegative (102–104). In a prospective study in the 
north and east of France, 28.6 % were lost to follow-up and differed significantly from the 
others who remained in the study (6). These studies can inform on the modes of 
contamination. They can never accurately predict the true HCV incidence among all the 
DUs. However, the incidence rate of new HCV contaminations among NIDUs remained low 
in the few cohort studies which included them: 1/422 (0.4/100 PY (95 % CI 0.0-1.2) (105), 
none in those who did not start injection (106).  
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even computed from a retrospective selection of patients who had at least two serum 
samples available and found initially seronegative (102–104). In a prospective study in the 
north and east of France, 28.6 % were lost to follow-up and differed significantly from the 
others who remained in the study (6). These studies can inform on the modes of 
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The four randomized studies of the impact of interventions to prevent hepatitis C infection 
among IDUs were not able to show significant differences (106–108). Despite an exclusion of 
severe psychiatric or somatic illnesses, which represent a significant bias, the drop-out rates 
were high. For example, Abou-Saleh et al. explored behavioral interventions among DUs 
already followed by drug treatment services. Among the 206 IDUS (initially 1354) who 
remained after exclusion of HCV positivity, of severe mental or physical illnesses or serious 
legal problems, 54 % refused or dropped out during the inclusion process, 95 were 
randomized, 82 % and 65 % were followed at six months and 12 months. In a per-protocol 
approach, the rate of contamination was higher at the end of six months (18 %) than after 12 
months (12 %) and there was no significant difference between the two interventions even if 
the trend was “in the anticipated direction” (108). In an intention to treat, drop-outs would 
have been considered as possible contaminations raising the contamination rate over 50 %.  
Hagan et al. (109), mixed up these studies with different other interventions from bleach 
disinfection of syringes to behavioral interventions, in a report with strong methodological 
bias. First, the majority of the 26 studies were not intended to assess the efficacy of an 
intervention but to measure the rate of new infections among a cohort of IDUs. Then, they 
included the univariate odds-ratios of seroconversion even if they were not retained in 
multivariate analysis. For example, in the French study, a 60 % reduction in HCV incidence 
was observed between the patients treated with oral substitution treatment (OST) and the 
others. However, once the level of cotton and syringe sharing were included, this difference 
disappeared because these levels were not equally distributed between the two groups.  
These observations explain why the quality of evidence of intervention impacts is found to 
be lacking and why it is so difficult to prove the efficacy of any harm reduction procedures. 
At best they can show that DUs retained in a programme fare better than those who stay 
outside or who quit. But they cannot prove that the decision to take part in the programmes 
does not select less risky behaviors and, most of all, that the proposal of these programmes 
to every DU would result in a significant decrease of new contaminations, which, of course, 
should be their aim.  
2.2.2.2 Cross sectional studies 
The results of repeated cross-sectional studies have the advantage of not being dependent of 
the retention rate in a programme. However, the population recruitment must be 
representative of the population studied and its modalities must not change from one 
period to the next. An incidence survey has been added to the cross-sectional approach in 
some cases. The community based study by Mehta et al. in Baltimore (110) and the study of 
IDUs attending Needle and Syringe Programs (NSP) in Autsralia by Falster et al. (111) can 
be considered as models:  
• Mehta et al. studied a cohort of IDUs initially recruited in 1988-1989 and then added 
new IDUs in 1994-1995, 1998 and 2005-2008. They followed those who were 
seronegative for HCV and HIV and compared the new recruits. They observed a 
significant decrease in HIV infection from 5.5 cases/100 patient/year in 1988-1989 to 
0/100 py in 2005-2008, whereas there was no significant change in HCV incidence. The 
prevalence study observed a decline in HCV prevalence among the youngest (39 years) 
and those who had a shorter injection history (<15 years). An increase in the duration of 
injection to reach a 80 % prevalence was observed between 1988-1989 (5-9 years ) and 
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2005-2008 (15-19 years). After adjustment for demographic and time since injection, 
significant differences were observed between HCV prevalence in 1988-1989 and 1994-
1995 on one hand and 2005-2008 on the other. A small proportion of this decline was 
explained by changes in drug-related risk behavior over time. It could be the 
consequence of a decrease of HCV prevalence. 
• In Australia all IDUs attending a NSP site participating in the study were invited to 
complete an anonymous questionnaire and to provide a capillary blood sample 
(participation rate: 41 to 61 %) every year between 1995 and 2004 (Falster 2009). After 
adjustment for covariates, HCV antibody seropositivity remained associated with a 
longer duration of injecting, older age, participation in the state of New South Wales, 
opiates as the last drug injected, imprisonment in the last year, female sex, daily or 
more frequent injection, sharing needles and syringes in the last month, sex work, and 
survey participation in 2000–2004. An increase in HCV prevalence was found within 
injection initiation cohorts over time, with prevalence appearing to reach saturation 
around 90% in the older cohorts. An increase from 1895-1996 to 2003-2004 in the 
prevalence of HCV infection among IDUs who had injected less than 7 years could 
reflect an increase in the prevalence of HCV in that population. 
2.2.2.3 France and Lyon: the course of an epidemic 
Knowing the methodological limits of any evaluation of an HCV epidemic among DUs and 
of the effectiveness of harm reduction programs, I will present the results of the studies I 
conducted in Lyon and in France and, taking into account the other French evaluation on 
the subject and my experience of thirty years of care to DUs, I will give a tentative 
interpretation of the course of the epidemic in France. 
2.2.2.3.1 Prison 
I conducted studies in Lyon’s prison because it was the only place, outside of complex 
snowball enquiries, were no bias was met, in the recruitment of IDUs, which could be 
related to a care demand. Every IDU entering Lyon’s prisons between 19987-1989, 1997-1999 
and 2009-2011 were asked to answer a questionnaire and to provide a blood sample. 
Acceptance was high (>90 %).  
• Among DUs entering prison, before 1990, injection was the rule (90 %) and heroin was 
the main product. This study showed a sharp decrease of “indiscriminate” sharing from 
65 % for those who had begun their drug use before 1980, to 15 % for those whose first 
use began after 1987. This change was related to the occurrence of the AIDS epidemic in 
1984-1985 and predated the free access to sterile needles and syringes of 1987 which, 
nevertheless, had an additional impact. After 1985, an increasing number of 
pharmacists agreed to sell syringes answering an increasing demand of IDUs. Follow-
up studies conducted in the same environment among injectors confirmed this trend in 
the change of behavior and of viral prevalence with a quasi disappearance of 
indiscriminate syringe sharing after 1992. Conversely, the absence of any sharing 
reported by less than 5 % of IDUs who had begun to inject before 1980, reached 70 % 
after 1990.  
• In 2009-2010, a radical change in drug consumption had occurred from heroin injection 
associated by less than 10 % of DUs to cocaine in speedballs in the eighties to an almost 
equal number of heroin and cocaine consumers (cocaine 82 %; heroin 70 %; 52,6 % used 
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both drugs). Only one fourth had injected. These results underline the change in drug 
use observed at a national level (95). The prevalence of injection was higher (29.5 %) 
among heroin addicts than among cocaine abusers (18.3 %) but, among injectors syringe 
and needle sharing was not different. There was no difference in HCV prevalence 
between non drug users (2.4 %) and NIDU (3.9 %, OR 1.7 95 % CI=0.7-4.2). This 
prevalence rose to 48.6 % for IDUs who said they had never shared their needles 
(OR/NIDU 23.9 95 percent CI=8.0-65.8) and to 66.7 % for those who had (OR/NIDU 
44.7 95 percent CI=13.6-167.4). HCV detection was also related to an older age and a 
longer drug use but had no relation, among injectors, with the nature (heroin or 
cocaine) of the drug used. One fourth (24,4 %) were nationals of countries belonging to 
the exUSSR which is in accordance with a trend observed in most French hepatitis units 
for some years.  
• In a comparison of IDUs entering prison in 1987-1989, 1997-1999 and 209-2011, the 
decrease of syphilis infections among that population as soon as 1986 (11 % before to 4.7 
% after) and its disappearance after 1990 demonstrated the decrease of the trade of sex 
for drug. In a multivariate analysis controlling for date of first injection, duration of 
injection, place of injection (for HIV alone) and risk sharing the Odds ratio of viral 
infection in 1987-1988 compared to 1997-1998 were 15,4 for HIV, 7,8 for HBV and 3,3 for 
HCV, indicating a decrease (certain for HBV and HIV, possible for HCV) in the 
prevalence of these infections among injecting drug users. On the contrary, no 
difference was observed between 1978-199 and 2009-2011. 
2.2.2.3.2 Multicenter cross-sectional studies 
In 1996 a multicenter study, at that time the largest state funded study of DUs, recruited 
1302 DUs in 3 French towns (Lille, Lyon, Paris) among GPs and their referral hospitals. 120 
data were collected. It confirmed the trend observed in Lyon’s prison with a decrease of the 
indiscriminate needle sharing. A consistent increase in age for first drug use since the end of 
the eighties was observed. Before 1981 and after 1991, the prevalence of syringe sharing 
without precaution was divided by 8 while that for spoons was only divided by 1.4, for 
cotton wool by 1.6 and that for back loading by 1.3. Needle sharing was more frequent at 
night (60% versus 30 %). The proportion of nightly exchanges increased during periods 
when patients were "high" (59%), during withdrawal (61 %) and at the time of a relapse (76 
%). This sharing at the time of relapse was unpredictable and represented approximately 
25% of cases. Shared material other than syringes were in decreasing order: spoons (46%), 
filtration cotton (39%) and ‘back loading’ (20%). 9 years after the legalization of the purchase 
of needles and syringes in pharmacies and 5 years after the opening of the first NSP in Paris, 
a very small proportion attended NSPs (7%) or vending machines (2%). Socio-economic 
variables were not associated with the extent of needle sharing (a continuous professional 
activity was only found in 20% of cases but only 3% of drug addicts in this study did not 
benefit from any kind of social assistance). Gender, living with a partner and housing were 
not significant. Only the level of education and, to a lesser degree, professional situation was 
of importance. The prevalence of needle exchanges without precautions decreased from 29% 
in users who had primary level of education compared to 12 % in those who had started 
high school. Prostitution was seldom reported by men (3 %), but 29 % of women recognized 
this practice which declined from 33 % before 1980 to 21 % after 1990, most frequently 
observed in occasional “hookers” (28 to 16 %). The prevalence of cutaneous abscesses (23 %) 
and of overdoses (29 %) had not changed with time.  
 




These studies confirmed the disappearance of the HIV epidemic and, on the contrary, a 
persistence of the HCV epidemic. This observation is concordant with the results of national 
surveys. In 2008, the estimated French total number of new HIV infections among IDUs was 
70 (95 % CI 0-190) with, for the first time, a majority of DUs newly discovered being born 
abroad (112)(Levu 2011). A credible story can be told:  
• Before the AIDS epidemic, if hepatitis were known to be present among DUs, they was 
ignored since their symptoms were few, no treatment was available and their death 
rates (fulminant or subfulminant hepatitis) were exceptional, much lower than those of 
deaths by overdoses, violence or suicides. With the sudden onset of the HIV epidemic, 
everything changed. DUs wasted and died and as soon as 1984-1985 everybody knew 
that AIDS was an infectious disease transmitted through sexual intercourse and blood 
transmission. The message had all the characteristics which make a message “stick”: it 
was simple (HIV infection led to death), unexpected (people paid attention), concrete (it 
was understood and remembered), credible (people agreed and believed), emotional 
(people cared) and led people to act (a credible story was told with a solution: condoms 
and sterile works). Paraphernalia use (the impact was obvious on needle and syringes, 
filters were mostly ignored) as well as sexual practices changed significantly. I observed 
a decrease in NSS which begun well before the law of 1987 on the free access to needle 
and syringes, sex for drug and the prevalence of syphilis declined at the same time and, 
furthermore, DUs died (those who took the most risks). As a result, the HIV epidemic 
disappeared in regions like Lyon were its prevalence had been low when the epidemic 
was discovered. In others (Paris, Bordeaux, the south of France), a small pool of DUs 
infected with HIV survived. They were slow progressors and were able to access HIV 
infectious specialists and wait until HAART were available. They remained a reservoir 
for some occasional contaminations (the respective role of injection and homo or 
heterosexual transmission in these new infections is unknown). This is in accordance 
with our multicenter study of 1996 and explains the discrepancy between the high rate 
of HIV prevalence observed in Marseille and the national observation of a very low 
incidence of new infections (113). Contrary to Jauffret-Roustide (101), I believe that the 
difference in HIV prevalence between Lille and Marseille in 2004, is not mainly related 
to a prevalence of injection, which was not significantly related to HIV seroprevalence 
in their survey, but to a difference in the course in the epidemic shown by our 1996 
study: Marseille had already one of the highest HIV prevalence in the early eighties and 
the explosion of drug use in Lille occurred in the late eighties, when people were aware 
of the HIV epidemic, explaining the constant low HIV prevalence. However, recent 
changes are observed with the occurrence of new cases coming form countries were 
HIV prevalence is high among IDUs (today countries from the ex-USSR, maybe Africa 
were drug use is expanding tomorrow). The impact of this new epidemic on native DUs 
is still unknown.  
• The course of the HBV epidemic followed that of HIV. To be infected, one must 
encounter a infectious carrier: 90 % of adults newly infected will spontaneously clear 
the virus and only a fraction of them will be infectious through sexual contacts and 
through NSS. If in the eighties and most of the nineties, a diagnosis of infection through 
drug use could be made when HBV together with HCV markers were detected, it was 
not the case anymore after 2000, or earlier with younger addicts only infected with 
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HCV. HDV, which needs an HBV coinfection, had disappeared at the end of the 
eighties, but comes back, sporadically, with eastern migrants.  
• For HCV, the course of the epidemic is radically different. It is obvious that in the early 
eighties, HCV, like HBV prevalence was high among IDUs, in the range of 80 to 90 %. 
There was no difference between French regions. Harm reduction did not exist. The 3 
surveys I conducted before 2000 give a coherent picture of their evolution. Before the 
discovery of the AIDS epidemic, the majority of IDUs took no precaution with their 
“works” (even if they injected only once in a recreational setting). Since most IDUs were 
infected the first year of injection, HCV prevalence among IDUs with an history of only 
few injections did not differ significantly from that of those who had been 
indiscriminate. A decrease in NSS occurred in the eighties resulting in a delay when 
duration of injection was considered, but the influence of the level of NSS, when it had 
occurred, was not significant, reflecting the persisting high HCV prevalence. The 1996 
survey emphasizes the low access to harm reduction programs such as NSP or vending 
machines at a time when most of the changes in the course of the HIV and HCV 
epidemic had occurred. NSS occurred at a time when pharmacies were closed, at a 
place where vending machines were absent and when a sudden craving was felt. 
Behavior reported by most of the few IDUs I followed who seroconverted. This 
situation was not exceptional in DUs receiving OST after 1996. A small but significant 
trend was noted toward a reduction in the epidemic when comparing IDUs who had 
begun injecting before 1990 and between 1990 and 1999. This decrease was sustained in 
2009 but the size of the sample is too small to make final conclusions. However, 
differences may exist between French regions. In Alsace, in a GP network, HCV 
prevalence among DUs under 30 years of age was only 7 % (114). This dissociation in 
the evolution of HIV and HCV epidemic has been observed in Vancouver (115) and in 
most countries were drug injection was present before 1980 (116,117).  
2.3 From an addition of successive layers of harm reduction to the recognition of the 
complexity of the control of risky behaviors 
A thorough synthesis and evaluation of harm reduction effectiveness has been published in 
an EMCDDA monograph in 2010 (118) following others (119–121) with the same 
conclusions: the absence of high-quality review evidence leading to question this efficacy. I 
will try to consider the respective impact of past harm reduction programmes and the 
improvement which could be implemented to improve their efficiency in the French context.  
2.3.1 Prevention 
2.3.1.1 Oral substitution treatment 
The massive introduction of OST in France in 1996 was followed by an instantaneous and 
tremendous change in the care for DUs. In 2002, it was assumed that one third of 
problematic opiate users (52 000) were engaged in long-term treatment with an additional 
22 000 receiving prescriptions on an irregular basis (122). OST introduction occurred at a 
time when the HIV epidemic among DUs was already controlled. Its impact is, thus, 
difficult to assess. However, OST in community setting is considered to reduce HIV 
seroconversion and to have a possible role in reducing the number of HCV seroconversions 
among DUs who remain in the programmes. From my experience and from the results of a 
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study of the migration of IDUs inside Lyon’s healthcare and penal institutions I conducted 
in 1989, OSTs have delayed the time of transition to injection among heroin users. But since 
many other variables have changed during that period, and since we still do not know the 
evolution of the prevalence of injectors, this assumption remains speculative. The problem 
which remains is what to do with the non compliant DUs, most at risk of infection or with 
those who do not attend OSTs? The change in the nature of the drugs consumed by DUs 
observed in the last years with an increase in cocaine/crack use could limit the impact of 
OST on these consumers and should lead to an evolution of the DPs even if, recently a 
disaffection for cocaine and a come-back of heroin through micronetworks of users-sellers 
(123) has been reported in France.  
2.3.1.2 Reduction of syringe and needle sharing (NSS) 
The first harm reduction programme implemented in France occurred in 1987 with a law 
allowing free access to needles and syringes in French pharmacies. The motivation behind 
this decision, like the decision, in 1996, to offer an easy access to OST, was more a protection 
of the heterosexual community from HIV and hepatitis viruses than an improvement of 
DUs’ care. For someone who lived that period, it is obvious that, this decision increased 
significantly a preexisting trend and was significantly associated to a quasi disappearance of 
indiscriminate NSS among IDUs. From my study in prison and the national survey of 1996 
as well as my own experience with the IDUs I followed at that time when no OST, beside 
neocodion, was available, it is “obvious” that it answered a demand of IDUs and decreased 
significantly NSS after they had discovered and realized the risk inherent to that practice. 
Following this first move, steribox containing needles, syringes, filters and condoms have 
been sold to IDUs for a low price or have been available through NSP which have been 
opened in the early nineties. In 1998, with an estimation of 2.8 injections per IDU per day, 
Lurie and al. estimated that between 920 million and 1.7 billion injections by IDUs took 
place each year in the United States (estimated 12 million in San Francisco and >80 million 
in New York City) (124). Using the same level of daily injections, with a conservative 
estimation of 80-100 000 IDUs, 80 and 100 000 million of injections could take place in 
France. An annual estimation of syringes sold to IDUs in France between 1996 and 2003 
made by the INVS increased from 1996 to 1999 (14.7 to 17.7 M) and then decreased 
dramatically from 1999 to 2003 (10.9 M) (125). This decrease was ascribed to an increase in 
OST during the same period. NSP accounted for only 1.5 M exchanges with large differences 
in the number of steribox exchanged yearly (253-10 000) between as many as 129 
programmes or vending machines. The observation that a syringe can be reused 10 times is 
not a surprise. Pharmacies after they began to give free steribox have been shown to 
quadruple in the first 6 months the number they dispensed to the same number of IDUs 
(126). In a survey of 35 large metropolitan areas in the US, the range of the number of 
syringes distributed was 2 per 10 injection events to 3 per 10 000 injection events (127). 
Sterile syringes for each shoot may be desired, but can this goal be reached and would it be 
sufficient to prevent receptive exchanges? For cocaine users, distribution of glass stems, 
rubber mouthpieces, brass screens, chopsticks, lip balm and chewing gum, reducing the 
harms associated with smoking crack, may decrease the number of injections (128). 
Considering what is unknown about the number of IDUs, their access to harm reduction 
programmes (HRPs), the efficacy of theses HRPs and the modes of viral contamination, one 
can be surprised that models fitting strategies to control the HCV epidemic can be proposed. 
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However, models exist even if they are oversimple and if some (many) of their initial 
assumptions on the rate of viral transmission or the efficacy of NSP and OST to prevent 
infection, may be problematic. The conclusion that high-risk DUs are infected early and that 
the rate of infection among low-risk groups will continue for years are truisms (34). 
Percolation-based approximations can be highly biased when one incorrectly assumes that 
infectious periods and when deterministic models assume that every contact is with a new 
individual. Thus, models should be significantly improved, for example, with the use of 
stochastic models which take into account lasting relationships and inclusion in groups, but 
they should also use additional data on specific populations (129,130). Despite these limits, 
Vickerman et al. suggest that, in the UK, NSP and OST have been able to limit 50 000 new 
infections in the UK, but even with their initial optimistic assumptions, they conclude that a 
reduction by half in chronic HCV prevalence would need OST and 100% NSP to be scaled 
up to 80 % coverage for at least 20 years (131). 
French results do not support a significant impact of harm reduction programmes on the 
course of the HIV and HCV epidemic outside of the free access to sterile needles and 
syringes in pharmacies (112).  
2.3.2 Hepatitis treatment 
The treatment of DUs’ viral infections has been considered since the occurrence of the AIDS 
epidemic. In the nineteen eighties, our diagnosis tools were limited and available treatments 
were experimental. In Lyon we used the first anti HBV antiviral in continuous perfusions of 
four weeks durations for severe HBV hepatitis as early as 1979, then with beta interferon for 
HBV/HDV coinfections and NonA NonB hepatitis in 1984 and alpha interferon for both 
since 1989 after the first randomized trials of 1987. This know-how encompassed also HIV 
infections and at every step we treated active IDUs years before OST could be prescribed 
(1996) in France. Our recruitment was biased, but we were able to screen and treat most of 
the DUs who asked for heroin detoxification or hepatitis and HIV treatment. On another 
level, a national consultation in 1991, concluded that HIV infected DUs did not differ from 
the other patients. Compliance was related to housing problems whatever the modalities of 
infection. Having treated DUs for their HIV infections since 1984 and for their hepatitis since 
1986, we did not agree with the recommendations of the French consensus conferences 
which denied the treatment of HCV hepatitis to active DUs in 1997. This position, initially 
controversial, has become the norm with an emerging consensus that DUs can be treated for 
their hepatitis on a case by case basis. In a study of the perception of their disease in 2000, 60 
IDUs successively entering Lyon’s prisons were interviewed. At least one liver biopsy had 
been performed in 49 (90 % of those whose hepatitis had been discovered more than 5 years 
earlier). 80 % of viremic DUs who had a significant fibrosis (> F1) had been treated and 50 % 
of the others on account of fatigue or a desire to be treated. The multi-disciplinary 
management we developed with success in the early nineteen nineties is now proposed as a 
possible solution to improve access to treatment (132–134). The possible impact of treating 
HCV infected DUs on the course of the epidemic has even been studied by different models 
which are the subject of debates (135,136).  
In France when we proposed to study the possibility of treating HCV hepatitis to decrease 
HCV prevalence in a nationally funded Clinical Hospital Research Programme in 2002, few 
hepatitis units received IDUs. In 2004, in a national observational study of 40 hepatitis units, 
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only two hepatitis reference centers treated a significant number of HCV hepatitis of drug 
users. In 2011, after three successive national plans, the situation has changed. 90 % of the 31 
hepatitis reference centers who treat two third of French HCV hepatitis declared that DUs’ 
hepatitis care was a strategic decision. Differences in history and location, as well as the size 
of the HCV specialist team (range 0.8-10) made each centre a special case. Various 
innovative solutions have been implemented, in some cases before the allocation of 
resources. A partnership was present with drug treatment programs (DTP) (85,2 %) and 
GPs’ network (25.9 %). 44.7 % found that care for DUs hepatitis did not need a specific 
competence. Perceived problems were reported by only 34.3 % of HCV specialists 
(absenteeism) and 48.3 % of nurses (absenteeism, blood access). Waiting times were similar 
for DUs and non-DUs. Our results support collaboration between services involved in DUs’ 
care. However their complete and complex integration may only be needed for the most 
precarious such as homeless adolescents.  
3. HCV, drug use, and the world complexity 
Biomedical knowledge of the HCV epidemic among DUs is obviously not enough to be able 
to control its course. My practice taught me that if objectification of DUs as well as of their 
hepatitis was inescapable, an understanding of its limits implies an integration of other 
aspects of our “being-here” (Dasein) such as the brain, society, social systems and ethics.  
• The “rationality” of one’s decision includes his lifetime experience, “being-here”. The 
human brain constructs the world from gestation onward in an interaction with its 
environment. This process governed by genes and their expression (epigenetic) (137) 
leads to more and more complex “logical” choices following statistical “Bayesian 
inferences” (138), the results of which may be forgotten but still predetermine future 
decisions by limiting the scope of one’s expectations. Its integrated complexity is mainly 
unconscious and organizes a memory which is more concerned by one’s future 
efficiency than by an accurate memorization of past events. It leaves a small place to 
what we consider as consciousness which has to decide among a limited number of 
preselections networked through sleep and “mind wandering” (139–142). Brain exercise 
like meditation could improve its efficiency. The development of the brain is crucially 
sensitive in its first months and years to its relations with its human environment which 
will make up the limits of its future “creativity” through the secure basis of its 
attachment (143–145). At adolescence, the brain restructuration will settle its adult 
functional frame (146) . Drug use and addiction represent only one dimension of this 
complex adaptative interaction which cannot be “revolutionized” by a single logical 
argumentation. The impact of the initial AIDS epidemic, with its massive death toll, 
observed in France in the nineteen eighties will not occur anymore. It was “one shot”. 
Prevention messages, treatment proposals have to take into account these changing 
individual ecologies. One can be immediately convinced by the description of the risk 
of NSS but will nevertheless engage in NSS when its result is an instant improvement in 
well being compared with an improbable success of hepatitis prevention over the future 
years of addiction and the high probability of dying before the advent of an improbable 
liver cancer.  
• Modern society, faced with the management of its growing complexity, has organized 
itself functionally around social systems which rationally objectify the world (147). 
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They follow an initial selection of their missions through binary codes (health/disease 
for medicine, presence or absence of an hepatitis for HCV specialists) which makes 
them “blind” to what has been excluded (the complexity of the world) and gives them a 
meaning which is the basis of their communication with their environment. These self-
referential systems fight to survive and extend their territories responding to stimulations 
(irritations) of their environment through the limited structural couplings they themselves 
made possible. Hepatologists will use scientific medical mathematics to modelize the 
HCV epidemic from scarce and improbable data to convince politics and economics to 
maintain and, even, increase their funding. Publication of these computations will 
improve the academic status of biostatisticians. The pharmaceutical industry will fund 
these studies which secure the outlet of their products and so on. For an hepatitis 
specialist DU exists first as a carrier of an HCV infection for an hepatitis specialists This 
practical discovery explains the absence of specificity of DUs’ hepatitis management 
reported by French HRCs: The only limit of HCV treatment was compliance, problem 
which was not restricted to DUs and, in our French study of HRCs, did not need a specific 
management for consulting DUs. The question of the control of the HCV epidemic was 
irrelevant. The global failure of society faced with the problem of drug use and of its 
management, the awareness of its social complexity are the source of the demand by the 
professionals of an association in the same place of diverse services addressing belonging 
to multiple social systems: they would “have to” manage the failures of one particular 
service which, once its limits recognized, would not be considered as such. 
• This organization ignores the complexity of one’s “being-here” and is the source of a 
modern reactivation of the ethical debate (148–151). A DU does not exist as such outside 
its representation by society’s Other. The practical success of HCV care cure but also 
prevention) is related to the capacity of each individual to recognize and make 
recognized the inscrutable “otherness” present in every human being. Rational 
objectification, which is at the core of every scientific approach, is supported by the 
emptiness of universal concepts which deny this recognition. This otherness is the 
source of an infinite demand which founds inter human relations. The limited offer 
which one can propose in return, leaves to this “neighbour”, who is to be “loved like 
oneself ”, the freedom to make the right choice. In its absence, the quenching of the 
scientific rational solution (see Descartes’s discourse of a method), when it is 
implemented, may be transformed into an unbearable violence which will force one to 
step out of the symbolic order to express one’s freedom and say no to an impossible but 
irrefutable proposal (see paragraph II.1.3.): “death drive” for Freud, “radical negativity” 
for German Idealism. This “acting-out” has its own inescapable rationality: the 
immediacy of one’s (emotional and conscious) survival in the “death struggle” of the 
Hegelian demand for recognition. Care and cure cannot be summed up as an accurate 
diagnosis and prescription. In my practice, this (not so) simple recognition of the other’s 
freedom had a constant practical impact. One of society’s responses is the development 
of a “third sector”, non-profit organizations outside of organized social systems which 
answer its latencies such as individual and social complexity but whose precarious 
survival depends on their perceived immediate social utility.  
4. Finally, let us try to be creative 
At the end of this general survey, limiting their scope to the HCV epidemic, four options are 
possible.  
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• The first would keep the status quo, leaving the community with the belief that harm 
reduction is efficient, efficiency which could be boosted by additional funding of each 
of these actions and a better collaboration between services leading to integration in 
drug treatment programmes which would encompass them all. The sole aim of many 
papers published in journals dedicated to drug use and DUs is to convince their reader 
of its validity. This position is held by each subsystem which, to survive and even grow 
has to convince its environment of its performance. In my opinion, it may appear as the 
less costly in energy and financial involvement, but I believe, in the long term, it will be 
the less efficient.  
• The second is more ambitious. It considers HCV hepatitis as an epidemic which should 
be controlled and DUs as users of services supplied by the healthcare system which 
may not be spontaneously desired by DUs but which use such as the treatment of HIV 
and hepatitis should be implemented to control these epidemics. From a DU’s stand 
point HCV hepatitis cannot be considered alone. It is never more than a part of his 
“being-here” for which society’s goals of harm reduction may not be relevant. To 
succeed society has to propose an environment “good-enough” to enable him to live 
without a continuous help of drugs. This option depends on the assumption that a 
better knowledge and a better management could control the HCV epidemic. Today, it 
remains a “wishful thinking” of existing social systems: 
• The initial assumption would be that the control of the HCV epidemic should 
associate prevention of new infections to the treatment of “all” (at least a large 
majority) the infected DUs (even not in DTP) to decrease viral prevalence to a level 
which would, by itself, limit the new contaminations, passing from an epidemic to 
sporadic cases, evolution observed for HIV in most countries where the initial 
prevalence remained low. 
• The first step would design and conduct an ethno-epidemiological study of a 
population in a geographical delimited area relevant for the proposed intervention. 
It would collect its socio-demographics, health status, social networks, drugs 
consumed and risks associated to that consumption, viral status and use of social 
and health care as well as its motivations, desires and plans (152).  
• From that collection, an analysis would define potentially different subgroups 
which would be targeted for different interventions which would try to build a 
“cultural” environment including a positive vision of HCV care and the 
conscience of the necessity of a global commitment needed to control the HCV 
epidemic. It would try to understand its course among these different subgroups 
including the possible viral reservoirs among DUs who do not attend healthcare 
services. The first goal of these programmes would be to win the trust of the 
concerned DUs by proposing services answering their need (desires). Beside 
proposing substitution treatments or social help to find work or housing, 
considering the cost of harm reduction and HCV treatment, one could propose 
conditional cash transfer or vouchers which have been used successfully in many 
countries to improve access to school or healthcare programmes and which is one 
of the few incentives proven to be efficient in cocaine addiction (153,154). Heroin 
treatment should be considered. It has been shown to be significantly more 
effective than methadone for difficult to maintain patients (155,156). This efficacy 
was also present in DUs without previous maintenance treatments (157). It can be 
delivered intranasally or orally (158). It has been shown to be cost-effective (159). 
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They follow an initial selection of their missions through binary codes (health/disease 
for medicine, presence or absence of an hepatitis for HCV specialists) which makes 
them “blind” to what has been excluded (the complexity of the world) and gives them a 
meaning which is the basis of their communication with their environment. These self-
referential systems fight to survive and extend their territories responding to stimulations 
(irritations) of their environment through the limited structural couplings they themselves 
made possible. Hepatologists will use scientific medical mathematics to modelize the 
HCV epidemic from scarce and improbable data to convince politics and economics to 
maintain and, even, increase their funding. Publication of these computations will 
improve the academic status of biostatisticians. The pharmaceutical industry will fund 
these studies which secure the outlet of their products and so on. For an hepatitis 
specialist DU exists first as a carrier of an HCV infection for an hepatitis specialists This 
practical discovery explains the absence of specificity of DUs’ hepatitis management 
reported by French HRCs: The only limit of HCV treatment was compliance, problem 
which was not restricted to DUs and, in our French study of HRCs, did not need a specific 
management for consulting DUs. The question of the control of the HCV epidemic was 
irrelevant. The global failure of society faced with the problem of drug use and of its 
management, the awareness of its social complexity are the source of the demand by the 
professionals of an association in the same place of diverse services addressing belonging 
to multiple social systems: they would “have to” manage the failures of one particular 
service which, once its limits recognized, would not be considered as such. 
• This organization ignores the complexity of one’s “being-here” and is the source of a 
modern reactivation of the ethical debate (148–151). A DU does not exist as such outside 
its representation by society’s Other. The practical success of HCV care cure but also 
prevention) is related to the capacity of each individual to recognize and make 
recognized the inscrutable “otherness” present in every human being. Rational 
objectification, which is at the core of every scientific approach, is supported by the 
emptiness of universal concepts which deny this recognition. This otherness is the 
source of an infinite demand which founds inter human relations. The limited offer 
which one can propose in return, leaves to this “neighbour”, who is to be “loved like 
oneself ”, the freedom to make the right choice. In its absence, the quenching of the 
scientific rational solution (see Descartes’s discourse of a method), when it is 
implemented, may be transformed into an unbearable violence which will force one to 
step out of the symbolic order to express one’s freedom and say no to an impossible but 
irrefutable proposal (see paragraph II.1.3.): “death drive” for Freud, “radical negativity” 
for German Idealism. This “acting-out” has its own inescapable rationality: the 
immediacy of one’s (emotional and conscious) survival in the “death struggle” of the 
Hegelian demand for recognition. Care and cure cannot be summed up as an accurate 
diagnosis and prescription. In my practice, this (not so) simple recognition of the other’s 
freedom had a constant practical impact. One of society’s responses is the development 
of a “third sector”, non-profit organizations outside of organized social systems which 
answer its latencies such as individual and social complexity but whose precarious 
survival depends on their perceived immediate social utility.  
4. Finally, let us try to be creative 
At the end of this general survey, limiting their scope to the HCV epidemic, four options are 
possible.  
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• The first would keep the status quo, leaving the community with the belief that harm 
reduction is efficient, efficiency which could be boosted by additional funding of each 
of these actions and a better collaboration between services leading to integration in 
drug treatment programmes which would encompass them all. The sole aim of many 
papers published in journals dedicated to drug use and DUs is to convince their reader 
of its validity. This position is held by each subsystem which, to survive and even grow 
has to convince its environment of its performance. In my opinion, it may appear as the 
less costly in energy and financial involvement, but I believe, in the long term, it will be 
the less efficient.  
• The second is more ambitious. It considers HCV hepatitis as an epidemic which should 
be controlled and DUs as users of services supplied by the healthcare system which 
may not be spontaneously desired by DUs but which use such as the treatment of HIV 
and hepatitis should be implemented to control these epidemics. From a DU’s stand 
point HCV hepatitis cannot be considered alone. It is never more than a part of his 
“being-here” for which society’s goals of harm reduction may not be relevant. To 
succeed society has to propose an environment “good-enough” to enable him to live 
without a continuous help of drugs. This option depends on the assumption that a 
better knowledge and a better management could control the HCV epidemic. Today, it 
remains a “wishful thinking” of existing social systems: 
• The initial assumption would be that the control of the HCV epidemic should 
associate prevention of new infections to the treatment of “all” (at least a large 
majority) the infected DUs (even not in DTP) to decrease viral prevalence to a level 
which would, by itself, limit the new contaminations, passing from an epidemic to 
sporadic cases, evolution observed for HIV in most countries where the initial 
prevalence remained low. 
• The first step would design and conduct an ethno-epidemiological study of a 
population in a geographical delimited area relevant for the proposed intervention. 
It would collect its socio-demographics, health status, social networks, drugs 
consumed and risks associated to that consumption, viral status and use of social 
and health care as well as its motivations, desires and plans (152).  
• From that collection, an analysis would define potentially different subgroups 
which would be targeted for different interventions which would try to build a 
“cultural” environment including a positive vision of HCV care and the 
conscience of the necessity of a global commitment needed to control the HCV 
epidemic. It would try to understand its course among these different subgroups 
including the possible viral reservoirs among DUs who do not attend healthcare 
services. The first goal of these programmes would be to win the trust of the 
concerned DUs by proposing services answering their need (desires). Beside 
proposing substitution treatments or social help to find work or housing, 
considering the cost of harm reduction and HCV treatment, one could propose 
conditional cash transfer or vouchers which have been used successfully in many 
countries to improve access to school or healthcare programmes and which is one 
of the few incentives proven to be efficient in cocaine addiction (153,154). Heroin 
treatment should be considered. It has been shown to be significantly more 
effective than methadone for difficult to maintain patients (155,156). This efficacy 
was also present in DUs without previous maintenance treatments (157). It can be 
delivered intranasally or orally (158). It has been shown to be cost-effective (159). 
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HCV prevention and treatment would only come second, tailored to the course of 
the epidemic, targeting opinion leaders through peers’ interventions explaining 
the ethical goal of the project which would not be limited to the individual gain 
of the cure of one’s hepatitis but would want to control the HCV epidemic in the 
area, control which would benefit not only DUs but also their family, friends and 
neighbors. Their success would be conditioned by a complete appropriateness 
between the discourse and the means: To improve the impact of NSP, a 
significant rise would be mandatory to decrease significantly the occurrence of 
receptive exchanges. It could mean a tenfold increase in the number of syringes 
exchanged, but it would not be enough. NSP should shift from exchange to 
distribution (160) allowing IDUs to store sterile syringes for future use and 
“providers” to distribute syringes to other IDUs who are in need of sterile 
syringes and cannot access a NSP or a pharmacy (161) This would help to cover 
unexpected “craving” episodes in former IDUs at times when pharmacies and 
NSP are closed which represent, at least in my experience, a significant cause of 
new contaminations. Home self-test for the diagnosis of HIV and HCV infection 
should be an option (65). As long as the HCV prevalence remains high, to be 
efficient, NSP as well as potential consumption rooms should be located in the 
neighborhood of every drug scene (162-164) embedded within existing spatial 
and social relations of DUs (165). Outreach, bringing services to the DUs with the 
lowest social functioning can also decrease NSS). Open scenes, where users could 
come to buy their drugs, find NSP and meet harm reduction services, could 
reduce the level of NSSHCV screening could only be considered if a treatment 
could be proposed to every infected DU. Interventions should be adapted to the 
evolution of each case. Building trust takes time, even more when every partner 
(from customers to professionals) are concerned.  
• The simplistic idea that one would only need to bring potential actors together to 
carry out a community project is long overdue [166]. Understanding the 
implications of the affiliation of professionals to social sub-systems could help 
them as well as those responsible for leading and managing programs to consider 
the limits of their individual scope, the need for an evolution of their missions and 
for new cooperative programs. The evolution of the French care of DUs’ hepatitis C 
bears witness of its feasibility. To reach these goals, time and specific resources 
must be allocated and a common will and trust between the different actors is 
mandatory to overcome the existing barriers to an effective integration of 
prevention and treatment of hepatitis C (167-169). The proposed approach makes 
the control of the HCV epidemic an example of a new health policy paradigm: 
efficient integrated services (medical and social) based on the knowledge of the 
health of a population in a designated area as advocated by most groups working 
on the improvement of clinical effectiveness. This multilevel approach to change 
should include the individual, group/team, organization, and larger 
environment/system level (170). 
• The third alternative would be the legalization (not a simple depenalization) of drug 
consumption. Of course this proposal may appear heretic when one considers drug 
related deaths and comorbidities. However, the rational behind the “war on drugs” was 
its possible success. 40 year after its implementation, one is forced to observe its failure, 
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failure which has a precedent with alcohol prohibition in the United States (171-181). 
The belief that this legalization would result in a huge increase in drug consumption 
can be compared to the fantasy of an increase in sexual promiscuity induced by sexual 
education in the eighties, which was proven to be false. The obvious benefit would be 
the huge amount of taxes which escapes today every government. The drug market is 
still one of the most perfect examples of a free market economy adapting its products to 
its customers and one of the most profitable. Of course, it would mean a negative 
impact on many social sub-systems devoted to this war like justice, police, customs or, 
even, medicine with a significant reduction of state spending. They would not able to 
“understand” a proposal which would negate the mission which justifies their existence 
and reduce their “power”. A global vision would be mandatory. One must also not 
forget drug dealers who have an interest in keeping their trade illegal and can spend 
large sums of money to bribe people who are able prevent that evolution. An initial 
transfer of marijuana market from organized crime to state management could assess 
the risks and benefits of this change of policy. Of course, its impact on the HCV 
epidemic would wait heroin and cocaine legalization which would only reduce the 
number of new contaminations.  
• The fourth and last solution would be the development of a vaccine comparable to the 
HBV vaccine and which could be implemented on a population basis at least at 
adolescence. Of course this solution, when available, could improve each one of the 
previous solutions.  
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HCV prevention and treatment would only come second, tailored to the course of 
the epidemic, targeting opinion leaders through peers’ interventions explaining 
the ethical goal of the project which would not be limited to the individual gain 
of the cure of one’s hepatitis but would want to control the HCV epidemic in the 
area, control which would benefit not only DUs but also their family, friends and 
neighbors. Their success would be conditioned by a complete appropriateness 
between the discourse and the means: To improve the impact of NSP, a 
significant rise would be mandatory to decrease significantly the occurrence of 
receptive exchanges. It could mean a tenfold increase in the number of syringes 
exchanged, but it would not be enough. NSP should shift from exchange to 
distribution (160) allowing IDUs to store sterile syringes for future use and 
“providers” to distribute syringes to other IDUs who are in need of sterile 
syringes and cannot access a NSP or a pharmacy (161) This would help to cover 
unexpected “craving” episodes in former IDUs at times when pharmacies and 
NSP are closed which represent, at least in my experience, a significant cause of 
new contaminations. Home self-test for the diagnosis of HIV and HCV infection 
should be an option (65). As long as the HCV prevalence remains high, to be 
efficient, NSP as well as potential consumption rooms should be located in the 
neighborhood of every drug scene (162-164) embedded within existing spatial 
and social relations of DUs (165). Outreach, bringing services to the DUs with the 
lowest social functioning can also decrease NSS). Open scenes, where users could 
come to buy their drugs, find NSP and meet harm reduction services, could 
reduce the level of NSSHCV screening could only be considered if a treatment 
could be proposed to every infected DU. Interventions should be adapted to the 
evolution of each case. Building trust takes time, even more when every partner 
(from customers to professionals) are concerned.  
• The simplistic idea that one would only need to bring potential actors together to 
carry out a community project is long overdue [166]. Understanding the 
implications of the affiliation of professionals to social sub-systems could help 
them as well as those responsible for leading and managing programs to consider 
the limits of their individual scope, the need for an evolution of their missions and 
for new cooperative programs. The evolution of the French care of DUs’ hepatitis C 
bears witness of its feasibility. To reach these goals, time and specific resources 
must be allocated and a common will and trust between the different actors is 
mandatory to overcome the existing barriers to an effective integration of 
prevention and treatment of hepatitis C (167-169). The proposed approach makes 
the control of the HCV epidemic an example of a new health policy paradigm: 
efficient integrated services (medical and social) based on the knowledge of the 
health of a population in a designated area as advocated by most groups working 
on the improvement of clinical effectiveness. This multilevel approach to change 
should include the individual, group/team, organization, and larger 
environment/system level (170). 
• The third alternative would be the legalization (not a simple depenalization) of drug 
consumption. Of course this proposal may appear heretic when one considers drug 
related deaths and comorbidities. However, the rational behind the “war on drugs” was 
its possible success. 40 year after its implementation, one is forced to observe its failure, 
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failure which has a precedent with alcohol prohibition in the United States (171-181). 
The belief that this legalization would result in a huge increase in drug consumption 
can be compared to the fantasy of an increase in sexual promiscuity induced by sexual 
education in the eighties, which was proven to be false. The obvious benefit would be 
the huge amount of taxes which escapes today every government. The drug market is 
still one of the most perfect examples of a free market economy adapting its products to 
its customers and one of the most profitable. Of course, it would mean a negative 
impact on many social sub-systems devoted to this war like justice, police, customs or, 
even, medicine with a significant reduction of state spending. They would not able to 
“understand” a proposal which would negate the mission which justifies their existence 
and reduce their “power”. A global vision would be mandatory. One must also not 
forget drug dealers who have an interest in keeping their trade illegal and can spend 
large sums of money to bribe people who are able prevent that evolution. An initial 
transfer of marijuana market from organized crime to state management could assess 
the risks and benefits of this change of policy. Of course, its impact on the HCV 
epidemic would wait heroin and cocaine legalization which would only reduce the 
number of new contaminations.  
• The fourth and last solution would be the development of a vaccine comparable to the 
HBV vaccine and which could be implemented on a population basis at least at 
adolescence. Of course this solution, when available, could improve each one of the 
previous solutions.  
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Addiction, increasingly perceived as a heterogeneous brain disorder, is one of the 
most peculiar psychiatric pathologies in that its management involves various, often 
non-overlapping, resources from the biological, psychological, medical, economical, 
social, and legal realms. Despite extensive efforts from the players of these various 
fields, to date there are no reliably effective treatments of addiction. This may stem 
from a lack of understanding of the etiology and pathophysiology of this disorder 
as well as from the lack of interest into the potential differences among patients in 
the way they interact compulsively with their drug. This book offers an overview 
of the psychobiology of addiction and its current management strategies from 
pharmacological, social, behavioural, and psychiatric points of view.
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